{"messages": [{"role": "user", "content": "**Pathway Name**: Bladder cancer - Homo sapiens (human)\n**Pathway Description**: The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIGLEC12 (elevated expression), arginine at position 122 of SIGLEC12, E-cadherin, matrix metalloproteinases, vascular endothelial growth factor, HRAS, fibroblast growth factor receptor 3, TP53, RB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of SIGLEC12 in bladder cancer correlates with increased immune cell infiltration and upregulation of oncogenic and immune checkpoint-related genes. This expression is associated with drug resistance signatures and occurs independently of tumor stage or metastatic status. SIGLEC12 lacks the canonical R122 residue but retains structural integrity, suggesting potential functional roles in sialic acid recognition. In bladder cancer, alterations in TP53 and RB1 genes contribute to invasive tumor progression, while HRAS and FGFR3 mutations are linked to low-grade papillary tumors. E-cadherin loss and MMP activity facilitate tumor invasion, and VEGF promotes angiogenesis, further supporting tumor growth and metastasis."}], "pathway_id": "hsa05219", "pubmed_id": "41303731", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Bladder cancer - Homo sapiens (human)\n**Pathway Description**: The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRKD2, MCM2 (phosphorylated at serine 139).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRKD2 phosphorylates MCM2 at serine 139, which promotes the malignant progression of bladder cancer cells by enhancing their proliferation, migration, invasion, and epithelial-mesenchymal transition."}], "pathway_id": "hsa05219", "pubmed_id": "41299687", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gsk-650394, SGK1, STAT3 (dephosphorylated), MYCL (expression reduced), CTSK (transcription promoted), NFATC1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SGK1 activates STAT3 through phosphorylation at Tyr705, which in turn upregulates MYCL expression. MYCL binds to the promoter of CTSK and promotes its transcription, thereby supporting osteoclast differentiation and bone resorption. Inhibition of SGK1 reduces STAT3 phosphorylation and MYCL expression, impairing osteoclastogenesis. Overexpression of MYCL can partially rescue this inhibition, indicating a direct regulatory role of MYCL in osteoclast development."}], "pathway_id": "hsa04380", "pubmed_id": "41266497", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: E 7820, ITGA2 (elevated levels), RANKL, MMP9, SPP1, ACP5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of ITGA2 promote osteoclast differentiation and bone destruction by upregulating RANKL and MMP9 while downregulating OPN (SPP1). This imbalance leads to increased osteoclast activity and reduced osteogenesis, resulting in osteolysis. Inhibition of ITGA2 decreases tumor proliferation and migration, reduces tumor volume, and suppresses osteoclast numbers. ITGA2 also enhances tumor invasion and disrupts bone metabolism by modulating osteoclastogenic signaling pathways. Targeted inhibition of ITGA2 restores bone homeostasis by suppressing osteoclast differentiation cascades and promoting osteogenic factors."}], "pathway_id": "hsa04380", "pubmed_id": "41174632", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Corosolic Acid (administration), tumor necrosis factor (TNF) superfamily member 11, nuclear factor kappa B, inhibitor of kappa light polypeptide gene enhancer in B-cells, alpha (phosphorylated), mitogen-activated protein kinase 1 (phosphorylated), c-Jun N-terminal kinase (phosphorylated), mitogen-activated protein kinase 14 (phosphorylated), nuclear factor of activated T-cells, cytoplasmic 1 (nuclear translocation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Corosolic acid binds to RANKL and inhibits its signaling, preventing the activation of the canonical NF-kB and MAPK pathways by suppressing the phosphorylation of IkappaB-alpha, ERK, JNK, and p38. This inhibition reduces the nuclear translocation of NFATc1, a key transcription factor for osteoclastogenesis, and downregulates osteoclast-specific transcriptional markers. Corosolic acid also disrupts F-actin ring assembly, a structural feature essential for osteoclast function, and modulates oxidative stress by decreasing reactive oxygen species production and enhancing antioxidant enzyme expression. These actions collectively suppress osteoclast differentiation and activity, thereby reducing bone resorption."}], "pathway_id": "hsa04380", "pubmed_id": "41151621", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2,3',5',6-Tetrahydroxy-trans-stilbene, Glutathione, TNFAIP3, SLC7A11 (reduced activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gnetol promotes ubiquitination and proteasomal degradation of SLC7A11 through enhanced K48-linked ubiquitination mediated by TNFAIP3. This interaction leads to reduced SLC7A11 activity, impairing cystine uptake and inducing ferroptosis in osteoclasts. Ferroptosis is characterized by lipid peroxidation, glutathione depletion, and increased labile iron levels, which ultimately suppress osteoclast viability and differentiation. This process contributes to the amelioration of osteoporosis by reducing excessive bone resorption."}], "pathway_id": "hsa04380", "pubmed_id": "41151451", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: osteoblast, osteoclast, tumor necrosis factor receptor superfamily member 11A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Osteoclasts and osteoblasts interact dynamically during bone remodeling through the basic multicellular unit (BMU), where osteoclasts mediate bone resorption and osteoblasts facilitate bone formation. Signaling through RANK promotes osteoclast differentiation and activation. During bone homeostasis, the coupling of osteoblast and osteoclast activity ensures balanced bone turnover. Disruption of this coupling contributes to pathological conditions such as osteoporosis, characterized by excessive bone resorption relative to bone formation."}], "pathway_id": "hsa04380", "pubmed_id": "41138824", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Osteoclast differentiation - Homo sapiens (human)\n**Pathway Description**: The osteoclasts, multinucleared cells originating from the hematopoietic monocyte-macrophage lineage, are responsible for bone resorption. Osteoclastogenesis is mainly regulated by signaling pathways activated by RANK and immune receptors, whose ligands are expressed on the surface of osteoblasts. Signaling from RANK changes gene expression patterns through transcription factors like NFATc1 and characterizes the active osteoclast.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), ALAS1, ALAS2, FECH (deficiency), ALAD (deficiency), PBGD (deficiency), UROD (deficiency), CPOX (deficiency), PPOX (deficiency), HMBS (deficiency), Ferrochelatase (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid is the initial and rate-limiting substrate in the heme biosynthesis pathway, synthesized by ALAS1 in the liver and ALAS2 in erythroid cells. Deficiencies in enzymes such as FECH, ALAD, PBGD, UROD, CPOX, PPOX, HMBS, and Ferrochelatase lead to the accumulation of toxic intermediates, including 5-aminolevulinic acid and porphyrins, which contribute to the development of various porphyrias. These disorders are associated with neurovisceral symptoms, photosensitivity, anemia, and neurotoxicity. Disruption of heme biosynthesis also underlies conditions such as acute intermittent porphyria, porphyria cutanea tarda, congenital erythropoietic porphyria, and X-linked sideroblastic anemia."}], "pathway_id": "hsa04380", "pubmed_id": "41130306", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NOTCH1 (high expression), MIR449A, MIF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NOTCH1 promotes cervical cancer cell proliferation by enhancing the G1-S phase transition of the cell cycle. High expression of NOTCH1 is associated with reduced plasma cell infiltration in the tumor microenvironment and impaired plasma cell differentiation through disruption of the MIF ligand-receptor pathway. NOTCH1 also contributes to radiotherapy resistance in cervical cancer cells. The miRNA MIR449A inhibits NOTCH1 expression, thereby suppressing tumor proliferation and enhancing radiosensitivity."}], "pathway_id": "hsa04330", "pubmed_id": "41306984", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JAG1, KRAS, MAPK1, ADAM17, JAG1 intracellular domain (generated via proteolytic cleavage), CTNNB1, NOTCH1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "JAG1 functions as a Notch ligand and undergoes proteolytic cleavage via the KRAS/ERK/ADAM17 signaling cascade, generating a nuclear JAG1 intracellular domain (Jag1-ICD) that drives reverse signaling. JAG1 is a transcriptional target of the Wnt/CTNNB1 signaling axis. Through both canonical Notch signaling and non-canonical reverse signaling, JAG1 promotes CRC progression and chemoresistance."}], "pathway_id": "hsa04330", "pubmed_id": "41294868", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LRIG1, NOTCH1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NOTCH1 signaling maintains quiescence in LRIG1-expressing stem cells within the laryngeal and vocal fold mucosa. Disruption of NOTCH1 leads to epithelial hyperplasia, expansion of secretory cell populations, and increased mucus production, indicating a regulatory role of NOTCH1 in preserving epithelial homeostasis and preventing excessive secretory differentiation."}], "pathway_id": "hsa04330", "pubmed_id": "41289377", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch signaling pathway, Notch signaling pathway genes (high expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "High expression of Notch pathway genes is associated with an immunosuppressive microenvironment and resistance to immune checkpoint inhibitors in gastrointestinal adenocarcinomas. This phenotype correlates with poor overall survival and elevated activity in angiogenesis, cell cycle progression, PI3K-AKT-mTOR signaling, TGF-beta signaling, and glycolysis. The Notch pathway contributes to tumor progression by suppressing pro-inflammatory immune cell infiltration and promoting resting/anti-inflammatory tumor-infiltrating immune cells."}], "pathway_id": "hsa04330", "pubmed_id": "41171465", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dichloroacetic Acid, RBPJ, Piezo1, PDK1 (upregulated), pyruvate dehydrogenase (inhibited), hypoxia-inducible factor 1-alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RBPJ mediates mechanotransduction-induced glycolytic reprogramming in macrophages by upregulating PDK1 expression, which inhibits pyruvate dehydrogenase (PDH), thereby promoting a metabolic shift toward glycolysis. This metabolic reprogramming supports M1-like macrophage polarization and contributes to inflammatory activation, which plays a role in the pathogenesis of thoracic aortic dissection."}], "pathway_id": "hsa04330", "pubmed_id": "41148245", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BDNF, NTRK2, TNF (reduced), IL18 (reduced), C1QA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BDNF activates the TRKB receptor, enhancing astrocyte survival and promoting neuroprotection. This signaling pathway mitigates neuronal damage and blood-brain barrier disruption, while also reducing pro-inflammatory cytokine production such as TNF and IL18. Activation of BDNF/TRKB signaling contributes to cognitive and motor recovery by preserving neuronal architecture and attenuating neuroinflammation."}], "pathway_id": "hsa04722", "pubmed_id": "41327445", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gnetin H (administration), Boro-Scopol, N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]benzo[b]thiophene-2-carboxamide, cAMP response element-binding protein (inhibited), brain-derived neurotrophic factor (inhibited), tropomyosin receptor kinase B, doublecortin, glial fibrillary acidic protein, ionized calcium-binding adapter molecule 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gnetin H promotes cell survival and enhances synaptic plasticity, as indicated by the preservation of long-term potentiation. It restores memory performance and cholinergic activity while reactivating CREB-BDNF signaling through the TrkB cascade. This signaling restoration supports hippocampal neurogenesis and reduces astrocytic and microglial reactivity. The involvement of TrkB is confirmed by the inhibition of CREB-BDNF signaling upon co-treatment with the TrkB antagonist ANA-12. Gnetin H also increases the number of DCX-positive neurogenic cells."}], "pathway_id": "hsa04722", "pubmed_id": "41241326", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, MECP2 (post-translational modifications), BDNF, microRNA 132, RYR1 (dysregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of MECP2 function leads to altered calcium ion signaling, which contributes to dendritic spine dysgenesis and altered excitation-inhibition balance. MECP2 regulates calcium-dependent transcriptional pathways, while calcium modulates MECP2 through post-translational modifications. BDNF and miR132 interact with MECP2 in a feedback regulatory axis, and dysregulation of RYR1 further perturbs calcium homeostasis. These molecular changes result in reduced structural plasticity and altered activity-driven gene expression, impairing neuronal connectivity."}], "pathway_id": "hsa04722", "pubmed_id": "41226529", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Fluorouracil, Cisplatin, K252a (administration), NTRK1 (elevated signaling), LNGFR, small interfering RNA (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated TrkA signaling promotes tumor growth and invasion in cutaneous squamous cell carcinoma (cSCC). TrkA inhibition reduces mitogenic and invasive markers, suppresses tumor progression, and decreases metastatic dissemination. This signaling pathway contributes to epidermal homeostasis and cancer cell survival. Inhibition of TrkA with K252a or siRNA mimics the antitumor effects of chemotherapeutics such as 5-fluorouracil and cisplatin."}], "pathway_id": "hsa04722", "pubmed_id": "41226473", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LRRK2, BDNF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "LRRK2 interacts with synaptic components and modulates the phosphorylation of key synaptic proteins. BDNF supports synapse maturation, maintenance, and plasticity through neurotrophic signaling. Impaired neurotrophic signaling disrupts synaptic function, contributing to synaptic dysfunction and neuronal degeneration."}], "pathway_id": "hsa04722", "pubmed_id": "41148193", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2,3,5,4'-Tetrahydroxystilbene 2-O-beta-D-glucoside, Cadmium (administration), Brain-Derived Neurotrophic Factor (activated), Tropomyosin Receptor Kinase B (activated), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (activated), Protein Kinase B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cadmium induces neurotoxicity through oxidative stress and inflammation, leading to microglial and astrocyte activation, neuronal damage, and impaired spatial learning and memory. 2,3,5,4'-Tetrahydroxystilbene-2-O-beta-D-glucoside mitigates these effects by activating the BDNF/TrkB and PI3K/Akt signaling pathways, which promote neuronal survival and reduce cytotoxic damage in both glial and neuronal cells."}], "pathway_id": "hsa04722", "pubmed_id": "41135432", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIRT3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of reactive oxygen species and mitochondrial dysfunction contribute to the progression of diabetic cardiomyopathy. SIRT3 modulates these processes by regulating mitochondrial metabolism and reducing oxidative stress, thereby influencing cardiac fibrosis and cardiomyocyte survival. Insulin resistance further exacerbates metabolic dysregulation and contractile dysfunction in cardiac tissue."}], "pathway_id": "hsa05415", "pubmed_id": "41287303", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nadide, SIRT3 (elevated activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated SIRT3 activity promotes mitochondrial function by deacetylating key metabolic enzymes and antioxidant proteins. This enhances cellular energy production and reduces reactive oxygen species accumulation, thereby mitigating oxidative stress and mitochondrial dysfunction associated with diabetic cardiomyopathy."}], "pathway_id": "hsa05415", "pubmed_id": "41276460", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDE4D, LGR6, IFI16, GDF11, TFEB, SFRP1, FGF21, TGR5, NR4A3, EZH2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cardiomyocyte fibrosis is associated with the activation of inflammatory pathways and the induction of programmed cell death mechanisms such as PANoptosis, cuproptosis, and ferroptosis. These processes are linked to mitochondrial dysfunction, which contributes to structural and functional cardiac alterations. Key regulators such as PDE4D, LGR6, IFI16, GDF11, TFEB, SFRP1, FGF21, TGR5, NR4A3, and EZH2 modulate these pathways and may influence the progression of diabetic cardiomyopathy through their roles in cellular signaling and metabolic regulation."}], "pathway_id": "hsa05415", "pubmed_id": "41183131", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, METTL14 (elevated expression), NLRP3 (increased stability), YTHDF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated METTL14 expression promotes m6A modification of NLRP3, which enhances NLRP3 protein stability. Increased NLRP3 stability contributes to pyrotoptic cell death, leading to myocardial damage in the context of diabetic cardiomyopathy. The m6A reader protein YTHDF1 mediates this effect by recognizing and stabilizing m6A-modified NLRP3 RNA."}], "pathway_id": "hsa05415", "pubmed_id": "41091242", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose (elevated levels), EGLN1 (upregulation), microtubule-associated protein 1 light chain 3B (LC3B), sequestosome 1 (SQSTM1).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of glucose induce endothelial dysfunction and impair myocardial angiogenesis in diabetic cardiomyopathy. EGLN1 upregulation under hyperglycemic conditions contributes to this angiogenesis defect. Inhibition of EGLN1 activates autophagy pathways, as indicated by increased conversion of LC3-I to LC3-II and reduced P62 levels, which in turn mitigates high glucose-induced endothelial dysfunction and restores angiogenesis in the diabetic heart."}], "pathway_id": "hsa05415", "pubmed_id": "41087486", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Beta-Lapachone, Temozolomide, NF-kappa B, RELA (nuclear translocation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of NF-kappa B signaling suppresses the nuclear translocation of RELA (p65), thereby reducing the transcriptional activity of the NF-kappa B complex. This suppression leads to decreased cell proliferation, inhibition of epithelial-mesenchymal transition, and reduced angiogenesis in glioblastoma cells."}], "pathway_id": "hsa04064", "pubmed_id": "41331117", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RPPH1, NFKB1 (phosphorylated), IL17A (upregulated), PLAC8 (activated), LRP12 (activated), CRABP2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RPPH1 enhances the phosphorylation of NFKB1 (NF-kappaB p65) and upregulates the expression of IL17A, leading to the activation of downstream oncogenic targets such as PLAC8, LRP12, and CRABP2. This promotes cell proliferation and suppresses apoptosis, contributing to the progression of acute myeloid leukemia through the NF-kappaB/Th17A signaling axis."}], "pathway_id": "hsa04064", "pubmed_id": "41324714", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin, Cyclophosphamide, Spautin-1 (administration), USP13, Ran (reduced stability), NF-kB.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "USP13 deubiquitinates Ran GTPase, stabilizing its protein levels through K11-linked ubiquitination modification. This interaction supports NF-kB signaling and contributes to chemoresistance in diffuse large B-cell lymphoma. Inhibition of USP13 with Spautin-1 reduces Ran stability and disrupts NF-kB activity, leading to increased reactive oxygen species (ROS) production, depletion of glutathione (GSH), and lipid peroxidation. These changes trigger ferroptosis, a form of regulated cell death, thereby enhancing the efficacy of chemotherapeutic agents like doxorubicin and cyclophosphamide."}], "pathway_id": "hsa04064", "pubmed_id": "41315297", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cardamonin (administration), 4'-Hydroxychalcone, Isoliquiritigenin, Xanthohumol, Tumor Necrosis Factor-alpha, RelA (nuclear translocation), Intercellular adhesion molecule 1 (expression), Nuclear factor kappa B inhibitor alpha (degradation), RelA cysteine 38 serine mutant (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tumor necrosis factor alpha activates the NF-kappa B signaling pathway, leading to the nuclear translocation of RelA and its binding to the ICAM-1 promoter, which promotes ICAM-1 expression. Cardamonin inhibits this process by preventing the nuclear translocation and DNA binding of RelA without affecting IkappaBalpha degradation. This inhibition is not mediated through covalent modification of cysteine 38 in RelA. Instead, cardamonin interacts with distinct sites on RelA, and mutations at these interaction sites abrogate TNF-alpha-induced nuclear translocation of RelA."}], "pathway_id": "hsa04064", "pubmed_id": "41302385", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ergosterol (administration), NFKB1 (Nuclear factor kappa B subunit 1), MAPK1 (Mitogen-activated protein kinase 1).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ergosterol suppresses the activation of the NF-kappaB signaling pathway, thereby reducing the transcription of pro-inflammatory mediators. Concurrently, it inhibits the MAPK pathway, which is involved in the regulation of extracellular matrix components such as collagen. This dual inhibition mitigates inflammation and prevents collagen matrix degradation, preserving extracellular matrix integrity and reducing oxidative stress-induced cellular damage."}], "pathway_id": "hsa04064", "pubmed_id": "41295413", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, protoporphyrin IX, Porphobilinogen, Hemin, ALAS1, ALAS2, PBGD, UROD, CPOX, FECH, ALAD, HMBS, Ferrochelatase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Heme biosynthesis begins with the condensation of glycine and succinyl-CoA to form 5-aminolevulinic acid (5-ALA) catalyzed by ALAS1 in the cytosol of most cells and ALAS2 in erythroid cells. 5-ALA is transported into mitochondria where it is converted to porphobilinogen (PBG) by ALAD. PBGD then catalyzes the formation of hydroxymethylbilane, which is cyclized to uroporphyrinogen III by UROD. Subsequent enzymatic steps, including those catalyzed by CPOX, HMBS, FECH, and Ferrochelatase, lead to the incorporation of iron into protoporphyrin IX to form heme. Disruption in any of these enzymes can lead to the accumulation of porphyrins and their precursors, resulting in clinical manifestations such as porphyria, oxidative stress, hepatic dysfunction, and neurotoxicity."}], "pathway_id": "hsa04064", "pubmed_id": "41294286", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TIPIN (phosphorylated), ATM, MDC1, NF-kappa B, c-FLIP (upregulated), CASP8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TIPIN is phosphorylated by ATM in response to DNA replication stress, which facilitates the recruitment of MDC1 to stalled replication forks. This interaction promotes ATM-dependent activation of the NF-kappa B signaling pathway. NF-kappa B activation leads to upregulation of the anti-apoptotic protein c-FLIP, which in turn inhibits caspase-8 activation and reduces cytotoxicity. Disruption of this signaling axis, such as through MDC1 depletion, impairs NF-kappa B activation, diminishes c-FLIP expression, and enhances caspase-8-mediated apoptosis. This mechanism contributes to the cellular response to DNA damage induced by topoisomerase inhibitors."}], "pathway_id": "hsa04064", "pubmed_id": "41291151", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Homo sapiens (human)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Honokiol (administration), CHUK (downregulated expression), Nuclear factor kappa B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Honokiol downregulates CHUK expression, which inhibits the activation of the NF-kappa B signaling pathway. Reduced NF-kappa B activity leads to suppressed transcription of genes involved in inflammation, immunity, and cell survival, thereby contributing to the antitumor effects observed in gastric cancer."}], "pathway_id": "hsa04064", "pubmed_id": "41290861", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HIF1A, FOXO, AKT3, EGFR, IL6, INS, MAPK1, MAPK3, PIK3R1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the HIF-1 and FoxO signaling pathways influences cognitive impairment through multiple molecular targets. These pathways interact with genes such as AKT3, EGFR, IL6, INS, MAPK1, MAPK3, and PIK3R1, which are involved in cellular signaling and regulation of metabolic and inflammatory processes. Dysregulation of these pathways contributes to the pathophysiology of depression-related cognitive dysfunction."}], "pathway_id": "hsa04066", "pubmed_id": "41326335", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-Butanol, Dexamethasone, HIF1A (activation), GPX4 (enhanced activity), ALPL, RUNX2 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the HIF-1alpha/GPX4 signaling pathway mitigates ferroptosis in bone marrow mesenchymal stem cells. This pathway enhances glutathione peroxidase 4 (GPX4) activity, which reduces lipid peroxidation and prevents cellular damage associated with ferroptosis. Concurrently, HIF-1alpha promotes osteogenic differentiation by upregulating key osteoblast markers such as ALPL and RUNX2. These combined effects contribute to the preservation of bone microstructure and the reversal of osteoporotic phenotypes."}], "pathway_id": "hsa04066", "pubmed_id": "41316326", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rhaponticin (administration), HIF1A (inhibited), PCNA (increased expression), CXCR4 (increased expression), BGLAP (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rhaponticin inhibits the expression of HIF1A, a key transcription factor in the HIF-1 signaling pathway, under hypoxic conditions. This suppression promotes the expression of PCNA, CXCR4, and BGLAP (osteocalcin), which are associated with cell proliferation, migration, and osteogenic differentiation. These effects contribute to enhanced alveolar bone repair and reduced gingival inflammation in periodontitis."}], "pathway_id": "hsa04066", "pubmed_id": "41315502", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), Oleic Acid (administration), Tetrandrine (administration), CCND1 (elevated levels), TGFB1 (elevated levels), CAT (reduced levels), ERBB2 (elevated levels), EGF (reduced levels), MMP9 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Quercetin, tetrandrine, and oleic acid modulate the HIF-1 signaling pathway by altering the expression of key regulatory genes and proteins. These compounds downregulate CCND1 and TGFB1 at both mRNA and protein levels, while upregulating CAT, suggesting a suppression of cell cycle progression and a reduction in oxidative stress. Additionally, quercetin downregulates ERBB2 and upregulates EGF, indicating a modulation of growth factor signaling. All three compounds also reduce MMP9 protein levels, which may inhibit extracellular matrix degradation and tumor invasion. Collectively, these effects contribute to the inhibition of cell proliferation, angiogenesis, and metabolic reprogramming under hypoxic conditions."}], "pathway_id": "hsa04066", "pubmed_id": "41305721", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HIF1A (activated), HIF1 (stabilized).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HIF1A is a subunit of the HIF1 transcription factor that becomes stabilized under hypoxic conditions. This stabilization allows HIF1 to regulate the expression of genes involved in vascular adaptation and oxygen homeostasis. Activation of HIF1A promotes vascular restructuring in response to low oxygen tension and contributes to the pathophysiology of ischemic cardiovascular diseases, including peripheral artery disease and coronary artery disease."}], "pathway_id": "hsa04066", "pubmed_id": "41303720", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HIF1A, ANGPTL4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HIF1A and ANGPTL4 regulate extracellular matrix degradation, inflammatory responses, and apoptosis in chondrocytes. These molecular changes contribute to the progression of osteoarthritis by promoting cartilage breakdown and cellular dysfunction."}], "pathway_id": "hsa04066", "pubmed_id": "41286526", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HIF1A (stabilized), CREBBP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Under hypoxic conditions, HIF-1 alpha subunit stabilizes and interacts with coactivators such as CREBBP to modulate transcriptional activity. HIF-1 acts as a master regulator of hypoxia-inducible genes, which encode proteins involved in oxygen delivery and adaptive responses to low oxygen. It contributes to chronic inflammation, immune microenvironment imbalance, extracellular matrix remodeling, epithelial-mesenchymal transition, angiogenesis, and epithelial differentiation. These processes are central to the pathogenesis of lung cancer with COPD (LC-COPD), indicating that HIF-1 signaling is a key driver of disease progression and poor prognosis in this condition."}], "pathway_id": "hsa04066", "pubmed_id": "41272363", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Formononetin (administration), Kaempferol (administration), Paeoniflorin (administration), Astragaloside (administration), HIF1A, VEGFA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Formononetin, kaempferol, paeoniflorin, and astragaloside modulate the HIF-1/VEGF signaling pathway to reduce synovitis. These compounds regulate immune and inflammatory responses by influencing the activity of HIF1A and VEGFA, thereby suppressing excessive inflammation in joint tissues."}], "pathway_id": "hsa04066", "pubmed_id": "41261625", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii, Cycloheximide, USP22 (elevated levels), HIF1A (increased stability), PATZ1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "USP22 binds to and stabilizes HIF-1alpha protein by deubiquitination, preventing its proteasomal degradation. PATZ1 transcriptionally activates USP22 by binding to its promoter, thereby increasing USP22 expression. Elevated USP22 levels lead to increased HIF-1alpha stability, which contributes to cardiomyocyte injury and cardiac dysfunction. This pathway promotes pathological cardiac remodeling and fibrosis."}], "pathway_id": "hsa04066", "pubmed_id": "41254007", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: neutrophil.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neutrophils, as a component of the innate immune system, migrate through endothelial cell layers to reach sites of inflammation. This transendothelial migration is facilitated by interactions between neutrophils and endothelial cells, enabling the cells to traverse the vascular endothelium in response to inflammatory signals."}], "pathway_id": "hsa04670", "pubmed_id": "41269551", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: VE-cadherin, PECAM1, NADPH oxidase (activated), Rac, matrix metalloproteinases (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Leukocytes extravasate through endothelial cells by forming membrane tunnels between adjacent endothelial cells. These tunnels are created as the leukocyte lifts the membrane of the upper endothelial cell while indenting and crawling over the membrane of the lower endothelial cell. This process involves actin polymerization and is associated with the regulation of endothelial junctions, including those mediated by VE-cadherin. Neutrophils preferentially use wider membrane overlaps as exit sites. The tunnel formation does not require PECAM-1 or VE-cadherin, but is influenced by endothelial cell signaling that affects junctional integrity and retraction. NADPH oxidase, activated via Rac, contributes to reactive oxygen species production and the activation of matrix metalloproteinases, which may facilitate the breakdown of VE-cadherin-mediated adhesion during the extravasation process."}], "pathway_id": "hsa04670", "pubmed_id": "40913770", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fibrins, THP-1, human umbilical vein endothelial cell, granulocyte-macrophage colony-stimulating factor (increased levels), interleukin-6 (increased levels), interleukin-10 (increased levels), interleukin-1 beta, tumor necrosis factor alpha (decreased levels), interleukin-12 subunit p40 (decreased levels), monocyte chemoattractant protein 1, interleukin-8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Human umbilical vein endothelial cells form a barrier that modulates monocyte migration. The presence of an endothelial cell barrier reduces the rate of monocyte transmigration in vitro. This barrier influences the secretion profile of inflammatory cytokines, with increased levels of interleukin-6, interleukin-10, and granulocyte-macrophage colony-stimulating factor, and decreased levels of tumor necrosis factor alpha and interleukin-12p40. These changes support the role of the endothelial barrier in regulating monocyte activation and migration during immune responses and tumor progression."}], "pathway_id": "hsa04670", "pubmed_id": "40673645", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Salicylic Acid (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rod-shaped salicylic acid-based polymeric particles reduce neutrophil transmigration across endothelial barriers, thereby decreasing neutrophil infiltration into inflamed tissues such as the lungs during acute lung injury. This reduction in transendothelial migration contributes to the mitigation of neutrophil-mediated inflammation."}], "pathway_id": "hsa04670", "pubmed_id": "40348611", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD4, CD8A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CD4+ and CD8+ T cells interact with the blood-brain barrier endothelial monolayer under physiological flow, facilitating transendothelial migration through a multistep extravasation cascade. This process involves immune cell infiltration into the central nervous system and is associated with neuroinflammatory conditions."}], "pathway_id": "hsa04670", "pubmed_id": "40230092", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KPNB1 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of endothelial cell-derived extracellular vesicles enriched in karyopherin subunit beta-1 (KPNB1) promote reverse transendothelial migration (rTEM) of neutrophils. This process facilitates abluminal-to-luminal migration of activated neutrophils across endothelial barriers, contributing to systemic inflammation and lung injury associated with sepsis and acute respiratory distress syndrome."}], "pathway_id": "hsa04670", "pubmed_id": "39119837", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Homo sapiens (human)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin, APLN, APJ, endothelial cell, immune cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin modulates the transendothelial migration of immune cells by inducing the internalization and desensitization of its receptor APJ in endothelial cells. This process reduces immune cell entry into the brain and limits leukocyte recruitment during neuroinflammation. Apelin also affects immune cell trafficking through the lung by modulating the expression of cell adhesion molecules involved in endothelial cell- immune cell interactions."}], "pathway_id": "hsa04670", "pubmed_id": "39060233", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Homo sapiens (human)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, PDE4, PDE4A, PDE4B, PDE4D.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate (cAMP) signaling in cardiomyocytes by hydrolyzing cAMP in subcellular compartments such as the sarcoplasmic reticulum, plasma membrane, and nuclear envelope. This activity modulates cardiomyocyte contractility, calcium handling, and hypertrophic responses, particularly during beta-adrenergic stimulation. PDE4 isoforms PDE4A, PDE4B, and PDE4D exhibit distinct subcellular localizations and contribute differentially to cardiac physiology and pathophysiology. Their compartmentalized activity ensures precise spatial and temporal control of cAMP signaling, which is essential for maintaining normal cardiac function and preventing maladaptive remodeling."}], "pathway_id": "hsa04261", "pubmed_id": "40136709", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Homo sapiens (human)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mavacamten (administration), ALPK3, ALPK3 truncation variant (truncation variant), cardiac troponin I, protein kinase A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ALPK3 truncation variants disrupt normal cardiac function, leading to hypertrophic cardiomyopathy and systolic dysfunction. These variants impair protein kinase A-mediated phosphorylation, including that of cardiac troponin I, which contributes to prolonged relaxation and increased diastolic calcium levels. Chronic adrenergic stimulation exacerbates hypertrophy in heterozygous carriers, suggesting a modulatory role of ALPK3 in adrenergic signaling pathways. Treatment with mavacamten partially restores contractile and calcium handling defects, indicating its potential therapeutic benefit in this condition."}], "pathway_id": "hsa04261", "pubmed_id": "40128237", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Homo sapiens (human)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Isoproterenol, Roflumilast, PDE4D (elevated expression), PDE4B, PINK1, PRKN, CREB1, SIRT1, PRKACA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated PDE4D expression reduces cAMP-PKA activity, which leads to suppressed CREB-SIRT1 signaling and inhibition of mitophagy. This results in increased oxidative stress, mitochondrial damage, and cardiomyocyte hypertrophy. PDE4D overexpression exacerbates these effects, while PDE4D inhibition or haploinsufficiency restores mitophagy and ameliorates cardiac hypertrophy and heart failure. PDE4B overexpression, in contrast, does not affect CREB-SIRT1 signaling or mitophagy but provides protection against oxidative stress and hypertrophy."}], "pathway_id": "hsa04261", "pubmed_id": "40015131", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbenoxolone (Administration), Gap junctions (Disrupted).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gap junctions facilitate direct intercellular communication between mesenchymal stromal cells and endothelial cells, promoting angiogenesis. Under hypoxic conditions, functional gap junctions support cell proliferation and migration. Disruption of gap junctions by carbenoxolone reduces the angiogenic potential and cellular activity of the conditioned medium."}], "pathway_id": "hsa04540", "pubmed_id": "41303722", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, 5'-Atp, Ins(1,4,5)P3, Apyrase, Carbenoxolone.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Calcium ion waves propagate through the human lens epithelium via a hybrid mechanism involving gap-junctional communication and ATP-mediated paracrine signaling. Gap junctions enable the direct diffusion of calcium and inositol 1,4,5-trisphosphate between adjacent cells, while extracellular ATP contributes to a partially regenerative signaling component. This dual-pathway mechanism supports coordinated cellular responses essential for maintaining ion homeostasis and tissue transparency."}], "pathway_id": "hsa04540", "pubmed_id": "41247130", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GJA5 (dysregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated or aberrant expression of GJA5 (Connexin 40) disrupts atrial electrical conduction and impairs cardiac electrical synchronization, contributing to the development of atrial fibrillation. GJA5 plays a critical role in intercellular communication through gap junction channels, and its dysregulation leads to structural and functional remodeling in atrial tissue."}], "pathway_id": "hsa04540", "pubmed_id": "41157922", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5'-Atp (released), L-Glutamic Acid (release), Connexin 43 (aberrantly activated hemichannels), Purinergic receptor P2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 43 (Cx43) forms gap junctions and hemichannels in astrocytes, facilitating ion homeostasis, metabolic support, and glial network signaling. Aberrant activation of Cx43 hemichannels disrupts calcium signaling, promotes the release of adenosine 5'-triphosphate and L-glutamic acid, and contributes to neuroinflammation. These effects are amplified through interactions with purinergic receptor P2, leading to a self-perpetuating pathological loop and reactive astrogliosis."}], "pathway_id": "hsa04540", "pubmed_id": "41062060", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: innexin, connexin, pannexin, connexin 43, connexin 36.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexins and pannexins form hemichannels that assemble into gap junctions, enabling the direct transfer of ions and small molecules between adjacent cells. Exposed transmembrane residues in TM1 and TM2 are more conserved than those in TM3 and TM4, particularly in connexins and pannexins. Residues within the extracellular extended hairpins of pannexins exhibit greater conformational flexibility compared to those in connexins, suggesting that structural rigidity in this region may be essential for hemichannel docking. Inter- and intra-hemichannel interface hotspots are conserved across the protein families, indicating their functional importance in gap junction assembly."}], "pathway_id": "hsa04540", "pubmed_id": "41061949", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Connexin 43 (Reduced activity), MYC, WNK1 (Expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 43 (Cx43) regulates c-MYC expression through modulation of WNK1 levels. Reduced Cx43 activity leads to decreased WNK1 expression, which in turn reduces c-MYC levels. This signaling axis contributes to the maintenance of cancer stem cell properties, including self-renewal and tumor initiation in glioblastoma."}], "pathway_id": "hsa04540", "pubmed_id": "40946315", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Potassium Cation (Exchange), Calcium Cation (Exchange), Connexin-43.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin-43 forms gap junction channels in astrocytes, facilitating the exchange of potassium and calcium ions between adjacent cells. These channels also mediate the transfer of neurotransmitters and inflammatory factors, contributing to intercellular communication in the brain. Disruption of Connexin-43-regulated gap junction function impairs both electrical and chemical signaling, which is associated with the progression of depression and altered neural homeostasis."}], "pathway_id": "hsa04540", "pubmed_id": "40913332", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, RYR2, GJA1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Calcium signals originating from the endoplasmic reticulum are mediated by ryanodine receptor 2 and propagate to neighboring cells through gap junctions formed by connexin 43. This mechanism facilitates intercellular communication during acute osmotic stress, contributing to the cellular response to hypotonic conditions."}], "pathway_id": "hsa04540", "pubmed_id": "40883966", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Homo sapiens (human)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp (transfer to adipocytes), Connexin 31, GJB3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Functional gap junctions between breast cancer cells and adipocytes enable the transfer of cyclic adenosine monophosphate (cAMP) from tumor cells to adipocytes. This cAMP signaling activates lipolysis in adipocytes in a gap junction-dependent manner. Connexin 31 (GJB3) facilitates this intercellular communication and promotes receptor triple-negative breast cancer growth and lipolysis activation in vivo. This direct interaction contributes to tumorigenesis."}], "pathway_id": "hsa04540", "pubmed_id": "40835606", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tirapazamine, AMFR, FAM134B (ubiquitinated), CRISPR-associated protein 9 (Cas9).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AMFR-mediated ubiquitination of FAM134B regulates endoplasmic reticulum-selective autophagy (ER-phagy) in hypoxia-adapted tumor cells. Inhibition of AMFR activity reduces FAM134B ubiquitination and suppresses ER-phagy. This disruption impairs hypoxia tolerance and leads to tumor growth inhibition, reduced metastasis, and enhanced immune response."}], "pathway_id": "hsa04141", "pubmed_id": "41250206", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-acetyl-alpha-D-galactosamine, GALNT6, HSPA5 (enhanced stability), ERN1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GALNT6 catalyzes the O-glycosylation of HSPA5 (GRP78/Bip) at threonine 203 by adding N-acetylgalactosamine, which enhances HSPA5 stability and facilitates its sustained interaction with ERN1 (IRE1) during endoplasmic reticulum stress. This interaction promotes persistent activation of the unfolded protein response, supporting tumor cell adaptation to ER stress and contributing to the proliferation of luminal-type breast cancer cells."}], "pathway_id": "hsa04141", "pubmed_id": "41197411", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DNAJC10, XBP1 (spliced (XBP1s)), EGFR (Promoter), SETD7, H3K4me3 (at the EGFR promoter), H3K4me1 (at the EGFR promoter), ERN1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNAJC10 suppresses EGFR transcription by inhibiting the splicing of XBP1 through the IRE1alpha branch of the UPR. XBP1s binds to the EGFR promoter and promotes the recruitment of SETD7 methyltransferase, leading to H3K4 methylation and enhanced gene expression. Inhibition of XBP1s splicing by DNAJC10 reduces H3K4me3 and H3K4me1 at the EGFR promoter, thereby decreasing EGFR expression. This suppression of EGFR transcription contributes to the inhibition of glioblastoma cell migration and invasion."}], "pathway_id": "hsa04141", "pubmed_id": "41191192", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, Doxorubicin, Protein Disulfide Isomerase A4 (elevated expression), Caspase-3, Tumor Protein p53 (wild-type), DNAJB12 (elevated expression), DNAJB14, Small Glutamine-rich Tetratricopeptide Repeat-containing Protein Alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ER stress induction activates the unfolded protein response (UPR), which promotes cancer cell chemoresistance. Under ER stress, PDIA4 redistributes from the endoplasmic reticulum to the cytosol, where it forms inhibitory interactions with caspase-3 and wild-type p53. This interaction attenuates the activity of both proteins, thereby inhibiting apoptosis and promoting cancer cell proliferation. The redistribution of PDIA4 is facilitated by DNAJB12, DNAJB14, and the cochaperone SGTA. Elevated expression of PDIA4 and DNAJB12 is associated with UPR activation in colorectal cancer."}], "pathway_id": "hsa04141", "pubmed_id": "41120732", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Spike glycoprotein, HCLS1-associated protein X-1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the unfolded protein response (UPR) is promoted by the interaction between the SARS-CoV-2 spike glycoprotein and the host protein HCLS1-associated protein X-1 (HAX1). This interaction limits the production of reactive oxygen species and reduces mitochondrial dysfunction, thereby helping to maintain host cell survival under conditions of endoplasmic reticulum stress."}], "pathway_id": "hsa04141", "pubmed_id": "40976714", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Homo sapiens (human)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vanadate (administration), TAP (conformational change), MHC-I, Binding immunoglobulin protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The transporter associated with antigen processing (TAP) facilitates the unidirectional transport of peptide antigens from the cytoplasm to the endoplasmic reticulum (ER) for loading onto major histocompatibility complex class I (MHC-I) molecules. TAP undergoes conformational changes driven by ATP binding and hydrolysis, transitioning from an inward-facing to an outward-facing state to enable peptide translocation and release into the ER lumen. Vanadate inhibits the transport cycle by trapping the transporter in a conformational intermediate. Excessive peptide accumulation in the ER activates the ER stress response. Trans-inhibition serves as a feedback mechanism to prevent overloading and ER stress."}], "pathway_id": "hsa04141", "pubmed_id": "40885191", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Baricitinib, Phospholipase D family member 4 (loss of function), Toll-like receptor 7 (excessive activation), Toll-like receptor 9 (excessive activation), Type I interferon.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss of function in Phospholipase D family member 4 results in impaired nucleic acid exonuclease activity. This leads to excessive activation of Toll-like receptors 7 and 9, which in turn hyperactivates downstream inflammatory signaling, particularly type I interferon signaling, in dendritic cells. This dysregulation promotes autoimmunity and expansion of plasmacytoid dendritic cells and plasma cells."}], "pathway_id": "hsa04072", "pubmed_id": "40931063", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TBC1D24 (upregulated), HIF1A (under hypoxia), ARF6, PLD (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hypoxia-inducible factor 1 alpha upregulates TBC1D24, which increases ARF6 expression and activates the phospholipase D signaling pathway. This activation promotes cell proliferation, tumor progression, and the acquisition of stem-like characteristics."}], "pathway_id": "hsa04072", "pubmed_id": "40790967", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid (exposure), Ginsenoside Rb1 (administration), Calcium Cation, 1-(6-(((17beta)-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione, 2-Aminoethoxydiphenyl borate, 1-(1-Naphthylmethyl)piperazine, U 73343, 2-(2-(4-(4-Nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate, Nifedipine, phospholipase C (activation), phospholipase D (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase C (PLC) and phospholipase D (PLD) mediate calcium ion (Ca) influx in vascular cells under conditions of palmitic acid exposure. In EA cells, activation of PLC facilitates Ca entry, whereas in MOVAS cells, PLD activation performs a similar function. Ginsenoside Rb1 modulates this process by restoring Ca influx impaired by palmitic acid, with distinct dependencies on PLC and PLD in different cell types. Inhibitors of PLC and PLD block Rb1-induced recovery, indicating a direct role of these enzymes in Ca signaling. Under normal conditions, Rb1 does not disrupt Ca homeostasis but influences phospholipid signaling pathways, leading to differential downstream effects in Ca regulation."}], "pathway_id": "hsa04072", "pubmed_id": "39970733", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (production), PLD2, mTOR (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased membrane tension activates phospholipase D2 (PLD2), which catalyzes the production of phosphatidic acid (PA). Phosphatidic acid directly stimulates the mammalian target of rapamycin (mTOR), promoting actin cytoskeleton remodeling and facilitating collective cell migration."}], "pathway_id": "hsa04072", "pubmed_id": "39939306", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Fluorouracil, GPLD1, PRSS8 (released), Wnt (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GPLD1 cleaves the GPI anchor of PRSS8, leading to the release of the protease from the plasma membrane. This release activates Wnt signaling and promotes the epithelial-mesenchymal transition in cancer cells, contributing to chemotherapy resistance and tumour relapse."}], "pathway_id": "hsa04072", "pubmed_id": "39743241", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (produced), phospholipase D, lysophosphatidic acid acyltransferase, mTOR complex 1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphatidic acid (PA) is produced by phospholipase D (PLD) and lysophosphatidic acid acyltransferase (LPAAT). PA functions as a cofactor for mTOR complex 1 (mTORC1), enhancing its activity. Activation of mTORC1 promotes tumor survival and contributes to resistance against platinum-based chemotherapeutics."}], "pathway_id": "hsa04072", "pubmed_id": "39716566", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CID 56972237, Phospholipase D1, Nuclear factor kappa B (activated), RELA proto-oncogene, NF-kB subunit.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D1 (PLD1) enhances nuclear factor kappa B (NF-B) activity by promoting the phosphorylation and nuclear translocation of RELA, a key subunit of NF-B. Activated NF-B, in turn, binds to the PLD1 promoter and increases its expression, forming a positive feedback loop. This interaction promotes cell proliferation, migration, and tumor growth in nasopharyngeal carcinoma. Inhibition of PLD1 with VU0155069 disrupts this loop and suppresses tumorigenesis."}], "pathway_id": "hsa04072", "pubmed_id": "38885836", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PLD1 (Active), ARL14, SNX1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ARL14 activates phospholipase D1 (PLD1), leading to the production of phosphatidic acid, a key second messenger in phospholipase D signaling. PLD1 activity is associated with membrane-associated signaling and cargo trafficking through the ESCRT-like complex containing SNX1."}], "pathway_id": "hsa04072", "pubmed_id": "38606629", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Homo sapiens (human)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0), RHOA, PLD1, MYH9, ZEB1 (suppressed), RHOA (phosphorylated at tyrosine 42) (phosphorylated at tyrosine 42), ROCK2, NCF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of RHOA at tyrosine 42 activates phospholipase D1 (PLD1), which catalyzes the production of phosphatidic acid (PA). PA binds to MYH9, promoting superoxide generation and the regulation of epithelial-mesenchymal transition (EMT) proteins. The RHOA-PLD1-MYH9 complex translocates to the nucleus and binds the ZEB1 promoter, suppressing ZEB1 mRNA expression and facilitating cell migration."}], "pathway_id": "hsa04072", "pubmed_id": "38275747", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Alpinetin (administration), Hypoxia-inducible factor 1 subunit alpha, Sequestosome 1, Src proto-oncogene tyrosine kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Alpinetin modulates mitophagy through interactions with HIF1A, SQSTM1, and SRC. These interactions contribute to the maintenance of mitochondrial homeostasis and neuroprotection in Parkinson's disease by regulating the selective degradation of dysfunctional mitochondria. This process supports the preservation of dopaminergic synaptic function and reduces neurodegeneration."}], "pathway_id": "hsa04137", "pubmed_id": "41331739", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Simvastatin (administration), Translocase of outer mitochondrial membrane 40 (reduced expression), Translocase of outer mitochondrial membrane 22 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of TOMM40 and TOMM22 leads to impaired mitochondrial function, characterized by decreased oxidative capacity, elevated superoxide production, and altered mitochondrial morphology. These changes are accompanied by increased mitophagy. Simvastatin exposure results in similar mitochondrial impairments through downregulation of TOMM40 and TOMM22, contributing to the development of myopathy."}], "pathway_id": "hsa04137", "pubmed_id": "41303460", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, Gemcitabine, TUBB6 (overexpression), CAT (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of TUBB6 in macrophages enhances lung adenocarcinoma cell proliferation, migration, and invasion through secreted factors. Conversely, increased CAT expression is associated with improved overall survival and a more favorable immune microenvironment. The interplay between TUBB6 and CAT influences macrophage mitophagy and tumor progression, with TUBB6 overexpression promoting malignant behavior and CAT potentially counteracting these effects."}], "pathway_id": "hsa04137", "pubmed_id": "41266404", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Obacunone (administration), 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone, PARP1 (expression), SIRT1 (expression), PINK1 (expression), PRKN (expression), MAP1LC3B (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Obacunone suppresses PARP1 expression while upregulating SIRT1, PINK1, Parkin, and LC3II, leading to the activation of mitophagy. This process reduces mitochondrial reactive oxygen species (mtROS) production, enhances cell viability, and decreases apoptosis in colonic epithelial cells. Inhibition of mitophagy or overexpression of PARP1 counteracts these protective effects, suggesting a direct role of the PARP1/SIRT1 signaling pathway in modulating mitophagy and cellular damage."}], "pathway_id": "hsa04137", "pubmed_id": "41253476", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Foenumoside B (administration), 3-Methyladenine, PINK1, Parkin, AMPK (activation), Phospho-AMPK (phosphorylation), Nrf2 (phosphorylation), Heme Oxygenase 1 (activation), Kelch-like ECH-associated protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Foenumoside B activates PINK1/Parkin-dependent mitophagy in alveolar epithelial cells, promoting the selective degradation of damaged mitochondria. This process is mediated through the activation of AMPK, which increases the phosphorylation state of AMPK and facilitates mitophagy. AMPK also enhances Nrf2 activity by promoting its phosphorylation and binding to the antioxidant response element (ARE) at the HO-1 promoter, while reducing Keap1-mediated degradation. This coordinated activation of mitophagy and Nrf2/HO-1 signaling reduces mitochondrial reactive oxygen species (mtROS) and restores cellular redox balance, thereby attenuating oxidative stress and associated pathological outcomes such as inflammation and fibrosis."}], "pathway_id": "hsa04137", "pubmed_id": "41239805", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Homo sapiens (human)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose (elevated levels), CASP8 (upregulated), COL1A1 (upregulated), Mitophagy-related proteins (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of D-glucose induce mitochondrial dysfunction and enhance mitophagy activity in retinal pigment epithelial cells. This process involves the upregulation of CASP8 and COL1A1, along with increased expression of mitophagy-related proteins and enhanced mitochondria-lysosome colocalization. These changes contribute to the pathogenesis of proliferative diabetic retinopathy and are associated with immune cell infiltration."}], "pathway_id": "hsa04137", "pubmed_id": "41234227", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (reduced clearance), Toll-like receptor 4, Nuclear factor kappa B, PEX5, DNMT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4-NF-B signaling downregulates PEX5 expression by upregulating DNMT1, leading to impaired peroxisome biogenesis and dysfunction. Peroxisomal dysfunction reduces the capacity to clear hydrogen peroxide and promotes epithelial-to-mesenchymal transition, thereby accelerating renal allograft fibrosis."}], "pathway_id": "hsa04146", "pubmed_id": "41092575", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bafilomycin A1 (administration), PEX14, OPTN, LC3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PEX14 serves as a docking site for OPTN on the peroxisomal membrane, facilitating the recruitment of the autophagic machinery to initiate pexophagy. The interaction between PEX14 and OPTN involves the coiled-coil domain of PEX14 and the ubiquitin-binding domain of OPTN. Colocalization of the PEX14-OPTN complex with LC3 indicates the involvement of the autophagy pathway in peroxisome degradation. Bafilomycin A1 inhibits this degradation, suggesting that the process is dependent on autophagic flux."}], "pathway_id": "hsa04146", "pubmed_id": "41071103", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide, Cholesterol, Catalase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysfunctional peroxisomes lead to mislocalization of catalase, resulting in excessive hydrogen peroxide accumulation. This oxidative stress triggers pexophagy and subsequent cholesterol accumulation in lysosomes, which contributes to the upregulation of pro-inflammatory cytokine production."}], "pathway_id": "hsa04146", "pubmed_id": "40856297", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PEX3, PEX16, PEX19.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Peroxisome biogenesis involves the coordinated action of early peroxins such as PEX3, PEX16, and PEX19, which initiate the formation of peroxisomal membranes. PEX19 facilitates the recognition, targeting, and insertion of membrane proteins at PEX3. Matrix proteins are transported via peroxisomal targeting signals to the peroxisomal membrane. Peroxisomes can multiply through growth and division from preexisting organelles, or through de novo synthesis from pre-peroxisomal vesicles. De novo synthesis involves a stepwise maturation process, though its physiological relevance remains under investigation. These organelles are essential for fatty acid oxidation, ether lipid biosynthesis, and free radical detoxification."}], "pathway_id": "hsa04146", "pubmed_id": "40855687", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (increased levels), CROT (overactivation), NRF2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CROT overactivation within peroxisomes drives chemoresistance in non-small cell lung cancer cells by modulating fatty acid oxidation and oxidative stress pathways. CROT promotes the production of hydrogen peroxide and reactive oxygen species, which stabilizes NRF2 by preventing its ubiquitination and degradation. This stabilization leads to increased nuclear translocation of NRF2, thereby inhibiting chemotherapy-induced ferroptosis. The resulting suppression of ferroptosis contributes to the resistance of cancer cells to chemotherapeutic agents."}], "pathway_id": "hsa04146", "pubmed_id": "40818823", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Homo sapiens (human)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PEX39, PEX7, PEX13.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PEX39 facilitates the peroxisomal import of proteins containing a type 2 peroxisomal targeting signal (PTS2) by binding to PEX7 and stabilizing its interaction with cargo proteins. PEX39 and PEX13, a peroxisomal membrane translocon protein, both contain an (R/K)PWE motif essential for PEX7 binding. This interaction enables the handover of PEX7 from the cytosolic PEX39 to the membrane-bound PEX13, supporting the import of PTS2-containing proteins into peroxisomes. Disruption of this mechanism may contribute to peroxisomal disease."}], "pathway_id": "hsa04146", "pubmed_id": "40739340", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Central carbon metabolism in cancer - Homo sapiens (human)\n**Pathway Description**: Malignant transformation of cells requires specific adaptations of cellular metabolism to support growth and survival. In the early twentieth century, Otto Warburg established that there are fundamental differences in the central metabolic pathways operating in malignant tissue. He showed that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even under normal oxygen concentrations (Warburg's Effects). More recently, it has been recognized that the 'Warburg effect' encompasses a similarly increased utilization of glutamine. From the intermediate molecules provided by enhanced glycolysis and glutaminolysis, cancer cells synthesize most of the macromolecules required for the duplication of their biomass and genome. These cancer-specific alterations represent a major consequence of genetic mutations and the ensuing changes of signalling pathways in cancer cells. Three transcription factors, c-MYC, HIF-1 and p53, are key regulators and coordinate regulation of cancer metabolism in different ways, and many other oncogenes and tumor suppressor genes cluster along the signaling pathways that regulate c-MYC, HIF-1 and p53.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Uridine, D-Ribose, UPP1 (decreased levels), METTL3 (reduced activity), KLF5 (increased expression), YTHDC1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of UPP1 catalyzes the conversion of uridine to ribose, which supports central carbon metabolism and enhances aerobic glycolysis in tumor cells. UPP1 expression is transcriptionally repressed by KLF5. KLF5 levels are regulated by the m6A-YTHDC1 complex, which is modulated by METTL3. Reduced METTL3 activity decreases m6A modification in the 3'UTR of KLF5, leading to reduced interaction with YTHDC1 and increased KLF5 expression. This regulatory cascade results in decreased UPP1 levels, impairing aerobic glycolysis and tumor malignancy."}], "pathway_id": "hsa05230", "pubmed_id": "41173378", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Central carbon metabolism in cancer - Homo sapiens (human)\n**Pathway Description**: Malignant transformation of cells requires specific adaptations of cellular metabolism to support growth and survival. In the early twentieth century, Otto Warburg established that there are fundamental differences in the central metabolic pathways operating in malignant tissue. He showed that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even under normal oxygen concentrations (Warburg's Effects). More recently, it has been recognized that the 'Warburg effect' encompasses a similarly increased utilization of glutamine. From the intermediate molecules provided by enhanced glycolysis and glutaminolysis, cancer cells synthesize most of the macromolecules required for the duplication of their biomass and genome. These cancer-specific alterations represent a major consequence of genetic mutations and the ensuing changes of signalling pathways in cancer cells. Three transcription factors, c-MYC, HIF-1 and p53, are key regulators and coordinate regulation of cancer metabolism in different ways, and many other oncogenes and tumor suppressor genes cluster along the signaling pathways that regulate c-MYC, HIF-1 and p53.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose (elevated consumption), L-Lactic Acid (production), L-Glutamine (upregulated metabolism), MYC, HIF1A, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated glucose consumption in melanoma cells drives increased glycolytic activity, resulting in the production of lactic acid even under normoxic conditions, a hallmark of the Warburg effect. Concurrently, glutamine metabolism is upregulated, supporting biosynthetic processes necessary for rapid cell proliferation. The transcription factors MYC, HIF1A, and TP53 coordinate the metabolic reprogramming by modulating glycolysis, glutaminolysis, and oxidative phosphorylation. This metabolic shift enhances energy production, macromolecule synthesis, and adaptation to hypoxic and nutrient-deprived tumor microenvironments. Altered lipid and one-carbon metabolism further contribute to nucleotide biosynthesis and redox homeostasis. Additionally, melanoma cells exploit metabolic crosstalk with immune cells by competing for nutrients and producing immunosuppressive metabolites, thereby promoting immune evasion and resistance to therapy."}], "pathway_id": "hsa05230", "pubmed_id": "40945210", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Central carbon metabolism in cancer - Homo sapiens (human)\n**Pathway Description**: Malignant transformation of cells requires specific adaptations of cellular metabolism to support growth and survival. In the early twentieth century, Otto Warburg established that there are fundamental differences in the central metabolic pathways operating in malignant tissue. He showed that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even under normal oxygen concentrations (Warburg's Effects). More recently, it has been recognized that the 'Warburg effect' encompasses a similarly increased utilization of glutamine. From the intermediate molecules provided by enhanced glycolysis and glutaminolysis, cancer cells synthesize most of the macromolecules required for the duplication of their biomass and genome. These cancer-specific alterations represent a major consequence of genetic mutations and the ensuing changes of signalling pathways in cancer cells. Three transcription factors, c-MYC, HIF-1 and p53, are key regulators and coordinate regulation of cancer metabolism in different ways, and many other oncogenes and tumor suppressor genes cluster along the signaling pathways that regulate c-MYC, HIF-1 and p53.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamine, Telaglenastat, Glutathione, ASNS (induction), GLS, mTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of ASNS promotes glutaminolysis and glutathione synthesis through metabolic reprogramming of glutamine metabolism, which supports intracellular redox homeostasis. This metabolic adaptation activates the mTOR signaling pathway, enhancing hepatocellular carcinoma progression. ASNS overexpression also supports cell proliferation, migration, and invasion. Inhibition of glutaminase with CB-839 disrupts amino acid metabolism and induces oxidative stress and apoptosis in HCC cells. However, ASNS induction in response to glutaminase inhibition attenuates these effects, thereby reducing the sensitivity of HCC cells to CB-839."}], "pathway_id": "hsa05230", "pubmed_id": "40779838", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine (hydrolyzed), Choline (produced), Acetate (produced), D-Glucose, Choline O-Acetyltransferase, Vesicular Acetylcholine Transporter, Solute Carrier Family 5 Member 5, Acetylcholinesterase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acetylcholine (ACh) is synthesized from choline and acetyl-CoA by choline O-acetyltransferase (ChAT) and packaged into synaptic vesicles via the vesicular acetylcholine transporter (VAChT). Upon release into the synaptic cleft, ACh binds to postsynaptic receptors, facilitating signal transmission. The high-affinity choline transporter SLC5A5 (CHT-1) recycles choline for reuse in ACh synthesis. Acetylcholinesterase (AChE) hydrolyzes ACh into choline and acetate, terminating the synaptic signal. The availability of glucose and choline can limit ACh synthesis and release, especially under conditions of high synaptic activity. These processes are central to the function of cholinergic synapses in learning, memory, and motor control."}], "pathway_id": "hsa04725", "pubmed_id": "41096935", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bisphenol A (exposure), ACHE, SLC5A7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bisphenol A exposure alters the expression of synaptic proteins and disrupts synaptic integrity in cholinergic neurons. This leads to reduced neuritic complexity and impaired synaptic function, potentially affecting cholinergic signaling through altered acetylcholine metabolism and choline uptake by the choline transporter. These changes may compromise the efficiency of cholinergic neurotransmission and contribute to neurodevelopmental and cognitive impairments."}], "pathway_id": "hsa04725", "pubmed_id": "41051886", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine, Acetylcholinesterase, Choline transporter, Nicotinic acetylcholine receptor, Muscarinic acetylcholine receptor, Phospholipase C, Inositol trisphosphate (modulating intracellular signaling), Cyclic adenosine monophosphate (modulating intracellular signaling), Calcium ion, Sodium ion.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acetylcholine binds to nicotinic and muscarinic acetylcholine receptors, triggering rapid sodium and calcium influx or modulating intracellular signaling through phospholipase C, inositol trisphosphate, and cyclic AMP pathways. Acetylcholinesterase hydrolyzes acetylcholine into choline and acetate, which is reuptaken via the choline transporter. Disruption of this pathway leads to impaired synaptic transmission, altered long-term potentiation and depression, and cholinergic neurodegeneration, contributing to cognitive and memory deficits."}], "pathway_id": "hsa04725", "pubmed_id": "40514243", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acetylcholine functions as a neurotransmitter and modulator in the central nervous system, influencing cognitive functions such as long-term and short-term memory, limbic activation, and alertness."}], "pathway_id": "hsa04725", "pubmed_id": "40340063", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: neuroligin, neurexin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuroligins and neurexins participate in the formation and stabilization of enteric synapses by recruiting presynaptic and postsynaptic elements, respectively. Alternative splicing of these proteins contributes to synaptic specificity, with certain isoforms preferentially promoting cholinergic synapse formation while others support serotonergic synaptogenesis. Soluble neurexin interferes with neurexin-neuroligin interactions, inhibiting synapse formation and neurotransmitter receptor recruitment."}], "pathway_id": "hsa04725", "pubmed_id": "40327378", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Homo sapiens (human)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine, MuSK (phosphorylated), CaMK2B (absence), acetylcholine receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MuSK regulates acetylcholine receptor clustering at the postsynapse. Phosphorylation of MuSK by CaMK2beta occurs in heterologous cells. However, absence of CaMK2beta in muscle cells leads to reduced acetylcholine receptor clustering. Despite this, MuSK phosphorylation remains unaffected, indicating compensatory mechanisms by other CaMK2 paralogs at the neuromuscular junction. Loss of CaMK2beta is not directly linked to synapse fragmentation or delayed muscle development."}], "pathway_id": "hsa04725", "pubmed_id": "40295530", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TTN, TTN truncating variants, ADRB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Truncating variants in the TTN gene lead to the production of truncated titin isoforms, resulting in structural and functional abnormalities in cardiac muscle. These variants are associated with dilated cardiomyopathy and can manifest through both haploinsufficiency and toxic gain-of-function mechanisms. The altered titin protein disrupts normal sarcomere architecture and function, contributing to impaired left ventricular contractility and eventual heart failure. Beta1-adrenergic receptor signaling may further exacerbate cardiac dysfunction by increasing intracellular cAMP and Ca2+ levels, potentially leading to arrhythmias and progressive myocardial damage."}], "pathway_id": "hsa05414", "pubmed_id": "41329234", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CAST (deficiency), calpastatin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in calpastatin, encoded by the CAST gene, leads to dysregulation of calpain activity. This results in structural abnormalities in cardiomyocytes, including hypertrophy, nuclear enlargement, and fibrosis, contributing to the development of dilated cardiomyopathy."}], "pathway_id": "hsa05414", "pubmed_id": "41300744", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LMNA (pathogenic variants), TTN (pathogenic variants).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pathogenic variants in LMNA and TTN contribute to the development of dilated cardiomyopathy by disrupting cardiac structural integrity and sarcomeric function. Epigenetic mechanisms such as DNA methylation, histone modifications, and chromatin remodeling regulate gene expression patterns in cardiomyocytes, influencing both genetic and environmental contributions to the disease. Altered epigenetic regulation and noncoding RNA activity can lead to impaired cardiac contractility, progressive ventricular dilation, and ultimately heart failure."}], "pathway_id": "hsa05414", "pubmed_id": "41265985", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KLF13, ACTC1 (increased expression), MYH7 (increased expression), ANP (increased expression), GATA4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KLF13 regulates the expression of ACTC1 and MYH7 through transactivation. A truncating mutation at position Tyr178 in KLF13 reduces its ability to transactivate these genes, leading to impaired cardiac function and contributing to the development of dilated cardiomyopathy. Additionally, the Tyr178* mutation diminishes the synergistic transactivation of ANP by KLF13 and GATA4, further affecting cardiac gene regulation."}], "pathway_id": "hsa05414", "pubmed_id": "41201692", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRYAB (mutated), ADRB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the CRYAB gene, such as the p.Arg123Gln variant, disrupt the function of the alpha-B crystallin protein, which plays a role in maintaining cardiac muscle integrity and preventing protein aggregation under stress. This disruption leads to impaired sarcomere stability and may contribute to dilated cardiomyopathy. Additionally, altered beta-adrenergic signaling, involving the beta1-adrenergic receptor (ADRB1), can increase intracellular cAMP and Ca2+ levels, potentially causing arrhythmias and further cardiac dysfunction, which may manifest as prolonged QT interval and long QT syndrome. The combination of these effects results in overlapping clinical features of both dilated cardiomyopathy and arrhythmia."}], "pathway_id": "hsa05414", "pubmed_id": "41153379", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferrostatin-1 (Administration), Resveratrol (Administration), Glucose-6-phosphate dehydrogenase (Dysregulation), Protein phosphatase 1 catalytic subunit gamma (Dysregulation), Myelin basic protein (Dysregulation), Lymphocyte-specific protein 1 (Dysregulation), High-mobility group nucleosome-binding domain 1 (Dysregulation), High-mobility group nucleosome-binding domain 2 (Dysregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulation of lactylation-related genes such as G6PD, PPP1CC, MBP, LSP1, HMGN1, and HMGN2 contributes to the pathogenesis of dilated cardiomyopathy. These genes are implicated in immunometabolic remodeling and cardiac tissue dysfunction. Ferrostatin-1 and Resveratrol interact with core lactylation-related genes to modulate cellular stress responses and metabolic pathways, influencing cardiac structure and function. Lactylation-driven gene expression patterns are associated with molecular subtypes of dilated cardiomyopathy, revealing a role for lactate metabolism in immune regulation and disease progression."}], "pathway_id": "hsa05414", "pubmed_id": "41137708", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: N-Glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: N-glycans or asparagine-linked glycans are major constituents of glycoproteins in eukaryotes. N-glycans are covalently attached to asparagine with the consensus sequence of Asn-X-Ser/Thr by an N-glycosidic bond, GlcNAc b1- Asn. Biosynthesis of N-glycans begins on the cytoplasmic face of the ER membrane with the transferase reaction of UDP-GlcNAc and the lipid-like precursor P-Dol (dolichol phosphate) to generate GlcNAc a1- PP-Dol. After sequential addition of monosaccharides by ALG glycosyltransferases [MD:M00055], the N-glycan precursor is attached by the OST (oligosaccharyltransferase) complex to the polypeptide chain that is being synthesized and translocated through the ER membrane. The protein-bound N-glycan precursor is subsequently trimmed, extended, and modified in the ER and Golgi by a complex series of reactions catalyzed by membrane-bound glycosidases and glycosyltransferases. N-glycans thus synthesized are classified into three types: high-mannose type, complex type, and hybrid type. Defects in N-glycan biosynthesis lead to a variety of human diseases known as congenital disorders of glycosylation [DS:H00118 H00119].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (Elevated levels), protoporphyrin IX (Accumulation), ALAS1, ALAS2, ALAD, PBGD, UROD, CPOX, PPOX, FECH, ALAS, UROS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) and protoporphyrin IX in blood and urine are associated with disruptions in heme biosynthesis. The accumulation of these intermediates is primarily due to inherited deficiencies in enzymes such as ALAS1, ALAS2, ALAD, PBGD, UROD, CPOX, PPOX, and FECH, which catalyze sequential steps in the heme synthesis pathway. Defects in these enzymes lead to the accumulation of delta-aminolevulinic acid and protoporphyrin IX, which can cause photosensitivity, neurological dysfunction, and other clinical manifestations of porphyria. Protoporphyrin accumulation in erythrocytes is a hallmark of erythropoietic protoporphyria, while the buildup of 5-ALA and porphobilinogen is characteristic of acute intermittent porphyria."}], "pathway_id": "hsa00510", "pubmed_id": "41125172", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: N-Glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: N-glycans or asparagine-linked glycans are major constituents of glycoproteins in eukaryotes. N-glycans are covalently attached to asparagine with the consensus sequence of Asn-X-Ser/Thr by an N-glycosidic bond, GlcNAc b1- Asn. Biosynthesis of N-glycans begins on the cytoplasmic face of the ER membrane with the transferase reaction of UDP-GlcNAc and the lipid-like precursor P-Dol (dolichol phosphate) to generate GlcNAc a1- PP-Dol. After sequential addition of monosaccharides by ALG glycosyltransferases [MD:M00055], the N-glycan precursor is attached by the OST (oligosaccharyltransferase) complex to the polypeptide chain that is being synthesized and translocated through the ER membrane. The protein-bound N-glycan precursor is subsequently trimmed, extended, and modified in the ER and Golgi by a complex series of reactions catalyzed by membrane-bound glycosidases and glycosyltransferases. N-glycans thus synthesized are classified into three types: high-mannose type, complex type, and hybrid type. Defects in N-glycan biosynthesis lead to a variety of human diseases known as congenital disorders of glycosylation [DS:H00118 H00119].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Galactose (added), Tris(hydroxymethyl)aminomethane (added), Manganese chloride.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Galactose incorporation into N-glycans is influenced by the presence of galactose and manganese chloride in the culture medium. Tris(hydroxymethyl)aminomethane modulates the incorporation of mannose and fucose during N-glycan biosynthesis. The concurrent use of tris(hydroxymethyl)aminomethane and galactose does not interfere with N-glycan modifications and does not negatively affect cell growth or antibody quality. These factors collectively regulate the glycosylation profile of bispecific antibodies, enabling closer resemblance to reference therapeutic monoclonal antibodies."}], "pathway_id": "hsa00510", "pubmed_id": "41016687", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: N-Glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: N-glycans or asparagine-linked glycans are major constituents of glycoproteins in eukaryotes. N-glycans are covalently attached to asparagine with the consensus sequence of Asn-X-Ser/Thr by an N-glycosidic bond, GlcNAc b1- Asn. Biosynthesis of N-glycans begins on the cytoplasmic face of the ER membrane with the transferase reaction of UDP-GlcNAc and the lipid-like precursor P-Dol (dolichol phosphate) to generate GlcNAc a1- PP-Dol. After sequential addition of monosaccharides by ALG glycosyltransferases [MD:M00055], the N-glycan precursor is attached by the OST (oligosaccharyltransferase) complex to the polypeptide chain that is being synthesized and translocated through the ER membrane. The protein-bound N-glycan precursor is subsequently trimmed, extended, and modified in the ER and Golgi by a complex series of reactions catalyzed by membrane-bound glycosidases and glycosyltransferases. N-glycans thus synthesized are classified into three types: high-mannose type, complex type, and hybrid type. Defects in N-glycan biosynthesis lead to a variety of human diseases known as congenital disorders of glycosylation [DS:H00118 H00119].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mannose 6-phosphate, IDUA (administration), M6PR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mannose 6-phosphate-containing N-glycans facilitate lysosomal targeting by binding to mannose 6-phosphate receptors, which mediate endocytosis and lysosomal delivery of glycoproteins. Phosphorylated N-glycans on iduronate-2-sulfatase enable high-affinity receptor interaction, supporting its efficient cellular uptake and therapeutic function in enzyme replacement therapy for mucopolysaccharidosis type II."}], "pathway_id": "hsa00510", "pubmed_id": "40782865", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Homo sapiens (human)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trans-2,3',4,5'-tetrahydroxystilbene, Resveratrol, Melanocortin 1 Receptor, Cyclic AMP, Microphthalmia-Associated Transcription Factor, Tyrosinase, Cell Division Cycle 42, Ras-Related Protein RAB-17, RAB11B, Member RAS Oncogene Family, RAC1, Ras-Related C3 Botulinum Toxin Substrate 1, Kinesin Family Member 5B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Oxyresveratrol suppress melanogenesis by down-regulating the MC1R/cAMP/MITF signaling pathway, which reduces the transcription of tyrosinase and other melanogenic enzymes. Oxyresveratrol also inhibits dendrite formation and melanosome transport through the down-regulation of small GTPases (CDC42, RAB17, RAB11B, RAC1) and the kinesin KIF5B, thereby reducing melanin transfer to keratinocytes."}], "pathway_id": "hsa04916", "pubmed_id": "40594379", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Homo sapiens (human)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fraxinol (administration), Tiliroside (administration), Morin (administration), Naringenin (administration), TYR (activated), Melanogenesis (increased).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fraxinol, tribuloside, morin, and naringenin upregulate melanogenesis and tyrosinase (TYR) activity through multiple signaling pathways. These compounds promote melanin synthesis, melanosome maturation, and transportation. Increased melanogenesis contributes to the restoration of pigmentation in hair, counteracting the phenotypic outcome of grey hair."}], "pathway_id": "hsa04916", "pubmed_id": "40457938", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Homo sapiens (human)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epigallocatechin Gallate (administration), Glabridin (administration), MITF (activity), microRNA (modulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Epigallocatechin-3-gallate and Glabridin synergistically interact with microphthalmia-related transcription factor (MITF) to inhibit melanogenesis. This interaction is mediated through the modulation of microRNA expression, which in turn suppresses excessive melanin production by downregulating MITF activity."}], "pathway_id": "hsa04916", "pubmed_id": "40407219", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Homo sapiens (human)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melanins, CALM2 (altered expression), KIT (altered expression), OCA2 (down-regulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impaired melanogenesis is associated with vitiligo, a condition characterized by melanocyte destruction and skin depigmentation. Disruption in melanin biosynthesis pathways, including REACTOME_MELANIN_BIOSYNTHESIS and KEGG_MELANOGENESIS, correlates with reduced melanin production. Down-regulation of key melanogenesis-related genes such as OCA2, along with altered expression of CALM2 and KIT, contributes to this disruption. Increased infiltration of T helper and Th2 immune cells further exacerbates melanocyte loss, linking immune dysregulation with impaired melanin synthesis."}], "pathway_id": "hsa04916", "pubmed_id": "40052928", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ORAOV1 (expression), PDCD1 (upregulation), PDCD1LG1 (upregulation), CTLA4 (upregulation), TPCN2 (co-expression), CCND1 (co-expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ORAOV1 expression promotes immunosuppressive tumor microenvironment formation by enhancing infiltration of regulatory T cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts. It also drives upregulation of immune checkpoint markers PDCD1 (PD-1), PDCD1LG1 (PD-L1), and CTLA4 (CTLA-4), contributing to immune evasion and resistance to immunotherapy. Co-expression with oncogenes TPCN2 and CCND1 further supports its role in tumor progression and immune modulation."}], "pathway_id": "hsa05235", "pubmed_id": "41321947", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Phenylnicotinic acid, MCTP2 (elevated expression), PDCD1LG1 (increased levels), CTLA4 (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated MCTP2 expression is associated with increased PD-L1 (PDCD1LG1) and CTLA-4 (CTLA4) levels, contributing to immune suppression in glioblastoma. High MCTP2 expression also correlates with drug resistance, particularly to SB52334. This resistance can be mitigated by combining MCTP2 knockdown with SB52334 treatment, reducing clonogenic potential and organoid viability. These findings indicate that MCTP2 facilitates immune evasion and drug resistance, potentially through upregulation of immune checkpoint molecules."}], "pathway_id": "hsa05235", "pubmed_id": "41291342", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: METTL14 (altered levels), PDCD1 (expression), CD274 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "METTL14 modulates the expression of PD-1 and PD-L1, key components of the immune checkpoint pathway. This regulation contributes to immune escape and therapeutic resistance in tumor cells. Altered METTL14 levels influence T cell differentiation and the tumor immune microenvironment, promoting tumor progression."}], "pathway_id": "hsa05235", "pubmed_id": "41164187", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDCD1LG1, PDCD1LG2, PDCD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PD-L1 and PD-L2 expressed by tumor cells and tumor-infiltrating immune cells interact with PD-1 on T cells to suppress T cell activation and effector functions, thereby contributing to immune evasion in endometrial carcinoma. Elevated PD-L1 and PD-L2 expression is associated with increased tumor-infiltrating lymphocytes, high tumor grade, non-endometrioid histology, and advanced tumor stage, suggesting a compensatory upregulation of immune checkpoint ligands in response to immune pressure."}], "pathway_id": "hsa05235", "pubmed_id": "41148619", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Kynurenine, EZH2 (Enhancer of Zeste Homolog 2), PDCD1LG1 (Programmed Death-Ligand 1), PDCD1 (Programmed Cell Death 1), CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4), JAK1 and JAK2 (Janus Kinase 1 and 2), B2M (Beta-2-Microglobulin), LAG3 (Lymphocyte-Activation Gene 3), HAVCR2 (Hepatitis A Virus Cellular Receptor 2).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated PD-L1 expression on tumor cells engages PD-1 receptors on T cells, leading to suppression of T cell-mediated immune responses. Oncogenic signaling pathways contribute to PD-L1 upregulation, while T cell exhaustion, characterized by co-expression of inhibitory receptors such as PD-1, TIM-3, and LAG-3, impairs T cell function. Epigenetic silencing of antigen presentation machinery via EZH2/PRC2 and loss of IFNgamma signaling components, such as JAK1/2 or B2M, further reduce immunogenicity and immune recognition. These mechanisms collectively contribute to a suppressive tumor microenvironment and resistance to immune checkpoint blockade."}], "pathway_id": "hsa05235", "pubmed_id": "41112253", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, protoporphyrin IX, ALAS1, ALAS2, PPOX, FECH, CPOX, UROD, UROS, HMBS, ALAD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The heme biosynthesis pathway begins with the conversion of glycine and succinyl-CoA to 5-aminolevulinic acid (5-ALA) by the enzyme ALAS1 in the liver and ALAS2 in erythroid cells. 5-ALA is then transported to the mitochondria and condensed into porphobilinogen by ALAD. Subsequent enzymatic steps involving CPOX, UROS, UROD, HMBS, PPOX, and FECH lead to the formation of protoporphyrin IX, which is finally combined with iron to form heme. Deficiencies or mutations in any of these enzymes can lead to the accumulation of porphyrins and neurotoxic intermediates, resulting in porphyria. These disorders manifest as neurological symptoms or cutaneous photosensitivity, depending on the specific enzyme defect and the pathway affected."}], "pathway_id": "hsa05235", "pubmed_id": "41112245", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TP53 (elevated expression), PDCD1 (reduced levels), CD274.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of TP53 is associated with reduced levels of PDCD1, leading to a decrease in the PDCD1/CD274 inhibitory signaling. This suppression of the PD-1/PD-L1 axis reduces immunosuppressive effects on T-cell activity, thereby enhancing immune surveillance and anti-tumor responses. Additionally, TP53 may inhibit the polarization of tumor-associated macrophages (TAMs) and M2 macrophages, which are known to promote tumor progression and resistance to immunotherapy. The negative correlation between TP53 and PDCD1, and the positive correlation between PDCD1 and CD274, suggest that TP53 plays a regulatory role in modulating immune cell infiltration and immune checkpoint activity."}], "pathway_id": "hsa05235", "pubmed_id": "41093922", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-O-(Beta-D-Xylopyranosyl(1->3)-Beta-D-Glucopyranosiduronic Acid)Oleanolic Acid, SUMO-specific protease 1 (elevated expression), Programmed death-ligand 1 (upregulation), Programmed cell death protein 1 (upregulation), Cytotoxic T-lymphocyte-associated protein 4 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of SUMO-specific protease 1 (SENP1) promotes gastric cancer progression by enhancing cell proliferation, migration, and suppressing apoptosis. SENP1 overexpression is associated with upregulation of immune-checkpoint proteins PD-L1 and PD-1, as well as CTLA4, which contribute to immune evasion by inhibiting T-cell activation. This mechanism supports tumor survival and immune suppression within the tumor microenvironment."}], "pathway_id": "hsa05235", "pubmed_id": "41092770", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BATF (inhibited), PD-L1 (reduced expression), STAT1 (activated), PD-1, TIM-3, LAG-3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BATF promotes tumor progression and immune evasion in cervical carcinoma by upregulating PD-L1 expression through activation of the STAT1 signaling pathway. This interaction enhances immune checkpoint signaling, suppressing T-cell infiltration and cytotoxic activity, thereby limiting antitumor immunity. Inhibition of BATF reduces PD-L1 expression and tumor growth, and when combined with anti-PD-L1 blockade, significantly enhances antitumor immune responses."}], "pathway_id": "hsa05235", "pubmed_id": "41075009", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GC-1008, Programmed cell death 1 ligand 1 (elevated expression), Interleukin 10, Interleukin 6, Signal transducer and activator of transcription 3, Purinergic receptor P2X, ligand-gated ion channel 7, Signal transducer and activator of transcription 6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PD-L1 facilitates immune evasion by engaging PD-1 receptors on T cells, thereby suppressing T-cell mediated anti-tumor immunity. Concurrently, IL-10 signaling enhances immunosuppressive activity within the tumor microenvironment. Activation of the IL-6/STAT3 and P2X7/STAT6 pathways contributes to chemoresistance by modulating survival and resistance mechanisms in tumor cells. These interactions collectively impair immune surveillance and promote tumor persistence."}], "pathway_id": "hsa05235", "pubmed_id": "41058699", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Homo sapiens (human)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDCD1, PDCD1LG1, TGFB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Programmed cell death 1 (PDCD1) interacts with its ligand programmed cell death 1 ligand 1 (PDCD1LG1) to inhibit T cell activation and effector function. This interaction is part of the immune checkpoint signaling pathway and contributes to immunosuppression, allowing tumor cells to evade immune surveillance. Transforming growth factor beta 1 (TGFB1) further enhances immunosuppressive conditions in the tumor microenvironment."}], "pathway_id": "hsa05235", "pubmed_id": "41050070", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ERCC5 (polymorphisms), XRCC1 (polymorphisms), XPD (polymorphisms), XRCC3 (polymorphisms), APEX1 (polymorphisms), XPC (polymorphisms).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Genetic variations in base excision repair (BER) and nucleotide excision repair (NER) pathway genes influence DNA repair capacity and modulate susceptibility to gastrointestinal cancer. Specific polymorphisms in ERCC5, XRCC1, XPD, XRCC3, APEX1, and XPC interact in a synergistic manner, increasing the likelihood of gastrointestinal cancer development through compromised DNA repair efficiency."}], "pathway_id": "hsa03410", "pubmed_id": "40849707", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: APEX1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNA base excision repair (BER) involves the sequential action of enzymes that recognize and remove damaged bases, followed by strand cleavage, gap filling, and ligation. APEX1 (also known as APE1) functions as the primary endonuclease that cleaves the phosphodiester backbone at apurinic/apyrimidinic (AP) sites. Defects in BER, including alterations in APEX1, compromise genomic stability and contribute to cancer development. Functional BER maintains the integrity of the genome by repairing small base lesions caused by oxidative and alkylation damage."}], "pathway_id": "hsa03410", "pubmed_id": "40779892", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: APE1, DNA glycosylase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apurinic/apyrimidinic endonuclease 1 (APE1) plays a central role in base excision repair (BER), where it processes apurinic/apyrimidinic (AP) sites following the initial action of DNA glycosylases. APE1 activity is essential for the efficient removal of small base lesions, contributing to the maintenance of genomic integrity through the BER pathway."}], "pathway_id": "hsa03410", "pubmed_id": "40757433", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MYC, POLB, MAX, MYC (delta C-terminal domain), MYC (DNA repair-inactive mutants).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MYC interacts with the POLB DNA polymerase and enhances its enzymatic activity, thereby accelerating the repair of oxidative DNA damage through the base excision repair pathway. This increased DNA repair capacity protects cells from RAS-induced senescence and supports continued proliferation in the presence of elevated reactive oxygen species. The DNA binding and heterodimerization domains of MYC are not required for this repair function. Enhanced DNA repair activity conferred by MYC promotes cell transformation when combined with RAS signaling."}], "pathway_id": "hsa03410", "pubmed_id": "40737085", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: XRCC1 (genetic polymorphisms), SMUG1 (genetic polymorphisms), MUTYH (genetic polymorphisms), MBD4 (genetic polymorphisms), TDG (genetic polymorphisms), OGG1 (genetic polymorphisms).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Variation in base excision repair (BER) genes contributes to the susceptibility to multiple sclerosis. Genetic polymorphisms in XRCC1, SMUG1, MUTYH, MBD4, TDG, and OGG1 alter the efficiency of BER, a pathway essential for repairing oxidative DNA damage. Disruption in BER function can lead to the accumulation of DNA lesions, potentially contributing to neuroinflammation and neurodegeneration characteristic of multiple sclerosis."}], "pathway_id": "hsa03410", "pubmed_id": "40724862", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Homo sapiens (human)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: tert-Butyl hydroperoxide, MBD4 (reduced expression), NTHL1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated oxidative stress induces DNA base lesions that are primarily repaired through the base excision repair (BER) pathway. Reduced expression of MBD4 and NTHL1, key BER components, correlates with impaired DNA repair capacity. This leads to the accumulation of oxidative DNA damage and altered repair kinetics, contributing to the pathogenesis of multiple sclerosis."}], "pathway_id": "hsa03410", "pubmed_id": "40563398", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (modulated levels), KSR1, MST1, LATS1, RHOA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KSR1 interacts with YAP1, MST1, and LATS1 to form a functional complex within the Hippo signaling pathway. This interaction modulates YAP1 protein levels and its transcriptional activity, potentially through the RhoA/actin signaling axis. This contributes to the regulation of cellular processes such as tissue homeostasis and proliferation."}], "pathway_id": "hsa04390", "pubmed_id": "41326667", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Dihydromyricetin (administration), integrin (increased levels), Hippo signaling pathway, Yes-associated protein 1 (elevated levels), ATP-binding cassette sub-family G member 1 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extracellular matrix stiffness increases integrin levels, which suppresses the Hippo signaling pathway and leads to elevated YAP levels. Activated YAP upregulates ATP-binding cassette sub-family G member 1 (ABCG1), which reduces ferroptosis sensitivity in lung adenocarcinoma cells. Inhibition of ABCG1 by dihydromyricetin enhances ferroptosis and may sensitize tumor cells to cell death."}], "pathway_id": "hsa04390", "pubmed_id": "41286767", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, CSRP3, MAZ, KRAS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 activates the transcription of CSRP3 (FHL3) through promoter interaction. FHL3 forms a complex with MAZ, which binds to G-quadruplex structures in the KRAS promoter region, enhancing KRAS transcription and downstream signaling. This activation contributes to the progression of hepatocellular carcinoma."}], "pathway_id": "hsa04390", "pubmed_id": "41184244", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MS4A1, YAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MS4A1 interacts with YAP1 to modulate macrophage polarization and cancer progression through the HIPPO signaling pathway. This interaction influences angiogenesis and promotes tumor malignancy."}], "pathway_id": "hsa04390", "pubmed_id": "41182411", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Irinotecan (administration), TEAD4 (Elevated activity), WWTR1, AREG, SOX11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TEAD4, a transcriptional coactivator in the Hippo signaling pathway, promotes tumor progression by translocating to the nucleus and interacting with transcription factors to regulate gene expression. Elevated TEAD4 activity contributes to increased cell migration and invasion in triple-negative breast cancer. Inhibition of TEAD4, either through genetic knockdown or treatment with irinotecan, significantly suppresses these malignant behaviors, indicating a direct role of TEAD4 in the regulation of tumor cell aggressiveness."}], "pathway_id": "hsa04390", "pubmed_id": "41168787", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: alpha-Synuclein, insulin-degrading enzyme, MST1 and MST2 kinases (suppressed), alpha-synuclein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Insulin-degrading enzyme (IDE) suppresses the Hippo signaling pathway by inhibiting MST1 and MST2 kinases. This suppression reduces alpha-synuclein pathology and prevents neuronal apoptosis, thereby conferring neuroprotection in dopaminergic neurons."}], "pathway_id": "hsa04390", "pubmed_id": "41136383", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, WWTR1, LATS1, LATS2, MST1, MST2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The Hippo signaling pathway regulates cell proliferation and apoptosis through the activity of MST1 and MST2 kinases, which phosphorylate and activate LATS1 and LATS2. Phosphorylated LATS1/2 in turn phosphorylate the transcriptional coactivators YAP1 and WWTR1 (TAZ), promoting their cytoplasmic retention and inhibiting their transcriptional activity. In the absence of Hippo pathway activation, YAP1 and TAZ translocate to the nucleus, where they interact with transcription factors to promote cell growth and proliferation. This pathway also influences differentiation and metabolic homeostasis, and its dysregulation contributes to reproductive dysfunction, metabolic-endocrine disturbances, and immune dysregulation."}], "pathway_id": "hsa04390", "pubmed_id": "41122711", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, WWTR1, FUS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 and WWTR1 form biomolecular condensates through phase separation, which regulate the Hippo signaling pathway by mediating transcriptional activation. The protein FUS modulates the biophysical properties of these TAZ condensates, influencing their transcriptional activity and contributing to pro-tumorigenic outcomes."}], "pathway_id": "hsa04390", "pubmed_id": "41116205", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132, RHOBTB2, KLHL13 (Stabilized), YAP1 (Modulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RHOBTB2 interacts with KLHL13 and stabilizes its protein expression by inhibiting proteasomal degradation. This stabilization enhances cell proliferation and migration while suppressing apoptosis and shortening the G0/G1 phase in acute myeloid leukemia. RHOBTB2 modulates Hippo-YAP1 signaling, contributing to increased malignancy."}], "pathway_id": "hsa04390", "pubmed_id": "41107424", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, CDK11, CCNL2, Neurofibromin 2 (phosphorylated at S518), LATS1 (degradation), Cullin 4, YAP1 and TEAD transcription factor complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CDK11 inactivates the Hippo signaling pathway by promoting CRL4-mediated ubiquitination and degradation of LATS1. The CDK11/CCNL2 complex phosphorylates Neurofibromin 2 (NF2) at the S518 site, reducing its binding to CRL4 in the nucleus. This interaction further inactivates the Hippo pathway, contributing to paclitaxel resistance in cervical cancer."}], "pathway_id": "hsa04390", "pubmed_id": "41074747", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: methyl 4-{[3-(piperidin-1-yl)propyl]amino}-9H-pyrimido[4,5-b]indole-7-carboxylate (administration), Dobutamine (administration), YAP1 (elevated levels), WWTR1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated YAP protein levels, primarily localized in the cytoplasm, indicate inhibition of the Hippo signaling pathway. This cytoplasmic sequestration of YAP suppresses its transcriptional activity, which normally promotes cell proliferation and growth. The pyrimido-indole derivative UM729 increases YAP levels and modulates Hippo pathway activity, thereby promoting hematopoietic stem and progenitor cell (HSPC) differentiation from human-induced pluripotent stem cells. Co-treatment with the YAP/TAZ inhibitor dobutamine further enhances HSPC marker expression, suggesting that controlled Hippo pathway modulation supports the generation of functional HSPCs with self-renewal and multilineage differentiation capabilities."}], "pathway_id": "hsa04390", "pubmed_id": "41052706", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Homo sapiens (human)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RPRM (extracellular secretion), TP53, protocadherin family, YAP1 (inactivation), WWTR1 (inactivation), TP73.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reprimo (RPRM) functions as an upstream regulator of the Hippo signaling pathway by modulating the activity of YAP1 and WWTR1 (TAZ). Upon extracellular secretion, RPRM interacts with components of the protocadherin family, initiating a signaling cascade that activates the Hippo pathway. This leads to phosphorylation and inactivation of YAP1/WWTR1, preventing their nuclear translocation and subsequent transcriptional activity. Inactivation of YAP1/WWTR1 promotes cell apoptosis and suppresses cell proliferation, primarily through interaction with TP73. This extracellular function of RPRM is distinct from its intracellular role in cell cycle regulation and DNA damage response."}], "pathway_id": "hsa04390", "pubmed_id": "41036848", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ursodeoxycholic Acid (administration), microRNA-125b (elevated levels), transforming growth factor beta, androgen receptors, tumor protein p53, tumor necrosis factor alpha, apelin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of microRNA-125b suppresses apelin and transforming growth factor beta (TGF-beta) while promoting androgen receptor (AR) expression. This modulation contributes to inflammation and fibrogenesis in the liver. MicroRNA-125b overexpression also suppresses tumor protein p53 and enhances pro-inflammatory genes such as tumor necrosis factor alpha (TNF-alpha). Ursodeoxycholic acid therapy reduces serum microRNA-125b levels, indicating a potential therapeutic role in attenuating fibrogenic and inflammatory processes."}], "pathway_id": "hsa04371", "pubmed_id": "40869103", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: APelin, APLNR, PLVAP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin signaling regulates the formation of fenestrated capillaries in the choroid plexus through the apelin receptor (APLNR). This signaling pathway is specifically required for the development of fenestrated endothelium, distinct from its role in angiogenesis or blood-brain barrier formation. APLNR expression correlates with that of PLVAP, a known marker of fenestrated endothelium, but Apelin signaling does not control PLVAP expression. Apelin ligand activity is localized to meningeal regions, where it guides the development of fenestrated vessels, contributing to cerebrovascular heterogeneity."}], "pathway_id": "hsa04371", "pubmed_id": "40830138", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: APJ (dimerized and biased agonism), ARRB1, GNAI1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin receptor (APJ) couples with both beta-arrestin1 (ARRB1) and Gi proteins (GNAI1) in a ligand-dependent manner, forming 2:2 and 2:1 receptor-ligand complexes that mediate distinct signaling outcomes. APJ dimerization and biased agonism influence the recruitment of beta-arrestin1 and Gi, thereby modulating downstream physiological processes such as cardiovascular function and metabolic regulation."}], "pathway_id": "hsa04371", "pubmed_id": "40790299", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin (elevated levels), APLN, FGF2, FGFR1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated apelin levels promote the proliferation and migration of bladder cancer cells by activating the FGF2/FGFR1 signaling pathway. This activation is evidenced by increased FGFR1 phosphorylation, which in turn enhances angiogenesis in human umbilical vein endothelial cells. Inhibition of apelin suppresses these effects, while overexpression of apelin intensifies them, indicating a direct regulatory role of apelin in modulating cancer progression through this pathway."}], "pathway_id": "hsa04371", "pubmed_id": "40579142", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: APJ, Apelin, Elabela.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin binds to the APJ receptor, a G-protein-coupled receptor, initiating downstream signaling cascades. This interaction plays a central role in regulating cardiovascular function, energy metabolism, and neuroendocrine stress responses. APJ is also involved in tumor angiogenesis and is associated with various pathological conditions including respiratory disease and appetite regulation. Apelin and APJ are expressed in multiple tissues, where they modulate physiological and pathological processes."}], "pathway_id": "hsa04371", "pubmed_id": "40419033", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1 (stimulated activity), ALAS2 (stimulated activity), TP53 (activated), NRF2 (activated), HMOX1 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) stimulate the activity of ALAS1 and ALAS2, the rate-limiting enzymes in heme biosynthesis, leading to increased heme production. Heme accumulation activates the P53 tumor suppressor pathway, promoting apoptosis in response to cellular stress. Concurrently, 5-ALA induces the NRF2-mediated antioxidant response, resulting in upregulation of HO-1, which facilitates heme degradation and reduces oxidative damage. These interactions collectively modulate cellular redox homeostasis and mitochondrial function."}], "pathway_id": "hsa04371", "pubmed_id": "40314976", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin, APJ receptor, APLN (apelin).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin binds to the APJ receptor, activating intracellular signaling pathways that sustain proliferative signaling, resist cell death, activate invasion and metastasis, induce vasculature, reprogram cellular metabolism, avoid immune destruction, promote tumor inflammation, and enable replicative immortality. These processes collectively contribute to tumor development and progression."}], "pathway_id": "hsa04371", "pubmed_id": "40243599", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Selinexor (administration), Caspase-3 (elevated activity), BCL2-associated X protein (elevated activity), Inducible nitric oxide synthase (upregulated), Ataxia-telangiectasia mutated (increased expression), Breast cancer 1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Selinexor inhibits nuclear export by interfering with nuclear export mechanisms, leading to the accumulation of nuclear export substrates in the nucleus. This disruption results in increased apoptosis, as evidenced by elevated Caspase-3 and Bax activity, and induces DNA damage, as indicated by increased ATM and BRCA1 expression. Additionally, Selinexor promotes oxidative stress through the upregulation of iNOS. These molecular changes contribute to reduced cell viability, suppressed cell proliferation, and inhibited cell migration in male germ cells."}], "pathway_id": "hsa03013", "pubmed_id": "41286980", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IPO7, COPI, L2, nuclear localization sequence.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IPO7, a nuclear pore import receptor, facilitates the transport of HPV from the Golgi apparatus to the nucleus. The C-terminal nuclear localization sequence of the HPV L2 protein directly interacts with IPO7 during COPI-dependent trafficking. This interaction enables the virus to access the nucleus during mitotic nuclear envelope breakdown, promoting successful infection."}], "pathway_id": "hsa03013", "pubmed_id": "41124246", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STAT1, KPNA1, KPNA2, NP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NP1 binds to the DNA-binding domain of STAT1 and the IBB domain of KPNA1, preventing the formation of the STAT1/KPNA1/KPNB1 complex. This interaction inhibits the nuclear translocation of STAT1, a critical step in type I interferon signaling."}], "pathway_id": "hsa03013", "pubmed_id": "41094750", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: AMPK (active), NUP50 (post-translationally regulated abundance).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AMPK post-translationally regulates the abundance of the nucleoporin NUP50 in response to nutrient availability and energetic stress. NUP50 promotes transcriptional activation of lipid catabolism through its intrinsically disordered region, which interacts directly with the transcriptional machinery to transactivate the promoters of catabolic genes. This signaling axis contributes to lifespan extension and metabolic stress defenses in C. elegans independently of NUP50's role in nuclear transport. AMPK-NUP50 signaling is conserved in humans, linking energy sensing to transcriptional plasticity and metabolic adaptation."}], "pathway_id": "hsa03013", "pubmed_id": "40992375", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: XPO1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "XPO1 mediates nuclear-to-cytoplasmic transport of proteins and mRNAs. It also associates with chromatin, recruiting oncogenic fusion proteins to target genes, thereby altering chromatin structure and function. This interaction promotes transcriptional activation and contributes to oncogenesis."}], "pathway_id": "hsa03013", "pubmed_id": "40991079", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MCIDAS, E2F4, E2F5, CRM1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cytoplasmic accumulation of MCIDAS is mediated by CRM1-dependent nuclear export, and this process is required for the cytoplasmic localization of E2F4 and E2F5. The MCIDAS-E2F4/5 complex facilitates de novo centriole biogenesis. Disruption of MCIDAS or its nuclear export pathway inhibits cytoplasmic accumulation of E2F4/5 and blocks centriole assembly."}], "pathway_id": "hsa03013", "pubmed_id": "40974574", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Homo sapiens (human)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: nuclear pore complex, nucleoporin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Nuclear pore complex dilation is influenced by nuclear membrane tension, which modulates the compositional plasticity of nuclear pore complexes. Variations in nucleoporin composition and pore dilation affect the selective transport of molecules between the nucleus and cytoplasm. This plasticity contributes to cell-type-specific nuclear transport properties and may influence cell fate decisions and tissue-specific disease manifestations."}], "pathway_id": "hsa03013", "pubmed_id": "40973737", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Homo sapiens (human)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: T-box transcription factor TBX21, Signal Transducer and Activator of Transcription 4, GATA Binding Protein 3, Signal Transducer and Activator of Transcription 6, Interleukin 4 (increased secretion), Interleukin 5 (increased secretion), Interleukin 13 (increased secretion), Interferon gamma (reduced production), Transforming Growth Factor Beta (increased production), Programmed Cell Death 1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated T regulatory (Treg) cell populations and increased TGF-beta production suppress Th1 cell differentiation during neonatal respiratory viral infections. Neonatal Tregs exert extrinsic inhibition of Th1 responses, resulting in reduced IFN-gamma production and antiviral immunity. In contrast, GATA-3 and STAT6 promote Th2 differentiation, leading to increased IL-4, IL-5, and IL-13 secretion. The Th1 response is also functionally restricted by PD-1 expression on neonatal CD4+ T cells. This imbalance between Th1 and Th2 responses contributes to a tolerogenic neonatal immune environment, which limits effective antiviral immunity and increases susceptibility to respiratory viral infections."}], "pathway_id": "hsa04658", "pubmed_id": "40280180", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Homo sapiens (human)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prim-O-Glucosylcimifugin, LCK, phosphorylated LCK (elevated expression), interleukin 4 (reduced production), interleukin 13 (reduced production), interleukin 5 (reduced production), thymic stromal lymphopoietin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of phosphorylated LCK (p-LCK) suppresses Th2 cell differentiation by modulating intracellular signaling pathways. This inhibition reduces the production of Th2-associated cytokines such as interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin 13 (IL-13), thereby attenuating inflammatory responses and alleviating atopic dermatitis."}], "pathway_id": "hsa04658", "pubmed_id": "40253253", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Homo sapiens (human)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cry1, CCAR2, CTIP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cry1 modulates the anti-resection activity of CCAR2 to limit CTIP activity during nightfall, thereby regulating the circadian oscillation of DNA end resection. This regulation influences the timing and extent of homologous recombination repair of DNA double-strand breaks."}], "pathway_id": "hsa03440", "pubmed_id": "41326346", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Homo sapiens (human)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BRCA1 and BRCA2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defects in BRCA1 and BRCA2 impair the homologous recombination repair pathway, leading to homologous recombination deficiency (HRD), which compromises the accurate repair of DNA double-strand breaks and increases genomic instability."}], "pathway_id": "hsa03440", "pubmed_id": "41260881", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Homo sapiens (human)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: WDFY2 (phosphorylated at serine 84), MRE11A, RAD50, NBN, ATM, CHEK2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "WDFY2 interacts with MRE11 and NBS1 to facilitate the assembly of the MRE11-RAD50-NBS1 (MRN) complex at DNA double-strand breaks. This interaction supports DNA end resection and the initiation of homologous recombination repair. Phosphorylation of WDFY2 at serine 84 by the ATM-CHEK2 signaling cascade enhances its recruitment to DNA damage sites. Deficiency in WDFY2 or the inability to phosphorylate serine 84 impairs MRN complex formation and homologous recombination, leading to reduced cell survival following DNA damage."}], "pathway_id": "hsa03440", "pubmed_id": "41196680", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Homo sapiens (human)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BRCA2 (loss), RAD51 (dissociation), FIGNL1, MMS22L-TONSL complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss of BRCA2 leads to defects in RAD51 nucleoprotein filament formation during homologous recombination. FIGNL1 acts as an anti-recombinase by removing RAD51 from DNA double-strand break sites, thereby impairing strand invasion and HR efficiency. In BRCA2-deficient cells, the absence of FIGNL1 sustains RAD51 loading at DSBs, restoring HR proficiency and promoting genome stability and cell viability. The MMS22L-TONSL complex interacts with FIGNL1 and supports HR in the absence of both BRCA2 and FIGNL1."}], "pathway_id": "hsa03440", "pubmed_id": "41166468", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Homo sapiens (human)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BRD3, TIP60, CHD4, HP1, Histone H4 Lysine 16, MBTD1, 53BP1, BRCA1 (Facilitated), R-loop-processing factors (Facilitated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BRD3 localizes to actively transcribed chromatin through its N-terminal bromodomains. Upon DNA double-strand breaks (DSBs) in these regions, the C-terminal extraterminal domain of BRD3 recruits CHD4 to replace HP1 with the TIP60 complex. This interaction promotes H4K16 acetylation and recruits MBTD1, forming chromatin barriers to 53BP1. These barriers facilitate the recruitment of BRCA1 and R-loop-processing factors, which support R-loop-mediated homologous recombination (HR). This process suppresses mutagenic non-homologous end-joining and contributes to genome stability in transcribed chromatin."}], "pathway_id": "hsa03440", "pubmed_id": "41134669", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CIP2A, TOPBP1, SLX4 (phosphorylated at Thr1260), POLQ, CDK1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CIP2A and TOPBP1 form a regulatory complex that facilitates the recruitment of SMX complex components and POLQ to mitotic chromatin. CDK1-dependent phosphorylation of SLX4 at Thr1260 enables its interaction with TOPBP1 BRCT domains 1/2, thereby promoting mitotic DNA synthesis (MiDAS). Concurrently, CIP2A enhances the mitotic localization of POLQ to support microhomology-mediated end-joining (MMEJ). Disruption of both MiDAS and MMEJ pathways results in genome instability, particularly in cells with impaired homologous recombination."}], "pathway_id": "hsa03450", "pubmed_id": "41309571", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TP53BP1 (accumulates at DNA double strand breaks), PRKDC (inhibited kinase activity), RIF1, Cas9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TP53BP1 accumulates at DNA double strand breaks and is involved in non-homologous end joining. It interacts genetically with PRKDC (DNA-PKcs), where the loss of TP53BP1 does not significantly affect blunt DSB repair but reduces efficiency when combined with PRKDC disruption. TP53BP1 and RIF1 function redundantly with PRKDC during blunt DSB repair but act in the same pathway to suppress microhomology deletions. Inhibition of PRKDC kinase activity increases radiosensitivity and promotes homology-directed repair."}], "pathway_id": "hsa03450", "pubmed_id": "41285797", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methotrexate, ZFP36L1 (reduced expression), DCLRE1C (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ZFP36L1 stabilizes DCLRE1C mRNA by preventing its degradation. Elevated levels of DCLRE1C enhance the efficiency of non-homologous end joining (NHEJ), a DNA repair mechanism that promotes resistance to methotrexate in osteosarcoma. ZFP36L1 directly binds to AU-rich elements in the 3' untranslated region of DCLRE1C mRNA, leading to its destabilization and reduced expression."}], "pathway_id": "hsa03450", "pubmed_id": "41285712", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: POLQ, POLD1, RPA1 (inhibitory effect on repair).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNA polymerase theta (POLQ) initiates microhomology-mediated end joining by aligning single-stranded DNA tails using short sequence homologies. DNA polymerase delta (POLD1) excises unpaired nucleotides one at a time, generating new 3' termini that allow POLQ to initiate a new microhomology search. This coordinated transfer of DNA between POLQ and POLD1 facilitates the selection of microhomologies during non-homologous end joining. The helicase-like domain of POLQ supports strand-capture and ATPase activity to counteract the inhibitory effect of RPA1 on repair."}], "pathway_id": "hsa03450", "pubmed_id": "41259142", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 7-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-fluorophenyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, CNOT7 (elevated expression), XRCC6, TRIM21, XRCC5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of CNOT7 stabilizes XRCC6 protein by inhibiting TRIM21-mediated K48-linked ubiquitination at lysine 526, thereby enhancing non-homologous end joining (NHEJ) and promoting efficient DNA double-strand break repair. CNOT7 also accelerates TRIM21 mRNA degradation through its deadenylase activity. This mechanism contributes to increased radiosensitivity and resistance to radiotherapy by maintaining NHEJ-mediated DNA repair. Inhibition of the XRCC6/XRCC5 heterodimer with STL127705, particularly in the absence of CNOT7, suppresses tumor growth and enhances DNA repair outcomes."}], "pathway_id": "hsa03450", "pubmed_id": "41249119", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GSK3B, TP53BP1 (phosphorylated), PTIP, RIF1, CTIP (recruitment), RPA3, BRCA1, RAD51.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GSK3B phosphorylates TP53BP1 at threonine 334, which disrupts its interaction with NHEJ effectors PTIP and RIF1, leading to their dissociation from DNA double-strand breaks. This phosphorylation inhibits TP53BP1-driven NHEJ and facilitates the recruitment of CtIP and RPA32 for DNA end resection. The disruption of TP53BP1 function promotes homologous recombination by enabling BRCA1 and RAD51 loading. Accumulation of the phospho-deficient T334A mutant of TP53BP1 at DNA breaks impairs end resection and suppresses HR activity. These events collectively regulate DSB repair pathway choice between NHEJ and HR."}], "pathway_id": "hsa03450", "pubmed_id": "41243969", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GSK3B, TP53BP1 (phosphorylated at threonine 334), PTIP, RIF1, CTIP, RPA32.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GSK3beta-mediated phosphorylation of TP53BP1 at threonine 334 disrupts its interaction with PTIP and RIF1, thereby inhibiting TP53BP1-directed nonhomologous end joining (NHEJ). This modification also promotes recruitment of CTIP and RPA32 to DNA damage sites, facilitating homologous recombination (HR). Phosphorylation at this site prevents aberrant accumulation of TP53BP1 at DNA double-strand breaks, which would otherwise impair end resection and suppress HR activity. This mechanism supports pathway choice between NHEJ and HR during DNA repair."}], "pathway_id": "hsa03450", "pubmed_id": "41243967", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAG1 and RAG2, SETX, XLF, ATM, AICDA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During V(D)J recombination, the RAG1/2 nuclease complex introduces DNA double-strand breaks (DSBs), which are subsequently repaired by nonhomologous end-joining (NHEJ). Senataxin (SETX) plays a regulatory role in this process by promoting recombination fidelity and preventing the formation of aberrant hybrid joints between coding and signal ends. Loss of SETX results in impaired V(D)J recombination and increased formation of unsealed coding ends, particularly in the absence of XLF or when ATM activity is inhibited. Additionally, SETX restricts aberrant end-joining between immunoglobulin heavy chain alleles during class-switch recombination, thereby limiting off-target DNA repair events."}], "pathway_id": "hsa03450", "pubmed_id": "41086252", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: XRCC4-like factor, PAXX, Helicase-like transcription factor, SAGA complex, Von Hippel-Lindau tumor suppressor (loss).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "XLF and PAXX exert opposing effects on double-strand break repair outcomes, influencing non-homologous end joining. HLTF participates in Cas9-induced DSB repair, while the SAGA complex contributes to microhomology-mediated end joining. Loss of VHL is associated with an indel mutational signature observed in renal carcinoma and hypoxia, suggesting a role in the mutagenic consequences of DSB repair."}], "pathway_id": "hsa03450", "pubmed_id": "41037600", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Formononetin (administration), APOL2, XRCC6 (increased levels), USP7, LIG4, XRCC4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "APOL2 binds to and stabilizes XRCC6 (Ku80) through enhancement of USP7-mediated deubiquitylation, which increases Ku80 protein levels and promotes non-homologous end joining (NHEJ)-mediated double-strand break (DSB) repair. This stabilization enhances genomic stability and contributes to radioresistance. Disruption of the APOL2-Ku80 interaction by formononetin restores radiosensitivity."}], "pathway_id": "hsa03450", "pubmed_id": "40953331", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Homo sapiens (human)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pyridostatin, ARID1A, non-homologous end joining proteins (stabilized).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ARID1A stabilizes non-homologous end joining factors at DNA breaks. Its deficiency leads to impaired accumulation of these repair proteins at sites of chromatin damage, resulting in defective repair of topoisomerase-induced DNA breaks. This contributes to increased genomic instability and sensitivity to G4 ligand-induced DNA damage."}], "pathway_id": "hsa03450", "pubmed_id": "40938753", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Steroid hormone biosynthesis - Homo sapiens (human)\n**Pathway Description**: Steroid hormones derived from cholesterol are a class of biologically active compounds in vertebrates. The cholesterol side-chain cleavage enzyme CYP11A1 catalyzes conversion of cholesterol, a C27 compound, to the first C21 steroid, pregnenolone, which is converted by a bifunctional enzyme complex to the gestagen hormone, progesterone [MD:M00107]. Pregnenolone and progesterone are the starting materials for the three groups of steroids: C21 steroids of glucocorticoids and mineralocorticoids, C19 steroids of androgens, and C18 steroids of estrogens. (i) Progesterone is converted by hydroxylations at carbons 21 and 11 to corticosterone, which is further modified by hydroxylation and oxydoreduction at carbon 18 to yield aldosterone, a mineralcorticoid [MD:M00108]. Cortisol, the main glucocorticoid, is formed from 17alpha-hydroxyprogesterone with 11-deoxycortisol as an intermediate [MD:M00109]. (ii) Male hormone testosterone is formed from pregnenolone by two pathways, delta5 pathway via dehydroepiandrosterone and delta4 pathway via androstenedione [MD:M00110]. The enzyme CYP17A1 is responsible for the 17,20 lyase and 17alpha-hydroxylase activities in respective pathways. (iii) Female hormones estrone and estradiol are formed from testosterone and 4-androstene-3,17-dione by oxidative removal of the C19 methyl group and subsequent aromatization of ring A. In addition to these three groups, recent studies show that there is another group, termed neurosteroids, synthesized in the brain rather than the peripheral endocrine gland.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dehydroepiandrosterone (elevated levels), Dihydrotestosterone (elevated levels), Ruscogenin, TXNIP (reduced expression), NLRP3, BRD4 (inhibited), AR (inhibited activity), histone H3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of dehydroepiandrosterone and dihydrotestosterone are associated with increased transcription of TXNIP, which promotes NLRP3 inflammasome activation. BRD4 binds to the acetylated promoter region of TXNIP, enhancing its transcription. This interaction is facilitated by androgen receptor binding to the same promoter. Inhibition of BRD4 or androgen receptor activity reduces TXNIP expression, leading to suppression of NLRP3 inflammasome activity and alleviation of reproductive and metabolic abnormalities."}], "pathway_id": "hsa00140", "pubmed_id": "41291276", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Steroid hormone biosynthesis - Homo sapiens (human)\n**Pathway Description**: Steroid hormones derived from cholesterol are a class of biologically active compounds in vertebrates. The cholesterol side-chain cleavage enzyme CYP11A1 catalyzes conversion of cholesterol, a C27 compound, to the first C21 steroid, pregnenolone, which is converted by a bifunctional enzyme complex to the gestagen hormone, progesterone [MD:M00107]. Pregnenolone and progesterone are the starting materials for the three groups of steroids: C21 steroids of glucocorticoids and mineralocorticoids, C19 steroids of androgens, and C18 steroids of estrogens. (i) Progesterone is converted by hydroxylations at carbons 21 and 11 to corticosterone, which is further modified by hydroxylation and oxydoreduction at carbon 18 to yield aldosterone, a mineralcorticoid [MD:M00108]. Cortisol, the main glucocorticoid, is formed from 17alpha-hydroxyprogesterone with 11-deoxycortisol as an intermediate [MD:M00109]. (ii) Male hormone testosterone is formed from pregnenolone by two pathways, delta5 pathway via dehydroepiandrosterone and delta4 pathway via androstenedione [MD:M00110]. The enzyme CYP17A1 is responsible for the 17,20 lyase and 17alpha-hydroxylase activities in respective pathways. (iii) Female hormones estrone and estradiol are formed from testosterone and 4-androstene-3,17-dione by oxidative removal of the C19 methyl group and subsequent aromatization of ring A. In addition to these three groups, recent studies show that there is another group, termed neurosteroids, synthesized in the brain rather than the peripheral endocrine gland.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ebselen (Administration), Peroxiredoxin 1, Autophagy-related protein 4 homolog B (redox-site Cys78 targeted through oxidation-reduction reactions).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRDX1 preserves the delipidating activity of Cys74 in ATG4B by targeting the redox-site Cys78 in ATG4B through oxidation-reduction reactions involving Cys52 and Cys173 in PRDX1. This regulation sustains autophagic flux and promotes lipophagy in Leydig cells, which is essential for testosterone synthesis. Impaired PRDX1 function disrupts lipophagy and testosterone production, contributing to testicular and systemic aging. Administration of the 2-cysteine mimic ebselen can partially restore these functions."}], "pathway_id": "hsa00140", "pubmed_id": "41261096", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Steroid hormone biosynthesis - Homo sapiens (human)\n**Pathway Description**: Steroid hormones derived from cholesterol are a class of biologically active compounds in vertebrates. The cholesterol side-chain cleavage enzyme CYP11A1 catalyzes conversion of cholesterol, a C27 compound, to the first C21 steroid, pregnenolone, which is converted by a bifunctional enzyme complex to the gestagen hormone, progesterone [MD:M00107]. Pregnenolone and progesterone are the starting materials for the three groups of steroids: C21 steroids of glucocorticoids and mineralocorticoids, C19 steroids of androgens, and C18 steroids of estrogens. (i) Progesterone is converted by hydroxylations at carbons 21 and 11 to corticosterone, which is further modified by hydroxylation and oxydoreduction at carbon 18 to yield aldosterone, a mineralcorticoid [MD:M00108]. Cortisol, the main glucocorticoid, is formed from 17alpha-hydroxyprogesterone with 11-deoxycortisol as an intermediate [MD:M00109]. (ii) Male hormone testosterone is formed from pregnenolone by two pathways, delta5 pathway via dehydroepiandrosterone and delta4 pathway via androstenedione [MD:M00110]. The enzyme CYP17A1 is responsible for the 17,20 lyase and 17alpha-hydroxylase activities in respective pathways. (iii) Female hormones estrone and estradiol are formed from testosterone and 4-androstene-3,17-dione by oxidative removal of the C19 methyl group and subsequent aromatization of ring A. In addition to these three groups, recent studies show that there is another group, termed neurosteroids, synthesized in the brain rather than the peripheral endocrine gland.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pregnenolone (accumulates), Dehydroepiandrosterone (detectable), Androstenedione (detectable), Testosterone (detectable), Dihydrotestosterone (detectable), Cortisone, Cortisol, 11beta-Hydroxyandrost-4-ene-3,17-dione, Adrenosterone.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pregnenolone accumulates in hair samples, reflecting active steroidogenesis. Dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone are detectable in both serum and hair, indicating peripheral androgen metabolism. Cortisone and cortisol are also present, suggesting involvement of glucocorticoid pathways. Androgen levels correlate with body size and composition, particularly in males, demonstrating sex-specific regulation of metabolic processes."}], "pathway_id": "hsa00140", "pubmed_id": "41259303", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Homo sapiens (human)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NDC80 complex (NDC80 and NUF2), Hyaluronan and proteoglycan link protein 3 (HAPLN3).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Artificial kinetochore-like decoys composed of the NDC80 complex compete with chromosomal kinetochores for HAPLN3-decorated microtubules, reducing excessive bipolar pulling forces on chromosomes. This competition prevents premature chromosome separation during meiosis I and II, thereby suppressing aneuploidy in aged oocytes."}], "pathway_id": "hsa04114", "pubmed_id": "41188464", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Homo sapiens (human)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BRCA2, RAD51 (recruitment), DMC1 (recruitment).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BRCA2 facilitates homologous recombination during meiosis by promoting the recruitment of RAD51 and DMC1 to programmed DNA double-strand breaks. Impairment in this recruitment leads to defective meiotic homologous recombination, resulting in oocyte depletion and the development of premature ovarian insufficiency."}], "pathway_id": "hsa04114", "pubmed_id": "40715368", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Homo sapiens (human)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Protein Phosphatase 2A Regulatory Subunit B56 (Disrupted), Protein Phosphatase 2A, Anaphase-Promoting Complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PP2A-B56 regulates key processes in meiosis by safeguarding centromeric cohesion and facilitating the transition between meiotic divisions. It contributes to chromosomal stability by modulating the spindle assembly checkpoint and anaphase-promoting complex activation. Through interactions with LxxIxE motif-containing substrates, PP2A-B56 ensures accurate chromosome segregation and maintains oocyte quality. Disruption of PP2A-B56 function can lead to chromosomal instability and compromised fertility."}], "pathway_id": "hsa04114", "pubmed_id": "40684918", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Homo sapiens (human)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CLASP1 (knockdown), PLK1, MAPK1 (phosphorylated), MAPK3 (phosphorylated), HDAC6 (increased levels), SIRT1 (increased levels), PRC1, DYNC1I1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CLASP1 associates with DYNC1I1 to facilitate PLK1-mediated spindle organization and cytokinesis during oocyte meiosis. It interacts with PLK1 and phosphorylated MAPK1 and MAPK3, contributing to microtubule-kinetochore attachment at metaphase I. CLASP1 knockdown increases levels of HDAC6 and SIRT1, reducing tubulin acetylation and impairing microtubule stability. CLASP1 also participates in PRC1-based central spindle formation at telophase I, ensuring proper cytokinesis."}], "pathway_id": "hsa04114", "pubmed_id": "40501366", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Homo sapiens (human)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACTR2 (downregulation), NDUFS1 (downregulation), TUBGCP3 (upregulation), HSPB1 (downregulation), EIF3B (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Differential expression of ACTR2, NDUFS1, TUBGCP3, HSPB1, and EIF3B is associated with the transition of human oocytes from the germinal vesicle (GV) to metaphase I (MI) phase. These proteins are involved in mitochondrial function, cell division, and signal transduction. Upregulation of TUBGCP3 and downregulation of other proteins correlate with the progression of oocyte maturation, suggesting a regulatory role in cellular metabolism and structural organization during meiosis."}], "pathway_id": "hsa04114", "pubmed_id": "40359387", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human)\n**Pathway Description**: Pluripotent stem cells (PSCs) are basic cells with an indefinite self-renewal capacity and the potential to generate all the cell types of the three germinal layers. The types of PSCs known to date include embryonic stem (ES) and induced pluripotent stem (iPS) cells. ES cells are derived from the inner cell mass (ICM) of blastocyst-stage embryos. iPS cells are generated by reprogramming somatic cells back to pluripotent state with defined reprogramming factors, Oct4, Sox2, Klf4 and c-Myc (also known as Yamanaka factors). PSCs including ES cells and iPS cells are categorized into two groups by their morphology, gene expression profile and external signal dependence. Conventional mouse-type ES/iPS cells are called 'naive state' cells. They are mainly maintained under the control of LIF and BMP signaling. On the other hand, human-type ES/iPS cells, which are in need of Activin and FGF signaling, are termed 'primed state'. However, these signaling pathways converge towards the activation of a core transcriptional network that is similar in both groups and involves OCt4, Nanog and Sox2. The three transcription factors and their downstream target genes coordinately promote self-renewal and pluripotency.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CID 146301742, SOX2 (levels), OCT4, Nanog, REST, NESTIN (expression), CTNNB1 (expression), MAPK3 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "REST regulates neurogenesis by modulating the expression of SOX2, a key transcription factor essential for neural stem cell proliferation. Inhibition of REST reduces SOX2 levels, leading to the disruption of the MAPK and WNT signaling pathways. This results in decreased expression of NESTIN, CTNNB1, and MAPK3, which are critical for maintaining neural stem cell identity and function."}], "pathway_id": "hsa04550", "pubmed_id": "41252060", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Splitomicin (administration), Suberohydroxamic acid (administration), 4-(4-chlorophenyl)-N-[(Z)-(3-methylcyclopentylidene)amino]-1,3-thiazol-2-amine (administration), 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione (administration), 2-(4-Methylphenyl)-2,3-dihydro-1,2-benzothiazol-3-one (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fibro-fatty substitution in the myocardium involves the differentiation of cardiac mesenchymal stromal cells into adipocytes and fibroblasts, resulting in lipid droplet accumulation and collagen deposition. Epigenetic regulators such as splitomicin, suberohydroxamic acid, CPTH6, BVT-948, and PBIT can influence the epigenetic landscape of these cells, thereby attenuating their adipogenic differentiation and reducing collagen production. This mechanism suggests that modulation of epigenetic processes can inhibit fibro-adipose replacement, potentially mitigating the pathological remodeling associated with arrhythmogenic cardiomyopathy."}], "pathway_id": "hsa05412", "pubmed_id": "41301483", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: desmosome, plakoglobin (nuclear translocated), beta-catenin, ryanodine receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defective desmosomal proteins lead to cardiomyocyte loss and fibrofatty replacement in the right ventricle. Disruption of desmosome function causes delocalization and nuclear translocation of plakoglobin, which competes with beta-catenin and inhibits Wnt/beta-catenin signaling. This shift promotes an adipocyte fate over a myocyte fate. Defects in the ryanodine receptor impair calcium homeostasis, contributing to myocyte death and arrhythmic risk. These molecular changes drive progressive myocardial remodeling and increase the likelihood of ventricular arrhythmias and sudden cardiac death."}], "pathway_id": "hsa05412", "pubmed_id": "41301430", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PKP2 (mutated), DSP (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in desmosomal proteins such as PKP2 and desmoplakin disrupt cardiac cell adhesion and structural integrity. This leads to myocyte loss and fibrofatty replacement, particularly in the right ventricle, contributing to arrhythmias and progressive cardiac dysfunction."}], "pathway_id": "hsa05412", "pubmed_id": "41206180", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LMNA (mutated (c.821C>T variant, p.A274D substitution)).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the LMNA gene, such as the c.821C>T variant resulting in the p.A274D amino acid substitution, are associated with arrhythmogenic right ventricular cardiomyopathy. This condition is characterized by the progressive replacement of myocardial tissue with fibrofatty deposits, particularly in the right ventricle, which can lead to malignant arrhythmias and sudden cardiac death. The use of patient-derived induced pluripotent stem cells enables the modeling of this disease in vitro, supporting the investigation of disease mechanisms and the development of targeted therapeutic strategies."}], "pathway_id": "hsa05412", "pubmed_id": "40925291", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DSC2 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of desmocollin-2 (DSC2) is associated with arrhythmogenic cardiomyopathy. DSC2 down-regulation correlates with myocyte loss and fibrofatty replacement in the myocardium. This reduction contributes to desmosomal dysfunction, leading to impaired cell-cell adhesion and increased susceptibility to mechanical stress. These changes may promote myocardial injury and arrhythmias, ultimately contributing to sudden cardiac death."}], "pathway_id": "hsa05412", "pubmed_id": "40879390", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Homo sapiens (human)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PLN, PLN p.Arg14del (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in phospholamban, such as the p.Arg14del variant, are associated with arrhythmogenic right ventricular cardiomyopathy and are linked to poor clinical outcomes. These genetic alterations may contribute to ventricular tachycardia and atypical right ventricular involvement. Patients with phospholamban mutations and atypical electrocardiographic findings have increased mortality risk. Atypical right ventricular involvement may also be associated with alternative pathologies such as myocarditis, ischaemia, or sarcoidosis, which present with distinct underlying aetiologies."}], "pathway_id": "hsa05412", "pubmed_id": "40832996", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1, ALAS2, FECH, CPOX, PPOX, UROD, HMBS, ALAD, CYP2E1, NFE2L2, HMOX1 (upregulation), BACH1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) initiate the heme biosynthetic pathway by being converted to porphobilinogen by ALAS1 and ALAS2. Disruption of this pathway, as seen in porphyrias, leads to the accumulation of intermediates such as delta-aminolevulinic acid dehydratase (ALAD), porphobilinogen deaminase (PPOX), and coproporphyrinogen oxidase (CPOX). This accumulation activates oxidative stress pathways, including the Nrf2 antioxidant response, which upregulates heme oxygenase-1 (HO-1) to mitigate cellular damage. However, prolonged heme pathway dysregulation can lead to chronic inflammation and promote cancer progression, particularly through the modulation of CYP2E1 and the transcriptional repressor Bach1."}], "pathway_id": "hsa04640", "pubmed_id": "41259534", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SOX17, RUNX1, DLL4, KITLG, FGF23, Hematopoietic stem cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hematopoietic stem cells (HSCs) mature within SOX17(+)RUNX1(+) hemogenic buds through an endothelial-to-hematopoietic transition. This process is regulated by instructive factors DLL4 and SCF, and restricted by FGF23. The resulting HSCs are capable of differentiating into both myeloid and lymphoid lineages, contributing to definitive hematopoiesis."}], "pathway_id": "hsa04640", "pubmed_id": "41086808", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: hematopoietic stem and progenitor cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hematopoietic stem and progenitor cells undergo clonal expansion and differentiation, giving rise to lineage-committed progenitor cells. Variations in their transcriptional states influence the kinetics of cell division and lineage commitment, resulting in distinct cellular behaviors that contribute to the overall dynamics of hematopoietic differentiation."}], "pathway_id": "hsa04640", "pubmed_id": "40890121", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KMT2A-AFF1 fusion protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The KMT2A-AFF1 fusion protein is associated with acute lymphoblastic leukemia and can drive lineage plasticity, enabling leukemic clones to transition between lymphoid and myeloid lineages. This plasticity allows the maintenance of immunoglobulin and T-cell receptor rearrangements while switching between acute lymphoblastic and acute myeloid leukemia phenotypes, contributing to therapeutic resistance and disease persistence."}], "pathway_id": "hsa04640", "pubmed_id": "40879568", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD5 (upregulated), CD7, CD161 (expressed), BCL11B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CD7(+) progenitor cells exhibit distinct developmental trajectories toward either T cell or innate lymphoid cell (ILC) fates. T cell commitment is marked by CD5 upregulation and is regulated by the transcription factor BCL11B, which suppresses myeloid differentiation while maintaining the potential for NK cell development. ILC-oriented differentiation is characterized by CD161 expression and an ILC-like gene signature. Both T cell- and ILC-oriented progenitor subsets retain developmental plasticity, allowing them to differentiate into T cells or NK cells under appropriate conditions."}], "pathway_id": "hsa04640", "pubmed_id": "40771806", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD34 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CD34 expression marks hematopoietic stem and progenitor cells, which undergo differentiation into erythroid and myeloid lineages. Erythroid lineage priming occurs during early stages of hematopoietic differentiation, preceding full commitment to erythroid fate. Myeloid lineage differentiation follows distinct trajectories involving lineage-specific regulators and surface markers. Molecular regulators serve as surrogates for cellular identity and functional potential, refining the classification and functional understanding of hematopoietic progenitor subsets."}], "pathway_id": "hsa04640", "pubmed_id": "40577131", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hematopoietic cell lineage - Homo sapiens (human)\n**Pathway Description**: Blood-cell development progresses from a hematopoietic stem cell (HSC), which can undergo either self-renewal or differentiation into a multilineage committed progenitor cell: a common lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A CLP gives rise to the lymphoid lineage of white blood cells or leukocytes-the natural killer (NK) cells and the T and B lymphocytes. A CMP gives rise to the myeloid lineage, which comprises the rest of the leukocytes, the erythrocytes (red blood cells), and the megakaryocytes that produce platelets important in blood clotting. Cells undergoing these differentiation process express a stage- and lineage-specific set of surface markers. Therefore cellular stages are identified by the specific expression patterns of these genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hematopoietic Stem Cell, T Cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hematopoietic stem cells originate in the bone marrow and give rise to T cells, which undergo development within the thymic microenvironment. These precursor cells enter the thymus through a process known as thymic seeding, where they follow differentiation trajectories to become mature T cells. The fate of thymus-seeding progenitors is influenced by the thymic microenvironment, and their ability to home to and differentiate within the thymus is essential for the generation of a functional T-cell repertoire."}], "pathway_id": "hsa04640", "pubmed_id": "40562079", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Shigellosis - Homo sapiens (human)\n**Pathway Description**: Shigellosis, or bacillary dysentery, is an intestinal infection caused by Shigella, a genus of enterobacteria. Shigella are potential food-borne pathogens that are capable of colonizing the intestinal epithelium by exploiting epithelial-cell functions and circumventing the host innate immune response. During basolateral entry into the host-cell cytoplasm, Shigella deliver a subset of effectors into the host cells through the type III secretion system. The effectors induce membrane ruffling through the stimulation of the Rac1-WAVE-Arp2/3 pathway, enabling bacterial entry into the epithelial cells. During multiplication within the cells, Shigella secrete another subset of effectors. VirG induces actin polymerization at one pole of the bacteria, allowing the bacteria to spread intracellularly and to infect adjacent cells. OspF, OspG and IpaH(9.8) downregulate the production of proinflammatory cytokines such as IL-8, helping bacteria circumvent the innate immune response.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Asiatic Acid (administration), Ciprofloxacin, Nalidixic Acid.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Asiatic acid disrupts bacterial membranes and enhances the activity of ciprofloxacin against Shigella flexneri. This combination inhibits biofilm formation and efflux pump activity, reducing intracellular bacterial viability. The treatment decreases bacterial burden and promotes recovery from intestinal tissue damage."}], "pathway_id": "hsa05131", "pubmed_id": "41319186", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Shigellosis - Homo sapiens (human)\n**Pathway Description**: Shigellosis, or bacillary dysentery, is an intestinal infection caused by Shigella, a genus of enterobacteria. Shigella are potential food-borne pathogens that are capable of colonizing the intestinal epithelium by exploiting epithelial-cell functions and circumventing the host innate immune response. During basolateral entry into the host-cell cytoplasm, Shigella deliver a subset of effectors into the host cells through the type III secretion system. The effectors induce membrane ruffling through the stimulation of the Rac1-WAVE-Arp2/3 pathway, enabling bacterial entry into the epithelial cells. During multiplication within the cells, Shigella secrete another subset of effectors. VirG induces actin polymerization at one pole of the bacteria, allowing the bacteria to spread intracellularly and to infect adjacent cells. OspF, OspG and IpaH(9.8) downregulate the production of proinflammatory cytokines such as IL-8, helping bacteria circumvent the innate immune response.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RNF213 (degraded).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Shigella evades host detection by degrading RNF213, a protein involved in the innate immune response to intracellular pathogens."}], "pathway_id": "hsa05131", "pubmed_id": "41178817", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Shigellosis - Homo sapiens (human)\n**Pathway Description**: Shigellosis, or bacillary dysentery, is an intestinal infection caused by Shigella, a genus of enterobacteria. Shigella are potential food-borne pathogens that are capable of colonizing the intestinal epithelium by exploiting epithelial-cell functions and circumventing the host innate immune response. During basolateral entry into the host-cell cytoplasm, Shigella deliver a subset of effectors into the host cells through the type III secretion system. The effectors induce membrane ruffling through the stimulation of the Rac1-WAVE-Arp2/3 pathway, enabling bacterial entry into the epithelial cells. During multiplication within the cells, Shigella secrete another subset of effectors. VirG induces actin polymerization at one pole of the bacteria, allowing the bacteria to spread intracellularly and to infect adjacent cells. OspF, OspG and IpaH(9.8) downregulate the production of proinflammatory cytokines such as IL-8, helping bacteria circumvent the innate immune response.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEPT7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased T3SS activation in Shigella flexneri leads to the recruitment of SEPT7 to intracellular bacteria. This recruitment correlates with reduced DNA and protein synthesis in host cells, suggesting that Shigella flexneri induces cell-cycle arrest to facilitate intracellular survival and replication."}], "pathway_id": "hsa05131", "pubmed_id": "41060329", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Epstein-Barr virus infection - Homo sapiens (human)\n**Pathway Description**: Epstein-Barr virus (EBV) is a gamma-herpes virus that widely infects human populations predominantly at an early age but remains mostly asymptomatic. EBV has been linked to a wide spectrum of human malignancies, including nasopharyngeal carcinoma and other hematologic cancers, like Hodgkin's lymphoma, Burkitt's lymphoma (BL), B-cell immunoblastic lymphoma in HIV patients, and posttransplant-associated lymphoproliferative diseases.  EBV has the unique ability to establish life-long latent infection in primary human B lymphocytes. During latent infection, EBV expresses a small subset of genes, including 6 nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), 3 latent membrane proteins (LMP-1, -2A, and -2B), 2 small noncoding RNAs (EBER-1 and 2). On the basis of these latent gene expression, three different latency patterns associated with the types of cancers are recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS1 (impaired activity), ALAS2 (impaired activity), Porphobilinogen deaminase (deficiency), Protoporphyrinogen oxidase (deficiency), Ferrochelatase (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid in the bloodstream result from impaired activity of enzymes in the heme biosynthesis pathway, particularly ALAS1 and ALAS2. Deficiencies in Porphobilinogen deaminase, Protoporphyrinogen oxidase, or Ferrochelatase further contribute to the accumulation of intermediate metabolites. These disruptions lead to the clinical manifestations of protoporphyria, including neurologic symptoms and photosensitivity."}], "pathway_id": "hsa05169", "pubmed_id": "41288024", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Epstein-Barr virus infection - Homo sapiens (human)\n**Pathway Description**: Epstein-Barr virus (EBV) is a gamma-herpes virus that widely infects human populations predominantly at an early age but remains mostly asymptomatic. EBV has been linked to a wide spectrum of human malignancies, including nasopharyngeal carcinoma and other hematologic cancers, like Hodgkin's lymphoma, Burkitt's lymphoma (BL), B-cell immunoblastic lymphoma in HIV patients, and posttransplant-associated lymphoproliferative diseases.  EBV has the unique ability to establish life-long latent infection in primary human B lymphocytes. During latent infection, EBV expresses a small subset of genes, including 6 nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), 3 latent membrane proteins (LMP-1, -2A, and -2B), 2 small noncoding RNAs (EBER-1 and 2). On the basis of these latent gene expression, three different latency patterns associated with the types of cancers are recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD27 and CD21, ZEB2 (up-regulated), TBX21 (up-regulated), EBNA2, CD27, antigen-presenting cell-related genes (up-regulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Epstein-Barr virus (EBV) infection reprograms autoreactive antinuclear antigen B cells, leading to their transformation into antigen-presenting cells. Infected B cells exhibit increased frequencies of CD27(+)CD21(low) memory B cells and express ZEB2, TBX21 (T-bet), and antigen-presenting cell transcriptional pathways. EBNA2 binds to the transcriptional start sites and regulatory regions of CD27, ZEB2, TBX21, and antigen-presenting cell genes, promoting their up-regulation. These reprogrammed B cells can present antigens to T peripheral helper cells, which in turn activate related EBV-negative antinuclear double-negative 2 B cells and plasmablasts, contributing to autoimmune responses in systemic lupus erythematosus."}], "pathway_id": "hsa05169", "pubmed_id": "41223250", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the PRNP gene are associated with the development of Gerstmann-Straussler-Scheinker syndrome, a rare autosomal-dominant neurodegenerative disorder. This condition manifests through progressive neurological and psychiatric symptoms, including agitation, confusion, dysarthria, gait instability, and sleep disturbance. These clinical features result from the misfolding and aggregation of the prion protein (PrP), leading to neuronal dysfunction and degeneration."}], "pathway_id": "hsa05020", "pubmed_id": "41327454", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (elevated levels of misfolded prion protein (PrPSc)), ALOX15.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of misfolded prion protein (PrPSc) trigger a conformational change in the cellular prion protein (PrPC), leading to the accumulation of protease-resistant aggregates. This conversion initiates a cascade of neurodegenerative processes, including oxidative stress, endoplasmic reticulum stress, and dysfunction of the ubiquitin-proteasome and endosomal-lysosomal systems. These pathological changes contribute to synaptic dysfunction, dendritic atrophy, and ultimately neuronal death. In the context of Creutzfeldt-Jakob disease, microglial reactivity is enhanced, as evidenced by the presence of amoeboid IBA1+ cells, which are associated with inflammatory responses in neurodegenerative proteinopathies."}], "pathway_id": "hsa05020", "pubmed_id": "41316489", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (normal cellular prion protein (PrPC)).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The conversion of the normal cellular prion protein (PrPC) into the misfolded pathogenic form (PrPSc) leads to the accumulation of protease-resistant aggregates, which are central to the pathogenesis of prion diseases such as Creutzfeldt-Jakob disease. This conformational change disrupts normal cellular function and triggers a cascade of neurotoxic effects, including oxidative stress, endoplasmic reticulum stress, and alterations in synaptic and dendritic structures. These processes contribute to neuronal cell death, resulting in progressive neurodegeneration, cognitive decline, and motor dysfunction."}], "pathway_id": "hsa05020", "pubmed_id": "41219908", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dystrophic microglial morphology is associated with advanced stages of neurodegeneration in prion disease. The conformational change from the normal cellular prion protein (PrPC) to the pathogenic scrapie isoform (PrPSc) contributes to the progression of neurodegeneration. This transformation is linked to microglial dysfunction, potentially due to a senescent state, which impairs the ability of microglia to perform essential physiological roles in the central nervous system."}], "pathway_id": "hsa05020", "pubmed_id": "41198557", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STX6 (knockdown), PrP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of the SNARE protein syntaxin-6 modulates intracellular trafficking of prion protein, influencing prion transmission and early disease establishment. Syntaxin-6 overexpression reduces cell-associated prion infectivity and promotes prion secretion, whereas its knockdown increases prion retention and alters disease-related prion morphology. These effects are consistent with a role in prion export and suggest that syntaxin-6 acts as a modifier of prion pathogenesis during early stages of disease development."}], "pathway_id": "hsa05020", "pubmed_id": "41186731", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (Polymorphisms).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Polymorphisms in the prion protein gene (PRNP) influence the stability and conversion efficiency of cellular prion protein (PrP(C)) into the infectious prion form (PrP(Sc)). These genetic variations modulate the pathogenesis of prion disease by altering the misfolding process or promoting the emergence of novel prion strains. The resulting host-prion interactions determine transmission barriers and disease phenotypes, contributing to strain diversity and host susceptibility."}], "pathway_id": "hsa05020", "pubmed_id": "41157580", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the PRNP gene cause the misfolding of the cellular prion protein (PrPC) into its pathogenic form (PrPSc), leading to neurodegeneration and the development of fatal familial insomnia. This neurodegeneration is particularly prominent in the thalamus, contributing to disruptions in sleep-wake cycles and resulting in insomnia, autonomic dysfunctions, motor disturbances, and cognitive decline."}], "pathway_id": "hsa05020", "pubmed_id": "41107634", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Misfolding and self-propagation of pathological proteins, such as the conversion of the cellular prion protein (PrPC) into the pathogenic isoform (PrPSc), contributes to the progression of prion disease. This conformational change results in the accumulation of protease-resistant protein aggregates, which are associated with neurodegeneration."}], "pathway_id": "hsa05020", "pubmed_id": "41004063", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Homo sapiens (human)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (mutated or variant), STX6 (genetically associated), GAL3ST1 (genetically associated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRNP encodes the prion protein (PrP), which exists in a normal cellular form (PrPC) and a misfolded, pathogenic form (PrPSc). Mutations or genetic variants in PRNP are associated with the conversion of PrPC to PrPSc, a key event in the pathogenesis of prion diseases. Genetic evidence from Mendelian and GWAS studies supports PRNP as a causal factor in disease progression. Additional risk loci, such as STX6 and GAL3ST1, have been identified through genetic association studies, suggesting involvement in prion disease susceptibility or progression. These genes contribute to mechanisms underlying neurodegeneration, including altered cellular trafficking, endosomal-lysosomal dysfunction, and neurotoxicity."}], "pathway_id": "hsa05020", "pubmed_id": "41004060", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: USP15, EIF3M, RPN9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The 26S proteasome exhibits compositional and conformational heterogeneity across subcellular compartments, with distinct interactomes and dynamic states influencing its function. Deubiquitinase USP15 interacts with the proteasome, potentially modulating ubiquitin-dependent degradation. In some proteasome variants, the translation initiation factor EIF3M replaces the subunit RPN9, indicating structural plasticity within the proteasome complex. These variations contribute to compartment-specific proteasomal regulation and substrate processing."}], "pathway_id": "hsa03050", "pubmed_id": "41315310", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, TRIM25, BRD7 (ubiquitinated at K119 via K48-linked chains), YB1 (activated), BCL2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM25 interacts with BRD7 and promotes its ubiquitination at the K119 site via K48-linked ubiquitin chains, leading to degradation through the ubiquitin proteasome pathway. This reduction in BRD7 protein stability activates the YB1/Bcl-2 transcriptional axis, which enhances cell proliferation, cell cycle progression, and resistance to paclitaxel in breast cancer. The interaction of TRIM25 with BRD7 is mediated through the PRYSPRY domain of TRIM25 and the N-terminal region of BRD7."}], "pathway_id": "hsa03050", "pubmed_id": "41315221", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PSMB5 (elevated expression), HLA class I.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of the proteasome subunit PSMB5 increases chymotrypsin-like proteasomal activity. This overexpression correlates with reduced cell surface HLA class I levels and the accumulation of ubiquitinated proteins. Persistent PSMB5 upregulation contributes to proteasomal dysregulation, which is associated with the progression of hepatocellular carcinoma and poor clinical outcomes in affected individuals."}], "pathway_id": "hsa03050", "pubmed_id": "41305476", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PSMC5 (loss of function), RPT6 (loss of function).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss of PSMC5/RPT6 function impairs proteasome activity, which results in protein aggregation, disruption of mitochondrial homeostasis, and dysregulation of lipid metabolism and immune signaling."}], "pathway_id": "hsa03050", "pubmed_id": "41298377", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132 (administration), Pevonedistat (administration), Pomalidomide, NTRK1, RET, TPM3-NTRK1 fusion protein (degradation), CCDC6-RET fusion protein, Cereblon, CUL4A, Compound 9 (administration at high concentrations), Compound 20.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TPM3-NTRK1 fusion protein degradation is mediated by Cereblon (CRBN)-dependent polyubiquitination and subsequent proteasomal degradation. This process is inhibited by proteasome inhibitors such as MG132 and Cullin neddylation inhibitor MLN4924. The activity of the degradation compound depends on bivalent binding, and its efficacy is reduced at high concentrations due to the 'hook effect'. In vivo administration of a derivative compound induces degradation of the oncoprotein in xenograft models. This mechanism effectively intercepts oncogenic signaling driven by TRKA and RET fusion proteins."}], "pathway_id": "hsa03050", "pubmed_id": "41290730", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PSMD11 (elevated levels), IL1RL1, PSMC4, IFIH1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of PSMD11 correlate with organ injury and dysfunction, including increased lactate dehydrogenase, aspartate aminotransferase, and hydroxybutyrate dehydrogenase activity, prolonged thrombin time, reduced platelet count, and higher viral load. PSMD11 is part of a proteasome-centered module associated with adverse clinical outcomes, indicating its role in modulating proteasomal activity in response to viral infection and multi-organ failure."}], "pathway_id": "hsa03050", "pubmed_id": "41268558", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bortezomib (Administration), 1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-2-(piperidin-1-yl)ethanone (Administration), Curcumin (Administration), Resveratrol (Administration), PARK2, STIP1, USP14, UCHL1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulation of ubiquitination and deubiquitination enzymes disrupts proteostasis, leading to the accumulation of neurotoxic proteins such as Abeta, tau, alpha-synuclein, and mHtt. This disruption contributes to protein aggregation, mitochondrial dysfunction, neuroinflammation, and altered synaptic function. Mutations in E3 ubiquitin ligases like PARK2 (Parkin) and CHIP, as well as deubiquitinases such as USP14 and UCHL1, impair the ubiquitin-proteasome system (UPS), which normally regulates protein degradation and subcellular localization. Post-translational modifications such as phosphorylation and acetylation further modulate UPS activity. Therapeutic strategies targeting the proteasome, including small molecules like bortezomib and IU1-47, as well as natural compounds like curcumin and resveratrol, aim to restore proteostasis and mitigate neurodegeneration."}], "pathway_id": "hsa03050", "pubmed_id": "41264052", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Homo sapiens (human)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melittin (administration), MG-132, Cycloheximide, PSMA7 (reduced levels), USP10, RNF20, CDH2 (downregulation), CDH1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melittin promotes the ubiquitination and proteasomal degradation of PSMA7 via interaction with USP10 and RNF20. This degradation reduces PSMA7 levels, leading to the downregulation of N-cadherin and upregulation of E-cadherin, which inhibits the epithelial-mesenchymal transition and suppresses lung cancer cell metastasis."}], "pathway_id": "hsa03050", "pubmed_id": "41254650", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid, FEZF2, GFP, CD200.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glutamate acts as the primary excitatory neurotransmitter in glutamatergic synapses, where it binds to ionotropic and metabotropic glutamate receptors to facilitate synaptic transmission and modulate neuronal activity. FEZF2, a transcription factor, regulates the fate specification of sub-cerebral projection neurons during forebrain development. Post-mitotic sub-cerebral projection neurons exhibit electrophysiological properties and form glutamatergic synapses, which are enhanced through co-culture with motor neurons. CD200 expression aids in the isolation of mature neuronal populations."}], "pathway_id": "hsa04724", "pubmed_id": "41332368", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Homer1, Gephyrin, Glutamate receptor, ionotropic, Vesicular glutamate transporter 2, GABRA2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Homer1 anchors ionotropic glutamate receptors to the postsynaptic membrane, facilitating excitatory synaptic transmission. Vesicular glutamate transporter 2 (VGluT2) is localized in presynaptic terminals and is in contact with Homer1+ puncta, indicating glutamatergic synaptic contacts. Gephyrin anchors GABA(A) receptors, particularly the alpha-2 subunit, to the membrane and is associated with inhibitory synapses. The colocalization of Homer1 and GABA(A)-alpha(2) is minimal, confirming the distinct spatial organization of excitatory and inhibitory synapses. These molecular arrangements support the synaptic architecture underlying somatosensation in the spinal dorsal horn."}], "pathway_id": "hsa04724", "pubmed_id": "41025159", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid, metabotropic glutamate receptor 7 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Metabotropic glutamate receptor 7 (mGluR7) functions as a glutamate sensor and inhibitor of glutamate release, thereby modulating excitotoxicity, neuroinflammation, synaptic plasticity, and mitochondrial integrity. Glutamate acts as the primary ligand for mGluR7, triggering G protein-coupled signaling that suppresses excessive neurotransmitter release at presynaptic terminals, particularly during hyperglutamatergic conditions. This regulation helps maintain synaptic homeostasis and protects against glutamate-induced neuronal damage."}], "pathway_id": "hsa04724", "pubmed_id": "40986261", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid (released into synaptic cleft), N-methyl-D-aspartate receptor, gamma-aminobutyric acid type A receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glutamatergic signaling involves the release of L-glutamic acid into the synaptic cleft, where it binds to N-methyl-D-aspartate receptors and gamma-aminobutyric acid type A receptors on postsynaptic cells. These receptors mediate excitatory and inhibitory synaptic transmission, respectively. In certain pathological contexts, cancer cells can form synapse-like structures with neurons and receive glutamate-mediated synaptic inputs, which can promote tumor proliferation through enhanced excitatory signaling. This synaptic signaling mechanism can be targeted therapeutically to inhibit tumor growth."}], "pathway_id": "hsa04724", "pubmed_id": "40931078", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glutamatergic and GABAergic neuronal activity promotes small cell lung cancer (SCLC) proliferation in the brain through paracrine and synaptic interactions. SCLC cells form functional synapses with cortical neurons, and exposure to neuronal activity induces depolarizing currents and intracellular calcium transients in SCLC cells, which are sufficient to drive tumor growth."}], "pathway_id": "hsa04724", "pubmed_id": "40931074", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SKT, PSD-95, SHANK3, RhoA, Rac1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SKT interacts with PSD-95 and SHANK3 as part of the postsynaptic density network, contributing to the structural and functional organization of glutamatergic synapses. Disruption of SKT leads to altered dendritic spine morphology and impaired glutamatergic pre- and postsynaptic function, which is associated with dysregulated RhoA and Rac1 GTPase activity. This results in delayed neuronal synchronization, altered cognitive and executive functions, and impaired motor coordination."}], "pathway_id": "hsa04724", "pubmed_id": "40892546", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Homo sapiens (human)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GRIA1 (altered expression), GRM2 (altered expression), GRM3 (altered expression), GRIA4 (altered expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hypomethylation of DNA in genes encoding subunits of glutamatergic synapse receptors, including GRIA1, GRM2, GRM3, and GRIA4, leads to altered gene expression and potentially disrupted glutamate signaling. This epigenetic modification may contribute to long-term changes in synaptic function and increase susceptibility to neurodevelopmental and psychiatric disorders."}], "pathway_id": "hsa04724", "pubmed_id": "40634142", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Circadian rhythm - Homo sapiens (human)\n**Pathway Description**: Circadian rhythm is an internal biological clock, which enables to sustain an approximately 24-hour rhythm in the absence of environmental cues. In mammals, the circadian clock mechanism consists of cell-autonomous transcription-translation feedback loops that drive rhythmic, 24-hour expression patterns of core clock components. The first negative feedback loop is a rhythmic transcription of period genes (PER1, PER2, and PER3) and chryptochrome genes (CRY1 and CRY2). PER and CRY proteins form a heterodimer, which acts on the CLOCK/BMAL1 heterodimer to repress its own transcription. PER and CRY proteins are phosphorylated by casein kinase epsilon (CKIepsilon), which leads to degradation and restarting of the cycle. The second loop is a positive feedback loop driven by the CLOCK/BMAL1 heterodimer, which initiates transcription of target genes containing E-box cis-regulatory enhancer sequences.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cryptochrome 1 (phosphorylated), Cell Cycle and Apoptosis Regulator 2 (anti-resection activity), CtBP-Interacting Protein (activity), DNA-Dependent Protein Kinase Catalytic Subunit.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cryptochrome 1 modulates the anti-resection activity of Cell Cycle and Apoptosis Regulator 2, limiting the activity of CtIP during nightfall. This regulation is dependent on DNA-Dependent Protein Kinase-mediated phosphorylation of Cryptochrome 1. These interactions contribute to the circadian oscillation of DNA resection, a key step in homologous recombination and DNA repair pathway selection."}], "pathway_id": "hsa04710", "pubmed_id": "41326346", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Circadian rhythm - Homo sapiens (human)\n**Pathway Description**: Circadian rhythm is an internal biological clock, which enables to sustain an approximately 24-hour rhythm in the absence of environmental cues. In mammals, the circadian clock mechanism consists of cell-autonomous transcription-translation feedback loops that drive rhythmic, 24-hour expression patterns of core clock components. The first negative feedback loop is a rhythmic transcription of period genes (PER1, PER2, and PER3) and chryptochrome genes (CRY1 and CRY2). PER and CRY proteins form a heterodimer, which acts on the CLOCK/BMAL1 heterodimer to repress its own transcription. PER and CRY proteins are phosphorylated by casein kinase epsilon (CKIepsilon), which leads to degradation and restarting of the cycle. The second loop is a positive feedback loop driven by the CLOCK/BMAL1 heterodimer, which initiates transcription of target genes containing E-box cis-regulatory enhancer sequences.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EZH2 (elevated expression), CLOCK (downregulation), CRY1 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of EZH2 promotes tumor proliferation and progression in hepatocellular carcinoma. EZH2 downregulates the expression of core circadian rhythm regulators CLOCK and CRY1, leading to disruption of circadian gene regulation. This dysregulation is associated with DNA damage, poor prognosis, and immune infiltration by Th2 cells and dendritic cells."}], "pathway_id": "hsa04710", "pubmed_id": "41298718", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Homo sapiens (human)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDLIM2 (polyubiquitination), TRIM27 (proteasomal degradation), PBXIP1, STAT3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PDLIM2 interacts with TRIM27, promoting its K27-linked polyubiquitination and subsequent proteasomal degradation, which attenuates STAT3 signaling activation. PBXIP1 enhances PDLIM2 polyubiquitination through the ubiquitinproteasome system, leading to PDLIM2 protein destabilization. These interactions contribute to the regulation of hepatocellular carcinoma progression via the TRIM27/STAT3 oncogenic axis."}], "pathway_id": "hsa04120", "pubmed_id": "41340074", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Homo sapiens (human)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GSK3B, CTNNB1, FBXW7, MAEA, RMND5A, GID complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GSK3B promotes the stabilization of CTNNB1 by preventing its ubiquitination via the GID complex. CTNNB1 ubiquitination and subsequent degradation are enhanced upon GSK3B suppression, independent of FBXW7. The GID complex, composed of MAEA and RMND5A, mediates this ubiquitination. Disruption of the interaction between MAEA and CTNNB1 by GSK3B leads to CTNNB1 stabilization, while knockdown of GID components rescues CTNNB1 levels. This mechanism operates within the context of ubiquitin-mediated proteolysis and the Wnt signaling pathway."}], "pathway_id": "hsa04120", "pubmed_id": "41258755", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Homo sapiens (human)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melittin (administration), PSMA7 (ubiquitinated), USP10, RNF20, CDH1 (upregulated), CDH2 (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melittin promotes RNF20-mediated ubiquitination and proteasomal degradation of PSMA7. PSMA7 interacts with USP10, which may deubiquitinate PSMA7, thereby stabilizing it. Melittin disrupts this interaction, leading to increased ubiquitination and degradation of PSMA7 via the ubiquitin-proteasome system. This results in the suppression of epithelial-mesenchymal transition (EMT) markers such as N-cadherin and the upregulation of E-cadherin, ultimately inhibiting cancer cell migration and metastasis."}], "pathway_id": "hsa04120", "pubmed_id": "41254650", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Homo sapiens (human)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TREM2, TRIM21, STAT1 (phosphorylated), SYK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TREM2 stabilizes STAT1 by preventing its ubiquitination mediated by TRIM21, while simultaneously promoting STAT1 phosphorylation via SYK. This leads to the upregulation of CCL8 and PD-L1, contributing to an immunosuppressive tumor microenvironment and gastric cancer progression."}], "pathway_id": "hsa04120", "pubmed_id": "41253786", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Homo sapiens (human)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DTL, SMAD4 (K48-linked ubiquitination), E3 ubiquitin ligase, CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DTL functions as an E3 ubiquitin ligase, catalyzing K48-linked ubiquitination of SMAD4, which targets it for proteasomal degradation. The loss of SMAD4 promotes Wnt/beta-catenin signaling, contributing to tumorigenesis."}], "pathway_id": "hsa04120", "pubmed_id": "41203163", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Homo sapiens (human)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT, Post-translational modifications.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Huntingtin (HTT) is a multifunctional scaffold protein involved in vesicular transport, transcriptional regulation, and energy metabolism. The mutant form of HTT (mHTT), characterized by an expanded polyglutamine (polyQ) tract in its N-terminal region, disrupts these functions. Post-translational modifications (PTMs) such as phosphorylation, ubiquitination, acetylation, and SUMOylation regulate HTT's conformation, aggregation, subcellular localization, and degradation. Dysregulation of these PTMs contributes to mHTT accumulation and selective neuronal vulnerability, promoting neurodegeneration."}], "pathway_id": "hsa05016", "pubmed_id": "41303392", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Homo sapiens (human)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT (mutant).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Repression of mutant HTT transcription reduces somatic instability of the CAG repeat in the huntingtin gene. This suggests that transcriptional silencing of mutant HTT may serve as a protective mechanism against repeat instability, a key pathological feature in Huntington disease progression."}], "pathway_id": "hsa05016", "pubmed_id": "41238535", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Homo sapiens (human)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Huntingtin, HTT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Expanded CAG repeats in the HTT gene lead to the production of mutant huntingtin (Htt) protein, which accumulates as toxic aggregates in neurons. This mutant protein disrupts cellular processes including vesicular transport, calcium homeostasis, mitochondrial function, and autophagy, ultimately contributing to neurodegeneration and the clinical features of Huntington disease."}], "pathway_id": "hsa05016", "pubmed_id": "41171314", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Homo sapiens (human)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant huntingtin (HTT) disrupts early neurodevelopment by impairing neural progenitor organization and function. This disruption is accompanied by a mitochondrial stress response, indicating a reduced capacity to manage cellular stress. These alterations suggest that the accumulation of cellular stress and impaired neurodevelopmental processes contribute to the progression of Huntington disease."}], "pathway_id": "hsa05016", "pubmed_id": "41147161", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Homo sapiens (human)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT (Huntingtin), TFEB (Transcription Factor EB), TFE3 (Transcription Factor E3), LGALS3 (Galectin-3).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Misfolded and aggregated mutant Huntingtin (muHTT) sequesters the transcription factors TFEB and TFE3 into protein inclusions, reducing their bioavailability. TFEB and TFE3 normally respond to lysosomal membrane permeabilization by activating lysophagy and lysosome biogenesis as part of lysosome quality control. In the presence of muHTT, this regulatory pathway is impaired, leading to the accumulation of damaged lysosomes and increased neuronal vulnerability. Galectin-3 (LGALS3) translocates to the lysosomal lumen in response to membrane permeabilization, and its accumulation is reduced when TFEB and TFE3 are overexpressed, suggesting that restoring their activity can mitigate lysosomal dysfunction and muHTT aggregation."}], "pathway_id": "hsa05016", "pubmed_id": "41145409", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SFRP1, WNT3A, CTNNB1, WIF1, DKK1, LRP5, LRP6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced DNA methylation levels at the promoter regions of WNT signaling pathway genes such as SFRP1, WNT3A, CTNNB1, DKK1, and LRP6 are associated with pulmonary tuberculosis. These epigenetic changes may lead to altered gene expression within the Wnt signaling cascade, potentially affecting cellular processes like proliferation, differentiation, and immune response. Decreased methylation of WNT3A and CTNNB1 is further linked to clinical features including fever and drug resistance, while increased SFRP1 methylation correlates with drug-induced liver injury and pulmonary infection. These methylation patterns may reflect dysregulation of Wnt signaling in the pathogenesis of tuberculosis."}], "pathway_id": "hsa04310", "pubmed_id": "41341575", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Esculin (administration), Bromopyruvic Acid, D-Glucose (increased uptake), Pyruvic Acid (increased production), Lactic Acid (increased generation), 5'-Atp (increased synthesis), Wnt (elevated activity), Catenin beta-1, Hypoxia-inducible factor 1-alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated activity of the Wnt/beta-catenin/HIF-1alpha pathway promotes aerobic glycolysis in gastric cancer cells, supporting tumor progression. Inhibition of this pathway by esculin reduces glucose uptake, pyruvate production, lactate generation, and ATP synthesis, thereby suppressing aerobic glycolysis. This metabolic inhibition correlates with decreased cell proliferation, migration, and invasion, and increased apoptosis. The suppression of this signaling axis also leads to reduced tumor growth in vivo."}], "pathway_id": "hsa04310", "pubmed_id": "41340325", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glycyrrhizin, CTNNB1, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glycyrrhizic acid interacts with CTNNB1 and AKT1, leading to the modulation of Wnt signaling. This results in enhanced osteogenesis and inhibited osteoclastogenesis, contributing to the anti-osteoporotic effects observed in the Wnt signaling pathway."}], "pathway_id": "hsa04310", "pubmed_id": "41320184", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACSM3 (over-expression), AKT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ACSM3 promotes tumorigenesis by impairing the WNT/AKT signaling pathway. ACSM3 over-expression suppresses breast cancer cell migration and invasion and enhances AKT phosphorylation, which is associated with tumor growth inhibition and reduced metastatic potential."}], "pathway_id": "hsa04310", "pubmed_id": "41318133", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Xav-939, YEATS2 (elevated expression), Vimentin (increased expression), CDH2 (increased expression), CDH1 (decreased expression), Wnt, CTNNB1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of YEATS2 activates Wnt/beta-catenin signaling, leading to increased expression of vimentin and N-cadherin while decreasing E-cadherin. This results in epithelial-mesenchymal transition, enhanced cell migration, and invasion in gastric cancer cells. The activation of beta-catenin and upregulation of Wnt signaling components drive these phenotypic changes."}], "pathway_id": "hsa04310", "pubmed_id": "41311083", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TMCO1 (elevated expression), CTNNB1 (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated TMCO1 expression promotes gastric cancer progression by activating the Wnt/beta-catenin signaling pathway, leading to increased CTNNB1 levels in the cytoplasm and nucleus. This activation inhibits apoptosis while enhancing tumor cell proliferation, migration, and invasion."}], "pathway_id": "hsa04310", "pubmed_id": "41311080", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Wnt, beta-catenin (bound to T-cell factor), T-cell factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Wnt signaling regulates cell fate and tissue regeneration by stabilizing cytoplasmic beta-catenin, which translocates to the nucleus and activates Wnt-regulated genes through interaction with T-cell factor family transcription factors. This pathway plays a central role in the differentiation of adipose-derived stem cells into tenocytes, a process essential for tendon regeneration and tissue engineering."}], "pathway_id": "hsa04310", "pubmed_id": "41307143", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lithium Carbonate (administration), Lithium Chloride, GSK3B (phosphorylated at serine 9), phosphorylated serine 9 of GSK3B (phosphorylated at serine 9), MYC, PARP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lithium modulates GSK3B activity through phosphorylation at serine 9, which disrupts Wnt/beta-catenin signaling. This disruption leads to reduced cell proliferation and impaired self-renewal capacity in colorectal cancer cells. Lithium induces caspase-independent apoptosis, as evidenced by increased Annexin-V/IP positivity and TUNEL staining, but without cleavage of caspase-3. PARP-1 cleavage occurs in some cell lines, indicating potential DNA fragmentation. These effects are associated with decreased viability and colony-forming efficiency in a cell-type-specific manner."}], "pathway_id": "hsa04310", "pubmed_id": "41303707", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Homo sapiens (human)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1, ALAS2, SLC40A1 (malfunction), Heme (dysregulated), IRP1, IRP2, TF (dysregulated), TFRC (dysregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) regulate the activity of aminolevulinic acid synthase 1 (ALAS1) and ALAS2, which are rate-limiting enzymes in the heme biosynthesis pathway. Disruption of ALAS1 and ALAS2 activity alters heme production, which in turn affects iron homeostasis through interactions with iron regulatory proteins IRP1 and IRP2. Heme serves as a cofactor for cytochromes and hemoproteins, and its dysregulation can lead to anemia or iron overload. Transferrin (TF) and transferrin receptor 1 (TFRC) mediate cellular iron uptake, and their dysregulation contributes to oxidative stress. Ferroportin (SLC40A1) facilitates iron export from cells, and its malfunction is associated with systemic iron accumulation."}], "pathway_id": "hsa04310", "pubmed_id": "41291818", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Homo sapiens (human)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gnetin H (administration), Boro-Scopol, N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]benzo[b]thiophene-2-carboxamide, cAMP response element-binding protein, Brain-derived neurotrophic factor, Tropomyosin receptor kinase B, Doublecortin (increased), Glial fibrillary acidic protein (reduced), Iba1 (ionized calcium-binding adapter molecule 1) (reduced).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gnetin H enhances synaptic plasticity by promoting long-term potentiation (LTP) in the hippocampus. It restores CREB-BDNF signaling through the TrkB cascade, which supports hippocampal neurogenesis by increasing DCX-positive neurogenic cells. This signaling also attenuates glial reactivity, as evidenced by reduced astrocytic (GFAP) and microglial (Iba1) activation. Activation of CREB-BDNF signaling contributes to the preservation of cholinergic activity, which is critical for cognitive and memory functions."}], "pathway_id": "hsa04720", "pubmed_id": "41241326", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Homo sapiens (human)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Fucose (metabolized), Fucokinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "L-fucose enhances excitatory neurotransmission and long-term potentiation by modulating presynaptic release. This effect is mediated through the FCSK-driven salvage pathway, which metabolizes l-fucose within cells. Impaired l-fucose metabolism is associated with synaptic deficits observed in Alzheimer's disease. Correction of this metabolic deficit through exogenous l-fucose administration restores long-term potentiation and mitigates synaptic dysfunction."}], "pathway_id": "hsa04720", "pubmed_id": "41202124", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Homo sapiens (human)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid, Baclofen, APP (soluble form (sAPPalpha)), GABBR1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Soluble amyloid precursor protein alpha (sAPPalpha) activates gamma-aminobutyric acid type B (GABA(B)) receptors, leading to presynaptic inhibition of glutamatergic synapses. This inhibition modulates long-term potentiation and prevents excessive synaptic modification, thereby maintaining associative memory function and reducing the risk of runaway synaptic plasticity."}], "pathway_id": "hsa04720", "pubmed_id": "41025328", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Homo sapiens (human)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dopamine modulates hippocampal synaptic plasticity by influencing spike-timing-dependent plasticity and intrinsic neuronal properties. Despite a reduction in neuronal excitability, dopamine facilitates the induction of long-term potentiation. This effect is contingent upon physiological dopamine levels, which are necessary for maintaining synaptic plasticity and enabling signal integration processes within CA1 pyramidal neurons."}], "pathway_id": "hsa04720", "pubmed_id": "40998967", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon-13 (labeled), D-Glucose (uniformly labeled), L-Glutamine (uniformly labeled).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Carbon-13 stable isotope labeling enables the tracing of metabolic flux through glycolysis, the tricarboxylic acid cycle, the hexosamine biosynthetic pathway, and glutaminolysis. Uniformly labeled glucose and glutamine serve as metabolic tracers, allowing the quantification of carbon incorporation into downstream metabolites. This approach provides a detailed view of carbon utilization in cellular metabolic networks."}], "pathway_id": "hsa00020", "pubmed_id": "41264887", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucose-6-Phosphate (reduced levels), Pyruvic Acid (reduced levels), S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate, Myosin Heavy Chain 7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated metabolic inflexibility in the heart, characterized by suppressed glycolysis, lipid oxidation, and tricarboxylic acid (TCA) cycle activity, leads to reduced levels of glucose-6-phosphate, pyruvate, and acetyl-CoA. This metabolic suppression impairs oxidative phosphorylation and mitochondrial function, contributing to impaired diastolic function and reduced contractility. The increased lactate-to-pyruvate ratio indicates a shift toward anaerobic glycolysis, further reflecting mitochondrial dysfunction and energy production deficits. These metabolic alterations are associated with excessive trabeculation and thinning of the compacted myocardial layer, features of left ventricular noncompaction. Downregulation of glycolytic and mitochondrial genes exacerbates this metabolic disruption."}], "pathway_id": "hsa00020", "pubmed_id": "41237118", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Citric Acid, cis-Aconitic acid, Isocitric Acid, 2-Oxoglutaric Acid, Succinic Acid, Fumaric Acid (elevated levels), Malic Acid (elevated levels), Oxaloacetic Acid, ERBB2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of fumaric acid and malic acid in HER2-positive breast cancer cells are associated with reduced sensitivity to trastuzumab. Accumulation of these TCA cycle metabolites diminishes the anti-proliferative and pro-apoptotic effects of trastuzumab, contributing to resistance in trastuzumab-sensitive cell lines. This metabolic shift suggests a role for fumaric and malic acid as predictive biomarkers for trastuzumab resistance in HER2-positive breast cancer."}], "pathway_id": "hsa00020", "pubmed_id": "41212217", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5'-Atp, PCK1 (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphoenolpyruvate carboxykinase 1 (PCK1) participates in gluconeogenesis and tricarboxylic acid cycle flux, and its activity influences mitochondrial function and kidney health. PCK1 deficiency increases susceptibility to kidney injury. PCK1 may mediate protective effects through its role in cataplerosis, a process that removes intermediates from the TCA cycle to support anabolic pathways and cellular energy homeostasis."}], "pathway_id": "hsa00020", "pubmed_id": "41110885", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Succinic Acid, Succinate receptor 1, Hypoxia-inducible factor 1 subunit alpha (stabilized).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Succinate, a key intermediate in the tricarboxylic acid cycle, acts as a signaling molecule by binding to Succinate receptor 1, thereby modulating innate immune responses. This interaction influences the production of reactive oxygen species and the stabilization of Hypoxia-inducible factor 1 subunit alpha. Depending on the cellular context, succinate can promote either pro-inflammatory or anti-inflammatory effects, contributing to immune cell modulation and tissue-specific inflammatory outcomes."}], "pathway_id": "hsa00020", "pubmed_id": "41080558", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Citrate cycle (TCA cycle) - Homo sapiens (human)\n**Pathway Description**: The citrate cycle (TCA cycle, Krebs cycle) is an important aerobic pathway for the final steps of the oxidation of carbohydrates and fatty acids. The cycle starts with acetyl-CoA, the activated form of acetate, derived from glycolysis and pyruvate oxidation for carbohydrates and from beta oxidation of fatty acids. The two-carbon acetyl group in acetyl-CoA is transferred to the four-carbon compound of oxaloacetate to form the six-carbon compound of citrate. In a series of reactions two carbons in citrate are oxidized to CO2 and the reaction pathway supplies NADH for use in the oxidative phosphorylation and other metabolic processes. The pathway also supplies important precursor metabolites including 2-oxoglutarate. At the end of the cycle the remaining four-carbon part is transformed back to oxaloacetate. According to the genome sequence data, many organisms seem to lack genes for the full cycle [MD:M00009], but contain genes for specific segments [MD:M00010 M00011].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tetrabromobisphenol A, Tetrachlorobisphenol A, Tetrabromobisphenol S, Alpha-Ketoglutarate (elevated levels), 5'-Atp (elevated levels), 5'-Adp (elevated levels), Glucose 6-phosphate (reduced levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of alpha-ketoglutarate, ATP, and ADP, along with reduced glucose 6-phosphate, indicate TCA cycle activation. This metabolic shift suggests increased mitochondrial activity and enhanced oxidative metabolism. The observed changes in TCA cycle metabolites reflect a disruption in cellular energy homeostasis, potentially contributing to metabolic dysfunction."}], "pathway_id": "hsa00020", "pubmed_id": "41066809", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Sphingolipid signaling pathway - Homo sapiens (human)\n**Pathway Description**: Sphingomyelin (SM) and its metabolic products are now known to have second messenger functions in a variety of cellular signaling pathways. Particularly, the sphingolipid metabolites, ceramide (Cer) and sphingosine-1-phosphate (S1P), have emerged as a new class of potent bioactive molecules. Ceramide can be generated de novo or by hydrolysis of membrane sphingomyelin by sphingomyelinase (SMase). Ceramide is subsequently metabolized by ceramidase to generate sphingosine (Sph) which in turn produces S1P through phosphorylation by sphingosine kinases 1 and 2 (SphK1, 2). Both ceramide and S1P regulate cellular responses to stress, with generally opposing effects. S1P functions as a growth and survival factor, acting as a ligand for a family of G protein-coupled receptors, whereas ceramide activates intrinsic and extrinsic apoptotic pathways through receptor-independent mechanisms.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ceramide, Sphingosine 1-Phosphate, Ganglioside GM1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ceramide and sphingosine-1-phosphate regulate physiological and pathological conditions by modulating sphingolipid signaling pathways in neurons and glia. Alterations in the sphingosine-1-phosphate/ceramide ratio and chain length profiles disrupt these pathways, contributing to neurological disorders. Ganglioside GM1 supports neuronal membrane receptor function and exhibits neurotrophic and neuroprotective properties, with reduced levels potentially linked to neurodegenerative disease progression."}], "pathway_id": "hsa04071", "pubmed_id": "41303601", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Sphingolipid signaling pathway - Homo sapiens (human)\n**Pathway Description**: Sphingomyelin (SM) and its metabolic products are now known to have second messenger functions in a variety of cellular signaling pathways. Particularly, the sphingolipid metabolites, ceramide (Cer) and sphingosine-1-phosphate (S1P), have emerged as a new class of potent bioactive molecules. Ceramide can be generated de novo or by hydrolysis of membrane sphingomyelin by sphingomyelinase (SMase). Ceramide is subsequently metabolized by ceramidase to generate sphingosine (Sph) which in turn produces S1P through phosphorylation by sphingosine kinases 1 and 2 (SphK1, 2). Both ceramide and S1P regulate cellular responses to stress, with generally opposing effects. S1P functions as a growth and survival factor, acting as a ligand for a family of G protein-coupled receptors, whereas ceramide activates intrinsic and extrinsic apoptotic pathways through receptor-independent mechanisms.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sphingosine 1-Phosphate, 4-Octadecene-1,3-diol, 2-(dimethylamino)-, (S-(R*,S*-(E)))-, sphingomyelin synthase (pharmacologically inhibited), fatty acid synthase (elevated activity), acetyl-CoA carboxylase (elevated activity), 3-hydroxy-3-methylglutaryl-CoA reductase, liver X receptor alpha, sterol regulatory element-binding transcription factor 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sphingolipid metabolism modulates tumor progression through opposing effects of ceramides and sphingosine-1-phosphate (S1P). Ceramides inhibit tumor growth by activating apoptotic pathways, while S1P promotes oncogenic signaling through G protein-coupled receptors. Pharmacological inhibition of sphingomyelin synthase, such as with N,N-dimethylsphingosine (D609), disrupts sphingolipid homeostasis and enhances the efficacy of tyrosine kinase inhibitors like sorafenib and lenvatinib. Altered lipid metabolism, including elevated fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC) activity, supports de novo lipogenesis and tumor cell proliferation. Cholesterol metabolism, regulated by HMG-CoA reductase (HMGCR), liver X receptor alpha (LXR), and sterol regulatory element-binding protein 1 (SREBP1), contributes to immunosuppressive tumor microenvironments and resistance to therapy. Targeting these metabolic pathways disrupts lipid homeostasis and promotes tumor cell death, including ferroptosis."}], "pathway_id": "hsa04071", "pubmed_id": "41179299", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Sphingolipid signaling pathway - Homo sapiens (human)\n**Pathway Description**: Sphingomyelin (SM) and its metabolic products are now known to have second messenger functions in a variety of cellular signaling pathways. Particularly, the sphingolipid metabolites, ceramide (Cer) and sphingosine-1-phosphate (S1P), have emerged as a new class of potent bioactive molecules. Ceramide can be generated de novo or by hydrolysis of membrane sphingomyelin by sphingomyelinase (SMase). Ceramide is subsequently metabolized by ceramidase to generate sphingosine (Sph) which in turn produces S1P through phosphorylation by sphingosine kinases 1 and 2 (SphK1, 2). Both ceramide and S1P regulate cellular responses to stress, with generally opposing effects. S1P functions as a growth and survival factor, acting as a ligand for a family of G protein-coupled receptors, whereas ceramide activates intrinsic and extrinsic apoptotic pathways through receptor-independent mechanisms.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sphingosine 1-Phosphate, Ceramide, ceramide kinase, sphingosine kinase 1 and 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ceramide promotes cell death through intrinsic and extrinsic apoptotic pathways, while sphingosine-1-phosphate (S1P) acts as a pro-survival lipid that activates G protein-coupled receptors. The balance between these two sphingolipid metabolites is regulated by ceramide kinase and sphingosine kinases 1 and 2. Disruption of this balance contributes to tumor growth, metastasis, and resistance to therapy by modulating processes such as apoptosis, angiogenesis, immunological evasion, and drug resistance."}], "pathway_id": "hsa04071", "pubmed_id": "41111470", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Sphingolipid signaling pathway - Homo sapiens (human)\n**Pathway Description**: Sphingomyelin (SM) and its metabolic products are now known to have second messenger functions in a variety of cellular signaling pathways. Particularly, the sphingolipid metabolites, ceramide (Cer) and sphingosine-1-phosphate (S1P), have emerged as a new class of potent bioactive molecules. Ceramide can be generated de novo or by hydrolysis of membrane sphingomyelin by sphingomyelinase (SMase). Ceramide is subsequently metabolized by ceramidase to generate sphingosine (Sph) which in turn produces S1P through phosphorylation by sphingosine kinases 1 and 2 (SphK1, 2). Both ceramide and S1P regulate cellular responses to stress, with generally opposing effects. S1P functions as a growth and survival factor, acting as a ligand for a family of G protein-coupled receptors, whereas ceramide activates intrinsic and extrinsic apoptotic pathways through receptor-independent mechanisms.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid (exposure), Fumonisin B1, CCL2, TNF, mesenchymal stromal cell, monocyte-derived macrophage.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Palmitic acid exposure in mesenchymal stromal cells increases ceramide synthesis, which contributes to enhanced suppression of monocyte-derived macrophage TNF production through a CCL2-dependent mechanism."}], "pathway_id": "hsa04071", "pubmed_id": "40770765", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (transcriptional activity), KSR1, MST1, LATS1, RHOA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KSR1 interacts with YAP1, MST1, and LATS1 to form a complex that modulates Hippo signaling. This interaction contributes to the regulation of YAP1 protein levels and its transcriptional activity, partially through the RhoA/actin signaling axis. These interactions support the control of organ size and tissue homeostasis."}], "pathway_id": "hsa04392", "pubmed_id": "41326667", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Dihydromyricetin (administration), integrin (increased expression), Hippo signaling pathway (suppressed), Yes-associated protein 1 (increased levels), ATP-binding cassette subfamily G member 1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extracellular matrix stiffness increases integrin expression, which suppresses the Hippo signaling pathway. This suppression leads to increased levels of Yes-associated protein 1 (YAP), which in turn upregulates ATP-binding cassette subfamily G member 1 (ABCG1). ABCG1 reduces ferroptosis sensitivity in lung adenocarcinoma cells. Dihydromyricetin downregulates ABCG1 expression, thereby sensitizing cells to ferroptosis."}], "pathway_id": "hsa04392", "pubmed_id": "41286767", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (dephosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1, the effector of the Hippo signaling pathway, is phosphorylated and inactivated in the cytoplasm, leading to its cytoplasmic retention. When inactivated, YAP1 translocates to the nucleus where it undergoes dephosphorylation, enabling it to modulate cellular processes such as proliferation and the inhibition of apoptosis. YAP1 activity is positively regulated by interactions with the extracellular matrix, which influences tissue growth and contributes to tumorigenesis."}], "pathway_id": "hsa04392", "pubmed_id": "41227346", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Irinotecan (Administration), TEA domain transcription factor 4 (Elevated expression), WW domain containing transcription regulator 1, Amphiregulin, SRY-box transcription factor 11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TEAD4 interacts with Hippo signaling pathway components to regulate gene transcription and promote tumor progression in triple-negative breast cancer. Elevated TEAD4 expression enhances cell migration and invasion. Inhibition of TEAD4, either through knockdown or treatment with irinotecan, suppresses these processes. Irinotecan binds to TEAD4, forming a stable complex that disrupts its function, thereby reducing tumor cell motility and aggressiveness."}], "pathway_id": "hsa04392", "pubmed_id": "41168787", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, Lactate, YAP1 (elevated activity), LATS1, LATS2, SOX9, CSF1, IGF1, IGF1R.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated YAP1 activity in cardiac fibroblasts induces glycolysis and promotes fibroinflammation. This metabolic shift is accompanied by the secretion of CSF1, which stimulates macrophage expansion. Macrophages, in turn, secrete IGF1, which binds to the IGF1 receptor on fibroblasts, enhancing their proliferation and fibrotic activity. YAP1 activation also disrupts fibroblast lineage fidelity, driving them toward a SOX9-expressing osteochondroprogenitor cell state. Inhibition of glycolysis or lactate production suppresses fibrosis, indicating a direct metabolic contribution to pathological outcomes."}], "pathway_id": "hsa04392", "pubmed_id": "41165345", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: alpha-Synuclein (elevated levels), Insulin-degrading enzyme (overexpression), MST1 and MST2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of insulin-degrading enzyme (IDE) correlates with elevated alpha-synuclein levels and increased neuronal apoptosis. IDE overexpression suppresses the Hippo signaling pathway, particularly by inhibiting MST1 and MST2 kinases, which in turn reduces alpha-synuclein pathology and protects dopaminergic neurons from degeneration. This pathway modulation contributes to neuroprotection and the mitigation of motor deficits."}], "pathway_id": "hsa04392", "pubmed_id": "41136383", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP, TAZ (in condensates), FUS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP and TAZ form biomolecular condensates through phase separation, which facilitates their transcriptional activation. The protein FUS modulates the biophysical properties of TAZ condensates, thereby influencing their transcriptional activity and contributing to tumorigenesis."}], "pathway_id": "hsa04392", "pubmed_id": "41116205", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132 (administration), RHOBTB2, YAP1, KLHL13 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RHOBTB2 stabilizes KLHL13 by inhibiting its proteasomal degradation, which contributes to the regulation of Hippo-YAP1 signaling. This interaction promotes cell proliferation and suppresses apoptosis in acute myeloid leukemia. KLHL13 protein levels are directly influenced by RHOBTB2 expression, and proteasome inhibition with MG132 reverses KLHL13 downregulation caused by RHOBTB2 knockdown."}], "pathway_id": "hsa04392", "pubmed_id": "41107424", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (elevated activity), CTGF, TEAD, MST1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1, in complex with TEAD, promotes the expression of its own negative regulator MST1, forming a feedback loop that modulates viral replication and beta-cell apoptosis during coxsackievirus B infections. Elevated YAP1 activity enhances viral replication and islet inflammation, while also contributing to beta-cell death and functional impairment. Inhibition of MST1 increases viral replication and decreases beta-cell apoptosis, indicating a regulatory balance between YAP1 and MST1 in controlling the interplay between viral infection and beta-cell viability."}], "pathway_id": "hsa04392", "pubmed_id": "41053097", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Homo sapiens (human)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RPRM (elevated levels), Reprimo, TP53, protocadherin family, Hippo, YAP, TP73.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Reprimo modulate Hippo signaling by activating YAP, which in turn interacts with p73 to induce apoptosis. This extracellular function of Reprimo is part of a signaling cascade initiated by p53 and involving the protocadherin family. Reprimo acts as an upstream regulator of Hippo signaling and promotes tumor suppression through extrinsic apoptotic pathways."}], "pathway_id": "hsa04392", "pubmed_id": "41036848", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mucin type O-glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: O-glycans are a class of glycans that modify serine or threonine residues of proteins. Biosynthesis of O-glycans starts from the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine. The first GalNAc may be extended with sugars including galactose, N-acetylglucosamine, fucose, or sialic acid, but not mannose, glucose, or xylose. Depending on the sugars added, there are four common O-glycan core structures, cores 1 through 4, and an additional four, cores 5 though 8. Mucins are highly O-glycosylated glycoproteins ubiquitous in mucous secretions on cell surfaces and in body fluids. Mucin O-glycans can be branched, and many sugars or groups of sugars are antigenic. Important modifications of mucin O-glycans include O-acetylation of sialic acid and O-sulfation of galactose and N-acetylglucosamine.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: UDP-D-galactose (transported into the Golgi lumen), N-acetyl-alpha-D-galactosamine, D-Galactose, N-Acetyl-D-Glucosamine, L-Fucose, N-Acetyl-Neuraminic Acid, SLC35A2, Ugalt, C1GALT1, GCNT2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "UDP-D-galactose transport into the Golgi lumen is mediated by SLC35A2/UDP-galactose transporter. This process is essential for the biosynthesis of galactose-containing glycans, including mucin-type O-glycans. Deficient transport leads to reduced mucin-type O-glycans on muscles and neuromuscular junctions, resulting in mislocalized NMJ boutons and basement membrane deficiencies. This disruption in O-glycosylation impairs NMJ architecture and contributes to neurological abnormalities."}], "pathway_id": "hsa00512", "pubmed_id": "41008563", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mucin type O-glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: O-glycans are a class of glycans that modify serine or threonine residues of proteins. Biosynthesis of O-glycans starts from the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine. The first GalNAc may be extended with sugars including galactose, N-acetylglucosamine, fucose, or sialic acid, but not mannose, glucose, or xylose. Depending on the sugars added, there are four common O-glycan core structures, cores 1 through 4, and an additional four, cores 5 though 8. Mucins are highly O-glycosylated glycoproteins ubiquitous in mucous secretions on cell surfaces and in body fluids. Mucin O-glycans can be branched, and many sugars or groups of sugars are antigenic. Important modifications of mucin O-glycans include O-acetylation of sialic acid and O-sulfation of galactose and N-acetylglucosamine.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-acetyl-alpha-D-galactosamine, Polypeptide N-acetylgalactosaminyltransferase, Polypeptide N-acetylgalactosaminyltransferase 6 (high activity), Spike glycoprotein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Protein O-glycosylation, specifically mucin-type O-glycosylation, is catalyzed by polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts), which initiate the process by transferring N-acetylgalactosamine to serine or threonine residues. Among these enzymes, ppGalNAc-T6 exhibits high activity in modifying the spike glycoprotein of SARS-CoV-2. O-glycosylation at the protomer-interface regions of the trimeric spike protein contributes to structural stability by forming hydrogen bonds and non-polar interactions between adjacent protomers. This modification enhances the trimeric conformation, which is critical for facilitating viral entry and membrane fusion. Increased O-glycosylation by ppGalNAc-T6 also leads to greater glycan heterogeneity and the addition of new glycosylation sites on the spike protein."}], "pathway_id": "hsa00512", "pubmed_id": "39066577", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mucin type O-glycan biosynthesis - Homo sapiens (human)\n**Pathway Description**: O-glycans are a class of glycans that modify serine or threonine residues of proteins. Biosynthesis of O-glycans starts from the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine. The first GalNAc may be extended with sugars including galactose, N-acetylglucosamine, fucose, or sialic acid, but not mannose, glucose, or xylose. Depending on the sugars added, there are four common O-glycan core structures, cores 1 through 4, and an additional four, cores 5 though 8. Mucins are highly O-glycosylated glycoproteins ubiquitous in mucous secretions on cell surfaces and in body fluids. Mucin O-glycans can be branched, and many sugars or groups of sugars are antigenic. Important modifications of mucin O-glycans include O-acetylation of sialic acid and O-sulfation of galactose and N-acetylglucosamine.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-acetyl-alpha-D-galactosamine (added), D-Galactose, N-Acetyl-D-Glucosamine, L-Fucose, N-Acetyl-Neuraminic Acid.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mucin-type O-glycans are synthesized through the sequential addition of sugars to serine or threonine residues, starting with the transfer of N-acetylgalactosamine (GalNAc). These glycans may be further extended with galactose, N-acetylglucosamine, fucose, or sialic acid, forming distinct core structures. O-glycans play a structural role in mucins, which provide protective barriers on epithelial surfaces, particularly in the airways and gastrointestinal tract. Additionally, O-glycans regulate receptor function, ligand binding, and serve as binding sites for carbohydrate-binding proteins, influencing developmental and homeostatic processes. Aberrant O-glycan patterns are associated with disease states such as cancer and inflammation."}], "pathway_id": "hsa00512", "pubmed_id": "34495529", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JAK, STAT, PI3K, AKT, MAPK, TREM2, P2X7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "JAK-STAT signaling is a key pathway involved in the regulation of microglial activation states, which influence neuroinflammatory responses. In neurodegenerative conditions such as Alzheimer's disease, JAK-STAT signaling modulates microglial phenotypes, shifting them between pro- and anti-inflammatory states. This pathway interacts with other signaling cascades such as PI3K-AKT and MAPK, which collectively influence microglial function, including phagocytic activity and cytokine production. Dysregulated JAK-STAT signaling contributes to chronic inflammation and neuronal damage, while balanced signaling supports neuroprotection and tissue repair."}], "pathway_id": "hsa04630", "pubmed_id": "41343028", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Interleukin-10, Interleukin-10 Receptors, Interleukin-10 Receptor 1, Janus Kinase (activated), Signal Transducer and Activator of Transcription (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Interleukin-10 (IL-10) binds to interleukin-10 receptors (IL-10Rs), initiating the JAK-STAT signaling pathway. This interaction activates Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) proteins, which dimerize and translocate to the nucleus to regulate gene expression. This pathway mediates immune regulation, inflammation resolution, and modulates disease pathogenesis through conserved signaling motifs such as the IL-10R1 GYXXQ motif. Evolutionarily conserved residues within receptor-ligand complexes contribute to the stability and specificity of signaling."}], "pathway_id": "hsa04630", "pubmed_id": "41300695", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin, ML323, USP1, TRAF2, HSPA9, ITPR1, VDAC1, NF-kB (activated), JAK-STAT signaling pathway (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced mitochondrial localization of mortalin disrupts calcium transport between the endoplasmic reticulum and mitochondria through the ITPR1-HSPA9-VDAC1 complex. This impaired calcium shuttling activates the NF-kB and JAK-STAT signaling pathways, which attenuate apoptosis."}], "pathway_id": "hsa04630", "pubmed_id": "41289404", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FOXP3 (Suppression), STAT5, SMAD3, Phosphatidylinositol-4,5-bisphosphate 3-kinase, AKT, NOTCH.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FOXP3 interacts with STAT5 or SMAD3 to enhance the suppressive potential of regulatory T cells (Tregs), thereby promoting immune homeostasis. In contrast, suppression of FOXP3 by PI3K/Akt or Notch signaling contributes to immune deregulation. These interactions position FOXP3 as a central regulator of Treg function and neuroimmune balance."}], "pathway_id": "hsa04630", "pubmed_id": "41269385", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Transglutaminase 1 (elevated expression), Interleukin 1 beta (expression), S100 calcium-binding protein A8 (expression), S100 calcium-binding protein A9 (expression), Keratin 1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Transglutaminase 1 (TGM1) is associated with activation of the cytokine-JAK-STAT signaling pathway. This pathway modulates the expression of inflammatory factors, including Interleukin 1 beta (IL-1), and keratinocyte differentiation markers such as S100A8, S100A9, and Keratin 1 (K1). These molecular changes contribute to the inflammatory and hyperproliferative phenotype observed in psoriasis."}], "pathway_id": "hsa04630", "pubmed_id": "41268597", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TNF-alpha (elevated levels), IL-1 beta (elevated levels), IL-6 (elevated levels), IL-10.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) contribute to inflammatory responses that promote ligamentum flavum thickening. These pro-inflammatory cytokines activate signaling pathways such as nuclear factor-kappaB (NF-kB), Janus kinase/signal transducer and activator of transcription (JAK/STAT), and mitogen-activated protein kinase (MAPK), which further amplify the inflammatory cascade and tissue remodeling. In contrast, interleukin-10 (IL-10) exerts anti-inflammatory effects by counteracting the actions of pro-inflammatory cytokines and suppressing the activation of these signaling pathways, thereby reducing tissue thickening and inflammation."}], "pathway_id": "hsa04630", "pubmed_id": "41246317", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphatidylinositol-4,5-bisphosphate 3-kinase, Protein kinase B (activated), Mitogen-activated protein kinase, Janus kinase, Signal transducer and activator of transcription (phosphorylated and dimerized).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the JAK/STAT pathway occurs through cytokine binding to receptors, leading to the phosphorylation and dimerization of STAT proteins, which translocate to the nucleus to regulate gene expression. Concomitant activation of the MAPK and PI3K/Akt pathways contributes to cell proliferation and survival. In papillary thyroid cancer, dysregulation of these pathways can lead to therapeutic resistance and reduced apoptosis. Natural compounds may modulate these pathways to restore apoptotic signaling and overcome resistance."}], "pathway_id": "hsa04630", "pubmed_id": "41226537", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenosine, ADORA2B (activated by adenosine), cyclic AMP (increased levels), Protein Kinase A (activated), SNAI1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of ADORA2B by adenosine increases intracellular cAMP levels, which activates Protein Kinase A (PKA). PKA subsequently activates the SNAI1 transcription factor, promoting epithelial-mesenchymal transition (EMT). This process enhances cell migration and invasion and contributes to immune escape in gastric cancer cells."}], "pathway_id": "hsa04024", "pubmed_id": "41346607", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prostaglandin E2, PTGER2, PTGER4, FOXP3 (increased expression), CD25 (increased expression), CTLA4 (increased expression), TNFRSF9 (increased expression), PTGS2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prostaglandin E2 binds to its receptors EP2 and EP4 on regulatory T cells (Tregs), activating the cAMP-PKA signaling pathway. This interaction induces the expression of Treg signature genes, including FOXP3, CD25, CTLA4, and 4-1BB, leading to the acquisition of a tumor-infiltrating Treg (TI-Treg) phenotype. These TI-Tregs exhibit enhanced suppressive activity against CD8+ T cells, thereby promoting tumor growth."}], "pathway_id": "hsa04024", "pubmed_id": "41343674", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Estrogens, Conjugated Synthetic A, Camp (increased levels), G protein-coupled estrogen receptor 1 (activated by Estrogens), G alpha (s) subunit, Adenylyl cyclase, Protein kinase A, Centrin 2 (phosphorylated), A-kinase anchoring protein 450.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of G protein-coupled estrogen receptor 1 by estrogens stimulates adenylyl cyclase via Galphas protein, leading to increased cyclic adenosine monophosphate levels and subsequent activation of protein kinase A. Protein kinase A, anchored to centrosomes via A-kinase anchoring protein 450, phosphorylates Centrin 2 at aberrant centrioles, contributing to centrosome amplification and altered centriole integrity. This signaling cascade disrupts normal centrosome regulation and promotes neoplastic transformation and tumor progression."}], "pathway_id": "hsa04024", "pubmed_id": "41299155", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1 (mutated), ALAS2 (mutated), FECH (mutated), ALAD (mutated), CPOX (mutated), PPOX (mutated), UROD (mutated), HMBS (mutated), Ferrochelatase (impaired function), Protoporphyrin IX (elevated levels), Biliverdin, Heme.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) and Protoporphyrin IX accumulate in individuals with disruptions in the heme biosynthesis pathway, particularly due to mutations in ALAS1, ALAS2, FECH, ALAD, CPOX, PPOX, UROD, or HMBS. These disruptions lead to the accumulation of toxic intermediates such as Protoporphyrin IX and 5-ALA, which generate reactive oxygen species and cause oxidative stress. This oxidative damage contributes to the clinical manifestations of porphyria, including neurotoxicity and skin photosensitivity. The impaired function of Ferrochelatase further reduces the incorporation of iron into protoporphyrin, exacerbating heme deficiency and cellular dysfunction."}], "pathway_id": "hsa04024", "pubmed_id": "41249257", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (accumulation), protoporphyrinogen oxidase, farnesyl pyrophosphate synthase, serine hydroxymethyltransferase 1, 5-aminolevulinate synthase 2, delta-aminolevulinic acid dehydratase, porphobilinogen deaminase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) in photodynamic therapy lead to the accumulation of protoporphyrin IX (PpIX), a photosensitizer that generates reactive oxygen species upon light exposure. This process induces oxidative stress, mitochondrial dysfunction, and ultimately ferroptosis in targeted cells. The biosynthesis of PpIX involves several enzymes including protoporphyrinogen oxidase (PPOX), farnesyl pyrophosphate synthase (FPPS), serine hydroxymethyltransferase 1 (SHMT1), 5-aminolevulinate synthase 2 (ALAS2), delta-aminolevulinic acid dehydratase (ALAD), and porphobilinogen deaminase (PBGD). Disruption of this pathway can lead to porphyria and increased susceptibility to apoptosis."}], "pathway_id": "hsa04024", "pubmed_id": "41226780", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp (elevated levels), Protein kinase A, cAMP response element-binding protein, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cyclic adenosine monophosphate (cAMP) activate the cAMP/PKA/CREB/PGC-1alpha signaling axis, which promotes mitochondrial biogenesis and respiratory chain activity. This pathway also modulates mitochondrial dynamics and contributes to apoptosis resistance. These effects are associated with distinct mitochondrial profiles observed in ovarian cancer subtypes."}], "pathway_id": "hsa04024", "pubmed_id": "41226512", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Adenosine A2A receptor, cAMP response element-binding protein 1 (activated), Runt-related transcription factor 2 (increased transcription).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ADORA2A promotes vascular smooth muscle cell osteogenic differentiation by enhancing CREB1 binding to the RUNX2 promoter, which increases RUNX2 transcription and leads to mineralization, contributing to vascular calcification."}], "pathway_id": "hsa04024", "pubmed_id": "41201506", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Homo sapiens (human)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Melatonin receptor 1A, G alpha (s) subunit, Adenylyl cyclase, Protein kinase A, cAMP response element-binding protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melatonin binds to Melatonin receptor 1A, activating the G alpha (s) subunit and initiating a signaling cascade that activates adenylyl cyclase. Adenylyl cyclase catalyzes the formation of cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A. Protein kinase A phosphorylates and activates the cAMP-responsive transcription factor CREB, leading to transgene expression from a synthetic promoter. This mechanism operates in response to diurnal melatonin rhythms, enabling temporal control of gene expression."}], "pathway_id": "hsa04024", "pubmed_id": "41198646", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GLI family zinc finger 2 (upregulated expression), SMO, Transforming growth factor beta 1, SMAD family member 3 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GLI family zinc finger 2 (GLI2) plays a central role in non-canonical Hedgehog signaling during chronic pancreatitis. GLI2 activation and nuclear translocation promote pancreatic stellate cell (PSC) activation, which contributes to fibrosis. TGF-beta1 signaling through SMAD3 enhances GLI2 expression and activity. In contrast, SMO inhibition does not consistently affect GLI2 levels or PSC activation, indicating that GLI2 can be activated independently of the canonical Hedgehog pathway. This mechanism supports the role of non-canonical Hedgehog signaling in driving PSC-mediated fibrosis."}], "pathway_id": "hsa04340", "pubmed_id": "41281756", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TIPE3 (expression), KAT2A, SETD7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TIPE3 activates the Hedgehog signaling pathway, leading to increased cell proliferation and metastasis in nasopharyngeal carcinoma. The expression of TIPE3 is regulated by enhancer elements marked with histone modifications H3K27ac and H3K4me3, which are modulated by the histone acetyltransferase KAT2A and the histone methyltransferase SETD7."}], "pathway_id": "hsa04340", "pubmed_id": "41231288", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cyclopamine, Hedgehog, Patched, Smoothened, Gli family zinc finger proteins, Suppressor of fused, Kinesin family member 7, Protein Kinase A, Casein Kinase I, Glycogen Synthase Kinase 3 Beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Aberrant activation of the Hedgehog signaling pathway contributes to the pathogenesis of chronic liver diseases and several types of cancer. Under normal conditions, the Ptch receptor inhibits Smoothened (Smo), preventing downstream activation of Gli proteins. In the absence of Hedgehog ligand, Gli proteins are phosphorylated by PKA, CKI, and GSK3B, leading to their degradation into repressor forms that suppress target gene transcription. Upon Hedgehog ligand binding, Ptch is displaced from the primary cilium, allowing Smo activation and promoting the nuclear accumulation of Gli activator forms. This results in the transcription of Hedgehog target genes, which can drive cellular proliferation and contribute to disease progression when dysregulated."}], "pathway_id": "hsa04340", "pubmed_id": "41201642", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PTCH1 (localizes to the primary cilium), SMO (activated), GLI family transcription factors (phosphorylated), SUFU, KIF7, Protein Kinase A, Casein Kinase I, Glycogen Synthase Kinase 3 Beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "In the absence of Hedgehog ligands, PTCH1 localizes to the primary cilium and inhibits the activity of SMO. In the presence of Hedgehog, PTCH1 is displaced, allowing SMO activation and subsequent translocation of the Gli, SUFU, and KIF7 complex to the ciliary tip. There, Gli dissociates from SUFU and is processed into the Gli activator form (GliA), which translocates to the nucleus to activate transcription of Hedgehog target genes. Phosphorylation of Gli by PKA, CKI, and GSK3B in the absence of Hedgehog signaling promotes the formation of the Gli repressor form (GliR), which suppresses transcription. This pathway regulates cell proliferation, tissue patterning, and stem cell maintenance during development."}], "pathway_id": "hsa04340", "pubmed_id": "41159321", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bryostatin 1 (administration), Hedgehog, Smoothened, Gli family zinc finger proteins.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bryostatin 1 inhibits Hedgehog signaling by suppressing the transcriptional activity of Gli proteins. This leads to reduced expression of key components within the Hedgehog pathway. The compound specifically targets the pathway downstream of Smoothened, thereby modulating Hedgehog-driven cellular processes such as transcription and proliferation."}], "pathway_id": "hsa04340", "pubmed_id": "41124592", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: claudin, claudin-16, claudin-19, claudin-14.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Claudin-14 preferentially associates with claudin-19, gradually replacing claudin-16 in claudin-19 copolymers within tight junctions. This claudin switch alters the paracellular calcium flux by modifying the composition of tight junction strands, thereby influencing renal calcium excretion and contributing to kidney stone pathogenesis."}], "pathway_id": "hsa04530", "pubmed_id": "41325524", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: OCLN, CLDN, JAM.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tight junction proteins, including OCLN, CLDN, and JAM, form the structural and functional basis of the blood-brain barrier. Disruption of these proteins compromises barrier integrity, allowing bacterial translocation across endothelial cells. This disruption is mediated by bacterial virulence factors that interfere with host cell signaling pathways, leading to impaired paracellular barrier function and increased CNS susceptibility to infection."}], "pathway_id": "hsa04530", "pubmed_id": "41318968", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Abl1, TJP2 (phosphorylated at N-terminus), JAK1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Abl1 directly binds to and phosphorylates the C-terminus of TJP2. Abl1 also activates JAK1, which phosphorylates the N-terminus of TJP2. This phosphorylation of TJP2 by Abl1 and JAK1 regulates cell morphology and migration. Abl1 activity is associated with reduced traction forces on the cell substrate, leading to inhibition of cell migration. These interactions position TJP2 as a key mediator in Abl1-dependent control of cellular behavior."}], "pathway_id": "hsa04530", "pubmed_id": "41259016", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (Accumulation), ALAS1 (Defect), ALAS2, PPOX (Defect), ALAD, FECH (Defect), CPOX (Defect), UROD, HMBS, Ferrochelatase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption in heme biosynthesis, particularly at the level of 5-aminolevulinic acid, leads to the accumulation of toxic intermediates such as 5-aminolevulinic acid and porphobilinogen. These intermediates can induce oxidative stress and mitochondrial dysfunction, contributing to neurological symptoms and systemic manifestations observed in porphyria. Defects in enzymes such as ALAS1, PPOX, FECH, and CPOX impair the sequential steps required for heme production, resulting in the accumulation of upstream porphyrin precursors. This metabolic imbalance can lead to increased permeability of the blood-brain barrier and neuroinflammation, exacerbating neurological dysfunction."}], "pathway_id": "hsa04530", "pubmed_id": "41205301", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rbt1, Zonula Occludens-1 (loss of function).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "A peptide derived from the Rbt1 protein promotes fungal invasion into the gut epithelium by disorganizing tight junctions. This disruption is associated with the downregulation of Zonula Occludens-1 (ZO-1), a constitutive protein of tight junction complexes. The loss of ZO-1 function leads to epithelial barrier dysfunction and facilitates paracellular permeability."}], "pathway_id": "hsa04530", "pubmed_id": "41165448", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Galactose, FUN14 Domain-Containing 1, Vascular Endothelial Cadherin, Occludin, Zonula Occludens 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FUNDC1 regulates mitophagy and mitochondrial homeostasis in endothelial cells. Reduced FUNDC1 expression leads to impaired mitophagy, mitochondrial swelling, and increased reactive oxygen species production. These changes contribute to endothelial cell senescence and elevated vascular permeability. Disruption of tight junctions, characterized by decreased expression of VE-cadherin, occludin, and ZO-1, further compromises endothelial barrier function. This cascade results in retinal vascular dysfunction and retinal dysfunction."}], "pathway_id": "hsa04530", "pubmed_id": "41135636", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Human adenovirus 7 (infection), Human adenovirus 3, Occludin, Claudin, Junctional adhesion molecules.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Infection with human adenovirus 7 leads to more severe epithelial barrier damage than human adenovirus 3, primarily through the disruption of tight junction integrity. This disruption involves the transmembrane proteins occludin, claudin, and junctional adhesion molecules, which are essential components of tight junctions. Compromised tight junction integrity results in increased paracellular flux and reduced transepithelial electrical resistance, contributing to epithelial barrier dysfunction and potentially facilitating higher viral dissemination through the bloodstream."}], "pathway_id": "hsa04530", "pubmed_id": "41130320", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRB3, NF2, RhoA, ROCK2, MYH9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CRB3 interacts with the actin cytoskeletal linker protein NF2 through its FERM-binding domain to regulate perijunctional actomyosin contractility. Disruption of CRB3 leads to increased RhoA activity and junctional tension, resulting in a hypercontractile actomyosin network and impaired assembly of the apical junctional complex. This compromises epithelial barrier function and increases intestinal permeability, particularly under inflammatory conditions. CRB3 and NF2 signaling coordinate mechanical tension to maintain tight junction organization during both homeostasis and inflammatory stress."}], "pathway_id": "hsa04530", "pubmed_id": "41122968", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIPA1L3, AMOT (binding to PATJ), PATJ.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SIPA1L3 interacts with AMOT through its PDZ domain, which inhibits the binding of AMOT to PATJ, thereby reducing AMOT anchoring to tight junctions. This interaction disrupts tight junction regulation and promotes tumorigenesis, cell proliferation, and invasion, contributing to the malignant phenotype."}], "pathway_id": "hsa04530", "pubmed_id": "41088697", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Homo sapiens (human)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 6,11-Dihydroquinoxalino[2,3-b]quinoxaline, IL33, ZO-1 (serine/threonine phosphorylation), NADPH oxidase 1 (activation), PRKCD (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IL33 induces serine/threonine phosphorylation of ZO-1, leading to tight junction disruption. This process is mediated through NOX1 and PRKCD signaling. IL33 signaling increases NADPH oxidase activity, which contributes to blood-retinal barrier disruption and pathological retinal neovascularization. Inhibition of NOX1 reduces NADPH oxidase activity and retinal vascular leakage."}], "pathway_id": "hsa04530", "pubmed_id": "41060718", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: OXT, Dopamine, OXTR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin (OXT) and dopamine signaling converge in the striatum, where they modulate reward-related processes and social behavior. Oxytocin binds to the oxytocin receptor (OXTR), a G-protein-coupled receptor, to influence striatal activity. Dopamine signaling interacts with oxytocinergic pathways, suggesting a crosstalk mechanism that integrates social and reward-related information to regulate behavioral and physiological responses."}], "pathway_id": "hsa04921", "pubmed_id": "40943630", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin, Oxytocin receptor (OXTR) (expressed on vagal afferent and efferent fibers and within brainstem nuclei), Glucagon-like peptide 1, Cholecystokinin, Nesfatin-1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin binds to oxytocin receptors (OXTR) expressed on vagal afferent and efferent fibers and within brainstem nuclei, modulating gastrointestinal motility, satiety, and energy homeostasis. These receptors interact with neuropeptidergic systems including glucagon-like peptide 1, cholecystokinin, and nesfatin-1 to regulate gut-brain signaling and appetite."}], "pathway_id": "hsa04921", "pubmed_id": "40869135", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Atosiban (administered), OXTR (activated), YAP1, Hippo signaling pathway, ARRB2, LATS1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the oxytocin receptor (OXTR) promotes the formation of a complex with ARRB2, which outcompetes LATS1 and inhibits its phosphorylation of YAP1. This leads to increased YAP1 signaling activity, which drives gastric cancer progression. YAP1, in turn, binds to the promoter region of OXTR, enhancing its expression and forming a positive feedback loop. Inhibition of OXTR activity by Atosiban promotes LATS1 phosphorylation, resulting in YAP1 phosphorylation and its sequestration in the cytoplasm, thereby suppressing gastric cancer progression."}], "pathway_id": "hsa04921", "pubmed_id": "40604321", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin modulates the activity of the social salience network, a brain circuit involved in evaluating sociosensory cues and regulating social motivation. Disruptions in this network lead to atypical social perception and engagement. Oxytocin signaling facilitates appropriate social responses by enhancing the function of this network, potentially correcting social behavioral phenotypes associated with neurodevelopmental conditions."}], "pathway_id": "hsa04921", "pubmed_id": "40484364", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Hemin, ALAS1 (deficiency), ALAS2 (deficiency), FECH (deficiency), ALAD (deficiency), PPOX (deficiency), UROD (deficiency), CPOX (deficiency), HMBS (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in heme biosynthesis enzymes such as ALAS1, ALAS2, FECH, ALAD, PPOX, UROD, CPOX, and HMBS leads to the accumulation of 5-aminolevulinic acid and other porphyrin precursors, which cause oxidative stress and neurological dysfunction. These disruptions in the heme biosynthesis pathway are associated with the development of porphyria and related clinical manifestations."}], "pathway_id": "hsa04921", "pubmed_id": "39607552", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin, OXTR (Dysregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin binds to its receptor, OXTR, a G-protein-coupled receptor, to regulate gastrointestinal motility, secretion, and inflammatory responses. Activation of the OXTR signaling pathway modulates gut motility and secretion while exerting protective effects against gut injury and nociception. This pathway also influences inflammatory processes in the gastrointestinal tract, playing a role in conditions such as inflammatory bowel disease and irritable bowel syndrome."}], "pathway_id": "hsa04921", "pubmed_id": "39456718", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 4-Aminopyridine, ADORA2A, DRD2 (signaling), OXTR (facilitating effect on DRD2).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The oxytocin receptor (OXTR) facilitates dopamine receptor D2 (DRD2) signaling in striatal astrocytes, contributing to the regulation of glutamatergic transmission. Adenosine A2A receptor (ADORA2A) exerts an inhibitory control over both DRD2-mediated signaling and the OXTR-facilitating effect on DRD2. These interactions occur within a high-order receptor complex composed of A2A, D2, and OTR, which modulates cytosolic calcium levels and endogenous glutamate release in response to 4-aminopyridine stimulation."}], "pathway_id": "hsa04921", "pubmed_id": "39201299", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cyclic ADP-Ribose (synthesis), 8-bromo-Cyclic ADP-Ribose (administration), CD38 molecule, Oxytocin (administration), Prostaglandin F2 alpha (administration), Endothelin-1 (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin, Prostaglandin F2 alpha, and Endothelin-1 induce intracellular calcium responses in human myometrial cells. CD38, an ADP-ribosyl cyclase, synthesizes cyclic ADP-ribose (cADPR), which functions as a second messenger in calcium signaling. The cADPR antagonist 8-bromo-cyclic ADP-ribose significantly reduces agonist-induced calcium influx, indicating that CD38/cADPR signaling contributes to the regulation of intracellular calcium and, consequently, uterine contraction."}], "pathway_id": "hsa04921", "pubmed_id": "39135342", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Aldosterone synthesis and secretion - Homo sapiens (human)\n**Pathway Description**: Aldosterone is a steroid hormone synthesized in and secreted from the outer layer of the adrenal cortex, the zona glomerulosa. Aldosterone plays an important role in the regulation of systemic blood pressure through the absorption of sodium and water. Angiotensin II (Ang II), potassium (K+) and adrenocorticotropin (ACTH) are the main extracellular stimuli which regulate aldosterone secretion. These physiological agonists all converge on two major intracellular signaling pathways: calcium (Ca2+) mobilization and an increase in cAMP production. The increase in cytosolic calcium levels activates calcium/calmodulin- dependent protein kinases (CaMK), and the increased cAMP levels stimulate the activity of cAMP-dependent protein kinase, or protein kinase A (PKA). The activated CaMK, and possibly PKA, activates transcription factors (NURR1 and NGF1B, CREB) to induce StAR and CYP11B2 expression, the early and late rate- limiting steps in aldosterone biosynthesis, respectively, thereby stimulating aldosterone secretion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aldosterone.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Aldosterone is synthesized and secreted from the adrenal cortex in response to extracellular signals such as angiotensin II, potassium, and ACTH. These signals activate intracellular pathways involving calcium mobilization and cAMP production, which in turn activate protein kinases such as CaMK and PKA. These kinases regulate transcription factors that induce the expression of StAR and CYP11B2, key enzymes in aldosterone biosynthesis, thereby promoting its secretion."}], "pathway_id": "hsa04925", "pubmed_id": "41178713", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Aldosterone synthesis and secretion - Homo sapiens (human)\n**Pathway Description**: Aldosterone is a steroid hormone synthesized in and secreted from the outer layer of the adrenal cortex, the zona glomerulosa. Aldosterone plays an important role in the regulation of systemic blood pressure through the absorption of sodium and water. Angiotensin II (Ang II), potassium (K+) and adrenocorticotropin (ACTH) are the main extracellular stimuli which regulate aldosterone secretion. These physiological agonists all converge on two major intracellular signaling pathways: calcium (Ca2+) mobilization and an increase in cAMP production. The increase in cytosolic calcium levels activates calcium/calmodulin- dependent protein kinases (CaMK), and the increased cAMP levels stimulate the activity of cAMP-dependent protein kinase, or protein kinase A (PKA). The activated CaMK, and possibly PKA, activates transcription factors (NURR1 and NGF1B, CREB) to induce StAR and CYP11B2 expression, the early and late rate- limiting steps in aldosterone biosynthesis, respectively, thereby stimulating aldosterone secretion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cholesterol (overload), Aldosterone (elevated secretion), NPC1 (reduced levels), STARD3, VDAC1, ITPR3, CYP11B2 (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced levels of NPC1 promote increased aldosterone production through two distinct mechanisms. First, NPC1 deficiency enhances lysosome-mitochondria interactions via the STARD3-VDAC1 complex, leading to mitochondrial cholesterol overload. Second, NPC1 deficiency activates cytoplasmic calcium signaling through IP3R3-mediated endoplasmic reticulum calcium release, which upregulates the expression of aldosterone synthase (CYP11B2). These processes collectively contribute to elevated aldosterone secretion."}], "pathway_id": "hsa04925", "pubmed_id": "41147391", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PPAR signaling pathway - Homo sapiens (human)\n**Pathway Description**: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR has three subtypes (PPARalpha, beta/delta, and gamma) showing different expression patterns in vertebrates. Each of them is encoded in a separate gene and binds fatty acids and eicosanoids. PPARalpha plays a role in the clearance of circulating or cellular lipids via the regulation of gene expression involved in lipid metabolism in liver and skeletal muscle. PPARbeta/delta is involved in lipid oxidation and cell proliferation. PPARgamma promotes adipocyte differentiation to enhance blood glucose uptake.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PPARG, ADIPOQ (downregulation), IRS1, AKT2 (downregulation), PPARA, PPARD, PPARG.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Downregulation of PPARG and ADIPOQ leads to impaired metabolic regulation and reduced adipocyte differentiation. Concurrent suppression of IRS1 and AKT2 disrupts insulin signaling, contributing to metabolic shutdown. Disruption of PPAR signaling pathways results in altered lipid metabolism and reduced clearance of cellular lipids, exacerbating chronic inflammation and tissue degeneration. These changes, combined with inflammatory amplification, impair wound healing processes."}], "pathway_id": "hsa03320", "pubmed_id": "41255536", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PPAR signaling pathway - Homo sapiens (human)\n**Pathway Description**: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR has three subtypes (PPARalpha, beta/delta, and gamma) showing different expression patterns in vertebrates. Each of them is encoded in a separate gene and binds fatty acids and eicosanoids. PPARalpha plays a role in the clearance of circulating or cellular lipids via the regulation of gene expression involved in lipid metabolism in liver and skeletal muscle. PPARbeta/delta is involved in lipid oxidation and cell proliferation. PPARgamma promotes adipocyte differentiation to enhance blood glucose uptake.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid, Poly(rC) binding protein 1 (suppression), Transforming growth factor beta-activated kinase 1 (activation), Peroxisome proliferator-activated receptor gamma (silencing), Phosphorylated AKT, Phosphorylated insulin receptor substrate 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PCBP1 and TAK1 contributes to glucose and lipid metabolism disorders by suppressing PPARgamma activity. Inhibition of TAK1 leads to increased PPARgamma expression, which in turn improves insulin signaling and reduces hepatic lipid accumulation. PPARgamma upregulation enhances glucose and lipid metabolism, while its silencing in TAK1-inhibited cells reverses these metabolic benefits. PCBP1 overexpression exacerbates metabolic dysfunction through TAK1 activation, whereas its suppression alleviates insulin resistance and promotes cell viability."}], "pathway_id": "hsa03320", "pubmed_id": "41253484", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PPAR signaling pathway - Homo sapiens (human)\n**Pathway Description**: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR has three subtypes (PPARalpha, beta/delta, and gamma) showing different expression patterns in vertebrates. Each of them is encoded in a separate gene and binds fatty acids and eicosanoids. PPARalpha plays a role in the clearance of circulating or cellular lipids via the regulation of gene expression involved in lipid metabolism in liver and skeletal muscle. PPARbeta/delta is involved in lipid oxidation and cell proliferation. PPARgamma promotes adipocyte differentiation to enhance blood glucose uptake.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Daidzein (administration), EP300 (mutated), CREBBP (mutated), PPARG (restored), ANGPT4, TEK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss of H3K27 acetylation due to EP300 and CREBBP mutations suppresses PPARgamma expression, leading to activation of the ANGPT4/TEK (Tie2) oncogenic signaling axis. This activation promotes tumor proliferation, invasion, and immune evasion through a regulatory T-cell-dominant microenvironment. Daidzein restores histone acetylation and PPARgamma expression, thereby inhibiting ANGPT4/Tie2 signaling and reversing tumor-promoting features, including epigenetic imbalance and immunosuppressive cytokine production."}], "pathway_id": "hsa03320", "pubmed_id": "41240538", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PPAR signaling pathway - Homo sapiens (human)\n**Pathway Description**: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR has three subtypes (PPARalpha, beta/delta, and gamma) showing different expression patterns in vertebrates. Each of them is encoded in a separate gene and binds fatty acids and eicosanoids. PPARalpha plays a role in the clearance of circulating or cellular lipids via the regulation of gene expression involved in lipid metabolism in liver and skeletal muscle. PPARbeta/delta is involved in lipid oxidation and cell proliferation. PPARgamma promotes adipocyte differentiation to enhance blood glucose uptake.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fucoxanthin (administration), PPARG, CTGF, IL6 (release), IL1B (release), IL8 (release), TNF (elevated levels), Reactive oxygen species (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of TNF induce proliferation, migration, and invasion of synovial cells, along with angiogenesis and the release of pro-inflammatory cytokines such as IL-6, IL-1, and IL-8. These effects are associated with increased reactive oxygen species and inflammation. Fucoxanthin suppresses these responses by modulating the PPAR-gamma/CTGF signaling pathway, thereby reducing inflammation, oxidative stress, and angiogenesis."}], "pathway_id": "hsa03320", "pubmed_id": "41229049", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PPAR signaling pathway - Homo sapiens (human)\n**Pathway Description**: Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are activated by fatty acids and their derivatives. PPAR has three subtypes (PPARalpha, beta/delta, and gamma) showing different expression patterns in vertebrates. Each of them is encoded in a separate gene and binds fatty acids and eicosanoids. PPARalpha plays a role in the clearance of circulating or cellular lipids via the regulation of gene expression involved in lipid metabolism in liver and skeletal muscle. PPARbeta/delta is involved in lipid oxidation and cell proliferation. PPARgamma promotes adipocyte differentiation to enhance blood glucose uptake.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS2, ALAS1, CPOX, PPOX, UROS, FECH, ALAD, HEX, BLVRA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruptions in the heme biosynthesis pathway, particularly in the activities of enzymes such as ALAS1, ALAS2, CPOX, PPOX, UROS, FECH, ALAD, HEX, and BLVRA, lead to the accumulation of porphyrins and their precursors, including 5-aminolevulinic acid. This accumulation results in the clinical manifestations of porphyria, such as photosensitivity, abdominal pain, and neurological symptoms. These effects are mediated through the toxic effects of porphyrins on tissues and the disruption of normal heme-dependent physiological processes."}], "pathway_id": "hsa03320", "pubmed_id": "41131963", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Homo sapiens (human)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRDX3 (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the PRDX3 gene lead to loss of function of the peroxiredoxin 3 protein, a mitochondria-specific antioxidant enzyme essential for maintaining cellular redox homeostasis. This disruption results in mitochondrial dysfunction and oxidative stress, contributing to progressive cerebellar degeneration, gait ataxia, and cognitive impairments. Additional clinical features such as increased thyroid autoantibodies and thyroid enlargement may reflect systemic effects of oxidative stress and impaired redox regulation."}], "pathway_id": "hsa05017", "pubmed_id": "41351775", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Homo sapiens (human)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: AFG3L2 (normal function), AFG3L2 p.Arg280Trp (heterozygous mutation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "A heterozygous mutation in the AFG3L2 gene, specifically p.Arg280Trp, leads to Spinocerebellar Ataxia Type 28. This mutation is associated with progressive cerebellar ataxia, oculomotor dysfunction, tremor, hypokinesia, dystonia, and epilepsy. The autosomal dominant mode of inheritance is observed, with clinical features including motor coordination deficits and neurological dysfunction. The mutation likely disrupts the normal function of AFG3L2, a mitochondrial AAA+ protease involved in the degradation of misfolded proteins, contributing to neurodegeneration through impaired mitochondrial proteostasis."}], "pathway_id": "hsa05017", "pubmed_id": "41263215", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Homo sapiens (human)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN3 (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Spinocerebellar ataxia type 3 (SCA3), caused by mutations in the ATXN3 gene, leads to progressive neurodegeneration of cerebellar neurons, resulting in impaired motor coordination, balance, and gait. Pathophysiological mechanisms include protein aggregation, transcriptional dysregulation, and impaired protein clearance, contributing to neuronal dysfunction and eventual cell death. These processes manifest as ataxia and mobility deficits characteristic of SCA3."}], "pathway_id": "hsa05017", "pubmed_id": "41249511", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Homo sapiens (human)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CAG repeat expansion (abnormal), polyglutamine tract (extended).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Abnormal CAG repeat expansion in the DNA sequence leads to the production of proteins containing extended polyglutamine tracts. These expanded polyglutamine-containing proteins undergo misfolding and aggregation, which disrupts cellular homeostasis and leads to transcriptional dysregulation. Accumulation of these pathological proteins interferes with normal neuronal function and ultimately results in neurodegeneration and neuronal death."}], "pathway_id": "hsa05017", "pubmed_id": "41213927", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Homo sapiens (human)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN3 (elevated expression of mutant with expanded CAG repeats).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of mutant ataxin 3 (ATXN3) with expanded CAG repeats leads to cerebellar Purkinje cell loss and spinal cord neurodegeneration. This results in progressive motor impairments and the formation of intranuclear inclusions. The severity of motor dysfunction correlates with the level of mutant ATXN3 expression in the cerebellum and spinal cord, contributing to the pathogenesis of spinocerebellar ataxia 3."}], "pathway_id": "hsa05017", "pubmed_id": "41170805", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Homo sapiens (human)\n**Pathway Description**: Cell surface proteins can be attached to the cell membrane via the glycolipid structure called glycosylphosphatidylinositol (GPI) anchor. Hundreds of GPI-anchored proteins have been identified in many eukaryotes ranging from protozoa and fungi to mammals. All protein-linked GPI anchors share a common core structure, characterized by the substructure Man (a1-4) GlcN (a1-6) myo-inositol-1P-lipid. Biosynthesis of GPI anchors proceeds in three stages: (i) preassembly of a GPI precursor in the ER membrane, (ii) attachment of the GPI to the C-terminus of a newly synthesized protein in the lumen of the ER, and (iii) lipid remodeling and/or carbohydrate side-chain modifications in the ER and the Golgi. Defects of GPI anchor biosynthesis gene result in a genetic disorder, paroxysmal nocturnal hemoglobinuria.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mci-186 (administration), PRNP (mutated (Y162X) with defective GPI anchor formation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defective GPI anchor formation in the PRNP Y162X mutation results in the extracellular accumulation of prion protein aggregates. This accumulation increases cellular vulnerability to oxidative stress. Treatment with edaravone mitigates oxidative stress sensitivity, suggesting a protective role in the context of GPI-anchorless prion disease."}], "pathway_id": "hsa00563", "pubmed_id": "40372528", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Homo sapiens (human)\n**Pathway Description**: Cell surface proteins can be attached to the cell membrane via the glycolipid structure called glycosylphosphatidylinositol (GPI) anchor. Hundreds of GPI-anchored proteins have been identified in many eukaryotes ranging from protozoa and fungi to mammals. All protein-linked GPI anchors share a common core structure, characterized by the substructure Man (a1-4) GlcN (a1-6) myo-inositol-1P-lipid. Biosynthesis of GPI anchors proceeds in three stages: (i) preassembly of a GPI precursor in the ER membrane, (ii) attachment of the GPI to the C-terminus of a newly synthesized protein in the lumen of the ER, and (iii) lipid remodeling and/or carbohydrate side-chain modifications in the ER and the Golgi. Defects of GPI anchor biosynthesis gene result in a genetic disorder, paroxysmal nocturnal hemoglobinuria.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PGAP3 (biallelic pathogenic variants).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Biallelic pathogenic variants in the PGAP3 gene disrupt glycosylphosphatidylinositol (GPI) anchor biosynthesis, leading to a congenital disorder of glycosylation (CDG). This disruption results in developmental delay, intellectual disability, seizures, and hyperphosphatemia. Additional clinical manifestations include brain malformations, behavioral abnormalities, and cleft palate."}], "pathway_id": "hsa00563", "pubmed_id": "37647829", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Homo sapiens (human)\n**Pathway Description**: Cell surface proteins can be attached to the cell membrane via the glycolipid structure called glycosylphosphatidylinositol (GPI) anchor. Hundreds of GPI-anchored proteins have been identified in many eukaryotes ranging from protozoa and fungi to mammals. All protein-linked GPI anchors share a common core structure, characterized by the substructure Man (a1-4) GlcN (a1-6) myo-inositol-1P-lipid. Biosynthesis of GPI anchors proceeds in three stages: (i) preassembly of a GPI precursor in the ER membrane, (ii) attachment of the GPI to the C-terminus of a newly synthesized protein in the lumen of the ER, and (iii) lipid remodeling and/or carbohydrate side-chain modifications in the ER and the Golgi. Defects of GPI anchor biosynthesis gene result in a genetic disorder, paroxysmal nocturnal hemoglobinuria.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PIGA (pathogenic variants).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pathogenic variants in the PIGA gene disrupt glycosylphosphatidylinositol (GPI)-anchor biosynthesis, leading to congenital disorders of glycosylation (CDG). This disruption is associated with a range of phenotypes, including hypotonia, epilepsy, global developmental delay, and congenital diaphragmatic hernia."}], "pathway_id": "hsa00563", "pubmed_id": "37589195", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: actomyosin (generating force), CDH1, cadherin-catenin complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Actomyosin-generated force exerted on the cadherin-catenin complex enhances the stability of adherens junctions. This biomechanical interaction stabilizes E-cadherin (CDH1) at cell-cell contacts, reinforcing intercellular adhesion and contributing to tissue integrity through the reorganization of the actin cytoskeleton."}], "pathway_id": "hsa04520", "pubmed_id": "41257349", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRB3 (disrupted), NF2 (disrupted), RHOA, ROCK2, MYH9, actin-myosin complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CRB3 interacts with Merlin (NF2) to regulate perijunctional actomyosin contractility and the assembly of the apical junctional complex (AJC). Disruption of CRB3 or NF2 leads to increased RhoA activity and junctional tension, which impairs AJC formation and compromises epithelial barrier function. This pathway plays a key role in maintaining intestinal barrier integrity and responding to inflammatory stress through modulation of actomyosin dynamics and junctional remodeling."}], "pathway_id": "hsa04520", "pubmed_id": "41122968", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CDH2, ACTN1, CTNNB1, IGFBP2 (exogenous).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Enhanced adherens junction assembly and sarcomeric organization promote contractile function in cardiomyocytes. Increased cell-cell contact suppresses beta-catenin nuclear translocation and reduces TCF/LEF transcriptional activity, which limits cell cycle progression. Disruption of adherens junctions or sarcomere components such as N-cadherin or alpha-actinin increases cell cycle activation. Exogenous IGFBP2 can override contact-dependent inhibition of proliferation in three-dimensional cardiac tissue."}], "pathway_id": "hsa04520", "pubmed_id": "41031396", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CTNNA1 (undergoes conformational change), VCL (independent).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Alpha-catenin undergoes a conformational change in its actin-binding domain during adherens junction maturation. This structural transition is associated with distinct alpha-catenin mobilities and increased protein turnover in mature junctions. The conformational state depends on the degree of junctional maturation and requires actin polymerisation, but is independent of vinculin binding. This dynamic behavior supports the formation of mechanically stable yet flexible cell-cell adhesions during epidermal differentiation."}], "pathway_id": "hsa04520", "pubmed_id": "40890526", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp (elevated levels), Roflumilast, Vascular endothelial cadherin (preservation), Intercellular adhesion molecule 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cyclic adenosine monophosphate (cAMP) reinforce the endothelial barrier and prevent alterations in vascular endothelial cadherin (VE-Cadherin)-composed adherens junctions. Disruption of these junctions leads to increased endothelial permeability and barrier dysfunction. Protection of VE-Cadherin junctions correlates with preservation of the actin cytoskeleton and reduced apoptosis in endothelial cells."}], "pathway_id": "hsa04520", "pubmed_id": "40643537", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (-)-Carnitine (administration), CDH1 (downregulation), CTNNB1 (downregulation), CTNND1 (downregulation), CTNNA1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hyperosmolar stress reduces epithelial barrier integrity by downregulating E-cadherin (CDH1), beta-catenin (CTNNB1), and p120-catenin (CTNND1), while upregulating alpha-catenin (CTNNA1). This disrupts adherens junction integrity, impairs cell migration, and delays wound healing. L-carnitine administration restores trans-epithelial resistance and normalizes adherens junction protein levels, thereby reestablishing epithelial barrier function and promoting wound healing."}], "pathway_id": "hsa04520", "pubmed_id": "40581139", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Novobiocin, OCLN, CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Relaxation of DNA supercoiling in Campylobacter jejuni induces an invasive phenotype that leads to the clustering of bacteria at epithelial cell junctions. This results in the disruption of tight junctions and adherens junctions, characterized by the loss of occludin and beta-catenin localization. Microtubule polymerization plays a critical role in this process, as its inhibition rescues beta-catenin disruption, indicating that microtubules are key mediators of the bacterial virulence mechanism."}], "pathway_id": "hsa04520", "pubmed_id": "40471665", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SRC, CDH5 (phosphorylated), TLR4, TRAF6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4 activates TRAF6, which in turn activates Src family kinases (SFKs), leading to the phosphorylation of adherens junction proteins such as VE-cadherin. This phosphorylation disrupts the integrity of cell-cell adhesions, resulting in increased endothelial cell permeability."}], "pathway_id": "hsa04520", "pubmed_id": "40455573", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Homo sapiens (human)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CDH1, CTNNB1 (stabilized by phosphorylation), CTNNA1, PVRL1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "E-cadherin forms cell-cell adhesion complexes by binding beta-catenin, which in turn interacts with alpha-catenin to link the complex to F-actin. Beta-catenin can be phosphorylated by kinases such as Src family members, leading to dissociation of the cadherin-catenin complex. Phosphorylation by casein kinase II stabilizes the complex. Nectins also contribute to cell-cell adhesion and regulate the actin cytoskeleton through Cdc42 and Rac. These interactions are essential for mechanotransduction and the maintenance of tissue integrity under mechanical stress."}], "pathway_id": "hsa04520", "pubmed_id": "40413856", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin secretion - Homo sapiens (human)\n**Pathway Description**: Pancreatic beta cells are specialised endocrine cells that continuously sense the levels of blood sugar and other fuels and, in response, secrete insulin to maintain normal fuel homeostasis. Glucose-induced insulin secretion and its potentiation constitute the principal mechanism of insulin release. Glucose is transported by the glucose transporter (GLUT) into the pancreatic beta-cell. Metabolism of glucose generates ATP, which inhibits ATP-sensitive K+ channels and causes voltage-dependent Ca2+ influx. Elevation of [Ca2+]i triggers exocytotic release of insulin granules. Insulin secretion is further regulated by several hormones and neurotransmitters. Peptide hormones, such as glucagon-like peptide 1 (GLP-1), increase cAMP levels and thereby potentiate insulin secretion via the combined action of PKA and Epac2. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates phospholipase C- (PLC-), and the stimulatory effects involve activation of protein kinase C (PKC), which stimulates exocytosis. In addition, ACh mobilizes intracellular Ca2+ by activation of IP3 receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Lysine (administration), Gamma-Aminobutyric Acid (administration), L-Glutamic Acid, D-Glucose, L-Lactic Acid, Pyruvic Acid, AASS (impaired activity), ALDH7A1, DHTKD1, HADH, GLUD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "L-lysine potentiates glucose-stimulated insulin secretion through AASS-dependent catabolism. AASS catalyzes the initial steps of lysine degradation, which supports GABA content and signaling in pancreatic beta cells. Impaired AASS activity reduces GABA levels and disrupts glutamate metabolism, leading to mitochondrial dysfunction, including reduced ATP/ADP ratios, diminished mitochondrial respiration, and increased lactate/pyruvate ratios. These metabolic disturbances impair cytosolic calcium responses and insulin secretion. Exogenous GABA partially restores insulin secretion in cells with suppressed AASS activity, indicating that GABA functions both as a metabolic substrate and a signaling effector in beta-cell function."}], "pathway_id": "hsa04911", "pubmed_id": "41167553", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin secretion - Homo sapiens (human)\n**Pathway Description**: Pancreatic beta cells are specialised endocrine cells that continuously sense the levels of blood sugar and other fuels and, in response, secrete insulin to maintain normal fuel homeostasis. Glucose-induced insulin secretion and its potentiation constitute the principal mechanism of insulin release. Glucose is transported by the glucose transporter (GLUT) into the pancreatic beta-cell. Metabolism of glucose generates ATP, which inhibits ATP-sensitive K+ channels and causes voltage-dependent Ca2+ influx. Elevation of [Ca2+]i triggers exocytotic release of insulin granules. Insulin secretion is further regulated by several hormones and neurotransmitters. Peptide hormones, such as glucagon-like peptide 1 (GLP-1), increase cAMP levels and thereby potentiate insulin secretion via the combined action of PKA and Epac2. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates phospholipase C- (PLC-), and the stimulatory effects involve activation of protein kinase C (PKC), which stimulates exocytosis. In addition, ACh mobilizes intracellular Ca2+ by activation of IP3 receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (synthesized), Calcium Cation (oscillations), glutamate decarboxylase 1, glutamate decarboxylase 2, gamma-aminobutyric acid A receptor, gamma-aminobutyric acid B receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Endogenous gamma-aminobutyric acid (GABA) is synthesized in pancreatic beta cells by glutamate decarboxylase 1 and 2 (GAD65 and GAD67). GABA modulates insulin secretion by suppressing calcium ion oscillations within islets. This effect is mediated through GABA(A) and GABA(B) receptors, which regulate the amplitude and duration of calcium signaling. Disruption of GABA signaling, such as through deletion of GAD65 and GAD67, results in excessive insulin secretion and impaired calcium oscillation dynamics. In the context of metabolic stress or type 2 diabetes, GABA responsiveness is lost, contributing to islet dysfunction and altered glucose homeostasis."}], "pathway_id": "hsa04911", "pubmed_id": "41106726", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin secretion - Homo sapiens (human)\n**Pathway Description**: Pancreatic beta cells are specialised endocrine cells that continuously sense the levels of blood sugar and other fuels and, in response, secrete insulin to maintain normal fuel homeostasis. Glucose-induced insulin secretion and its potentiation constitute the principal mechanism of insulin release. Glucose is transported by the glucose transporter (GLUT) into the pancreatic beta-cell. Metabolism of glucose generates ATP, which inhibits ATP-sensitive K+ channels and causes voltage-dependent Ca2+ influx. Elevation of [Ca2+]i triggers exocytotic release of insulin granules. Insulin secretion is further regulated by several hormones and neurotransmitters. Peptide hormones, such as glucagon-like peptide 1 (GLP-1), increase cAMP levels and thereby potentiate insulin secretion via the combined action of PKA and Epac2. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates phospholipase C- (PLC-), and the stimulatory effects involve activation of protein kinase C (PKC), which stimulates exocytosis. In addition, ACh mobilizes intracellular Ca2+ by activation of IP3 receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dihydroberberine (administration), Berberine, GCK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dihydroberberine promotes glucose-stimulated insulin secretion by forming stable complexes with glucokinase (GCK). This interaction enhances insulin release from pancreatic beta-cells. The effects are dependent on GCK activity, as they are significantly reduced in the absence of GCK. Additionally, dihydroberberine prevents cell apoptosis in pancreatic beta-cells."}], "pathway_id": "hsa04911", "pubmed_id": "41077968", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin secretion - Homo sapiens (human)\n**Pathway Description**: Pancreatic beta cells are specialised endocrine cells that continuously sense the levels of blood sugar and other fuels and, in response, secrete insulin to maintain normal fuel homeostasis. Glucose-induced insulin secretion and its potentiation constitute the principal mechanism of insulin release. Glucose is transported by the glucose transporter (GLUT) into the pancreatic beta-cell. Metabolism of glucose generates ATP, which inhibits ATP-sensitive K+ channels and causes voltage-dependent Ca2+ influx. Elevation of [Ca2+]i triggers exocytotic release of insulin granules. Insulin secretion is further regulated by several hormones and neurotransmitters. Peptide hormones, such as glucagon-like peptide 1 (GLP-1), increase cAMP levels and thereby potentiate insulin secretion via the combined action of PKA and Epac2. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates phospholipase C- (PLC-), and the stimulatory effects involve activation of protein kinase C (PKC), which stimulates exocytosis. In addition, ACh mobilizes intracellular Ca2+ by activation of IP3 receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N6-Methyladenosine (reduced levels), IGF2R (reduced function), SQSTM1 (reduced expression), MAP1LC3B (reduced expression), ULK1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced IGF2R function impairs insulin secretion and cell proliferation in pancreatic beta-cells. IGF2R deficiency leads to decreased autophagy, as evidenced by reduced expression of SQSTM1 (p62), MAP1LC3B (LC3B), and ULK1. These effects are associated with diminished beta-cell mass and impaired glucose homeostasis. In both mouse and human type 2 diabetes, IGF2R dysfunction correlates with reduced N6-methyladenosine (m6A) mRNA methylation, suggesting a regulatory role in RNA metabolism and cellular adaptation."}], "pathway_id": "hsa04911", "pubmed_id": "41042627", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin (administration), Focal adhesion kinase (overexpression), NFE2L2 (expression), HDAC5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Doxorubicin induces ferroptosis in cardiomyocytes by suppressing focal adhesion kinase (FAK) activity. FAK overexpression mitigates this effect by upregulating Nuclear factor erythroid 2-related factor 2 (NRF2), which in turn inhibits ferroptosis and reduces cardiotoxicity. The protective role of FAK is mediated, at least in part, through the FAK/NRF2 axis, and this pathway may involve histone deacetylase 5 (HDAC5)."}], "pathway_id": "hsa04216", "pubmed_id": "41351524", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Erastin (administration), MECP2, GPX4, GCLM, SLC7A11, FN1, ACTA2, CDH1, CDH2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MECP2 suppresses ferroptosis by upregulating GPX4, GCLM, and SLC7A11, which increase glutathione levels and reduce lipid peroxidation markers such as malondialdehyde and Fe(2+). This ferroptosis suppression supports epithelial-mesenchymal transition (EMT) by maintaining the expression of fibronectin, alpha-smooth muscle actin, and N-cadherin, while reducing E-cadherin. GPX4 activation enhances EMT marker expression, whereas GPX4 inhibition reduces these effects. Ferroptosis induction by erastin reverses EMT and inhibits MECP2-driven proliferation and migration in retinal pigment epithelial cells."}], "pathway_id": "hsa04216", "pubmed_id": "41347811", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TREX1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TREX1 plays a role in promoting the proliferative, migratory, and invasive capacities of prostate cancer cells. Its downregulation leads to suppression of these cellular processes, suggesting a contribution to tumor progression. TREX1 is associated with ferroptosis and immunogenic cell death pathways, indicating its involvement in modulating cell fate decisions in cancer."}], "pathway_id": "hsa04216", "pubmed_id": "41346575", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin (administration), Rsl3 (administration), Hydrogen Peroxide (increased levels), Ferrous cation (accumulation), GPX4 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Doxorubicin induces tumor cell death through both apoptosis and ferroptosis pathways, while also promoting hydrogen peroxide production. Ferroptosis is enhanced through the accumulation of ferrous ions and hydrogen peroxide, which, in combination with GPX4 inhibition by RSL3, disrupts the cellular redox balance and leads to increased oxidative stress and cell death."}], "pathway_id": "hsa04216", "pubmed_id": "41340500", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Solute Carrier Family 7 Member 11 (elevated expression), Interleukin 1 Beta (increased production), Interleukin 6 (increased production), Tumor Necrosis Factor Alpha (increased production).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Solute Carrier Family 7 Member 11 (SLC7A11, also known as SAT1) is associated with acute pancreatitis and contributes to inflammatory responses. SAT1 upregulation correlates with increased production of pro-inflammatory cytokines, including Interleukin 1 Beta, Interleukin 6, and Tumor Necrosis Factor Alpha. Reduction of SAT1 expression attenuates inflammation, suggesting a regulatory role in immune and inflammatory processes linked to ferroptosis."}], "pathway_id": "hsa04216", "pubmed_id": "41340461", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doconexent, Tocopherols (Administration), Epigallocatechin Gallate (Administration), alpha Lipoic acid (Administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ferroptosis is a regulated cell death mechanism involving iron-dependent lipid peroxidation, which contributes to the progression of Alzheimer's disease. Docosahexaenoic acid (DHA)-rich brain phospholipids are particularly vulnerable to this process. Plant-derived dietary antioxidants such as tocopherol, epigallocatechin gallate, curcumin, quercetin, baicalein, and alpha-lipoic acid inhibit ferroptosis and may prevent cognitive decline by reducing lipid peroxidation and oxidative damage in the brain."}], "pathway_id": "hsa04216", "pubmed_id": "41338951", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Streptozocin, ELAVL1 (elevated expression), ACSL4 (stabilized expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated ELAVL1 expression promotes Schwann cell ferroptosis by binding to the 3'-UTR of ACSL4 mRNA, which stabilizes ACSL4 expression. This stabilization enhances lipid peroxidation and reactive oxygen species production, contributing to oxidative stress and myelin damage in the context of diabetic neuropathy."}], "pathway_id": "hsa04216", "pubmed_id": "41331855", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Beta-2-microglobulin (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Beta-2-microglobulin in hypertrophic adipocytes promotes iron overload and ferroptosis, which contributes to the M1 polarization of adipose tissue macrophages and the progression of chronic inflammation and metabolic disorders associated with obesity."}], "pathway_id": "hsa04216", "pubmed_id": "41330906", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CHAC1 (altered expression), CDO1 (altered expression), HILPDA (altered expression), GSK3B (altered expression), DPEP1 (altered expression), BRD4 (altered expression), NUPR1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ferroptosis is a regulated form of cell death characterized by lipid peroxidation and iron-dependent reactive oxygen species (ROS) accumulation. In aortic dissection, altered expression of ferroptosis-related genes such as CHAC1, CDO1, HILPDA, GSK3B, DPEP1, BRD4, and NUPR1 suggests a role in disease progression. These genes may influence cellular redox homeostasis and lipid metabolism, contributing to endothelial and fibroblast dysfunction. Downregulation of GSK3B and BRD4 in endothelial cells and reduced DPEP1 in fibroblasts may disrupt protective cellular mechanisms, promoting ferroptotic cell death and tissue damage in aortic tissue."}], "pathway_id": "hsa04216", "pubmed_id": "41327739", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-Isobutyl-1-methylxanthine, Aquaporin 8 (reduced expression), Acyl-CoA Synthetase Family Member 2 (reduced expression), Acyl-CoA Synthetase Long-Chain Family Member 4 (elevated expression), Interleukin 1 Beta (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) contributes to ferroptosis by promoting lipid peroxidation through the incorporation of polyunsaturated fatty acids into membrane phospholipids. This process is associated with inflammatory bowel disease, where it correlates with increased immature dendritic cell activity. Reduced expression of Acyl-CoA Synthetase Family Member 2 (ACSF2) and Aquaporin 8 (AQP8) is linked to impaired metabolic and water transport functions in affected tissues. Increased Interleukin 1 Beta (IL1B) expression contributes to the inflammatory response characteristic of the disease. These molecular changes are embedded within broader metabolic processes, including the tricarboxylic acid cycle and inositol phosphate metabolism, which influence immune cell infiltration and disease progression."}], "pathway_id": "hsa04216", "pubmed_id": "41326462", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Anterior Gradient 2 (elevated expression), Tumor Protein p53 (activation), Solute Carrier Family 40 Member 1, Ferroportin 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of AGR2 suppresses ferroptosis by modulating the p53 signaling pathway. AGR2 deficiency activates p53, which downregulates the iron exporter FPN1 (SLC40A1), leading to intracellular iron accumulation and subsequent ferroptosis. This regulatory axis contributes to tumor progression in pancreatic cancer, as co-elevation of AGR2 and FPN1 is associated with poor clinical outcomes."}], "pathway_id": "hsa04216", "pubmed_id": "41326375", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EZH2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EZH2 functions as a core enzyme in epigenetic regulation and serves as a pivotal node linking epigenetic processes, tumorigenesis, immune control, and ferroptosis. Under conditions of iron metabolism imbalance and lipid peroxidation accumulation, ferroptosis occurs in various immune cell types, contributing to immune microenvironment regulation. This process is influenced by epigenetic mechanisms, which can modulate ferroptotic susceptibility and immune cell function."}], "pathway_id": "hsa04216", "pubmed_id": "41326356", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Homo sapiens (human)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JQ1 compound, TRIB2 (downregulation), CAV1 (downregulation), ENO3 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of TRIB2, CAV1, and ENO3 contributes to tumor progression by modulating ferroptosis and immune microenvironment dynamics. Downregulation of these genes following super-enhancer inhibition correlates with reduced tumor viability and altered immune cell infiltration. Increased immune checkpoint gene expression and reduced immunotherapy responsiveness are associated with an immunosuppressive tumor microenvironment."}], "pathway_id": "hsa04216", "pubmed_id": "41325548", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Losartan, Dipeptidyl peptidase 3 (circulating), RAP1 GEF 4 (upregulated), RAP1A (activated), Phosphofructokinase, platelet, Y-box binding protein 1, ADP-ribosylation factor 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Circulating dipeptidyl peptidase 3 (DPP3) upregulates RAPGEF4 in lung endothelial cells, leading to activation of the RAP1A signaling pathway through the DPP3-PFKP-YBX1 axis. This activation promotes angiogenesis and remodeling of the vascular niche, which enhances lung metastasis."}], "pathway_id": "hsa04015", "pubmed_id": "41311249", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Abt 263, RAP1A (activation), BCL2 and BCL2L1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of RAP1A signaling in leukemia cells is associated with transcriptional rewiring that promotes an adverse immune microenvironment. This signaling pathway contributes to resistance mechanisms in T cell acute lymphoblastic leukemia. Inhibition of RAP1A signaling increases sensitivity to the anti-apoptotic inhibitors BCL2 and BCL2L1, thereby enhancing the cytotoxic effect of navitoclax."}], "pathway_id": "hsa04015", "pubmed_id": "41271691", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: F11R (reduced expression), ZO-1 (decreased levels), E-cadherin (decreased levels), N-cadherin (increased levels), vimentin (increased levels), Rap1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of F11R promotes epithelial-mesenchymal transition (EMT) by decreasing E-cadherin and ZO-1 levels while increasing N-cadherin and vimentin. This shift in adhesion molecule expression enhances cell migration and invasion while reducing apoptosis. Concurrently, F11R downregulation activates Rap1 signaling, which contributes to tumor progression by modulating cell adhesion and polarity."}], "pathway_id": "hsa04015", "pubmed_id": "41058282", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FAT1 (reduced expression), RAP1A, CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of FAT1 leads to dysregulation of the Rap1 signaling pathway, resulting in impaired cell adhesion and cytoskeletal abnormalities. Decreased activation of Rap1 is associated with disrupted beta-catenin junctions in urinary epithelial cells, contributing to glomerulotubular nephropathy."}], "pathway_id": "hsa04015", "pubmed_id": "40976965", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DLC1 (loss), RIAM, PXN, TLN1, RHOA (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DLC1 regulates RhoA activity in a stiffness-dependent manner, with its loss leading to myofibrillar disarray. DLC1, RIAM, and paxillin preferentially interact with talin at specific extracellular matrix stiffness levels, and these interactions are preserved in the absence of mechanical tension. This mechanosensitive imprinting of the talin interactome modulates RhoA activity, thereby influencing cardiomyocyte remodeling and cardiac function."}], "pathway_id": "hsa04015", "pubmed_id": "40911671", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Esi-09, RAPGEF3, RAP1A, RAP1B, AKT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAPGEF3 activates RAP1A, which in turn activates AKT signaling, promoting cell proliferation and survival. This signaling axis contributes to tumor progression in basal-subtype lung squamous cell carcinoma."}], "pathway_id": "hsa04015", "pubmed_id": "40781157", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAP1 (active), RAC1 (active).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAP1 activity precedes and persists after cell protrusion events, and directly activates RAC1 to promote protrusion formation. This unidirectional interaction between RAP1 and RAC1 couples protrusion with adhesion, as sustained RAP1 signaling contributes to the stabilization of newly formed protrusions and enhances cell attachment. This mechanism supports coordinated cell migration."}], "pathway_id": "hsa04015", "pubmed_id": "40768328", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N6-Methyladenosine, PLCE1 (elevated expression), RAP1A, METTL14, VEGFA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PLCE1 activates the Rap1 signaling pathway, which promotes the secretion of VEGF. Rap1 activation counteracts the effects of PLCE1 knockdown, including reduced cell proliferation, blocked epithelial-mesenchymal transition, and impaired angiogenic capacity. PLCE1 mRNA is stabilized through m6A modification mediated by METTL14, contributing to its elevated expression in choriocarcinoma."}], "pathway_id": "hsa04015", "pubmed_id": "40760271", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, exchange protein directly activated by cAMP (activation), exchange protein directly activated by cAMP 1 (activation), Ras-related protein 1 (regulation), Ras-related protein 2 (regulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "cyclic adenosine monophosphate activates exchange proteins directly activated by cAMP (EPAC), which function as guanine nucleotide exchange factors for the small GTPases Ras-related protein 1 (Rap1) and Ras-related protein 2 (Rap2). EPAC1, a specific isoform of EPAC, also participates in the formation of biomolecular condensates. These activities contribute to the regulation of vascular remodeling through modulation of cell adhesion, migration, proliferation, and differentiation. Dysregulation of this pathway is associated with pathological vascular conditions such as atherosclerosis, hypertension, and retinopathy."}], "pathway_id": "hsa04015", "pubmed_id": "40706319", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Homo sapiens (human)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IgSF11, RAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IgSF11 forms a complex with RAP1, and this interaction facilitates melanoma cell migration and invasion. The L372-R378 region of IgSF11 is required for RAP1 recruitment and the promotion of melanoma cell migration. This signaling contributes to epithelial-mesenchymal transition, a process associated with cancer progression."}], "pathway_id": "hsa04015", "pubmed_id": "40635001", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium (extracellular), Glucagon-like peptide 1, Calcium-sensing receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Extracellular calcium acts through the calcium-sensing receptor (CaSR) and voltage-gated calcium channels to trigger intracellular calcium influx in intestinal L-cells. This calcium influx is essential for the exocytosis of glucagon-like peptide 1 (GLP-1), a hormone that regulates glucose homeostasis by enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing appetite. Calcium thus functions as a signaling ion that links nutrient sensing in the gastrointestinal tract to hormonal regulation of blood glucose."}], "pathway_id": "hsa04922", "pubmed_id": "41219603", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucagon, protein kinase A, cAMP response element-binding protein (phosphorylated), phosphofructokinase 1 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucagon promotes hepatic glucose output by stimulating glycogenolysis and gluconeogenesis while inhibiting glycogenesis and glycolysis. It activates adenylate cyclase to produce cAMP, which in turn activates protein kinase A (PKA). PKA phosphorylates downstream targets such as cAMP response element-binding protein (CREB) and the bifunctional enzyme phosphofructokinase 1, modulating glycolytic and gluconeogenic flux. These actions collectively enhance hepatic glucose production and maintain euglycemia."}], "pathway_id": "hsa04922", "pubmed_id": "41206016", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Semaglutide (administered), Glucagon-Like Peptide 1, UBE2B (reduced), U2 small nuclear RNA auxiliary factor 1 (degraded), tumor protein p53 (modulated), cyclin-dependent kinase inhibitor 1A (modulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "UBE2B promotes endothelial apoptosis and inhibits proliferation by ubiquitinating and degrading U2AF1, thereby modulating the p53/p21 signaling pathway. Semaglutide, a GLP-1 receptor agonist, reduces endothelial injury by decreasing UBE2B expression, oxidative stress, and apoptosis."}], "pathway_id": "hsa04922", "pubmed_id": "41186784", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucagon-Like Peptide 1, glucagon-like peptide 1 receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucagon-like peptide 1 (GLP-1) binds to the glucagon-like peptide 1 receptor, activating signaling pathways that reduce systemic and tissue inflammation. This anti-inflammatory effect occurs through both weight loss-dependent and -independent mechanisms, contributing to the reduction of chronic diseases such as cardiovascular disease, chronic kidney disease, and metabolic liver disease in individuals with type 2 diabetes and obesity."}], "pathway_id": "hsa04922", "pubmed_id": "41178710", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEC31A (reversed by reducing ER stress), INSR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEC31A expression increases in alpha cells under inflammatory stress, and its upregulation is reversed by reducing ER stress. SEC31A interacts with the insulin receptor, linking stress adaptation to insulin signaling in alpha cells. This interaction may contribute to the regulation of alpha cell survival during stress conditions."}], "pathway_id": "hsa04922", "pubmed_id": "41093834", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucagon, Gcgr, Protein Kinase A, cAMP Response Element-Binding Protein, Mechanistic Target of Rapamycin Complex 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucagon activates the Gcgr-PKA-Creb-mTORC1 signaling pathway in proximal tubular epithelial cells, leading to reduced energy production and increased lipogenesis. This metabolic rewiring contributes to lipid accumulation and renal injury, promoting the progression of diabetic kidney disease."}], "pathway_id": "hsa04922", "pubmed_id": "41022721", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glucagon signaling pathway - Homo sapiens (human)\n**Pathway Description**: Glucagon is conventionally regarded as a counterregulatory hormone for insulin and plays a critical anti-hypoglycemic role by maintaining glucose homeostasis in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Glucagon also stimulates hepatic mitochondrial beta-oxidation to supply energy for glucose production. Glucagon performs its main effect via activation of adenylate cyclase. The adenylate-cyclase-derived cAMP activates protein kinase A (PKA), which then phosphorylates downstream targets, such as cAMP response element binding protein (CREB) and the bifunctional enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (one of the isoforms being PFK/FBPase 1, encoded by PFKFB1).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Glucagon-like peptide 1 receptor (ligand-induced activation), Beta-arrestin (recruitment), Extracellular domain.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucagon-like peptide 1 receptor (GLP-1R) exhibits biased agonism, wherein certain ligands preferentially activate specific downstream signaling pathways. This receptor's extracellular domain plays a critical role in determining the signaling bias. Ligand-induced activation of GLP-1R can lead to the production of cyclic adenosine monophosphate (cAMP) or the recruitment of beta-arrestin. Mutations within the extracellular domain can selectively disrupt beta-arrestin recruitment while preserving cAMP production, indicating a structural basis for biased signaling. This mechanism contributes to the differential therapeutic effects and side effects observed in the treatment of type II diabetes mellitus and obesity."}], "pathway_id": "hsa04922", "pubmed_id": "40998235", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - Homo sapiens (human)\n**Pathway Description**: Apoptosis is a genetically programmed process for the elimination of damaged or redundant cells by activation of caspases (aspartate-specific cysteine proteases). The onset of apoptosis is controlled by numerous interrelating processes. The 'extrinsic' pathway involves stimulation of members of the tumor necrosis factor (TNF) receptor subfamily, such as TNFRI, CD95/Fas or TRAILR (death receptors), located at the cell surface, by their specific ligands, such as TNF-alpha, FasL or TRAIL, respectively. The 'intrinsic' pathway is activated mainly by non-receptor stimuli, such as DNA damage, ER stress, metabolic stress, UV radiation or growth-factor deprivation. The central event in the 'intrinsic' pathway is the mitochondrial outer membrane permeabilization (MOMP), which leads to the release of cytochrome c. These two pathways converge at the level of effector caspases, such as caspase-3 and caspase-7. The third major pathway is initiated by the constituents of cytotoxic granules (e.g. Perforin and Granzyme B) that are released by CTLs (cytotoxic T-cells) and NK (natural killer) cells. Granzyme B, similarly to the caspases, cleaves its substrates after aspartic acid residues, suggesting that this protease has the ability to activate members of the caspase family directly. It is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate. TNF family of ligands activates anti-apoptotic or cell-survival signals as well as apoptotic signals. NGF and Interleukin-3 promotes the survival, proliferation and differentiation of neurons or hematopoietic cells, respectively. Withdrawal of these growth factors leads to cell death, as described above.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDCD4, Eukaryotic translation initiation factor 4A, Janus kinase, Signal transducer and activator of transcription, Phosphatidylinositol-4,5-bisphosphate 3-kinase, Protein kinase B, Mitogen-activated protein kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PDCD4 inhibits protein synthesis by binding to eIF4A through its MA3 domain. It suppresses cell proliferation, invasion, and metastasis while promoting apoptosis. In leukemia, the dysregulation of signaling pathways such as JAK/STAT, PI3K/AKT, and MAPK leads to blocked apoptosis, enhanced self-renewal, and impaired differentiation. PDCD4 regulates these processes by modulating the activity of these abnormally activated pathways, thereby influencing leukemic cell survival and progression."}], "pathway_id": "hsa04210", "pubmed_id": "41351720", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - Homo sapiens (human)\n**Pathway Description**: Apoptosis is a genetically programmed process for the elimination of damaged or redundant cells by activation of caspases (aspartate-specific cysteine proteases). The onset of apoptosis is controlled by numerous interrelating processes. The 'extrinsic' pathway involves stimulation of members of the tumor necrosis factor (TNF) receptor subfamily, such as TNFRI, CD95/Fas or TRAILR (death receptors), located at the cell surface, by their specific ligands, such as TNF-alpha, FasL or TRAIL, respectively. The 'intrinsic' pathway is activated mainly by non-receptor stimuli, such as DNA damage, ER stress, metabolic stress, UV radiation or growth-factor deprivation. The central event in the 'intrinsic' pathway is the mitochondrial outer membrane permeabilization (MOMP), which leads to the release of cytochrome c. These two pathways converge at the level of effector caspases, such as caspase-3 and caspase-7. The third major pathway is initiated by the constituents of cytotoxic granules (e.g. Perforin and Granzyme B) that are released by CTLs (cytotoxic T-cells) and NK (natural killer) cells. Granzyme B, similarly to the caspases, cleaves its substrates after aspartic acid residues, suggesting that this protease has the ability to activate members of the caspase family directly. It is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate. TNF family of ligands activates anti-apoptotic or cell-survival signals as well as apoptotic signals. NGF and Interleukin-3 promotes the survival, proliferation and differentiation of neurons or hematopoietic cells, respectively. Withdrawal of these growth factors leads to cell death, as described above.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Uric Acid, DLP1 (activated), FIS1, P110 (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Uric acid upregulates DLP1 expression and promotes its activation and mitochondrial translocation. DLP1 interacts with FIS1 to mediate mitochondrial fission. Excessive mitochondrial fission leads to the generation of reactive oxygen species, inflammatory factor release, and apoptosis. Inhibition of the DLP1/FIS1 interaction by P110 prevents mitochondrial translocation of DLP1, reduces mitochondrial fission, and attenuates apoptosis and oxidative stress in renal tubular epithelial cells."}], "pathway_id": "hsa04210", "pubmed_id": "41351411", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - Homo sapiens (human)\n**Pathway Description**: Apoptosis is a genetically programmed process for the elimination of damaged or redundant cells by activation of caspases (aspartate-specific cysteine proteases). The onset of apoptosis is controlled by numerous interrelating processes. The 'extrinsic' pathway involves stimulation of members of the tumor necrosis factor (TNF) receptor subfamily, such as TNFRI, CD95/Fas or TRAILR (death receptors), located at the cell surface, by their specific ligands, such as TNF-alpha, FasL or TRAIL, respectively. The 'intrinsic' pathway is activated mainly by non-receptor stimuli, such as DNA damage, ER stress, metabolic stress, UV radiation or growth-factor deprivation. The central event in the 'intrinsic' pathway is the mitochondrial outer membrane permeabilization (MOMP), which leads to the release of cytochrome c. These two pathways converge at the level of effector caspases, such as caspase-3 and caspase-7. The third major pathway is initiated by the constituents of cytotoxic granules (e.g. Perforin and Granzyme B) that are released by CTLs (cytotoxic T-cells) and NK (natural killer) cells. Granzyme B, similarly to the caspases, cleaves its substrates after aspartic acid residues, suggesting that this protease has the ability to activate members of the caspase family directly. It is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate. TNF family of ligands activates anti-apoptotic or cell-survival signals as well as apoptotic signals. NGF and Interleukin-3 promotes the survival, proliferation and differentiation of neurons or hematopoietic cells, respectively. Withdrawal of these growth factors leads to cell death, as described above.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aotaphenazine (administration), Doxorubicin, TOP2A (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Aotaphenazine binds to and inhibits topoisomerase II, leading to DNA damage and disruption of DNA topology. This inhibition results in the induction of apoptosis, characterized by early and late apoptotic cell populations. Aotaphenazine also causes S-phase cell cycle arrest and a reduction in the G2/M phase population, contributing to its anticancer activity."}], "pathway_id": "hsa04210", "pubmed_id": "41348751", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - Homo sapiens (human)\n**Pathway Description**: Apoptosis is a genetically programmed process for the elimination of damaged or redundant cells by activation of caspases (aspartate-specific cysteine proteases). The onset of apoptosis is controlled by numerous interrelating processes. The 'extrinsic' pathway involves stimulation of members of the tumor necrosis factor (TNF) receptor subfamily, such as TNFRI, CD95/Fas or TRAILR (death receptors), located at the cell surface, by their specific ligands, such as TNF-alpha, FasL or TRAIL, respectively. The 'intrinsic' pathway is activated mainly by non-receptor stimuli, such as DNA damage, ER stress, metabolic stress, UV radiation or growth-factor deprivation. The central event in the 'intrinsic' pathway is the mitochondrial outer membrane permeabilization (MOMP), which leads to the release of cytochrome c. These two pathways converge at the level of effector caspases, such as caspase-3 and caspase-7. The third major pathway is initiated by the constituents of cytotoxic granules (e.g. Perforin and Granzyme B) that are released by CTLs (cytotoxic T-cells) and NK (natural killer) cells. Granzyme B, similarly to the caspases, cleaves its substrates after aspartic acid residues, suggesting that this protease has the ability to activate members of the caspase family directly. It is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate. TNF family of ligands activates anti-apoptotic or cell-survival signals as well as apoptotic signals. NGF and Interleukin-3 promotes the survival, proliferation and differentiation of neurons or hematopoietic cells, respectively. Withdrawal of these growth factors leads to cell death, as described above.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gemcitabine, Saikosaponin D (administration), AKT1 (inhibited), MTOR (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Saikosaponin D synergistically enhances the antitumor effects of Gemcitabine in pancreatic cancer by inhibiting the AKT/mTOR signaling pathway. This inhibition leads to suppressed cell proliferation and the induction of apoptosis and autophagy. The combined treatment overcomes drug resistance by promoting programmed cell death and increasing autophagosome formation, thereby enhancing the cytotoxic effects of Gemcitabine."}], "pathway_id": "hsa04210", "pubmed_id": "41347830", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - Homo sapiens (human)\n**Pathway Description**: Apoptosis is a genetically programmed process for the elimination of damaged or redundant cells by activation of caspases (aspartate-specific cysteine proteases). The onset of apoptosis is controlled by numerous interrelating processes. The 'extrinsic' pathway involves stimulation of members of the tumor necrosis factor (TNF) receptor subfamily, such as TNFRI, CD95/Fas or TRAILR (death receptors), located at the cell surface, by their specific ligands, such as TNF-alpha, FasL or TRAIL, respectively. The 'intrinsic' pathway is activated mainly by non-receptor stimuli, such as DNA damage, ER stress, metabolic stress, UV radiation or growth-factor deprivation. The central event in the 'intrinsic' pathway is the mitochondrial outer membrane permeabilization (MOMP), which leads to the release of cytochrome c. These two pathways converge at the level of effector caspases, such as caspase-3 and caspase-7. The third major pathway is initiated by the constituents of cytotoxic granules (e.g. Perforin and Granzyme B) that are released by CTLs (cytotoxic T-cells) and NK (natural killer) cells. Granzyme B, similarly to the caspases, cleaves its substrates after aspartic acid residues, suggesting that this protease has the ability to activate members of the caspase family directly. It is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate. TNF family of ligands activates anti-apoptotic or cell-survival signals as well as apoptotic signals. NGF and Interleukin-3 promotes the survival, proliferation and differentiation of neurons or hematopoietic cells, respectively. Withdrawal of these growth factors leads to cell death, as described above.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, Z-VAD-fmk, Signal Transducer and Activator of Transcription 1, Signal Transducer and Activator of Transcription 1 alpha (elevated expression), Fas cell surface death receptor (upregulated), Caspase 8 (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Signal Transducer and Activator of Transcription 1 (STAT1), particularly the STAT1alpha isoform, induces apoptosis by upregulating the Fas cell surface death receptor (FAS) and Caspase 8 (CASP8). STAT1 directly binds to the promoter regions of the FAS and CASP8 genes, thereby promoting their transcription and activation. Activation of FAS and CASP8 leads to the initiation of the extrinsic apoptotic pathway, culminating in increased apoptotic cell death. This mechanism contributes to enhanced sensitivity to paclitaxel in ovarian cancer cells, reducing chemoresistance and tumor growth."}], "pathway_id": "hsa04210", "pubmed_id": "41347829", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, Family with sequence similarity 172 member A, Phosphatidylinositol-4,5-bisphosphate 3-kinase (activation), Protein kinase B (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FAM172A promotes epithelial ovarian cancer progression and induces resistance to cisplatin by modulating the PI3K/Akt signaling pathway. Activation of PI3K and subsequent phosphorylation of Akt by FAM172A enhances cell proliferation, migration, and invasion. This signaling cascade also contributes to the resistance of ovarian cancer cells to platinum-based chemotherapy, thereby promoting tumor aggressiveness and treatment failure."}], "pathway_id": "hsa01524", "pubmed_id": "41339379", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, THBS1 (overexpression), CDH1 (downregulation), CDH2 (upregulation), VIM (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "THBS1 promotes platinum resistance in ovarian clear cell carcinoma by activating the epithelial-mesenchymal transition (EMT) pathway. This is evidenced by the downregulation of E-cadherin (CDH1) and upregulation of N-cadherin (CDH2) and vimentin (VIM), which are hallmarks of EMT. THBS1 overexpression correlates with increased cell migration, invasion, and resistance to cisplatin, while its knockdown reverses these effects and reduces tumor cell survival."}], "pathway_id": "hsa01524", "pubmed_id": "41308635", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cisplatin resistance arises through multiple mechanisms, including reduced drug influx, increased drug efflux, intracellular detoxification, impaired DNA binding, enhanced DNA repair, defective apoptotic signaling, and altered oncogenic pathways. These resistance mechanisms contribute to the diminished efficacy of platinum-based therapies in cancer treatment."}], "pathway_id": "hsa01524", "pubmed_id": "41306662", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II) (administration), caspase-3 and caspase-7, BBC3 (reduced expression), PMAIP1 (reduced expression), JUN (increased expression), ATP7A (minor differences in expression), ATP7B (minor differences in expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxaliplatin resistance in pancreatic ductal adenocarcinoma is primarily associated with impaired apoptotic response rather than reduced drug uptake. At equivalent intracellular platinum levels, resistant cells exhibit delayed caspase-3/7 activation, reduced expression of pro-apoptotic genes BBC3 and PMAIP1, and increased expression of the anti-apoptotic gene JUN. These molecular alterations contribute to diminished cell death despite effective DNA damage. Drug transporter expression levels, including ATP7A and ATP7B, show only minor differences and do not significantly impact oxaliplatin resistance."}], "pathway_id": "hsa01524", "pubmed_id": "41268611", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hesperidin (administration), Cyclanoline, Tetrandrine (administration), Cisplatin (administration), TTK, AURKA, BCL2, VDR, NFKB1, CDK1, DNMT1, SMAD7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cisplatin resistance in ovarian cancer is associated with dysregulation of genes involved in cell cycle control, DNA repair, and apoptosis. Threonine tyrosine kinase (TTK), aurora kinase A (AURKA), and cyclin-dependent kinase 1 (CDK1) contribute to aberrant cell cycle progression, while B-cell lymphoma 2 (BCL2) and nuclear factor kappa B subunit 1 (NFKB1) promote resistance by suppressing apoptosis. Methylation of DNA is regulated by DNA methyltransferase 1 (DNMT1), which may alter gene expression patterns that support resistance mechanisms. Hesperidin, cissamine, and tetrandrine demonstrate potential to modulate these pathways by interacting with AURKA, vitamin D receptor (VDR), and TTK, respectively, suggesting a role in reversing resistance and restoring platinum drug sensitivity."}], "pathway_id": "hsa01524", "pubmed_id": "41239601", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II), Selinexor, XPO1 (elevated expression), TP53, CDKN1A (upregulation), SLC7A11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated XPO1 expression promotes the cytoplasmic export of p53, reducing its nuclear retention and tumor suppressive activity. Inhibition of XPO1 by KPT-330 facilitates p53 nuclear retention, which upregulates CDKN1A (p21) and downregulates SLC7A11, a key regulator of cystine uptake. This leads to G2/M phase cell cycle arrest, mitochondrial dysfunction, and activation of both apoptosis and ferroptosis. These effects synergistically enhance the sensitivity of cancer cells to oxaliplatin."}], "pathway_id": "hsa01524", "pubmed_id": "41133455", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Homo sapiens (human)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carboplatin, 5-Aza-2'-deoxycytidine (administration), Tazemetostat (administration), Maternally Expressed Gene 3 (upregulation), DNA Methyltransferase 3 Beta (elevated expression), Enhancer of Zeste Homolog 2 (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of DNA methyltransferase 3 beta (DNMT3B) and enhancer of zeste homolog 2 (EZH2) contributes to platinum drug resistance through epigenetic silencing of the maternally expressed gene 3 (MEG3). Upregulation of MEG3 following treatment with decitabine and tazemetostat enhances carboplatin sensitivity, suggesting that epigenetic modulation can restore platinum responsiveness by reversing aberrant DNA methylation and histone modification patterns."}], "pathway_id": "hsa01524", "pubmed_id": "41130098", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GnRH signaling pathway - Homo sapiens (human)\n**Pathway Description**: Gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH. The GnRHR is coupled to Gq/11 proteins to activate phospholipase C which transmits its signal to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates the intracellular protein kinase C (PKC) pathway and IP3 stimulates release of intracellular calcium. In addition to the classical Gq/11, coupling of Gs is occasionally observed in a cell-specific fashion. Signaling downstream of protein kinase C (PKC) leads to transactivation of the epidermal growth factor (EGF) receptor and activation of mitogen-activated protein kinases (MAPKs), including extracellular-signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and p38 MAPK. Active MAPKs translocate to the nucleus, resulting in activation of transcription factors and rapid induction of early genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Muricholic acid (administration), GnRH (enhanced expression), TGR5, PI3K, Akt, mTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Muricholic acid activates TGR5 in GnRH neurons, which triggers the PI3K/Akt/mTOR signaling pathway. This activation enhances the expression of gonadotropin-releasing hormone (GnRH), leading to premature sexual development and reproductive maturation in female mice."}], "pathway_id": "hsa04912", "pubmed_id": "40920933", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GnRH signaling pathway - Homo sapiens (human)\n**Pathway Description**: Gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH. The GnRHR is coupled to Gq/11 proteins to activate phospholipase C which transmits its signal to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates the intracellular protein kinase C (PKC) pathway and IP3 stimulates release of intracellular calcium. In addition to the classical Gq/11, coupling of Gs is occasionally observed in a cell-specific fashion. Signaling downstream of protein kinase C (PKC) leads to transactivation of the epidermal growth factor (EGF) receptor and activation of mitogen-activated protein kinases (MAPKs), including extracellular-signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and p38 MAPK. Active MAPKs translocate to the nucleus, resulting in activation of transcription factors and rapid induction of early genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IGSF10, RET, CDC42 (activation), GAS1, GnRH.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The IGSF10-RET-GAS1-CDC42 pathway regulates the migration of GnRH neurons. IGSF10 binds to RET and GAS1, forming an inhibitory complex that prevents the formation of a stimulatory RET-GFRA complex, thereby inhibiting CDC42 activation. Defective regulation of RET-CDC42 by IGSF10 mutants is associated with impaired GnRH neuron migration and delayed puberty."}], "pathway_id": "hsa04912", "pubmed_id": "40700020", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Daraxonrasib, Afatinib, [[2-[[(5S,8S,10aR)-8-[[(2S)-5-amino-1-(benzhydrylamino)-1,5-dioxopentan-2-yl]carbamoyl]-3-[8-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oct-7-ynoyl]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1H-indol-5-yl]-difluoromethyl]phosphonic acid, KRAS (activation), RAF1, EGFR, STAT3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS activation drives tumor progression in pancreatic ductal adenocarcinoma (PDAC) by engaging downstream effectors such as RAF1 and upstream regulators like EGFR. Inhibition of KRAS, EGFR, and STAT3 disrupts multiple signaling nodes within the KRAS pathway, leading to tumor regression and sustained suppression of tumor resistance. This combinatorial disruption prevents adaptive resistance mechanisms and promotes complete tumor regression in orthotopic PDAC models."}], "pathway_id": "hsa04014", "pubmed_id": "41329731", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KRAS (mutated), RAS, RAF1, PIK3CA, RALGDS, KRAS G12C (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS mutations promote oncogenesis by constitutively activating RAS signaling, leading to sustained downstream activation of effectors such as RAF1 and PIK3CA. This persistent signaling drives cell proliferation, survival, and migration. The G12C mutation in KRAS locks the protein in an active GTP-bound state, enhancing its oncogenic potential. Inhibitors targeting the inactive state of KRAS(G12C) can transiently suppress tumor growth, but resistance often develops due to compensatory signaling pathways or additional mutations. RALGDS also mediates RAS signaling, contributing to cytoskeletal remodeling and tumor progression."}], "pathway_id": "hsa04014", "pubmed_id": "41309533", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PCNP (elevated expression), UHRF2, ERBB3, RAS, RAF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PCNP transcriptionally upregulates UHRF2, which in turn activates the ErbB3/Ras/Raf1 signaling pathway. Activation of this pathway promotes hepatocellular carcinoma progression by enhancing cellular proliferation, invasion, and tumor formation."}], "pathway_id": "hsa04014", "pubmed_id": "41271959", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAS (disrupted regulatory balance), RAF1, PI3K, RALGDS, GAP, NF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAS proteins function as molecular switches that regulate cell proliferation, differentiation, and tissue homeostasis by cycling between inactive GDP-bound and active GTP-bound states. Activation of RAS-GTP promotes signaling through effectors such as RAF1, PI3K, and RALGDS, influencing multiple cellular processes. RAS signaling must be downmodulated to maintain pluripotent stem cells and preserve adult stem cell quiescence. Terminal differentiation is facilitated by the inactivation of RAS through the GTPase-activating protein NF1. Disruption of this regulatory balance leads to aberrant cell differentiation and contributes to developmental disorders and cancer progression."}], "pathway_id": "hsa04014", "pubmed_id": "41248180", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Naringenin, Lidocaine, RAS (reduced gene expression), MAK (reduced gene expression), ERK (reduced gene expression), MMP2 (decreased expression), MMP9 (decreased expression), CDH2 (reduced levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced RAS, MAK, and ERK gene expression leads to suppression of epithelial-mesenchymal transition. This inhibition is associated with decreased expression of MMP2 and MMP9, as well as reduced N-cadherin levels, which collectively impair cell migration and invasion."}], "pathway_id": "hsa04014", "pubmed_id": "41226554", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAS (oncogenic), HRAS (G12V), MERTK (activated), STK38 (recruited), RAC1 (activated), CDC42 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oncogenic RAS activates MERTK through the RAS signaling pathway, which in turn recruits STK38 kinase. STK38 kinase activity is essential for RAS-induced cell migration and MERTK tyrosine phosphorylation. This interaction also promotes the activation of RAC1 and CDC42, which contribute to enhanced cell motility."}], "pathway_id": "hsa04014", "pubmed_id": "41226428", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Homo sapiens (human)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neurofibromin 1, SRY-box transcription factor 9, Cyclin-dependent kinase inhibitor 2A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Biallelic loss of Neurofibromin 1 (NF1), a negative regulator of RAS signaling, leads to constitutive activation of the RAS pathway in Schwann cells. This dysregulation promotes a glial-to-mesenchymal transition, a process associated with tumor progression and loss of tumor suppressor function. SRY-box transcription factor 9 (Sox9) is a key driver of this transition and contributes to tumor growth. Concurrently, loss of Cyclin-dependent kinase inhibitor 2A (Cdkn2a) further destabilizes cellular control mechanisms. These combined events facilitate the malignant transformation of neurofibromas into malignant peripheral nerve sheath tumors."}], "pathway_id": "hsa04014", "pubmed_id": "41223283", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trametinib, CoREST, MYC, NOLC1 (Overexpressed), U1 small nuclear RNA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The CoREST complex transcriptionally regulates RNA processing genes, including those encoding essential spliceosome components such as small nuclear ribonucleoproteins (snRNPs). Disruption of CoREST leads to impaired spliceosome function, characterized by altered alternative mRNA isoform expression and reduced cell viability. This disruption is associated with decreased 2'-O-methylation of U1 snRNA, a modification essential for proper spliceosomal activity. NOLC1, a downstream target of CoREST involved in ribosomal RNA processing, can partially restore viability and splicing patterns when overexpressed in CoREST-deficient cells. Depletion of NOLC1 increases sensitivity to the MEK inhibitor trametinib in melanoma cells."}], "pathway_id": "hsa03040", "pubmed_id": "41227344", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SF3B1, SF3B1 K700E (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SF3B1 is a core component of the spliceosome that plays a key role in branch point recognition and 3' splice site selection. Mutations in SF3B1, such as the K700E variant, alter the recognition of 3' splice sites, leading to the utilization of cryptic splice sites. These SF3B1-sensitive splice junctions are characterized by extended polypyrimidine tracts and weaker canonical splice sites compared to SF3B1-resistant junctions. Additionally, SF3B1-sensitive splice junctions exhibit greater RNA structural flexibility and reduced structural differentiation at the NAG splicing motif, contributing to altered splicing outcomes in the presence of SF3B1 mutations."}], "pathway_id": "hsa03040", "pubmed_id": "41058062", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RPB9, U2AF1 (released), U2AF2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RPB9, a subunit of RNA polymerase II, interacts with U2AF1 to initiate 3' splice site recognition. This interaction facilitates exon definition by promoting the recruitment of U2AF2, which heterodimerizes with U2AF1. The binding of U2AF2 also triggers the release of U2AF1 from the elongating RNA polymerase II complex, thereby partitioning the steps of splice site recognition and spliceosome assembly during cotranscriptional splicing."}], "pathway_id": "hsa03040", "pubmed_id": "40997183", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RNU4ATAC, RNU6ATAC.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bi-allelic variants in RNU4ATAC and RNU6ATAC disrupt the function of the minor spliceosome, leading to intron retention in minor intron-containing genes. This disruption manifests as transcriptome-wide splicing outliers, contributing to the development of spliceopathies."}], "pathway_id": "hsa03040", "pubmed_id": "40975062", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRNKL1 (disruption of function), TP53 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of CRNKL1 function leads to impaired splicing and widespread cellular stress, as indicated by p53 activation. This results in reduced brain development, characterized by microcephaly and pontocerebellar hypoplasia, and is associated with altered expression of neuronal and cell cycle genes, leading to reduced cell proliferation and severe neurological dysfunction."}], "pathway_id": "hsa03040", "pubmed_id": "40857589", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GPATCH3, DHX15 (activated), CXCR3 (accurate splicing), CD44 (accurate splicing), FOXP3 (accurate splicing).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GPATCH3 interacts with the RNA helicase DHX15 and enhances its ATPase activity, which promotes proper spliceosome disassembly. This interaction is essential for maintaining accurate splicing of pre-mRNA. Loss of GPATCH3 leads to splicing alterations in immunoregulatory genes such as CXCR3, CD44, and FOXP3. These splicing changes contribute to the suppression of cytotoxic T cell and NK cell infiltration, while promoting the accumulation of immunosuppressive cells like myeloid-derived suppressor cells and cancer-associated fibroblasts. This dysregulation supports the formation of an immunosuppressive tumor microenvironment and facilitates tumor immune evasion."}], "pathway_id": "hsa03040", "pubmed_id": "40861452", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: AQR, SF3B1, SF3B4, CDC40, PRPF8, PRPF31.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Spliceosome dysfunction leads to the upregulation of naturally occurring NMD-targeted mRNA isoforms. This increase is associated with reduced activity of catalytic spliceosome components and may result from both indirect effects, such as missplicing of mRNAs encoding NMD factors, and direct roles of specific spliceosome proteins including AQR, SF3B1, SF3B4, and CDC40 in the NMD pathway. The accumulation of NMD substrates correlates with the degree of NMD inhibition, contributing to cellular dysfunction in conditions involving spliceosome disruption."}], "pathway_id": "hsa03040", "pubmed_id": "40856040", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: U1 snRNP (disrupted function), U1 snRNP complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The U1 snRNP complex recognizes 5'-splice sites in pre-mRNA and initiates the splicing process by assembling into the spliceosome. This complex plays a central role in spliceosome formation and the regulation of gene expression. Disruption of U1 snRNP function leads to impaired splicing, contributing to the development of neurodegeneration, cancer, and autoimmune and eye diseases."}], "pathway_id": "hsa03040", "pubmed_id": "40830087", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SRRM3, SRRM4, SRRM3 and SRRM4, U1 snRNP, U2 snRNP, U4 snRNP, U5 snRNP, U6 snRNP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Microexon inclusion is regulated by the efficiency of recruiting early spliceosomal components, particularly influenced by the core splicing architecture and RNA sequence length constraints. SRRM3 and SRRM4 facilitate the inclusion of microexons by enhancing the recruitment of early spliceosomal complexes such as U1 and U2 snRNPs. Variations in these interactions determine whether a microexon exhibits high or low sensitivity to SRRM3/4 activity, thereby influencing its splicing outcome in a cell-type-specific manner."}], "pathway_id": "hsa03040", "pubmed_id": "40775527", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Homo sapiens (human)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Topotecan, Irinotecan, USP15, U2-type spliceosomal complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "USP15 interacts with proteins enriched in the U2-type spliceosomal complex and RNA helicase activity, thereby modulating pre-mRNA splicing. This regulation contributes to tumor progression and chemoresistance through altered RNA processing and epithelial-mesenchymal transition."}], "pathway_id": "hsa03040", "pubmed_id": "40762380", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Human T-cell leukemia virus 1 infection - Homo sapiens (human)\n**Pathway Description**: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). It is also strongly implicated in non-neoplastic chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Expression of Tax, a viral regulatory protein is critical to the pathogenesis. Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. The modulation of the signaling by Tax involve its binding to transcription factors like CREB/ATF, NF-kappa B, and SRF.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lenacapavir, Tax, capsid protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The HTLV-1 capsid protein forms essential lattice interfaces required for virus infectivity. A ligand-binding pocket within this protein is critical for maintaining capsid integrity and function. Disruption of this pocket by anti-capsid drugs like lenacapavir can inhibit viral infectivity, representing a viable strategy for therapeutic intervention. The Tax protein, a viral regulatory factor, contributes to pathogenesis by modulating host signaling pathways related to cell proliferation and anti-apoptosis."}], "pathway_id": "hsa05166", "pubmed_id": "41345105", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Human T-cell leukemia virus 1 infection - Homo sapiens (human)\n**Pathway Description**: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). It is also strongly implicated in non-neoplastic chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Expression of Tax, a viral regulatory protein is critical to the pathogenesis. Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. The modulation of the signaling by Tax involve its binding to transcription factors like CREB/ATF, NF-kappa B, and SRF.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide, Abt 263, Fucoxanthin, Peridinin, Thymoquinone, BCL2 (upregulated), BCL2L1 (upregulated), MCL1 (upregulated), BCL2A1 (upregulated), BAX (downregulated), BIM (downregulated), BID (downregulated), Tax, HBZ, NFKB1, JAK-STAT signaling pathway.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deltaretroviral infection, including that by Human T-cell Leukemia Virus type 1 (HTLV-1), leads to dysregulation of BCL-2 family proteins. Viral oncoproteins such as Tax and HBZ upregulate anti-apoptotic members including BCL2, BCL2L1, MCL1, and BCL2A1, while suppressing pro-apoptotic proteins such as BAX, BIM, and BID. This imbalance prolongs the survival of infected lymphocytes, facilitates clonal expansion, and contributes to genomic instability and malignant transformation. The resistance to apoptosis conferred by this dysregulation supports viral persistence and leukemogenesis."}], "pathway_id": "hsa05166", "pubmed_id": "41201565", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Human T-cell leukemia virus 1 infection - Homo sapiens (human)\n**Pathway Description**: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). It is also strongly implicated in non-neoplastic chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Expression of Tax, a viral regulatory protein is critical to the pathogenesis. Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. The modulation of the signaling by Tax involve its binding to transcription factors like CREB/ATF, NF-kappa B, and SRF.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tax.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The HTLV-1 Tax protein functions as a transcriptional co-factor that interacts with host transcription factors such as CREB/ATF, NF-B, and SRF, leading to the activation of signaling pathways involved in anti-apoptosis and cell proliferation. These molecular interactions contribute to the transformation of CD4+ T-cells and the development of adult T-cell leukemia/lymphoma (ATLL), as well as chronic inflammatory conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)."}], "pathway_id": "hsa05166", "pubmed_id": "41157604", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Human T-cell leukemia virus 1 infection - Homo sapiens (human)\n**Pathway Description**: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). It is also strongly implicated in non-neoplastic chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Expression of Tax, a viral regulatory protein is critical to the pathogenesis. Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. The modulation of the signaling by Tax involve its binding to transcription factors like CREB/ATF, NF-kappa B, and SRF.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tax (elevated levels), cAMP response element-binding protein, nuclear factor kappa B, serum response factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of the HTLV-1 Tax protein promote the proliferation and survival of infected T-cells through the activation of transcription factors CREB, NF-kappaB, and SRF. Tax modulates cellular signaling pathways by interacting with host cell factors, leading to the transcriptional activation of both its own promoter and host cellular genes. This transcriptional activation contributes to the transformation of HTLV-1-infected cells, a critical step in the development of adult T-cell leukemia/lymphoma."}], "pathway_id": "hsa05166", "pubmed_id": "41153438", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Human T-cell leukemia virus 1 infection - Homo sapiens (human)\n**Pathway Description**: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that is associated with adult T-cell leukemia/lymphoma (ATL). It is also strongly implicated in non-neoplastic chronic inflammatory diseases such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Expression of Tax, a viral regulatory protein is critical to the pathogenesis. Tax is a transcriptional co-factor that interfere several signaling pathways related to anti-apoptosis or cell proliferation. The modulation of the signaling by Tax involve its binding to transcription factors like CREB/ATF, NF-kappa B, and SRF.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (Elevated levels), ALAS2, ALAS1, FECH, CPOX, PPOX, UROS, UROD, HMBS, ALAD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid in erythropoietic protoporphyria result from impaired activity of ferrochelatase (FECH), which is essential for the final step of heme biosynthesis. This disruption leads to the accumulation of protoporphyrin in erythrocytes and plasma, contributing to photosensitivity and oxidative stress. The enzymatic pathway is governed by a series of heme biosynthetic enzymes, including ALAS2, FECH, CPOX, PPOX, UROS, UROD, HMBS, and ALAD. Deficiency or mutations in FECH are the primary cause of this condition, while dysregulation of ALAS1 and ALAS2 can also contribute to porphyria-related metabolic disturbances. The accumulation of protoporphyrin leads to mitochondrial dysfunction and increased reactive oxygen species production, exacerbating cellular damage and clinical manifestations."}], "pathway_id": "hsa05166", "pubmed_id": "40915004", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Erlotinib Hydrochloride, EGFR, YAP1, SAV1 (degradation), HERC4 (through interaction with EGFR).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EGFR promotes degradation of SAV1 through its interaction with the E3 ubiquitin ligase HERC4, thereby inhibiting the Hippo signaling pathway. This inhibition leads to the nuclear translocation of YAP, which activates downstream Hippo target genes. Activation of YAP signaling contributes to retinal fibrosis. Pharmacological inhibition of EGFR enhances YAP signaling and reduces diabetic retinal fibrosis by preventing SAV1 degradation."}], "pathway_id": "hsa04012", "pubmed_id": "41257731", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Naringenin, Lidocaine, Epidermal Growth Factor Receptor (suppressed), Rat Sarcoma Proto-Oncogene (reduced expression), Mitogen-Activated Protein Kinase (reduced expression), Extracellular Signal-Regulated Kinase (reduced expression), Matrix Metallopeptidase 2 (decreased expression), Matrix Metallopeptidase 9 (decreased expression), Cadherin 2 (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Suppression of the EGFR signaling pathway leads to reduced expression of RAS, MAK, and ERK, which inhibits epithelial-mesenchymal transition. This results in decreased expression of matrix metallopeptidases (MMP2 and MMP9) and N-cadherin, thereby reducing cancer cell migration and invasion. These molecular changes contribute to the anti-metastatic effect observed in colorectal cancer cells."}], "pathway_id": "hsa04012", "pubmed_id": "41226554", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ERBB2, ERBB3 (activated), FOXA1 (bound to chromatin), ESR1 (occupancy), EP300, HDAC2 (recruited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HER2 and HER3 receptor activation promotes the deacetylation of FOXA1 by recruiting HDAC2, which modifies FOXA1 at the WD1 domain. This deacetylation enhances FOXA1 binding to chromatin, particularly at ER-independent regions, and reduces estrogen receptor occupancy. Increased FOXA1 chromatin binding contributes to hormone insensitivity and endocrine therapy resistance in luminal breast cancer, thereby promoting cancer progression."}], "pathway_id": "hsa04012", "pubmed_id": "41224124", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epidermal Growth Factor (administration), KRAS, epidermal growth factor receptor (activated), mitogen-activated protein kinase kinase (activated), extracellular signal-regulated kinase (activated), major histocompatibility complex class I, C-X-C motif chemokine 9 (diminished), CD8-positive T cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS signaling inhibits interferon-mediated MHC-I expression and suppresses CD8(+) T cell activity through the EGFR/MEK/ERK pathway, resulting in immune evasion and resistance to immunotherapy. Epidermal growth factor activates EGFR, initiating MEK/ERK signaling, which in turn suppresses CXCL9 expression and diminishes T cell infiltration."}], "pathway_id": "hsa04012", "pubmed_id": "41219194", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acridine Orange Base, NEUROG1 (elevated levels), BECN1, MAP1LC3A, EGFR, PIK3CA, AKT1, MTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of neuroglobin (NEUROG1) promote autophagy by increasing the expression of BECN1 and MAP1LC3A in glioblastoma cells. This autophagy induction suppresses cell proliferation, migration, and invasion. NEUROG1 interacts with the EGFR receptor and inhibits the EGFR/PIK3CA/AKT1/MTOR signaling pathway, resulting in suppression of tumor growth, induction of apoptosis, and cell cycle arrest at the S phase."}], "pathway_id": "hsa04012", "pubmed_id": "41214713", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EGFR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Epidermal growth factor receptor (EGFR) regulates RNA polymerase II (Pol II) through direct phosphorylation of the carboxyl-terminal domain (CTD) of Pol II. This phosphorylation modifies the transcriptional activity of Pol II at signal-responsive genes, thereby modulating gene transcription in response to extracellular signals."}], "pathway_id": "hsa04012", "pubmed_id": "41197002", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Homo sapiens (human)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Receptor tyrosine kinase, RNA polymerase II.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Receptor tyrosine kinases exert direct regulatory effects on RNA polymerase II within the nucleus, influencing transcriptional activity."}], "pathway_id": "hsa04012", "pubmed_id": "41196973", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid, Creatine (reduced levels), N-Acetyl-L-Aspartic Acid (reduced levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced levels of total creatine and total N-acetylaspartate are associated with impaired neuronal metabolism and bioenergetics. Dysfunction in GABAergic and glutamatergic pathways correlates with these metabolic alterations, potentially contributing to the pathophysiology of Autism Spectrum Disorder."}], "pathway_id": "hsa04727", "pubmed_id": "41107264", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (released), GABRA1 (Gamma-aminobutyric acid receptor subunit alpha-1), GABRE (Gamma-aminobutyric acid receptor subunit epsilon).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gamma-aminobutyric acid (GABA) is released from enteric cholinergic neurons in response to activation of the septo-enteric circuit. This GABA binds to GABA(A) receptors containing the epsilon subunit on tumor cells, promoting tumor growth. Increased activity in the lateral septum enhances this signaling, contributing to the progression of colorectal cancer."}], "pathway_id": "hsa04727", "pubmed_id": "40841473", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (release).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GABAergic synapses involve the release of gamma-aminobutyric acid (GABA), which modulates neuronal activity through synaptic and paracrine interactions. Neuronal activity induces membrane depolarization in small cell lung cancer (SCLC) cells, leading to calcium transients that promote tumor proliferation. This synaptic communication between neurons and SCLC cells contributes to intracranial tumor growth."}], "pathway_id": "hsa04727", "pubmed_id": "40931074", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid, Endophilin A1, Gephyrin, GABRA1 (Synaptic recruitment and stabilization).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Endophilin A1 interacts with the inhibitory postsynaptic scaffold protein Gephyrin and promotes the organization of the inhibitory postsynaptic density. This interaction facilitates the synaptic recruitment and stabilization of gamma-aminobutyric acid type A (GABAA) receptors. Disruption of Endophilin A1 reduces inhibitory synaptic transmission and disrupts the balance between excitatory and inhibitory functions in neural circuits, leading to increased susceptibility to epilepsy."}], "pathway_id": "hsa04727", "pubmed_id": "41036704", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (clearance), GABA receptor, GABA A receptor, GABA B receptor, GABA C receptor, GABA transporter.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gamma-aminobutyric acid (GABA) binds to GABA A, B, and C receptors, mediating inhibitory neurotransmission in the central nervous system. GABA A and C receptors are ionotropic and mediate fast inhibitory responses through chloride channel activation, while GABA B receptors are metabotropic and regulate slower responses via G-protein signaling. GABA release is regulated by presynaptic GABA B autoreceptors and is cleared from the synaptic cleft by GABA transporters. These mechanisms collectively regulate synaptic plasticity, functional connectivity, and neuronal network dynamics."}], "pathway_id": "hsa04727", "pubmed_id": "40819006", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (cleared), GABA-A receptor (activated), GABA-B receptor (activated), GABA-C receptor (activated), GABA transporter.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gamma-aminobutyric acid (GABA) binds to ionotropic GABA-A and GABA-C receptors, as well as metabotropic GABA-B receptors, to mediate inhibitory neurotransmission. Activation of GABA-A and GABA-C receptors leads to chloride ion influx, hyperpolarizing the neuron and reducing excitability. GABA-B receptor activation modulates synaptic transmission through G-protein-coupled signaling pathways. GABA is cleared from the synaptic cleft by GABA transporters (GATs), which terminate its inhibitory effect and maintain extracellular GABA levels. These mechanisms collectively regulate neuronal firing and synaptic plasticity."}], "pathway_id": "hsa04727", "pubmed_id": "40307951", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Levetiracetam (administration), BIN1 (elevated levels), SLC32A1, SLC17A7, Amyloid-beta A4 protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of BIN1 regulate endocytosis at inhibitory synapses by modulating the exocytosis and endocytosis of vGAT-containing vesicles, thereby controlling GABA release. Reduction of BIN1 function decreases the number of inhibitory synapses and accelerates vGAT vesicle cycling, leading to increased extracellular GABA levels. This disruption in inhibitory signaling results in elevated neuronal calcium levels and hyperexcitability, which in turn increases glutamate release due to loss of inhibitory control. Levetiracetam, an antiepileptic drug, acts on presynaptic mechanisms to reduce inhibitory synapse loss and mitigate hyperexcitability."}], "pathway_id": "hsa04727", "pubmed_id": "40674214", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GABRA4, GABRB1, GABRG2, GABRQ, KCNQ2, KCNQ3, KCNMA1, GRIN2A, GRIN2B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GABAergic synaptic function involves the activity of ionotropic GABA receptors such as GABRA4, GABRB1, GABRG2, and GABRQ, which mediate inhibitory neurotransmission by modulating chloride ion flux. Disruption in the expression of these receptor subunits can alter synaptic transmission and membrane potential regulation. Additionally, voltage-gated potassium channels (KCNQ2, KCNQ3, KCNMA1) contribute to membrane potential stability and synaptic function. Alterations in these genes may disrupt synaptic signaling and contribute to impaired inhibitory neurotransmission."}], "pathway_id": "hsa04727", "pubmed_id": "40233852", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRAJA1 (elevated expression), spinophilin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PRAJA1 enhances GABAergic transmission, contributing to increased inhibitory signaling in synaptic circuits. PRAJA1 regulates synaptic architecture and transmission by targeting spinophilin for ubiquitination and degradation, thereby influencing synaptic remodeling and spine density. Modulation of PRAJA1 levels alters the excitatory/inhibitory balance, directly impacting synaptic plasticity and memory-related processes such as object recognition and spatial memory."}], "pathway_id": "hsa04727", "pubmed_id": "40243483", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid, Parvalbumin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Parvalbumin-positive interneurons, a subset of GABAergic interneurons, regulate gain-control and the timing of neuronal signal propagation through fast-spiking activity. These interneurons mediate feedforward and feedback inhibition in cortical circuits by rapidly converting excitatory inputs into inhibitory outputs via the neurotransmitter gamma-aminobutyric acid (GABA)."}], "pathway_id": "hsa04727", "pubmed_id": "40494084", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Parvalbumin (enhanced function), GABA receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Parvalbumin interneurons regulate neuronal functional connectivity and are essential for synapse formation during motor recovery after stroke. Their activation correlates with increased gamma oscillation, a brain rhythm associated with cognitive and motor processes. Reduced dendritic spine density and external synaptic input in stroke-projecting neurons are linked to diminished GABAergic input, which disrupts inhibitory signaling. Enhanced parvalbumin interneuron function promotes the formation of new synaptic connections, thereby improving motor performance and facilitating recovery."}], "pathway_id": "hsa04727", "pubmed_id": "40089466", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: GABAergic synapse - Homo sapiens (human)\n**Pathway Description**: Gamma aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the mammalian central nervous system (CNS). When released in the synaptic cleft, GABA binds to three major classes of receptors: GABAA, GABAB, and GABAC receptors. GABAA and GABAC receptors are ionotropic and mediate fast GABA responses by triggering chloride channel openings, while GABAB receptors are metabotropic and mediate slower GABA responses by activating G-proteins and influencing second messenger systems. GABAA receptors, the major sites for fast inhibitory neurotransmission in the CNS, are regulated by phosphorylation mechanisms, affecting both their functional properties and their cell surface mobility and trafficking. GABA release by the presynaptic terminal is negatively regulated by GABAB autoreceptors, and is cleared from the extracellular space by GABA transporters (GATs) located either on the presynaptic terminal or neighboring glial cells.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cannabidiol (administration), Lysophosphatidylinositol (LPI-GPR55 signaling), SCN1A (reduced expression), Voltage-gated sodium channel subunit alpha-1 (restored function), G protein-coupled receptor 55 (LPI-GPR55 signaling).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of SCN1A leads to impaired function of the voltage-gated sodium channel Nav1.1 in GABAergic interneurons, resulting in diminished inhibitory neurotransmission and increased neuronal excitability. This disruption contributes to synaptic excitatory-inhibitory imbalance, promoting seizure activity and autistic-like behaviors. Lysophosphatidylinositol activates GPR55, which enhances excitatory signaling and further elevates the excitatory-inhibitory ratio, thereby amplifying seizure susceptibility. Cannabidiol modulates both ion channels and GPR55, reducing LPI-GPR55 signaling and restoring synaptic balance by decreasing excitatory drive and promoting inhibitory tone."}], "pathway_id": "hsa04727", "pubmed_id": "40048808", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Carbohydrate digestion and absorption - Homo sapiens (human)\n**Pathway Description**: Dietary carbohydrate in humans and omnivorous animals is a major nutrient. The carbohydrates that we ingest vary from the lactose in milk to complex carbohydrates. These carbohydrates are digested to monosaccharides, mostly glucose, galactose and fructose, prior to absorption in the small intestine. Glucose and galactose are initially transported into the enterocyte by SGLT1 located in the apical brush border membrane and then exit through the basolateral membrane by either GLUT2 or exocytosis. In a new model of intestinal glucose absorption, transport by SGLT1 induces rapid insertion and activation of GLUT2 in the brush border membrane by a PKC betaII-dependent mechanism. Moreover, trafficking of apical GLUT2 is rapidly up-regulated by glucose and artificial sweeteners, which act through T1R2 + T1R3/alpha-gustducin to activate PLC-beta2 and PKC-beta II. Fructose is transported separately by the brush border GLUT5 and then released out of the enterocyte into the blood by GLUT2.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, Estradiol, ESR1 (upon estrogen signaling), ESR2, SLC5A1 (expression), SLC2A2 (expression), PKC, NGFR, CD36.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Estrogen modulates glucose absorption in the duodenum via estrogen receptor alpha (ERalpha)-dependent upregulation of sodium/glucose cotransporter 1 (SGLT1) and glucose transporter 2 (GLUT2). This regulation involves the activation of protein kinase C (PKC) signaling downstream of ERalpha. Estrogen receptor beta (ERbeta) does not appear to play a significant role in this process. Reduced estrogen levels correlate with decreased SGLT1 and GLUT2 expression, leading to impaired glucose absorption and altered glucose tolerance."}], "pathway_id": "hsa04973", "pubmed_id": "40716951", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nadide, Calcium Cation, Cobalt chloride (cocl2), Nicotinamide phosphoribosyltransferase, Protein kinase, cGMP-dependent, Cyclic guanosine monophosphate.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the cGMP-PKG signaling pathway by nicotinamide phosphoribosyltransferase (NAMPT) promotes the formation of oxidative muscle fibers and enhances mitochondrial function. This pathway also reduces apoptosis and protects against ischemic limb injury. Inhibition of cGMP-PKG signaling suppresses the formation of oxidative muscle fibers induced by NAMPT."}], "pathway_id": "hsa04022", "pubmed_id": "41310770", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp, Vericiguat, guanylate cyclase soluble subunit alpha 1, lactate dehydrogenase A (activated), glutathione peroxidase 4 (phosphorylated), protein kinase G.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PKG phosphorylates LDHA at threonine 95, activating its moonlighting kinase function. This activated LDHA phosphorylates GPX4, reducing its chaperone-mediated autophagy-dependent degradation and thereby suppressing ferroptosis. This pathway protects against cardiac microvascular reperfusion injury by preserving GPX4 activity and reducing lipid peroxidation, ultimately preventing endothelial cell death and cardiac dysfunction."}], "pathway_id": "hsa04022", "pubmed_id": "40856046", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp, Fetuin-A, Toll-like receptor 4, Myeloid differentiation primary response 88, Src family kinase, Phosphoinositide 3-kinase, Protein kinase B, cGMP-dependent protein kinase, mitogen-activated protein kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fetuin-A binds to platelet Toll-like receptor 4 (TLR-4), which activates the TLR-4/MyD88 signaling cascade. This interaction also activates Src family kinase (SFK), phosphoinositide 3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways, contributing to platelet activation. Additionally, the cGMP/PKG signaling pathway is engaged, further promoting platelet aggregation, dense granule ATP release, P-selectin exposure, integrin activation, platelet spreading, and clot retraction. These molecular events collectively enhance thrombosis formation."}], "pathway_id": "hsa04022", "pubmed_id": "40578606", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Metformin (administration), CID 151449452, Cgmp, Phosphodiesterase 6D (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Low-dose metformin inhibits castration-resistant prostate cancer progression by modulating PDE6D activity, which induces purine metabolic alterations and activates the cGMP/PKG signaling pathway. PDE6D overexpression is associated with increased resistance to metformin. Co-treatment with the PDE6D inhibitor TMX-4100 enhances tumor suppression by restoring pathway activity and reducing resistance."}], "pathway_id": "hsa04022", "pubmed_id": "40216151", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp, APOA1 antisense RNA 1 (elevated expression), cGMP-dependent protein kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of APOA1 antisense RNA 1 modulates glucose metabolism reprogramming and activates the cGMP-dependent protein kinase signaling pathway, promoting tumor malignant biological behaviors and enhancing tumor cell drug resistance."}], "pathway_id": "hsa04022", "pubmed_id": "39889939", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methyl (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylate, RGS7 (elevated expression), PKG1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated RGS7 expression suppresses the cGMP-PKG signaling pathway, reducing PKG1 activity and contributing to atrial fibrillation progression. Inhibition of RGS7 activates PKG1, which attenuates apoptosis, inflammation, oxidative stress, and cardiac fibrosis while enhancing mitochondrial membrane potential. Activation of PKG1 through cGMP signaling mitigates pathological cardiac remodeling associated with atrial fibrillation."}], "pathway_id": "hsa04022", "pubmed_id": "40086518", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Celastrol (administration), 5-Aminolevulinic Acid, Phosphodiesterase 5A, Cyclic Guanosine Monophosphate (increased levels), cGMP-dependent protein kinase (activated), Transient receptor potential cation channel subfamily C member 6 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphodiesterase 5 (PDE5) regulates intracellular levels of cyclic guanosine monophosphate (cGMP), a second messenger that activates cGMP-dependent protein kinase (PKG). Elevated cGMP-PKG signaling leads to calcium desensitization in smooth muscle cells, promoting relaxation. In pulmonary hypertension, dysregulation of this pathway contributes to vascular remodeling and right ventricular dysfunction. Celastrol modulates PDE5 activity, increasing cGMP levels and subsequently activating PKG. This activation suppresses smooth muscle cell proliferation, induces apoptosis, and reduces fibrosis in pulmonary arteries. Additionally, PKG phosphorylates TRPC6, a calcium-permeable ion channel, thereby inhibiting calcium influx and downstream hypertrophic signaling. These effects collectively ameliorate pulmonary vascular remodeling and improve right ventricular function."}], "pathway_id": "hsa04022", "pubmed_id": "39887769", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Homo sapiens (human)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp, Calcium Cation (administration with A23187), Calcimycin, protein phosphatase 1, cGMP-dependent protein kinase, calcium-dependent protein kinases, guanylate cyclase alpha (basal activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "cGMP and calcium ions regulate the egress of Plasmodium falciparum from host erythrocytes by activating their respective kinases, PKG and CDPKs. Protein phosphatase 1 (PP1) modulates cGMP homeostasis by controlling the basal activity of guanylate cyclase alpha, which in turn influences PKG-dependent Ca2+ signaling. PP1 also directly regulates the rounding-up of the parasitophorous vacuole, a critical early step in egress. Disruption of this step in PP1-null parasites can be bypassed by calcium ionophores like A23187, which restore normal egress kinetics and initiate vacuole rounding. This establishes PP1 as a key upstream regulator of the cGMP-PKG signaling pathway during blood-stage egress."}], "pathway_id": "hsa04022", "pubmed_id": "39808636", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: RIG-I-like receptor signaling pathway - Homo sapiens (human)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). The RLR proteins include RIG-I, MDA5, and LGP2 and are expressed in both immune and nonimmune cells. Upon recognition of viral nucleic acids, RLRs recruit specific intracellular adaptor proteins to initiate signaling pathways that lead to the synthesis of type I interferon and other inflammatory cytokines, which are important for eliminating viruses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Double stranded RNA, DHX58 (upregulated), DDX58, IFIH1, IRF3, RELA, TLR3, interferon.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "LGP2 (DHX58) is upregulated in response to viral infection and dsRNA stimulation through TLR3 and RIG-I-like receptor pathways. This induction occurs at the transcriptional level and is partially independent of interferon and cytokine signaling. IRF3 and, to a lesser extent, RELA contribute to this IFN-independent regulation. The expression of LGP2 modulates antiviral responses by influencing the activity of RIG-I and MDA5, enhancing the host's ability to maintain innate immune defenses when interferon production is impaired."}], "pathway_id": "hsa04622", "pubmed_id": "41171864", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: RIG-I-like receptor signaling pathway - Homo sapiens (human)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). The RLR proteins include RIG-I, MDA5, and LGP2 and are expressed in both immune and nonimmune cells. Upon recognition of viral nucleic acids, RLRs recruit specific intracellular adaptor proteins to initiate signaling pathways that lead to the synthesis of type I interferon and other inflammatory cytokines, which are important for eliminating viruses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RIG-I (K48-linked ubiquitination), RNF125, ZCCHC3, TRIM25.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RIG-I participates in the recognition of viral RNA and initiates signaling pathways that lead to interferon production. RIG-I undergoes K63-linked ubiquitination mediated by TRIM25, a modification essential for its activation. ZCCHC3 facilitates the interaction between RIG-I and TRIM25. Disruption of this complex inhibits RIG-I ubiquitination and activation. RNF125 mediates K48-linked ubiquitination of RIG-I, leading to its proteasomal degradation. Inhibition of TRIM25-RIG-I complex formation and induction of RIG-I degradation both prevent RIG-I signaling, thereby suppressing interferon production and innate immune responses."}], "pathway_id": "hsa04622", "pubmed_id": "41070967", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: RIG-I-like receptor signaling pathway - Homo sapiens (human)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). The RLR proteins include RIG-I, MDA5, and LGP2 and are expressed in both immune and nonimmune cells. Upon recognition of viral nucleic acids, RLRs recruit specific intracellular adaptor proteins to initiate signaling pathways that lead to the synthesis of type I interferon and other inflammatory cytokines, which are important for eliminating viruses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RIG-I, MDA5, LGP2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RIG-I-like receptors, including RIG-I, MDA5, and LGP2, detect non-self RNA derived from intracellular viral replication. Upon recognition, these receptors initiate signaling pathways that lead to the production of type I interferons and inflammatory cytokines, which mediate antiviral responses. This RNA sensing mechanism is a critical component of the innate immune system."}], "pathway_id": "hsa04622", "pubmed_id": "40877499", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: RIG-I-like receptor signaling pathway - Homo sapiens (human)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). The RLR proteins include RIG-I, MDA5, and LGP2 and are expressed in both immune and nonimmune cells. Upon recognition of viral nucleic acids, RLRs recruit specific intracellular adaptor proteins to initiate signaling pathways that lead to the synthesis of type I interferon and other inflammatory cytokines, which are important for eliminating viruses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RIG-I, MDA5, LGP2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RIG-I-like receptors, including RIG-I, MDA5, and LGP2, recognize non-self RNA in the cytosol and initiate signaling pathways that lead to the production of type I interferons. These interferons mediate antiviral defense and modulate immune responses by activating downstream signaling cascades such as JAK-STAT, NF-kappaB, and MAPK. This signaling contributes to inflammatory activation and immune regulation in response to viral infection."}], "pathway_id": "hsa04622", "pubmed_id": "40676381", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: RIG-I-like receptor signaling pathway - Homo sapiens (human)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). The RLR proteins include RIG-I, MDA5, and LGP2 and are expressed in both immune and nonimmune cells. Upon recognition of viral nucleic acids, RLRs recruit specific intracellular adaptor proteins to initiate signaling pathways that lead to the synthesis of type I interferon and other inflammatory cytokines, which are important for eliminating viruses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LINC02888, PPIB, LAPTM5 (elevated), RIG-I (reduced activation), IRF7 (reduced activation), ISG15 (reduced activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "LINC02888 interacts with PPIB, which stabilizes LAPTM5 mRNA through binding to its 3'UTR, leading to increased LAPTM5 protein expression. Elevated LAPTM5 suppresses RIG-I-like receptor signaling, resulting in reduced activation of RIG-I, IRF7, and ISG15. This suppression diminishes the innate immune response, promoting tumor progression and immune evasion."}], "pathway_id": "hsa04622", "pubmed_id": "40495222", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Homo sapiens (human)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Superoxide, 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole (administration), Diacylglycerol Kinase Inhibitor Ii (administration), Protein Kinase C beta type (activation), Protein Kinase C epsilon type, Diacylglycerol kinase beta, Neutrophil cytosolic factor 1 (recruitment).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation and accumulation of Protein Kinase C beta type at the phagosomal cup/phagosome facilitates superoxide production during Fc gamma R-mediated phagocytosis. This process involves the recruitment of Neutrophil cytosolic factor 1, a substrate of Protein Kinase C beta type, to the phagosomal site. Superoxide is primarily generated at the phagosomal membrane rather than intracellular granules, and this production is inhibited by cPKC inhibitors such as Go6976. Diacylglycerol kinase beta regulates this process, as its inhibition with R59949 enhances superoxide generation."}], "pathway_id": "hsa04666", "pubmed_id": "15383592", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Homo sapiens (human)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FCGR, SRC family kinases (inhibited), CSK (gain-of-function form), LYN, HCK, SRC, SYK, VAV1 (phosphorylated), CBL (phosphorylated), FCGR2B (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fc gamma receptor-mediated tyrosine phosphorylation is essential for macrophage phagocytosis. The initial phosphorylation events are initiated by Src family kinases, with Lyn and Hck specifically capable of fully transducing the signaling cascade required for Syk activation, actin cytoskeleton rearrangement, and phagosome formation. In contrast, c-Src fails to mediate these processes due to its exclusion from detergent-resistant membranes. C-terminal Src kinase (CSK) negatively regulates Src family kinase activity, and its gain-of-function form inhibits Fc gamma R-mediated signaling. Phosphorylation of Vav and c-Cbl occurs across all Src family kinase constructs, whereas phosphorylation of FCGR2B, associated with negative signaling, is reconstituted only by Lyn and Hck."}], "pathway_id": "hsa04666", "pubmed_id": "10861086", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Homo sapiens (human)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ceramide (accumulation), C2-Ceramide, Phytosphingosine acetamide, N-((1S,2R)-2-Hydroxy-1-(hydroxymethyl)heptadecyl)acetamide, Sphingosine, Sphinganine, Phosphatidylethanol (formation), FCGR, PLD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ceramide, generated through the activation of the sphingomyelin cycle, acts as a negative regulator of Fc gamma R-mediated phagocytosis in human polymorphonuclear leukocytes. This inhibition is associated with the suppression of phosphatidylethanol formation, suggesting that phospholipase D is an intracellular target of ceramide. The accumulation of ceramide coincides with the termination of phagocytosis, indicating a regulatory role in the dynamics of the phagocytic process."}], "pathway_id": "hsa04666", "pubmed_id": "9058737", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Homo sapiens (human)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-(5-Isoquinolinylsulfonyl)-2-Methylpiperazine, Staurosporine, Phorbol 12-myristate 13-acetate, 1-Oleoyl-2-acetylglycerol, FCGR (cross-linked on monocytes), FCGR1, FCGR2, PLCG1 (activated), PRKCA (activated by exogenous activators such as Phorbol 12-myristate 13-acetate), PRKCB (activated), PRKCE (activated by exogenous activators such as Phorbol 12-myristate 13-acetate).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cross-linking of Fc gamma receptors on monocytes activates phospholipase C, which generates second messengers that subsequently activate protein kinase C (PKC). Activation of PKC isozymes such as PKC-beta and PKC-epsilon leads to translocation of these enzymes to the membrane, correlating with enhanced intracellular killing of bacteria. However, activation of PKC-alpha and PKC-epsilon by exogenous activators such as phorbol 12-myristate 13-acetate (PMA) inhibits PLC-mediated signaling and prevents Fc gamma R-mediated bacterial killing through feedback inhibition. This indicates that specific PKC isozymes play dual roles in both promoting and suppressing Fc gamma R-mediated intracellular bacterial killing in monocytes."}], "pathway_id": "hsa04666", "pubmed_id": "7608554", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aflatoxin B1 (administration), Ciclopirox (administration), Irinotecan (administration), FCGBP (elevated expression levels), BTN3A3 (elevated expression levels), WDR91 (elevated expression levels), SLC25A45 (elevated expression levels), BTNL3 (elevated expression levels), CTLA4 (expression levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression levels of FCGBP, BTN3A3, WDR91, SLC25A45, and BTNL3 are associated with ovarian cancer progression. Aflatoxin B1 exhibits strong binding affinity to SLC25A45, ciclopirox to BTN3A3, and irinotecan to WDR91, suggesting potential drug-target interactions. Variations in immune cell infiltration, including naive B cells, and expression levels of immune checkpoint genes such as CTLA4, influence the tumor microenvironment. High tumor mutation burden correlates with improved survival outcomes, and differences in drug IC50 values between risk groups indicate variable drug sensitivity. These interactions contribute to the overall prognosis of ovarian cancer."}], "pathway_id": "hsa04148", "pubmed_id": "41189168", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIAH2 (Elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SIAH2 is involved in efferocytosis-related cell-to-cell communication, particularly in the internalization and digestion phases of the process. It contributes to keratinocyte migration and angiogenesis during wound healing. Elevated SIAH2 expression correlates with enhanced macrophage efferocytosis and is associated with poor clinical outcomes in diabetic foot ulcers."}], "pathway_id": "hsa04148", "pubmed_id": "41183121", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: P2RX1 (Expression), IFNG (Expression), IL1A (Expression), CD93 (Expression), XKR8 (Expression), SIAH2 (Expression), F2RL1 (Expression), TLR4 (Expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Efferocytosis facilitates the clearance of apoptotic cells and contributes to tumor immune evasion. The expression of efferocytosis-related genes including P2RX1, IFNG, IL1A, CD93, XKR8, SIAH2, F2RL1, and TLR4 influences immune infiltration and modulates immunotherapy and chemotherapy sensitivity in the tumor microenvironment."}], "pathway_id": "hsa04148", "pubmed_id": "41198835", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rosiglitazone, 2-Chloro-5-nitrobenzanilide, PPAR gamma.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PPAR gamma attenuates efferocytosis impairment in macrophages and reduces pathogen-induced inflammatory responses. Activation of PPAR gamma is associated with the restoration of efferocytic capacity, which may mitigate the progression of chronic apical periodontitis."}], "pathway_id": "hsa04148", "pubmed_id": "41155449", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 7-Ketocholesterol, Palmitic Acid, TRIB3 (Increased expression), ATF4, RAB27A (Downregulated expression), TRIB3 (Q84R variant) (Administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lipid-induced endoplasmic reticulum stress activates the ATF4 signaling pathway in macrophages, leading to upregulation of TRIB3. Increased TRIB3 expression results in downregulation of RAB27A, which impairs focal exocytosis of intracellular membrane pools toward phagosomes containing apoptotic cells. This disruption delays phagosome closure and inhibits efferocytosis. Consequently, defective efferocytosis promotes plaque necrosis and contributes to atherosclerosis progression. The TRIB3 Q84R variant enhances TRIB3 activity, further impairing efferocytosis in macrophages."}], "pathway_id": "hsa04148", "pubmed_id": "41186004", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MSR1, MERTK (downregulation), CASP3, PARP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MSR1 promotes macrophage efferocytosis by facilitating the clearance of apoptotic cells. This process is associated with the upregulation of MERTK and involves the recognition of apoptotic markers such as CASP3 and PARP1. Impaired MSR1 function reduces efferocytosis, leading to reduced MERTK expression and enhanced inflammatory responses."}], "pathway_id": "hsa04148", "pubmed_id": "41138691", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MCUR1 (Downregulated), CYP27B1 (Downregulated), G6PC (Downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "M2 macrophage polarization is associated with efferocytosis, a process that promotes anti-inflammatory and pro-resolving effects. The genes MCUR1, CYP27B1, and G6PC are linked to this pathway and are involved in the regulation of macrophage efferocytosis and polarization. These genes are downregulated in the context of diabetic kidney disease, contributing to impaired macrophage function and chronic inflammation."}], "pathway_id": "hsa04148", "pubmed_id": "41122706", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Annexin A1, Pannexin-1, Annexin A5, CD93 molecule, Serpin family E member 1, Milk fat globule-EGF factor 8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "M2-polarized macrophages exhibit enhanced phagocytic activity, facilitating the engulfment and clearance of apoptotic cells through efferocytosis. This process is mediated by proteins encoded by genes such as ANXA1, PANX1, ANXA5, CD93, SERPINE1, and MFGE8. Impaired efferocytosis leads to unresolved inflammation, whereas its activation promotes mucosal repair and reduces inflammatory damage in ulcerative colitis."}], "pathway_id": "hsa04148", "pubmed_id": "41050686", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Efferocytosis - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hodgkin-Reed Sternberg cells (activity), RelB, MerTK (increased expression), CD209 (increased expression), CD14 (increased expression), CD36 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Efferocytosis pathway enrichment is associated with Hodgkin-Reed Sternberg (HRS) cell activity. Macrophages engage in efferocytosis-related interactions with HRS cells, and increased expression of MerTK, CD209, CD14, and CD36 correlates with M2 macrophage polarization. This process contributes to immune checkpoint regulation in the tumor microenvironment."}], "pathway_id": "hsa04148", "pubmed_id": "40976706", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycolysis / Gluconeogenesis - Homo sapiens (human)\n**Pathway Description**: Glycolysis is the process of converting glucose into pyruvate and generating small amounts of ATP (energy) and NADH (reducing power). It is a central pathway that produces important precursor metabolites: six-carbon compounds of glucose-6P and fructose-6P and three-carbon compounds of glycerone-P, glyceraldehyde-3P, glycerate-3P, phosphoenolpyruvate, and pyruvate [MD:M00001]. Acetyl-CoA, another important precursor metabolite, is produced by oxidative decarboxylation of pyruvate [MD:M00307]. When the enzyme genes of this pathway are examined in completely sequenced genomes, the reaction steps of three-carbon compounds from glycerone-P to pyruvate form a conserved core module [MD:M00002], which is found in almost all organisms and which sometimes contains operon structures in bacterial genomes. Gluconeogenesis is a synthesis pathway of glucose from noncarbohydrate precursors. It is essentially a reversal of glycolysis with minor variations of alternative paths [MD:M00003].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphoenolpyruvate, PCK2 (increased expression), PCK1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphoenolpyruvate carboxykinase 2 (PCK2) counteracts ferroptosis through its catalytic activity, which is independent of mitochondrial stress. The expression of PCK2 increases under ferroptotic stress, and its ablation enhances susceptibility to ferroptosis. This protective effect is partially mediated by the production of phosphoenolpyruvate. In contrast, phosphoenolpyruvate carboxykinase 1 (PCK1) does not substitute for PCK2 in this regulatory function, indicating a distinct role for PCK2 in modulating ferroptosis."}], "pathway_id": "hsa00010", "pubmed_id": "40712389", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycolysis / Gluconeogenesis - Homo sapiens (human)\n**Pathway Description**: Glycolysis is the process of converting glucose into pyruvate and generating small amounts of ATP (energy) and NADH (reducing power). It is a central pathway that produces important precursor metabolites: six-carbon compounds of glucose-6P and fructose-6P and three-carbon compounds of glycerone-P, glyceraldehyde-3P, glycerate-3P, phosphoenolpyruvate, and pyruvate [MD:M00001]. Acetyl-CoA, another important precursor metabolite, is produced by oxidative decarboxylation of pyruvate [MD:M00307]. When the enzyme genes of this pathway are examined in completely sequenced genomes, the reaction steps of three-carbon compounds from glycerone-P to pyruvate form a conserved core module [MD:M00002], which is found in almost all organisms and which sometimes contains operon structures in bacterial genomes. Gluconeogenesis is a synthesis pathway of glucose from noncarbohydrate precursors. It is essentially a reversal of glycolysis with minor variations of alternative paths [MD:M00003].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Morin (administration), D-Glucose, Pyruvic Acid, 5'-Atp, 5'-Adp, Adenosine Monophosphate, Oxygen, glucose-6-phosphatase (activity), glucokinase, glucose-6-phosphate dehydrogenase, pyruvate kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Morin inhibits gluconeogenesis by suppressing the activity of glucose-6-phosphatase and other key enzymes involved in this metabolic pathway. It also stimulates glycogenolysis and glycolysis, increasing glucose release from glycogen stores. Morin disrupts mitochondrial energy metabolism by inhibiting the electron transport chain, impairing ATP/ADP and ATP/AMP ratios, and functioning as an uncoupling agent of oxidative phosphorylation, thereby reducing ATP synthesis. These effects are associated with elevated oxygen consumption and reduced membrane integrity in hepatic cells. Morin also inhibits citric acid cycle activity under gluconeogenic conditions, further impairing hepatic glucose production. The combined inhibition of gluconeogenesis and stimulation of glycogenolysis may contribute to an antihyperglycemic effect, but mitochondrial toxicity, including reduced cell viability in HepG2 and VERO cells, suggests potential therapeutic limitations."}], "pathway_id": "hsa00010", "pubmed_id": "40586287", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycolysis / Gluconeogenesis - Homo sapiens (human)\n**Pathway Description**: Glycolysis is the process of converting glucose into pyruvate and generating small amounts of ATP (energy) and NADH (reducing power). It is a central pathway that produces important precursor metabolites: six-carbon compounds of glucose-6P and fructose-6P and three-carbon compounds of glycerone-P, glyceraldehyde-3P, glycerate-3P, phosphoenolpyruvate, and pyruvate [MD:M00001]. Acetyl-CoA, another important precursor metabolite, is produced by oxidative decarboxylation of pyruvate [MD:M00307]. When the enzyme genes of this pathway are examined in completely sequenced genomes, the reaction steps of three-carbon compounds from glycerone-P to pyruvate form a conserved core module [MD:M00002], which is found in almost all organisms and which sometimes contains operon structures in bacterial genomes. Gluconeogenesis is a synthesis pathway of glucose from noncarbohydrate precursors. It is essentially a reversal of glycolysis with minor variations of alternative paths [MD:M00003].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glyceryl 1-phosphate, PCK2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gluconeogenesis, the metabolic reverse of glycolysis, is activated in macrophages under low glucose conditions, generating glycolytic intermediates and glycerol 3-phosphate. This process depends on phosphoenolpyruvate carboxykinase (PCK2), the mitochondrial isoform of the enzyme that catalyzes the conversion of oxaloacetate to phosphoenolpyruvate. PCK2-deficient macrophages are unable to sustain partial gluconeogenesis, indicating a central role for this enzyme in the metabolic flexibility of macrophages. The activation of gluconeogenesis correlates with anti-inflammatory macrophage polarization, as indicated by increased vascular endothelial growth factor expression and reduced CD80 surface marker levels in proinflammatory macrophages."}], "pathway_id": "hsa00010", "pubmed_id": "41160607", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycolysis / Gluconeogenesis - Homo sapiens (human)\n**Pathway Description**: Glycolysis is the process of converting glucose into pyruvate and generating small amounts of ATP (energy) and NADH (reducing power). It is a central pathway that produces important precursor metabolites: six-carbon compounds of glucose-6P and fructose-6P and three-carbon compounds of glycerone-P, glyceraldehyde-3P, glycerate-3P, phosphoenolpyruvate, and pyruvate [MD:M00001]. Acetyl-CoA, another important precursor metabolite, is produced by oxidative decarboxylation of pyruvate [MD:M00307]. When the enzyme genes of this pathway are examined in completely sequenced genomes, the reaction steps of three-carbon compounds from glycerone-P to pyruvate form a conserved core module [MD:M00002], which is found in almost all organisms and which sometimes contains operon structures in bacterial genomes. Gluconeogenesis is a synthesis pathway of glucose from noncarbohydrate precursors. It is essentially a reversal of glycolysis with minor variations of alternative paths [MD:M00003].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methylglyoxal (administration), Interleukin-6 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methylglyoxal diminishes hepatic gluconeogenesis while stimulating glycolysis, leading to a catabolic metabolic state. This shift is accompanied by a deficiency in mitochondrial energy supply and downregulation of gluconeogenic enzymes. Concurrently, methylglyoxal increases hepatic interleukin-6 expression, contributing to systemic inflammation. Adipose tissue metabolism is altered, with AMPK-induced lipolysis elevated in retroperitoneal fat and ketogenesis increased in the liver, while triglyceride content decreases."}], "pathway_id": "hsa00010", "pubmed_id": "40265308", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycolysis / Gluconeogenesis - Homo sapiens (human)\n**Pathway Description**: Glycolysis is the process of converting glucose into pyruvate and generating small amounts of ATP (energy) and NADH (reducing power). It is a central pathway that produces important precursor metabolites: six-carbon compounds of glucose-6P and fructose-6P and three-carbon compounds of glycerone-P, glyceraldehyde-3P, glycerate-3P, phosphoenolpyruvate, and pyruvate [MD:M00001]. Acetyl-CoA, another important precursor metabolite, is produced by oxidative decarboxylation of pyruvate [MD:M00307]. When the enzyme genes of this pathway are examined in completely sequenced genomes, the reaction steps of three-carbon compounds from glycerone-P to pyruvate form a conserved core module [MD:M00002], which is found in almost all organisms and which sometimes contains operon structures in bacterial genomes. Gluconeogenesis is a synthesis pathway of glucose from noncarbohydrate precursors. It is essentially a reversal of glycolysis with minor variations of alternative paths [MD:M00003].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose (synthesized), Pyruvic Acid (generated), 5'-Atp (generated), Nadh (generated), acetyl CoA (derived).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glycolysis converts D-glucose into pyruvic acid while generating adenosine 5'-triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH). This metabolic process produces key precursor metabolites such as glucose-6-phosphate, fructose-6-phosphate, and glyceraldehyde-3-phosphate. Acetyl-CoA is derived from the oxidative decarboxylation of pyruvate. Gluconeogenesis represents the metabolic reversal of glycolysis, enabling the synthesis of glucose from non-carbohydrate precursors."}], "pathway_id": "hsa00010", "pubmed_id": "40095490", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ZMIZ1, ESR1, PGR, E2F transcription factor (decreased signaling), Cyclin A2 (decreased signaling), Forkhead box M1 (decreased signaling).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ZMIZ1 colocalizes with an ESR1-binding super enhancer and functions as a coregulator of estrogen receptor alpha in uterine tissue. Disruption of ZMIZ1 impairs cell proliferation and decidual differentiation, leading to infertility and accelerated uterine fibrosis. Loss of ZMIZ1 results in reduced expression of progesterone receptor (PGR) and diminished stromal and epithelial cell proliferation. Transcriptomic changes include decreased signaling through E2F, CCNA2, and FOXM1 pathways. Estrogen-induced gene responses are also attenuated in the absence of ZMIZ1."}], "pathway_id": "hsa04915", "pubmed_id": "41321316", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ESR1, ZMIZ1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ZMIZ1 interacts with estrogen receptor alpha (ESR1) to regulate stromal proliferation and decidualization, which are essential for endometrial integrity. Impaired ESR1 activity due to ZMIZ1 deficiency disrupts estrogen responsiveness, leading to endometriosis, endometrial cancer, infertility, and accelerated fibrosis."}], "pathway_id": "hsa04915", "pubmed_id": "41321319", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Di(2-ethylhexyl) phthalate (administration), Estrogen Receptor 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Di(2-ethylhexyl) phthalate interacts with Estrogen Receptor 1 (ESR1), a key component of the estrogen signaling pathway. This interaction disrupts normal estrogen receptor-mediated signaling, contributing to dysregulation of apoptosis, inflammation, and extracellular matrix degradation. These molecular alterations are implicated in the disruption of bone homeostasis and the progression of bone-related pathologies."}], "pathway_id": "hsa04915", "pubmed_id": "41303381", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STAMBP, ESR1 (increased activity), ESR2, Membrane-bound Estrogen Receptor, GPER1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "STAMBP, a deubiquitinase, directly reduces K48-linked polyubiquitination levels of ESR1 (ERalpha), thereby increasing its protein stability. This enhanced stability of ESR1 activates downstream oncogenic signaling pathways, promoting cell proliferation, metastasis, and epithelial-mesenchymal transition in estrogen receptor-positive breast cancer. The increased ESR1 activity also contributes to endocrine resistance, including resistance to tamoxifen."}], "pathway_id": "hsa04915", "pubmed_id": "41301420", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Estradiol (administration), G protein-coupled estrogen receptor 1 (excessive activation), protein kinase A (activated), Centrin 2 (phosphorylated), G protein subunit alpha s (activated), adenylyl cyclase (activated), A kinase (PRKA) anchor protein 450.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of G protein-coupled estrogen receptor 1 (GPER1) by estrogen or agonists stimulates Galphas protein-mediated adenylyl cyclase activity, increasing cyclic AMP (cAMP) levels and activating protein kinase A (PKA). PKA, anchored at centrosomes via A kinase anchor protein 450 (AKAP450), phosphorylates Centrin 2, particularly at aberrant centrioles, influencing centrosome number and centriole integrity. Excessive GPER1-PKA signaling leads to centrosome amplification and structural abnormalities, contributing to neoplastic transformation and tumor progression in colon cancer cells."}], "pathway_id": "hsa04915", "pubmed_id": "41299155", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Estrogen signaling pathway - Homo sapiens (human)\n**Pathway Description**: Estrogens are steroid hormones that regulate a plethora of physiological processes in mammals, including reproduction, cardiovascular protection, bone integrity, cellular homeostasis, and behavior. Estrogen mediates its cellular actions through two signaling pathways classified as \"nuclear-initiated steroid signaling\" and \"membrane-initiated steroid signaling\". In the \"nuclear\" pathway, estrogen binds either ERalpha or ERbeta, which in turn translocates to the nucleus, binds DNA at ERE elements and activates the expression of ERE-dependent genes. In \"membrane\" pathway, Estrogen can exert its actions through a subpopulation of ER at the plasma membrane (mER) or novel G-protein coupled E2 receptors (GPER). Upon activation of these receptors various signaling pathways (i.e. Ca2+, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Alternariol (administration), (3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER (activation by Alternariol), HIF1A (modulated by Alternariol), PIK3CA (activated by HIF1A), CLDN1 (modulated by Alternariol), AKT1 (activated), AR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AOH induces oxidative stress and DNA damage in ovarian cancer cells, partially mediated by GPER1. Activation of GPER1 by AOH leads to increased reactive oxygen species (ROS) production and subsequent DNA damage. This effect is partially inhibited by the GPER1 antagonist G15. AOH also modulates the HIF1alpha/PI3K/Akt signaling pathway, which may contribute to its pro-oxidative effects. Furthermore, AOH influences CLDNs, which are key components of tight junctions, potentially altering cellular barrier function. These findings suggest that AOH exerts its biological effects through interactions with GPER1 and downstream signaling pathways involving HIF1alpha, PI3K, and CLDNs."}], "pathway_id": "hsa04915", "pubmed_id": "41298511", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MSH2 (reduced expression), MSH6 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of MSH2 and MSH6 correlates with breast tumorigenesis, indicating impaired DNA mismatch repair activity in breast cancer development."}], "pathway_id": "hsa03430", "pubmed_id": "41283256", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MLH1, KRAS, BRAF, CTNNB1, PIK3CA, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defective DNA mismatch repair (MMR) leads to microsatellite instability-high (MSI-H), a condition associated with increased mutation rates in genes such as BRAF, TP53, and MLH1. These alterations contribute to genomic instability and distinct tumor phenotypes, including immunogenicity and altered mutational landscapes. Mutations in KRAS, PIK3CA, and CTNNB1 are characteristic of chromosomally stable tumors, while elevated microsatellite alterations at tetranucleotide repeats (EMAST) delineate distinct subtypes with intermediate or high instability, influencing tumor differentiation, size, and molecular behavior."}], "pathway_id": "hsa03430", "pubmed_id": "41308359", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MLH1, POLE.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MLH1 promoter methylation leads to silencing of the MLH1 gene, a core component of the DNA mismatch repair (MMR) pathway, resulting in MMR deficiency. This deficiency contributes to genomic instability and increased mutation rates. In some cases, MLH1 promoter methylation co-occurs with POLE dysfunction, characterized by ultramutated tumors and distinct mutational signatures. These combined molecular alterations may manifest as endometrial carcinoma with features overlapping those of Lynch syndrome, despite absence of germline mutations. Comprehensive genomic profiling is necessary to distinguish these molecular subtypes and inform clinical management."}], "pathway_id": "hsa03430", "pubmed_id": "41297483", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MSH4 (disrupted), MSH5 (disrupted), MLH3, PMS2 (compromised).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Variants in MSH4 and MSH5 disrupt meiosis and impair spermatogenesis, contributing to male infertility. These genes are essential for maintaining genome integrity through DNA repair mechanisms in sperm formation. Defects in PMS2 also compromise DNA repair processes, leading to impaired fertility. Collectively, these genes play a critical role in preserving genomic stability during spermatogenesis."}], "pathway_id": "hsa03430", "pubmed_id": "41257861", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CCND1 (elevated expression), TP53, Mismatch Repair Proteins (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Cyclin D1 (CCND1) is associated with mismatch repair (MMR) deficiency. This deficiency contributes to genomic instability and is linked to reduced overall survival and recurrence-free survival in endometrial carcinoma."}], "pathway_id": "hsa03430", "pubmed_id": "41219637", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SPOP (Altered SPOP function, including mutations), PDCD1LG2, AR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Altered SPOP function, including mutations, is associated with elevated PD-L1 expression and reduced tumor-infiltrating lymphocytes, particularly CD8+ T cells. These changes correlate with increased Gleason scores and are linked to microsatellite instability (MSI) and mismatch repair (MMR) defects. These molecular alterations contribute to an immunosuppressive tumor microenvironment in prostate cancer."}], "pathway_id": "hsa03430", "pubmed_id": "41243500", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Homo sapiens (human)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MLH1 and PMS2, MSH2 and MSH6, PMS2, MSH6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mismatch repair deficiency leads to the loss of functional MLH1/PMS2 or MSH2/MSH6 protein pairs, resulting in microsatellite instability-high (MSI-High) and impaired DNA repair capacity. Isolated loss of PMS2 or MSH6 may occur in the context of MSI-H, indicating partial dysfunction of the MMR pathway. Complex loss of multiple MMR proteins also correlates with MSI-H, suggesting widespread disruption of DNA repair. In some cases, loss of one or more MMR proteins occurs without MSI-H, indicating a dissociation between IHC findings and molecular instability. Conversely, retention of all four MMR proteins with MSI-H suggests an alternative mechanism of DNA instability independent of MMR protein loss. These phenotypic variations influence immunotherapy response, with complex and isolated MMR aberrations associated with higher response rates compared to retained or mismatched IHC/MSI profiles."}], "pathway_id": "hsa03430", "pubmed_id": "41167636", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, Oxidative phosphorylation complex (impaired).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mitochondrial dysfunction leads to impaired oxidative phosphorylation, which disrupts energy production and contributes to sepsis-acquired weakness. This dysfunction is accompanied by increased oxidative stress and impaired calcium homeostasis, which further exacerbate cellular damage. Dysregulated mitochondrial quality control mechanisms fail to remove damaged mitochondria, perpetuating the cycle of dysfunction and contributing to muscle injury."}], "pathway_id": "hsa00190", "pubmed_id": "41331895", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (elevated levels), Hemin, ALAS1 (defects), FECH (defects), HMBS (defects), PPOX (defects), UROS (defects), CPOX (defects), ALAD (defects), UROD (defects).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defects in heme biosynthesis pathway enzymes such as ALAS1, FECH, HMBS, PPOX, UROS, CPOX, ALAD, and UROD lead to the accumulation of 5-aminolevulinic acid and protoporphyrin IX. These intermediates disrupt normal heme production and cause metabolic dysregulation. Elevated levels of 5-aminolevulinic acid and protoporphyrin IX contribute to neurotoxicity and photosensitivity, which are hallmark clinical features of porphyria. The disruption in heme biosynthesis results in impaired mitochondrial function and increased oxidative stress, further exacerbating cellular dysfunction and tissue damage."}], "pathway_id": "hsa00190", "pubmed_id": "41277553", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATM (downregulation), PPARGC1A (decreased expression), TFAM (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ATM downregulation leads to decreased expression of PGC-1alpha, NRF-1, and TFAM, resulting in mitochondrial dysfunction characterized by reduced membrane potential, impaired oxidative phosphorylation, and increased oxidative stress. This disruption contributes to the inhibition of tumor cell proliferation and migration."}], "pathway_id": "hsa00190", "pubmed_id": "41232593", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATP6V1E1 (reduced expression), NDUFB5 (reduced expression), Amyloid-beta, Tau protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ATP6V1E1 and NDUFB5 is associated with impaired oxidative phosphorylation and lysosomal acidification, contributing to mitochondrial dysfunction in neurodegenerative conditions. Decreased levels of these proteins correlate with elevated amyloid-beta and Tau pathology, indicating a role in the progression of neurodegenerative disease. Their expression in microglia suggests involvement in immune cell infiltration and systemic metabolic dysregulation."}], "pathway_id": "hsa00190", "pubmed_id": "41242442", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, protoporphyrin IX, Hemin, ALAS1, ALAS2, FECH (deficiency), CPOX (deficiency), PPOX, UROD, HMBS, ALAD, Ferrochelatase, Bach1, Nrf2 (activated), HMOX1 (repressed), Heme oxygenase 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The heme biosynthesis pathway is initiated by the conversion of 5-aminolevulinic acid (5-ALA) to porphobilinogen, catalyzed by ALAD. Subsequent enzymatic steps involving ALAS1/ALAS2, CPOX, PPOX, UROD, HMBS, and FECH lead to the formation of protoporphyrin IX (PpIX), which is then chelated with ferrous iron by ferrochelatase to produce heme. Heme is a critical cofactor in hemoglobin, myoglobin, and various cytochromes. Disruption in any of these enzymes, such as FECH or CPOX, leads to the accumulation of porphyrins and intermediates, causing oxidative stress and cellular dysfunction. Nrf2 activation in response to oxidative stress upregulates HMOX1 (HO-1), which degrades heme to biliverdin, iron, and carbon monoxide. Bach1 represses HMOX1 under normal conditions. Excess iron and reactive oxygen species (ROS) resulting from heme metabolism or heme oxygenase activity can trigger ferroptosis or apoptosis. Defects in heme biosynthesis are associated with porphyrias, while dysregulated heme metabolism contributes to mitochondrial dysfunction and erythropoietic disorders."}], "pathway_id": "hsa00190", "pubmed_id": "41241674", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Retapamulin (administration), oxidative phosphorylation subunits, mitochondrial translation initiation factor 3, mitochondrial tRNAs (with modifications at the anticodon stem loop).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mitochondrial translation produces essential subunits of the oxidative phosphorylation system, which are critical for energy production. Mitochondrial translation initiation is mediated by mitochondrial translation initiation factor 3 (mtIF 3), which facilitates initiation from internal open reading frames. Modifications at the anticodon stem loop of mitochondrial tRNAs influence translation efficiency. Retapamulin, a translation inhibitor, enables the assessment of mitochondrial translation kinetics, including initiation and elongation rates, and helps identify sites of programmed ribosome collisions across the mitochondrial transcriptome."}], "pathway_id": "hsa00190", "pubmed_id": "41232526", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Terbinafine (administration), Mito-TEMPO, SQLE (overexpression), LONP1, TFAM.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Overexpression of SQLE stabilizes mitochondrial transcription factor A (TFAM) by directly interacting with Lon peptidase 1 (LONP1), preventing TFAM proteolysis. This interaction leads to enhanced mitochondrial oxidative phosphorylation and the accumulation of mitochondrial reactive oxygen species (mtROS), promoting tumor growth. Inhibition of SQLE with terbinafine suppresses this metabolic dysregulation and reduces tumor progression."}], "pathway_id": "hsa00190", "pubmed_id": "41254141", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Hemin, ALAS1, ALAS2, FECH, ALAD, PBGD, UROD, CPOX, PPOX, HMBS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid (5-ALA) is the initial substrate in the heme biosynthetic pathway, which is catalyzed sequentially by ALAS1 in the cytoplasm and ALAS2 in mitochondria. The pathway proceeds through a series of enzymatic reactions involving FECH, ALAD, PBGD, UROD, CPOX, PPOX, and HMBS to produce heme. Disruption of any of these enzymes leads to the accumulation of pathway intermediates and impaired heme synthesis, which can result in porphyria and associated neurological or cutaneous symptoms. Heme is essential for oxygen transport, electron transport, and enzymatic functions in erythropoiesis and mitochondrial energy production."}], "pathway_id": "hsa00190", "pubmed_id": "41216931", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Homo sapiens (human)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Artesunate (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Artesunate inhibits mitochondrial respiration, which disrupts oxidative phosphorylation in acute myeloid leukemia cells, particularly in leukemia stem cells. This metabolic disruption contributes to the inhibition of AML progression and may overcome resistance to venetoclax. The effect is specific to leukemic cells with minimal impact on normal hematopoietic stem cells."}], "pathway_id": "hsa00190", "pubmed_id": "41188278", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Homo sapiens (human)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1, ALAS2, HMOX1 (expression), BECN1, ATG5, NRF2 (activation), KEAP1, NQO1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) increase the production of heme via the heme oxygenase 1 (HMOX1) pathway, which leads to the accumulation of reactive oxygen species and the induction of oxidative stress. This stress activates the NRF2-KEAP1 signaling axis, promoting the expression of antioxidant enzymes such as NQO1 and HMOX1. Concurrently, 5-ALA-induced heme accumulation disrupts mitochondrial function, triggering the release of pro-apoptotic signals. Autophagy is activated through the BECN1-ATG5 complex as a compensatory response to cellular stress and damaged organelles, but excessive activation may contribute to cell death. These processes collectively contribute to the regulation of cell survival and death in response to heme pathway dysregulation."}], "pathway_id": "hsa04068", "pubmed_id": "40975143", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Homo sapiens (human)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sesamin (administration), Acetaminophen, Forkhead box protein O1, Forkhead box protein O.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Foxo1 regulates autophagy and inhibits ferroptosis in response to acetaminophen-induced hepatotoxicity. Reduced Foxo1 expression is associated with enhanced autophagy and suppressed ferroptosis, contributing to the protection of hepatocytes against drug-induced injury. Sesamin modulates these processes by targeting Foxo1 activity."}], "pathway_id": "hsa04068", "pubmed_id": "41254937", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Homo sapiens (human)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 13-(Benzyloxy)-13-oxotridecanoic acid, AKT1, DAB2, FOXO1 (dephosphorylated), BIM (transcriptionally activated), BAX (activated), CYCS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dephosphorylation of FOXO1 leads to its nuclear translocation and transcriptional activation of the proapoptotic gene BIM. This activation results in the translocation of BAX and BIM to mitochondria and the release of cytochrome-c into the cytosol, initiating mitochondrial injury and apoptosis in proximal tubule epithelial cells. This process is associated with albumin overload and impaired Akt signaling."}], "pathway_id": "hsa04068", "pubmed_id": "41152299", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Homo sapiens (human)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Reynoutrin (administration), FYN (dephosphorylated), SIRT1 (activated), FOXO3 (activated), NRF2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reynoutrin inhibits FYN kinase activity through direct interaction and hydrogen bond formation. This inhibition leads to reduced phosphorylation of FYN, which in turn activates the SIRT1/FOXO3 and NRF2 antioxidant signaling pathways. Activation of these pathways enhances antioxidant enzyme activity, mitigating oxidative stress and ameliorating renal injury associated with diabetic nephropathy."}], "pathway_id": "hsa04068", "pubmed_id": "40818186", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Homo sapiens (human)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FOXO (activated), AKT, PIK3CA, MAPK8, PRKAA1, SMAD4, TRAF6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of FOXO transcription factors by AKT, downstream of PI3K, leads to their cytoplasmic retention and reduced transcriptional activity. In contrast, JNK and AMPK phosphorylate and activate FOXO under stress or energy deprivation, promoting stress resistance and metabolic adaptation. FOXO signaling influences apoptosis, protein synthesis, and oxidative stress resistance. SMAD4 and TRAF6 are involved in myocyte survival and suppression of fibrosis, particularly through interactions with TGF-beta and MAPK pathways. These mechanisms collectively regulate cellular homeostasis, myocyte function, and response to metabolic and stress stimuli."}], "pathway_id": "hsa04068", "pubmed_id": "40748585", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Relaxin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Human relaxin-2 (\"relaxin\"), originally identified as a peptidic hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti-fibrotic and angiogenic effects in both males and females. It belongs to the so-called relaxin peptide family which includes the insulin-like peptides INSL3 and INSL5, and relaxin-3 (H3) as well as relaxin. INSL3 has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. These members of relaxin peptide family exert such effects binding to different kinds of receptors, classified as relaxin family peptide (RXFP) receptors: RXFP1, RXFP2, RXFP3, and RXFP4. These G protein-coupled receptors predominantly bind relaxin, INSL3, relaxin-3, and INSL-5, respectively. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Both RXFP3 and RXFP4 inhibit cAMP production, and RXFP3 activate MAP kinases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RXFP1, GR, RLN2 (administration), RLN1 (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Relaxin-2 activates relaxin family peptide receptor 1 (RXFP1) to modulate the biology and function of blood cells. This interaction influences circulating blood cell counts and exerts inhibitory effects on megakaryocytes, thrombocytes, and mast cells. Relaxin-2 also modulates granulocyte and agranulocyte morphology, differentiation, and function. Relaxin-1 regulates dendritic cell maturation and cytokine secretion. RXFP1 signaling contributes to anti-inflammatory, anti-apoptotic, and anti-fibrotic effects, and may play a role in the pathophysiology of blood malignancies and preeclampsia."}], "pathway_id": "hsa04926", "pubmed_id": "41196672", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Relaxin signaling pathway - Homo sapiens (human)\n**Pathway Description**: Human relaxin-2 (\"relaxin\"), originally identified as a peptidic hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti-fibrotic and angiogenic effects in both males and females. It belongs to the so-called relaxin peptide family which includes the insulin-like peptides INSL3 and INSL5, and relaxin-3 (H3) as well as relaxin. INSL3 has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. These members of relaxin peptide family exert such effects binding to different kinds of receptors, classified as relaxin family peptide (RXFP) receptors: RXFP1, RXFP2, RXFP3, and RXFP4. These G protein-coupled receptors predominantly bind relaxin, INSL3, relaxin-3, and INSL-5, respectively. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Both RXFP3 and RXFP4 inhibit cAMP production, and RXFP3 activate MAP kinases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RXFP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Relaxin binds to relaxin family peptide receptor 1 (RXFP1), a G protein-coupled receptor, to mediate cardiovascular modulation and anti-fibrotic effects. RXFP1 activates signaling pathways that generate second messengers such as cAMP and nitric oxide, contributing to its physiological actions."}], "pathway_id": "hsa04926", "pubmed_id": "40998237", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (6)-Gingerol (administration), AKT1, phosphorylated AKT (elevated levels), HSP90AA1, EGFR, MAPK3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "6-gingerol inhibits glioma cell proliferation and migration while promoting apoptosis and inducing G1 phase cell cycle arrest. This is primarily achieved through the suppression of the PI3K-AKT signaling pathway, as evidenced by the downregulation of phosphorylated AKT. Key targets of 6-gingerol within this pathway include AKT1, HSP90AA1, EGFR, and MAPK3, which are involved in the regulation of cell survival and growth."}], "pathway_id": "hsa04151", "pubmed_id": "41351348", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), AKT1 (activation), PI3K (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Quercetin inhibits hepatocellular carcinoma growth by targeting the PI3K/AKT signaling pathway. Activation of PI3K leads to phosphorylation and activation of AKT1, which promotes cell survival and proliferation. Inhibition of this pathway by quercetin results in reduced tumor volume and weight, as well as increased apoptosis in cancer cells."}], "pathway_id": "hsa04151", "pubmed_id": "41351405", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Curcumin, CCND1 (destabilized), DILA1 (reduced expression), NFKB1, PIK3CA (downregulation), AKT1 (downregulation), MTOR (downregulation), VEGFA, MMP2, BCL2, PTEN (increased expression), TIMP3 (increased expression), RECK (increased expression), BAX (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of DILA1 destabilizes Cyclin D1 protein and leads to downregulation of PI3K/AKT/mTOR pathway components, including PIK3CA, AKT1, and MTOR. This downregulation inhibits cell proliferation and migration while promoting apoptosis. Simultaneously, increased expression of PTEN, TIMP3, RECK, and BAX contributes to the suppression of oncogenic signaling and the induction of programmed cell death."}], "pathway_id": "hsa04151", "pubmed_id": "41348684", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PI3K-AKT (sustained or dysregulated activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PI3K-AKT signaling modulates microglial activation states, influencing the balance between neuroprotective and pro-inflammatory responses. Activation of this pathway supports anti-inflammatory microglial phenotypes that facilitate plaque clearance and tissue recovery. However, sustained or dysregulated PI3K-AKT activity may contribute to persistent inflammation and neuronal damage in neurodegenerative conditions."}], "pathway_id": "hsa04151", "pubmed_id": "41343028", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CCL2, CCR2 (activation), PIK3CA, AKT1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CCL2 activates the CCR2 receptor, triggering downstream signaling through the PI3K/AKT pathway. Activation of this pathway promotes cancer cell proliferation, migration, and epithelial-mesenchymal transition."}], "pathway_id": "hsa04151", "pubmed_id": "41341593", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), Isorhamnetin (administration), Kaempferol (administration), TNF, AKT1 (phosphorylated), SRC.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The PI3K-Akt signaling pathway is activated through the phosphorylation of Akt, which is regulated by upstream signals such as TNF and SRC. AKT1, a key component of the pathway, modulates cellular processes including survival, growth, and metabolism. Inhibition or modulation of this pathway by bioactive compounds like quercetin, isorhamnetin, and kaempferol can influence inflammatory responses and apoptosis. These interactions contribute to the regulation of cell survival and may affect disease progression associated with chronic inflammation."}], "pathway_id": "hsa04151", "pubmed_id": "41334661", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FAM172A, Phosphatidylinositol-4,5-bisphosphate 3-kinase (activation), Protein kinase B (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FAM172A activates the PI3K-Akt signaling pathway, which promotes epithelial ovarian cancer progression by enhancing cell proliferation, migration, and invasion. This activation contributes to tumor growth and metastasis and is associated with resistance to platinum-based chemotherapy. The PI3K-Akt pathway also modulates chemosensitivity, and its regulation by FAM172A leads to reduced efficacy of cisplatin. Modulation of PI3K signaling can counteract the oncogenic effects induced by FAM172A."}], "pathway_id": "hsa04151", "pubmed_id": "41339379", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phytate (administration), An inositol, phosphatidylinositol-4,5-bisphosphate 3-kinase (phosphorylated), phosphatidylinositol-4,5-bisphosphate 3-kinase (phosphorylated) (elevated activity), v-akt murine thymoma viral oncogene homolog (phosphorylated), v-akt murine thymoma viral oncogene homolog (phosphorylated) (phosphorylated), mechanistic target of rapamycin kinase (activated), CD163 antigen (downregulated), CD206 antigen (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated activity of the PI3K/AKT signaling pathway promotes colorectal cancer metastasis by enhancing tumor cell survival and proliferation. Inhibition of PI3K and AKT phosphorylation reduces the activation of downstream effectors, including the mammalian target of rapamycin, thereby suppressing tumor progression. Downregulation of M2 macrophage polarization markers CD163 and CD206 reduces the immunosuppressive tumor microenvironment, favoring anti-tumor immune responses. Co-administration of myo-inositol hexakisphosphate and myo-inositol synergistically inhibits these processes, leading to decreased liver metastasis and improved survival."}], "pathway_id": "hsa04151", "pubmed_id": "41339008", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Homo sapiens (human)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphatidylinositol 3-kinase (activated), Protein kinase B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the PI3K-Akt signaling pathway regulates fundamental cellular functions including transcription, translation, proliferation, and survival. Phosphatidylinositol 3-kinase (PI3K) catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits and activates protein kinase B (Akt). Once activated, Akt phosphorylates downstream substrates that inhibit neuronal apoptosis, modulate neurotransmitter balance, and regulate synaptic plasticity. These actions contribute to the suppression of neuroinflammation, mitigation of oxidative stress, and restoration of excitation/inhibition homeostasis in the central nervous system."}], "pathway_id": "hsa04151", "pubmed_id": "41327653", "species": "hsa"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAS (oncogenic), HRAS, MERTK (tyrosine phosphorylation), STK38, RAC1, CDC42.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oncogenic RAS activates MERTK through a mechanism that involves STK38 kinase activity. STK38 promotes tyrosine phosphorylation of MERTK, which in turn contributes to the activation of RAC1 and CDC42. This signaling cascade enhances cell migration, a key process in oncogenic Ras-induced transformation and tumor progression."}], "pathway_id": "mmu04014", "pubmed_id": "41226428", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nf1 (Biallelic loss), Sox9 (Elevated expression), Cdkn2a (Loss), Ras.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Biallelic loss of Nf1 leads to dysregulation of the Ras signaling pathway, promoting glial-to-mesenchymal transition and tumor progression. Elevated expression of Sox9 supports this transition and tumor growth. Subsequent loss of Cdkn2a and acquisition of additional tumor suppressor gene variants further drive malignant transformation. Activation of Ras signaling contributes to the pathogenesis of malignant peripheral nerve sheath tumors."}], "pathway_id": "mmu04014", "pubmed_id": "41223283", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PCNP (elevated levels), UHRF2, ERBB3, RAS, RAF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of PCNP transcriptionally upregulate UHRF2, which in turn activates the ErbB3/Ras/Raf1 signaling pathway. Activation of this pathway promotes hepatocellular carcinoma progression by enhancing proliferation, invasion, and tumor formation, and is associated with increased disease recurrence."}], "pathway_id": "mmu04014", "pubmed_id": "41271959", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epidermal Growth Factor, KRAS, EGFR, MEK, ERK, Major Histocompatibility Complex Class I, C-X-C Motif Chemokine Ligand 9, CD8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS signaling inhibits interferon-mediated MHC-I expression and suppresses CXCL9 production through the EGFR/MEK/ERK pathway, resulting in reduced CD8+ T cell activity and impaired anti-tumor immune responses. This mechanism contributes to the establishment of an immunosuppressive tumor microenvironment, promoting resistance to immunotherapy."}], "pathway_id": "mmu04014", "pubmed_id": "41219194", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CID 139600278, Trametinib (administration), Kras (mutated), Leukemia Inhibitory Factor, Leukemia Inhibitory Factor Receptor, Ras, Raf, Myelocytomatosis oncogene.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS mutations activate downstream MAPK and PI3K/AKT signaling pathways, promoting tumor progression and resistance to therapy. In Ras/Raf-driven ovarian cancer, trametinib, a MEK inhibitor, has limited efficacy due to compensatory activation of the LIF/LIFR signaling axis. EC359, a selective LIFR inhibitor, suppresses LIFR downstream signaling and enhances trametinibs efficacy by inducing ferroptosis and reducing cell viability and clonogenic survival. Combination therapy downregulates mitochondrial translation and MYC target genes while upregulating apoptosis-related genes, thereby inhibiting tumor growth."}], "pathway_id": "mmu04014", "pubmed_id": "41154625", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ras signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Ras proteins are GTPases that function as molecular switches for signaling pathways regulating cell proliferation, survival, growth, migration, differentiation or cytoskeletal dynamism. Ras proteins transduce signals from extracellular growth factors by cycling between inactive GDP-bound and active GTP-bound states. The exchange of GTP for GDP on RAS is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Activated RAS (RAS-GTP) regulates multiple cellular functions through effectors including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nucleotide-dissociation stimulator (RALGDS).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ALKBH8, KRAS (increased translation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ALKBH8 catalyzes tRNA modification at uridine 34, which enhances codon-specific translation elongation. This activity promotes the translation of mRNAs containing adenine-ending codons, including the KRAS proto-oncogene. Increased translation of KRAS contributes to intestinal tumorigenesis by enhancing oncogenic signaling."}], "pathway_id": "mmu04014", "pubmed_id": "41083459", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Chronic myeloid leukemia - Mus musculus (house mouse)\n**Pathway Description**: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), protoporphyrin IX (accumulation), Hydrogen Peroxide, ALAS1 (Disruption), ALAS2 (Disruption), FECH (Disruption), CPOX (Disruption), UROD (Disruption), PPOX (Disruption), HMBS (Disruption), SLC40A1 (altered expression), FTH1 (altered expression), FTL, TFR1 (altered expression), SLC11A2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of heme biosynthesis pathway components, including ALAS1, ALAS2, FECH, CPOX, UROD, PPOX, and HMBS, leads to the accumulation of 5-aminolevulinic acid (5-ALA) and Protoporphyrin IX (PpIX), which contribute to oxidative stress and mitochondrial dysfunction. Erythropoiesis relies on heme for hemoglobin synthesis, and mutations or dysregulation in this pathway can result in anemia. Iron overload, facilitated by altered expression of ferroportin (SLC40A1), ferritin heavy chain (FTH1), and transferrin receptor 1 (TFR1), exacerbates heme-related pathologies. These molecular changes are associated with clinical phenotypes including iron overload, anemia, and porphyria."}], "pathway_id": "mmu05220", "pubmed_id": "40976411", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Chronic myeloid leukemia - Mus musculus (house mouse)\n**Pathway Description**: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KDM1A, DOT1L, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DOT1L co-occupies LSD1-bound enhancers and contributes to the repression of transcriptional programs independent of its enzymatic activity. Genetic inactivation of DOT1L increases sensitivity to LSD1 inhibitors, leading to cell cycle arrest and apoptosis induction in TP53 mutant blast-phase myeloproliferative neoplasms. The loss of DOT1L cooperates with LSD1 inhibition to activate tumor suppressive programs."}], "pathway_id": "mmu05220", "pubmed_id": "40781484", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Chronic myeloid leukemia - Mus musculus (house mouse)\n**Pathway Description**: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Fluorouracil (administration), 5-Aza-2'-deoxycytidine (low-dose administration), GSDME, CASP3, BCR-ABL.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-fluorouracil induces pyroptosis in chronic myeloid leukemia cells through the caspase-3/GSDME pathway. Low-dose decitabine reverses methylation-induced silencing of GSDME, thereby enhancing the activation of this pathway. The combination of 5-fluorouracil and decitabine promotes pyroptotic cell death and stimulates antitumor immune responses. CD71-mediated uptake facilitates the selective targeting of 5-fluorouracil-loaded nanoparticles to CML cells, enhancing therapeutic efficacy while reducing off-target toxicity."}], "pathway_id": "mmu05220", "pubmed_id": "40148810", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Alzheimer disease - Mus musculus (house mouse)\n**Pathway Description**: Alzheimer disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. It was proposed that Abeta form Ca2+ permeable pores and bind to and modulate multiple synaptic proteins, including NMDAR, mGluR5 and VGCC, leading to the overfilling of neurons with calcium ions. Consequently, cellular Ca2+ disruptions will lead to neuronal apoptosis, autophagy deficits, mitochondrial abnormality, defective neurotransmission, impaired synaptic plasticity and neurodegeneration in AD. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ceftriaxone (administration), Nmda, Glutamate transporter 1 (upregulation), N-Methyl-D-aspartate receptor (elevated extrasynaptic activity), Amyloid precursor protein; Presenilin 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extrasynaptic NMDA receptor (eNMDAR) activity induces intracellular calcium influx, leading to mitochondrial calcium overload and disruption of mitochondrial membrane potential. This mitochondrial dysfunction contributes to cognitive deficits. Ceftriaxone mitigates these effects by upregulating glutamate transporter-1 (GLT-1), which reduces glutamate spillover and subsequent eNMDAR activation. This inhibition of eNMDAR-mediated calcium influx prevents mitochondrial calcium accumulation and preserves mitochondrial membrane potential, thereby protecting against mitochondrial damage and cognitive impairment."}], "pathway_id": "mmu05010", "pubmed_id": "41327376", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleotide excision repair - Mus musculus (house mouse)\n**Pathway Description**: Nucleotide excision repair (NER) is a mechanism to recognize and repair bulky DNA damage caused by compounds, environmental carcinogens, and exposure to UV-light. In humans hereditary defects in the NER pathway are linked to at least three diseases: xeroderma pigmentosum (XP), Cockayne syndrome (CS), and trichothiodystrophy (TTD). The repair of damaged DNA involves at least 30 polypeptides within two different sub-pathways of NER known as transcription-coupled repair (TCR-NER) and global genome repair (GGR-NER). TCR refers to the expedited repair of lesions located in the actively transcribed strand of genes by RNA polymerase II (RNAP II). In GGR-NER the first step of damage recognition involves XPC-hHR23B complex together with XPE complex (in prokaryotes, uvrAB complex). The following steps of GGR-NER and TCR-NER are similar.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aldehyde, Formaldehyde, VCP, p97, proteasome, TFIIS, RNA polymerase II.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Endogenous aldehyde-induced DNA-protein crosslinks (DPCs) interfere with transcription and are resolved by transcription-coupled repair (TCR). The removal of formaldehyde-induced DPCs requires the conventional TCR complex, VCP/p97, and the proteasome. TFIIS-dependent cleavage of RNA polymerase II transcripts helps overcome transcriptional roadblocks caused by DPCs. Deficiencies in aldehyde clearance and TCR lead to the accumulation of DPCs in actively transcribed regions, contributing to genotoxic stress and metabolic disease."}], "pathway_id": "mmu03420", "pubmed_id": "38600234", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Eukaryotic translation elongation factor 1 alpha 1 (elevated activity), Signal transducer and activator of transcription 1 (phosphorylated), Phosphorylated signal transducer and activator of transcription 1 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) overexpression enhances phosphorylation of signal transducer and activator of transcription 1 (p-STAT1) without altering total STAT1 protein levels, leading to T cell dysfunction. This dysregulation skews the balance between T helper 1 (Th1) and T helper 2 (Th2) cells toward a Th1-dominant profile. Elevated EEF1A1 activity contributes to the development of renal pathology, including immune complex deposition and proteinuria, through mechanisms involving impaired ubiquitination and proteasomal degradation."}], "pathway_id": "mmu05322", "pubmed_id": "41262540", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Cichoriin (administration), guanylate-binding protein 2 (elevated levels), chitinase 3-like 1, C-X3-C motif chemokine receptor 1, cyclin D1, plakophilin 4, nuclear factor kappa B (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of GBP2 are associated with the pathogenesis of lupus nephritis. Activation of the NF-kappaB signaling pathway contributes to inflammatory responses and immune dysregulation in renal tissues. Disruption of purine metabolism further exacerbates disease progression. Cichoriin, a bioactive compound, binds to GBP2 and modulates NF-kappaB activity, thereby reducing inflammation and alleviating renal damage."}], "pathway_id": "mmu05322", "pubmed_id": "41199598", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prednisone, AIM2 (inhibition), PRDM1 (decreased expression), BCL6 (increased expression), XBP1 (decreased expression), PAX5 (increased expression), CD19, CD27, CD138, CD69.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of AIM2 promotes B cell differentiation through the activation of Blimp-1 and XBP-1 while suppressing Bcl-6 and PAX5. This leads to increased production of IgG autoantibodies and renal deposition of complement components C3 and C4, contributing to renal damage in systemic lupus erythematosus. Inhibition of AIM2 reduces Blimp-1 and XBP-1 expression, increases Bcl-6 and PAX5 levels, suppresses B cell differentiation, and decreases IgG production, thereby alleviating renal pathology and complement deposition."}], "pathway_id": "mmu05322", "pubmed_id": "41311071", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tlr7, Tlr9, TIR domain of Tlr9, TIR domain of Tlr7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR7 and TLR9 are nucleic acid receptors that detect RNA and DNA, respectively, and are essential in the development of pathogenic autoimmune antibodies in systemic lupus erythematosus. TLR7 promotes disease progression, whereas TLR9 exerts a protective effect. The intracellular TIR signaling domains of these receptors contribute to their opposing roles in autoimmunity, with the TIR domain of TLR7 enhancing pro-disease signaling and the TIR domain of TLR9 dampening it. This divergence in signaling underlies the differential regulation of immune responses in lupus."}], "pathway_id": "mmu05322", "pubmed_id": "41178711", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melatonin, Melatonin receptor (upon activation), Protein kinase A, cAMP response element-binding protein (phosphorylated), PR domain containing 1 (downregulated), Interferon regulatory factor 4 (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melatonin receptor activation inhibits protein kinase A (PKA) signaling and reduces phosphorylation of cAMP response element-binding protein (CREB). This leads to epigenetic downregulation of PR domain containing 1 (PRDM1) and interferon regulatory factor 4 (IRF4), which are key transcription factors involved in plasmablast and plasma cell differentiation. As a result, abnormal B cell differentiation into antibody-secreting cells is suppressed, thereby reducing autoantibody production and mitigating autoimmune disease progression."}], "pathway_id": "mmu05322", "pubmed_id": "41139225", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Systemic lupus erythematosus - Mus musculus (house mouse)\n**Pathway Description**: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterised by the production of IgG autoantibodies that are specific for self-antigens, such as DNA, nuclear proteins and certain cytoplasmic components, in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy. Immune complexes comprising autoantibody and self-antigen is deposited particulary in the renal glomeruli and mediate a systemic inflammatory response by activating complement or via Fc{gamma}R-mediated neutrophil and macrophage activation. Activation of complement (C5) leads to injury both through formation of the membrane attack complex (C5b-9) or by generation of the anaphylatoxin and cell activator C5a. Neutrophils and macrophages cause tissue injury by the release of oxidants and proteases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lyn, B Cell Receptor, Toll-Like Receptor, Type I Interferon, Interferon-Stimulated Gene.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lyn kinase-independent functions restrain autoantibody production, glomerulonephritis, and Toll-like receptor signaling. These mechanisms also modulate interferon-stimulated gene expression, thymic epithelial cell development, and T cell selection. In contrast, Lyn kinase-dependent functions regulate B cell receptor signaling, dendritic cell phenotype, and type I interferon production."}], "pathway_id": "mmu05322", "pubmed_id": "41105783", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pak3 (mutated (R67C)), PXF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PAK3-R67C mutation alters PAK3 function and increases its interaction with PAK-interacting exchange factors (PIX). This disruption leads to reduced hippocampal synaptic efficacy and defects in long-term potentiation. These synaptic impairments contribute to impaired emotional learning and memory, as well as motor and social behavioral deficits. The mutation is associated with intellectual disability and features consistent with autism spectrum disorders."}], "pathway_id": "mmu04720", "pubmed_id": "41223971", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Fucose (administration), Fucokinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "L-fucose enhances excitatory neurotransmission and long-term potentiation through modulation of presynaptic release. This effect is mediated by the metabolism of l-fucose via fucokinase (FCSK) through the salvage pathway. Impaired l-fucose signaling contributes to synaptic deficits, and restoration of l-fucose levels supports the recovery of LTP in pathological conditions."}], "pathway_id": "mmu04720", "pubmed_id": "41202124", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lei-Dab7 (administration), (Z)-6,7-dichloro-3-(hydroxyimino)indolin-2-one, Morphine, KCNN2 (enhanced activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Enhanced activity of KCNN2-encoded small-conductance calcium-activated potassium channels in the dorsal hippocampus impairs long-term potentiation and modulates morphine-context memory formation and retrieval. Pharmacological blockade of KCNN2 channels with Lei-Dab7 or activation with NS309 disrupts morphine-induced contextual memory encoding and retrieval, suggesting a regulatory role for these channels in opioid-related contextual memory processes."}], "pathway_id": "mmu04720", "pubmed_id": "41266560", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cck-33, CCKBR (absent), CCK (released).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cholecystokinin (CCK) is released in the auditory cortex following high-frequency stimulation of the medial geniculate body, contributing to the induction of thalamocortical long-term potentiation (LTP). Activation of the CCK-B receptor (CCKBR) in the auditory cortex is necessary for this LTP expression. In aged mice, endogenous CCK release is impaired, preventing LTP, but exogenous CCK administration restores LTP and improves frequency discrimination. This mechanism is absent in juvenile mice due to the lack of CCKBR expression."}], "pathway_id": "mmu04720", "pubmed_id": "41264484", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lzts3, Prosapip1, SPAR, PSD95 (synaptic localization), GluN2B (synaptic localization), NMDAR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prosapip1 interacts with SPAR and facilitates the synaptic localization of PSD-95 and the GluN2B subunit of the NMDA receptor (NMDAR) in the dorsal hippocampus. This proper localization of synaptic proteins supports NMDAR-mediated transmission and the induction of long-term potentiation (LTP) in the CA1 region, which underlies learning and memory processes."}], "pathway_id": "mmu04720", "pubmed_id": "41295083", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methamphetamine (exposure), intersectin 1, Rac GTPase cdc42 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methamphetamine exposure induces hippocampal neurite outgrowth and increased dendritic spine density, leading to enhanced basal synaptic transmission and impaired long-term potentiation. Activation of the intersectin1/cdc42 signaling pathway in the synaptic compartment mediates these morphological and functional adaptations. This pathway modulates actin cytoskeleton dynamics, contributing to neuronal remodeling and altered synaptic plasticity."}], "pathway_id": "mmu04720", "pubmed_id": "41196340", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Norepinephrine (administration), Adrenergic receptor beta (activation), Glutamate receptor ionotropic AMPA 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of adrenergic receptor beta by norepinephrine enhances homosynaptic potentiation of synaptic transmission and modulates heterosynaptic plasticity in the CA1 region of the hippocampus. This modulation includes heterosynaptic facilitation of complex spike bursting and cooperative synaptic interactions required for complex spike burst-dependent long-term potentiation. Additionally, adrenergic receptor beta activation enhances a complex spike burst-dependent form of heterosynaptic depression, promoting synaptic competition where facilitation of long-term potentiation at one synapse is associated with suppression at others."}], "pathway_id": "mmu04720", "pubmed_id": "41090633", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Mus musculus (house mouse)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-tert-butylhydroxylamine, synaptophysin (differentially palmitoylated), postsynaptic density protein 95 (differentially palmitoylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Protein-specific S-palmitoylation changes occur during the induction of long-term potentiation, influencing synaptic vesicle cycling, cytoskeletal dynamics, and neurotransmitter release. Differentially palmitoylated proteins, including synaptophysin and postsynaptic density protein 95, exhibit distinct temporal patterns of modification, supporting synaptic and neural network plasticity. S-palmitoylation modulates synaptic protein function by altering localization and molecular interactions, and its regulation is essential for organizing neuronal spiking and enabling long-term potentiation, particularly in the stratum radiatum of the hippocampus."}], "pathway_id": "mmu04720", "pubmed_id": "41074974", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Mus musculus (house mouse)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STX6 (increased expression), PRNP, Prion protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Syntaxin-6 modulates prion pathogenesis by influencing intracellular trafficking of disease-related prion protein (PrP). Knockdown of syntaxin-6 leads to perinuclear accumulation of PrP and reduced prion secretion from infected cells, suggesting a role in prion export. Increased expression of syntaxin-6 decreases cell-associated prion infectivity and alters the morphology of disease-related PrP. These effects are consistent with a trafficking mechanism and influence early stages of prion disease in vivo, increasing transmission risk following low-dose inoculation."}], "pathway_id": "mmu05020", "pubmed_id": "41186731", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Mus musculus (house mouse)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Copper, PRNP, PRNP H95Y (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Substitution of histidine 95 by tyrosine in the prion protein (PRNP H95Y) disrupts the non-octapeptide repeat copper-binding site, leading to spontaneous neurodegeneration and spongiform encephalopathy. This mutation promotes the conformational conversion of the cellular prion protein (PrPC) into the pathogenic isoform (PrPSc), which accumulates and causes prion disease in vivo."}], "pathway_id": "mmu05020", "pubmed_id": "41100505", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Mus musculus (house mouse)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP, PrPSc (accumulation), PRNP E219K (naturally occurring variant).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The host-encoded prion protein (PrP) undergoes a conformational change to a misfolded, pathogenic isoform known as PrPSc. This misfolded form accumulates and is associated with neurodegeneration. A naturally occurring variant, PRNP E219K, supports in vitro amplification of prions through Real-Time Quaking-Induced Conversion (RT-QuIC), enabling detection and differentiation of prion strains based on amplification kinetics."}], "pathway_id": "mmu05020", "pubmed_id": "40637424", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin (administration), Temozolomide (administration), 5-Fluorouracil, Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II), Irinotecan, mismatch repair system (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Downregulation of the mismatch repair (MMR) system leads to hypermutation, which increases the number of neoantigens in tumor cells. This hypermutability enhances CD8+ T cell recognition and initiates immune surveillance and immunoediting. Combinatorial exposure to cisplatin and temozolomide induces adaptive MMR suppression, promoting chemotherapy-dependent neoantigen generation and long-term immunological memory. This process also remodels the innate immune microenvironment, supporting durable anti-tumor immune responses."}], "pathway_id": "mmu03430", "pubmed_id": "40513578", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TAR DNA-binding protein 43, MutL homolog 1 (altered expression), MutS homolog 2 (altered expression), MutS homolog 3 (altered expression), MutS homolog 6 (altered expression), PMS1 homolog 2 (altered expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TAR DNA-binding protein 43 (TDP43) regulates the expression of key DNA mismatch repair (MMR) genes, including MutL homolog 1 (MLH1) and MutS homolog 6 (MSH6), through modulation of alternative transcript splicing and mRNA stability. Altered expression of MMR genes such as MLH1, MSH2, MSH3, MSH6, and PMS2 leads to impaired DNA mismatch repair and increased genomic instability. This dysregulation contributes to the accumulation of DNA double-strand breaks and DNA damage signaling, particularly under conditions of TDP43 proteinopathy."}], "pathway_id": "mmu03430", "pubmed_id": "40985771", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mlh1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in mismatch repair, as indicated by the absence of Mlh1 function, contributes to the development of lung adenocarcinoma. This condition is associated with increased genomic instability and the accumulation of mutations that generate neoantigens. Tumors with mismatch repair deficiency exhibit a distinct immune microenvironment, with variable infiltration of immune cells. Immune checkpoint blockade, such as anti-PD-1 therapy, can lead to tumor burden reduction, although the therapeutic response is influenced by tumor location and the presence of clonal heterogeneity."}], "pathway_id": "mmu03430", "pubmed_id": "40553884", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Butyric Acid (administration), MLH1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Butyric acid, a metabolite produced by Fusobacterium nucleatum, induces the downregulation of MLH1 protein through activation of the autophagy-lysosome pathway. Reduced MLH1 expression leads to impaired mismatch repair, resulting in microsatellite instability and genomic instability."}], "pathway_id": "mmu03430", "pubmed_id": "40458404", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Irinotecan (administration), Pemrametostat, PRMT5, PMS2 (deficiency), cGAS, STING, TIGIT (increased expression), CD8+ T cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of PRMT5 enhances the sensitivity of cancer cells to Irinotecan, a DNA-damaging chemotherapeutic agent, and induces a mismatch repair deficiency-like state characterized by PMS2 deficiency. This leads to the release of cytosolic double-stranded DNA, which activates the cGAS-STING signaling pathway. Activation of this pathway promotes the production of type I interferons and enhances dendritic cell-T cell-dependent anti-tumor immune responses. Concurrently, PRMT5 inhibition combined with Irinotecan increases TIGIT expression on CD8+ T cells, contributing to immune checkpoint modulation and improved anti-tumor efficacy."}], "pathway_id": "mmu03430", "pubmed_id": "40344511", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Shikonin, Manganese(2+), cGAS, programmed death-ligand 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Suppression of tumor-cell mismatch repair activates the cGAS-mediated interferon (IFN) response, which increases the expression of PD-L1. This process is associated with immunogenic cell death and contributes to immune checkpoint blockade resistance in head and neck squamous cell carcinoma."}], "pathway_id": "mmu03430", "pubmed_id": "40190094", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epz020411, PRMT6, MSH2 (dimethylation at R171 and R219), MSH6, MSH3, cGAS, STING.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRMT6 mediates dimethylation of MSH2 at arginine residues R171 and R219, which disrupts the formation of the MutS and MutS complexes by preventing the recruitment of MSH3 and MSH6. This modification impairs the mismatch repair (MMR) capacity, leading to mutagenesis and genomic instability. Loss or inhibition of PRMT6 results in cytosolic DNA accumulation, which activates the cGAS-STING signaling pathway and enhances immune response. This mechanism contributes to the destabilization of MMR complexes and promotes an MSI-like phenotype in microsatellite-stable cells, thereby sensitizing them to immune checkpoint blockade."}], "pathway_id": "mmu03430", "pubmed_id": "40086819", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Msh3, Pms1, Msh2, Mlh1, HTT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated CAG-repeat expansion rates in mutant Huntingtin (HTT) lead to transcriptional dysregulation and protein aggregation in striatal medium-spiny neurons. The Msh3 and Pms1 proteins, components of the mismatch repair (MMR) complex, accelerate somatic CAG-repeat expansion, which contributes to the progressive accumulation of mHTT and the onset of neuronal dysfunction. Reduction or elimination of Msh3 or Pms1 activity significantly decreases the rate of CAG-repeat expansion, thereby preventing mHTT aggregation and maintaining CAG repeat lengths below a pathogenic threshold. This results in the amelioration of synaptic, astrocytic, and locomotor impairments associated with Huntingtons disease."}], "pathway_id": "mmu03430", "pubmed_id": "39938516", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nutlin 3, AXIN1, AXIN2, TP53, ACVR2A, BMPR2, NRAS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mismatch repair deficiency leads to genomic instability and spontaneous acquisition of oncogenic mutations. Mutations in AXIN1 and AXIN2 disrupt the Wnt signaling pathway, while NRAS mutations activate the EGF receptor pathway. ACVR2A and BMPR2 mutations affect BMP signaling, and TP53 mutations impair p53 tumor suppressor function. These mutations collectively enable organoid independence from stem cell niche factors and promote tumor formation upon xenotransplantation."}], "pathway_id": "mmu03430", "pubmed_id": "39487295", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, SET, MYC, CCL5 (expression), FBXW7 (interaction with c-Myc).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SET represses CCL5 expression and upregulates mismatch repair protein expression in a c-Myc-dependent manner, which limits CD8+ T cell infiltration and migration into tumor tissues. Additionally, SET disrupts the interaction between FBXW7 and c-Myc, impairing c-Myc ubiquitination and proteasomal degradation. These effects contribute to reduced immunogenicity and promote immune evasion in microsatellite stable colorectal cancer."}], "pathway_id": "mmu03430", "pubmed_id": "39420583", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: O6-Methyl-2'-deoxyguanosine (elevated levels), N-Methyl-N'-nitro-N-nitrosoguanidine (administration), DNA polymerase zeta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNA polymerase zeta (Pol ) facilitates translesion synthesis by misincorporating thymidine opposite O6-methyldeoxyguanosine (O6-medG) lesions and extending from these mismatches. This activity contributes to mutagenicity. However, DNA mismatch repair (MMR) efficiently corrects these Pol -dependent misinsertions, thereby reducing the overall mutagenic potential of O6-medG. The mutational signature induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) is shaped by the lesion spectrum and modulated by the presence of MMR, resulting in a mutational pattern resembling single base substitution signature 11 observed in cancer."}], "pathway_id": "mmu03430", "pubmed_id": "39216121", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mismatch repair - Mus musculus (house mouse)\n**Pathway Description**: DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key role in maintaining genomic stability. MMR corrects DNA mismatches generated during DNA replication, thereby preventing mutations from becoming permanent in dividing cells. MMR also suppresses homologous recombination and was recently shown to play a role in DNA damage signaling. Defects in MMR are associated with genome-wide instability, predisposition to certain types of cancer including HNPCC, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and sterility in mammalian systems.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Msh2, Rb1, Trp53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defective DNA mismatch repair (MMR) results in elevated tumor mutational burden (TMB) and increased neoantigen load, thereby enhancing tumor immunogenicity. Msh2 deficiency disrupts MMR integrity, contributing to genomic instability. This instability, combined with concurrent loss of Rb1 and Trp53, drives the development of aggressive small cell lung cancer (SCLC). The elevated immunogenicity associated with MMR deficiency correlates with increased sensitivity to immune checkpoint blockade."}], "pathway_id": "mmu03430", "pubmed_id": "39542886", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch1, Lgr5, Wnt (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Notch suppression licenses intestinal stem cell fate commitment in the context of Wnt-active zones. Wnt signaling activates intestinal stem cell niches, while Notch-mediated lateral inhibition ensures the proper 1:40 stem cell to progenitor ratio. This spatiotemporal coordination of Notch suppression and Wnt activation is conserved across species, including mouse embryonic intestine, where Notch suppression promotes the specification of Lgr5+ progenitors."}], "pathway_id": "mmu04330", "pubmed_id": "41337595", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Retinoic Acid (administration), Tbx21 (expression), Notch, Clec9a.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tbx21-expressing cDC2As require retinoic acid signaling to sustain differentiation through the Notch signaling pathway. This mechanism supports the maintenance of Tbx21+ cDC2A identity in the spleen."}], "pathway_id": "mmu04330", "pubmed_id": "41272166", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Estradiol (administration), Notch receptor (suppression), Nestin, ESR1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Notch signaling maintains Nestin-positive perivascular cells in a quiescent state. Suppression of Notch signaling by estrogen, mediated through estrogen receptor alpha (ESR1), promotes cell cycle re-entry and differentiation of these cells into epithelial cells, contributing to re-epithelialization."}], "pathway_id": "mmu04330", "pubmed_id": "41261095", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lrig1, Notch1 (Active).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lrig1 marks a quiescent stem cell population in laryngeal and vocal fold mucosa, contributing to long-term tissue homeostasis and epithelial regeneration. These cells maintain quiescence through Notch1 signaling. Disruption of Notch1 leads to epithelial hyperplasia, expansion of secretory cell populations, and increased mucus production."}], "pathway_id": "mmu04330", "pubmed_id": "41289377", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ADAM metallopeptidase domain 10 (inhibited), Notch receptor (decreased levels), Eph receptor (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ADAM10 regulates tumour growth and microenvironment dynamics by mediating the shedding of membrane-bound proteins, including Notch and Eph receptors. This proteolytic activity influences cell proliferation, angiogenesis, cell-cell adhesion, migration, and differentiation. Reduction in ADAM10 activity decreases levels of these receptors and their ligands, impairing signaling pathways that promote tumour progression and vascularization. Inhibition of ADAM10 alters extracellular matrix composition and promotes collagen fibril reduction, while also inducing chondrocyte differentiation in tumour tissues."}], "pathway_id": "mmu04330", "pubmed_id": "41226720", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch, Neuralized, Mind bomb 1, NEURL1, NEURL1B, Delta-like 1, Jagged 1, Delta-like 4, Jagged 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NEURL proteins activate Notch signaling through a subset of mammalian ligands that contain a Neuralized binding motif. This motif, with the consensus sequence NxxN, is present in Delta-like 1 (DLL1) and Jagged 1 (JAG1), but absent in Delta-like 4 (DLL4) and Jagged 2 (JAG2). This selective activation mechanism contributes to the limited role of NEURL proteins in mammalian development and cellular homeostasis."}], "pathway_id": "mmu04330", "pubmed_id": "41174261", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Valproic Acid (administration), Notch receptor, BMP10 (upregulation), Nrg1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the Notch signaling pathway promotes cardiac trabeculation and heart development. Valproic acid functions as a Notch pathway activator, which in turn upregulates downstream effectors such as BMP10 and Nrg1. These factors contribute to the structural maturation and internal complexity of developing cardiac tissue, including the formation of atrium- and ventricle-like structures."}], "pathway_id": "mmu04330", "pubmed_id": "41111166", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cebpa, Notch, Dlk1, Polycomb Repressive Complex 2, Ddit3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cebpa suppresses Notch signaling at the Dlk1 enhancer, modulating its expression. This regulation influences the timing of Notch activation, which controls the differentiation pattern of Alveolar Type 1 and Type 2 cells, resulting in a 'salt and pepper' distribution. Cebpa activity is regulated by Polycomb Repressive Complex 2. Downregulation of Cebpa enables re-access to AT2 cell fate plasticity and activates a 'defender' AT2 state distinct from the reparative state."}], "pathway_id": "mmu04330", "pubmed_id": "41087371", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MAPK14, Integrin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated matrix-integrin receptor interactions at focal adhesions within fibroblasts enhance diastolic tension sensation, promoting fibroblast expansion. This mechanosensitized state contributes to the structural reorganization of the extracellular matrix and myocardial stiffening. p38-mediated signaling in fibroblasts regulates these responses, which influence the progression of dilated cardiomyopathy and cardiomyocyte remodeling."}], "pathway_id": "mmu04510", "pubmed_id": "40934290", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEMA5A, Focal Adhesion Kinase (phosphorylated), PAXILLIN (phosphorylated), RhoA (activated), ITGB1 (activated), ACTIN-RELATED PROTEIN 3 (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEMA5A modulates focal adhesion signaling by influencing the phosphorylation of Focal Adhesion Kinase (FAK) and PAXILLIN, as well as the activation of RhoA and Integrin 1. These effects regulate focal adhesion dynamics and lamellipodia organization, which are essential for cell migration and adhesion. SEMA5A also affects Arp3 nucleation and expression, contributing to actin cytoskeleton remodeling. Reduced SEMA5A levels correlate with decreased cell migration, viability, and tumor growth, indicating its role in promoting melanoma aggressiveness."}], "pathway_id": "mmu04510", "pubmed_id": "41310710", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tws119 (administration), MACF1, NR2F1, CTNNB1 (nuclear accumulation), PAXILLIN (upregulation), FAK (upregulation), ITGB1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MACF1 promotes focal adhesion formation and enhances cell proliferation, adhesion, and migration in lung adenocarcinoma by activating the WNT/CTNNB1 signaling pathway. It facilitates CTNNB1 nuclear translocation, which upregulates the expression of focal adhesion-related genes such as PAXILLIN, FAK, and ITGB1. NR2F1 acts as a transcriptional activator of MACF1 by directly binding to its promoter. The loss of MACF1 impairs focal adhesion assembly and reduces metastatic potential. CTNNB1 nuclear accumulation is essential for these effects, as evidenced by the restoration of focal adhesion by the CTNNB1 agonist TWS119 in MACF1-deficient cells."}], "pathway_id": "mmu04510", "pubmed_id": "41102854", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Miuraenamide A (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of miuraenamide A increase the number of focal adhesions while decreasing their size, which reduces adhesion energy and force. This alteration in focal adhesion structure does not affect cell contractility or amoeboid migration, which operate independently of adhesion. However, it impairs mesenchymal migration, which depends on adhesion-based mechanisms."}], "pathway_id": "mmu04510", "pubmed_id": "40911607", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, CDC6 (interacting with Tmod3), Tmod3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CDC6 interacts with Tmod3 in the cytoplasm, enhancing CDC6 protein stability and promoting focal adhesion assembly. This interaction facilitates actin cytoskeleton remodeling, which contributes to the development of drug resistance phenotypes."}], "pathway_id": "mmu04510", "pubmed_id": "41339304", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TRIM29, KRT14 (KRT14-positive), ZYXIN.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM29 interacts with KRT14-positive intermediate filaments, which regulate focal adhesion stability. This interaction contributes to cytoskeletal organization and promotes cell migration and invasion in bladder cancer."}], "pathway_id": "mmu04510", "pubmed_id": "40908312", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KIF3A (disruption), Rab Coupling Protein (localization at the leading edge), Integrin beta-1, RAB11A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KIF3AC facilitates the recycling of endocytosed 1 integrin from the Rab11 endocytic recycling compartment back to the plasma membrane. This process supports the polarized formation of new focal adhesions at the leading edge of migrating cells. RCP interacts with 1 integrin in a KIF3AC-dependent manner, enabling directional trafficking toward the cell front. Disruption of KIF3AC function impairs integrin recycling, RCP localization at the leading edge, and the establishment of polarized focal adhesions, thereby inhibiting cell migration."}], "pathway_id": "mmu04510", "pubmed_id": "40705420", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RB1 (reduced expression), GJA1, CDH11, VCL (lower levels), YAP1 and WWTR1 (TAZ), PPARG (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of RB1 in osteoblasts leads to decreased levels of vinculin, a focal adhesion protein. Vinculin plays a critical role in transducing signals to YAP1 and TAZ (WWTR1) transcription factors, which suppress adipocyte differentiation while promoting osteoblast differentiation. Lower vinculin levels result in diminished YAP/TAZ nuclear localization and activity, contributing to the concurrent expression of adipocyte-specific genes and incomplete osteoblast differentiation. Increased expression of PPARG, an adipocyte master transcription factor, further suppresses vinculin levels, reinforcing the shift toward an adipogenic lineage. These molecular interactions underlie the mixed differentiation phenotype observed in Rb1-deficient osteoblasts."}], "pathway_id": "mmu04510", "pubmed_id": "40769383", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cep290, CEP290, APC, PAXILLIN (stabilized).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CEP290 forms a complex with APC at the centrosome, which stabilizes the focal adhesion molecule paxillin at the leading edge of non-ciliated cells. This interaction supports focal adhesion formation, which is essential for maintaining cell morphology, enabling collective cell migration, and ensuring proper adhesion to the extracellular matrix. Disruption of the APC-CEP290 complex results in reduced focal adhesion stability, leading to impaired cellular motility and adhesive capacity."}], "pathway_id": "mmu04510", "pubmed_id": "40632733", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aminonucleoside (administration), [(2R,3R,4S,5S,6R)-6-[(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5R,6R)-2-[(2R,3R,4S,5S,6R)-3,5-disulfonatooxy-2-(sulfonatooxymethyl)-6-[(2R,3S,4R,5R,6R)-2,4,5-trisulfonatooxy-6-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,5-disulfonatooxy-6-(sulfonatooxymethyl)oxan-4-yl]oxy-3,4,5-trisulfonatooxyoxan-2-yl]methyl phosphate.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Puromycin aminonucleoside induces cytoskeletal disruption in podocytes, leading to reduced formation of focal adhesions and stress fibers. This disruption is associated with podocyte injury. Heparanase inhibition with PI-88 prevents these cytoskeletal abnormalities, preserving focal adhesion integrity and reducing monolayer permeability in podocytes."}], "pathway_id": "mmu04510", "pubmed_id": "40495439", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Mus musculus (house mouse)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Ethynyl-2'-deoxyuridine, TNIK, RHOA, ROCK2 (activation), LIMK1 (activation), F-actin (organization), tubulin (organization).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TNIK regulates the organization of F-actin and microtubules through the RHO/ROCK2/LIMK1 signaling pathway, which controls focal adhesion turnover and mitosis. This regulation influences cell spreading, growth, and movement. TNIK also modulates sensitivity to chemotherapeutic drugs in lung adenocarcinoma cells."}], "pathway_id": "mmu04510", "pubmed_id": "40464520", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Brg1-associated factor, Brg1-associated factor complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuronal activity triggers rapid remodeling of the BAF ATP-dependent chromatin remodeling complex, leading to changes in subunit composition, phosphorylation, and dephosphorylation of its components. These modifications occur within minutes and are associated with alterations in chromatin accessibility, supporting activity-dependent developmental processes such as dendritic outgrowth."}], "pathway_id": "mmu03082", "pubmed_id": "40494354", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CHD7, Chd7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CHD7 enzymatic activity is essential for establishing a permissive chromatin landscape at target genes, characterized by open chromatin architecture and active histone modifications. This chromatin remodeling activity supports gene regulation and promotes neural development, particularly neurite development. Disruption of CHD7 ATPase function leads to chromatin dysregulation, impairing these developmental processes."}], "pathway_id": "mmu03082", "pubmed_id": "40915599", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Srg3 (elevated expression), Interleukin-1 beta (expression), M1 macrophage (reduced proportion), M2 macrophage, Interleukin-17 (production).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Srg3 reduces the proportion of IL1-expressing M1 macrophages in adipose tissues, leading to a decrease in the M1/M2 macrophage ratio. This shift is associated with reduced adipocyte size and improved glucose tolerance. Srg3 also suppresses IL17-producing T cells and neutrophils in adipose tissues, contributing to immune homeostasis in these compartments."}], "pathway_id": "mmu03082", "pubmed_id": "39519233", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Smarca4, E2A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Smarca4 interacts with the E2A transcription factor at proximal promoters and regulates distal enhancer activity to coordinate the activation of a lymphoid gene signature in murine multipotent progenitors. This interaction is essential for the specification of lymphoid cell fate from multipotent progenitors and governs the developmental restriction toward lymphoid lineages."}], "pathway_id": "mmu03082", "pubmed_id": "39232562", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Chromodomain helicase DNA binding protein 8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels or functional impairment of CHD8 disrupt chromatin remodeling, leading to altered gene expression patterns that contribute to the development of autism spectrum disorder. CHD8 missense mutations with high pathogenic scores impair either chromatin-remodeling function directly or through alternative mechanisms, resulting in ASD-like phenotypes in mice."}], "pathway_id": "mmu03082", "pubmed_id": "38438524", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BCL7B, BCL7C.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ATP-dependent BAF chromatin remodeling complexes regulate gene expression programs that influence the self-renewal, commitment, and lineage-specific differentiation of hematopoietic stem cells. BCL7B and BCL7C are subunits of these complexes, but their absence does not impair steady-state hematopoiesis or the maintenance of hematopoietic stem cell function."}], "pathway_id": "mmu03082", "pubmed_id": "40187480", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CHD7, Chd7, WDR5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CHD7 regulates cardiovascular development by modulating gene expression in neural crest cells. It functions through both ATP-dependent chromatin remodeling and ATP-independent interactions, such as direct binding to WDR5, a core component of H3K4 methyltransferase complexes. This interaction enables CHD7 to recruit histone-modifying enzymes to target loci, thereby influencing epigenetic regulation and developmental gene networks essential for cardiac morphogenesis."}], "pathway_id": "mmu03082", "pubmed_id": "33127760", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TRIM28, SETDB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM28 interacts with SETDB1 to mediate H3K9 trimethylation at endogenous retrovirus sequences. Sumoylation and ATP-dependent chromatin remodeling factors facilitate the proper localization of TRIM28 and enhance its interaction with SETDB1, contributing to transcriptional silencing."}], "pathway_id": "mmu03082", "pubmed_id": "32823517", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BAF, RNA Polymerase II (during promoter-proximal pausing), Pluripotency Transcription Factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BAF dynamically unwraps and evicts nucleosomes at accessible chromatin regions. RNA Polymerase II promoter-proximal pausing stabilizes BAF chromatin occupancy and enhances ATP-dependent nucleosome eviction by BAF. Pluripotency transcription factor chromatin binding confers locus specificity for productive chromatin remodeling and nucleosome eviction by BAF, facilitating transcriptional activation through ATP-dependent chromatin remodeling."}], "pathway_id": "mmu03082", "pubmed_id": "38049663", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Smarca5, Smarca1, Smarca5 conditional knockout mice.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The ATP-dependent chromatin remodeling enzyme Smarca5 (Snf2h) is essential for the proliferation of retinal progenitor cells. Deficiency in Smarca5 leads to defective S-phase progression and impaired cell division, resulting in increased apoptosis and disrupted retinal lamination. Although cell fate specification remains unaffected, the absence of Smarca5 function causes the loss of the photoreceptor layer and leads to a non-functional retina. These effects are associated with disruptions in chromatin structure and regulation of nuclear processes including transcription and DNA replication."}], "pathway_id": "mmu03082", "pubmed_id": "37048108", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SmarcA5, Oct4, Nanog (reduced expression), Sox17 (reduced expression), Gata6 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SMARCA5 regulates preimplantation development by maintaining proper chromatin structure and facilitating lineage specification. Its depletion disrupts inner cell mass differentiation, leading to impaired epiblast and primitive endoderm formation. This is associated with reduced expression of key transcription factors such as NANOG, SOX17, and GATA6. SMARCA5 also modulates gene expression at the blastocyst stage, affecting transcriptional regulation and cell proliferation pathways."}], "pathway_id": "mmu03082", "pubmed_id": "33899080", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5'-Atp, HELLS, LSH, SNF2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HELLS, a member of the SNF2 ATP-dependent chromatin-remodeling complex, utilizes ATP hydrolysis to modify nucleosome structure and chromatin packaging during DNA replication, transcription, and repair. The mouse homologue LSH contributes to heterochromatin maintenance and genome-wide DNA methylation. These activities collectively regulate genome stability and epigenetic control of gene expression."}], "pathway_id": "mmu03082", "pubmed_id": "36012581", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: INO80, H2A.Z, ARP8, ARP5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ino80, the core catalytic subunit of the INO80 complex, binds to hypha-specific promoters and facilitates the eviction of H2A.Z from these regions. This removal of H2A.Z is necessary for the transcriptional activation of hypha-specific genes. Ino80-dependent chromatin remodeling supports hyphal development and contributes to the pathogenicity of Candida albicans. Additionally, Ino80 plays a role in the DNA damage response in conjunction with Arp5, a subunit specific to the INO80 complex."}], "pathway_id": "mmu03082", "pubmed_id": "35713098", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Smarca5, Snf2h, Prkar2b.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The ATP-dependent chromatin remodeler Snf2h (Smarca5) regulates meiotic cell cycle progression by modulating chromatin accessibility at the promoters of meiosis-related genes, such as Prkar2b. This chromatin remodeling activity facilitates transcription of key meiotic genes, thereby promoting meiotic resumption and maturation-promoting factor (MPF) activation. Disruption of Snf2h function leads to impaired transcription of these genes and failure of meiotic progression, resulting in infertility."}], "pathway_id": "mmu03082", "pubmed_id": "31919188", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ATP-dependent chromatin remodeling - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACTL6B, Fos, Fosl2, Fosb, Junb, Actl6b.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ACTL6B is a subunit of the neuronal BAF complex involved in ATP-dependent chromatin remodeling. Loss of ACTL6B relieves repression of early response genes, including AP1 transcription factors such as Fos, Fosl2, Fosb, and Junb. This leads to increased chromatin accessibility at AP1 binding sites and transcriptional changes in late response genes. These transcriptional alterations are associated with impaired neural connectivity and behavioral phenotypes including social and memory impairments, repetitive behaviors, and hyperactivity, which are consistent with autism spectrum disorder."}], "pathway_id": "mmu03082", "pubmed_id": "32312822", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, POU5F1, NANOG, SOX2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 nuclear entry in inner cell mass (ICM) cells is temporally regulated during preimplantation development, with total cell number influencing the timing of Hippo/YAP activation. In embryos with reduced cell numbers, YAP1 nuclear localization in ICM cells is delayed at the mid-blastocyst stage. However, increasing total cell number restores YAP1 nuclear entry timing to that observed in normal diploid embryos. This delay is transient, as most ICM cells exhibit nuclear YAP1 by the late-blastocyst stage. The Hippo/YAP signaling pathway contributes to the regulation of ICM/trophectoderm patterning and is temporally linked to the expression of pluripotency markers such as POU5F1, NANOG, and SOX2."}], "pathway_id": "mmu04392", "pubmed_id": "41129931", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, YAP1 (elevated activity), LATS1, LATS2, IGF1, IGF1R, CSF1 (elevated), SOX9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated YAP activity in cardiac fibroblasts promotes glycolysis, which drives fibroinflammation and fibrosis. YAP induces a shift toward an osteochondroprogenitor cell state, marked by SOX9 expression. YAP also activates CSF1 secretion, which promotes macrophage expansion. These macrophages secrete IGF1, which binds to the IGF1 receptor on cardiac fibroblasts to further enhance their proliferation and fibrotic activity. Inhibition of glycolysis or lactate production reduces fibroinflammation and fibrosis. LATS1 and LATS2, as Hippo kinases, normally suppress YAP activity to restrict these processes."}], "pathway_id": "mmu04392", "pubmed_id": "41165345", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, FHL3 (induced expression), MAZ, KRAS (enhanced transcription).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 promotes hepatocellular carcinoma progression by inducing the expression of FHL3. FHL3 interacts with MAZ to recruit it to G-quadruplex structures, thereby enhancing KRAS transcription and activating downstream oncogenic signaling pathways."}], "pathway_id": "mmu04392", "pubmed_id": "41184244", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Dihydromyricetin, integrin, Hippo signaling pathway, YAP1, ABCG1 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extracellular matrix stiffness increases integrin expression, which suppresses the Hippo signaling pathway. This suppression leads to increased YAP1 activity, which in turn upregulates ABCG1 expression. Elevated ABCG1 levels reduce ferroptosis sensitivity in lung adenocarcinoma cells, thereby promoting therapy resistance and tumor progression."}], "pathway_id": "mmu04392", "pubmed_id": "41286767", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Xmu-MP-1, ACADL (overexpression), EBF3, YAP1, Phosphorylated YAP at serine 127 (phosphorylated at serine 127), CTGF, CYR61, ANKRD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EBF3 transcriptionally activates ACADL by binding to its promoter. ACADL overexpression leads to phosphorylation of YAP at serine 127, inhibiting its nuclear localization and suppressing the expression of Hippo/YAP target genes CTGF, CYR61, and ANKRD1. This results in reduced breast cancer cell growth and tumor development. Inhibition of MST1/2 kinase activity with XMU-MP-1 reverses the suppressive effect of ACADL on Hippo/YAP signaling."}], "pathway_id": "mmu04392", "pubmed_id": "41270467", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: alpha-Synuclein (accumulation), insulin-degrading enzyme (overexpression), MST1 and MST2 (inhibited), SNCA (alpha-synuclein).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced insulin-degrading enzyme (IDE) levels correlate with increased alpha-synuclein (-syn) accumulation and dopaminergic neuron degeneration, contributing to Parkinson's disease pathology. IDE overexpression suppresses the Hippo signaling pathway by inhibiting MST1 and MST2, thereby reducing -syn pathology and neuronal apoptosis. This suppression of the Hippo pathway contributes to neuroprotection and the preservation of dopaminergic neurons."}], "pathway_id": "mmu04392", "pubmed_id": "41136383", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ITGB2, ICAM1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ITGB2 mediates neutrophil transendothelial migration primarily through its interaction with ICAM1 on endothelial cells. This interaction promotes neutrophil adherence, migration, and infiltration, as well as the formation of neutrophil extracellular traps. These processes contribute to neuroinflammation and increased blood-brain barrier permeability, which can exacerbate tissue damage following injury."}], "pathway_id": "mmu04670", "pubmed_id": "39923080", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pecam1, Cd99, Neutrophils.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neutrophil extravasation in the lung occurs via homophilic interactions between leukocyte and endothelial cell PECAM-1 and CD99. These proteins facilitate transendothelial migration, allowing neutrophils to cross the alveolar capillary endothelium during inflammatory responses, including chemical, bacterial, and ischemia/reperfusion injury. This process is essential for the recruitment of neutrophils into the lung airspace."}], "pathway_id": "mmu04670", "pubmed_id": "40445608", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin (administration), APJ receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin modulates the transendothelial migration of leukocytes by targeting the expression of cell adhesion molecules. It induces internalization and desensitization of the APJ receptor in endothelial cells, thereby reducing leukocyte recruitment during acute inflammation. This mechanism contributes to the suppression of immune cell infiltration into inflammatory tissues."}], "pathway_id": "mmu04670", "pubmed_id": "39060233", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KPNB1 (enriched in endothelial cell-derived extracellular vesicles).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Karyopherin subunit beta-1 (KPNB1), enriched in endothelial cell-derived extracellular vesicles, promotes abluminal-to-luminal reverse transendothelial migration (rTEM) of neutrophils. This process contributes to systemic inflammation and lung injury in sepsis. Neutrophils undergoing rTEM exhibit an activated phenotype and are associated with acute respiratory distress syndrome (ARDS)."}], "pathway_id": "mmu04670", "pubmed_id": "39119837", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Temsirolimus (administration), PECAM1 (activation), neutrophil granulocyte.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Temsirolimus induces endothelial barrier dysfunction through the activation of platelet endothelial cell adhesion molecule-1 (PECAM1), leading to increased neutrophil transendothelial migration. This disruption of the capillary-alveolar barrier facilitates neutrophil infiltration into the alveolar space, which contributes to the development of pulmonary injury."}], "pathway_id": "mmu04670", "pubmed_id": "37820453", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (elevated levels), ALAS1, FECH, ALAD, CPOX, PPOX, UROD, HMBS, Ferrochelatase, ALAS2, PBGD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The heme biosynthesis pathway begins with the condensation of glycine and succinyl-CoA to form -aminolevulinic acid (5-aminolevulinic acid), catalyzed by ALAS1 in the liver and ALAS2 in erythroid cells. 5-aminolevulinic acid is then converted to porphobilinogen by ALAD, which is further processed through a series of enzymatic steps involving PBGD, UROD, HMBS, CPOX, and PPOX to form protoporphyrin IX. Ferrochelatase inserts iron into protoporphyrin IX to yield heme. Deficiencies in any of these enzymes lead to the accumulation of intermediate metabolites such as protoporphyrin IX and 5-aminolevulinic acid, which can cause porphyria. Elevated levels of these intermediates disrupt normal heme production and result in symptoms including photosensitivity, cutaneous lesions, acute abdominal pain, neurological symptoms, anemia, and hepatic dysfunction."}], "pathway_id": "mmu04670", "pubmed_id": "37199607", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Leukocyte transendothelial migration - Mus musculus (house mouse)\n**Pathway Description**: Leukocyte migaration from the blood into tissues is vital for immune surveillance and inflammation. During this diapedesis of leukocytes, the leukocytes bind to endothelial cell adhesion molecules (CAM) and then migrate across the vascular endothelium. A leukocyte adherent to CAMs on the endothelial cells moves forward by leading-edge protrusion and retraction of its tail. In this process, alphaL /beta2 integrin activates through Vav1, RhoA, which subsequently activates the kinase p160ROCK. ROCK activation leads to MLC phosphorylation, resulting in retraction of the actin cytoskeleton. Moreover, Leukocytes activate endothelial cell signals that stimulate endothelial cell retraction during localized dissociation of the endothelial cell junctions. ICAM-1-mediated signals activate an endothelial cell calcium flux and PKC, which are required for ICAM-1 dependent leukocyte migration. VCAM-1 is involved in the opening of the \"endothelial passage\" through which leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase activation and the production of reactive oxygen species (ROS) in a Rac-mediated manner, with subsequent activation of matrix metallopoteinases and loss of VE-cadherin-mediated adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PECAM1 (Engagement at the endothelial cell border), VEGFR2 (Signaling at tyrosine 1175), CDH5, Neutrophil.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Engagement of PECAM1 on the leukocyte pseudopod with PECAM1 at the endothelial cell border initiates transendothelial migration. This interaction activates a mechanotransduction complex involving CDH5 and VEGFR2. VEGFR2 signaling, specifically at tyrosine 1175, is required for efficient diapedesis. Disruption of endothelial VEGFR2 significantly reduces neutrophil extravasation, indicating a critical role for VEGFR2 in the process of leukocyte transmigration during inflammation."}], "pathway_id": "mmu04670", "pubmed_id": "37643615", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TBC1D24 (upregulation under hypoxia), ARF6 (increased expression), PLD (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TBC1D24 upregulation under hypoxia increases ARF6 expression and activates the PLD signaling pathway, which promotes cell viability, proliferation, and stem-like characteristics in breast cancer cells."}], "pathway_id": "mmu04072", "pubmed_id": "40790967", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Baricitinib (administration), PLD4 (loss-of-function mutations), TLR7 (excessive activation), TLR9 (excessive activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss-of-function mutations in PLD4 impair its exonuclease activity, leading to excessive activation of TLR7 and TLR9. This results in hyperactivation of downstream inflammatory signaling pathways, particularly type I interferon signaling, which contributes to the development of autoimmunity and systemic lupus erythematosus. The hyperactivation is associated with cell-intrinsic expansion of plasmacytoid dendritic cells and plasma cells. Targeting type I interferon signaling with JAK inhibitors such as baricitinib can mitigate the pathological effects of PLD4 deficiency."}], "pathway_id": "mmu04072", "pubmed_id": "40931063", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0), PRKCI, PLD1 (Elevated phosphatidic acid synthesis), G protein-coupled receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated phosphatidic acid synthesis via phospholipase D (PLD1) activates protein kinase C zeta (PRKCI), which mediates G protein-coupled receptor (GPCR) signaling. This leads to the nuclear translocation of TFEB and acidic vesicle formation, disrupting endolysosomal homeostasis and impairing insulin receptor signaling."}], "pathway_id": "mmu04072", "pubmed_id": "39768174", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Fluorouracil, GPLD1, PRSS8 (Released from plasma membrane), Wnt signaling pathway (Activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GPLD1 cleaves the GPI anchor of PRSS8, leading to its release from the plasma membrane and subsequent activation of Wnt signaling and epithelial-mesenchymal transition in cancer cells. This process promotes cancer progression and contributes to chemotherapy resistance and tumor relapse."}], "pathway_id": "mmu04072", "pubmed_id": "39743241", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PLD1 (increased expression), RELA (phosphorylated), NF-kappa-B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PLD1 enhances NF-B signaling activity by promoting the phosphorylation and nuclear translocation of RELA, a key subunit of NF-B. Activated NF-B, in turn, binds to the PLD1 promoter and increases its expression, forming a positive feedback loop. This interaction supports tumorigenesis through the promotion of cell proliferation and migration."}], "pathway_id": "mmu04072", "pubmed_id": "38885836", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (production), Phosphatidylinositol 4,5-bisphosphate, Phospholipase D (upregulated), Raf-1 (modulation of activity and translocation), mTOR (modulation of activity and translocation), KIT (increased expression), DGKG (increased expression), TFRC (increased expression), SLC40A1 (increased expression), SLC7A11 (increased expression), TRP53 (increased expression), FTH1 (increased expression), GPX4 (increased expression), HMOX1 (increased expression), ALOX15 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D (PLD) catalyzes the production of phosphatidic acid (PA), a lipid second messenger that regulates membrane trafficking, actin cytoskeleton remodeling, and cell survival. PA interacts directly with signaling proteins such as Raf-1 and mTOR, modulating their activity and translocation. Under hypoxic conditions, PLD signaling is upregulated, contributing to lipid metabolism disturbances. This disruption activates the ferroptosis pathway, leading to increased expression of genes such as KIT, DGKG, TFRC, SLC40A1, SLC7A11, TRP53, FTH1, GPX4, HMOX1, and ALOX15, which collectively promote oxidative lipid peroxidation and cell death through ferroptosis, resulting in splenic injury."}], "pathway_id": "mmu04072", "pubmed_id": "38451609", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Diglycerides (generation), Prostaglandin E2 (synthesis), PLD1 (activity), PLD2, cPLA2 (phosphorylation), PKC (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PLD1 activity is required for prostaglandin E2 formation in osteoblastic cells. PLD1 generates diacylglycerol, which activates protein kinase C, leading to the phosphorylation and activation of cytosolic phospholipase A2. This cascade promotes the release of arachidonic acid, a precursor for prostaglandin E2 synthesis, which contributes to osteogenic processes."}], "pathway_id": "mmu04072", "pubmed_id": "37951067", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (generated), PLD1, GFAP (upregulated), STAT3 (activated), FAK (activated), AURKA (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D1 (PLD1) promotes astrocytic differentiation by generating phosphatidic acid (PA), which activates the FAK/AURKA/STAT3 signaling pathway. This pathway leads to the upregulation of glial fibrillary acidic protein (GFAP), a marker of astrocyte differentiation. STAT3 activation is required for PA-induced astrocytic differentiation, indicating a direct regulatory role of this signaling cascade in the process."}], "pathway_id": "mmu04072", "pubmed_id": "36162649", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TP53BP1 (accumulates), RIF1, PRKDC (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TP53BP1 accumulates at DNA double strand breaks and interacts genetically with PRKDC during non-homologous end joining. Loss of TP53BP1 does not impair blunt DSB repair but reduces repair efficiency when combined with PRKDC disruption. TP53BP1 and RIF1 function in the same pathway to suppress microhomology deletions and may serve as a backup to PRKDC in blunt DSB repair. Inhibition of PRKDC kinase activity increases radiosensitivity and promotes homology-directed repair, independent of TP53BP1 status."}], "pathway_id": "mmu03450", "pubmed_id": "41285797", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 7-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-fluorophenyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, CNOT7, XRCC6 (K48-linked ubiquitination at lysine 526), TRIM21 (mediated K48-linked ubiquitination at lysine 526), XRCC5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CNOT7 interacts with XRCC6 to stabilize its protein levels by inhibiting TRIM21-mediated K48-linked ubiquitination at lysine 526. This stabilization enhances non-homologous end joining (NHEJ) mediated DNA double-strand breaks (DSBs) repair. CNOT7 also accelerates TRIM21 mRNA degradation through its deadenylase activity. Reduced CNOT7 expression impairs NHEJ repair and increases apoptosis, thereby promoting radiosensitivity. STL127705, an inhibitor of the XRCC6/XRCC5 heterodimer, suppresses DNA repair efficiency when combined with radiation."}], "pathway_id": "mmu03450", "pubmed_id": "41249119", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LIG4 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "LIG4 is a critical component of the non-homologous end joining (NHEJ) pathway, which repairs DNA double-strand breaks. Transcriptional regulation of LIG4 is essential for maintaining appropriate levels of NHEJ activity, particularly in developing lymphocytes. In these cells, LIG4 expression is controlled by a promoter-proximal intronic regulatory element. Disruption of this regulatory element leads to impaired LIG4 upregulation, defects in lymphocyte development, and altered antigen receptor rearrangement. Proper regulation of LIG4 prevents excessive NHEJ activity, which can be genotoxic."}], "pathway_id": "mmu03450", "pubmed_id": "40913103", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mitomycin C, Cisplatin, Carboplatin, PRKDC, RAD54L (elevated expression), POLQ (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Double strand breaks generated during interstrand crosslink repair are repaired through non-homologous end joining, theta-mediated end joining, and homologous recombination. The absence of PRKDC (DNA-PKcs) correlates with increased homologous recombination activity and resistance to DNA crosslinkers such as mitomycin C and cisplatin. Elevated RAD54L and POLQ expression is associated with enhanced cell survival following cisplatin exposure. In contrast, deficiency in theta-mediated end joining increases sensitivity to cisplatin, particularly in the absence of non-homologous end joining and homologous recombination. These pathways therefore play opposing roles in the repair of replication-associated double strand breaks and determine cellular response to DNA crosslinking agents."}], "pathway_id": "mmu03450", "pubmed_id": "40913914", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Azd-7648 (chemical modulation), Polq (targeted knockdown), Ku, DNA ligase, LIG4, XRCC4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Non-homologous end joining (NHEJ) repairs DNA double-strand breaks by direct ligation of DNA ends without sequence homology, involving the Ku heterodimer, DNA ligase IV (LIG4), and XRCC4. In contrast, microhomology-mediated end joining (MMEJ) utilizes short regions of microhomology to facilitate repair. MMEJ-biased repair pathways generally result in higher gene knock-in efficiency compared to NHEJ-biased pathways. Inhibition of NHEJ through targeted knockdown of Polq or chemical modulation with compounds like AZD7648 can shift repair preference toward MMEJ, thereby increasing the efficiency of gene integration. This mechanism underlies the development of universal and highly efficient knock-in strategies in mouse embryos."}], "pathway_id": "mmu03450", "pubmed_id": "40664653", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HNRNPL, CSTF2, TP53BP1 (recruited), XRCC5 (recruited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The HNRNPL and CSTF2 proteins form a complex that promotes non-homologous end joining (NHEJ) during DNA double-strand break repair at the immunoglobulin heavy chain locus. This complex facilitates the recruitment of TP53BP1 and XRCC5 to the sites of DNA damage, enhancing the efficiency of class switch recombination and locus suicide recombination through enhanced eRNA transcription and RNA polymerase II elongation at the 3' regulatory region."}], "pathway_id": "mmu03450", "pubmed_id": "40902003", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lactate (Glycolysis-derived), LDHA, XLF (lactylated), XRCC6, XRCC5, ATM, GCN5, XRCC4, LIG4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glycolysis-derived lactate promotes lactylation of XLF at lysine 288 within its Ku-binding motif, enhancing its interaction with Ku80. This modification increases XLF recruitment to DNA double-strand breaks and strengthens its binding to the Ku70/80 heterodimer. The lactylated XLF-Ku complex facilitates structural changes in the Ku80 vWA domain, thereby promoting efficient non-homologous end-joining repair. Deficiency in XLF lactylation impairs this repair mechanism and increases cellular sensitivity to chemotherapeutic agents."}], "pathway_id": "mmu03450", "pubmed_id": "40680721", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD84, SLAMF7, PRKDC (expression), LIG4 (expression), XRCC5 (expression), DCLRE1C (expression), AKT1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CD84 promotes the expression of nonhomologous end-joining (NHEJ) core factors, including PRKDC, LIG4, XRCC5, and DCLRE1C, by recruiting SLAMF7 and activating the AKT1 signaling pathway. This upregulation enhances NHEJ repair capacity, reducing DNA double-strand breaks and preventing cell apoptosis. Inhibition of CD84 suppresses NHEJ activity, leading to the accumulation of DNA damage and the induction of apoptosis in acute myeloid leukemia cells."}], "pathway_id": "mmu03450", "pubmed_id": "40633676", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-homologous end-joining - Mus musculus (house mouse)\n**Pathway Description**: Nonhomologous end joining (NHEJ) eliminates DNA double-strand breaks (DSBs) by direct ligation. NHEJ involves binding of the KU heterodimer to double-stranded DNA ends, recruitment of DNA-PKcs (MRX complex in yeast), processing of ends, and recruitment of the DNA ligase IV (LIG4)-XRCC4 complex, which brings about ligation. A recent study shows that bacteria accomplish NHEJ using just two proteins (Ku and DNA ligase), whereas eukaryotes require many factors. NHEJ repairs DSBs at all stages of the cell cycle, bringing about the ligation of two DNA DSBs without the need for sequence homology, and so is error-prone.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Peposertib (administration), TP53, Trp53, DNA-PK (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impairment of the non-homologous end-joining pathway, particularly through inhibition of DNA-PK, increases radiosensitivity in TP53-deficient SHH medulloblastoma cells. This radiosensitization leads to enhanced cell death, demonstrating a synthetic lethal interaction between DNA repair deficiency and DNA damage from radiation. Inhibition of DNA-PK by peposertib enhances the efficacy of radiotherapy in these tumor models."}], "pathway_id": "mmu03450", "pubmed_id": "40562042", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-Butanol, Dexamethasone, HIF1A (activation), GPX4 (enhanced antioxidant capacity), ALP, RUNX2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the HIF-1/GPX4 signaling pathway mitigates ferroptosis in bone marrow mesenchymal stem cells (BMSCs) by enhancing the antioxidant capacity of GPX4. HIF-1 upregulation promotes osteogenic differentiation, proliferation, and migration of BMSCs. Inhibition of HIF-1 abolishes these protective effects, indicating that HIF-1 is a central regulator of the anti-ferroptotic and osteogenic processes. This pathway contributes to the improvement of bone microstructure and the suppression of glucocorticoid-induced bone loss."}], "pathway_id": "mmu04066", "pubmed_id": "41316326", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Kaempferol (administration), HIF1A, PIEZO1, Reactive Oxygen Species (elevated levels), NLRP3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Kaempferol inhibits the Piezo1/HIF-1/ROS/NLRP3 signaling cascade, thereby suppressing glycolytic metabolism and pyroptotic cell death in renal tissues. This pathway modulation contributes to the reduction of renal injury and improvement of renal function in chronic kidney disease."}], "pathway_id": "mmu04066", "pubmed_id": "41248717", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-2-Hydroxyglutaric acid (elevated levels), HIF1A (enhanced expression and activity), Hypoxia-inducible factor 1 subunit alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of L-2-hydroxyglutaric acid promote histone lactylation modification of HIF1A, enhancing its expression and activity. This modification suppresses ferroptosis and increases the resistance of renal cancer cells to oxidative stress. Consequently, this leads to enhanced cell proliferation, migration, and invasion, contributing to tumor progression and metastasis."}], "pathway_id": "mmu04066", "pubmed_id": "41198650", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trichostatin A (administration), HDAC6 (through its deacetylase activity), HIF1A, BNIP3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HDAC6 modulates autophagy by regulating the HIF-1/BNIP3 signaling pathway through its deacetylase activity. This interaction contributes to tumor progression and therapeutic resistance. Inhibition of HDAC6 with Trichostatin A suppresses BNIP3 expression, decreases autophagic activity, and reduces lung tumor formation."}], "pathway_id": "mmu04066", "pubmed_id": "41173051", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Panaxadiol (administration), Dimethyl Sulfoxide, FG 4592, HIF1A (stabilization), STAT3 (activity), CD274 (activity), CCND1 (expression), MYC (expression), VEGFA (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Panaxadiol inhibits the proliferation and immune evasion of esophageal squamous cell carcinoma cells by suppressing HIF-1, STAT3, and PD-L1 activity. HIF-1 stabilization is reduced, leading to decreased expression of downstream targets such as VEGFA and proliferation markers like cyclin D1 and c-Myc. Inhibition of PD-L1 enhances CD8+ T cell-mediated cytotoxicity, thereby reducing tumor viability and promoting anti-tumor immune responses."}], "pathway_id": "mmu04066", "pubmed_id": "41138756", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hepatitis B - Mus musculus (house mouse)\n**Pathway Description**: Hepatitis B virus (HBV) is an enveloped virus and contains a partially double-stranded relaxed circular DNA (RC-DNA) genome. After entry into hepatocytes, HBV RC-DNA is transported to the nucleus and converted into a covalently closed circular molecule cccDNA. The cccDNA is the template for transcription of all viral RNAs including the pregenomic RNA (pgRNA), encoding for 7 viral proteins: large, middle, and small envelope proteins (LHBs, MHBs, and SHBs) that form the surface antigen (HBsAg), the core antigen (HBcAg), the e antigen (HBeAg), the HBV polymerase, and the regulatory protein X (HBx). The pgRNA interacts with the viral polymerase protein to initiate the encapsidation into the core particles. Through endoplasmic reticulum, the core particles finish assembling with the envelope proteins and are released. HBV infection leads to a wide spectrum of liver diseases raging from chronic hepatitis, cirrhosis to hepatocellular carcinoma. The mechanism of liver injury is still not clear. However, HBV proteins target host proteins, involved in a variety of functions, thus regulating transcription, cellular signaling cascades, proliferation, differentiation, and apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rotenone, Mitoquinone cation, Mito-TEMPO, Oligomycin A, superoxide dismutase 2, vacuolar protein sorting 13A, vacuolar ATPase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HBV replication inhibits mitochondrial respiratory chain activity, leading to elevated mitochondrial reactive oxygen species (mtROS) levels. Increased mtROS levels cause lysosomal membrane permeabilization and lysosomal alkalinization, which impairs the lysosomal degradation capacity and promotes HBV replication. This effect is mediated through both mtROS-dependent and mtROS-independent mechanisms, including reduced mitochondrial ATP production and disrupted mitochondria-lysosome contacts. Inhibition of mitochondrial complex I promotes endosomal trafficking of HBV components, facilitating viral secretion. These interactions suggest that mitochondrial function plays a critical role in the regulation of HBV clearance through modulation of lysosomal acidification and autophagy."}], "pathway_id": "mmu05161", "pubmed_id": "41055213", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hepatitis B - Mus musculus (house mouse)\n**Pathway Description**: Hepatitis B virus (HBV) is an enveloped virus and contains a partially double-stranded relaxed circular DNA (RC-DNA) genome. After entry into hepatocytes, HBV RC-DNA is transported to the nucleus and converted into a covalently closed circular molecule cccDNA. The cccDNA is the template for transcription of all viral RNAs including the pregenomic RNA (pgRNA), encoding for 7 viral proteins: large, middle, and small envelope proteins (LHBs, MHBs, and SHBs) that form the surface antigen (HBsAg), the core antigen (HBcAg), the e antigen (HBeAg), the HBV polymerase, and the regulatory protein X (HBx). The pgRNA interacts with the viral polymerase protein to initiate the encapsidation into the core particles. Through endoplasmic reticulum, the core particles finish assembling with the envelope proteins and are released. HBV infection leads to a wide spectrum of liver diseases raging from chronic hepatitis, cirrhosis to hepatocellular carcinoma. The mechanism of liver injury is still not clear. However, HBV proteins target host proteins, involved in a variety of functions, thus regulating transcription, cellular signaling cascades, proliferation, differentiation, and apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PSMB5 (overexpression), Proteasome subunit beta 5 (increased activity), Major Histocompatibility Complex Class I (reduced surface expression), Ubiquitinated proteins (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HBV infection elevates the expression and activity of the proteasome subunit PSMB5 (5), which enhances chymotrypsin-like proteasomal activity. This increased activity correlates with elevated levels of ubiquitinated proteins and reduced surface expression of Major Histocompatibility Complex Class I (MHC I). Persistent PSMB5 overexpression contributes to proteasomal dysregulation, which is associated with the development of hepatocellular carcinoma (HCC)."}], "pathway_id": "mmu05161", "pubmed_id": "41305476", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hepatitis B - Mus musculus (house mouse)\n**Pathway Description**: Hepatitis B virus (HBV) is an enveloped virus and contains a partially double-stranded relaxed circular DNA (RC-DNA) genome. After entry into hepatocytes, HBV RC-DNA is transported to the nucleus and converted into a covalently closed circular molecule cccDNA. The cccDNA is the template for transcription of all viral RNAs including the pregenomic RNA (pgRNA), encoding for 7 viral proteins: large, middle, and small envelope proteins (LHBs, MHBs, and SHBs) that form the surface antigen (HBsAg), the core antigen (HBcAg), the e antigen (HBeAg), the HBV polymerase, and the regulatory protein X (HBx). The pgRNA interacts with the viral polymerase protein to initiate the encapsidation into the core particles. Through endoplasmic reticulum, the core particles finish assembling with the envelope proteins and are released. HBV infection leads to a wide spectrum of liver diseases raging from chronic hepatitis, cirrhosis to hepatocellular carcinoma. The mechanism of liver injury is still not clear. However, HBV proteins target host proteins, involved in a variety of functions, thus regulating transcription, cellular signaling cascades, proliferation, differentiation, and apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), protoporphyrin IX (accumulation), Hemin, ALAS1 (Defects in), ALAD (Defects in), FECH (Defects in), HMBS (Defects in), UROS (Defects in), CPOX (Defects in), PPOX (Defects in), ALAS2, SLC25A38 (reduced activity), Ferrochelatase (reduced activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defects in heme biosynthesis pathway enzymes such as ALAS1, ALAD, FECH, HMBS, UROS, CPOX, and PPOX lead to the accumulation of intermediates like 5-aminolevulinic acid and protoporphyrin IX. These intermediates are toxic and contribute to the pathogenesis of porphyria. Disruption of the pathway results in impaired heme production, which is essential for oxygen transport and electron transfer in mitochondria. Accumulation of PpIX causes photosensitivity and cutaneous symptoms, while 5-ALA accumulation is associated with neurological manifestations. The reduced activity of ferrochelatase and transporters like SLC25A38 further exacerbates heme deficiency and metabolic imbalance."}], "pathway_id": "mmu05161", "pubmed_id": "41297320", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hepatitis B - Mus musculus (house mouse)\n**Pathway Description**: Hepatitis B virus (HBV) is an enveloped virus and contains a partially double-stranded relaxed circular DNA (RC-DNA) genome. After entry into hepatocytes, HBV RC-DNA is transported to the nucleus and converted into a covalently closed circular molecule cccDNA. The cccDNA is the template for transcription of all viral RNAs including the pregenomic RNA (pgRNA), encoding for 7 viral proteins: large, middle, and small envelope proteins (LHBs, MHBs, and SHBs) that form the surface antigen (HBsAg), the core antigen (HBcAg), the e antigen (HBeAg), the HBV polymerase, and the regulatory protein X (HBx). The pgRNA interacts with the viral polymerase protein to initiate the encapsidation into the core particles. Through endoplasmic reticulum, the core particles finish assembling with the envelope proteins and are released. HBV infection leads to a wide spectrum of liver diseases raging from chronic hepatitis, cirrhosis to hepatocellular carcinoma. The mechanism of liver injury is still not clear. However, HBV proteins target host proteins, involved in a variety of functions, thus regulating transcription, cellular signaling cascades, proliferation, differentiation, and apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N6-Methyladenosine, KLF16, IGF2BP2, IGF2BP3, C12orf49 (Upregulated), CD274, SPOP, HBX.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HBX promotes the N6-methyladenosine modification of KLF16 mRNA, which enhances the binding of IGF2BP2 and IGF2BP3, thereby increasing KLF16 mRNA stability. KLF16 upregulates the expression of C12orf49, which competes with SPOP for binding to PD-L1, thereby blocking SPOP-mediated ubiquitination and degradation of PD-L1. This leads to elevated PD-L1 levels, contributing to immune evasion in hepatocellular carcinoma."}], "pathway_id": "mmu05161", "pubmed_id": "41238928", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melanins, Mrs2159, DEAH-box helicase 9 (elevated expression), tribbles pseudokinase 3 (repression), tyrosinase (downregulation), microphthalmia-associated transcription factor (increased expression and activation), tyrosinase-related protein 1 (downregulation), dopachrome tautomerase (downregulation), melanocortin 1 receptor, cAMP response-element binding protein (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of DEAH-box helicase 9 (DHX9) and repression of tribbles pseudokinase 3 (TRIB3) through promoter binding suppress melanin synthesis in melanocytes. This suppression is mediated by the inhibition of tyrosinase activity and downregulation of melanogenic genes including tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT). Melanogenesis is also regulated by the melanocortin 1 receptor (MC1R), which activates cAMP response-element binding protein (CREB), leading to increased expression and activation of microphthalmia-associated transcription factor (MITF), a key regulator of melanin biosynthesis. Additionally, reduced inflammatory mediator production and enhanced phagocytic activity in macrophages contribute to anti-inflammatory effects and pigment-clearance in hyperpigmentation disorders."}], "pathway_id": "mmu04916", "pubmed_id": "41137953", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bortezomib (administration), (E)-1-(3-chloro-4-fluorophenyl)-4-((5-nitrofuran-2-yl)methylene)pyrazolidine-3,5-dione (administration), Caspase-3, Proteasome (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Stimulation of melanogenesis in melanoma cells is associated with reduced sensitivity to proteasome inhibition by bortezomib, as evidenced by diminished proteasome inhibition and attenuated induction of apoptosis. In contrast, inhibition of the ubiquitination process at the E1 enzyme by PYZD-4409 leads to decreased cell viability and increased apoptosis regardless of melanogenesis status. The ubiquitin-proteasome system plays a central role in regulating cellular protein turnover, and its disruption affects cell survival and death pathways."}], "pathway_id": "mmu04916", "pubmed_id": "41067125", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rotenone (administration), N-Acetyl-L-Cysteine (administration), 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (administration), tyrosinase-related protein 1 (TYRP1) (transcriptional expression), tyrosinase (TYR) (transcriptional expression), MITF (protein level), extracellular signal-regulated kinase (ERK) (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rotenone inhibits melanogenesis by suppressing the transcriptional expression of tyrosinase-related protein 1 (TYRP1) and tyrosinase (TYR). This effect is primarily mediated through a reduction in the protein level of microphthalmia-associated transcription factor (MITF). Rotenone induces mitochondrial reactive oxygen species (ROS) production, which activates extracellular signal-regulated kinase (ERK). ERK activation contributes to MITF degradation, thereby reducing melanin synthesis. Inhibition of ROS production or ERK activity prevents MITF degradation and restores melanin synthesis."}], "pathway_id": "mmu04916", "pubmed_id": "41061299", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pentamethylquercetin (administration), TYR (increased expression), TRP1 (increased expression), TPC2 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "3,5,7,3',4'-pentamethoxyflavone inhibits two-pore channel 2 (TPC2), which results in increased expression and activity of tyrosinase (TYR) and tyrosinase-related protein 1 (TRP1), thereby stimulating melanin synthesis."}], "pathway_id": "mmu04916", "pubmed_id": "41254057", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Tyrosine, Levodopa, (alphaS)-alpha-Amino-3,4-dioxo-1,5-cyclohexadiene-1-propanoic acid, TYR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TYR catalyzes the oxidation of L-tyrosine to L-3,4-dihydroxyphenylalanine and subsequently to dopaquinone, which are essential steps in melanin synthesis. Inhibition of TYR activity reduces melanogenesis, thereby decreasing melanin production and the risk of hyperpigmentation caused by UVB radiation exposure."}], "pathway_id": "mmu04916", "pubmed_id": "40806718", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trans-2,3',4,5'-tetrahydroxystilbene, Resveratrol, Melanocortin 1 Receptor (expression), Cyclic Adenosine Monophosphate (expression), Microphthalmia-Associated Transcription Factor (expression), Tyrosinase (expression), Tyrosinase-Related Protein 1 (expression), Dopachrome Tautomerase (expression), Cell Division Cycle 42 (expression), Ras-Related Protein Rab-17 (expression), Ras-Related Protein Rab-11B (expression), Ras-Related C3 Botulinum Toxin Substrate 1 (expression), Kinesin Family Member 5B (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxyresveratrol inhibits melanogenesis by down-regulating the MC1R/cAMP/MITF signaling pathway, reducing the expression of tyrosinase, tyrosinase-related protein 1, and dopachrome tautomerase. It also suppresses dendrite formation and melanosome transport by down-regulating the expression of small GTPases (CDC42, RAB17, RAB11B, RAC1) and the kinesin KIF5B, thereby impairing melanin transfer to keratinocytes."}], "pathway_id": "mmu04916", "pubmed_id": "40594379", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Resveratrol (administration), Dihydroresveratrol (administration), Microphthalmia-Associated Transcription Factor (levels), cAMP Response Element-Binding Protein (phosphorylation), Tyrosinase (levels), Tyrosinase-Related Protein, Phosphorylated cAMP Response Element-Binding Protein (levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Resveratrol and dihydroresveratrol inhibit melanogenesis by suppressing the expression and phosphorylation of CREB and reducing the levels of MITF and TYR. These compounds also exhibit antioxidant activity by scavenging free radicals. Dihydroresveratrol demonstrates greater affinity for CREB compared to resveratrol, leading to a more pronounced reduction in p-CREB and TYR protein levels. This results in decreased melanin synthesis and tyrosinase activity, suggesting a potential role in skin depigmentation and protection."}], "pathway_id": "mmu04916", "pubmed_id": "40507810", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epigallocatechin Gallate (administration), Glabridin (administration), MITF (downregulation), microRNA (modulated by MITF downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Epigallocatechin-3-gallate and Glabridin synergistically interact with the microphthalmia-related transcription factor (MITF), leading to its downregulation. This interaction modulates microRNA expression, resulting in the inhibition of melanogenesis and reduction of excessive melanin deposition."}], "pathway_id": "mmu04916", "pubmed_id": "40407219", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Melanogenesis - Mus musculus (house mouse)\n**Pathway Description**: Cutaneous melanin pigment plays a critical role in camouflage, mimicry, social communication, and protection against harmful effects of solar radiation. Melanogenesis is under complex regulatory control by multiple agents. The most important positive regulator of melanogenesis is the MC1 receptor with its ligands melanocortic peptides. MC1R activates the cyclic AMP (cAMP) response-element binding protein (CREB). Increased expression of MITF and its activation by phosphorylation (P) stimulate the transcription of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT), which produce melanin. Melanin synthesis takes place within specialized intracellular organelles named melanosomes. Melanin-containing melanosomes then move from the perinuclear region to the dendrite tips and are transferred to keratinocytes by a still not well-characterized mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+-)-3-Phenyllactic acid, Lactic Acid (administration), L-Pyroglutamic Acid (administration), Malic Acid (administration), tyrosinase (activity), tyrosinase-related protein 1 (activity), tyrosinase-related protein 2 (activity), Pmel (expression), Slc45a2 (expression), Ctns (expression), Oca2 (expression), Bace2 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "3-phenyllactic acid, lactic acid, L-pyroglutamic acid, and malic acid inhibit tyrosinase activity through mixed- or competitive-type mechanisms. These compounds reduce melanin production by suppressing key enzymes in melanogenesis, including tyrosinase, tyrosinase-related protein 1, and tyrosinase-related protein 2. In addition, they modulate the expression of genes involved in melanogenesis and metabolism, such as Pmel, Slc45a2, Ctns, Oca2, and Bace2. The acidification effects of certain carboxylic acids further contribute to reduced tyrosinase activity. These compounds also inhibit DOPA auto-oxidation, a key step in melanin formation, suggesting multiple mechanisms of action in melanin regulation."}], "pathway_id": "mmu04916", "pubmed_id": "40286213", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Piezo1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Piezo1 balances membrane and cortex tension to stabilize intercellular junctions. Disruption of Piezo1 function leads to an imbalance in cell contractility and membrane tension, which delays the maturation of cell-cell adhesions. This delay impairs the formation of functional tight junctions and compromises the integrity of the epithelial barrier."}], "pathway_id": "mmu04520", "pubmed_id": "40741726", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ctnna1 (undergoes conformational change), Actb, Vinc, Cdh1, Ctnnb1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During adherens junction maturation, -catenin undergoes a conformational change in its actin-binding domain. This structural transition correlates with the degree of junctional maturation and requires actin polymerization. The conformational state influences -catenin mobility and turnover, particularly increasing in mature junctions. This transition contributes to the formation of mechanically stable yet dynamic cell-cell adhesions, which are essential for epidermal differentiation and tissue integrity."}], "pathway_id": "mmu04520", "pubmed_id": "40890526", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRB3, NF2, RHOA, ROCK2, MYH9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CRB3 interacts with the actin cytoskeletal linker protein Merlin (NF2) to regulate perijunctional actomyosin contractility and the organization of the apical junctional complex (AJC). This interaction modulates cell-cell adhesion and intestinal barrier function by controlling RhoA activity and junctional tension. Disruption of CRB3 or NF2 leads to increased actomyosin contractility, impaired AJC assembly, and heightened intestinal permeability. These effects are mediated through RHOA and ROCK2 signaling pathways, which influence cytoskeletal dynamics and junctional architecture during both de novo junction formation and inflammation-induced remodeling."}], "pathway_id": "mmu04520", "pubmed_id": "41122968", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEPT9 (localizes to apical junctions), MYH9 (recruited to perijunctional actomyosin belt).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEPT9 localizes to apical junctions in intestinal epithelial cells, where it supports the assembly of tight and adherens junctions by recruiting nonmuscle myosin IIC (MYH9) to the perijunctional actomyosin belt. This interaction is essential for maintaining intestinal epithelial barrier integrity. Loss of SEPT9 leads to mislocalization of junctional proteins and disruption of the actomyosin belt, resulting in leaky gut and increased susceptibility to intestinal inflammation. Reduced SEPT9 expression is associated with impaired barrier function in inflammatory bowel disease."}], "pathway_id": "mmu04520", "pubmed_id": "41055961", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CDH5 (phosphorylated), FYN.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of VE-cadherin (CDH5) at adherens junctions by FYN increases junctional permeability, thereby modulating aqueous humor outflow and intraocular pressure regulation."}], "pathway_id": "mmu04520", "pubmed_id": "39746990", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation (elevated levels), CTNNB1 (reduced expression), CDH1 (reduced expression), TJP1 (reduced expression), OCLN (reduced expression), CACNA1G, RHOA (activated), ROCK1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated cytoplasmic calcium ion levels disrupt respiratory epithelial barrier integrity by inducing endoplasmic reticulum stress and activating the RHOA/ROCK1 signaling pathway, which promotes cytoskeletal rearrangement. This leads to reduced expression of tight junction proteins (ZO-1, occludin) and adherens junction components (CTNNB1, CDH1). The T-type voltage-gated calcium channel CACNA1G facilitates calcium influx, contributing to this barrier disruption. Disruption of these junctional complexes impairs cell-cell adhesion and increases epithelial permeability."}], "pathway_id": "mmu04520", "pubmed_id": "39950866", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: AFDN (loss), CDH1, Actin-Myosin complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Afadin loss disrupts the maturation of adherens junctions by impairing the mechanical linkage between E-cadherin and F-actin. This destabilization leads to reduced cell-cell adhesion, increased anoikis resistance, and promotes a noncohesive cellular phenotype. These changes facilitate single-cell invasion and metastasis, particularly in breast cancer, through the loss of epithelial architecture and actin cytoskeleton organization."}], "pathway_id": "mmu04520", "pubmed_id": "40026293", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fibronectin Leucine Rich Transmembrane protein 2, Vascular Endothelial Cadherin, Numb.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FLRT2 interacts with VE-cadherin and together with the endocytic adaptor protein Numb modulates adherens junction morphology in endothelial cells. This interaction influences endothelial cell proliferation, sprouting, and polarity, and contributes to the development of the blood-brain barrier by regulating crosstalk between adherens and tight junctions."}], "pathway_id": "mmu04520", "pubmed_id": "39609404", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neuropilin-1 (expression level variation on perivascular cells by tissue), Vascular endothelial growth factor receptor 2, Vascular endothelial cadherin (suppressed phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuropilin-1 modulates vascular endothelial growth factor receptor 2 signaling by presenting vascular endothelial growth factor A to VEGFR2. This interaction influences the phosphorylation state of vascular endothelial cadherin, a key component of adherens junctions in endothelial cells. Increased phosphorylation of VE-cadherin correlates with enhanced vascular permeability, whereas suppressed phosphorylation reduces vascular leakage. The expression level of Neuropilin-1 on perivascular cells varies by tissue, affecting the local regulation of VEGFA/VEGFR2 signaling and endothelial cell adhesion dynamics."}], "pathway_id": "mmu04520", "pubmed_id": "39668325", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Mus musculus (house mouse)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gsk 10116790A, GI254023X, TRPV4 (activation), E-cadherin, ADAM10.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRPV4 channel activation induces calcium influx, which stimulates ADAM10-mediated cleavage of E-cadherin, resulting in the formation of a ~35 kDa C-terminal fragment and a reduction in alveolar epithelial barrier integrity. This process is associated with adherens junction disruption and is inhibited by TRPV4 deficiency or ADAM10 antagonism."}], "pathway_id": "mmu04520", "pubmed_id": "39451235", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nicotinamide Adenine Dinucleotide Phosphate, Cyclin-dependent kinase inhibitor 2A, Tumor protein p53, Glucose-6-phosphate dehydrogenase (increased expression), Nuclear factor erythroid 2-related factor 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the first step of the pentose phosphate pathway, generating NADPH and ribulose-5-phosphate. In CDKN2A-deleted malignant peripheral nerve sheath tumors (MPNSTs), increased dependency on the pentose phosphate pathway and NADPH metabolism supports tumor growth and viability. The redox-regulated transcription factor NRF2 regulates G6PD transcription, and its downregulation reduces G6PD expression and MPNST proliferation. This NRF2-G6PD axis represents a metabolic vulnerability in these tumors."}], "pathway_id": "mmu00030", "pubmed_id": "40802750", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nicotinamide Adenine Dinucleotide Phosphate (increased production), G6PD (elevated expression and activity), PGD (elevated expression and activity), TALDO1 (restoration of activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression and activity of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (PGD) enhance the oxidative phase of the pentose phosphate pathway, leading to increased production of nicotinamide adenine dinucleotide phosphate (NADPH). This increase in NADPH supports the Nrf2 pathway, which promotes antioxidant defense mechanisms and reduces oxidative stress. Concurrently, restoration of transaldolase 1 (TALDO1) activity contributes to the non-oxidative phase, facilitating the interconversion of phosphorylated sugars. These metabolic changes collectively improve cellular redox homeostasis and mitigate inflammatory and neurodegenerative processes associated with experimental autoimmune encephalomyelitis."}], "pathway_id": "mmu00030", "pubmed_id": "41232381", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ovatodiolide (administration), Phosphoribosyl Pyrophosphate, Glucose-6-phosphate dehydrogenase (dimer formation and enzymatic activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ovatodiolide binds to the lysine 403 residue of Glucose-6-phosphate dehydrogenase, promoting its acetylation and inhibiting dimer formation and enzymatic activity. This modulation suppresses the overactivation of the pentose phosphate pathway, thereby attenuating renal fibrosis. The partial inhibition of G6PD activity preserves basal levels of the pathway necessary for cellular survival and physiological function."}], "pathway_id": "mmu00030", "pubmed_id": "40578038", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucose 6-phosphate, Nicotinamide Adenine Dinucleotide Phosphate (production), Hydrogen Peroxide (elevated levels), D-glucopyranose 1-phosphate, G6PD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucose 1-phosphate allosterically induces G6PD to bind glycogen, leading to liquid-liquid phase separation and recruitment of pentose phosphate pathway enzymes. This compartmentalizes the reaction cascade, directing glucose 6-phosphate toward NADPH production, which reduces hydrogen peroxide and maintains redox homeostasis."}], "pathway_id": "mmu00030", "pubmed_id": "40499549", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphoribosyl Pyrophosphate (increased synthesis), phosphoribosyl pyrophosphate synthetase, phosphoribosyl pyrophosphate synthetase 2 (genetic inactivation), phosphoribosyl pyrophosphate synthetase 1, MYC proto-oncogene, bHLH transcription factor, nicotinamide adenine dinucleotide phosphate (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Myc overexpression stimulates the oxidative pentose phosphate pathway, leading to increased phosphoribosyl pyrophosphate synthesis and elevated NADPH levels. Hyperactivation of phosphoribosyl pyrophosphate synthetase, particularly the PRPS2 isozyme, modulates redox status in lymphoma cells. Genetic inactivation of PRPS2 results in reductive stress and cell death, whereas PRPS1 activity is associated with resistance to thioredoxin and glutathione network-targeting chemotherapeutics."}], "pathway_id": "mmu00030", "pubmed_id": "40446642", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Mus musculus (house mouse)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N4-Acetylcytidine (increased level), NAT10 (elevated levels), YAP1, G6PD (increased activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of NAT10, induced by YAP1 through promoter binding, increase N4-acetylcytidine modification in the 3' UTR of G6PD, enhancing its mRNA stability. This stabilization leads to increased G6PD activity, which activates the pentose phosphate pathway, thereby promoting tumor proliferation and metastasis."}], "pathway_id": "mmu00030", "pubmed_id": "40303290", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Deoxycholic Acid (administration), Farnesoid X receptor (expression), NLR family pyrin domain containing 3 (activity), Interleukin 17A (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deoxycholic acid suppresses farnesoid X receptor expression, which inhibits the NLRP3IL17A signaling axis, thereby promoting Th17 cell differentiation and contributing to inflammatory cell infiltration."}], "pathway_id": "mmu04659", "pubmed_id": "41305918", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GC-1008, CD3 and CD28, Regulatory T cell, T helper 2 cell, T helper 17 cell, CD4 positive T cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Transforming growth factor beta (TGF) promotes regulatory T cell (Treg) differentiation from nave CD4 positive T cells. This differentiation is associated with the suppression of T helper 2 (Th2) and T helper 17 (Th17) cell populations. The increase in Tregs and the reduction in Th2 and Th17 cells contribute to the formation of an anti-inflammatory microenvironment. This process modulates immune responses and supports skin barrier restoration."}], "pathway_id": "mmu04659", "pubmed_id": "41174821", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Aspirin, TNF receptor-associated factor 6 (increased expression), signal transducer and activator of transcription 3, interleukin-17-producing CD4+ T helper cells (elevated levels), ubiquitin-conjugating enzyme E2 N.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of interleukin-17-producing CD4+ T helper cells (Th17) contribute to inflammation through the activation of signal transducer and activator of transcription 3 (STAT3). TNF receptor-associated factor 6 (TRAF6) facilitates ubiquitination of STAT3, promoting its degradation. Ubiquitin-conjugating enzyme E2 N (UBE2N) interacts with TRAF6 to modulate this ubiquitination process. Increased TRAF6 expression leads to reduced STAT3 levels and inhibition of Th17 cell differentiation, thereby attenuating inflammatory responses."}], "pathway_id": "mmu04659", "pubmed_id": "41320749", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Andrographin, Skullcapflavone I, Wogonin, Luteolin, signal transducer and activator of transcription 3, interleukin 17A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of signal transducer and activator of transcription 3 (STAT3) activity suppresses Th17 cell differentiation, reducing interleukin 17A (IL-17A) production. This attenuation of the Th17 response contributes to the amelioration of inflammation and the progression of ulcerative colitis."}], "pathway_id": "mmu04659", "pubmed_id": "41101067", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vs-4718, Fak (inhibited genetically or pharmacologically with PND1186), RelA (nuclear translocated), Il17a (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Focal adhesion kinase (FAK) promotes Th17 cell differentiation by stimulating NF-B signaling. FAK facilitates the nuclear translocation of the NF-B subunit RelA, which binds to the promoter region of the Il17a gene, thereby inducing IL-17A expression. Inhibition of FAK, either genetically or pharmacologically with PND1186, reduces NF-B activity and subsequently suppresses Th17 differentiation."}], "pathway_id": "mmu04659", "pubmed_id": "41050684", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prostaglandin E2, PTGER2, PTGER4, cyclic AMP (activation), protein kinase A (activation), forkhead box P3 (expression), CD25 (expression), CTLA-4 (expression), TNFRSF9 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prostaglandin E2 binds to EP2 and EP4 receptors on regulatory T cells (Tregs), activating the cAMP-PKA signaling pathway. This activation induces the expression of Treg signature genes, including FOXP3, CD25, CTLA-4, and 4-1BB, promoting the tumor-infiltrating Treg (TI-Treg) phenotype. TI-Tregs exhibit enhanced suppressive activity against CD8+ T cells, thereby inhibiting antitumor immunity and supporting tumor growth."}], "pathway_id": "mmu04024", "pubmed_id": "41343674", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bicarbonate Ion (administration), Camp, Fer tyrosine kinase (phosphorylation), Epidermal growth factor receptor, Protein kinase A, Src tyrosine kinase (phosphorylated), Catsper channel.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bicarbonate activates the soluble adenylyl cyclase (SAC) to generate cyclic adenosine monophosphate (cAMP), which activates protein kinase A (PKA). PKA phosphorylates and activates Src tyrosine kinase, which in turn activates the Fer tyrosine kinase. Fer tyrosine kinase then mediates the activation of the epidermal growth factor receptor (EGFR), contributing to the regulation of sperm capacitation. This signaling cascade is modulated by intracellular calcium influx through the Catsper channel, with calcium levels inversely affecting Fer phosphorylation and activation."}], "pathway_id": "mmu04024", "pubmed_id": "41303701", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tanshinone Iia, Camp (elevated levels), protein kinase A, cAMP response element-binding protein (phosphorylated), brain-derived neurotrophic factor (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cyclic adenosine monophosphate activate protein kinase A, which in turn phosphorylates cAMP response element-binding protein. Phosphorylated CREB promotes the transcription of brain-derived neurotrophic factor. Increased BDNF supports neural stem cell proliferation, differentiation, and survival, thereby enhancing hippocampal neurogenesis."}], "pathway_id": "mmu04024", "pubmed_id": "41273473", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp (reduced levels), Cgmp (decreased levels), phosphodiesterase 3A (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Luteinizing hormone (LH) triggers cyclic adenosine monophosphate (cAMP) production in granulosa cells, which diffuses rapidly through gap junctions into the oocyte. In the oocyte, a decrease in cyclic guanosine monophosphate (cGMP) relieves inhibition of phosphodiesterase 3A (PDE3A), promoting cAMP degradation. Subsequent closure of gap junctions between granulosa cells prevents further cAMP influx into the oocyte, reducing its cAMP levels below baseline and reinitiating meiotic progression."}], "pathway_id": "mmu04024", "pubmed_id": "41329740", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dipyridamole (administration), Phosphodiesterase 12, Cyclic adenosine monophosphate (elevated levels), CAMP response element-binding protein (phosphorylated), Receptor-interacting serine-threonine kinase 3, Mixed lineage kinase domain-like protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dipyridamole inhibits phosphodiesterase 12 (PDE12), leading to increased levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP activates cAMP response element-binding protein (CREB) through phosphorylation, which suppresses pro-inflammatory signaling and attenuates necroptosis by inhibiting receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like protein (MLKL). This mechanism reduces inflammation and necroptosis in the renal tubules, thereby preserving renal function and histological integrity."}], "pathway_id": "mmu04024", "pubmed_id": "41242596", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tetrodotoxin, Secretin receptor, Inositol 1,4,5-trisphosphate receptor (modulated), Protein kinase A (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Secretin binds to its receptor, Secretin receptor, expressed on interstitial cells of Cajal (ICC) in the deep muscular plexus (ICC-DMP), leading to Gs-coupled cAMP production. This activates Protein kinase A (PKA), which subsequently inhibits Ca2+ transients in ICC-DMP by modulating Inositol 1,4,5-trisphosphate receptors. This inhibition suppresses excitatory enteric neurotransmission and reduces intestinal motility, suggesting that ICC-DMP function as integration hubs for hormonal and neural signaling in the regulation of intestinal transit."}], "pathway_id": "mmu04024", "pubmed_id": "41198902", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenosine A2A receptor (ADORA2A), cAMP response element-binding protein 1 (CREB1) (Facilitated), runt-related transcription factor 2 (RUNX2) (Enhanced).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ADORA2A promotes vascular smooth muscle cell osteogenic differentiation by facilitating CREB1 binding to the RUNX2 promoter, thereby enhancing RUNX2 transcription and subsequent mineralization."}], "pathway_id": "mmu04024", "pubmed_id": "41201506", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (-)-Sweroside (administration), Cystic Fibrosis Transmembrane Conductance Regulator.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sweroside binds to the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, which facilitates the activation of the cAMP signaling pathway. This pathway upregulates key proteins involved in second messenger signaling, contributing to the modulation of reproductive processes and the alleviation of recurrent pregnancy loss."}], "pathway_id": "mmu04024", "pubmed_id": "41197342", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ins(1,4,5)P3, Adenylyl cyclase (Inhibited), Protein kinase A (Inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Adenylyl cyclase activates the cAMP signaling cascade by catalyzing the conversion of ATP to cAMP. Protein kinase A is activated by cAMP and modulates cellular processes through phosphorylation. Inhibition of adenylyl cyclase or protein kinase A reduces intracellular calcium release and subsequent skeletal muscle contraction. Inositol 1,4,5-trisphosphate (IP3) mediates calcium signaling, which leads to localized myotube contraction."}], "pathway_id": "mmu04024", "pubmed_id": "41193387", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CCL2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CCL2 contributes to the progression of liver fibrosis by promoting neutrophil infiltration and extracellular trap formation. Elevated neutrophil infiltration is associated with increased accumulation of neutrophil extracellular traps (NETs), which drive chronic inflammation and tissue remodeling characteristic of fibrotic disease."}], "pathway_id": "mmu04613", "pubmed_id": "41057887", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIGLEC9 (activation), C3 (activation), H2AC14 (activation), H4C11 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neutrophil extracellular trap (NET) formation contributes to the progression of pulpitis through the activation of sialic acid-binding immunoglobulin-like lectin-9 (SIGLEC9), complement C3 (C3), H2A clustered histone 14 (H2AC14), and H4 clustered histone 11 (H4C11). These proteins are involved in the regulation of NETosis, a process in which neutrophils release extracellular chromatin structures that trap and kill pathogens. Excessive NET formation leads to tissue damage and necrosis in dental pulp. The regulation of these genes occurs, in part, through a ceRNA network involving long non-coding RNAs and circular RNAs that modulate the expression of their target mRNAs."}], "pathway_id": "mmu04613", "pubmed_id": "40902508", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ENO1, MPO, IFITM2, RAP1B, ERK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neutrophil extracellular traps (NETs) mediate Treg differentiation during sepsis by anchoring enolase 1 (ENO1) to the membrane of CD4+ T cells through myeloperoxidase (MPO). ENO1 recruits interferon-induced transmembrane protein 2 (IFITM2), which functions as a DNA receptor sensing NET-derived DNA. This interaction activates RAS-associated protein 1B (RAP1B) and its downstream extracellular signal-regulated kinase (ERK) signaling pathway, leading to enhanced Treg differentiation and function, thereby contributing to immunosuppression."}], "pathway_id": "mmu04613", "pubmed_id": "40892462", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pevonedistat, NEDD8 (neddylation), TRIM56, STING1 (K63-linked ubiquitination), NFKB1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neutrophil extracellular traps (NETs) promote the binding of NEDD8 to the ubiquitin ligase TRIM56, leading to K63-linked ubiquitination of STING1 and subsequent activation of the NF-kB signaling pathway. This process drives neuroinflammation and neuronal apoptosis. Inhibition of neddylation with MLN4924 prevents this interaction, reducing neuronal death and preserving blood-brain barrier integrity."}], "pathway_id": "mmu04613", "pubmed_id": "40756356", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenosine (administration), ELANE, MPO, TNF, ITGB2, ITGAM.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Adenosine reduces markers of neutrophil extracellular trap (NET) formation, including ELANE and MPO, while downregulating pro-inflammatory mediators TNF, ITGB2, and ITGAM. This leads to a reduction in systemic inflammation and adipose tissue lipid accumulation, thereby ameliorating postmenopausal obesity. The suppression of NETosis contributes to a lessened inflammatory microenvironment in adipose tissue, which is associated with improved metabolic outcomes."}], "pathway_id": "mmu04613", "pubmed_id": "40634416", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Mus musculus (house mouse)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Itaconic acid, Acod1, UBR5 (alkylation modified), PAD4 (reduced activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acod1 enhances the enzymatic activity of UBR5 through alkylation modification, which promotes K48-linked polyubiquitination and subsequent degradation of PAD4. This process inhibits NETosis. Reduced PAD4 activity decreases the formation of neutrophil extracellular traps (NETs), which are implicated in the pathogenesis of sepsis and associated with increased inflammation and organ damage."}], "pathway_id": "mmu04613", "pubmed_id": "40586264", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lipid and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Atherosclerosis is a chronic inflammatory disease marked by a narrowing of the arteries from lipid-rich plaques present within the walls of arterial blood vessels. It represents the root cause of the majority of cardiovascular diseases (CVDs) and their complications, including conditions such as coronary artery disease, myocardial infarction and stroke.  An elevated level of low density lipoprotein (LDL) cholesterol constitutes a major risk factor for genesis of atherosclerosis. LDL can accumulate within the blood vessel wall and undergo modification by oxidation. Oxidized LDL (oxLDL) leads to endothelial dysfunction leading to expression of adhesion molecules and recruitment of monocyte in subendothelial space. The monocytes proliferate, differentiate into macrophages, and take up the lipoproteins, forming cholesterol-engorged \"foam cells.\" With the time, the foam cells die, leaving a 'necrotic core' of crystalline cholesterol and cell debris. Smooth muscle cells proliferate and migrate into the region, laying down a protective cap over the lesion. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which mediates the recognition and internalization of oxLDL, is involved in all of these events critical in the pathogenesis of atherosclerosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Arachidonic Acid (incorporation), Eicosapentaenoic Acid (administered), Doconexent, Eicosanoids (production), lysophosphatidylcholine acyltransferase 3 (inhibited), tumor necrosis factor receptor 1 (ubiquitinated), nuclear factor kappa B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lysophosphatidylcholine acyltransferase 3 (LPCAT3) catalyzes the incorporation of arachidonic acid into phospholipids, promoting the formation of lipid rafts. These lipid rafts are essential for the translocation and ubiquitination of the tumor necrosis factor receptor 1 (TNFR1) signaling complex, leading to nuclear factor kappa B (NF-B) activation. NF-B activation drives the expression of proinflammatory cytokines and cell adhesion molecules, contributing to vascular inflammation and endothelial dysfunction. Arachidonic acid-derived eicosanoids further amplify these inflammatory responses and promote atherogenesis. Inhibition of LPCAT3 reduces arachidonic acid incorporation, decreases eicosanoid production, and attenuates lipid raft-mediated signaling, thereby reducing plaque formation and vascular inflammation. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can replace arachidonic acid in phospholipids, further reducing proinflammatory signaling and disease progression."}], "pathway_id": "mmu05417", "pubmed_id": "41236634", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Graft-versus-host disease - Mus musculus (house mouse)\n**Pathway Description**: Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD8, T cell, B cell, T follicular helper cell, CD4 T cell, natural killer cell, cytotoxic T lymphocyte.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "In graft-versus-host disease, donor T cells recognize host antigens and mediate immune responses. Acute GVHD is characterized by a Th1 response and significant B cell depletion, with males exhibiting a more potent cytotoxic T lymphocyte response. Chronic GVHD involves T follicular helper cell activity, leading to increased B cell and autoantibody production, with females showing a more pronounced response. These sex-based differences influence splenic cellular composition and immune activation, contributing to distinct immunological outcomes."}], "pathway_id": "mmu05332", "pubmed_id": "40972650", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Graft-versus-host disease - Mus musculus (house mouse)\n**Pathway Description**: Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CD8, HLA-DR, CD27, TCF7, FOXP3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CD8+ HLA-DR+ CD27+ T cells function as regulatory precursor cells by suppressing T cell expansion and promoting immune regulation. These cells induce FOXP3 expression in both CD4 regulatory T cells and themselves, thereby enhancing immune tolerance. Their activity reduces T cell activation and alleviates graft-versus-host disease pathology while preserving antileukemia activity. The expansion of these regulatory precursors correlates with the restoration of immune homeostasis following allogeneic stem cell transplantation."}], "pathway_id": "mmu05332", "pubmed_id": "40929249", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Graft-versus-host disease - Mus musculus (house mouse)\n**Pathway Description**: Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (3R,9S)-7,7-dimethyl-4-propan-2-yl-3-[4-(trifluoromethyl)phenyl]spiro[3,6,8,9-tetrahydrofuro[3,4-c]quinoline-1,4'-oxane]-9-ol (administration), 5-Aminolevulinic Acid, Rimonabant (administration), Cannabinoid receptor 1, regulatory T cells (increased frequency), T cells, pan T cells, major histocompatibility complex class I, major histocompatibility complex class II, CD80 antigen.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BI-5756, a cannabinoid receptor 1 (CB1) agonist, increases the frequency of regulatory T cells (Tregs) in primary murine T cells following activation. This effect is mediated through CB1 receptor signaling, as the immunomodulatory activity of BI-5756 is blocked by rimonabant, a selective CB1 antagonist. The upregulation of Tregs by BI-5756 leads to reduced graft-versus-host disease (GvHD) severity in vivo, associated with improved survival, enhanced platelet recovery, and bone marrow reconstitution of B and T cells. Additionally, BI-5756 suppresses tumor cell growth and enhances T cell-mediated anti-tumor responses by upregulating MHC I, MHC II, and CD80 on tumor cells."}], "pathway_id": "mmu05332", "pubmed_id": "40942043", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Graft-versus-host disease - Mus musculus (house mouse)\n**Pathway Description**: Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically disparate host cells. GVHD pathophysiology can be summerized in a three-step process. Step 1 involves the development of an inflammatory milieu resulting from damage in the host tissues induced by the preparative chemotherapy or radiotherapy regimen. Damaged tissues secrete inflammatory cytokines, including interleukin 1 (IL-1), and tumor necrosis factor (TNF-alpha ). During step 2, antigen-presenting cells (APCs) trigger the activation of donor-derived T cells, which induce further T-cell expansion, induce cytotoxic T lymphocytes (CTL) and natural killer (NK) cells responses and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. Also, nitric oxide (NO) is produced by activated macrophages, and it may contribute to the tissue damage seen during step 3. During step 3, the effector phase, activated CTL and NK cells mediate cytotoxicity against target host cells through Fas-Fas ligand interactions and perforin-granzyme B.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Semaglutide (administration), Glucagon-like peptide 1 receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Allogeneic T cells homing to the gut express a functional Glucagon-like peptide 1 receptor (GLP-1R), as evidenced by the induction of Glp1r mRNA transcripts in the ileum. However, activation of GLP-1R signaling through semaglutide does not reduce the severity of systemic or intestinal inflammation, nor does it attenuate gut injury in the context of acute graft-versus-host disease. This indicates that GLP-1R signaling does not significantly modulate the inflammatory processes or tissue damage associated with this condition."}], "pathway_id": "mmu05332", "pubmed_id": "40846075", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sorafenib (administration), STOML2, Prohibitin, RAF1, Mitogen-activated protein kinase kinase, Extracellular signal-regulated kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "STOML2 interacts with Prohibitin (PHB) to activate the RAF1/MEK/ERK signaling pathway, which promotes cell proliferation, invasion, and migration while inhibiting apoptosis. This pathway also influences autophagy and contributes to tumor progression. Sorafenib, a RAF1 inhibitor, suppresses this signaling cascade, reducing cell migration and autophagy-related protein expression."}], "pathway_id": "mmu04010", "pubmed_id": "41347828", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Liquiritin (administration), Peroxisome Proliferator-Activated Receptor Gamma (activation), Receptor Activator of Nuclear Factor Kappa-B Ligand (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Liquiritin inhibits osteoclastogenesis and bone resorption by suppressing the activity of the MAPK/NF-B signaling pathway. It also induces apoptosis in osteoclasts through the activation of PPAR, leading to the downregulation of osteoclast-specific genes and the mitigation of bone loss."}], "pathway_id": "mmu04010", "pubmed_id": "41308395", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenosine, Inosine, ADAR1, MMP9 (increased expression), MAPK1 (phosphorylated), FOS (activated), CDH2 (increased expression), VIM (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ADAR1 promotes proliferation, migration, and invasion of non-small cell lung cancer cells via the MAPK/ERK pathway. ADAR1 upregulates the phosphorylation of ERK, which in turn activates the transcription factor c-FOS. This cascade leads to increased expression of matrix metalloproteinase 9 (MMP9), a protease involved in extracellular matrix remodeling and cancer cell motility. ADAR1 also modulates cell adhesion and induces an epithelial-mesenchymal transition-like phenotype, as evidenced by the upregulation of N-cadherin and vimentin. These molecular changes collectively enhance tumorigenic and metastatic potential."}], "pathway_id": "mmu04010", "pubmed_id": "41309247", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ergosterol (administration), Nuclear factor kappa B (activation), Mitogen-activated protein kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ergosterol inhibits the nuclear factor kappa B (NF-B) pathway, which mediates inflammation, and the mitogen-activated protein kinase (MAPK) pathway, which regulates collagen degradation. This dual inhibition reduces oxidative stress and inflammatory responses, preserving extracellular matrix integrity and epidermal function."}], "pathway_id": "mmu04010", "pubmed_id": "41295413", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Agrimonolide (administration), Interleukin-1 beta (expression), Interleukin-6 (expression), Tumor necrosis factor alpha (expression), Nuclear factor kappa B, Toll-like receptor 4, Ionized calcium-binding adapter molecule 1 (levels), Glial fibrillary acidic protein (levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Agrimonolide suppresses neuroinflammatory responses by inhibiting microglial and astrocytic activation. It reduces the expression of proinflammatory cytokines IL-1, IL-6, and TNF. Agrimonolide inhibits the activation of the NF-B and MAPK signaling pathways, as well as the TLR4-mediated signaling pathway. This inhibition leads to decreased glial activation, as indicated by reduced levels of IBA-1 and GFAP, contributing to the attenuation of neuroinflammatory processes."}], "pathway_id": "mmu04010", "pubmed_id": "41275992", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRKCG, PRKCG G118D, RGS8 (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of RGS8 in cerebellar Purkinje cells correlates with the non-manifesting phenotype observed in mice carrying the PRKCG G118D mutation. This increase in RGS8 may represent a compensatory mechanism that modulates G protein signaling pathways, potentially mitigating the pathogenic effects of the PRKCG mutation and delaying the onset of Purkinje cell dysfunction and neurodegeneration associated with spinocerebellar ataxia type 14."}], "pathway_id": "mmu05017", "pubmed_id": "41074411", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRKCG (excluded), PRKCG (G128D mutant) (mutant), VGLUT2 (reduced levels), GLAST, GluD2, GFAP, VGAT (impaired delivery).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of the G128D mutant form of protein kinase C (PRKCG) in Purkinje cells leads to the formation of cytoplasmic aggregates and mislocalization of these cells during development. This results in progressive gait deficits that worsen with age. The mutant PKC specifically disrupts climbing-fiber synapses, as evidenced by reduced levels of vesicular glutamate transporter 2 (VGLUT2), and alters axonal transport mechanisms, including impaired delivery of the vesicular GABA transporter (VGAT) to deep cerebellar nuclei. Accumulation of mutant PKC within the axon initial segment (AIS) leads to structural deterioration of the AIS, which excludes PKC from distal axons. Concurrently, glial dysfunction is observed, with reduced glutamate/aspartate transporter (GLAST) function and decreased expression of delta-2 glutamate receptor (GluD2), contributing to progressive motor impairment."}], "pathway_id": "mmu05017", "pubmed_id": "41287930", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN2 (hyperphosphorylation), SQSTM1 (hyperphosphorylation), OPTN (hyperphosphorylation), UBQLN2 (hyperphosphorylation), TNIP1 (hyperphosphorylation), TAX1BP1 (hyperphosphorylation), WNK1 (hypophosphorylation), SPARCL1 (hypophosphorylation), PSMD9 (hypophosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated polyglutamine (polyQ) expansions in ataxin-2 (ATXN2) induce neurodegeneration by disrupting autophagy and endocytosis pathways. Hyperphosphorylation of ATXN2 flanking the polyQ region, along with SQSTM1, OPTN, UBQLN2, TNIP1, and TAX1BP1, correlates with impaired protein clearance. Simultaneously, hypophosphorylation of WNK1, SPARCL1, and PSMD9 suggests dysregulation of proteasomal and actin-related functions. These alterations are mediated by proline-rich motifs adjacent to the polyQ tract in ATXN2, which interact with SRC-homology domain type 3 (SH3) proteins. This leads to actin modulator enrichment and contributes to the pathogenesis of spinocerebellar ataxia type 2."}], "pathway_id": "mmu05017", "pubmed_id": "40992657", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN3, ATXN3 (mutant) (overexpression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Overexpression of mutant ATXN3 in hindbrain regions leads to the formation of ATXN3 aggregates within neuronal cells. This pathological accumulation is associated with mild motor impairments and increased recruitment of astrocytes and microglia. These inflammatory responses contribute to myelin damage and result in cerebellar white matter loss, which is a consistent pathological feature of SCA3 neuropathology."}], "pathway_id": "mmu05017", "pubmed_id": "40754098", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ataxin-1 (aggregation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in the ATXN1 gene lead to the production of a misfolded ataxin-1 protein, which undergoes aggregation and disrupts normal cellular function. This results in the progressive degeneration of cerebellar Purkinje cells, contributing to motor incoordination, muscle atrophy, and gait impairments. These impairments manifest as reduced gait speed, decreased stride length, altered stance phase, and diminished limb loading capacity, reflecting progressive cerebellar dysfunction."}], "pathway_id": "mmu05017", "pubmed_id": "40965523", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN3 (mutated), mutant ATXN3 (mutated), Bmal1 (reduced expression), Per2 (reduced expression), arginine vasopressin (reduced expression), vasoactive intestinal polypeptide (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant ATXN3 protein impairs circadian rhythm regulation by reducing the expression of neuropeptides arginine vasopressin and vasoactive intestinal polypeptide in the suprachiasmatic nucleus and paraventricular nucleus. It also suppresses clock gene expression in the cerebellum, including Bmal1 and Per2. This disruption leads to fragmented rest-activity patterns, reduced sleep efficiency, and altered core body temperature rhythms. Wild-type ATXN3 normally activates Bmal1 and Per2 promoters, but this function is lost in the mutant form due to polyglutamine expansion."}], "pathway_id": "mmu05017", "pubmed_id": "40692435", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRKCG (elevated activity), PRKCG knockout, PRKCA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated activity of protein kinase C gamma (PRKCG) impairs the formation and maturation of Purkinje cell dendritic spines, reducing the number of mature, mushroom-shaped spines. This disruption in dendritic spine development compromises synapse establishment and cerebellar function, contributing to neuronal degeneration and cerebellar dysfunction associated with spinocerebellar ataxia."}], "pathway_id": "mmu05017", "pubmed_id": "40675361", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trimethadione (administration), SPTBN2, CaMKII (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulated calcium homeostasis leads to enhanced autophosphorylation of calcium-calmodulin dependent kinase II (CaMKII) and phosphorylation of its targets. This disruption in calcium signaling contributes to Purkinje cell dendritic morphology abnormalities and motor coordination deficits. Inhibition of T-type calcium channels by trimethadione ameliorates interlimb coordination impairments associated with -III spectrin deficiency."}], "pathway_id": "mmu05017", "pubmed_id": "40594196", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATXN2 (elevated CAG repeat expansions), Myf6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated CAG repeat expansions in ATXN2 lead to progressive motor impairment and Purkinje cell atrophy. These pathological changes contribute to cerebellar dysfunction and muscle atrophy, particularly in aged individuals. Altered expression of Myf6 in muscle tissue is associated with age-dependent deterioration of muscle differentiation and development, further exacerbating the loss of motor coordination and muscle mass."}], "pathway_id": "mmu05017", "pubmed_id": "40556342", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Mus musculus (house mouse)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: THAP11, THAP11 (mutant) (mutated), TREM2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant THAP11, characterized by polyglutamine expansion, leads to protein aggregation in the cerebellum and contributes to neurodegeneration. This mutant form enhances the transcription of TREM2, which results in microglial activation. TREM2-mediated microglial activity is associated with the progression of cerebellar neuronal loss and motor dysfunction."}], "pathway_id": "mmu05017", "pubmed_id": "40459937", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, METTL14 (elevated expression), NLRP3 (upregulation), YTHDF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated METTL14 expression promotes m6A modification of NLRP3, enhancing its stability and thereby increasing pyroptosis. This contributes to myocardial damage in diabetic cardiomyopathy. YTHDF1, as an m6A reader protein, mediates the upregulation of NLRP3 through this modification."}], "pathway_id": "mmu05415", "pubmed_id": "41091242", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid (elevated levels), Fgf9 (administration), Nrf2 (activated), SQSTM1, Keap1 (degradation), Prkaa1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated glucose and palmitic acid levels disrupt AMPK activity and autophagy, leading to impaired p62-mediated degradation of Keap1 and reduced nuclear translocation of Nrf2. This results in increased oxidative stress, mitochondrial dysfunction, and lipid accumulation, contributing to cardiac hypertrophy and fibrosis. Activation of AMPK by fibroblast growth factor 9 (FGF9) restores autophagy, promotes Keap1 degradation, and enhances Nrf2 activation, thereby reducing oxidative stress and preserving mitochondrial integrity."}], "pathway_id": "mmu05415", "pubmed_id": "41291247", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Icariin (administration), 5-Aminolevulinic Acid, NFE2L2 (activation), HMOX1 (expression), SOD2 (expression), PPARGC1A (activation), TOMM20 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated reactive oxygen species (ROS) levels contribute to mitochondrial dysfunction and oxidative stress in diabetic cardiomyopathy. Nrf2 activation induces the expression of antioxidant enzymes such as HMOX1 and SOD2, which mitigate oxidative damage. Icariin increases Nrf2 expression and activates downstream targets including PGC1- and TOM20, enhancing mitochondrial function and antioxidant defense. This pathway attenuates myocardial hypertrophy, fibrosis, and cardiomyocyte death by suppressing ROS accumulation and restoring mitochondrial integrity."}], "pathway_id": "mmu05415", "pubmed_id": "41038331", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Hemin, ALAS1, ALAS2, FECH, CPOX, UROD, ALAD, HMBS, PPOX, BLVRA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid (5-ALA) is the initial substrate in the heme biosynthesis pathway, which is catalyzed by ALAS1 in the liver and ALAS2 in erythroid cells to produce porphobilinogen. Subsequent enzymatic steps, including FECH, CPOX, UROD, ALAD, HMBS, PPOX, and BLVRA, sequentially synthesize heme. Disruption in any of these enzymes leads to the accumulation of heme precursors, causing porphyria. Accumulation of 5-ALA and porphobilinogen is associated with neurological symptoms and photosensitivity. Heme deficiency also results in impaired oxygen transport and mitochondrial dysfunction."}], "pathway_id": "mmu05415", "pubmed_id": "40850600", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PDZK1 (normal expression), EGFR (phosphorylated at critical tyrosine residues), AKT1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of PDZK1 promotes cardiac fibroblast activation and extracellular matrix deposition by inhibiting the interaction between PDZK1 and the carboxyl terminus of EGFR. This interaction normally prevents EGFR phosphorylation at critical tyrosine residues, thereby suppressing downstream Akt signaling. Activation of the EGFR-Akt pathway leads to increased cardiac fibrosis and dysfunction, contributing to the progression of diabetic cardiomyopathy."}], "pathway_id": "mmu05415", "pubmed_id": "40816504", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bicarbonate Ion, Camp (increased levels), Calcium Cation (influx), Fer tyrosine kinase (activated), Epidermal growth factor receptor (phosphorylated and activated), Proto-oncogene tyrosine-protein kinase Src (phosphorylated and activated), Cation channel of sperm.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During sperm capacitation, bicarbonate activates the soluble adenylyl cyclase (SAC) to increase intracellular cyclic adenosine monophosphate (cAMP) levels, which in turn activates protein kinase A (PKA). PKA phosphorylates and activates the proto-oncogene tyrosine-protein kinase Src, which subsequently activates the Fer tyrosine kinase. Activated Fer then promotes the phosphorylation and activation of the epidermal growth factor receptor (EGFR). This signaling cascade, mediated by calcium influx through the CatSper channel, regulates the acrosome reaction and prevents spontaneous acrosomal reaction, thereby supporting sperm fertilizing capacity."}], "pathway_id": "mmu04012", "pubmed_id": "41303701", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epidermal Growth Factor (administration), KRAS (activated), EGFR, MEK, ERK, Major Histocompatibility Complex Class I, C-X-C Motif Chemokine Ligand 9, CD8+ T Cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS signaling inhibits interferon-mediated MHC-I expression and suppresses CD8+ T cell activity through the EGFR/MEK/ERK pathway, leading to tumor immune evasion and resistance to immunotherapy. Activation of wild-type KRAS by EGF promotes an immunosuppressive tumor microenvironment by reducing CXCL9 expression, impairing T cell infiltration and function."}], "pathway_id": "mmu04012", "pubmed_id": "41219194", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Daraxonrasib, Afatinib, [[2-[[(5S,8S,10aR)-8-[[(2S)-5-amino-1-(benzhydrylamino)-1,5-dioxopentan-2-yl]carbamoyl]-3-[8-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oct-7-ynoyl]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1H-indol-5-yl]-difluoromethyl]phosphonic acid, KRAS (inhibited), EGFR (inhibited), RAF1, STAT3 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of KRAS, EGFR, and STAT3 signaling components leads to tumor regression in pancreatic ductal adenocarcinoma. Simultaneous suppression of these pathways prevents the emergence of tumor resistance, as these pathways are interconnected in promoting tumor survival and proliferation. Inhibition of upstream (EGFR), downstream (RAF1), and orthogonal (STAT3) KRAS signaling disrupts the compensatory mechanisms that drive tumor recurrence, resulting in sustained tumor regression."}], "pathway_id": "mmu04012", "pubmed_id": "41329731", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Erlotinib, EGFR, YAP1, SAV1, HECT domain and C2 4, E3 ubiquitin-protein ligase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EGFR promotes the degradation of SAV1 by enhancing its interaction with the E3 ubiquitin-protein ligase Herc4. This degradation of SAV1 inhibits the Hippo signaling pathway, leading to the nuclear translocation of YAP and activation of its downstream target genes. As a result, YAP signaling is stimulated, contributing to retinal fibrosis in diabetic conditions."}], "pathway_id": "mmu04012", "pubmed_id": "41257731", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Isoguanosine, Epidermal Growth Factor Receptor (activation), Phosphatidylinositol-4,5-bisphosphate 3-kinase (activation), Protein Kinase B (activation), Mitogen-Activated Protein Kinase (activation), Extracellular Signal-Regulated Kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Crotonoside inhibits the proliferation, migration, and angiogenesis of non-small cell lung cancer cells by suppressing EGFR activation. This suppression leads to the attenuation of downstream PI3K/Akt and MAPK/ERK signaling pathways, which are critical for oncogenic progression and survival."}], "pathway_id": "mmu04012", "pubmed_id": "41175581", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Osimertinib, IFITM3 (expression), MET, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IFITM3 interacts with MET to activate the AKT signaling pathway, leading to the development of osimertinib resistance in EGFR-mutant non-small cell lung cancer. This resistance is associated with the tumor microenvironment, which drives IFITM3 expression through cytokine signaling."}], "pathway_id": "mmu04012", "pubmed_id": "41152910", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CLDN, OCLN, JAM.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Claudin family members (CLDNs) form tight junction (TJ) paracellular barriers by assembling into distinct transmembrane complexes. Each CLDN establishes a unique ion conductivity and paracellular selectivity, either autonomously or through nonautonomous interactions. These interactions contribute to epithelial barrier diversity and organ-specific homeostasis. Occludin (OCLN) and junctional adhesion molecules (JAMs) further stabilize TJ structure and regulate paracellular permeability. The functional diversity of CLDNs supports distinct biological roles in cell polarity and paracellular transport."}], "pathway_id": "mmu04530", "pubmed_id": "41171911", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium, Cldn16, Cldn19, Cldn14 (elevated levels), Dynamin 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of CLDN14 associate with CLDN19, promoting the gradual replacement of CLDN16 in CLDN19 copolymers within tight junctions. This claudin switch reduces paracellular calcium flux and alters renal calcium excretion. The structural remodeling of claudins occurs independently of dynamin-mediated endocytosis and influences the overall permeability of the paracellular barrier, contributing to the pathogenesis of kidney stone disease."}], "pathway_id": "mmu04530", "pubmed_id": "41325524", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid (administration), Tenovin-1, Bapta, Ebselen, Sirolimus, Claudin-10b (expressed), Claudin-1, Claudin-15, ZO-1, Taste receptor type 1, member 1, Taste receptor type 1, member 3, Mechanistic target of rapamycin kinase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extracellular glutamate induces the expression of Claudin-10b (CLDN10b) in intestinal epithelial cells, contributing to the maintenance of paracellular barrier function. This effect is mediated through a T1R1/T1R3 receptor complex that triggers intracellular calcium influx, which in turn activates the mTOR signaling pathway. Activation of mTOR is essential for the upregulation of CLDN10b mRNA. Disruption of calcium signaling or mTOR activity inhibits this effect. Claudin-10b expression is reduced in aged tissues and under senescence-inducing conditions, but glutamate treatment reverses this decline, thereby restoring intestinal tight junction integrity and paracellular barrier function."}], "pathway_id": "mmu04530", "pubmed_id": "41293822", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CRB3, NF2, RHOA, ROCK2, MYH9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CRB3 interacts with NF2 to regulate perijunctional actomyosin contractility and apical junctional complex (AJC) organization. CRB3 deficiency increases RhoA activity and junctional tension, leading to a hypercontractile actomyosin network and impaired AJC assembly. This disruption compromises epithelial barrier function and increases intestinal permeability. NF2 knockdown phenocopies CRB3 loss, indicating a cooperative role in maintaining AJC integrity. ROCK2 and MYH9 inhibition can reverse hypercontractility, restoring junctional architecture. Together, CRB3 and NF2 signaling coordinate mechanical tension to regulate barrier assembly during homeostasis and inflammatory conditions."}], "pathway_id": "mmu04530", "pubmed_id": "41122968", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Galactose, FUN14 domain-containing protein 1 (reduced levels), Vascular endothelial cadherin (reduced expression), Occludin (reduced expression), Zonula occludens-1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FUNDC1 regulates mitochondrial homeostasis through mitophagy. Reduced FUNDC1 levels impair mitophagy, leading to mitochondrial dysfunction and increased reactive oxygen species production. This contributes to endothelial cell senescence and increased vascular permeability. Mitochondrial dysfunction and oxidative stress are associated with tight junction disruption, as evidenced by reduced expression of VE-cadherin, occludin, and ZO-1. These changes result in vascular dysfunction and retinal degeneration."}], "pathway_id": "mmu04530", "pubmed_id": "41135636", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SIPA1L3, AMOT (binding to PATJ), PATJ.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SIPA1L3 interacts with AMOT through its PDZ domain, which inhibits the binding of AMOT to PATJ and reduces AMOT anchoring to tight junctions. This disruption compromises tight junction integrity and promotes tumorigenesis, cell proliferation, and invasion, contributing to a malignant phenotype."}], "pathway_id": "mmu04530", "pubmed_id": "41088697", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 6,11-Dihydroquinoxalino[2,3-b]quinoxaline, interleukin-33, zonula occludens-1 (phosphorylation at the Thr861 residue), NADPH oxidase 1 (inhibited), protein kinase C delta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Interleukin-33 induces zonula occludens-1 serine/threonine phosphorylation, specifically at the Thr861 residue, leading to tight junction disruption. This process is mediated by NADPH oxidase 1 and protein kinase C delta signaling. Activation of this signaling cascade compromises blood-retinal barrier integrity and promotes pathological angiogenesis. Inhibition of NADPH oxidase 1 activity reduces NADPH oxidase activity and pathological retinal neovascularization."}], "pathway_id": "mmu04530", "pubmed_id": "41060718", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Tight junction - Mus musculus (house mouse)\n**Pathway Description**: Tight junctions (TJs) are essential for establishing a selectively permeable barrier to diffusion through the paracellular space between neighboring cells. TJs are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many different proteins that form large complexes. These are proposed to be involved in junction assembly, barrier regulation, cell polarity, gene transcription, and other pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEPT9 (loss), MYH9 (loss).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEPT9 localizes to the apical junctions of intestinal epithelial cells, overlapping with tight and adherens junctions. SEPT9 interacts with and recruits nonmuscle myosin IIC (MYH9) to the perijunctional actomyosin belt. This recruitment is necessary for the assembly of tight and adherens junctions, thereby supporting intestinal epithelial barrier integrity. Loss of SEPT9 or MYH9 results in barrier disruption and increased intestinal permeability, contributing to inflammatory conditions such as inflammatory bowel disease."}], "pathway_id": "mmu04530", "pubmed_id": "41055961", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Mus musculus (house mouse)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Myc proto-oncogene protein (elevated levels), DNA polymerase beta, Ras GTPase, MAX proto-oncogene, basic helix-loop-helix transcription factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of MYC interact with DNA polymerase beta (Pol ) and enhance its enzymatic activity, accelerating the repair of oxidative DNA damage through the base excision repair pathway. This repair activity prevents RAS-induced senescence, allowing RAS-driven cells to continue proliferating despite increased reactive oxygen species production. MYC's DNA repair function supports cooperation with RAS in cellular transformation, independent of its DNA-binding domain."}], "pathway_id": "mmu03410", "pubmed_id": "40737085", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Mus musculus (house mouse)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Potassium Bromate, RNA-binding motif protein 39 (elevated), 8-oxoguanine DNA glycosylase 1 (increased).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated RNA-binding motif protein 39 (RBM39) interacts with the mRNA of 8-oxoguanine DNA glycosylase 1 (OGG1), stabilizing its transcript and increasing OGG1 protein expression. This enhances base excision repair efficiency in hepatocellular carcinoma cells under oxidative stress conditions. Increased OGG1 levels support the removal of oxidative DNA damage, promoting cell proliferation, migration, and invasion while inhibiting apoptosis."}], "pathway_id": "mmu03410", "pubmed_id": "40364450", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Base excision repair - Mus musculus (house mouse)\n**Pathway Description**: Base excision repair (BER) is the predominant DNA damage repair pathway for the processing of small base lesions, derived from oxidation and alkylation damages. BER is normally defined as DNA repair initiated by lesion-specific DNA glycosylases and completed by either of the two sub-pathways: short-patch BER where only one nucleotide is replaced and long-patch BER where 2-13 nucleotides are replaced. Each sub-pathway of BER relies on the formation of protein complexes that assemble at the site of the DNA lesion and facilitate repair in a coordinated fashion. This process of complex formation appears to provide an increase in specificity and efficiency to the BER pathway, thereby facilitating the maintenance of genome integrity by preventing the accumulation of highly toxic repair intermediates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Potassium Bromate, DNA ligase 1, DNA ligase III, DNA polymerase beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During base excision repair, DNA polymerase beta inserts nucleotides at the site of DNA damage, after which DNA ligase I or III seals the resulting nick. Inhibition of DNA ligase activity impairs the nick sealing step, particularly when mismatches or oxidized nucleotides are present. This disruption leads to reduced efficiency in gap filling and the accumulation of deleterious repair intermediates, increasing cellular sensitivity to oxidative stress."}], "pathway_id": "mmu03410", "pubmed_id": "38736258", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: N-Glycan biosynthesis - Mus musculus (house mouse)\n**Pathway Description**: N-glycans or asparagine-linked glycans are major constituents of glycoproteins in eukaryotes. N-glycans are covalently attached to asparagine with the consensus sequence of Asn-X-Ser/Thr by an N-glycosidic bond, GlcNAc b1- Asn. Biosynthesis of N-glycans begins on the cytoplasmic face of the ER membrane with the transferase reaction of UDP-GlcNAc and the lipid-like precursor P-Dol (dolichol phosphate) to generate GlcNAc a1- PP-Dol. After sequential addition of monosaccharides by ALG glycosyltransferases [MD:M00055], the N-glycan precursor is attached by the OST (oligosaccharyltransferase) complex to the polypeptide chain that is being synthesized and translocated through the ER membrane. The protein-bound N-glycan precursor is subsequently trimmed, extended, and modified in the ER and Golgi by a complex series of reactions catalyzed by membrane-bound glycosidases and glycosyltransferases. N-glycans thus synthesized are classified into three types: high-mannose type, complex type, and hybrid type. Defects in N-glycan biosynthesis lead to a variety of human diseases known as congenital disorders of glycosylation [DS:H00118 H00119].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Mannose (administration), Mpi (reduced activity), Oligosaccharyltransferase complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced activity of Mpi leads to impaired N-glycan biosynthesis, resulting in a significant increase in unoccupied N-glycan sites. This deficiency in glycosylation alters glycoprotein function, contributing to multisystemic phenotypes including erythrocyte dysfunction, hepatic impairment, gastrointestinal disruption, and altered fluid homeostasis. Administration of D-mannose partially restores N-glycan synthesis and rescues the associated phenotypes."}], "pathway_id": "mmu00510", "pubmed_id": "40693465", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), (+)-Ursolic Acid (administration), Tlr4 (elevated expression), Tumor necrosis factor alpha (elevated expression), Toll-like receptor 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated TLR4 and TNF- expression in the spinal cord and sciatic nerve contributes to neuroinflammation and neuropathic pain. Quercetin and ursolic acid bind to TLR4 and TNF-, leading to reduced expression of these proteins and alleviation of inflammatory signaling. This suppression of TLR4/TNF- signaling reduces neuroinflammation and improves pain-related behaviors."}], "pathway_id": "mmu04620", "pubmed_id": "41311070", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Imiquimod, Tlr7 (downregulation), Myd88, Irf7 (upregulation), Ifnb1 (reduced levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR7 activates the MyD88-dependent signaling cascade, leading to the induction of IRF7 and subsequent production of IFN-. This pathway is essential for initiating antiviral and antimicrobial immune responses. During Toxoplasma gondii infection, TLR7 is initially upregulated, promoting IFN- expression. However, this response is later suppressed, resulting in reduced IFN- levels and impaired immune defense. This biphasic regulation of TLR7, MyD88, and IRF7 modulates IFN- production and contributes to immune evasion by the parasite."}], "pathway_id": "mmu04620", "pubmed_id": "41307494", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Trimetazidine, Pentylenetetrazole, Nuclear factor kappa B, Toll-like receptor 4, High mobility group box 1 (elevated levels), Interleukin 1 beta, Interleukin 6, Tumor necrosis factor alpha, Gamma-aminobutyric acid, L-glutamic acid (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated neuroinflammatory signaling through HMGB1 activates TLR4, leading to NF-B pathway activation and subsequent production of proinflammatory cytokines such as IL-1, IL-6, and TNF-. This inflammatory cascade contributes to excitotoxicity and seizure activity by disrupting GABAergic neurotransmission and increasing glutamate levels. Inhibition of this HMGB1-TLR4-NF-B axis reduces neuroinflammation, enhances GABA signaling, and lowers glutamate, thereby attenuating epileptogenesis and seizure severity."}], "pathway_id": "mmu04620", "pubmed_id": "41317216", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon Tetrachloride, Interleukin-1 beta (production), Interleukin-6 (production), Tumor necrosis factor alpha (production), Toll-like receptor 4 (activation), TNF receptor-associated factor 6, Myeloid differentiation primary response 88, Alpha-smooth muscle actin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of TLR4 in M1 macrophages triggers the TLR4/TRAF6/MyD88 signaling pathway, leading to the production of proinflammatory cytokines such as IL-1, IL-6, and TNF-. This inflammatory response contributes to hepatic stellate cell activation and the progression of liver fibrosis. Inhibition of this pathway reduces M1 macrophage polarization, decreases cytokine production, and attenuates fibrotic collagen deposition and hepatic stellate cell activation."}], "pathway_id": "mmu04620", "pubmed_id": "41296792", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Agrimonolide (administration), Toll-like receptor 4, nuclear factor kappa B (activation), mitogen-activated protein kinase (activation), interleukin 1 beta (production), interleukin 6 (production), tumor necrosis factor alpha (production), ionized calcium-binding adapter molecule 1 (expression), glial fibrillary acidic protein (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Agrimonolide inhibits microglial and astrocytic activation, thereby reducing the production of proinflammatory cytokines such as interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. It suppresses the activation of the nuclear factor kappa B and mitogen-activated protein kinase signaling pathways. Agrimonolide also inhibits the TLR4-mediated signaling pathway, which is associated with neuroinflammatory responses. This inhibition leads to decreased expression of IBA-1 and glial fibrillary acidic protein, markers of glial activation, and attenuates neuroinflammation."}], "pathway_id": "mmu04620", "pubmed_id": "41275992", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Perfluorooctanesulfonic acid (administration), 5-Aminolevulinic Acid, Toll-like receptor, Toll-like receptor 2; Toll-like receptor 4, Myeloid differentiation primary response 88, Nuclear factor kappa B, Mitogen-activated protein kinase, Interferon beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Perfluorooctanesulfonic acid induces pulmonary inflammation and fibrosis through the activation of Toll-like receptor 2 and 4 signaling pathways. Engagement of TLR2 and TLR4 triggers MyD88-dependent and MyD88-independent signaling cascades, leading to the rapid activation of nuclear factor kappa B and mitogen-activated protein kinase, which promote the production of proinflammatory cytokines and upregulation of costimulatory molecules. Systemic translocation of perfluorooctanesulfonic acid results in suppression of sex hormone synthesis, disrupting steroidogenesis in Leydig and granulosa cells."}], "pathway_id": "mmu04620", "pubmed_id": "41273825", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-methylpentanoic acid, Icatibant Acetate, Toll-like receptor 9, Bradykinin receptor B1 (increased expression), Bradykinin receptor B2 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in Toll-like receptor 9 leads to increased expression of bradykinin receptor B1 and B2 in the colonic epithelium following infectious colitis, which contributes to the development of visceral hyperalgesia. This mechanism is associated with the pathophysiology of post-infectious irritable bowel syndrome. Inhibition of these receptors reduces visceral pain, suggesting a role for bradykinin signaling in the manifestation of the disorder."}], "pathway_id": "mmu04620", "pubmed_id": "41293152", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxylipin, Tlr4, Irf3, Cgas, Sting1, Ifnb1 (Elevated), Il1b, Ptgs2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated type I interferon signaling in macrophages with the m.5019A>G mitochondrial tRNA mutation occurs through two distinct phases. An early phase is driven by TLR4 and IRF3 activation, while a later phase involves mitochondrial nucleic acids and the cGAS-STING pathway. This IFN- induction suppresses pro-IL-1 and COX2 expression via autocrine signaling. Concurrently, mitochondrial dysfunction leads to reduced pro-inflammatory cytokines and oxylipins, resulting in an imbalanced innate immune response."}], "pathway_id": "mmu04620", "pubmed_id": "41266309", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ccl4 (elevated levels), Rho GTPase-activating protein 15, T cell receptor delta chain, Tumor necrosis factor, Forkhead box P3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of the Ccl4-expressing naive B cell subset correlate with activation of toll-like receptor signaling. Concurrently, increased populations of CD8+ effector T cells expressing Arhgap15, gamma delta T cells expressing Trdc, helper T cells expressing Tnf, and regulatory T cells expressing Foxp3 are associated with activation of NF-kappa B and TNF signaling pathways. These signaling events contribute to inflammatory and immune responses in the context of renal fibrosis."}], "pathway_id": "mmu04620", "pubmed_id": "41269996", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: C-type lectin receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: C-type lectin receptors (CLRs) are a large superfamily of proteins characterized by the presence of one or more C-type lectin-like domains (CTLDs). CLRs function as pattern-recognition receptors (PRRs) for pathogen-derived ligands in dendric cells, macrophages, neutrophils, etc., such as Dectin-1 and Dectin-2 for recognition of fungi-derived B-glucan and high mannose-type carbohydrates. Upon ligand binding, CLRs stimulate intracellular signaling cascades that induce the production of inflammatory cytokines and chemokines, consequently triggering innate and adaptive immunity to pathogens.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CLEC9A (from inhibitory to activating), CLEC7A (from inhibitory to activating), INPP5D (Recruitment).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNGR-1 (CLEC9A) binds to F-actin exposed on dead cell remnants and promotes cross-presentation of associated antigens. Recruitment of the phosphatase SHIP1 (INPP5D) to DNGR-1 limits conventional dendritic cell activation. This signaling mechanism prevents excessive activation of dendritic cells while preserving their capacity for antigen cross-presentation. Mutation of a single amino acid adjacent to the signaling motif of DNGR-1 can switch its function from inhibitory to activating, but at the cost of reduced antigen cross-presentation. A similar mutation in Dectin-1 (CLEC7A) also alters its signaling balance, reducing activation while increasing cross-presentation efficiency. This indicates a functional trade-off in C-type lectin receptor signaling between immune activation and antigen presentation."}], "pathway_id": "mmu04625", "pubmed_id": "41162754", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: C-type lectin receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: C-type lectin receptors (CLRs) are a large superfamily of proteins characterized by the presence of one or more C-type lectin-like domains (CTLDs). CLRs function as pattern-recognition receptors (PRRs) for pathogen-derived ligands in dendric cells, macrophages, neutrophils, etc., such as Dectin-1 and Dectin-2 for recognition of fungi-derived B-glucan and high mannose-type carbohydrates. Upon ligand binding, CLRs stimulate intracellular signaling cascades that induce the production of inflammatory cytokines and chemokines, consequently triggering innate and adaptive immunity to pathogens.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CLEC12A (activated), CD11c, CD80, MHC class I, TNF-alpha, Interleukin-1 beta, CD4 positive T cells (activated), CD8 positive cytotoxic T cells (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CLEC12A signaling suppresses protective immune responses during neurotropic picornavirus infection. Activation of CLEC12A reduces T cell infiltration and pro-inflammatory cytokine production, including TNF-alpha and Interleukin-1 beta. This results in delayed viral clearance and increased hippocampal pathology. In contrast, CLEC12A deficiency enhances CD4 positive T cell and CD8 positive cytotoxic T cell activation, leading to improved viral elimination and reduced neuronal and axonal damage in the hippocampus."}], "pathway_id": "mmu04625", "pubmed_id": "41214106", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: C-type lectin receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: C-type lectin receptors (CLRs) are a large superfamily of proteins characterized by the presence of one or more C-type lectin-like domains (CTLDs). CLRs function as pattern-recognition receptors (PRRs) for pathogen-derived ligands in dendric cells, macrophages, neutrophils, etc., such as Dectin-1 and Dectin-2 for recognition of fungi-derived B-glucan and high mannose-type carbohydrates. Upon ligand binding, CLRs stimulate intracellular signaling cascades that induce the production of inflammatory cytokines and chemokines, consequently triggering innate and adaptive immunity to pathogens.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cinnamaldehyde (administration), CLEC7A (activation), SYK (activation), CARD9 (activation), NFKB1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cinnamaldehyde induces -1,3-glucan exposure on the cell wall of Candida albicans, which promotes recognition by Dectin-1 on macrophages. This interaction activates the Syk/CARD9/NF-B signaling cascade, resulting in enhanced phagocytosis and increased secretion of pro-inflammatory cytokines, thereby facilitating fungal clearance."}], "pathway_id": "mmu04625", "pubmed_id": "41031111", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: C-type lectin receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: C-type lectin receptors (CLRs) are a large superfamily of proteins characterized by the presence of one or more C-type lectin-like domains (CTLDs). CLRs function as pattern-recognition receptors (PRRs) for pathogen-derived ligands in dendric cells, macrophages, neutrophils, etc., such as Dectin-1 and Dectin-2 for recognition of fungi-derived B-glucan and high mannose-type carbohydrates. Upon ligand binding, CLRs stimulate intracellular signaling cascades that induce the production of inflammatory cytokines and chemokines, consequently triggering innate and adaptive immunity to pathogens.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CLEC5A (expression in tolerogenic dendritic cells), Interleukin-10 (increased production), Interleukin-6 (decreased levels), Forkhead box P3, Nuclear factor kappa B (suppressed signaling activity), Alpha-synuclein (accumulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CLEC5A expression in tolerogenic dendritic cells enhances immunomodulatory function by increasing interleukin-10 production and decreasing interleukin-6 levels. This leads to increased Forkhead box P3-positive regulatory T cell induction and suppression of nuclear factor kappa B signaling activity, resulting in reduced neuroinflammation. Administration of CLEC5A-expressing dendritic cells ameliorates dopaminergic neuron loss and alpha-synuclein accumulation, decreases CD45highCD11b+CD86+ macrophage infiltration, and improves locomotor activity in neurodegenerative models."}], "pathway_id": "mmu04625", "pubmed_id": "40917058", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: C-type lectin receptor signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: C-type lectin receptors (CLRs) are a large superfamily of proteins characterized by the presence of one or more C-type lectin-like domains (CTLDs). CLRs function as pattern-recognition receptors (PRRs) for pathogen-derived ligands in dendric cells, macrophages, neutrophils, etc., such as Dectin-1 and Dectin-2 for recognition of fungi-derived B-glucan and high mannose-type carbohydrates. Upon ligand binding, CLRs stimulate intracellular signaling cascades that induce the production of inflammatory cytokines and chemokines, consequently triggering innate and adaptive immunity to pathogens.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Laminaran, Clec7a (inhibited), Syk, Nfkb1, Ccl2 (elevated expression), Ccr2, Tgfb1, Smad2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dectin-1 promotes macrophage infiltration through activation of the Syk/NF-B/CCL2-CCR2 signaling axis and facilitates macrophage-to-myofibroblast transition by activating TGF-/Smad signaling, leading to renal fibrosis. Inhibition of Dectin-1 reduces macrophage infiltration and myofibroblast transition, thereby attenuating fibrotic progression in the kidney."}], "pathway_id": "mmu04625", "pubmed_id": "40959267", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Wdpcp, WDPCP (Impairment at the apical cell surface), Ptch1, Smo, Gli, Sufu, Kif7, Prkaca, Csnk1a1, Gsk3b.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impairment of WDPCP function at the apical cell surface disrupts cilia formation and Hedgehog signaling. Mutation of conserved residues D481 and W482 in WDPCP leads to structural instability and loss of its ciliary localization. This disruption results in developmental abnormalities such as neural tube defects, craniofacial malformation, anophthalmia, and polydactyly. Restoring both D481 and W482 in WDPCP is necessary for recovery of normal function and phenotypic correction. The failure of mutant WDPCP to localize to the cell surface prevents proper ciliary assembly, which is essential for Hedgehog signal transduction through Ptch, Smo, and the Gli-Sufu-Kif7 complex."}], "pathway_id": "mmu04340", "pubmed_id": "41268724", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cilk1 (Reduced expression), Ptch1 (Downregulation), Sostdc1 (Downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced Cilk1 expression disrupts primary ciliary dynamics, leading to decreased ciliary frequency and increased ciliary length. This disruption impairs Hedgehog signaling activity, as evidenced by the downregulation of Hh target genes Ptch1 and Sostdc1. Decreased Hh signaling activity promotes the formation of diastemal supernumerary teeth. In the absence of Cilk1, the severity of Hh signaling suppression correlates with progressive changes in tooth patterning, including the enlargement of supernumerary teeth and, ultimately, molar fusion."}], "pathway_id": "mmu04340", "pubmed_id": "41320695", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Shh (secreted by the epithelium).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sonic hedgehog (Shh) secreted by the epithelium functions as a chemoattractive cue for mesenchymal cells, promoting their localized convergent flow toward the epithelium. This mesenchymal cell movement generates a compressive force that drives epithelial constriction and eventual splitting, facilitating tracheal-esophageal separation. Disruption of Shh signaling prevents this process, leading to failure of epithelial splitting."}], "pathway_id": "mmu04340", "pubmed_id": "41309607", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GLI family zinc finger 2 (inhibited), Gli family zinc finger 2, Smoothened (inhibited), Transforming growth factor beta 1, SMAD family member 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GLI family zinc finger 2 (GLI2) promotes pancreatic stellate cell activation and fibrosis in chronic pancreatitis through a non-canonical Hedgehog signaling pathway. TGF-1 activates GLI2 via the SMAD3 signaling cascade, leading to increased nuclear translocation and expression of GLI2 in activated pancreatic stellate cells. This process contributes to the progression of fibrosis, and GLI2 inhibition reduces stellate cell activation. In contrast, Smoothened (SMO) inhibition does not consistently affect GLI2 levels or stellate cell activation, indicating that GLI2 functions independently of the canonical Hedgehog pathway in this context."}], "pathway_id": "mmu04340", "pubmed_id": "41281756", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS1, ALAS2, CPOX, FECH, ALAD, PBGD, UROD, HMBS, SLC25A38, CPS1, ACO1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The heme biosynthesis pathway begins with the condensation of glycine and succinyl-CoA to form 5-aminolevulinic acid (5-ALA), catalyzed by ALAS1 in the cytoplasm and ALAS2 in the mitochondria. 5-ALA is transported into mitochondria via SLC25A38 and converted to porphobilinogen (PBG) by ALAD. PBG is then oxidized to hydroxymethylbilane by PBGD, which is further processed by UROD and HMBS to form uroporphyrinogen III. This compound is converted to coproporphyrinogen III by CPOX and then to protoporphyrin IX by FECH. Protoporphyrin IX is combined with ferrous iron in a reaction catalyzed by FECH to form heme. Disruptions in any of these enzymatic steps can lead to the accumulation of intermediate porphyrins and porphyrin precursors, resulting in porphyria. Accumulation of 5-ALA and PBG is associated with acute intermittent porphyria, while deficiencies in FECH lead to erythropoietic protoporphyria. These disruptions can cause oxidative stress, mitochondrial dysfunction, neurological symptoms, and photosensitivity due to the phototoxic properties of accumulated porphyrins. Anemia can also occur as a consequence of impaired heme synthesis in erythroid cells."}], "pathway_id": "mmu04340", "pubmed_id": "41148821", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acrylamide (elevated exposure), Melatonin, Malonaldehyde, Sonic Hedgehog (normalized expression), GLI Family Zinc Finger 3 (normalized expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated acrylamide exposure reduces Sonic Hedgehog (SHH) protein expression in the embryonic intestine and liver while increasing GLI3 protein levels, leading to impaired Hedgehog signaling and embryonic growth restriction. This disruption is associated with increased oxidative stress and reduced placental vascular endothelial growth factor (VEGF) expression, contributing to placental dysfunction and embryotoxicity. Normalization of SHH and GLI3 expression, along with mitigation of oxidative stress and restoration of VEGF-mediated angiogenesis, supports healthy embryonic development."}], "pathway_id": "mmu04340", "pubmed_id": "41091251", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sorafenib, SLC25A39 (elevated levels), Hedgehog, Patched, Smoothened, Gli family transcription factor (as Gli activator), Suppressor of fused, Kinesin family member 7, Protein kinase A, Casein kinase I, Glycogen synthase kinase 3 beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of SLC25A39 regulate the Hedgehog signaling pathway, promoting tumor progression and drug resistance in hepatocellular carcinoma. Activation of the Hedgehog pathway occurs when Hedgehog ligand binds to the Patched receptor, allowing Smoothened to activate downstream signaling. This leads to the translocation of Gli proteins to the ciliary tip, where they dissociate from Sufu and Kif7, enabling the formation of Gli activator (GliA) that translocates to the nucleus and activates transcription of Hedgehog target genes. This pathway supports cell proliferation and maintains cancer stem cell characteristics, contributing to tumor progression and resistance to chemotherapeutic agents like Sorafenib."}], "pathway_id": "mmu04340", "pubmed_id": "41093994", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glasdegib (administration), Bosutinib, SMO (elevated expression), GLI2 (elevated expression), ABL1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of SMO and GLI2 in chronic myeloid leukemia stem/progenitor cells correlates with tyrosine kinase inhibitor resistance. Inhibition of SMO, either genetically or pharmacologically via Glasdegib, reduces the survival of these resistant leukemic stem cells. SMO inhibition also enhances the sensitivity of these cells to Bosutinib, a tyrosine kinase inhibitor, thereby restoring drug efficacy in nonresponder populations."}], "pathway_id": "mmu04340", "pubmed_id": "41090792", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gata4 (down-regulated), Nkx2-5 (down-regulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of ciliary gene function impairs cilia structure and function, leading to disrupted Hedgehog signaling in cardiomyocytes. This disruption results in the down-regulation of key transcription factors Gata4 and Nkx2-5, contributing to the development of Tetralogy of Fallot."}], "pathway_id": "mmu04340", "pubmed_id": "41071877", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vismodegib (administration), Sonic Hedgehog (signaling), Yes-associated protein 1 (amplification).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the Sonic Hedgehog signaling pathway promotes tumorigenesis in histiocytic sarcoma. Amplification of Yes-associated protein 1 contributes to the malignant progression. Inhibition of Sonic Hedgehog signaling by vismodegib and suppression of Yes-associated protein 1 activity induce antitumor effects."}], "pathway_id": "mmu04340", "pubmed_id": "41066014", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Smo (activated), Gli1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the Smoothened (Smo) protein inhibits the G1/S phase transition and proliferation of cardiac fibroblasts. This effect is mediated through the downstream transcription factor Gli1, which, when activated, suppresses the proliferative activity of these cells. The Smo/Gli1 signaling pathway contributes to the attenuation of cardiac fibrosis by reducing extracellular matrix deposition and improving cardiac structure and function."}], "pathway_id": "mmu04340", "pubmed_id": "41060747", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Mus musculus (house mouse)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Natriuretic Peptide, C-Type, Vosoritide (administration), 2-(3,4-dimethoxybenzyl)-7-((1R)-1-((1R)-1-hydroxyethyl)-4-phenylbutyl)-5-methyl imidazo(5,1-f)(1,2,4)triazin-4 (3H)-one, phosphodiesterase 2 (activation), L-type calcium channel, beta-adrenergic receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of phosphodiesterase 2 (PDE2) by C-type natriuretic peptide (CNP) analog vosoritide reduces arrhythmogenic activity in cardiomyocytes under -adrenergic stress. This occurs through the suppression of spontaneous Ca waves and sparks, as well as the reduction of L-type Ca current amplitudes. These effects are mediated via cGMP-dependent signaling and are dependent on PDE2 activity, as demonstrated by the prevention of these effects upon PDE2 inhibition or deletion. This mechanism contributes to the anti-arrhythmic properties of vosoritide in diabetic hearts."}], "pathway_id": "mmu04261", "pubmed_id": "40965622", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Mus musculus (house mouse)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii, Rac1 (S-palmitoylation), AT1R, PKA, beta-adrenergic receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rac1 S-palmitoylation modulates adrenergic signaling and PKA-dependent phosphorylation of substrates in cardiomyocytes. Impairment of Rac1 palmitoylation leads to increased PKA substrate phosphorylation following -adrenergic stimulation, which is associated with more severe cardiac hypertrophy and progression to cardiac failure. This effect appears independent of increased PKA enzymatic activity, suggesting altered phosphatase function at PKA-regulated phosphosites. Under conditions of chronic stress such as pressure overload or AT1R overexpression, reduced Rac1 palmitoylation exacerbates pathological remodeling and functional decline in the heart."}], "pathway_id": "mmu04261", "pubmed_id": "40924486", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Mus musculus (house mouse)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adrenergic receptor alpha-1A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the 1A-adrenergic receptor in cardiomyocytes contributes to the maintenance of cellular homeostasis following myocardial injury. Loss of 1A-adrenergic receptor function is associated with increased cardiomyocyte loss and fibroblast accumulation in the infarct border zone. This receptor is involved in regulating pathways related to cell adhesion, cell cycle progression, and stress response, which may underlie its protective role in cardiac remodeling."}], "pathway_id": "mmu04261", "pubmed_id": "40705823", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adrenergic signaling in cardiomyocytes - Mus musculus (house mouse)\n**Pathway Description**: Cardiac myocytes express at least six subtypes of adrenergic receptor (AR) which include three subtypes of beta-AR (beta-1, beta-2, beta-3) and three subtypes of the alpha-1-AR (alpha-1A, alpha-1B, and alpha-1C). In the human heart the beta-1-AR is the pre- dominate receptor. Acute sympathetic stimulation of cardiac beta-1-ARs induces positive inotropic and chronotropic effects, the most effective mechanism to acutely increase output of the heart, by coupling to Gs, formation of cAMP by adenylyl cyclase (AC), and PKA- dependent phosphorylation of various target proteins (e.g., ryanodine receptor [RyR]; phospholamban [PLB], troponin I [TnI], and the L-type Ca2+ channel [LTCC]). Chronic beta-1-AR stimulation is detrimental and induces cardiomyocyte hypertrophy and apoptosis. beta-2-AR coupled to Gs exerts a proapoptotic action as well as beta-1-AR, while beta-2-AR coupled to Gi exerts an antiapoptotic action.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Isoproterenol, Norepinephrine, PKP2 (deficiency), ADRB1 (available intracellularly), SLC22A3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced abundance of sarcolemma beta-1-adrenergic receptors (ADRB1) in PKP2-deficient myocytes limits the functional adrenergic response. Despite this reduction, intracellular ADRB1 receptors remain available, allowing for the activation of heterogeneous intracellular signaling cascades. This altered receptor distribution contributes to regional variability in excitability and conduction, facilitating the development of cell-generated triggered activity and arrhythmogenic substrate heterogeneity. Decreased sympathetic terminal density and uneven myocardial distribution further modulate local sympathetic input, promoting arrhythmia susceptibility."}], "pathway_id": "mmu04261", "pubmed_id": "40383179", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phagosome - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis is the process of taking in relatively large particles by a cell, and is a central mechanism in the tissue remodeling, inflammation, and defense against infectious agents. A phagosome is formed when the specific receptors on the phagocyte surface recognize ligands on the particle surface. After formation, nascent phagosomes progressively acquire digestive characteristics. This maturation of phagosomes involves regulated interaction with the other membrane organelles, including recycling endosomes, late endosomes and lysosomes. The fusion of phagosomes and lysosomes releases toxic products that kill most bacteria and degrade them into fragments. However, some bacteria have strategies to escape the bactericidal mechanisms associated with phagocytosis and survive within host phagocytes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (synthesis), protoporphyrin IX (synthesis), ALAS1, ALAS2, FECH, CPOX, PPOX.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The heme biosynthesis pathway involves the sequential enzymatic conversion of 5-aminolevulinic acid (5-ALA) to protoporphyrin IX (PpIX), culminating in heme formation via ferrochelatase. ALAS1 and ALAS2 catalyze the initial step by condensing glycine and succinyl-CoA to produce 5-ALA. Subsequent enzymes, including CPOX and PPOX, facilitate the oxidation and isomerization of porphyrin intermediates. Disruption in this pathway leads to the accumulation of PpIX and other intermediates, which can result in anemia and neurological dysfunction due to impaired oxygen transport and mitochondrial function."}], "pathway_id": "mmu04145", "pubmed_id": "41163242", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteoglycans in cancer - Mus musculus (house mouse)\n**Pathway Description**: Many proteoglycans (PGs) in the tumor microenvironment have been shown to be key macromolecules that contribute to biology of various types of cancer including proliferation, adhesion, angiogenesis and metastasis, affecting tumor progress. The four main types of proteoglycans include hyaluronan (HA), which does not occur as a PG but in free form, heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), dematan sulfate proteoglycans (DSPG) and keratan sulfate proteoglycans (KSPGs) [BR:00535]. Among these proteoglycans such as HA, acting with CD44, promotes tumor cell growth and migration, whereas other proteoglycans such as syndecans (-1~-4), glypican (-1, -3) and perlecan may interact with growth factors, cytokines, morphogens and enzymes through HS chains [BR:00536], also leading to tumor growth and invasion. In contrast, some of the small leucine-rich proteolgycans, such as decorin and lumican, can function as tumor repressors, and modulate the signaling pathways by the interaction of their core proteins and multiple receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GPC3, CD44, Syndecan, Glypican, Perlecan, Decorin, Lumican.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glypican-3 (GPC3) interacts with heparan sulfate proteoglycans to modulate tumor growth and progression in hepatocellular carcinoma. Tumor cell migration is influenced by proteoglycan interactions, particularly through CD44-mediated signaling. Tumor-infiltrating T cells exhibit enhanced cytotoxicity and chemotaxis when localized to the tumor microenvironment, with reduced exhaustion contributing to improved therapeutic outcomes. Proteoglycans such as syndecans, glypicans, and perlecan facilitate growth factor and cytokine signaling, promoting tumor invasion. In contrast, small leucine-rich proteoglycans like decorin and lumican inhibit tumor progression by modulating receptor signaling pathways. Tumor infiltration and CAR-T cell functionality are enhanced through locoregional administration, leading to improved tumor growth inhibition and liver function preservation."}], "pathway_id": "mmu05205", "pubmed_id": "41267637", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteoglycans in cancer - Mus musculus (house mouse)\n**Pathway Description**: Many proteoglycans (PGs) in the tumor microenvironment have been shown to be key macromolecules that contribute to biology of various types of cancer including proliferation, adhesion, angiogenesis and metastasis, affecting tumor progress. The four main types of proteoglycans include hyaluronan (HA), which does not occur as a PG but in free form, heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), dematan sulfate proteoglycans (DSPG) and keratan sulfate proteoglycans (KSPGs) [BR:00535]. Among these proteoglycans such as HA, acting with CD44, promotes tumor cell growth and migration, whereas other proteoglycans such as syndecans (-1~-4), glypican (-1, -3) and perlecan may interact with growth factors, cytokines, morphogens and enzymes through HS chains [BR:00536], also leading to tumor growth and invasion. In contrast, some of the small leucine-rich proteolgycans, such as decorin and lumican, can function as tumor repressors, and modulate the signaling pathways by the interaction of their core proteins and multiple receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glypican 3 (expressed), Chimeric Antigen Receptor Invariant Natural Killer T Cell (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glypican 3 (GPC3) is selectively expressed on hepatocellular carcinoma (HCC) cells and serves as a target for chimeric antigen receptor (CAR)-modified invariant natural killer T (iNKT) cells. These CAR-iNKT cells exert specific cytotoxic activity against GPC3-positive HCC cells, leading to suppression of tumor progression and enhanced survival. The CAR-iNKT cells demonstrate favorable in vivo persistence with minimal off-target toxicity, indicating their potential as a therapeutic strategy for HCC."}], "pathway_id": "mmu05205", "pubmed_id": "41264124", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteoglycans in cancer - Mus musculus (house mouse)\n**Pathway Description**: Many proteoglycans (PGs) in the tumor microenvironment have been shown to be key macromolecules that contribute to biology of various types of cancer including proliferation, adhesion, angiogenesis and metastasis, affecting tumor progress. The four main types of proteoglycans include hyaluronan (HA), which does not occur as a PG but in free form, heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), dematan sulfate proteoglycans (DSPG) and keratan sulfate proteoglycans (KSPGs) [BR:00535]. Among these proteoglycans such as HA, acting with CD44, promotes tumor cell growth and migration, whereas other proteoglycans such as syndecans (-1~-4), glypican (-1, -3) and perlecan may interact with growth factors, cytokines, morphogens and enzymes through HS chains [BR:00536], also leading to tumor growth and invasion. In contrast, some of the small leucine-rich proteolgycans, such as decorin and lumican, can function as tumor repressors, and modulate the signaling pathways by the interaction of their core proteins and multiple receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HMMR (elevated levels), GSK3B, CTNNB1 (stabilized), CDH1, CDH2 (increased expression), VIM (increased expression), CCND1 (upregulation), MYC (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of hyaluronan-mediated motility receptor (HMMR) suppress the phosphorylation activity of glycogen synthase kinase 3 beta (GSK3B), which limits the ubiquitination and degradation of beta-catenin (CTNNB1). This stabilization of beta-catenin leads to the activation of Wnt/-catenin signaling, promoting epithelial-mesenchymal transition (EMT) and enhancing tumor growth, cell migration, and invasion. Increased expression of EMT markers such as N-cadherin (CDH2) and vimentin (VIM), along with upregulation of downstream effectors like cyclin D1 (CCND1) and c-MYC (MYC), further supports this process."}], "pathway_id": "mmu05205", "pubmed_id": "41168860", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteoglycans in cancer - Mus musculus (house mouse)\n**Pathway Description**: Many proteoglycans (PGs) in the tumor microenvironment have been shown to be key macromolecules that contribute to biology of various types of cancer including proliferation, adhesion, angiogenesis and metastasis, affecting tumor progress. The four main types of proteoglycans include hyaluronan (HA), which does not occur as a PG but in free form, heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), dematan sulfate proteoglycans (DSPG) and keratan sulfate proteoglycans (KSPGs) [BR:00535]. Among these proteoglycans such as HA, acting with CD44, promotes tumor cell growth and migration, whereas other proteoglycans such as syndecans (-1~-4), glypican (-1, -3) and perlecan may interact with growth factors, cytokines, morphogens and enzymes through HS chains [BR:00536], also leading to tumor growth and invasion. In contrast, some of the small leucine-rich proteolgycans, such as decorin and lumican, can function as tumor repressors, and modulate the signaling pathways by the interaction of their core proteins and multiple receptors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FN1 (derived from macrophages), SDC4 (present on gastric cancer cells), Hippo signaling pathway (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Macrophage-derived fibronectin 1 (FN1) interacts with syndecan-4 (SDC4) on gastric cancer cells, leading to the inhibition of the Hippo signaling pathway. This inhibition enhances tumor cell proliferation, migration, and invasion, thereby promoting peritoneal cavity metastasis."}], "pathway_id": "mmu05205", "pubmed_id": "41005547", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dipyridamole (administration), Phosphodiesterase 12, Receptor-interacting serine-threonine kinase 3, Mixed lineage kinase domain-like protein, cAMP response element-binding protein (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dipyridamole inhibits phosphodiesterase 12 (PDE12), thereby restoring intracellular cAMP levels and promoting cAMP response element-binding protein (CREB) phosphorylation. This leads to suppression of pro-inflammatory cytokine production, including tumor necrosis factor alpha (TNF-) and interleukin-6 (IL-6). Additionally, dipyridamole attenuates necroptosis by inhibiting the RIPK3/MLKL signaling axis, thereby reducing renal inflammation and tissue injury."}], "pathway_id": "mmu04217", "pubmed_id": "41242596", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Necrostatin-1, RIPK1 (phosphorylated), RIPK3 (phosphorylated), MLKL (phosphorylated), IL6 (production), TNF (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of TNF activate the necroptosis signaling pathway through the phosphorylation of RIPK1 and RIPK3, leading to the oligomerization and membrane translocation of MLKL. This process results in plasma membrane permeabilization and cell death. In the diaphragm, necroptosis contributes to structural and functional impairment, which manifests as diaphragm dysfunction. Concurrently, TNF induces the production of inflammatory cytokines such as IL6, amplifying the inflammatory response and further compromising tissue integrity."}], "pathway_id": "mmu04217", "pubmed_id": "41276342", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Caspase 8 (loss), CFLAR (elevated expression), N4BP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Caspase 8, independent of its apoptotic function, modulates inflammation through cleavage of N4BP1, a suppressor of NF-kB signaling. Elevated expression of Caspase 8 and CFLAR in infected tissues contributes to pathological inflammation. This signaling axis drives cytokine release and inflammatory responses, linking Caspase 8 activity to disease severity in SARS-CoV-2 infection. Loss of Caspase 8 reduces inflammation and disease outcomes without requiring pyroptosis or necroptosis signaling."}], "pathway_id": "mmu04217", "pubmed_id": "41233351", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RIPK3 (inhibition), MLKL (activation), FGF2 (increased level).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RIPK3 activation in microglia initiates necroptosis, leading to MLKL activation and subsequent release of FGF2, which promotes retinal ganglion cell apoptosis. This process is accompanied by increased inflammatory responses and structural damage in the retina. Inhibition of RIPK3 suppresses MLKL/FGF2 signaling, reduces neuronal death, and preserves retinal structure and function."}], "pathway_id": "mmu04217", "pubmed_id": "41199082", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Necrostatin-1s, SPOP, RIPK3 (polyubiquitination), RIPK1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SPOP promotes the polyubiquitination and degradation of RIPK3, thereby inhibiting necrosome formation and reducing cellular sensitivity to necroptosis. SPOP also interacts with RIPK1, protecting it from ubiquitination and degradation, which enhances RIPK1 expression and increases cellular sensitivity to apoptosis. Inhibition of RIPK1 kinase activity with 7-Cl-O-Nec-1 suppresses both SPOP-mediated apoptosis and SPOP deficiency-mediated necroptosis."}], "pathway_id": "mmu04217", "pubmed_id": "41122967", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Imiquimod, RIPK3 (elevated expression), RIPK1, MLKL, IL36A (Regulated), nuclear factor kappa B (Activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated RIPK3 expression in keratinocytes promotes skin inflammation through two mechanisms: activation of necroptosis via RIPK1 and MLKL, and regulation of the IL-36/NF-B signaling axis through an MLKL-independent pathway. This dual activity leads to increased inflammatory responses, immune cell recruitment, and disruption of the epidermal barrier, contributing to the pathogenesis of inflammatory skin disease."}], "pathway_id": "mmu04217", "pubmed_id": "41136377", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Mus musculus (house mouse)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Stimulator of Interferon Genes, Z-DNA Binding Protein 1 (transcriptionally primed), Receptor-Interacting Serine-Threonine Kinase 3, Mixed Lineage Kinase Domain-Like Protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "STING activates ZBP1 through transcriptional priming and promotes Z-nucleic acid amplification, leading to the engagement of the ZBP1-RIPK3-MLKL necroptotic signaling axis and the induction of necroptosis. This process contributes to the development of interferonopathy."}], "pathway_id": "mmu04217", "pubmed_id": "41106365", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), AKT1 (activation), PIK3CA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Quercetin inhibits hepatocellular carcinoma progression by modulating the PI3K/AKT signaling pathway. It suppresses the phosphorylation and activation of AKT1, a downstream effector of PI3K. Inhibition of this pathway reduces cell survival and promotes tumor cell death, thereby decreasing tumor volume and weight in tumor-bearing models."}], "pathway_id": "mmu04151", "pubmed_id": "41351405", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, FAM172A (induced malignant behaviors), Phosphatidylinositol 3-kinase (modulated), Protein kinase B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated FAM172A expression activates the PI3K-Akt signaling pathway, promoting tumor progression, cell proliferation, migration, and invasion in epithelial ovarian cancer. This pathway activation also contributes to chemoresistance, particularly to cisplatin. Modulation of PI3K signaling can reverse FAM172A-induced malignant behaviors, indicating that FAM172A exerts its oncogenic effects primarily through the PI3K-Akt pathway."}], "pathway_id": "mmu04151", "pubmed_id": "41339379", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phytate (administration), An inositol (administration), PIK3CA, phosphorylated PIK3CA (elevated levels), AKT1, phosphorylated AKT1 (elevated levels), MTOR (elevated levels), CD163 (elevated levels), CD206 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phytic acid and inositol inhibit colorectal cancer metastasis by downregulating the PI3K/AKT signaling pathway. Reduced phosphorylation of PI3K and AKT leads to decreased activation of mTOR, thereby suppressing cancer cell proliferation and survival. Concurrently, these compounds modulate macrophage polarization by decreasing the expression of M2 macrophage markers CD163 and CD206, shifting the tumor microenvironment toward an anti-tumor phenotype. This mechanism contributes to reduced tumor growth and liver metastasis."}], "pathway_id": "mmu04151", "pubmed_id": "41339008", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Z-VAD-fmk, IGF1R, MYH, CASP3, ALIX, TSG101, PIK3CA, AKT1, MTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apoptotic extracellular vesicles (apoVs) derived from skeletal muscle cells contain insulin-like growth factor 1 receptor (IGF1R), which, upon uptake by recipient cells, activates the PI3K/AKT/mTOR signaling pathway. This activation promotes myogenic differentiation and enhances skeletal muscle development. Inhibition of IGF1R or PI3K activity reduces the pro-differentiation effects of apoVs. ApoVs also counteract age-related muscle loss by facilitating normal myogenic processes."}], "pathway_id": "mmu04151", "pubmed_id": "41344911", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glycyrrhizin, CTNNB1 (stabilized), AKT1 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the PI3K-Akt signaling pathway promotes osteogenesis and suppresses osteoclastogenesis. AKT1 phosphorylation regulates downstream effectors involved in cell survival and proliferation, while CTNNB1 stabilization enhances Wnt signaling, which supports bone formation. Glycyrrhizic acid interacts with AKT1 and CTNNB1, potentially modulating their activity to influence bone remodeling processes."}], "pathway_id": "mmu04151", "pubmed_id": "41320184", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palbociclib (resistance), Pik-75 (administered), Phosphatidylinositol-4,5-bisphosphate 3-kinase (phosphorylated), Protein kinase B (activated), Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, Cyclin E1 (reduced expression), Cell division cycle 6 (reduced expression), Cell division cycle 25A (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the PI3K-AKT pathway promotes resistance to palbociclib by sustaining cell cycle progression and inhibiting apoptosis. Co-treatment with PIK75 suppresses PI3K and AKT phosphorylation, thereby reducing the expression of cell cycle regulators CCNE1, CDC6, and CDC25A. This dual intervention disrupts the cell cycle and enhances apoptosis in esophageal squamous cell carcinoma cells."}], "pathway_id": "mmu04151", "pubmed_id": "41315778", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphatidylinositol-3,4,5-trisphosphate, Sunitinib, CSF1R, RTK, PI3K, AKT, MTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CSF1R promotes epithelial proliferation through the activation of the PI3K/AKT/mTOR signaling pathway. Ligands such as CSF1 and IL34 bind to CSF1R, initiating downstream signaling events that enhance epithelial cell growth and clonogenicity. This pathway contributes to prostate growth and the progression of benign prostatic hyperplasia."}], "pathway_id": "mmu04151", "pubmed_id": "41313502", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ifebemtinib, Paclitaxel, Focal Adhesion Kinase (inhibited phosphorylation), BCL2 (reduced levels), BAX (elevated levels), CDH1 (increased levels), CDH2 (decreased levels), VIM (decreased levels), Cyclin-Dependent Kinase 1, Lysine-Specific Demethylase 1 (downregulation), Phosphoinositide 3-Kinase Interacting Protein 1 (increased accumulation), Phosphatidylinositol 3-Kinase, Protein Kinase B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of FAK phosphorylation and downregulation of LSD1 leads to relief of transcriptional repression on PIK3IP1, a negative regulator of the PI3K/Akt pathway. This results in increased accumulation of PIK3IP1, which in turn suppresses PI3K/Akt signaling. Concurrently, elevated BAX levels and reduced BCL2 levels promote apoptosis, while increased E-cadherin and decreased N-cadherin and vimentin inhibit cell migration. These combined effects contribute to cell cycle arrest at the G2/M phase and suppression of tumor proliferation and metastasis."}], "pathway_id": "mmu04151", "pubmed_id": "41315520", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine, Dopamine receptor D1, Dopamine receptor D2, Purinergic receptor P2Y12.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dopamine signaling influences microglial surveillance of the frontal cortex through interactions with D1- and D2-type dopamine receptors. Microglial contacts with dopaminergic axons precede bouton formation, suggesting a role in synaptic plasticity. Activation of the purinergic receptor P2RY12 in microglia is necessary for enhanced surveillance and axonal bouton development during adolescence, indicating a bidirectional interaction between dopaminergic signaling and microglial activity that supports adolescent frontal cortical plasticity."}], "pathway_id": "mmu04728", "pubmed_id": "40858614", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine (administration), Gamma-Aminobutyric Acid, Serotonin (elevated levels), D1 dopamine receptor, 5-hydroxytryptamine receptor 1B (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dopamine inhibits gamma-aminobutyric acid (GABA) release from D1 receptor-expressing medium spiny neuron terminals in a frequency-dependent manner. This effect is mediated not by dopamine receptors, but by the activation of 5-hydroxytryptamine receptor 1B (5-HT1B). Dopamine also enhances extracellular serotonin levels by inhibiting serotonin reuptake, which in turn modulates basal ganglia output through serotonergic signaling. This interaction contributes to the regulation of motor and behavioral functions and may underlie the therapeutic effects of dopaminergic medications in Parkinson's disease and psychostimulant-related disorders."}], "pathway_id": "mmu04728", "pubmed_id": "41191762", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine (released from presynaptic terminals), dopamine transporter (SLC6A3).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dopamine is released from presynaptic terminals and undergoes reuptake via dopamine transporters at perisynaptic sites, confining its action to synaptic clefts and supporting synaptic transmission. Under tonic or low-frequency phasic activity, transporters efficiently limit dopamine diffusion. However, during high-frequency or synchronized firing, dopamine release may exceed reuptake capacity, leading to extrasynaptic diffusion and volume transmission. Dopamine transporter activity thus regulates the spatial and temporal dynamics of dopaminergic signaling."}], "pathway_id": "mmu04728", "pubmed_id": "40435241", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vglut1 (localized to presynaptic terminals), Dopamine receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Vglut1 is localized to presynaptic terminals where it mediates vesicular glutamate transport. Dopaminergic synaptosomes contain presynaptic varicosities and associated postsynaptic elements, reflecting synaptic connectivity in the striatum. These synaptosomes can be enriched through fluorescence-activated sorting, enabling the study of projection-specific synaptic structures and their molecular composition."}], "pathway_id": "mmu04728", "pubmed_id": "40220095", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1, ALAS2, P5CS, SLC25A38, FECH, ALAD, CPOX, PPOX, UROD, HMBS, Ferrochelatase, Delta-aminolevulinic acid dehydratase, Protoporphyrinogen oxidase, Uroporphyrinogen decarboxylase, Hydroxymethylbilane synthase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid in the heme biosynthesis pathway are catalyzed by ALAS1 in erythroid cells and ALAS2 in non-erythroid tissues. These enzymes initiate heme synthesis, which proceeds through enzymatic steps involving P5CS, SLC25A38, FECH, ALAD, CPOX, PPOX, UROD, and HMBS. Disruption of these enzymes leads to accumulation of intermediates such as aminolevulinic acid and porphyrins, causing mitochondrial dysfunction and oxidative stress. These metabolic imbalances contribute to neurological dysfunction, anemia, and neurodegeneration by inducing apoptosis and neuroinflammation."}], "pathway_id": "mmu04728", "pubmed_id": "40202070", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dopaminergic synapse - Mus musculus (house mouse)\n**Pathway Description**: Dopamine (DA) is an important and prototypical slow neurotransmitter in the mammalian brain, where it controls a variety of functions including locomotor activity, motivation and reward, learning and memory, and endocrine regulation. Once released from presynaptic axonal terminals, DA interacts with at least five receptor subtypes in the central nervous system (CNS), which have been divided into two groups: the D1-like receptors (D1Rs), comprising D1 and D5 receptors, both positively coupled to adenylyl cyclase and cAMP production, and the D2-like receptors (D2Rs), comprising D2, D3, and D4 receptors, whose activation results in inhibition of adenylyl cyclase and suppression of cAMP production. In addition, D1Rs and D2Rs modulate intracellular Ca2+ levels and a number of Ca2+ -dependent intracellular signaling processes. Through diverse cAMP- and Ca2+-dependent and - independent mechanisms, DA influences neuronal activity, synaptic plasticity, and behavior. Presynaptically localized D2Rs regulate synthesis and release of DA as the main autoreceptor of the dopaminergic system.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine (increased release), WWC1 (mutated), KIBRA (degraded).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The WWC1 mutation leads to the degradation of KIBRA protein through the proteasomal pathway, resulting in increased dopamine release in the dorsal striatum. This dysregulation disrupts synaptic function and alters dopaminergic signaling, contributing to synaptic imbalance and behavioral phenotypes associated with neurodevelopmental disorders."}], "pathway_id": "mmu04728", "pubmed_id": "40153501", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mavacamten (Administration), Myosin-binding protein C, MYBPC3, L348P mutation in MYBPC3 (L348P mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Myosin-binding protein C (cMyBP-C) slows both phases of cardiac myofibril relaxation, which are characterized as a slow isometric phase (kREL,slow) and a fast exponential phase (kREL,fast). These phases reflect cross-bridge-dependent and cross-bridge-independent relaxation mechanisms, respectively. Phosphorylation of cMyBP-C accelerates the fast phase of relaxation, while the L348P mutation in cMyBP3 increases its affinity for actin and significantly slows both relaxation phases. Loss of cMyBP-C leads to myofilament Ca2+ desensitization and faster relaxation kinetics. Mavacamten, a myosin inhibitor, accelerates both relaxation phases independently of cMyBP-C presence. These findings suggest that cMyBP-C modulates cardiac relaxation through both cross-bridge-dependent and cross-bridge-independent mechanisms, and its dysfunction contributes to diastolic dysfunction in hypertrophic cardiomyopathy."}], "pathway_id": "mmu05410", "pubmed_id": "40936293", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: S100A9 (elevated expression), TLR2 (upregulation), ANP (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of S100A9 in cardiomyocytes promotes TLR2 upregulation, which in turn enhances the expression of S100A9, establishing a positive feedback loop. This reciprocal activation contributes to the hypertrophic response in cardiomyocytes under mechanical stress. The resulting hypertrophy is associated with increased expression of atrial natriuretic peptide (ANP), a marker of cardiac stress. This inflammatory signaling pathway exacerbates maladaptive cardiac remodeling and may accelerate the progression of hypertrophic cardiomyopathy."}], "pathway_id": "mmu05410", "pubmed_id": "40694254", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: S-[2-[3-[[4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate, Pyruvic Acid (conversion to acetyl-CoA), D-Glucose, PDK4 (inhibited), Mybpc3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated PDK4 activity suppresses the conversion of pyruvate to acetyl-CoA, which impairs tricarboxylic acid cycle flux and reduces glucose oxidation in cardiomyocytes. This metabolic disturbance contributes to impaired cardiac function and progression to heart failure in hypertrophic cardiomyopathy. Inhibition of PDK4 restores glucose utilization and attenuates heart failure symptoms in Mybpc3 knockout models."}], "pathway_id": "mmu05410", "pubmed_id": "40728184", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cdkn1a (elevated levels), Pcna, Pold1, Mybpc3, Myh6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased DNA synthesis in cardiomyocytes leads to endoreplication and replication stress-induced DNA damage. p21 binds to PCNA, reducing its interaction with POLD1, thereby inhibiting DNA synthesis and cardiomyocyte hypertrophy. PCNA-POLD1-mediated endoreplication drives pathological cardiomyocyte growth, while elevated p21 levels act as a negative regulator of this process. Targeting PCNA or POLD1 prevents DNA synthesis and hypertrophic cardiomyocyte growth, reducing pathological left ventricular hypertrophy and improving diastolic function."}], "pathway_id": "mmu05410", "pubmed_id": "40948130", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tspan9 (elevated expression), SQSTM1 (impairment of cargo recognition and transport functions).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Tspan9 in cardiac tissue promotes pathological cardiac hypertrophy and heart failure. Tspan9 interacts with p62, a key regulator of autophagy, impairing its cargo recognition and transport functions. This interaction suppresses autophagy, a process critical for cellular homeostasis and stress response. Reduced autophagy activity contributes to the development of cardiac hypertrophy and impairs the heart's ability to respond to pressure overload."}], "pathway_id": "mmu05410", "pubmed_id": "40406987", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mavacamten (administration), ALPK3 (heterozygous truncating variant), Alpha-protein kinase 3, Troponin I, cardiac, Myosin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ALPK3, a cardiac pseudo-kinase, when present as a heterozygous truncating variant, contributes to the development of hypertrophic cardiomyopathy. This variant leads to systolic dysfunction and cardiac hypertrophy, particularly under adrenergic stress. Cardiomyocytes exhibit reduced sarcomere length, prolonged relaxation, and elevated diastolic calcium levels. Protein kinase A-mediated phosphorylation, including that of cardiac troponin I, is diminished. These effects are associated with reduced myosin heads in the super-relaxed state, indicating impaired contractile efficiency. Treatment with mavacamten, a myosin inhibitor, partially restores contractile and calcium handling functions."}], "pathway_id": "mmu05410", "pubmed_id": "40128237", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NAP1L1 (p.D349E) (mutated), cGAS (Cyclic GMP-AMP Synthase), STING (Stimulator of Interferon Genes), Type I Interferon (produced).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The NAP1L1 p.D349E mutation disrupts nucleosome formation, leading to DNA leakage into the cytoplasm. This DNA activates the cGAS-STING signaling pathway, which triggers the production of type I interferons and other inflammatory molecules. This immune response contributes to the development of cardiac hypertrophy."}], "pathway_id": "mmu05410", "pubmed_id": "40169585", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mybpc3 (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hypertrophic cardiomyopathy is associated with mutations in the Mybpc3 gene, which leads to sarcomeric dysfunction and increased myofilament calcium sensitivity. This results in compensatory left ventricular hypertrophy and impaired myocardial strain patterns, including reduced global longitudinal strain in both ventricles and torsion abnormalities. These strain abnormalities are closely linked to mitochondrial morphological changes and dysfunction, which contribute to early myocardial dysfunction in the absence of overt hypertrophy."}], "pathway_id": "mmu05410", "pubmed_id": "40003877", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hypertrophic cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PTN (secreted), SDC4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pleiotrophin (PTN) secreted by cardiac fibroblasts interacts with Syndecan 4 (SDC4) to promote fibroblast proliferation and myocardial fibrosis. This interaction also stimulates macrophage inflammatory responses, contributing to the progression of hypertrophic cardiomyopathy under pressure overload conditions."}], "pathway_id": "mmu05410", "pubmed_id": "39765325", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mex3a, Olfactory Receptor (protein expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mex3a-mediated post-transcriptional silencing of olfactory receptor transcripts prevents premature endoplasmic reticulum stress during the polygenic stage of neuronal differentiation. This silencing ensures that olfactory receptor protein expression and the associated ER stress signals are delayed until the onset of singular olfactory receptor transcription. By decoupling transcription from protein-induced stress, Mex3a supports the selection of a single olfactory receptor allele and maintains the specificity of axon guidance, which is essential for the formation of the glomerular map in the olfactory bulb."}], "pathway_id": "mmu04360", "pubmed_id": "40668674", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Plexin B1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Plexin B1 regulates astrocyte membrane integrity and process plasticity, enabling spatial alignment and contact-dependent avoidance. This ensures organized astrocyte morphology and the formation of a glial bridge, which guides axon pathfinding across injury sites. Disruption of Plexin B1 function leads to impaired astrocyte agility, disorganization, and ineffective wound corralling, resulting in misguided axons, enlarged lesions, and impaired neural repair following spinal cord injury."}], "pathway_id": "mmu04360", "pubmed_id": "41253783", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GALNT2, PLD3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GALNT2 and PLD3 contribute to floor plate-mediated axon guidance during neurodevelopment. Disruption of these genes impairs the ability of floor plate-derived signals to guide commissural axons, leading to defects in ventral patterning and bilateral connectivity."}], "pathway_id": "mmu04360", "pubmed_id": "40674484", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cas, ITGB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cas proteins function as intracellular adaptor proteins that mediate axon fasciculation and guidance in cortical white matter tracts, including the anterior commissure and thalamocortical axons. These proteins operate within non-neuronal cortical cells to regulate proper axon pathfinding. 1-integrin signaling is also required for thalamocortical axon projection, though Cas proteins appear to function through a different receptor pathway during anterior commissure fasciculation."}], "pathway_id": "mmu04360", "pubmed_id": "41202094", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Coro1A (functional interaction with TRIM67), TRIM67 (functional interaction with Coro1A), Netrin-1, Deleted in Colorectal Carcinoma (DCC).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Coro1A localizes to growth cones and filopodial structures and is required for netrin-1dependent axon turning and branching. Coro1A interacts with TRIM67, which binds the netrin-1 receptor DCC, and together they mediate netrin-dependent neuronal morphogenesis. Loss of Coro1A or TRIM67 results in impaired corpus callosum development and disrupted axon guidance. The functional interaction between Coro1A and TRIM67 is essential for proper netrin signaling and cytoskeletal remodeling during neuronal development."}], "pathway_id": "mmu04360", "pubmed_id": "41085995", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (accumulation), ALAS1 (impaired activity), FECH (impaired activity), ALAD (impaired activity), PBGD (impaired activity), UROD (impaired activity), CPOX (impaired activity), ALAS2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) in erythroid cells lead to the accumulation of protoporphyrin IX (PpIX) due to impaired activity of ALAS1, ALAD, PBGD, UROD, CPOX, or FECH in the heme biosynthesis pathway. This disruption results in the accumulation of neurotoxic porphyrins, which induce oxidative stress and mitochondrial dysfunction. These metabolic disturbances contribute to the clinical manifestations of porphyria, including neurological symptoms and photosensitivity."}], "pathway_id": "mmu04360", "pubmed_id": "40806490", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NeuroD2, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NeuroD2 regulates axon guidance and axonal projection in hippocampal neurons. Its activity is linked to the AKT signaling pathway, which influences cellular aging and hippocampal integrity. NeuroD2 targets show altered expression with age, contributing to changes in axon guidance molecule expression."}], "pathway_id": "mmu04360", "pubmed_id": "40579006", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Roundabout receptor, Robo1 (expressed in fly neurons), Robo2 (expressed in fly neurons), Robo3, Slit.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Robo family receptors regulate midline crossing during axon guidance by mediating Slit-dependent midline repulsion. Robo1 and Robo2 function in canonical midline repulsion in mice, where they respond to Slit ligands to repel axons from the midline. This signaling mechanism is evolutionarily conserved, as mouse Robo1 and Robo2 can partially rescue midline crossing defects in Drosophila when expressed in fly neurons. In contrast, Robo3 isoforms do not mediate midline repulsion in response to Slit, and their expression in Drosophila embryos does not influence axon guidance. These findings indicate that the core signaling mechanisms of Robo receptors are conserved across species, although functional divergence limits cross-species substitution."}], "pathway_id": "mmu04360", "pubmed_id": "40609949", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Ephrin-A5 (induced), Focal adhesion kinase (phosphorylated), Protein tyrosine kinase 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ephrin-A5-induced axon repulsion is regulated by point contact-restricted cAMP signaling. This localized cAMP signaling modulates focal adhesion kinase (FAK) phosphorylation, influencing the assembly and disassembly of point contacts. These processes are essential for axon guidance and the refinement of terminal axonal arbors in developing retinal ganglion cells, contributing to the proper wiring of neuronal circuits."}], "pathway_id": "mmu04360", "pubmed_id": "39775847", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KATNA1, SPAST, TTLL6, TTLL11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tubulin polyglutamylation modulates the activity of microtubule-severing enzymes, including p60-katanin and spastin, which regulate axon guidance during neuronal development. The polyglutamylases TTLL6 and TTLL11 exhibit distinct functional specificity in this process, with TTLL11 selectively tuning spastin activity in motor axon guidance. Disruption of spastin function, such as through haploinsufficiency, can lead to axonal degeneration, a process mitigated by TTLL11-mediated regulation."}], "pathway_id": "mmu04360", "pubmed_id": "39613968", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rac1, Nectin3, Vangl2, Dvl3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rac1 regulates the junctional localization of core planar cell polarity (PCP) proteins Vangl2 and Dvl3 in cochlear supporting cells, which influences the turning behavior of spiral ganglion neuron type II peripheral afferents. Nectin3 contributes to this process by mediating cell adhesion, thereby guiding the directional extension of axons toward their target outer hair cells."}], "pathway_id": "mmu04360", "pubmed_id": "40207531", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ntn1 (loss), Slit1 (loss), Slit2 (loss).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Netrin-1 (Ntn1) and Slit proteins (Slit1 and Slit2) regulate axonal guidance during the development of the spinal cord dorsal funiculus. Ntn1 influences the turning angles of axons without affecting bifurcation, whereas Slit signaling contributes to proper guidance during axon branching. Combined loss of Ntn1 and Slit proteins leads to disorganized axonal structures and misprojection. These guidance cues act independently but synergistically to ensure precise formation of T-shaped axonal bifurcations through modulation of cytoskeletal dynamics in growth cones."}], "pathway_id": "mmu04360", "pubmed_id": "39159057", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Axon guidance - Mus musculus (house mouse)\n**Pathway Description**: Axon guidance represents a key stage in the formation of neuronal network. Axons are guided by a variety of guidance factors, such as netrins, ephrins, Slits, and semaphorins. These guidance cues are read by growth cone receptors, and signal transduction pathways downstream of these receptors converge onto the Rho GTPases to elicit changes in cytoskeletal organization that determine which way the growth cone will turn.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sema3A, Neuropilin 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEMA3A activates focal adhesion kinase signaling through the SEMA3A-NRP1 axis, promoting cell migration and anoikis resistance. It enhances metastatic competence and drives macrophage infiltration while skewing their polarization toward an M2-like phenotype. This results in reduced T cell infiltration and compromised antitumor immunity."}], "pathway_id": "mmu04360", "pubmed_id": "38670629", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid, GADD45G, SIRT1 (increased stability), PRKAA1, SREBF1, FASN, ACACA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GADD45 directly binds to SIRT1 and inhibits its ubiquitination, thereby increasing SIRT1 protein stability. Enhanced SIRT1 stability promotes AMPK phosphorylation, which in turn suppresses SREBP1-mediated transcription of lipogenic genes such as FASN and ACACA. This mechanism reduces hepatic lipogenesis and lipid accumulation."}], "pathway_id": "mmu04120", "pubmed_id": "41203689", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SMN1 (deficiency), YBX1 (ubiquitination degradation), TRAF6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SMN deficiency promotes ubiquitination degradation of YBX1 via TRAF6, resulting in impaired hypertrophic chondrocyte differentiation and delayed endochondral ossification, which contributes to systemic bone dysplasia."}], "pathway_id": "mmu04120", "pubmed_id": "41320719", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Casticin (administration), 5-Aminolevulinic Acid, EGFR, SMYD2, KDM5B (interaction with SMYD2), STUB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Casticin binds to SMYD2 and inhibits its activity, leading to increased K80 methylation of SMYD2. This modification enhances the interaction between SMYD2 and STUB1, promoting ubiquitination and subsequent degradation of SMYD2. The reduction in SMYD2 levels increases the sensitivity of non-small-cell lung cancer cells to EGFR tyrosine kinase inhibitors. This process is modulated by KDM5B, whose interaction with SMYD2 is suppressed by Casticin, further contributing to SMYD2 degradation and enhanced chemosensitivity."}], "pathway_id": "mmu04120", "pubmed_id": "41314435", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TREM2, TRIM21, STAT1, SYK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TREM2 stabilizes STAT1 by inhibiting its ubiquitination mediated by TRIM21, while promoting STAT1 phosphorylation through SYK. This leads to the upregulation of CCL8 and PD-L1, contributing to the formation of an immunosuppressive tumor microenvironment and tumor progression."}], "pathway_id": "mmu04120", "pubmed_id": "41253786", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melittin (administration), PSMA7 (degradation), USP10, RNF20, CDH1, CDH2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melittin promotes the ubiquitination and proteasome-mediated degradation of PSMA7 through the recruitment of RNF20 and the inhibition of USP10. This degradation leads to reduced expression of EMT-related proteins N-cadherin and increased expression of E-cadherin, thereby suppressing the epithelial-mesenchymal transition and inhibiting lung cancer metastasis."}], "pathway_id": "mmu04120", "pubmed_id": "41254650", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DTL, SMAD4 (K48-linked ubiquitination), CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DTL functions as an E3 ubiquitin ligase that mediates K48-linked ubiquitination of SMAD4, leading to its proteasomal degradation. This degradation relieves the inhibitory effect of SMAD4 on the Wnt/-catenin signaling pathway, resulting in its activation. Activation of the Wnt/-catenin pathway promotes tumor progression through enhanced cell proliferation, migration, and invasion."}], "pathway_id": "mmu04120", "pubmed_id": "41203163", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Mus musculus (house mouse)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neoprzewaquinone A (administration), EGFR (reduced levels), AKT (phosphorylated), BAD (phosphorylated), CASP3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neoprzewaquinone A binds directly to epidermal growth factor receptor (EGFR), promoting its ubiquitin-mediated degradation. This leads to a reduction in EGFR levels and subsequent suppression of the PI3K-AKT signaling pathway, as evidenced by decreased phosphorylation of AKT and BAD. The inhibition of this pathway contributes to increased apoptosis and reduced proliferation, migration, and invasion of hepatocellular carcinoma cells."}], "pathway_id": "mmu04120", "pubmed_id": "41130376", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Mus musculus (house mouse)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Huntingtin (mutated), NLRP3, Neuronal Nuclei Protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant Huntingtin (Htt) activates the NLRP3 inflammasome in brain microvascular endothelial cells, leading to increased expression of pyroptosis-related proteins. This process induces endothelial cell pyroptosis, which disrupts blood-brain barrier function and contributes to neuronal damage."}], "pathway_id": "mmu05016", "pubmed_id": "41241436", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Mus musculus (house mouse)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant huntingtin (HTT) accumulates in the hippocampus, striatum, and hypothalamus, leading to the formation of protein aggregates. These aggregates are associated with impaired hippocampal long-term potentiation and deficits in visuospatial attention, long-term memory, and spatial memory. Mutant HTT also contributes to motor impairments and metabolic changes, including reduced body weight and fat mass. Anxiolytic-like behavior and reduced brain weight are observed as downstream effects of HTT dysfunction."}], "pathway_id": "mmu05016", "pubmed_id": "41044411", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Mus musculus (house mouse)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quinolinic Acid, Sonic hedgehog, Dopamine receptor D1 (activated), Dopamine receptor D2 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysfunction of medium spiny neurons (MSNs) contributes to impaired basal ganglia circuitry, leading to motor deficits. Dopamine modulates MSN excitability through activation of dopamine receptor D1 and D2, influencing synaptic activity and neuronal output. Reconstructing these pathways through integration of functional MSNs restores synaptic currents and behavioral performance, while modulation of the sonic hedgehog pathway supports the differentiation of authentic MSNs from pluripotent cells."}], "pathway_id": "mmu05016", "pubmed_id": "41090351", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Mus musculus (house mouse)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, phosphodiesterase 10A (reduced expression), G protein subunit alpha-olf (reduced expression), dopamine receptor D1 (decreased expression), dopamine receptor D2 (decreased expression), adenosine A2A receptor (decreased levels), mu-type opioid receptor (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of G protein subunit alpha-olf and phosphodiesterase 10A in the striosomes correlates with impaired striatal cAMP signaling. This is accompanied by decreased dopamine receptor D1 and D2 expression, as well as adenosine A2A receptor levels, which contribute to neuronal dysfunction. Conversely, elevated mu-type opioid receptor expression suggests a compensatory or compartment-specific response in striosomal neurons. These molecular imbalances are associated with increased vulnerability of striosomal projection neurons, leading to neurodegeneration and motor dysfunction."}], "pathway_id": "mmu05016", "pubmed_id": "40943492", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Mus musculus (house mouse)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT, Htt (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of mutant huntingtin (Htt) leads to the formation of intracellular aggregates, particularly in striatal neurons. This aggregation is associated with progressive motor dysfunction and cognitive deficits. Striatal neuronal dysfunction and gliosis contribute to the neurodegenerative process, consistent with the pathophysiology observed in Huntington disease."}], "pathway_id": "mmu05016", "pubmed_id": "40812504", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Regulatory T cell (Differentiation), T helper 2 cell (Population), T helper 17 cell (Population), CD4 positive T cell, CD3 and CD28 (Stimulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Regulatory T cell differentiation is promoted, while T helper 2 and T helper 17 cell populations are inhibited, contributing to the formation of an anti-inflammatory microenvironment. This shift in T cell subset balance reduces immune activation and inflammation associated with atopic dermatitis. Regulatory T cells derived from nave CD4 T cells stimulated via CD3 and CD28 signaling play a key role in modulating immune responses and restoring skin barrier integrity."}], "pathway_id": "mmu04658", "pubmed_id": "41174821", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-Acetyl-L-alanine (administration), Dinitrofluorobenzene, Interleukin-4 (expression), Interferon gamma (expression), GATA binding protein 3 (upregulation), T-box transcription factor TBX21.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "N-acetyl-L-alanine suppresses Th2 differentiation by decreasing the expression of IL-4 and preventing the upregulation of GATA3 in CD4+ cells. It also increases IFN- expression, promoting Th1 activity. This modulation reduces eosinophil and mast cell infiltration and lowers IgE levels, contributing to the amelioration of atopic dermatitis-like symptoms."}], "pathway_id": "mmu04658", "pubmed_id": "40916644", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vitamin D3 (administration), 6-Formylindolo(3,2-b)carbazole (administration), 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide, Vitamin D receptor, Aryl hydrocarbon receptor (antagonism with CH223191).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The aryl hydrocarbon receptor (AHR) and vitamin D receptor (VDR) influence CD4+ T cell differentiation by modulating the balance between Th1, Th2, Th17, and Treg cell populations. Activation of AHR by its ligand 6-formylindolo[3,2-b]carbazole (FICZ) or by vitamin D3 promotes the differentiation of Th2 and Th17 cells. In contrast, AHR antagonism with CH223191 increases Th1 cell prevalence and alters the Th1/Treg and Th1/Th2 cell ratios. Vitamin D3 also shows potential as a ligand for AHR, suggesting a shared regulatory mechanism in T cell fate determination."}], "pathway_id": "mmu04658", "pubmed_id": "40685510", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rpl13a, CD4, M1 macrophage, M2 macrophage.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ribosomal protein L13a regulates macrophage polarization beyond the classical M1-M2 binary model. Its deficiency results in altered macrophage diversity and polarity, with enhanced expression of both M1 and M2 markers under known inducers. This disruption extends to T cell lineages, where the absence of L13a leads to increased expression of Th1 and Th2 signature genes in CD4+ T cells. These changes suggest that L13a plays a central role in modulating immune cell differentiation and polarization through mechanisms involving signaling molecule phosphorylation and global gene expression reprogramming."}], "pathway_id": "mmu04658", "pubmed_id": "40631353", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Arsenite (exposure), T helper cell type 1 (enhanced expression), T helper cell type 2 (enhanced expression), regulatory T cell (enhanced expression), T helper cell type 17 (reduced expression), tumor necrosis factor alpha (increased levels), interleukin 1 beta (increased levels), interleukin 6 (increased levels), toll-like receptor 4 (increased expression), myeloid differentiation factor 2 (increased expression), myeloid differentiation primary response 88 (increased expression), nuclear factor kappa B (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sodium arsenite exposure increases the production of pro-inflammatory cytokines including tumor necrosis factor alpha, interleukin 1 beta, and interleukin 6. These cytokines contribute to inflammatory reactions and influence the differentiation of CD4+ T cell subsets. Arsenite also enhances the expression of transcription factors and cytokines associated with T helper cell type 1, T helper cell type 2, and regulatory T cells, while reducing those linked to T helper cell type 17. Concurrently, arsenite activates the DAMPs-TLR4/NF-B signaling pathway, increasing the expression of TLR4, MD2, MyD88, and NF-B, which modulates immune cell responses and inflammatory outcomes."}], "pathway_id": "mmu04658", "pubmed_id": "40627198", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sorafenib (administration), signal transducer and activator of transcription 4, transforming growth factor beta 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sorafenib suppresses Th1 and Th17 cell differentiation through the modulation of STAT4 and TGF-1 signaling pathways, respectively. It also promotes Treg cell polarization, contributing to the reduction of pro-inflammatory immune responses. This action inhibits the accumulation of Th1 and Th17 cells in the brain and supports anti-inflammatory immune regulation, which can mitigate autoimmune disease progression."}], "pathway_id": "mmu04658", "pubmed_id": "40389044", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th1 and Th2 cell differentiation - Mus musculus (house mouse)\n**Pathway Description**: Immunity to different classes of microorganisms is orchestrated by separate lineages of effector T helper (TH)-cells, which differentiate from naive CD4+ precursor cells in response to cues provided by antigen presenting cells (APC) and include T helper type 1 (Th1) and Th2. Th1 cells are characterized by the transcription factor T-bet and signal transducer and activator of transcription (STAT) 4, and the production of IFN-gamma. These cells stimulate strong cell-mediated immune responses, particularly against intracellular pathogens. On the other hand, transcription factors like GATA-3 and STAT6 drive the generation of Th2 cells that produce IL-4, IL-5 and IL-13 and are necessary for inducing the humoral response to combat parasitic helminths (type 2 immunity) and isotype switching to IgG1 and IgE. The balance between Th1/Th2 subsets determines the susceptibility to disease states, where the improper development of Th2 cells can lead to allergy, while an overactive Th1 response can lead to autoimmunity.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: T-bet (T-box expressed in T cells), Signal Transducer and Activator of Transcription 4, Interferon gamma (increased), GATA binding protein 3, Signal Transducer and Activator of Transcription 6, Interleukin 4 (increased), Interleukin 5 (increased), Interleukin 13 (increased), Programmed Cell Death 1 (expressed on Th1 cells), Transforming Growth Factor Beta (increased).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "T-bet and STAT4 drive Th1 differentiation, leading to the production of IFN-gamma and activation of cell-mediated immunity. In contrast, GATA-3 and STAT6 promote Th2 differentiation, associated with IL-4, IL-5, and IL-13 production for humoral immunity and IgG1/IgE isotype switching. Regulatory T cells (Tregs) exert suppressive effects through TGF- signaling, which inhibits Th1 formation. PD-1 expression on Th1 cells further restricts their function. An increased Treg population and TGF- signaling in neonates contribute to reduced Th1 differentiation and antiviral immunity."}], "pathway_id": "mmu04658", "pubmed_id": "40280180", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TGF-beta signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The transforming growth factor-beta (TGF-beta) family members, which include TGF-betas, activins and bone morphogenetic proteins (BMPs), are structurally related secreted cytokines found in species ranging from worms and insects to mammals. A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation and migration are regulated by TGF-beta family members. TGF-beta family member binds to the Type II receptor and recruits Type I, whereby Type II receptor phosphorylates and activates Type I. The Type I receptor, in turn, phosphorylates receptor-activated Smads ( R-Smads: Smad1, Smad2, Smad3, Smad5, and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, Smad complexes activate specific genes through cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Chlorogenic Acid (administration), TGF beta 1 (expression), fibroblast growth factor 2 (expression), collagen type I alpha 1 chain (expression), SMAD family member 3 (expression), actin alpha 2 smooth muscle (expression), catenin beta 1 (expression), transforming growth factor beta receptor 1, fibroblast growth factor receptor 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Chlorogenic acid interacts with transforming growth factor beta receptor 1 (TGFR1) and fibroblast growth factor receptor 2 (FGFR2), inhibiting the downstream signaling pathways of TGF-beta 1 and FGF-2. This suppression reduces the expression of fibrotic markers including TGF-beta 1, fibroblast growth factor 2, collagen type I alpha 1 chain, SMAD family member 3, actin alpha 2 smooth muscle, and catenin beta 1. These effects lead to reduced collagen deposition, basement membrane thickening, and extracellular matrix accumulation, thereby alleviating renal fibrosis."}], "pathway_id": "mmu04350", "pubmed_id": "41343096", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TGF-beta signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The transforming growth factor-beta (TGF-beta) family members, which include TGF-betas, activins and bone morphogenetic proteins (BMPs), are structurally related secreted cytokines found in species ranging from worms and insects to mammals. A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation and migration are regulated by TGF-beta family members. TGF-beta family member binds to the Type II receptor and recruits Type I, whereby Type II receptor phosphorylates and activates Type I. The Type I receptor, in turn, phosphorylates receptor-activated Smads ( R-Smads: Smad1, Smad2, Smad3, Smad5, and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, Smad complexes activate specific genes through cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Galunisertib, TGFBR1 (co-targeted with PD-1 therapy), LGALS9 (levels), CD8-positive exhausted T cells (terminal exhaustion), Ly108-positive CX3CR1-positive T cells (exhausted CD8 T cells).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated TGFBR1 expression in hepatocytes promotes Galectin-9 secretion, which suppresses antitumor immunity by inducing T cell exhaustion. Inhibition of TGFBR1 reduces Galectin-9 levels and reprograms CD8 T cells from terminal exhaustion toward stem-like and effector states, enhancing their capacity to control liver metastases. This effect is independent of macrophages and CD4 T cells. Co-targeting TGFBR1 with PD-1 therapy further promotes the conversion of exhausted CD8 T cells into Ly108CX3CR1 subsets, which are associated with improved antitumor responses."}], "pathway_id": "mmu04350", "pubmed_id": "41309539", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TGF-beta signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The transforming growth factor-beta (TGF-beta) family members, which include TGF-betas, activins and bone morphogenetic proteins (BMPs), are structurally related secreted cytokines found in species ranging from worms and insects to mammals. A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation and migration are regulated by TGF-beta family members. TGF-beta family member binds to the Type II receptor and recruits Type I, whereby Type II receptor phosphorylates and activates Type I. The Type I receptor, in turn, phosphorylates receptor-activated Smads ( R-Smads: Smad1, Smad2, Smad3, Smad5, and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, Smad complexes activate specific genes through cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TGFBR2 (Reduced activity in reproductive contexts), Tgfbr2, Pgr, ESR1, SMAD4, Foxa2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Signaling via TGFBR2 attenuates estrogen signaling while enhancing progesterone signaling in the endometrial epithelium. TGFBR2 regulates the expression of Pgr through interactions involving ESR1 and SMAD4, which are required for Pgr transcription. Reduced TGFBR2 activity leads to endometrial hyperplasia, disrupted decidualization, impaired spiral artery formation, and immune cell invasion, ultimately resulting in female infertility and, in reproductive contexts, the development of reproductive tract tumors."}], "pathway_id": "mmu04350", "pubmed_id": "41337483", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TGF-beta signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The transforming growth factor-beta (TGF-beta) family members, which include TGF-betas, activins and bone morphogenetic proteins (BMPs), are structurally related secreted cytokines found in species ranging from worms and insects to mammals. A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation and migration are regulated by TGF-beta family members. TGF-beta family member binds to the Type II receptor and recruits Type I, whereby Type II receptor phosphorylates and activates Type I. The Type I receptor, in turn, phosphorylates receptor-activated Smads ( R-Smads: Smad1, Smad2, Smad3, Smad5, and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, Smad complexes activate specific genes through cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IGF2BP3, EMP1 (m6A-modified), SMAD7, SMAD3 (Unphosphorylated), SMAD4 (Unphosphorylated), VASP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IGF2BP3 binds to m<sup>6</sup>A-modified EMP1 mRNAs and enhances their stability. This stabilization promotes the interaction between VASP and SMAD7, which reduces SMAD7's inhibitory effect on SMAD3/4 phosphorylation. Phosphorylated SMAD3/4 forms a complex with SMAD4 and translocates to the nucleus to activate TGF-beta signaling. This pathway activation contributes to pancreatic cancer invasion and is associated with immune cell infiltration and tumor microenvironment remodeling."}], "pathway_id": "mmu04350", "pubmed_id": "41285728", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TGF-beta signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The transforming growth factor-beta (TGF-beta) family members, which include TGF-betas, activins and bone morphogenetic proteins (BMPs), are structurally related secreted cytokines found in species ranging from worms and insects to mammals. A wide spectrum of cellular functions such as proliferation, apoptosis, differentiation and migration are regulated by TGF-beta family members. TGF-beta family member binds to the Type II receptor and recruits Type I, whereby Type II receptor phosphorylates and activates Type I. The Type I receptor, in turn, phosphorylates receptor-activated Smads ( R-Smads: Smad1, Smad2, Smad3, Smad5, and Smad8). Once phosphorylated, R-Smads associate with the co-mediator Smad, Smad4, and the heteromeric complex then translocates into the nucleus. In the nucleus, Smad complexes activate specific genes through cooperative interactions with other DNA-binding and coactivator (or co-repressor) proteins.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (accumulation), ALAS1, ALAS2 (deficiency), FECH (deficiency), UROD (deficiency), PPOX (deficiency), HMBS (deficiency), CPOX (deficiency), ALAD (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in heme biosynthesis enzymes such as ALAS2, FECH, UROD, PPOX, HMBS, CPOX, or ALAD leads to the accumulation of 5-aminolevulinic acid and protoporphyrin IX. These intermediates disrupt normal heme synthesis and induce oxidative stress, which in turn causes neurological dysfunction and characteristic symptoms of porphyria. Elevated levels of 5-aminolevulinic acid and protoporphyrin IX interfere with cellular homeostasis and contribute to the pathophysiology of acute and cutaneous porphyrias."}], "pathway_id": "mmu04350", "pubmed_id": "41281741", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Mus musculus (house mouse)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Thyroxine (TSH receptor-dependent production), Interleukin-2 (elevated levels), Interferon gamma (elevated levels), Interleukin-4, Thyroid-stimulating hormone receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of interferon gamma (IFN-) and interleukin-2 (IL-2) promote Th1-mediated immune responses that contribute to hyperthyroidism by stimulating thyroid-stimulating hormone receptor (TSH receptor)-dependent thyroxine (T4) production. Interleukin-4 (IL-4) counteracts Th1 responses by promoting Th2 polarization, which helps restore immune homeostasis and reduce TSH receptor activation. Modulation of these cytokines can normalize thyroid follicular architecture and reduce serum thyroxine levels, ameliorating hyperthyroidism and restoring body weight gain."}], "pathway_id": "mmu05320", "pubmed_id": "41010493", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Mus musculus (house mouse)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Tryptophan, Lactic Acid, L-Alanine, Ido1/tdo-IN-4, IDO1, TDO, PIK3CA, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated inflammation and dysregulated T cell subsets contribute to thyroid damage in Hashimoto's thyroiditis. Tryptophan metabolism influences immune responses by modulating the PI3K-Akt signaling pathway. Supplementation with tryptophan reduces inflammatory factors and alleviates thyroid damage, whereas inhibition of tryptophan metabolism exacerbates these effects. This suggests that tryptophan metabolism plays a regulatory role in immune homeostasis and thyroid function."}], "pathway_id": "mmu05320", "pubmed_id": "40963608", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Mus musculus (house mouse)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (accumulation), ALAS1, ALAS2, FECH (impaired activity), CPOX (impaired activity), PPOX (impaired activity), UROD (impaired activity), HMBS (impaired activity), ALAD (impaired activity), CYP11B1, HSPA1A, IL6 (increased production), TNF (increased production), NRF2 (upregulation), HMOX1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) are metabolized through the heme biosynthesis pathway, primarily via the actions of ALAS1 and ALAS2 enzymes, to produce protoporphyrin IX (PpIX). Accumulation of PpIX can induce oxidative stress and mitochondrial dysfunction, leading to cellular damage and apoptosis. This process is exacerbated by impaired activities of FECH, CPOX, PPOX, UROD, HMBS, and ALAD, which are essential for the normal progression of heme synthesis. In response, cells upregulate Nrf2 and its downstream target HO-1 to mitigate oxidative stress. However, persistent heme pathway dysregulation can trigger inflammatory responses, characterized by increased production of IL6 and TNF. These mechanisms are relevant in conditions such as porphyrias and neurodegenerative disorders, and PpIX is also a photosensitizer used in photodynamic therapy to induce localized cell death."}], "pathway_id": "mmu05320", "pubmed_id": "40500868", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAD51, NIPBL.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAD51 facilitates homologous recombination by mediating strand invasion and DNA synthesis during double-strand break repair. Cohesin, particularly the loop-extruding subunit NIPBL, promotes chromatin loop formation at the break site, which enhances break-chromatin interactions and facilitates the homology search. This process is most effective during the S and G2 phases of the cell cycle, when DNA end resection occurs."}], "pathway_id": "mmu03440", "pubmed_id": "41343630", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: WDFY2, MRN complex, MRE11, RAD50, NBS1, ATM-CHK2 signaling pathway (Active), serine 84 of WDFY2 (phosphorylated), WDFY2 S84A mutant (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "WDFY2 facilitates the formation of the MRE11-RAD50-NBS1 (MRN) complex at DNA double-strand breaks by interacting with MRE11 and NBS1, thereby promoting DNA end resection and homologous recombination repair. Phosphorylation of WDFY2 at serine 84 by the ATM-CHK2 axis is required for its recruitment to DNA damage sites. Deficiency in WDFY2 or the presence of a non-phosphorylatable S84A mutant impairs MRN complex assembly and reduces homologous recombination efficiency, leading to compromised genome integrity and decreased cell survival following DNA damage."}], "pathway_id": "mmu03440", "pubmed_id": "41196680", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N6-Methyladenosine, IGF2 mRNA-binding protein 2, DEAH-box helicase 9, RAD51 RecA homolog (loading).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The m6A reader IGF2BP2, in conjunction with the RNA helicase DHX9, is recruited to DNA double-strand breaks to remove DNA-RNA hybrids in an m6A-dependent manner. This process prevents hybrid accumulation, facilitates RAD51 loading, and promotes homologous recombination-mediated DNA repair."}], "pathway_id": "mmu03440", "pubmed_id": "41100254", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Spautin-1 (administered), Ataxia-Telangiectasia Mutated, tRNA Methyltransferase 10A (degraded), Breast Cancer 1, Ubiquitin Specific Peptidase 10 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ATM phosphorylates TRMT10A at serine-28 in response to DNA damage, which facilitates the recruitment of BRCA1 and promotes efficient homologous recombination repair. This signaling axis supports DNA repair and resistance to PARP inhibition. Disruption of TRMT10A impairs homologous recombination, increasing sensitivity to PARP inhibitors. USP10 stabilizes TRMT10A, and its inhibition with spautin-1 leads to TRMT10A degradation and enhanced tumor cell death in the context of PARP inhibition."}], "pathway_id": "mmu03440", "pubmed_id": "41071892", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2'3'-Cyclic guanosine monophosphate-adenosine monophosphate, cGAS (Prolonged chromatin binding), TRIM41 (weakened ubiquitination), VCP, FANCI, RAD50.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prolonged chromatin binding of cGAS enhances the interaction between repair factors FANCI and RAD50, facilitating RAD50 recruitment to DNA damage sites and thereby potentiating homologous recombination repair. This effect is mediated through weakened ubiquitination and interaction with TRIM41 and P97, which increases the stability of cGAS at chromatin. These molecular changes contribute to enhanced DNA repair capacity, which in turn antagonizes cellular and tissue aging and extends life span."}], "pathway_id": "mmu03440", "pubmed_id": "41066557", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAD51 (reduced activity), BRCA1, BRCA2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAD51 plays a central role in homologous recombination by mediating strand invasion and DNA synthesis during the repair of DNA double-strand breaks. Deficiency in RAD51 activity, particularly when not compensated by alternative repair pathways such as single-strand annealing or alternative end-joining, increases genetic instability. However, reduced RAD51 activity in the absence of these mutagenic pathways is associated with decreased tumorigenesis. This suggests that RAD51-mediated homologous recombination supports tumor progression by enabling cancer cells to overcome replication stress during genome replication, rather than acting as a tumor suppressor."}], "pathway_id": "mmu03440", "pubmed_id": "40993217", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Homologous recombination - Mus musculus (house mouse)\n**Pathway Description**: Homologous recombination (HR) is essential for the accurate repair of DNA double-strand breaks (DSBs), potentially lethal lesions. HR takes place in the late S-G2 phase of the cell cycle and involves the generation of a single-stranded region of DNA, followed by strand invasion, formation of a Holliday junction, DNA synthesis using the intact strand as a template, branch migration and resolution. It is investigated that RecA/Rad51 family proteins play a central role. The breast cancer susceptibility protein Brca2 and the RecQ helicase BLM (Bloom syndrome mutated) are tumor suppressors that maintain genome integrity, at least in part, through HR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ZSWIM7, SWSAP1, SPIDR, Zswim7, Swsap1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of the SWS1-complex, composed of ZSWIM7, SWSAP1, and SPIDR, impairs interhomolog homologous recombination (IH-HR), a critical process for meiotic progression in oocytes. Defective IH-HR leads to meiotic arrest and subsequent premature ovarian insufficiency (POI), characterized by primary or early secondary amenorrhea and delayed puberty. Loss of function variants in ZSWIM7 or SWSAP1 result in reduced or absent IH-HR activity, destabilizing the complex and disrupting genome integrity during meiosis."}], "pathway_id": "mmu03440", "pubmed_id": "40991243", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: H-His-His-Ala-Ser-Pro-Arg-Lys-OH, Cyclin-Dependent Kinase 2 (inhibited or deleted).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cyclin-Dependent Kinase 2 (CDK2) activity modulates endothelial cell cycle progression in response to fluid shear stress. Activation of CDK2 under physiological shear stress promotes late G1 cell cycle arrest, which supports vascular stability. Inhibition or deletion of CDK2 disrupts this regulatory mechanism, leading to inward artery remodeling and the development of pulmonary and systemic hypertension. This cellular dysregulation contributes to the progression of atherosclerosis."}], "pathway_id": "mmu05418", "pubmed_id": "39752487", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Yoda-1, Piezo1 (reduced expression), Histone deacetylase 2 (increased activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Low shear stress promotes neutrophil extracellular trap (NET) formation through downregulation of Piezo1, a mechanosensitive ion channel. Reduced Piezo1 expression decreases calcium influx and increases histone deacetylase 2 (HDAC2) activity, leading to elevated reactive oxygen species levels and subsequent NETosis. This process contributes to endothelial cell apoptosis and adherence, thereby exacerbating atherosclerosis progression."}], "pathway_id": "mmu05418", "pubmed_id": "38412763", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5'-Atp (increased levels), PANX1, Endothelial cell.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Shear stress-induced release of adenosine triphosphate from red blood cells contributes to the initiation and progression of atherosclerosis. Increased extracellular ATP levels enhance endothelial cell intracellular calcium signaling, leading to endothelial barrier dysfunction, lipid accumulation, and inflammatory cell infiltration. Deletion of Pannexin 1, a mechanosensitive ATP-permeable channel in red blood cells, reduces aortic plaque burden in hypercholesterolemic conditions. This mechanism is spatially aligned with disturbed flow patterns and contributes to sex disparities in atherosclerosis."}], "pathway_id": "mmu05418", "pubmed_id": "39982440", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (elevated levels), Luteolin (elevated levels), Kaempferol (elevated levels), Naringenin (elevated levels), Tanshinone Iia, Beta-Carotene (elevated levels), 7-O-Methylisomucronulatol (elevated levels), Piperine (elevated levels), Isorhamnetin (elevated levels), Xyloidone (elevated levels), AKT1 (expression), EGFR (expression), FOS (expression), MAPK1 (expression), MAPK14 (expression), STAT3 (expression), TP53 (expression), VEGFA (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Quercetin, Luteolin, Kaempferol, Naringenin, Tanshinone IIA, Beta-carotene, 7-O-Methylisomucronulatol, Piperine, Isorhamnetin, and Xyloidone inhibit the expression of AKT1, EGFR, FOS, MAPK1, MAPK14, STAT3, TP53, and VEGFA. These genes are involved in signaling pathways associated with fluid shear stress and atherosclerosis. Inhibition of these genes may reduce oxidative stress and inflammation, contributing to the suppression of atherogenesis."}], "pathway_id": "mmu05418", "pubmed_id": "36819991", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Resveratrol, Uncoupling protein 2 (expression), Kruppel-like factor 2, Forkhead box protein O1 (activity), AMP-activated protein kinase (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Kruppel-like factor 2 (KLF2) mediates fluid shear stress-dependent regulation of Uncoupling protein 2 (UCP2) expression in endothelial cells. UCP2 expression is required to suppress proinflammatory and profibrotic signaling, thereby preventing the development of a proatherogenic endothelial phenotype. UCP2 deficiency activates Forkhead box protein O1 (FoxO1), a key proinflammatory transcriptional regulator, which promotes vascular inflammation and atherogenesis. UCP2 also modulates AMP-activated protein kinase (AMPK) phosphorylation, which is necessary for the inhibition of FoxO1 activity."}], "pathway_id": "mmu05418", "pubmed_id": "35899624", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cholesterol (accumulation), Apolipoprotein E (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Atherosclerosis development is associated with disturbed shear stress profiles at arterial sites such as bifurcations and curved segments. These regions promote inflammatory and oxidative conditions in endothelial cells, contributing to plaque formation. Apolipoprotein E deficiency leads to cholesterol accumulation, which exacerbates atherosclerosis. Regional variations in vessel stiffness, particularly in lipid-rich plaque areas, induce heterogeneous endothelial shear stress, which influences disease progression."}], "pathway_id": "mmu05418", "pubmed_id": "34482227", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methotrexate (administration), YAP1 (downregulation), WWTR1 (downregulation), PRKAA1 (activation), JUN (activation), NFKB1 (activation), KLF2 (activation), NRF2 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methotrexate inhibits disturbed flow-induced activation of YAP and TAZ, which are effectors of the Hippo pathway. This suppression is mediated through AMPK1 activation. Downregulation of YAP/TAZ reduces endothelial pro-inflammatory signaling and monocyte adhesion, thereby decreasing plaque formation. In parallel, sustained laminar flow promotes atheroprotective transcription factors such as KLF2 and Nrf2, while disturbed flow activates pro-inflammatory pathways including AP-1 and NF-B, contributing to atherogenesis."}], "pathway_id": "mmu05418", "pubmed_id": "31730006", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Coxsackievirus and Adenovirus Receptor (elevated levels), Kruppel-Like Factor 2, Activator Protein 1, Nuclear Factor Kappa B (activation), Platelet Endothelial Cell Adhesion Molecule 1 (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disturbed flow increases the expression of Coxsackievirus and Adenovirus Receptor (CAR) in endothelial cells through the Krppel-Like Factor 2 (KLF2)/Activator Protein 1 (AP-1) axis, while unidirectional laminar shear stress decreases CAR expression. Elevated CAR levels promote endothelial inflammation by enhancing Nuclear Factor Kappa B (NF-B) activation, contributing to atherogenesis. CAR modulates endothelial mechanotransduction by regulating Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1) phosphorylation."}], "pathway_id": "mmu05418", "pubmed_id": "31776326", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fluid shear stress and atherosclerosis - Mus musculus (house mouse)\n**Pathway Description**: Shear stress represents the frictional force that the flow of blood exerts at the endothelial surface of the vessel wall and plays a central role in vascular biology and contributes to the progress of atherosclerosis. Sustained laminar flow with high shear stress upregulates expressions of endothelial cell (EC) genes and proteins that are protective against atherosclerosis. The key shear stress-induced transcription factors that govern the expression of these genes are Kruppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like 2 (Nrf2). On the other hand, disturbed flow with associated reciprocating, low shear stress generally upregulates the EC genes and proteins that promote oxidative and inflammatory states in the artery wall, resulting in atherogenesis. Important transcriptional events that reflect this condition of ECs in disturbed flow include the activation of activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappaB).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LIMS2 (reduced expression), Vascular Cell Adhesion Molecule 1 (upregulation), Intercellular Adhesion Molecule 1 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced LIMS2 expression in response to disturbed flow leads to increased endothelial inflammation through the upregulation of VCAM-1 and ICAM-1. This inflammatory response contributes to the progression of atherosclerosis."}], "pathway_id": "mmu05418", "pubmed_id": "32752897", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cxcl1, AKT (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cxcl1 activates AKT phosphorylation, which promotes the formation of neutrophil extracellular traps (NETs). NET formation subsequently enhances cardiomyocyte apoptosis and fibroblast proliferation, contributing to cardiac remodeling."}], "pathway_id": "mmu05414", "pubmed_id": "41177419", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferrostatin-1 (Administration), Resveratrol (Administration), Glucose-6-phosphate dehydrogenase (Dysregulated), Protein phosphatase 1 catalytic subunit gamma (Dysregulated), Myelin basic protein (Dysregulated), Lymphocyte-specific protein 1 (Dysregulated), High mobility group nucleosome-binding domain 1 (Dysregulated), High mobility group nucleosome-binding domain 2 (Dysregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulated lactylation-related genes, including G6PD, PPP1CC, MBP, LSP1, HMGN1, and HMGN2, contribute to immunometabolic remodeling in dilated cardiomyopathy. These genes modulate immune infiltration and cardiac remodeling, with fibroblasts identified as key signaling sources. Lactylation is associated with altered metabolic and immune processes that influence disease progression. Ferrostatin-1 and Resveratrol may target these genes to modulate their activity."}], "pathway_id": "mmu05414", "pubmed_id": "41137708", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Interleukin-36 (upregulated), Interleukin-36 gamma (upregulated), Interleukin-36 alpha (upregulated), Interleukin-36 receptor, Nuclear factor kappa B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Interleukin-36 isoforms, particularly IL36G and IL36A, are upregulated in dilated cardiomyopathy and contribute to pro-fibrotic and inflammatory responses through the IL-36R-NF-B signaling axis. Activation of this pathway promotes myocardial inflammation and tissue remodeling, which are central to the pathophysiology of dilated cardiomyopathy."}], "pathway_id": "mmu05414", "pubmed_id": "41160318", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: High Mobility Group Nucleosome Binding 3 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Downregulation of High Mobility Group Nucleosome Binding 3 (HMGN3) in cardiomyocytes disrupts chromatin architecture, leading to altered gene expression patterns and increased apoptosis. This chromatin reorganization contributes to the pathological cardiac phenotype observed in dilated cardiomyopathy and heart failure."}], "pathway_id": "mmu05414", "pubmed_id": "41117190", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RBM20 (Q374fs variant), TTN (Dysregulated), LDB3 (Dysregulated), CAMK2D (Dysregulated), OBSCN (Dysregulated), RYR2 (Dysregulated), CASQ1 (Upregulated), MYBPC2 (Upregulated), MYOT (Upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The Q374fs variant in RBM20 alters RNA splicing and gene expression, leading to dysregulation of sarcomere-related genes such as TTN, LDB3, CAMK2D, OBSCN, and RYR2. This variant also upregulates CASQ1, MYBPC2, and MYOT, which are involved in calcium handling and striated muscle contraction. These changes disrupt striated muscle function and calcium homeostasis in cardiac cells, resulting in cardiac dysfunction characterized by reduced fractional shortening and prolonged QRS and corrected QT intervals."}], "pathway_id": "mmu05414", "pubmed_id": "41076636", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MAPK14, fibroblast, cardiomyocyte.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cardiomyocyte hypocontractility initiates a mechanosensitized response in cardiac fibroblasts, leading to their hyperproliferative expansion. This expansion results in the reorganization of fibrillar collagen and increased myocardial stiffness, which is mediated by heightened matrix-integrin receptor interactions and diastolic tension at focal adhesions. The p38 mitogen-activated protein kinase (MAPK14) signaling pathway is essential in regulating these fibroblast responses. Inhibition of p38 suppresses fibroblast proliferation and prevents cardiomyocyte structural remodeling, thereby improving cardiac contractility and mitigating the severity of dilated cardiomyopathy."}], "pathway_id": "mmu05414", "pubmed_id": "40934290", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Calcium Cation, beta-1 adrenergic receptor (inhibited activity), A-kinase anchoring protein 6 beta, calcineurin, nuclear factor of activated T cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated beta-1 adrenergic receptor (1AR) activity localized to the Golgi membrane facing the outer nuclear membrane regulates a perinuclear cAMP compartment that includes the A-kinase anchoring protein 6 signalosome. This localized cAMP compartment drives cAMP-dependent protein kinase activity independently of plasma membrane ARs. Activation of this pathway leads to Ca2+-dependent calcineurin and nuclear factor of activated T cells signaling, which induces myocyte hypertrophy and pathological cardiac remodeling. Inhibition of perinuclear 1AR activity reduces these effects and improves cardiac function in models of familial dilated cardiomyopathy."}], "pathway_id": "mmu05414", "pubmed_id": "40665895", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tetrahydrocannabinol (administration), Cannabinoid receptor 1 (tonic signaling).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Delta-9-tetrahydrocannabinol disrupts the intrasynaptic nanoscale stoichiometry of presynaptic cannabinoid receptor 1 (CB1R) coupling to the release machinery, leading to reduced synaptic variability. Tonic cannabinoid signaling influences synaptic strength in a target cell-dependent manner by modulating the ratio of CB1Rs to the synaptic release machinery."}], "pathway_id": "mmu04723", "pubmed_id": "38809980", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Arachidonylglycerol (degraded), Anandamide (degraded), Cnr1 (lacking), Cnr2 (lacking), Gpr55 (lacking), Dagla (expressed), Daglb (expressed), Mgll (expressed), Napepld, Faah.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Type 1 cannabinoid receptors (CB1R) are expressed in neurons of the paraventricular nucleus of the hypothalamus (PVN) and are involved in retrograde endocannabinoid signaling. 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide, AEA) are the primary endocannabinoids acting through these receptors. The enzymes DAGLA and DAGLB synthesize 2-AG, while MGLL degrades it. AEA is synthesized by NAPE-PLD and degraded by FAAH. During development, a shift occurs from DAGLB to DAGLA as the dominant 2-AG-synthesizing enzyme. Astrocytes express both DAGL isoforms and MGLL but lack expression of major cannabinoid receptors. This configuration suggests that endocannabinoid signaling in the PVN modulates afferent input activity rather than local neurocircuits."}], "pathway_id": "mmu04723", "pubmed_id": "40497964", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Arachidonylglycerol (elevated levels), Nitric Oxide (produced), metabotropic glutamate receptor 1, cannabinoid receptor 1 (long-term downregulation), diacylglycerol lipase alpha, fatty acid amide hydrolase (reduced), monoacylglycerol lipase (reduced), neuronal nitric oxide synthase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "2-arachidonoylglycerol (2-AG) is synthesized in Purkinje neurons via a metabotropic glutamate receptor 1 (mGluR1)-initiated cascade and acts as a retrograde messenger to activate cannabinoid receptor 1 (CB1R) on presynaptic terminals, reducing neurotransmitter release. Neuronal nitric oxide synthase (nNOS) produces nitric oxide (NO), which modulates CB1R expression and activity. In the absence of nNOS, diacylglycerol lipase alpha levels increase, leading to elevated 2-AG. This is accompanied by transient upregulation of CB1R at early developmental stages, followed by long-term downregulation. Fatty acid amide hydrolase and monoacylglycerol lipase, which degrade endocannabinoids, are also reduced in the absence of nNOS, contributing to persistent endocannabinoid signaling. These changes are associated with excitotoxic phenotypes and altered synaptic plasticity in the cerebellum."}], "pathway_id": "mmu04723", "pubmed_id": "36402869", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Amg-9810, N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide, Insulin-like Growth Factor 1, Insulin-like Growth Factor 1 Receptor, Gonadotropin-Releasing Hormone, Gamma-Aminobutyric Acid Type A Receptor, Transient Receptor Potential Vanilloid 1 (activation), Cannabinoid Receptor Type 1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Insulin-like Growth Factor 1 (IGF-1) suppresses the tonic retrograde endocannabinoid signaling pathway in gonadotropin-releasing hormone (GnRH) neurons. This suppression involves the inhibition of transient receptor potential vanilloid 1 (TRPV1), a component of the endocannabinoid machinery. By reducing the activation of cannabinoid receptor type 1 (CB1), IGF-1 relieves the endocannabinoid-mediated inhibition of GABAergic neurotransmission. This disinhibition increases the frequency of GABAergic miniature postsynaptic currents, thereby enhancing the firing activity of GnRH neurons and modulating the hypothalamo-pituitary-gonadal axis."}], "pathway_id": "mmu04723", "pubmed_id": "33361699", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Corticosterone (administration), Dexamethasone, Mifepristone, glucocorticoid receptor (activated), cannabinoid receptor 1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Corticosterone suppresses glutamate release from vagal afferent terminals in the nucleus of the solitary tract. This suppression occurs through glucocorticoid receptor activation in postsynaptic neurons, which triggers retrograde endocannabinoid signaling. Activation of cannabinoid receptor 1 on presynaptic terminals subsequently inhibits glutamate release, modulating autonomic reflex pathways."}], "pathway_id": "mmu04723", "pubmed_id": "32966126", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Mus musculus (house mouse)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Arachidonylglycerol (increased levels), Camp (increased levels), Diacylglycerol lipase alpha (activated), Protein kinase A (activated), Dopamine receptor D1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "2-arachidonoyl glycerol (2-AG) is synthesized by diacylglycerol lipase alpha (DGL) in post-synaptic neurons in response to calcium influx following depolarization. DGL activity is enhanced by phosphorylation at serine 798 by protein kinase A (PKA). Activation of dopamine receptor D1 (D1R) increases intracellular cAMP levels, which in turn activates PKA, leading to increased DGL phosphorylation and 2-AG production. This results in enhanced depolarization-induced suppression of excitation, a form of synaptic depression mediated by endocannabinoid signaling."}], "pathway_id": "mmu04723", "pubmed_id": "31985073", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Epstein-Barr virus infection - Mus musculus (house mouse)\n**Pathway Description**: Epstein-Barr virus (EBV) is a gamma-herpes virus that widely infects human populations predominantly at an early age but remains mostly asymptomatic. EBV has been linked to a wide spectrum of human malignancies, including nasopharyngeal carcinoma and other hematologic cancers, like Hodgkin's lymphoma, Burkitt's lymphoma (BL), B-cell immunoblastic lymphoma in HIV patients, and posttransplant-associated lymphoproliferative diseases.  EBV has the unique ability to establish life-long latent infection in primary human B lymphocytes. During latent infection, EBV expresses a small subset of genes, including 6 nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), 3 latent membrane proteins (LMP-1, -2A, and -2B), 2 small noncoding RNAs (EBER-1 and 2). On the basis of these latent gene expression, three different latency patterns associated with the types of cancers are recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ganciclovir, KDM1A, REST, ZNF217, KMT2D.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The lysine-specific histone demethylase 1 (KDM1A), in complex with REST corepressor 1 (REST) and zinc finger protein 217 (ZNF217), binds to a specific DNA motif associated with Epstein-Barr virus (EBV) reactivation. This complex removes histone 3 lysine 4 (H3K4) methylation marks and restricts host DNA looping, thereby maintaining EBV latency. In contrast, the H3K4 lysine methyltransferase 2D (KMT2D) supports EBV lytic reactivation by promoting H3K4 methylation. Disruption of this demethylase complex leads to EBV lytic reactivation and increased sensitivity to antiviral agents such as ganciclovir."}], "pathway_id": "mmu05169", "pubmed_id": "41174223", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Epstein-Barr virus infection - Mus musculus (house mouse)\n**Pathway Description**: Epstein-Barr virus (EBV) is a gamma-herpes virus that widely infects human populations predominantly at an early age but remains mostly asymptomatic. EBV has been linked to a wide spectrum of human malignancies, including nasopharyngeal carcinoma and other hematologic cancers, like Hodgkin's lymphoma, Burkitt's lymphoma (BL), B-cell immunoblastic lymphoma in HIV patients, and posttransplant-associated lymphoproliferative diseases.  EBV has the unique ability to establish life-long latent infection in primary human B lymphocytes. During latent infection, EBV expresses a small subset of genes, including 6 nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, and -LP), 3 latent membrane proteins (LMP-1, -2A, and -2B), 2 small noncoding RNAs (EBER-1 and 2). On the basis of these latent gene expression, three different latency patterns associated with the types of cancers are recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Talazoparib (administration), PARP1, MYC (activation), EBNA2 (expression), TP53 (chromatin association).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PARP1 inhibition reduces MYC oncogene expression and disrupts the chromatin association of MYC, EBNA2, and TP53. This leads to transcriptional reprogramming and dysregulation of MYC targets. Additionally, PARP1 inhibition decreases the expression of the viral oncoprotein EBNA2, which is required for MYC activation. These effects collectively impair EBV-driven lymphomagenesis."}], "pathway_id": "mmu05169", "pubmed_id": "40622706", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, 2'3'-Cyclic guanosine monophosphate-adenosine monophosphate, Lucifer Yellow, Connexin 43 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced astrocytic Connexin 43 (Cx43) expression impairs gap junction intercellular communication (GJIC), leading to disrupted functional connectivity and decreased neuronal excitability. This disruption is associated with enhanced type I interferon responses and activation of the cGAS-STING pathway. Compromised GJIC is confirmed by impaired transfer of Lucifer Yellow, cyclic adenosine monophosphate (cAMP), and cyclic GMP-AMP (cGAMP) between adjacent cells. These alterations contribute to depressive-like behavioral outcomes."}], "pathway_id": "mmu04540", "pubmed_id": "41238086", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GJB2 (deficiency in the cochlea), GJA3 (upregulation), GJB6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cx26 deficiency in the cochlea leads to upregulation of the gap junction gene Cx46 (GJA3), which is typically expressed in the eye. Cx46 localizes to the same anatomical sites as Cx26 and integrates into the same gap junctional plaques, suggesting a compensatory mechanism for the loss of Cx26 function. This upregulation is specific to Cx26 deficiency and not observed following Cx30 (GJB6) deficiency. The activation of the phototransduction pathway appears to drive this compensatory increase in Cx46 expression, potentially restoring some aspects of gap junctional communication in the cochlea."}], "pathway_id": "mmu04540", "pubmed_id": "41115329", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Cgmp, phosphodiesterase 3A (inhibition).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Luteinizing hormone (LH) signaling in granulosa cells initiates the resumption of meiosis in the oocyte. This is mediated by the diffusion of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) through gap junctions. A decrease in oocyte cAMP levels occurs due to the reduction of cGMP, which relieves the inhibition of phosphodiesterase 3A (PDE3A), and is further facilitated by the closure of gap junctions between granulosa cells. This prevents further cAMP influx into the oocyte, thereby lowering its cAMP concentration and promoting meiotic progression."}], "pathway_id": "mmu04540", "pubmed_id": "41329740", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gja1 (upregulation), Gjb2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 43 (Gja1) upregulation in endothelial cells following injury promotes gap junction-mediated cell-to-cell communication, which facilitates endothelial cell migration and proliferation during wound healing. This process is dependent on the phosphorylation status of Cx43, particularly at serine residues S255, S262, S279, and S282. Disruption of Cx43 expression or phosphorylation impairs endothelial wound closure, suggesting that Cx43 function is essential for the timely restoration of vascular integrity following injury."}], "pathway_id": "mmu04540", "pubmed_id": "41060772", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, GJA1, Ucn3 (Released by beta cells).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 36 (GJA1) forms low-density gap junction channels that facilitate direct communication between delta and beta cells in pancreatic islets. These channels contribute to the coordination of calcium oscillations between the two cell types. Urocortin 3 (Ucn3) is released by beta cells and acts on delta cells to modulate their activity, particularly at high glucose concentrations. Delta cell activity is further regulated by somatostatin, which is secreted to inhibit insulin release from beta cells. The combination of paracrine signaling and gap junction coupling leads to heterogeneous coordination patterns among delta cells, with most being entrained by beta cell calcium oscillations."}], "pathway_id": "mmu04540", "pubmed_id": "40956879", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cx43 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of connexin43 (Cx43) in astrocytes increase intercellular gap junction coupling, which is associated with reduced astrocytic cell volume and branching. This enhanced coupling contributes to the suppression of chronic epileptic activity and the reduction of hippocampal sclerosis, indicating a protective role of astroglial network communication in epilepsy progression."}], "pathway_id": "mmu04540", "pubmed_id": "40965686", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Connexin 43 (reduced levels), c-MYC, WNK1 (decreased activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 43 promotes tumor initiation and cancer stem cell survival by modulating the WNK1-c-MYC signaling axis. Reduction in Connexin 43 levels leads to decreased WNK1 activity, which in turn reduces c-MYC expression, thereby suppressing tumor growth and self-renewal capabilities."}], "pathway_id": "mmu04540", "pubmed_id": "40946315", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 4-Phenylbutyric Acid (administration), Cx43 (proper folding and trafficking), Cx47, ERp29.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of gap junction intercellular communication (GJIC) is associated with downregulation of connexin 43 (Cx43) and connexin 47 (Cx47), leading to impaired central nervous system (CNS) homeostasis. 4-phenylbutyric acid (4-PBA) enhances the expression of ERp29, a molecular chaperone that supports the proper folding and trafficking of Cx43. By preserving Cx43 and Cx47 levels in infected CNS cells, 4-PBA counteracts virus-induced downregulation and maintains functional gap junctions. This preservation of GJIC limits viral spread and reduces the severity of neuroinflammatory demyelination."}], "pathway_id": "mmu04540", "pubmed_id": "40919868", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbenoxolone (administration), Connexin 43, Gja1, Growth Differentiation Factor 15.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin 43 (Cx43), encoded by Gja1, forms gap junctions that facilitate electrical communication between adipocytes and sensory neurons. Gap junction-mediated electrical communication allows optogenetic stimulation of adipocytes to enhance firing of adjacent sensory neurons. This effect is blocked by carbenoxolone, a gap junction inhibitor. The resulting sensory neuron activation contributes to the regulation of food intake and glucose metabolism."}], "pathway_id": "mmu04540", "pubmed_id": "40915562", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp (transfer), GJB3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Functional gap junctions between breast cancer cells and adipocytes enable the transfer of cAMP from cancer cells to adipocytes. This cAMP activates lipolysis in adipocytes in a gap junction-dependent manner. Connexin 31 (GJB3) contributes to the promotion of receptor triple-negative breast cancer growth and the activation of lipolysis. This direct intercellular communication enhances tumorigenesis by supporting fatty acid metabolism in tumor-associated adipocytes."}], "pathway_id": "mmu04540", "pubmed_id": "40835606", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, Cx43.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mechanical stimulation triggers extracellular calcium ion influx into C2C12 cells through mechanosensitive and T-type calcium channels. This calcium influx contributes to tunneling nanotube (TNT)-mediated electrical coupling, which is partially facilitated by the gap junction protein Connexin 43 (Cx43). The coupling is predominantly unidirectional and is involved in intercellular signal transmission."}], "pathway_id": "mmu04540", "pubmed_id": "40532305", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Mus musculus (house mouse)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GJA4, GJA5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Endothelial gap junction coupling, primarily mediated by connexin 37 (GJA4) and connexin 40 (GJA5), facilitates the long-range propagation of vasodilation signals through the cerebral vasculature. This process is essential for neurovascular coupling, enabling rapid and coordinated increases in local cerebral blood flow in response to neural activity. Disruption of this coupling impairs the spatial and temporal spread of vasodilation, thereby reducing the efficiency of energy resource distribution in the brain."}], "pathway_id": "mmu04540", "pubmed_id": "40675149", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Apoptosis is an evolutionarily conserved process used by multicellular organisms to developmentally regulate cell number or to eliminate cells that are potentially detrimental to the organism. The major players are caspases, caspase inhibitors, members of the Bcl-2 family of pro- and anti-apoptotic proteins and adaptors of the Ced-4/APAF-1 type. Mammals, by comparison with Caenorhabditis and Drosophila, exhibit highly complex extrinsic and intrinsic pathways for apoptosis induction. However, recent analyses of whole genome sequences from cnidarians (e.g. Hydra) suggest that the caspase and Bcl-2 families were already highly complex in cnidarians and that Caenorhabditis and Drosophila lost many of the genes involved in apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, BIRC5 (inhibited), GZMB (elevated levels), CASP3 (increased expression), VEGFA (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated Granzyme B levels activate the apoptotic pathway, leading to increased Caspase 3 expression and subsequent tumor cell death. Inhibition of Survivin, an anti-apoptotic protein, enhances this effect. Reduced VEGF expression suppresses angiogenesis, further limiting tumor growth."}], "pathway_id": "mmu04215", "pubmed_id": "41343102", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apoptosis - multiple species - Mus musculus (house mouse)\n**Pathway Description**: Apoptosis is an evolutionarily conserved process used by multicellular organisms to developmentally regulate cell number or to eliminate cells that are potentially detrimental to the organism. The major players are caspases, caspase inhibitors, members of the Bcl-2 family of pro- and anti-apoptotic proteins and adaptors of the Ced-4/APAF-1 type. Mammals, by comparison with Caenorhabditis and Drosophila, exhibit highly complex extrinsic and intrinsic pathways for apoptosis induction. However, recent analyses of whole genome sequences from cnidarians (e.g. Hydra) suggest that the caspase and Bcl-2 families were already highly complex in cnidarians and that Caenorhabditis and Drosophila lost many of the genes involved in apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Z-VAD-fmk, CASP3, PDCD6IP, TSG101, MYH, IGF1R, PIK3CA, AKT1, MTOR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apoptotic extracellular vesicles (apoVs) are generated during myogenic differentiation and contain pro-differentiation proteins such as IGF1R. These apoVs are internalized by recipient cells and promote myogenic differentiation through the activation of the PI3K/AKT/mTOR signaling pathway. Inhibition of apoptosis reduces apoV production and impairs myogenic differentiation, as evidenced by decreased myosin heavy chain expression. ApoVs also enhance skeletal muscle development in young mice and ameliorate age-related muscle loss."}], "pathway_id": "mmu04215", "pubmed_id": "41344911", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prolactin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Prolactin (PRL) is a polypeptide hormone known to be involved in a wide range of biological functions including osmoregulation, lactation, reproduction, growth and development, endocrinology and metabolism, brain and behavior, and immunomodulation. PRL mediates its action through PRLR, a transmembrane protein of the hematopoietin cytokine receptor superfamily. At the protein level, the long PRLR isoform (long-R) and several short PRLR isoforms (short-R) have been detected. Acting through the long-R, PRL activates many signaling cascades including Jak2/Stat, the major cascade, Src kinase, phosphatidylinositol-3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways. PRL cannot activate Jak2/Stat5 through the short-R, but can activate pathways including MAPK and PI3K pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prlr.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prolactin receptor (Prlr) signaling in the hypothalamus modulates maternal core body temperature during pregnancy, contributing to thermal adaptation and enhancing offspring survival in warm environments."}], "pathway_id": "mmu04917", "pubmed_id": "40639999", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prolactin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Prolactin (PRL) is a polypeptide hormone known to be involved in a wide range of biological functions including osmoregulation, lactation, reproduction, growth and development, endocrinology and metabolism, brain and behavior, and immunomodulation. PRL mediates its action through PRLR, a transmembrane protein of the hematopoietin cytokine receptor superfamily. At the protein level, the long PRLR isoform (long-R) and several short PRLR isoforms (short-R) have been detected. Acting through the long-R, PRL activates many signaling cascades including Jak2/Stat, the major cascade, Src kinase, phosphatidylinositol-3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways. PRL cannot activate Jak2/Stat5 through the short-R, but can activate pathways including MAPK and PI3K pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRLR (activation), JAK2, STAT5 (phosphorylation), GR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the prolactin receptor long-form (PRLR) stimulates the JAK2/STAT5 signaling cascade in the hippocampus. Phosphorylated STAT5 interacts with the glucocorticoid receptor (GR), forming a transcriptional repressor complex that inhibits GR-dependent gene expression. This interaction contributes to hippocampal GR dysfunction, which is associated with depression-like behavior. Elevated PRLR expression and JAK2/STAT5 activation are linked to reduced GR expression and impaired nuclear translocation, leading to altered stress responses and depressive phenotypes."}], "pathway_id": "mmu04917", "pubmed_id": "41223679", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prolactin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Prolactin (PRL) is a polypeptide hormone known to be involved in a wide range of biological functions including osmoregulation, lactation, reproduction, growth and development, endocrinology and metabolism, brain and behavior, and immunomodulation. PRL mediates its action through PRLR, a transmembrane protein of the hematopoietin cytokine receptor superfamily. At the protein level, the long PRLR isoform (long-R) and several short PRLR isoforms (short-R) have been detected. Acting through the long-R, PRL activates many signaling cascades including Jak2/Stat, the major cascade, Src kinase, phosphatidylinositol-3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways. PRL cannot activate Jak2/Stat5 through the short-R, but can activate pathways including MAPK and PI3K pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pten (inactivation), Akt, Erk, Prolactin (signaling).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pten inactivation leads to Akt activation in pituitary cells, promoting cell cycle progression and tumorigenesis. This effect is specifically observed in prolactin-producing cells, resulting in prolactinoma formation. Downregulation of ERK signaling is associated with tumorigenic changes, while decreased vascularization and reduced cell adhesion proteins contribute to tumor development. Prolactin signaling is implicated in the pathogenesis of pituitary tumors."}], "pathway_id": "mmu04917", "pubmed_id": "39428000", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prolactin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Prolactin (PRL) is a polypeptide hormone known to be involved in a wide range of biological functions including osmoregulation, lactation, reproduction, growth and development, endocrinology and metabolism, brain and behavior, and immunomodulation. PRL mediates its action through PRLR, a transmembrane protein of the hematopoietin cytokine receptor superfamily. At the protein level, the long PRLR isoform (long-R) and several short PRLR isoforms (short-R) have been detected. Acting through the long-R, PRL activates many signaling cascades including Jak2/Stat, the major cascade, Src kinase, phosphatidylinositol-3-kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways. PRL cannot activate Jak2/Stat5 through the short-R, but can activate pathways including MAPK and PI3K pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prolactin receptor, JAK2, STAT5, mTOR, PI3K, AKT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prolactin receptor-mediated activation of the JAK2/STAT5/mTOR signaling pathway promotes mammary epithelial cell lactation and the synthesis of milk proteins and lipids. Concurrent activation of the PI3K/AKT signaling pathway enhances mammary epithelial cell proliferation. These processes collectively support mammary gland development and prepare for lactation."}], "pathway_id": "mmu04917", "pubmed_id": "39393720", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Disulfiram (administration), TBK1 (activation), IRF3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disulfiram induces apoptosis in Kaposi's sarcoma-associated herpesvirus (KSHV)-positive primary effusion lymphoma (PEL) cells by activating antiviral innate immunity. This activation involves the TANK binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) signaling axis, which is critical for suppressing KSHV reactivation and virion production. Disruption of TBK1 or IRF3 reverses the antiviral and antitumor effects of disulfiram, indicating that these proteins are essential mediators of its therapeutic activity. Disulfiram also inhibits the initiation and progression of PEL tumors."}], "pathway_id": "mmu05167", "pubmed_id": "40036222", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Isogarcinol, Epidermal Growth Factor Receptor (expression), Cyclin A2 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cambogin inhibits the expression of Epidermal Growth Factor Receptor (EGFR) and Cyclin A2, leading to the suppression of SARS-CoV-2 replication and virion production. This compound also reduces the growth of Kaposi's sarcoma-associated herpesvirus (KSHV)-induced tumours. Its action targets host genes commonly affected by both SARS-CoV-2 and KSHV, thereby blocking viral infection and tumorigenesis."}], "pathway_id": "mmu05167", "pubmed_id": "39655540", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PAX5, RB1 (increased protein expression), E2F transcription factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PAX5 binds to RB1 and increases its protein expression, leading to repression of RB/E2F-regulated genes and induction of G1 cell cycle arrest. Down-regulation of PAX5 contributes to oncogenesis in primary effusion lymphoma by impairing B-cell differentiation and promoting tumor progression. PAX5 functions as a tumor suppressor by modulating cell cycle control and restoring B-cell identity markers."}], "pathway_id": "mmu05167", "pubmed_id": "39096792", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STAT3, CD19, Interleukin-21, CD23 (in B cells infected with gammaherpesviruses).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "STAT3 promotes B cell proliferation and differentiation during gammaherpesvirus infection, supporting viral latency. It facilitates the downregulation of surface CD23 in B cells infected with gammaherpesviruses and modulates the germinal center response. Loss of STAT3 impairs these processes, leading to reduced viral latency and enhanced interferon-stimulated gene expression. STAT3 also suppresses type I and type II interferon responses in infected B cells, thereby limiting antiviral immunity."}], "pathway_id": "mmu05167", "pubmed_id": "38170993", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Echinomycin (administration), MYC (expression), HIF1A (expression), KDM4B (expression), MAPT (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Echinomycin inhibits the expression of MYC and HIF1A, two oncoproteins involved in Kaposi's sarcoma-associated herpesvirus (KSHV) pathogenesis. This inhibition leads to reduced cell growth in KSHV-positive tumor cells and induces viral lytic gene expression without increasing infectious virion production. Additionally, Echinomycin modulates the expression of KDM4B and MAPT, which are essential for the survival of KSHV-infected tumor cells."}], "pathway_id": "mmu05167", "pubmed_id": "37143124", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Mus musculus (house mouse)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CUL4B, E3 ubiquitin ligase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CUL4B, an E3 ubiquitin ligase, facilitates the establishment of latency in germinal center B cells during gammaherpesvirus infection. This process involves the ubiquitylation of host proteins, which alters their stability, localization, or function, thereby supporting persistent viral infection. The activity of CUL4B contributes to the long-term survival of the virus within B cells, enabling chronic gammaherpesvirus infection."}], "pathway_id": "mmu05167", "pubmed_id": "37962378", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BATF, PD-L1 (reduced expression), PD-1, STAT1, TIM-3, LAG-3, CD8, CD4, GZMB (increased level), IFNG (increased level).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "BATF promotes tumor proliferation and immune evasion by upregulating PD-L1 expression via the STAT1 signaling pathway. Elevated PD-L1 expression on tumor cells engages PD-1 receptors on T cells, suppressing T-cell mediated anti-tumor immunity. BATF deficiency reduces PD-L1 expression and enhances CD8 and CD4 T-cell infiltration, increasing the production of cytotoxic molecules such as granzyme B and IFN-. This leads to increased anti-tumor immunity and reduced tumor growth and metastasis."}], "pathway_id": "mmu05235", "pubmed_id": "41075009", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Anlotinib (administration), Programmed Death-Ligand 1 (downregulation), Programmed Cell Death Protein 1, Janus Kinase 2, Signal Transducer and Activator of Transcription 3, Vascular Endothelial Growth Factor A (downregulation), Ki-67 Antigen.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Anlotinib reduces expression of Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor A (VEGF-A) by suppressing the JAK2/STAT3 signaling pathway. This downregulation decreases intratumoral microvascular density and alters tumor vascular structure. Concurrently, anlotinib promotes CD4+ T-cell infiltration into the tumor microenvironment. The combination of PD-1/PD-L1 blockade with anlotinib enhances T-cell-mediated antitumor activity by restoring immune surveillance and suppressing immunosuppressive mechanisms."}], "pathway_id": "mmu05235", "pubmed_id": "41083765", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tasquinimod (administration), S100A9, PARP1, STAT3 (phosphorylated at Tyr705), CD274 (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "S100A9 interacts with PARP1 and promotes its degradation through the ubiquitin-proteasome pathway. This leads to increased phosphorylation of STAT3 at Tyr705, which in turn enhances the transcription of PD-L1. Elevated PD-L1 expression contributes to immune evasion by suppressing T-cell mediated immune responses. Inhibition of S100A9 with Tasquinimod restores sensitivity to anti-PD-1 therapy by reducing PD-L1 expression."}], "pathway_id": "mmu05235", "pubmed_id": "40658314", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Metformin (administration), Programmed Cell Death Protein 1 (Present on T cells), Programmed Death-Ligand 1 (expressed on tumor cells), TPP1 (administration), Interferon Gamma.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PD-L1 expression on tumor cells engages PD-1 receptors on T cells, suppressing T cell-mediated anti-tumor immune responses and promoting immune evasion. Metformin inhibits PD-L1 expression while inducing apoptosis and suppressing tumor cell proliferation. The peptide inhibitor TPP1 blocks the PD-1/PD-L1 interaction, restoring T cell activation and promoting IFN- secretion. Combined targeting of PD-L1 and tumor cell proliferation through these mechanisms results in effective tumor growth inhibition."}], "pathway_id": "mmu05235", "pubmed_id": "40592481", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TRIM6 (ablated), cGAS (stabilization), STING1, CD8, PDCD1, CD274.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM6 catalyzes K27-linked polyubiquitination of cGAS, leading to its proteasomal degradation and suppression of the cGAS-STING1 signaling pathway. This inhibition reduces CD8+ T cell infiltration and impairs antitumor immunity. TRIM6 ablation stabilizes cGAS, activates the cGAS-STING1 axis, enhances CD8+ T cell infiltration, and synergizes with PD-L1 immune checkpoint blockade to promote antitumor immune responses in microsatellite stable gastric tumors."}], "pathway_id": "mmu05235", "pubmed_id": "40817248", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2'3'-Cyclic guanosine monophosphate-adenosine monophosphate (administration), Programmed Cell Death Ligand 1 (upregulation in hepatocellular carcinoma), Stimulator of Interferon Genes (activation), CD8-positive T cell, M2 macrophage.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "cGAMP activates the STING signaling pathway, leading to increased cytotoxic activity of CD8+ T cells and reversal of the immunosuppressive tumor microenvironment characterized by M2 macrophages. This transformation converts cold tumors into hot tumors. Additionally, cGAMP induces upregulation of PD-L1 expression in hepatocellular carcinoma, enhancing the efficacy of PD-L1 blockade through anti-PD-L1 nanobodies and strengthening the immune response by inhibiting the PD-1/PD-L1 immune checkpoint."}], "pathway_id": "mmu05235", "pubmed_id": "40943568", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KCTD9 (high expression), PDCD1, CD8.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "High expression of KCTD9 correlates with improved colon cancer prognosis and is associated with increased CD8-positive - T-cell activation and infiltration. This enhanced T-cell activity contributes to improved anti-tumor efficacy of PD-1 inhibitors, suggesting that KCTD9 plays a role in modulating immune response and tumor immunity."}], "pathway_id": "mmu05235", "pubmed_id": "40561177", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PD-L1 expression and PD-1 checkpoint pathway in cancer - Mus musculus (house mouse)\n**Pathway Description**: Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: OTUD1, STAT3, CD274, PDCD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "OTUD1 interacts with and deubiquitinates STAT3, stabilizing the protein and inhibiting its nuclear translocation and transcriptional activity. This leads to reduced PD-L1 expression on tumor cells. Lower PD-L1 levels decrease engagement with PD-1 receptors on T cells, thereby enhancing antitumor immunity and impairing immune evasion mediated by the PD-1/PD-L1 pathway."}], "pathway_id": "mmu05235", "pubmed_id": "40506611", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Atf3 (deficiency), Rap1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Atf3 deficiency activates the Rap1 signaling pathway, which promotes mesodermal commitment and enhances endothelial cell development and maturation."}], "pathway_id": "mmu04015", "pubmed_id": "41064856", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Losartan, Dipeptidyl peptidase 3 (circulating), RAP1 GEF 4 (upregulated), Phosphofructokinase, platelet type, Y-box binding protein 1, ADP-ribosylation factor 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Circulating Dipeptidyl peptidase 3 (DPP3) upregulates RAP1 GEF 4 (RAPGEF4) to activate the Rap1 signaling pathway in lung endothelial cells through the DPP3-PFKP-YBX1 axis. This activation promotes angiogenesis and remodeling of the vascular niche, which facilitates lung metastasis."}], "pathway_id": "mmu04015", "pubmed_id": "41311249", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Esi-09, RAPGEF3 (Inhibited), RAP1A, RAP1B, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAPGEF3 activates RAP1A, which in turn activates AKT signaling, promoting cell proliferation and survival. This signaling axis contributes to tumor progression in basal-subtype lung squamous cell carcinoma. Inhibition of RAPGEF3 disrupts this pathway and suppresses tumor growth."}], "pathway_id": "mmu04015", "pubmed_id": "40781157", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAS, RAP1 (activated), PI3K-AKT (activated), MAPK.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rap1 signaling is activated during the early stages of wound healing, where it interacts with Ras and MAPK pathways to regulate cell proliferation and migration. Concurrent activation of PI3K-Akt signaling supports cell survival and growth. These signaling cascades are modulated by extracellular vesicles, which enhance cytokine secretion and reprogram inflammatory mediator dynamics, promoting fibroblast and keratinocyte activity. This coordinated signaling enhances tissue regeneration and wound closure."}], "pathway_id": "mmu04015", "pubmed_id": "40728022", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IgSF11, RAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IgSF11 interacts with RAP1 to form a signaling complex that promotes melanoma cell migration and invasion. This interaction facilitates the epithelial-mesenchymal transition and enhances the malignant phenotype of melanoma cells through the integration of cell adhesion and signaling pathways."}], "pathway_id": "mmu04015", "pubmed_id": "40635001", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: beta-Glycerophosphate, PARP1, POLG (downregulated), Adora2a (activated), Rap1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PARP1-mediated PARylation of POLG triggers PARylation-dependent ubiquitination of POLG, leading to its downregulation and subsequent mitochondrial dysfunction. This process activates the Adora2a/Rap1 signaling pathway, which induces vascular smooth muscle cell ferroptosis. The resulting ferroptosis exacerbates vascular calcification."}], "pathway_id": "mmu04015", "pubmed_id": "40401372", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: THEMIS2 (elevated expression), DOCK4 (phosphorylation at serine 1787), TBK1, CRK, RAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of THEMIS2 promotes metastasis by recruiting TBK1 to DOCK4, leading to phosphorylation at serine 1787 of DOCK4. This modification enhances the interaction between DOCK4 and CRK, which in turn activates Rap1 signaling. Activation of Rap1 contributes to epithelial-mesenchymal transition and cytoskeletal rearrangement, thereby increasing the migratory and invasive capacities of ovarian cancer cells."}], "pathway_id": "mmu04015", "pubmed_id": "40227532", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ingenol Mebutate, Collagen Type VI Alpha 1 Chain (inhibited), Exchange Protein Directly Activated by cAMP, Ras-related Protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "COL6A1 activates the EPAC/RAP1 signaling axis, which enhances osteoclast differentiation and formation. This leads to increased subchondral bone remodeling and contributes to osteoarthritis progression. Inhibition of COL6A1 reduces these effects, attenuating osteoclast-mediated bone resorption and slowing the development of osteoarthritis."}], "pathway_id": "mmu04015", "pubmed_id": "40143596", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nocodazole.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Spindle Assembly Checkpoint (SAC) function during meiosis I is modulated by oocyte cytoplasmic volume. Increased cytoplasmic volume reduces SAC efficiency, leading to a higher proportion of oocytes bypassing SAC-induced metaphase I arrest and proceeding to polar body extrusion and meiosis II. Conversely, reduced cytoplasmic volume enhances SAC activity, preventing premature progression through meiosis I. This relationship is specific to the prophase stage, before nuclear envelope breakdown, suggesting that SAC function depends on nuclear-associated factors whose cytoplasmic concentration is influenced by oocyte volume."}], "pathway_id": "mmu04114", "pubmed_id": "41144805", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: REC8 (reduced levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced levels of REC8, a meiotic cohesin, lead to premature sister chromatid separation during meiosis. When REC8 levels fall below a critical threshold, the structural integrity of chromosome cohesion is compromised, increasing the likelihood of aneuploidy in oocytes. This effect is nonlinear, such that moderate reductions in REC8 do not significantly impact chromatid stability until a vulnerability threshold is crossed. Additional factors, such as cytoskeletal disruption and centromere dysfunction, can further exacerbate chromatid separation in the context of weakened cohesion, contributing to elevated aneuploidy rates in aged oocytes."}], "pathway_id": "mmu04114", "pubmed_id": "41184483", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pluripotent stem cells, Oocyte-like cells (differentiation into germinal vesicle-stage).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pluripotent stem cells can differentiate into germinal vesicle-stage oocyte-like cells under specific in vitro conditions. These oocyte-like cells exhibit characteristics of early oocyte development, including the capacity for meiotic resumption, a process essential for oocyte maturation and progression through meiosis."}], "pathway_id": "mmu04114", "pubmed_id": "41187705", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NDC80-NUF2 complex, HURP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Premature chromosome separation during meiosis I and II in oocytes leads to chromosome mis-segregation and aneuploidy. Artificial kinetochores composed of NDC80-NUF2-tethered protein particles compete with chromosomal kinetochores for HURP-decorated microtubules. This competition reduces excessive bipolar microtubule pulling forces exerted on chromosomes, thereby preventing premature separation and suppressing aneuploidy."}], "pathway_id": "mmu04114", "pubmed_id": "41188464", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Camp, Cgmp, Phosphodiesterase 3A (active).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Luteinizing hormone signaling in granulosa cells initiates a decrease in cGMP levels in the oocyte, which relieves the inhibition of PDE3A phosphodiesterase. This leads to the degradation of cAMP within the oocyte. Additionally, LH induces the closure of gap junctions between granulosa cells, preventing further diffusion of cAMP into the oocyte. The combined reduction of cAMP in the oocyte reinitiates meiotic progression."}], "pathway_id": "mmu04114", "pubmed_id": "41329740", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YWHAZ (phosphorylated at distinct residues), AKT1, CDC25B (phosphorylated), MAPK8, CSNK1A1, YWHAQ.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of YWHAZ at serine 58 by AKT1 promotes meiotic resumption in mouse oocytes. This phosphorylation event facilitates the interaction between YWHAZ and phosphorylated CDC25B, a key regulator of cell cycle progression. YWHAZ also forms a heterodimer with YWHAQ. These interactions are mediated through signaling pathways involving MAPK8, CSNK1A1, and AKT1, which phosphorylate YWHAZ at distinct residues. This signaling cascade contributes to the regulation of meiotic arrest and resumption."}], "pathway_id": "mmu04114", "pubmed_id": "41237317", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Histone H2B, Tubulin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Histone H2B is involved in chromatin structure and labeling during meiosis in mouse oocytes, while tubulin forms the microtubule spindle necessary for chromosome segregation. During oocyte meiosis, these components contribute to the accurate separation of chromosomes, a process essential for preventing aneuploidy and ensuring proper embryonic development."}], "pathway_id": "mmu04114", "pubmed_id": "41144491", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EIF4E2, MOS (Increased), CCNB1 (Increased), EIF4E, PATL2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "4E-T binds eIF4E and PATL2 to repress the translation of maternal mRNAs in prophase-I-arrested oocytes. This translational repression is essential for maintaining the prophase-I arrest. Loss of 4E-T leads to premature translation of meiotic regulators such as MOS and CCNB1, resulting in spontaneous resumption of meiosis. Functional inactivation of 4E-T disrupts this repression mechanism, causing untimely meiotic progression and destabilizing the oocyte pool in female vertebrates."}], "pathway_id": "mmu04114", "pubmed_id": "40877279", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, Nocodazole, PSRC1, Spindle Assembly Checkpoint, Kinetochore-Microtubule.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PSRC1 localizes to the poles of the spindle during mouse oocyte meiosis and plays a critical role in maintaining proper spindle assembly and microtubule organization. Disruption of PSRC1 function results in abnormal spindle morphology, persistent activation of the spindle assembly checkpoint, impaired kinetochore-microtubule attachments, and an increased incidence of aneuploidy. Both reduced and excessive PSRC1 levels lead to defects in spindle formation and elevated rates of large polar bodies, indicating that PSRC1 is essential for accurate chromosome segregation during oocyte maturation."}], "pathway_id": "mmu04114", "pubmed_id": "40810374", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Mus musculus (house mouse)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KIF11, Kif11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KIF11, a kinesin motor protein also known as Eg5, drives spindle bipolarization by sliding antiparallel microtubules, thereby elongating the spindle structure in acentrosomal oocytes. During meiosis I, this process is essential for stretching homologous chromosome pairs and establishing chromosome biorientation at the spindle equator. Insufficient KIF11 function leads to impaired spindle elongation, resulting in a partially bipolarized spindle. This defect allows chromosome stretching in the inner equatorial region but not in the outer region, where merotelic kinetochore-microtubule attachments are more likely to form. Biallelic functional KIF11 is therefore necessary for proper bipolar spindle assembly and spatially differential chromosome biorientation during meiosis I in oocytes."}], "pathway_id": "mmu04114", "pubmed_id": "40835973", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cushing syndrome - Mus musculus (house mouse)\n**Pathway Description**: Cushing syndrome (CS) is a rare disorder resulting from prolonged exposure to excess glucocorticoids via exogenous and endogenous sources. The typical clinical features of CS are related to hypercortisolism and include accumulation of central fat, moon facies, neuromuscular weakness, osteoporosis or bone fractures, metabolic complications, and mood changes. Traditionally, endogenous CS is classified as adrenocorticotropic hormone (ACTH)-dependent (about 80%) or ACTH- independent (about 20%). Among ACTH-dependent forms, pituitary corticotroph adenoma (Cushing's disease) is most common. Most pituitary tumors are sporadic, resulting from monoclonal expansion of a single mutated cell. Recently recurrent activating somatic driver mutations in the ubiquitin-specific protease 8 gene (USP8) were identified in almost half of corticotroph adenoma. Germline mutations in MEN1 (encoding menin), AIP (encoding aryl-hydrocarbon receptor-interacting protein), PRKAR1A (encoding cAMP-dependent protein kinase type I alpha regulatory subunit) and CDKN1B (encoding cyclin-dependent kinase inhibitor 1B; also known as p27 Kip1) have been identified in familial forms of pituitary adenomas. However, the frequency of familial pituitary adenomas is less than 5% in patients with pituitary adenomas. Among ACTH-independent CS, adrenal adenoma is most common. Rare adrenal causes of CS include primary bilateral macronodular adrenal hyperplasia (BMAH) or primary pigmented nodular adrenocortical disease (PPNAD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Resmetirom, Liothyronine, acyl-CoA binding protein (elevated levels), diazepam binding inhibitor, gamma-aminobutyric acid (GABA) A receptor subunit gamma2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of acyl-CoA binding protein (ACBP), encoded by the Dbi gene, contribute to the pathogenesis of Cushing's syndrome by promoting increased food intake, weight gain, excessive adiposity, liver damage, hypertriglyceridaemia, and type 2 diabetes. ACBP interacts with the Gabrg2 receptor, and its activity can be inhibited through autoantibody induction, neutralizing antibodies, Dbi gene knockout, Gabrg2 mutation, or thyroid hormone-based transcriptional suppression. Targeting ACBP/DBI disrupts the metabolic and physiological disturbances associated with Cushing's syndrome."}], "pathway_id": "mmu04934", "pubmed_id": "39578649", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cushing syndrome - Mus musculus (house mouse)\n**Pathway Description**: Cushing syndrome (CS) is a rare disorder resulting from prolonged exposure to excess glucocorticoids via exogenous and endogenous sources. The typical clinical features of CS are related to hypercortisolism and include accumulation of central fat, moon facies, neuromuscular weakness, osteoporosis or bone fractures, metabolic complications, and mood changes. Traditionally, endogenous CS is classified as adrenocorticotropic hormone (ACTH)-dependent (about 80%) or ACTH- independent (about 20%). Among ACTH-dependent forms, pituitary corticotroph adenoma (Cushing's disease) is most common. Most pituitary tumors are sporadic, resulting from monoclonal expansion of a single mutated cell. Recently recurrent activating somatic driver mutations in the ubiquitin-specific protease 8 gene (USP8) were identified in almost half of corticotroph adenoma. Germline mutations in MEN1 (encoding menin), AIP (encoding aryl-hydrocarbon receptor-interacting protein), PRKAR1A (encoding cAMP-dependent protein kinase type I alpha regulatory subunit) and CDKN1B (encoding cyclin-dependent kinase inhibitor 1B; also known as p27 Kip1) have been identified in familial forms of pituitary adenomas. However, the frequency of familial pituitary adenomas is less than 5% in patients with pituitary adenomas. Among ACTH-independent CS, adrenal adenoma is most common. Rare adrenal causes of CS include primary bilateral macronodular adrenal hyperplasia (BMAH) or primary pigmented nodular adrenocortical disease (PPNAD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Orexin A, Cortisol, OX1R, MTOR, RPS6KB1, HSD3B1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Orexin-A activates the mTOR/p70S6K1 signaling pathway in adrenocortical cells, which suppresses autophagy. This suppression of autophagy increases the expression of HSD3B1, the rate-limiting enzyme in cortisol synthesis, thereby promoting cortisol secretion."}], "pathway_id": "mmu04934", "pubmed_id": "37572990", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cushing syndrome - Mus musculus (house mouse)\n**Pathway Description**: Cushing syndrome (CS) is a rare disorder resulting from prolonged exposure to excess glucocorticoids via exogenous and endogenous sources. The typical clinical features of CS are related to hypercortisolism and include accumulation of central fat, moon facies, neuromuscular weakness, osteoporosis or bone fractures, metabolic complications, and mood changes. Traditionally, endogenous CS is classified as adrenocorticotropic hormone (ACTH)-dependent (about 80%) or ACTH- independent (about 20%). Among ACTH-dependent forms, pituitary corticotroph adenoma (Cushing's disease) is most common. Most pituitary tumors are sporadic, resulting from monoclonal expansion of a single mutated cell. Recently recurrent activating somatic driver mutations in the ubiquitin-specific protease 8 gene (USP8) were identified in almost half of corticotroph adenoma. Germline mutations in MEN1 (encoding menin), AIP (encoding aryl-hydrocarbon receptor-interacting protein), PRKAR1A (encoding cAMP-dependent protein kinase type I alpha regulatory subunit) and CDKN1B (encoding cyclin-dependent kinase inhibitor 1B; also known as p27 Kip1) have been identified in familial forms of pituitary adenomas. However, the frequency of familial pituitary adenomas is less than 5% in patients with pituitary adenomas. Among ACTH-independent CS, adrenal adenoma is most common. Rare adrenal causes of CS include primary bilateral macronodular adrenal hyperplasia (BMAH) or primary pigmented nodular adrenocortical disease (PPNAD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Corticosterone, Cortisone, 11-Dehydrocorticosterone, Cortisol, HSD11B1, HSD11B1 mRNA (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated glucocorticoid levels lead to tissue-specific modulation of 11 hydroxysteroid dehydrogenase type-1 (HSD11B1) mRNA expression. In the hippocampus and liver, increased glucocorticoid exposure results in decreased HSD11B1 mRNA levels, whereas in abdominal adipose tissue, it causes an increase in HSD11B1 mRNA. This differential regulation contributes to localized alterations in glucocorticoid bioavailability and activity, influencing metabolic and neuroendocrine functions in Cushing syndrome."}], "pathway_id": "mmu04934", "pubmed_id": "35339573", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Memantine, Inhba (restored), Bdnf (restored), Homer1 (restored), Atf3, Egr1, Fos, Npas4, Ppp1r1b.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Excitotoxic extrasynaptic NMDA receptor signaling suppresses key neuroprotective genes such as Inhba and Bdnf, along with genes involved in synaptic function like Homer1. This transcriptional dysregulation is mediated through CREB inactivation and disruption of the ERK/MAPK-ELK1/SRF signaling pathway. The suppression of these genes contributes to neurodegeneration and reduced synaptic plasticity. Inhibition of extrasynaptic NMDA receptor signaling restores expression of Inhba, Homer1, and Bdnf, thereby attenuating neurodegenerative processes and improving disease markers."}], "pathway_id": "mmu04722", "pubmed_id": "41339520", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tanshinone Iia (administration), Camp, BDNF (elevated production), PKA, CREB (phosphorylated), neural stem cells, ApoE.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tanshinone IIA increases cyclic adenosine monophosphate (cAMP) levels, leading to the activation of protein kinase A (PKA) and subsequent phosphorylation of cAMP response element binding protein (CREB). This cascade results in elevated brain-derived neurotrophic factor (BDNF) production, which promotes the proliferation, differentiation, and survival of neural stem cells in the hippocampus. These processes contribute to enhanced hippocampal neurogenesis."}], "pathway_id": "mmu04722", "pubmed_id": "41273473", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Salicin (administration), Boro-Scopol, Brain-derived neurotrophic factor (expression), Presenilin 1, Acetylcholinesterase (levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Salicin modulates the neurotrophin signaling pathway by influencing the expression and activity of brain-derived neurotrophic factor (BDNF), a key mediator of neuronal survival and synaptic plasticity. It also affects acetylcholinesterase (AChE) levels, thereby influencing cholinergic signaling and cognitive function. Additionally, Salicin interacts with presenilin 1 (PSEN-1), a core component of the -secretase complex involved in amyloid precursor protein processing. These interactions contribute to the mitigation of memory dysfunction and neurodegeneration through the modulation of oxidative stress and inflammatory pathways."}], "pathway_id": "mmu04722", "pubmed_id": "41192561", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2,2,6,6-Tetramethylpiperidin-1-ol, Tempol (administration), Malonaldehyde, Gamma-Aminobutyric Acid, L-Glutamic Acid, Dihydroethidium, BDNF (reduced activity), NTRK2, CREB1, GABAergic Neurons.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated reactive oxygen species (ROS) levels induce oxidative stress, which downregulates brain-derived neurotrophic factor (BDNF) expression. Reduced BDNF activity attenuates the CREB/BDNF/TrkB signaling pathway, leading to impaired GABAergic neuron development and function. This disruption contributes to cognitive impairments and neurodevelopmental abnormalities. Antioxidants such as Tempol reduce ROS levels, restore BDNF activity, and alleviate oxidative damage to GABAergic neurons, thereby mitigating the pathological effects of oxidative stress in neurodevelopment."}], "pathway_id": "mmu04722", "pubmed_id": "41161374", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SRY (sex determining region Y)-box 9 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SOX9 upregulation induces a stem-like transcriptional state in high-grade serous ovarian cancer cells, leading to increased chemoresistance. This transcriptional reprogramming promotes the formation of a cancer stem cell-like subpopulation, which is associated with resistance to platinum-based chemotherapy."}], "pathway_id": "mmu01524", "pubmed_id": "41031891", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, FAM172A (elevated expression), Phosphatidylinositol-4,5-bisphosphate 3-kinase, Protein kinase B (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of FAM172A promotes epithelial ovarian cancer progression by activating the PI3K/Akt signaling pathway. This activation enhances cell proliferation, migration, and invasion, contributing to tumor growth and metastasis. Additionally, FAM172A-induced activation of the PI3K/Akt pathway confers resistance to cisplatin, a platinum-based chemotherapeutic agent, by modulating cellular responses to DNA damage and apoptosis."}], "pathway_id": "mmu01524", "pubmed_id": "41339379", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Platinum, TP53 (mutated (R175G)), CHD1 (targeted), IL7R (targeted).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TP53 R175H and R175G mutations exhibit distinct functional properties in promoting platinum resistance and tumor progression. TP53 R175H is associated with the upregulation of extracellular matrix-related genes, while TP53 R175G activates cytokine receptor interaction and membrane trafficking pathways. The chromatin remodeling protein CHD1 selectively interacts with TP53 R175G, modulating its transcriptional activity, including that of IL7R. This interaction contributes to resistance against platinum-based drugs. Targeting CHD1 or IL7R can synergistically enhance platinum sensitivity in tumors harboring the TP53 R175G mutation."}], "pathway_id": "mmu01524", "pubmed_id": "41249788", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin (administration), Carboplatin (administration), LRRC8A (acetylated), LRRC8D (acetylated), NAA60, BRCA1, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cisplatin and carboplatin require the volume-regulated anion channel subunits LRRC8A and LRRC8D for approximately 50% of their cellular uptake. N-terminal acetylation of LRRC8A and LRRC8D by NAA60 enhances their functionality, promoting efficient platinum drug uptake. Disruption of this acetylation reduces drug influx, leading to resistance in BRCA1 and TP53-deficient cells. This mechanism underscores the role of NAA60 in modulating platinum drug sensitivity through regulation of LRRC8A/D activity."}], "pathway_id": "mmu01524", "pubmed_id": "41053424", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II), Selinexor, XPO1 (elevated expression), TP53 (nuclear retention), CDKN1A (upregulation), SLC7A11 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated XPO1 expression promotes platinum drug resistance by facilitating the cytoplasmic export of tumor suppressor proteins such as p53. Inhibition of XPO1 by KPT-330 results in nuclear retention of p53, which upregulates CDKN1A and downregulates SLC7A11. This leads to G2/M phase arrest, mitochondrial dysfunction, and the induction of both apoptosis and ferroptosis, thereby restoring sensitivity to oxaliplatin in resistant colorectal cancer cells."}], "pathway_id": "mmu01524", "pubmed_id": "41133455", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cisplatin, Hydroxychloroquine, 4-Phenylbutyric Acid, DNAJC5 (elevated expression), HSPA5, ERN1, XBP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of DNAJC5 upregulates the BiP-IRE1-XBP1 endoplasmic reticulum stress signaling pathway, which activates autophagy in epithelial ovarian cancer cells. This autophagic process enhances resistance to cisplatin by reducing apoptosis and promoting cell survival. Inhibition of autophagy reverses this resistance, indicating a direct role for DNAJC5-mediated ER stress and autophagy in platinum drug resistance."}], "pathway_id": "mmu01524", "pubmed_id": "41038875", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Baicalin (effect), Cisplatin (reduced detoxification), GSTP1 (inhibited activity), Cysteine 47, JNK (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Baicalin interacts with the cysteine 47 residue of glutathione S-transferase  (GSTP1), inhibiting its activity. This inhibition reduces the detoxification capacity of GSTP1, thereby increasing intracellular accumulation of cisplatin. In parallel, baicalin activates the c-Jun N-terminal kinase (JNK) pathway in cisplatin-resistant head and neck squamous cell carcinoma cells. The combined effect of enhanced cisplatin retention and JNK pathway activation leads to increased apoptosis and reversal of cisplatin resistance. Mutation of cysteine 47 in GSTP1 abrogates this effect, confirming the direct dependence of the mechanism on GSTP1 modification."}], "pathway_id": "mmu01524", "pubmed_id": "40987408", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SYCP2 (elevated expression), ABL1 (inhibited), RAD51.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of SYCP2 contributes to platinum resistance in ovarian cancer. ABL1-mediated tyrosine phosphorylation of SYCP2 at residue Y739 enhances its function at R-loop sites by promoting RAD51 localization and facilitating transcription-coupled homologous recombination repair. This repair mechanism supports cancer cell survival under DNA damage conditions. Inhibition of ABL1 disrupts this phosphorylation, impairs homologous recombination repair, and increases cancer cell death in platinum-resistant ovarian cancer."}], "pathway_id": "mmu01524", "pubmed_id": "40918650", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Peiminine (administration), Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II), BCL2 (downregulation), BAX (upregulation), PARP1 (cleavage), CYCS (release), CASP3 (cleavage), CASP9 (cleavage), RAS, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Peiminine enhances the efficacy of oxaliplatin against gastric cancer by simultaneously activating the mitochondrial apoptosis pathway and inhibiting the RAS/PI3K/AKT survival pathway. This dual mechanism is characterized by upregulation of BAX, release of cytochrome c, and cleavage of caspase-9, caspase-3, and PARP, while suppressing BCL2 and phospho-AKT. These interactions promote apoptosis and reduce tumor cell proliferation, contributing to improved tumor growth inhibition in preclinical models."}], "pathway_id": "mmu01524", "pubmed_id": "40912051", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (administration), CDH2 (reduced expression), CTNNB1 (reduced levels), VIM (reduced expression), SNAI1 (reduced levels), SNAI2 (reduced levels), PIK3CA, AKT1, GSK3B (suppressed).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hydrogen peroxide inhibits the PI3K/AKT/GSK3 signaling pathway, leading to the degradation of EMT regulators SNAI1, SNAI2, and CTNNB1. This suppression reduces the expression of EMT markers CDH2 and VIM, thereby inhibiting cell migration and invasion. These effects contribute to the suppression of metastasis and the reversal of platinum drug resistance in ovarian cancer."}], "pathway_id": "mmu01524", "pubmed_id": "40772995", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Platinum drug resistance - Mus musculus (house mouse)\n**Pathway Description**: Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, Bms-777607 (administration), Sotuletinib (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tumor-associated macrophages (TAMs), particularly the M2-polarized subset, promote resistance to paclitaxel in ovarian cancer by increasing tumor cell viability and reducing drug sensitivity. The presence of TAMs within the tumor microenvironment contributes to chemotherapy resistance, and targeting TAMs using CSF-1R inhibitors like BLZ945 can enhance the efficacy of paclitaxel by reducing tumor burden and preventing regrowth. Receptor tyrosine kinase inhibition with BMS777607 also reduces TAM-mediated resistance by repolarizing M2 macrophages."}], "pathway_id": "mmu01524", "pubmed_id": "40747680", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Artesunate (administration), Signal Transducer and Activator of Transcription 3 (inhibited phosphorylation), Tumor Protein p53, Cyclin-Dependent Kinase Inhibitor 1A (reduced expression), Alpha Smooth Muscle Actin (expression), Fibronectin 1 (expression), Collagen Type I Alpha 1 Chain (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Artesunate inhibits the phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3), which leads to the suppression of Tumor Protein p53 (p53)-mediated fibroblast senescence. This inhibition reduces the expression of senescence-associated markers such as Cyclin-Dependent Kinase Inhibitor 1A (p21), as well as myofibroblast markers like Alpha Smooth Muscle Actin (-SMA) and extracellular matrix proteins including Fibronectin 1 and Collagen Type I Alpha 1 Chain. These effects contribute to the attenuation of pulmonary fibrosis and collagen deposition."}], "pathway_id": "mmu04630", "pubmed_id": "41271031", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IL27RA, IL27RA knockout, IL6 (increased production), TJP1 (reduced expression), OCLN (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "IL27RA activates the JAK-STAT signaling pathway in immune cells, leading to increased production of IL6 and contributing to intestinal inflammation. This inflammatory response compromises the integrity of the intestinal mucosal barrier by reducing the expression of tight junction proteins such as TJP1 and OCLN, thereby promoting necrotizing enterocolitis."}], "pathway_id": "mmu04630", "pubmed_id": "41315384", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Curcumin (administration), STAT3, IL6 (elevated levels), TNF (elevated levels), IL1B (elevated levels), AKT1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Curcumin interacts with STAT3 and other key inflammatory proteins, modulating the JAK-STAT signaling pathway. This interaction suppresses the production of pro-inflammatory cytokines such as IL-6, TNF, and IL-1, thereby reducing inflammatory responses. Activation of AKT1 may also be affected, influencing downstream signaling cascades that regulate cell survival and inflammation."}], "pathway_id": "mmu04630", "pubmed_id": "41129534", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), Luteolin (administration), Apigenin (administration), Interleukin-6 (administration), Signal Transducer and Activator of Transcription 3 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The JAK-STAT signaling pathway is modulated by the binding of IL-6 to its receptor, which activates JAK kinases and subsequently phosphorylates STAT3. Activated STAT3 dimerizes and translocates to the nucleus to regulate gene expression involved in cell survival and proliferation. In hepatocellular carcinoma, the IL-6/STAT3 pathway promotes tumor progression by inhibiting apoptosis and suppressing immune responses. Quercetin, luteolin, and apigenin bind to STAT3, inhibiting its activation and downstream signaling, thereby reducing tumor growth and enhancing anti-tumor immunity."}], "pathway_id": "mmu04630", "pubmed_id": "41127994", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Curcumin, Unc119, Gnat1, Gnat2, Klhl18, UNC119 (dysfunction), GNAT1 (normal translocation disrupted), GNAT2 (normal translocation disrupted), JAK, STAT, Nuclear factor kappa B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "UNC119 dysfunction disrupts the normal translocation of GNAT1 and GNAT2 in photoreceptor cells, leading to progressive cone-rod dystrophy and photoreceptor degeneration. This disruption activates the JAK-STAT and NF-B signaling pathways in the retina, which contributes to inflammatory responses and further photoreceptor cell loss."}], "pathway_id": "mmu04630", "pubmed_id": "41107067", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Isorhamnetin 3-O-glucoside (administered), withalongolide L, Janus Kinase 2 (inhibited), Signal Transducer and Activator of Transcription 3 (phosphorylation suppressed), Interleukin 6 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of IL-6 activates JAK2, which subsequently phosphorylates STAT3, initiating its dimerization and nuclear translocation to regulate inflammatory gene expression. Inhibition of JAK2 prevents STAT3 phosphorylation, thereby suppressing the downstream inflammatory signaling cascade. Isorhamnetin-3-O-glucoside acts as a JAK2 inhibitor, reducing IL-6/JAK2/STAT3 signaling and attenuating inflammation and oxidative stress in the colon. This suppression also decreases the production of pro-inflammatory cytokines and protects against gut barrier disruption."}], "pathway_id": "mmu04630", "pubmed_id": "41101072", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ERAP1, MHC I, CD8+ T cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ERAP1 cleaves peptides in the endoplasmic reticulum to generate MHC I epitopes, which are essential for antigen presentation on the cell surface. Efficient ERAP1 activity enhances the presentation of antigens to CD8+ T cells, leading to increased T cell proliferation and the generation of effector memory CD8+ T cells. This process enhances immune stimulation and contributes to the inhibition of tumor growth."}], "pathway_id": "mmu04141", "pubmed_id": "41183209", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: DNAJC10, EGFR (reduced expression), XBP1 (splicing), IRE1A, SETD7 (recruitment).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "DNAJC10 regulates XBP1 splicing via the IRE1A branch of the unfolded protein response. Inhibition of XBP1 splicing by DNAJC10 reduces its binding to the EGFR promoter, thereby suppressing EGFR transcription. This suppression is mediated through reduced recruitment of the SETD7 methyltransferase, which decreases H3K4 methylation at the EGFR promoter. Reduced EGFR expression diminishes cell migration and invasion, thereby inhibiting tumor infiltration."}], "pathway_id": "mmu04141", "pubmed_id": "41191192", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cholesterol (increased levels), EMC2, FDFT1 (stabilized), HSP90.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EMC2 interacts with HSP90 to stabilize FDFT1 protein and ensure its proper localization in the endoplasmic reticulum membrane by preventing its degradation through ERAD. This interaction promotes intracellular cholesterol biosynthesis. Increased cholesterol levels impair ferroptosis susceptibility, thereby supporting tumor cell survival."}], "pathway_id": "mmu04141", "pubmed_id": "40931051", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FICD, HSPA5 (adenylylated), FAM134B, HSPA1A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FICD-mediated adenylylation of BiP (HSPA5) reduces its ability to induce the unfolded protein response and interact with FAM134B, thereby limiting ER-selective autophagy. Loss of FICD enhances BiP-dependent activation of the unfolded protein response and promotes ER-selective autophagy in stressed cardiomyocytes, which contributes to improved proteostasis and reduced cardiac hypertrophy and heart failure."}], "pathway_id": "mmu04141", "pubmed_id": "40820977", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tanshinone Iia (administration), SIRT5, METTL3, PINK1, Parkin, PERK (elevated levels), CHOP (elevated levels), NRF1, PPARGC1A, TFAM, ATF5 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tanshinone IIA interacts with SIRT5 and METTL3 to modulate the mitochondria-endoplasmic reticulum unfolded protein response. This interaction stabilizes mitochondrial function, restores mitochondrial membrane potential, and regulates calcium overload. Tanshinone IIA upregulates protective proteins such as PGC1-, TFAM, and NRF1 while downregulating ER stress markers including PERK, CHOP, and ATF5. These effects reduce oxidative stress and endoplasmic reticulum stress, thereby preventing microvascular endothelial damage and promoting mitochondrial biogenesis."}], "pathway_id": "mmu04141", "pubmed_id": "40543233", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sel1L, Derlin-1 (Reduced levels), Endoplasmic Reticulum Chaperones (Increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SEL1L forms a complex with HRD1 to facilitate ER-associated degradation (ERAD), a process essential for degrading misfolded proteins within the endoplasmic reticulum (ER). Disruption of SEL1L in Sertoli cells reduces HRD1 protein levels and impairs ERAD function, leading to elevated ER stress and increased expression of ER chaperones. This suggests a compensatory adaptation to maintain ER homeostasis despite compromised ERAD activity. Despite these perturbations, spermatogenesis remains intact, indicating that Sertoli cells can sustain their function under conditions of ER stress."}], "pathway_id": "mmu04141", "pubmed_id": "40498659", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Mus musculus (house mouse)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SEL1L, HRD1 (reduced levels), HSPA5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The SEL1L-HRD1 complex participates in ER-associated degradation (ERAD), a process that targets misfolded proteins for proteasomal degradation, thereby maintaining ER homeostasis. SEL1L depletion in spermatogenic cells does not impair ER homeostasis or induce ER stress, despite reducing HRD1 levels in spermatids. The absence of SEL1L does not lead to ER dilation, cell death, or disruption of male germ cell differentiation, indicating that the SEL1L-HRD1 complex is not essential for these processes in this cell type."}], "pathway_id": "mmu04141", "pubmed_id": "40412517", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Relaxin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Human relaxin-2 (\"relaxin\"), originally identified as a peptidic hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti-fibrotic and angiogenic effects in both males and females. It belongs to the so-called relaxin peptide family which includes the insulin-like peptides INSL3 and INSL5, and relaxin-3 (H3) as well as relaxin. INSL3 has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. These members of relaxin peptide family exert such effects binding to different kinds of receptors, classified as relaxin family peptide (RXFP) receptors: RXFP1, RXFP2, RXFP3, and RXFP4. These G protein-coupled receptors predominantly bind relaxin, INSL3, relaxin-3, and INSL-5, respectively. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Both RXFP3 and RXFP4 inhibit cAMP production, and RXFP3 activate MAP kinases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Estradiol, Relaxin (administration), Relaxin Family Peptide Receptor 1, Estrogen Receptor Alpha (phosphorylated at serine 118), Dual Specificity Phosphatase 1 (increased expression), Dual Specificity Phosphatase 5 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Relaxin binds to Relaxin Family Peptide Receptor 1 (RXFP1) and modulates estrogen receptor alpha (ER) activity in myometrial cells by reducing phosphorylation of ER at serine 118. This reduction in phosphorylation correlates with decreased ER genomic binding and altered regulation of the hormone-responsive transcriptome, including both downregulation and upregulation of specific genes. The inhibitory effects of relaxin on estrogen signaling require the activity of dual-specificity phosphatases DUSP1 and DUSP5, and result in diminished estrogen-dependent myometrial cell contraction."}], "pathway_id": "mmu04926", "pubmed_id": "39283953", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Relaxin signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Human relaxin-2 (\"relaxin\"), originally identified as a peptidic hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti-fibrotic and angiogenic effects in both males and females. It belongs to the so-called relaxin peptide family which includes the insulin-like peptides INSL3 and INSL5, and relaxin-3 (H3) as well as relaxin. INSL3 has clearly defined specialist roles in male and female reproduction, relaxin-3 is primarily a neuropeptide involved in stress and metabolic control, and INSL5 is widely distributed particularly in the gastrointestinal tract. These members of relaxin peptide family exert such effects binding to different kinds of receptors, classified as relaxin family peptide (RXFP) receptors: RXFP1, RXFP2, RXFP3, and RXFP4. These G protein-coupled receptors predominantly bind relaxin, INSL3, relaxin-3, and INSL-5, respectively. RXFP1 activates a wide spectrum of signaling pathways to generate second messengers that include cAMP and nitric oxide, whereas RXFP2 activates a subset of these pathways. Both RXFP3 and RXFP4 inhibit cAMP production, and RXFP3 activate MAP kinases.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sphingosine 1-Phosphate (elevated levels), Serelaxin, Beclin-1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Relaxin signaling increases sphingosine 1-phosphate (S1P) levels in cardiomyocytes and cardiac tissue, which modulates inflammation, fibrosis, and apoptosis. This pathway also reduces beclin-1 expression, indicating suppression of autophagy. Elevated S1P contributes to improved cardiac function and reduced post-ischemic remodeling."}], "pathway_id": "mmu04926", "pubmed_id": "35614179", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch, Wnt, Lgr5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Wnt signaling activation establishes spatial domains permissive for intestinal stem cell (ISC) specification. Within these Wnt-active zones, Notch-mediated lateral inhibition restricts ISC fate to a subset of cells, maintaining an approximate 1:40 ratio of ISCs to surrounding epithelial cells. Suppression of Notch signaling licenses fate commitment in these zones, promoting the emergence of Lgr5+ progenitor cells in the developing intestinal epithelium."}], "pathway_id": "mmu04310", "pubmed_id": "41337595", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACSM3 (over-expressed), AKT (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ACSM3 is associated with increased tumor growth and metastatic potential in breast cancer. ACSM3 functions as a tumor suppressor by modulating the WNT/AKT signaling pathway, which leads to the inhibition of cell proliferation, migration, and invasion. Over-expression of ACSM3 results in increased AKT phosphorylation and suppression of malignant cellular behaviors."}], "pathway_id": "mmu04310", "pubmed_id": "41318133", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glycyrrhizin (administration), CTNNB1, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the Wnt signaling pathway promotes osteogenesis while inhibiting osteoclastogenesis. Glycyrrhizic acid interacts with CTNNB1 and AKT1, modulating their activity and thereby influencing Wnt signaling to support bone formation and reduce bone resorption."}], "pathway_id": "mmu04310", "pubmed_id": "41320184", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucagon-Like Peptide 1, WISP1 (increased expression), LYZ (increased expression), SOX9 (increased expression), DEFA1 (increased expression), GCG (significantly downregulated), CHGA (significantly downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated WNT pathway activity in the tumor microenvironment correlates with increased expression of Paneth cell-associated markers including WISP1, LYZ, SOX9, and DEFA1. Concurrently, enteroendocrine cell-specific genes such as GCG and CHGA are significantly downregulated, contributing to reduced hormone and peptide secretion. This disruption in enteroendocrine signaling is associated with altered cell cycle regulation, increased proliferation, and reduced apoptosis, ultimately impacting overall survival."}], "pathway_id": "mmu04310", "pubmed_id": "41303610", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fgf22, Fgfr1 (expression), Fgfr2 (expression), Ctnnb1, Shh, Notch1, Bmp2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fgf22 promotes hair follicle stem cell (HFSC) proliferation and differentiation by activating Wnt/-Catenin, Sonic Hedgehog (Shh), and Notch signaling pathways, while simultaneously inhibiting BMP signaling. This leads to increased expression of Fgfr1 and Fgfr2 in HFSCs, enhanced cell viability, reduced apoptosis, and greater EdU incorporation, indicating active cell cycle progression. The absence of Fgf22 diminishes these effects, resulting in suppressed proliferation, increased apoptosis, and reduced differentiation of HFSCs."}], "pathway_id": "mmu04310", "pubmed_id": "41301478", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Borussertib (administration), SYT4, PSMC6 (stabilization), CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SYT4 interacts with PSMC6 through its C2B domain, leading to stabilization of the PSMC6 protein. This interaction activates the Wnt/-catenin signaling pathway, resulting in increased cell proliferation, cell cycle progression, and suppression of apoptosis. Inhibition of SYT4 with borussertib disrupts this interaction and attenuates the oncogenic effects associated with Wnt/-catenin pathway activation."}], "pathway_id": "mmu04310", "pubmed_id": "41281742", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FZD6 (inhibited), SRC, STAT3, WEE1, PLK1, PKMYT1 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of FZD6 in prostate cancer cells promotes tumor proliferation and resistance to therapy through activation of SRC kinase and STAT3. FZD6 also supports DNA double-strand break repair via WEE1 regulation through PLK1. Inhibition of FZD6 impairs DNA repair capacity and sensitizes prostate cancer cells to genotoxic agents. This effect is further enhanced by concurrent inhibition of PKMYT1, a WEE kinase family member, revealing a therapeutic vulnerability in FZD6-dependent prostate cancers."}], "pathway_id": "mmu04310", "pubmed_id": "41286306", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SHANK1, EZH2 (elevated levels), CTNNB1, IDH1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SHANK1 inhibits Wnt/-catenin signaling by reducing -catenin levels and the expression of downstream target genes. SHANK1 is epigenetically silenced through H3K27 trimethylation at its promoter by EZH2, a component of the polycomb repressive complex 2. This silencing contributes to the maintenance of glioblastoma stem cells and tumor progression. Reduced SHANK1 expression correlates with elevated -catenin and EZH2 levels in glioblastoma tissues."}], "pathway_id": "mmu04310", "pubmed_id": "41274253", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EFNB2 (elevated expression), CTNNB1 (stabilized and translocated to nucleus), WNT (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated Ephrin-B2 expression promotes tumor growth by enhancing cell proliferation and inhibiting apoptosis. This is mediated through activation of the Wnt/-catenin signaling pathway, where Ephrin-B2 facilitates the stabilization and nuclear translocation of -catenin, leading to the activation of Wnt-regulated genes. This results in disruption of the cell cycle at the G0/G1 phase and contributes to oncogenic progression."}], "pathway_id": "mmu04310", "pubmed_id": "41268595", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nkx2-2as, CTNNB1 (oncogenic), TCF7, MYC, AXIN2, BTG2 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Nkx2-2as downregulates oncogenic targets CTNNB1 (-catenin), TCF7, and MYC, while upregulating tumor suppressor genes AXIN2 and BTG2. BTG2 activation contributes to the inhibition of -catenin signaling, thereby suppressing breast cancer progression by reducing cell proliferation and migration and promoting apoptosis."}], "pathway_id": "mmu04310", "pubmed_id": "41273605", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Mus musculus (house mouse)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-Methyladenine (administration), PTEN-induced putative kinase 1 (activation), E3 ubiquitin-protein ligase Parkin (activation), Muscle RING-finger protein 1, Atrogin-1 (Fbxo32), Myogenin, Myogenic differentiation 1, Fibronectin type III domain-containing protein 5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the PINK1/Parkin-dependent mitophagy pathway reduces mitochondrial reactive oxygen species accumulation, restoring mitochondrial quality control. This process promotes the MyoG/MyoD1-driven anabolic program while suppressing the MuRF1/MAFbx-mediated catabolic response. Consequently, muscle protein homeostasis is restored, leading to improved myofiber cross-sectional area and skeletal muscle function. Disruption of this mitophagy pathway by 3-methyladenine reverses these effects, indicating its central role in maintaining muscle integrity."}], "pathway_id": "mmu04137", "pubmed_id": "41308393", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Mus musculus (house mouse)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Alpinetin (administration), Hypoxia-inducible factor 1-alpha, Sequestosome 1, Proto-oncogene tyrosine-protein kinase Src.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Alpinetin interacts with HIF1A, SQSTM1, and SRC to modulate mitophagy, a selective autophagic process that removes dysfunctional mitochondria. This regulation helps maintain mitochondrial integrity and function, thereby contributing to neuroprotection and potentially mitigating the progression of Parkinson's disease."}], "pathway_id": "mmu04137", "pubmed_id": "41331739", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Mus musculus (house mouse)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rac1, mitochondrion.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rac1 promotes the formation of the actin cytoskeleton around damaged mitochondria, facilitating their removal through mitophagy. This process preserves cellular metabolic capacity and maintains epithelial function in the proximal tubule. Disruption of Rac1 activity leads to impaired mitochondrial function, intracellular lipid accumulation, energy depletion, and proximal tubule cell atrophy."}], "pathway_id": "mmu04137", "pubmed_id": "41248288", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Mus musculus (house mouse)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Foenumoside B (administration), 3-Methyladenine, PTEN-induced putative kinase 1, E3 ubiquitin protein ligase Parkin, AMP-activated protein kinase, Nuclear factor (erythroid-derived 2)-like 2 (phosphorylated), Heme oxygenase 1 (upregulated), Kelch-like ECH-associated protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Foenumoside B activates PINK1/Parkin-dependent mitophagy in alveolar epithelial cells, promoting the selective degradation of damaged mitochondria. This process reduces mitochondrial reactive oxygen species (mtROS) and prevents the accumulation of DNA damage markers such as H2AX and comet tail moments. Foenumoside B also enhances AMPK signaling, which is essential for maintaining mitophagy and mitochondrial function. AMPK activation facilitates Nrf2 phosphorylation, stabilizes Nrf2 by reducing Keap1-mediated degradation, and enhances Nrf2 binding to the HO-1 promoter, thereby upregulating the antioxidant response. These mechanisms collectively suppress oxidative stress, preserve redox homeostasis, and protect against mitochondrial and cellular damage."}], "pathway_id": "mmu04137", "pubmed_id": "41239805", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Mus musculus (house mouse)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, PTEN-induced kinase 1, E3 ubiquitin-protein ligase PARK2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of reactive oxygen species lead to mitochondrial dysfunction. Depolarized mitochondria are recognized through the loss of mitochondrial membrane potential, which activates the kinase PINK1. PINK1 recruits the E3 ubiquitin ligase Parkin to the outer mitochondrial membrane, initiating ubiquitination of mitochondrial proteins. This ubiquitination marks damaged mitochondria for degradation through the autophagy-lysosome pathway, a process termed mitophagy. Functional mitophagy maintains mitochondrial homeostasis and prevents the accumulation of dysfunctional mitochondria, which can otherwise contribute to oxidative stress and cellular degeneration."}], "pathway_id": "mmu04137", "pubmed_id": "41197760", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Isoproterenol, Norepinephrine (diminished response), Calcium Cation, Plakophilin-2 (deficiency), Beta-1 adrenergic receptor (reduction in abundance), Organic cation transporter 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Plakophilin-2 deficiency leads to a reduction in the abundance of sarcolemmal beta-1 adrenergic receptors in cardiac myocytes. This deficiency results in a diminished response to norepinephrine but not isoproterenol, indicating that intracellular adrenergic receptors remain functional. The altered distribution and reduced density of sympathetic nerve terminals in the myocardium contribute to heterogeneous adrenergic signaling. This signaling heterogeneity, combined with impaired calcium transient dynamics, facilitates the development of triggered activity and arrhythmias. These changes create a substrate for life-threatening arrhythmias by promoting regional differences in excitability and conduction."}], "pathway_id": "mmu05412", "pubmed_id": "40383179", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dsg2 (disruption of function).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Disruption of desmoglein-2 function leads to fibrotic remodeling in cardiac tissue. Fibrotic areas undergo electrophysiological remodeling, acting as a low-pass filter for conduction. This results in frequency-dependent conduction failure at high stimulation rates, promoting reentrant arrhythmias even in regions that appear electrophysiologically stable at lower frequencies. These changes contribute to the pro-arrhythmic substrate observed in arrhythmogenic cardiomyopathy."}], "pathway_id": "mmu05412", "pubmed_id": "41053445", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Givinostat (administration), Pparg (expression), Cebpa (expression), Adipoq (expression), Col1a1 (expression), Col6a1 (expression), Postn (expression), Desmoglein 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Givinostat reduces the proliferation and differentiation of cardiac fibroadipogenic precursors (cFAPs) by downregulating key regulators of adipogenic differentiation and lipid metabolism, including Pparg, Cebpa, and Adipoq. Under pro-fibrotic conditions, givinostat also decreases the expression of extracellular matrix-related genes such as Col1a1, Col6a1, and Postn. This modulation inhibits the formation of fibro-fatty tissue, a hallmark of arrhythmogenic cardiomyopathy, by suppressing both adipogenic and fibrogenic pathways."}], "pathway_id": "mmu05412", "pubmed_id": "40945272", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fludeoxyglucose F-18 (elevated uptake), Plakoglobin (deficiency), Jup.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Plakoglobin deficiency leads to arrhythmogenic cardiomyopathy and progressive cardiac remodeling. This condition is characterized by the development of fibrotic scar tissue and myocardial inflammation. In affected cardiomyocytes, 18F-Fluorodeoxyglucose uptake is elevated, primarily in regions adjacent to fibrotic areas rather than within inflammatory cells. This hypermetabolic signal correlates with hypertrophy of cardiomyocytes, suggesting a compensatory metabolic remodeling in response to tissue injury and desmosomal dysfunction. The absence of plakoglobin disrupts desmosomal integrity, contributing to myocyte loss and altered cell fate, which may promote fibrofatty replacement of myocardium."}], "pathway_id": "mmu05412", "pubmed_id": "40028850", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Mus musculus (house mouse)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PKP2 (defective function), DSG2 (defective function), DSP (defective function).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Defective function of desmosomal proteins such as plakophilin 2 (PKP2), desmoglein 2 (DSG2), and desmoplakin (DSP) leads to disruption of mechanical coupling between cardiomyocytes. This disruption compromises the structural integrity of intercalated discs, contributing to progressive myocardial loss and fibro-fatty replacement. These changes are associated with arrhythmogenic cardiomyopathy. Aberrant signaling through the Wnt/-catenin pathway and the Hippo pathway further influences cellular fate decisions, potentially promoting adipocyte differentiation over myocyte maintenance, thereby exacerbating the fibro-fatty remodeling characteristic of the disease."}], "pathway_id": "mmu05412", "pubmed_id": "38892395", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Leukotriene B4, Fc gamma receptor, Fc gamma receptor I (receptor ligation), Leukotriene B4 receptor 1 (recruited into lipid rafts), G protein subunit alpha i3, Src proto-oncogene tyrosine-protein kinase (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fc gamma receptor I (Fc gamma RI) forms a complex with leukotriene B4 receptor 1 (BLT1) within lipid raft membrane microdomains following receptor ligation. This complex includes G protein subunit alpha i3 and Src proto-oncogene tyrosine-protein kinase, with Src-mediated phosphorylation of BLT1 being essential for complex formation. The recruitment of BLT1 into lipid rafts enhances phagocytic and microbicidal activity in macrophages, contributing to antimicrobial defense."}], "pathway_id": "mmu04666", "pubmed_id": "19657115", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phospholipase D, Phospholipase D1, Phospholipase D2, Ral GTPases, RalA, RalB, Fc gamma receptors, Fc gamma receptor (stimulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fc gamma receptor stimulation triggers phagocytosis in macrophages by initiating signals that lead to actin cytoskeleton rearrangement and membrane remodeling, resulting in phagosome formation. RalA activates phospholipase D (PLD) during this process, enhancing its activity and promoting phagocytosis. RalA colocalizes with PLD1 and PLD2 at the phagocytic cup, and its interaction with both PLD isoforms increases transiently in response to Fc gamma R stimulation. In contrast, RalB exhibits antagonistic effects, negatively modulating the process. These interactions contribute to the regulation of Fc gamma R-mediated phagocytosis."}], "pathway_id": "mmu04666", "pubmed_id": "20679536", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Wortmannin, Gab2 (recruited to the nascent phagosome), PI3K, p85 subunit of PI3K, SHP-2, AKT (enhanced activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gab2 is recruited to the nascent phagosome during Fc gamma R-mediated phagocytosis, where it associates with PI3K and SHP-2. This interaction facilitates PI3K lipid production and enhances Akt activation, which is essential for the progression of phagocytosis. Recruitment of Gab2 to the phagosome requires its pleckstrin homology domain and is dependent on PI3K activity. Deficiency in Gab2 impairs Fc gamma R-mediated phagocytosis and reduces Akt activation."}], "pathway_id": "mmu04666", "pubmed_id": "12821647", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (increased levels), ALAS1, ALAS2 (upregulated), PPOX, FECH (reduced activity), CPOX, UROD, HMBS, ALAD, SLC25A38.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Deficiency in ferrochelatase (FECH) disrupts the final step of heme biosynthesis, leading to the accumulation of protoporphyrin in erythroid precursors and plasma. This accumulation results in photosensitivity and hemolytic anemia. Reduced FECH activity impairs the insertion of iron into protoporphyrin IX, causing protoporphyrin to accumulate. Protoporphyrin is a photosensitizer that generates reactive oxygen species upon light exposure, contributing to oxidative stress and membrane damage in erythrocytes. ALAS2, the erythroid-specific aminolevulinic acid synthase, is upregulated in response to heme deficiency, further increasing the production of 5-aminolevulinic acid and exacerbating the metabolic imbalance."}], "pathway_id": "mmu04666", "pubmed_id": "16081846", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ins(1,4,5)P3, Calcium Cation (increased levels), Phospholipase C gamma 2 (deficiency), Fc epsilon receptor I, Fc gamma receptor (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase C gamma 2 (PLC2) is essential for Fc gamma receptor (FcR)-mediated calcium flux and inositol 1,4,5-trisphosphate production. Activation of FcR leads to PLC2 phosphorylation, which in turn generates inositol 1,4,5-trisphosphate and increases intracellular calcium ion levels. This signaling cascade is critical for degranulation and cytokine secretion in mast cells and inflammatory responses in macrophages. However, PLC2 is not required for FcR-mediated phagocytosis, which remains intact despite the absence of calcium flux in PLC2-deficient macrophages."}], "pathway_id": "mmu04666", "pubmed_id": "12471105", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FCGR (activation), CSK, SRC (activation), LYN (activation), HCK (activation), SYK (activation), VAV1 (phosphorylation), CBL (phosphorylation), FCGR2B (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of Fc gamma receptors (FCGR) initiates a tyrosine phosphorylation cascade essential for phagocytosis. Src family kinases, including LYN and HCK, mediate this signaling by associating with detergent-resistant membranes, enabling SYK activation, actin cytoskeleton rearrangement, and phagosome formation. In contrast, SRC, which is excluded from these membranes, fails to restore full phagocytic signaling. Phosphorylation of VAV1 and CBL occurs in all cases, but phosphorylation of FCGR2B is specifically mediated by LYN and HCK. This differential involvement of Src family kinases ensures selective signal transduction necessary for effective phagocytosis."}], "pathway_id": "mmu04666", "pubmed_id": "10861086", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: FCGR (Expressed on leukocytes), FCGR2B (Present in endothelial cells).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FC gamma R expressed on leukocytes initiate immunological effector functions including phagocytosis, antibody-dependent cellular cytotoxicity, degranulation, release of inflammatory mediators, and production of oxygen radicals. The Fc gamma R also regulate antibody production. Soluble forms of FC gamma R modulate immune activity, while FCGR2B on endothelial cells regulate IgG levels in blood and facilitate maternal IgG transport to the fetus."}], "pathway_id": "mmu04666", "pubmed_id": "9562738", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Mus musculus (house mouse)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 4-Bromophenacyl bromide, Egta, Dexamethasone, Indomethacin, Aspirin, Fc gamma receptor IIb, Fc gamma receptor IIa, Phospholipase A2 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of phospholipase A2 associated with Fc gamma receptor IIb inhibits phagocytosis of IgG2b-coated immune complexes. This inhibition occurs through a mechanism that blocks the interaction of Fc gamma receptor IIb with cytoskeletal components, thereby impairing phagosome formation. In contrast, Fc gamma receptor IIa-mediated phagocytosis remains unaffected by phospholipase A2 activity."}], "pathway_id": "mmu04666", "pubmed_id": "2522483", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Thyroid hormone signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The thyroid hormones (THs) are important regulators of growth, development and metabolism. The action of TH is mainly mediated by T3 (3,5,3'-triiodo-L-thyronine). Thyroid hormones, L-thyroxine (T4) and T3 enter the cell through transporter proteins. Although the major form of TH in the blood is T4, it is converted to the more active hormone T3 within cells. T3 binds to nuclear thyroid hormone receptors (TRs), which functions as a ligand-dependent transcription factor and controls the expression of target genes (genomic action). Nongenomic mechanisms of action is initiated at the integrin receptor. The plasma membrane alpha(v)beta(3)-integrin has distinct binding sites for T3 and T4. One binding site binds only T3 and activates the phosphatidylinositol 3-kinase (PI3K) pathway. The other binding site binds both T3 and T4 and activates the ERK1/2 MAP kinase pathway.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Liothyronine (reduced levels), Thyroxine, WD repeat and SOCS box-containing protein 1 (elevated expression), type II iodothyronine deiodinase, thyroid hormone receptor beta 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated WSB1 expression promotes colorectal cancer progression by ubiquitinating and degrading DIO2, thereby reducing intracellular T3 levels. This leads to impaired T3/TR1 signaling, which contributes to increased cancer stemness, metastasis, and malignant progression."}], "pathway_id": "mmu04919", "pubmed_id": "41110484", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Thyroid hormone signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The thyroid hormones (THs) are important regulators of growth, development and metabolism. The action of TH is mainly mediated by T3 (3,5,3'-triiodo-L-thyronine). Thyroid hormones, L-thyroxine (T4) and T3 enter the cell through transporter proteins. Although the major form of TH in the blood is T4, it is converted to the more active hormone T3 within cells. T3 binds to nuclear thyroid hormone receptors (TRs), which functions as a ligand-dependent transcription factor and controls the expression of target genes (genomic action). Nongenomic mechanisms of action is initiated at the integrin receptor. The plasma membrane alpha(v)beta(3)-integrin has distinct binding sites for T3 and T4. One binding site binds only T3 and activates the phosphatidylinositol 3-kinase (PI3K) pathway. The other binding site binds both T3 and T4 and activates the ERK1/2 MAP kinase pathway.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (4-(4-Hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid (administration), Thyroid hormone receptor beta (elevated expression), Androgen receptor, NK3 homeobox 1, Kallikrein-related peptidase 3, Crystallin mu.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Thyroid hormone receptor beta (TR) mediates thyroid hormone signaling in prostate cancer. TR activation promotes androgen receptor (AR) signaling and the expression of AR target genes such as NK3 homeobox 1 (Nkx3.1) and kallikrein-related peptidase 3 (KLK3, also known as PSA), contributing to prostate cancer growth and progression. Inhibition of TR with the selective antagonist NH-3 reduces AR activity, suppresses the expression of Nkx3.1 and KLK3, and inhibits prostate cancer cell proliferation. This effect is particularly pronounced in castration-resistant prostate cancer models. Elevated TR expression and mutations in thyroid hormone signaling are associated with the onset of prostate cancer, indicating TR as a driver of tumorigenesis in this disease."}], "pathway_id": "mmu04919", "pubmed_id": "41088246", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phenylephrine, U 46619, Angiotensin Ii, Serotonin, Volasertib, PLK1 (Inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PLK1 activity enhances vascular and erectile smooth muscle contraction in response to Angiotensin II and neurogenic stimuli. Inhibition of PLK1 reduces Angiotensin II-induced contraction in pudendal and small mesenteric arteries and attenuates neurogenic contraction at low frequencies in the corpus cavernosum. PLK1 does not modulate contraction mediated by Phenylephrine, U46619, or Serotonin."}], "pathway_id": "mmu04270", "pubmed_id": "41227386", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Zinc(2+) (influx), 2-[4-(2,3-dimethylphenyl)piperazin-1-yl]-N-(2-ethoxyphenyl)acetamide (administration), Angiotensin Ii, TRPC6, Transforming growth factor beta 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Zinc ion influx through TRPC6 channels negatively regulates transforming growth factor beta 1-induced contractile differentiation of vascular smooth muscle cells. This process is associated with the progression of vascular remodeling in response to chronic angiotensin II exposure. Pharmacological activation of TRPC6 with PPZ2 prevents the intracellular zinc ion reduction and inhibits the contractile phenotype transition, thereby attenuating vascular remodeling."}], "pathway_id": "mmu04270", "pubmed_id": "40001570", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lysyl Oxidase, Myosin Light Chain.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lysyl Oxidase (LOX) regulates extracellular matrix development, cytoskeletal organization, and cell contraction in vascular smooth muscle cells. LOX deficiency disrupts cytoskeletal organization and myosin light-chain phosphorylation, leading to irregular smooth muscle contraction. These changes contribute to aneurysm formation by impairing medial vascular smooth muscle cell function and structural integrity."}], "pathway_id": "mmu04270", "pubmed_id": "39632420", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Valproic Acid (administration), Phenylephrine, Sodium Butyrate, Valpromide, RhoA, phosphorylated myosin light chain at serine 19 (phosphorylated), acetylated histone H3 at lysine 9 and 14 (elevated levels), HDAC5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Valproic acid inhibits vascular smooth muscle contraction by suppressing RhoA expression and reducing the phosphorylation of myosin light chain at serine 19. This effect is mediated through the inhibition of histone deacetylases, which increases histone acetylation levels, particularly at lysine 9 and 14 of histone H3. The reduction in RhoA activity diminishes Rho-associated protein kinase signaling, a key driver of smooth muscle contraction. This pathway contributes to endothelium-dependent aortic relaxation and may mitigate vasospastic vascular diseases."}], "pathway_id": "mmu04270", "pubmed_id": "40856063", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii, GPRC5C, angiotensin II receptor type 1, myosin light chain, inositol phosphate.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GPRC5C facilitates angiotensin II-dependent vascular contraction by forming a dimer with the angiotensin II receptor type 1 (AT1), enhancing receptor-ligand binding and downstream signaling. This interaction leads to increased calcium mobilization and myosin light chain phosphorylation, which are essential for smooth muscle contraction. Disruption of GPRC5C reduces angiotensin II-induced arterial contraction and ameliorates arterial hypertension."}], "pathway_id": "mmu04270", "pubmed_id": "38597112", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS2, ALAD, PBGD, UROD, CPOX, PPOX, FECH (disrupted), ALAS1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid (5-ALA) is a precursor in the heme biosynthesis pathway, which involves a series of enzymatic reactions including those catalyzed by ALAS2, ALAD, PBGD, UROD, CPOX, PPOX, and FECH. Disruption of this pathway, particularly at the FECH enzyme level, leads to the accumulation of protoporphyrin IX, especially in erythroid cells, resulting in erythropoietic protoporphyria. This accumulation causes increased photosensitivity and phototoxic reactions upon exposure to light. ALAS1 also contributes to heme production in non-erythroid tissues. The imbalance in heme synthesis and the subsequent protoporphyrin accumulation disrupt normal erythropoiesis and contribute to the clinical manifestations of porphyria."}], "pathway_id": "mmu04270", "pubmed_id": "38147352", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Mus musculus (house mouse)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SMTNL1, SmtNL1, SmtNL1 wild-type, SmtNL1 knockout.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Smoothelin-like 1 (SMTNL1) modulates vascular smooth muscle contraction by regulating contractile performance in vascular smooth muscle cells. Loss of SMTNL1 leads to elevated vascular tone, which contributes to cardiac dysfunction through increased afterload. This results in compensatory increases in ejection fraction and fractional shortening, as well as altered cardiac morphology. In male mice, SMTNL1 deficiency is associated with impaired left ventricular relaxation, reflected in elevated LV filling pressure, prolonged isovolumetric relaxation time, and increased E/E' ratio. These changes indicate diastolic dysfunction, suggesting that SMTNL1 plays a critical role in maintaining normal myocardial relaxation and vascular homeostasis."}], "pathway_id": "mmu04270", "pubmed_id": "36342379", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin resistance - Mus musculus (house mouse)\n**Pathway Description**: Insulin resistance is a condition where cells become resistant to the effects of insulin. It is often found in people with health disorders, including obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular diseases. In this diagram multiple mechanisms underlying insulin resistance are shown: (a) increased phosphorylation of IRS (insulin receptor substrate) protein through serine/threonine kinases, such as JNK1 and IKKB, and protein kinase C, (b) increased IRS-1 proteasome degradation via mTOR signaling pathway, (c) decreased activation of signaling molecules including PI3K and AKT, (d) increase in activity of phosphatases including PTPs, PTEN, and PP2A. Regulatory actions such as oxidative stress, mitochondrial dysfunction, accumulation of intracellular lipid derivatives (diacylglycrol and ceramides), and inflammation (via IL-6 and TNFA) contribute to these mechanisms. Consequently, insulin resistance causes reduced GLUT4 translocation, resulting in glucose takeup and glycogen synthesis in skeletal muscle as well as increased hepatic gluconeogenesis and decreased glycogen synthesis in liver. At the bottom of the diagram, interplay between O-GlcNAcylation and serine/threonine phosphorylation is shown. Studies suggested that elevated O-GlcNAc level was correlated to high glucose-induced insulin resistance. Donor UDP-GlcNAc is induced through hexosamine biosynthesis pathway and added to proteins by O-GlcNAc transferase. Elevation of O-GlcNAc modification alters phosphorylation and function of key insulin signaling proteins including IRS-1, PI3K, PDK1, Akt and other transcription factor and cofactors, resulting in the attenuation of insulin signaling cascade.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Palmitic Acid (elevated levels), phosphorylated AKT (expression), solute carrier family 2, facilitated glucose transporter member 4 (abundance).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of palmitic acid impair insulin signaling by decreasing phosphorylated AKT expression and GLUT4 abundance, resulting in reduced glucose uptake in skeletal muscle cells."}], "pathway_id": "mmu04931", "pubmed_id": "41305671", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin resistance - Mus musculus (house mouse)\n**Pathway Description**: Insulin resistance is a condition where cells become resistant to the effects of insulin. It is often found in people with health disorders, including obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular diseases. In this diagram multiple mechanisms underlying insulin resistance are shown: (a) increased phosphorylation of IRS (insulin receptor substrate) protein through serine/threonine kinases, such as JNK1 and IKKB, and protein kinase C, (b) increased IRS-1 proteasome degradation via mTOR signaling pathway, (c) decreased activation of signaling molecules including PI3K and AKT, (d) increase in activity of phosphatases including PTPs, PTEN, and PP2A. Regulatory actions such as oxidative stress, mitochondrial dysfunction, accumulation of intracellular lipid derivatives (diacylglycrol and ceramides), and inflammation (via IL-6 and TNFA) contribute to these mechanisms. Consequently, insulin resistance causes reduced GLUT4 translocation, resulting in glucose takeup and glycogen synthesis in skeletal muscle as well as increased hepatic gluconeogenesis and decreased glycogen synthesis in liver. At the bottom of the diagram, interplay between O-GlcNAcylation and serine/threonine phosphorylation is shown. Studies suggested that elevated O-GlcNAc level was correlated to high glucose-induced insulin resistance. Donor UDP-GlcNAc is induced through hexosamine biosynthesis pathway and added to proteins by O-GlcNAc transferase. Elevation of O-GlcNAc modification alters phosphorylation and function of key insulin signaling proteins including IRS-1, PI3K, PDK1, Akt and other transcription factor and cofactors, resulting in the attenuation of insulin signaling cascade.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pyridoxal, Kynurenine, Lecithin, AMP-activated protein kinase (upregulation of gene expression), Phosphoinositide 3-kinase (upregulation of gene expression), Protein kinase B (upregulation of gene expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated serum glucose and lipid levels contribute to the development of insulin resistance. Activation of the AMPK/PI3K/AKT signaling pathway enhances insulin sensitivity by promoting glucose uptake and lipid metabolism. Upregulation of AMPK, PI3K, and AKT gene expression in liver and adipose tissue supports this pathways activity. Modulation of gut microbiota, including increased abundance of beneficial bacteria such as Kineothrix, Bacteroides, and Alloprevotella, correlates with improved insulin signaling and reduced hepatic damage. Metabolites such as pyridoxal, kynurenine, and lecithin are associated with this metabolic improvement and may influence insulin signaling through yet-to-be fully characterized mechanisms."}], "pathway_id": "mmu04931", "pubmed_id": "41238930", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, POU5F1, NANOG, SOX2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 nuclear entry in inner cell mass (ICM) cells during preimplantation development is temporally regulated by total cell number. At lower cell counts, YAP1 nuclear localization is delayed, which affects the timing of Hippo/YAP1 activation. This delay does not disrupt ICM/trophectoderm patterning or pluripotency markers such as POU5F1, NANOG, and SOX2. Increasing total cell number restores the timing of YAP1 nuclear entry to that observed in normal blastocysts. This mechanism suggests that total cell number is a key determinant of Hippo/YAP1 activity during early lineage specification."}], "pathway_id": "mmu04390", "pubmed_id": "41129931", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, Lactate (increased levels), YAP1 (elevated activity), LATS1, LATS2, IGF1 (increased levels), IGF1R (activated), CSF1 (increased levels), SOX9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated YAP activity in cardiac fibroblasts promotes glycolysis and fibroinflammation. YAP-induced glycolysis increases lactate production and supports fibroblast proliferation and fibrosis. Activation of YAP disrupts fibroblast lineage fidelity, leading to an osteochondroprogenitor cell state characterized by SOX9 expression. YAP also drives the secretion of CSF1, which promotes macrophage expansion. These macrophages, in turn, secrete IGF1, which activates IGF1 receptor signaling in fibroblasts, further enhancing their proliferation and fibrotic response."}], "pathway_id": "mmu04390", "pubmed_id": "41165345", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Xmu-MP-1, ACADL (overexpression), EBF3, Phosphorylated YAP at Serine 127 (phosphorylation at serine 127), YAP1, CTGF, CYR61, ANKRD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EBF3 transcriptionally activates ACADL expression by binding to its promoter. ACADL overexpression inhibits Hippo/YAP signaling by blocking phosphorylation of YAP at serine 127 and preventing its nuclear localization. This suppression of nuclear YAP reduces the activation of downstream target genes CTGF, CYR61, and ANKRD1, which in turn inhibits cell growth and tumor development. Inhibition of MST1/2 kinase activity with XMU-MP-1 reverses the suppressive effect of ACADL on tumor progression."}], "pathway_id": "mmu04390", "pubmed_id": "41270467", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Dihydromyricetin, Integrin (increased expression), YAP1 (activated), ABCG1 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated extracellular matrix stiffness increases integrin expression, which suppresses the Hippo signaling pathway and leads to increased YAP1 activity. Activated YAP1 upregulates ABCG1, a transporter that reduces ferroptosis sensitivity. This mechanism contributes to the suppression of ferroptosis in lung adenocarcinoma cells, promoting tumor survival and resistance to cell death."}], "pathway_id": "mmu04390", "pubmed_id": "41286767", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (overexpression), CTGF, TEAD, MST1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1, in complex with the transcription factor TEAD, induces the expression of its own negative regulator MST1. This interaction forms a feedback loop that modulates viral replication and -cell apoptosis during coxsackievirus B infections. YAP1 overexpression enhances viral replication and islet inflammation, while MST1 inhibition increases viral replication and reduces -cell death. YAP1 also promotes CTGF expression and contributes to -cell dedifferentiation and impaired insulin secretion, linking Hippo pathway activity to glucose intolerance and islet dysfunction."}], "pathway_id": "mmu04390", "pubmed_id": "41053097", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP (increased levels), USP52 (inhibited), Connective Tissue Growth Factor, Cysteine-Rich Angiogenic Inducer 61.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "USP52 stabilizes YAP by removing K11-linked ubiquitin chains, leading to increased YAP protein levels and activation of downstream target genes such as CTGF and CYR61. This promotes cell proliferation, migration, and invasion while attenuating ferroptosis. Elevated YAP activity suppresses ferroptosis, a form of iron-dependent cell death, thereby supporting tumor growth. USP52 inhibition reduces YAP levels and enhances CD8+ T-cell infiltration, increasing tumor sensitivity to immunotherapy."}], "pathway_id": "mmu04390", "pubmed_id": "40962058", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Reynoutrin (administration), FYN, SIRT1, FOXO3, NRF2 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reynoutrin inhibits FYN kinase activity, leading to the activation of the SIRT1/FOXO3 and NRF2 antioxidant signaling pathways. This inhibition reduces oxidative stress and enhances the activity of antioxidant enzymes, thereby ameliorating renal injury associated with diabetic nephropathy."}], "pathway_id": "mmu04068", "pubmed_id": "40818186", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Metenkefalin (administration), Interleukin 6 Signal Transducer (upregulated expression), Tumor Necrosis Factor Receptor Superfamily Member 2 (upregulated expression), C-C Motif Chemokine Ligand 24 (upregulated expression), Major Histocompatibility Complex Class I (upregulated expression), Major Histocompatibility Complex Class II (upregulated expression), CD28 Molecule (upregulated expression), Forkhead Box Protein O1 (modulated), Spleen Tyrosine Kinase, Cyclin D1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methionine enkephalin upregulates the expression of IL6ST, TNFR2, and CCL24, which promote inflammatory responses and immune cell recruitment. It enhances antigen presentation through increased expression of MHC I, MHC II, and CD28, thereby initiating adaptive immunity. Additionally, it modulates the FOXO-CYCD1 signaling axis to inhibit the cell cycle, contributing to antiviral activity in macrophages."}], "pathway_id": "mmu04068", "pubmed_id": "40858872", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sesamin (administration), Acetaminophen, FOXO1 (activity suppressed).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of FOXO1 leads to enhanced autophagy and inhibited ferroptosis. These processes collectively contribute to the attenuation of acetaminophen-induced hepatotoxicity. Sesamin modulates these outcomes, and its protective effect is mediated through the suppression of FOXO1 activity."}], "pathway_id": "mmu04068", "pubmed_id": "41254937", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 13-(Benzyloxy)-13-oxotridecanoic acid, AKT1 (downregulated), DAB2, FOXO1 (expression downregulated), BCL2L11 (activated), BAX (activated), CYCS (release into cytosol).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dephosphorylation of FOXO1 results in its nuclear translocation, leading to the transcriptional activation of the proapoptotic protein BIM. This activation promotes the translocation of BAX and BIM to mitochondria, causing cytochrome c release into the cytosol and initiating apoptosis. This process is triggered by the downregulation of Akt signaling in proximal tubule epithelial cells under conditions of albumin overload."}], "pathway_id": "mmu04068", "pubmed_id": "41152299", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), FOXO (nuclear localization), AKT, PIK3CA, MAPK8, PRKAA1 (stress-induced activation), SNAI1 (suppressed), VIM (suppressed), FN1 (suppressed).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid regulate energy metabolism through the modulation of non-canonical Smad signaling pathways, including the PI3K/AKT, MAPK, and FoxO pathways. Activation of the PI3K/AKT pathway leads to phosphorylation of FoxO proteins, promoting their cytoplasmic sequestration and reducing their transcriptional activity. In contrast, stress-induced activation of JNK and AMPK promotes FoxO phosphorylation and nuclear localization, enhancing the expression of genes involved in stress resistance and metabolic adaptation. Inhibition of the MAPK pathway reduces epithelial-mesenchymal transition (EMT) by suppressing the expression of EMT-related proteins such as SNAI1, FN1, and VIM, thereby attenuating fibrotic progression and inflammation."}], "pathway_id": "mmu04068", "pubmed_id": "40579132", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: STAT1 (increased expression), STAT3 (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased expression of STAT1 and decreased expression of STAT3 lead to enhanced apoptosis in glioma U251 cells. This effect is associated with the modulation of multiple nodes within the FOXO signaling pathway, which regulates cellular processes including apoptosis and stress resistance. These changes contribute to the induction of programmed cell death and the suppression of tumor progression."}], "pathway_id": "mmu04068", "pubmed_id": "40402343", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Matrix Metallopeptidase 2, Interleukin 1 Alpha, Matrix Metallopeptidase 3, Hepatocyte Growth Factor, Haptoglobin, Interleukin 10, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha, Toll-Like Receptor 4, Matrix Metallopeptidase 9, Heme Oxygenase 1 (enhanced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated oxidative stress activates the FoxO signaling pathway, which regulates cellular responses to stress through the modulation of genes involved in inflammation and antioxidant defense. Activation of FoxO transcription factors enhances the expression of genes such as HMOX1, which catalyzes heme degradation to reduce oxidative damage. Simultaneously, inflammatory signaling through TLR4 and IL1A promotes the production of pro-inflammatory cytokines and matrix metallopeptidases (MMP2, MMP3, MMP9), leading to extracellular matrix degradation and tissue injury. The anti-inflammatory cytokine IL10 counteracts this process by suppressing immune activation. PPARGC1A supports mitochondrial biogenesis and energy homeostasis under stress conditions. These interactions contribute to immune cell infiltration and macrophage polarization, ultimately shaping the progression of inflammatory and degenerative tissue phenotypes."}], "pathway_id": "mmu04068", "pubmed_id": "40303487", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Mus musculus (house mouse)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Spermidine (administration), MTOR (deficiency), TFRC, FTL, SLC40A1, NFE2L2, HIF1A, AKT1 (chronically activated in absence of mTOR), FBXL5, IREB2, NCOA4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "mTOR regulates iron homeostasis in skeletal muscle through modulation of NRF2/NFE2L2, HIF1A, and AKT1 signaling. mTOR deficiency disrupts iron metabolism by impairing the transcriptional regulation of iron-related genes by NRF2 and HIF1A. This leads to ferritin accumulation through derepression of ferritin translation via suppression of the FBXL5-IREB2 axis and autophagosomal sequestration of ferritin mediated by NCOA4. Chronic AKT1 activation in the absence of mTOR contributes to autophagy impairments, which further exacerbates ferritin accumulation. Spermidine supplementation restores AKT1-FOXO signaling, enhances endolysosomal ferritin turnover, and reduces total ferritin levels in dystrophic muscle."}], "pathway_id": "mmu04068", "pubmed_id": "40293459", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pancreatic cancer - Mus musculus (house mouse)\n**Pathway Description**: Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Daraxonrasib, Afatinib, [[2-[[(5S,8S,10aR)-8-[[(2S)-5-amino-1-(benzhydrylamino)-1,5-dioxopentan-2-yl]carbamoyl]-3-[8-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]oct-7-ynoyl]-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1H-indol-5-yl]-difluoromethyl]phosphonic acid, KRAS (activated), RAF1, EGFR, TP53, STAT3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "KRAS activation engages downstream effectors such as RAF1, upstream regulators like EGFR, and orthogonal pathways involving STAT3. Inhibition of these three nodesKRAS, EGFR, and STAT3disrupts the KRAS signaling network, leading to complete and sustained regression of pancreatic ductal adenocarcinoma tumors. This multi-targeted suppression prevents tumor resistance and inhibits tumor progression in models of KRAS/TP53-driven disease."}], "pathway_id": "mmu05212", "pubmed_id": "41329731", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pancreatic cancer - Mus musculus (house mouse)\n**Pathway Description**: Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JUP (Inactivated), FOXM1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of JUP (-catenin) promotes pancreatic ductal adenocarcinoma tumorigenesis and progression by enhancing cell proliferation, migration, and invasion. JUP is transcriptionally activated by FOXM1, which binds directly to the JUP promoter. This FOXM1-JUP axis contributes to metastasis and therapeutic resistance, particularly to gemcitabine and oxaliplatin. Inactivation of JUP attenuates these oncogenic effects and reverses resistance, indicating that this transcriptional pathway functions as a dual oncogenic driver in pancreatic cancer."}], "pathway_id": "mmu05212", "pubmed_id": "41310714", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pancreatic cancer - Mus musculus (house mouse)\n**Pathway Description**: Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N6-Methyladenosine, IGF2BP3 (elevated expression), EMP1 (stabilized), SMAD7, SMAD3 and SMAD4 (phosphorylated), VASP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of IGF2BP3, an m6A reader protein, stabilizes EMP1 mRNA through recognition of m6A modifications. This stabilization facilitates the interaction between VASP and SMAD7, thereby inhibiting the suppressive effect of SMAD7 on SMAD3/4 phosphorylation. Consequently, TGF- signaling is activated, promoting tumor cell invasion in pancreatic ductal adenocarcinoma. This IGF2BP3/EMP1 axis also contributes to immune microenvironment remodeling within the tumor."}], "pathway_id": "mmu05212", "pubmed_id": "41285728", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACSM3 (over-expression), AKT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ACSM3 promotes tumor growth and metastasis in breast cancer. ACSM3 functions as a tumor suppressor by modulating the WNT/AKT signaling pathway, which inhibits cell proliferation, migration, and invasion. Over-expression of ACSM3 suppresses these processes and increases AKT phosphorylation."}], "pathway_id": "mmu05224", "pubmed_id": "41318133", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PHLDB2 (elevated expression), CDH1, CDH2, VIM, SNAI1, MMP2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PHLDB2 promotes tumor progression in triple-negative breast cancer by facilitating epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling. PHLDB2 drives EMT through the suppression of E-cadherin and the induction of N-cadherin, vimentin, Snail, and MMP-2. This process enhances cell migration and proliferation, contributing to focal adhesion and ECM-receptor interaction pathways. PHLDB2 forms dynamic, phase-separated condensates that organize signaling events, thereby supporting tumor growth and metastasis."}], "pathway_id": "mmu05224", "pubmed_id": "41319208", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lactic Acid, TTN (deficiency or mutation), DLL4, SLC16A3, NOTCH2, CD8-positive T cells (anti-tumor activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TTN deficiency or mutation in triple-negative breast cancer leads to DLL4 secretion, which activates the NOTCH2 signaling pathway in myeloid-derived suppressor cells (MDSCs). This activation enhances MCT4-mediated glycolysis, promoting lactate production and excretion by MDSCs. DLL4-driven MDSCs induce histone lactate modification in tumor cells, supporting stemness-mediated drug resistance and suppressing CD8-positive T cell anti-tumor activity. This metabolic reprogramming of MDSCs contributes to neoadjuvant therapy resistance."}], "pathway_id": "mmu05224", "pubmed_id": "41326912", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paclitaxel, TRIM25, BRD7, YB-1, BCL2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM25 interacts with BRD7 and promotes its ubiquitination at the K119 site through the ubiquitin proteasome pathway, thereby reducing BRD7 protein stability. This leads to the activation of the YB1/Bcl-2 transcriptional axis, which in turn enhances cell proliferation, cell cycle progression, and chemoresistance in breast cancer. The negative correlation between TRIM25 and BRD7 expression contributes to malignant progression and poor prognosis."}], "pathway_id": "mmu05224", "pubmed_id": "41315221", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CAND1, ERBB2 (high protein stability), CUL7, CAND1 knockdown (knockdown), NEDD8 conjugation to CUL7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CAND1 stabilizes HER2 protein expression by directly interacting with it. This interaction prevents HER2 ubiquitination, which is mediated by the E3 ligase CUL7. CAND1 knockdown enhances CUL7 neddylation, thereby activating its ligase activity and promoting HER2 ubiquitination and degradation. HER2 overexpression counteracts the anti-proliferative effects of CAND1 loss, indicating that HER2 protein stability is a critical factor in breast cancer progression."}], "pathway_id": "mmu05224", "pubmed_id": "41310794", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Breast cancer - Mus musculus (house mouse)\n**Pathway Description**: Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Losartan (administered), DPP3 (ISGylated), RAPGEF4 (overexpressed), RAP1A, PFKP, YBX1, ARF4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Breast cancer cells secrete DPP3 via small extracellular vesicles, which upregulates RAPGEF4 in lung endothelial cells to activate the Rap1 signaling pathway. This activation promotes angiogenesis and remodelling of the vascular niche in the lung, facilitating lung metastasis. ISGylated DPP3 is selectively packaged into extracellular vesicles via ARF4, and inhibition of ISGylation by losartan prevents this process."}], "pathway_id": "mmu05224", "pubmed_id": "41311249", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Terpenoid backbone biosynthesis - Mus musculus (house mouse)\n**Pathway Description**: Terpenoids, also known as isoprenoids, are a large class of natural products consisting of isoprene (C5) units. There are two biosynthetic pathways, the mevalonate pathway [MD:M00095] and the non-mevalonate pathway or the MEP/DOXP pathway [MD:M00096], for the terpenoid building blocks: isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). The action of prenyltransferases then generates higher-order building blocks: geranyl diphosphate (GPP), farsenyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP), which are the precursors of monoterpenoids (C10), sesquiterpenoids (C15), and diterpenoids (C20), respectively. Condensation of these building blocks gives rise to the precursors of sterols (C30) and carotenoids (C40). The MEP/DOXP pathway is absent in higher animals and fungi, but in green plants the MEP/DOXP and mevalonate pathways co-exist in separate cellular compartments. The MEP/DOXP pathway, operating in the plastids, is responsible for the formation of essential oil monoterpenes and linalyl acetate, some sesquiterpenes, diterpenes, and carotenoids and phytol. The mevalonate pathway, operating in the cytosol, gives rise to triterpenes, sterols, and most sesquiterpenes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), ALAS1, ALAS2, PBGD, UROS, CPOX, FECH, ALAD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) initiate heme biosynthesis through the action of ALAS1 and ALAS2, which catalyze the condensation of glycine and succinyl-CoA to form 5-aminolevulinic acid. PBGD subsequently converts 5-ALA to porphobilinogen, which is processed by UROS to form uroporphyrinogen III. CPOX and FECH further catalyze the conversion of uroporphyrinogen III to heme. Defects in any of these enzymes lead to the accumulation of intermediates, causing oxidative stress, mitochondrial dysfunction, and impaired heme production, which underlie the pathogenesis of porphyria and anemia."}], "pathway_id": "mmu00900", "pubmed_id": "40146774", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Mus musculus (house mouse)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PSMB5 (elevated expression), MHC class I, ubiquitinated proteins.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of the proteasome subunit PSMB5 increases chymotrypsin-like proteasomal activity. This overexpression leads to the downregulation of MHC class I on the cell surface and the accumulation of ubiquitinated proteins. PSMB5 upregulation is associated with HBV-associated liver pathology and contributes to the progression of hepatocellular carcinoma (HCC)."}], "pathway_id": "mmu03050", "pubmed_id": "41305476", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Mus musculus (house mouse)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melittin, PSMA7 (degraded), USP10, RNF20, CDH1, CDH2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melittin interacts with ubiquitin-specific peptidase 10 (USP10), promoting the ubiquitination and degradation of proteasome 20S subunit alpha 7 (PSMA7) via ring finger protein 20 (RNF20). This degradation of PSMA7 suppresses the epithelial-mesenchymal transition by reducing N-cadherin expression and increasing E-cadherin levels, thereby inhibiting cell migration and lung cancer metastasis."}], "pathway_id": "mmu03050", "pubmed_id": "41254650", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Mus musculus (house mouse)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neuronal membrane proteasome (predominant expression), MrgprA3, Cysltr2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The neuronal membrane proteasome (NMP) is localized to the plasma membrane of somatosensory neurons and facilitates neuron-to-neuron communication through the release of signaling peptides. It is essential for the normal response of sensory neurons to mechanical and noxious stimuli, contributing to the regulation of touch, pain, and itch sensation. The NMP is predominantly expressed in MrgprA3+ and Cysltr2+ neuron subtypes, which are responsible for mechanical, pain, and itch sensation."}], "pathway_id": "mmu03050", "pubmed_id": "41144432", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Mus musculus (house mouse)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rotenone, PSMB8 (elevated expression), SNCA, CD8+ T cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated PSMB8 expression is associated with -synuclein aggregation in dopaminergic neurons. PSMB8 localizes within the core of mature Lewy bodies in the substantia nigra, indicating its role in synucleinopathy pathology. PSMB8 inhibition reduces -synuclein accumulation and apoptosis in dopaminergic neurons, independent of the proteasomal or autophagy-lysosomal pathways. This inhibition also attenuates CD8+ T cell degranulation and improves neuronal survival in co-culture models, suggesting a link between -synuclein burden and immune-mediated neurotoxicity."}], "pathway_id": "mmu03050", "pubmed_id": "41172742", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Mus musculus (house mouse)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bortezomib (administration), (E)-1-(3-chloro-4-fluorophenyl)-4-((5-nitrofuran-2-yl)methylene)pyrazolidine-3,5-dione (administration), Ubiquitin-activating enzyme E1 (inhibited activity), Proteasome (inhibited activity), Caspase-3 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bortezomib (BTZ) inhibits proteasome activity, leading to reduced cell viability and induction of apoptosis through activation of caspase-3. In melanogenesis-stimulated B16-F10 cells, proteasome inhibition by BTZ is attenuated, reducing its cytotoxic effects. In contrast, inhibition of ubiquitination at the E1 enzyme by PYZD-4409 reduces cell viability and induces apoptosis regardless of melanogenesis status. Melanogenesis modulates the sensitivity of melanoma cells to proteasome-targeted therapy."}], "pathway_id": "mmu03050", "pubmed_id": "41067125", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Retapamulin (administration), mitochondrial translation initiation factor 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mitochondrial translation produces essential subunits of the oxidative phosphorylation system. The process involves mitochondrial ribosome traversal along transcripts, regulated by factors such as mitochondrial translation initiation factor 3. Internal open reading frames and programmed mitoribosome collision sites contribute to the complexity of mitochondrial translation initiation. Retapamulin, a translation inhibitor, allows for the quantification of mitoribosome occupancy, elongation, and initiation rates, providing insight into the stoichiometry and kinetics of mitochondrial protein synthesis."}], "pathway_id": "mmu00190", "pubmed_id": "41232526", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ATP6V1E1 (altered expression in microglia), NDUFB5 (altered expression in microglia), Amyloid-beta (increased), Microtubule-associated protein Tau (increased).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of ATP6V1E1 and NDUFB5 correlates with impaired oxidative phosphorylation and lysosomal acidification, contributing to mitochondrial dysfunction and neurodegeneration. These changes are associated with increased Amyloid-beta and Tau pathology. Downregulation of mitochondrial complex I and V-ATPase subunits indicates a systemic disruption of energy metabolism and lysosomal function, which exacerbates disease progression. Altered expression of these genes in microglia is linked to dysregulated immune cell infiltration."}], "pathway_id": "mmu00190", "pubmed_id": "41242442", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: cytochrome c oxidase, COX20 (reduced levels), cytochrome c oxidase subunit 2, transmembrane protein 177 (disrupted), SURF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TMEM177 stabilizes COX20, a chaperone essential for the assembly of cytochrome c oxidase (complex IV) in mitochondria. This stabilization supports the maintenance of COX2 levels, which are necessary for the proper function of complex IV in oxidative phosphorylation. Disruption of TMEM177 leads to reduced COX20 levels and impaired complex IV assembly, resulting in altered mitochondrial energy production and reduced viability in knockout mice."}], "pathway_id": "mmu00190", "pubmed_id": "41253195", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Deoxyglucose (elevated levels), Metformin (administration), Glycolysis-related proteins, Oxidative phosphorylation signaling proteins.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 2-Deoxy-D-glucose and metformin disrupt glycolysis and oxidative phosphorylation pathways, leading to impaired primordial follicle formation. This metabolic dysregulation alters oocyte development, reduces key gene expression, and disrupts the recruitment and maintenance of pre-granulosa cells. These disruptions also affect cell proliferation and apoptosis, indicating that glucose metabolism is essential for the proper formation and function of primordial follicles in mice."}], "pathway_id": "mmu00190", "pubmed_id": "41251108", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Terbinafine (administration), Mito-TEMPO (administration), SQLE (overexpression), LONP1, TFAM.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Overexpression of SQLE impairs LONP1-mediated TFAM degradation through direct interaction with LONP1, leading to increased mitochondrial OXPHOS and the accumulation of mtROS. This metabolic reprogramming contributes to tumor growth in bladder cancer. Inhibition of SQLE by terbinafine suppresses this process, reducing mitochondrial OXPHOS and mtROS levels, thereby inhibiting tumor progression. Clearance of mtROS using Mito-TEMPO also attenuates tumor growth in models of SQLE overexpression."}], "pathway_id": "mmu00190", "pubmed_id": "41254141", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Artesunate (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acute myeloid leukemia (AML) exhibits increased dependence on oxidative phosphorylation (OXPHOS), particularly in leukemia stem cells. Inhibition of mitochondrial respiration, such as through artesunate, disrupts this metabolic dependency and reduces tumor cell survival. This metabolic vulnerability can be exploited to enhance therapeutic efficacy, particularly in overcoming resistance to venetoclax. Normal hematopoietic stem cells remain relatively unaffected, preserving essential hematopoietic function."}], "pathway_id": "mmu00190", "pubmed_id": "41188278", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+-)-Palmitoyl carnitine, Octanoylcarnitine, Nnt (loss of function), Cpt1b (decreased expression), Cpt2 (decreased expression), Slc25a20 (decreased expression), Chrna1 (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Loss of Nnt function leads to reduced expression of oxidative phosphorylation-related genes, particularly subunits of complex I and complex V. This dysfunction is associated with decreased expression of Cpt1b, Cpt2, and Slc25a20, which are involved in fatty acid transport and -oxidation. These changes correlate with reduced oxygen consumption rates when palmitoylcarnitine and octanoylcarnitine are used as substrates. Additionally, downregulation of Chrna1 suggests impaired neuromuscular junction function, indicating a broader impact of Nnt deficiency on mitochondrial energy pathways and neuromuscular development."}], "pathway_id": "mmu00190", "pubmed_id": "41167363", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pyruvic Acid.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Enhanced pyruvate oxidation promotes coupling between glycolysis and glucose oxidation, thereby maintaining mitochondrial oxidative phosphorylation. This process supports electron transport chain efficiency and sustains myocardial mitochondrial oxidative metabolism."}], "pathway_id": "mmu00190", "pubmed_id": "41101068", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxidative phosphorylation - Mus musculus (house mouse)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin (administration), Dt-2216, MYC (suppressed activity), MTOR (suppressed activity), oxidative phosphorylation (upregulation), BCL2L1, BCL2, MCL1, CASP3 and CASP7 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Quiescent triple-negative breast cancer cells exhibit suppressed MYC and MTOR activity and upregulate oxidative phosphorylation (OXPHOS) genes and respiratory function in response to DNA-damaging agents such as doxorubicin. This metabolic shift is associated with mitochondrial elongation and increased fusion, enhancing mitochondrial biomass and respiratory capacity. These OXPHOS-high cells depend on BCL-XL for survival, as its inhibition leads to mitochondrial fragmentation, loss of respiratory function, and activation of caspase 3/7, culminating in cell death. BCL-XL inhibition does not significantly affect BCL2 or MCL1, and BCL-XL degraders like DT2216 enhance the efficacy of anthracycline-based chemotherapy by selectively targeting these persistent tumor cells."}], "pathway_id": "mmu00190", "pubmed_id": "41090785", "species": "mmu"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rheumatoid arthritis - Rattus norvegicus (rat)\n**Pathway Description**: Rheumatoid arthritis (RA) is a chronic autoimmune joint disease where persistent inflammation affects bone remodeling leading to progressive bone destruction. In RA, abnormal activation of the immune system elevates pro-inflammatory cytokines and chemokines levels, which can promote synovial angiogenesis and leukocyte infiltration. The synovium forms a hyperplastic pannus with infiltrated macrophage-like and fibroblast-like synoviocytes and invades joints by secreting proteinases and inducing osteoclast differentiation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS1, ALAS2, FECH, CPOX, PPOX, UROD, BLVRA, HMBS, ALAD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid (5-ALA) is the initial substrate in the heme biosynthesis pathway, which is catalyzed by ALAS1 in the liver and ALAS2 in erythroid cells. The sequential enzymatic processing of 5-ALA by FECH, CPOX, PPOX, UROD, BLVRA, HMBS, and ALAD leads to the formation of heme. Disruption of this pathway results in the accumulation of toxic intermediates and reduced heme levels, contributing to oxidative stress and impaired erythropoiesis. Deficiencies in any of these enzymes can lead to heme deficiency, which manifests as anemia and other related metabolic dysfunctions."}], "pathway_id": "rno05323", "pubmed_id": "41197929", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rheumatoid arthritis - Rattus norvegicus (rat)\n**Pathway Description**: Rheumatoid arthritis (RA) is a chronic autoimmune joint disease where persistent inflammation affects bone remodeling leading to progressive bone destruction. In RA, abnormal activation of the immune system elevates pro-inflammatory cytokines and chemokines levels, which can promote synovial angiogenesis and leukocyte infiltration. The synovium forms a hyperplastic pannus with infiltrated macrophage-like and fibroblast-like synoviocytes and invades joints by secreting proteinases and inducing osteoclast differentiation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), Activating Transcription Factor 4 (hyperactivation), Runt-related Transcription Factor 2, Receptor Activator of Nuclear Factor Kappa-B Ligand, RAD21 Cohesin Complex Component, Core Binding Factor Beta Subunit, Histone Deacetylase 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Quercetin inhibits ATF4 hyperactivation in osteoblasts, which restores the balance between RUNX2 and RANKL expression. This modulation suppresses osteoclast differentiation and bone resorption, thereby reducing bone erosion in rheumatoid arthritis. ATF4 interacts with transcription factors RAD21, CBFB, and HDAC2, and Quercetin exhibits strong binding affinity to these proteins, further contributing to the inhibition of pathological bone remodeling."}], "pathway_id": "rno05323", "pubmed_id": "41185011", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rheumatoid arthritis - Rattus norvegicus (rat)\n**Pathway Description**: Rheumatoid arthritis (RA) is a chronic autoimmune joint disease where persistent inflammation affects bone remodeling leading to progressive bone destruction. In RA, abnormal activation of the immune system elevates pro-inflammatory cytokines and chemokines levels, which can promote synovial angiogenesis and leukocyte infiltration. The synovium forms a hyperplastic pannus with infiltrated macrophage-like and fibroblast-like synoviocytes and invades joints by secreting proteinases and inducing osteoclast differentiation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fludarabine (administration), Signal Transducer and Activator of Transcription 1 (elevated expression), Microtubule-Associated Protein 1 Light Chain 3 (increased expression), Acyl-CoA Synthetase Long-Chain Family Member 4 (increased expression), Sequestosome 1 (decreased expression), Glutathione Peroxidase 4 (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of STAT1 in synovial macrophages activates inflammatory pathways and contributes to rheumatoid arthritis progression by modulating autophagy and ferroptosis. STAT1 activation increases the expression of LC3 and ACSL4 while decreasing p62 and GPX4, promoting ferroptotic cell death and autophagic flux. Treatment with fludarabine reverses these effects, suggesting that STAT1 signaling is a key regulator of macrophage-driven inflammation and tissue destruction in rheumatoid arthritis."}], "pathway_id": "rno05323", "pubmed_id": "41131607", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin (administration), Angiotensin Ii (elevated levels), D-Glucose (intracellular levels), Pyruvic Acid (intracellular levels), Lactic Acid (intracellular levels), OXTR, JAK2 (phosphorylation), STAT3 (phosphorylation), LDHA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated angiotensin II levels induce cardiac hypertrophy by promoting fibrotic changes and activating the JAK2/STAT3 signaling pathway. Oxytocin increases the expression of oxytocin receptors (OXTR), which in turn inhibits the phosphorylation of JAK2 and STAT3. This suppression of JAK2/STAT3 signaling contributes to the attenuation of cardiac hypertrophy. Additionally, oxytocin improves cardiac glucose metabolism by increasing intracellular glucose and pyruvic acid levels while decreasing lactate production and lactate dehydrogenase activity. Downregulation of OXTR reverses the protective effects of oxytocin, indicating that the OXTR/JAK2/STAT3 axis plays a central role in mediating its anti-hypertrophic action."}], "pathway_id": "rno04921", "pubmed_id": "39613260", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oxytocin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Oxytocin (OT) is a nonapeptide synthesized by the magno-cellular neurons located in the supraoptic (SON) and paraventricular (PVN) nuclei of the hypothalamus. It exerts a wide variety of central and peripheral effects. However, its best-known and most well-established roles are stimulation of uterine contractions during parturition and milk release during lactation. Oxytocin also influences cardiovascular regulation and various social behaviors. The actions of OT are all mediated by one type of OT receptor (OTR). This is a transmembrane receptor belonging to the G-protein-coupled receptor superfamily. The main signaling pathway is the Gq/PLC/Ins3 pathway, but the MAPK and the RhoA/Rho kinase pathways are also activated, contributing to increased prostaglandin production and direct contractile effect on myometrial cells. In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin, Oxytocin receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin signaling in the dorsal hippocampus promotes prosocial eating in rats by enhancing food consumption in the presence of a familiar conspecific. Activation of the oxytocin receptor in this brain region facilitates the social transmission of food preference learning and supports social recognition memory. These effects are specific to familiar social contexts and do not influence baseline food intake under isolated conditions."}], "pathway_id": "rno04921", "pubmed_id": "39038641", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Wnt3a, DVL2, CTNNB1 (stabilized), GSK3B (elevated activity), phospho-GSK3B, MKI67 (upregulated), DCX (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of Wnt3a and -catenin, along with elevated GSK-3 activity, correlates with impaired hippocampal neurogenesis and depressive-like behaviors. Activation of the Wnt/-catenin pathway through inhibition of GSK-3 and upregulation of Dishevelled-2 stabilizes -catenin, allowing it to translocate to the nucleus and promote the expression of genes involved in neuronal differentiation and cell proliferation. This pathway positively regulates Ki67 and doublecortin, markers of neurogenesis and immature neurons, thereby supporting hippocampal structural integrity and function."}], "pathway_id": "rno04310", "pubmed_id": "41183669", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ginsenoside K (administration), beta-catenin (nuclear translocation), glycogen synthase kinase 3 beta, phosphorylated glycogen synthase kinase 3 beta (phosphorylation), cyclin D1 (expression), vascular endothelial growth factor (expression), tumor necrosis factor alpha.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ginsenoside Compound K inhibits the Wnt/-catenin signaling pathway by suppressing the phosphorylation of GSK-3, which leads to the stabilization and nuclear translocation of -catenin. This suppression reduces the expression of cyclin D1 and vascular endothelial growth factor (VEGF), thereby attenuating synovial angiogenesis and endothelial cell activation. The inhibition of this pathway contributes to the alleviation of synovial inflammation and joint injury."}], "pathway_id": "rno04310", "pubmed_id": "41273048", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Furan-2yl-isoxazole-3-carboxylic acid (3-imidazol-1yl-propyl)-amide, CKAP4, WNT3A, WNT5A, CTNNB1 (inhibited), ACTA2 (increased expression), COL1A1 (increased expression), COL3A1 (increased expression), VIM (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CKAP4 interacts with WNT3A and WNT5A to activate -catenin signaling, leading to increased -smooth muscle actin, collagen I and III, and vimentin expression in atrial fibroblasts. This activation promotes fibroblast migration and collagen synthesis, contributing to atrial fibrosis and increasing vulnerability to atrial fibrillation. Inhibition of -catenin/TCF signaling attenuates these effects."}], "pathway_id": "rno04310", "pubmed_id": "41159262", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Wnt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Wnt proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. There are at least three different Wnt pathways: the canonical pathway, the planar cell polarity (PCP) pathway and the Wnt/Ca2+ pathway. In the canonical Wnt pathway, the major effect of Wnt ligand binding to its receptor is the stabilization of cytoplasmic beta-catenin through inhibition of the bea-catenin degradation complex. Beta-catenin is then free to enter the nucleus and activate Wnt-regulated genes through its interaction with TCF (T-cell factor) family transcription factors and concomitant recruitment of coactivators. Planar cell polarity (PCP) signaling leads to the activation of the small GTPases RHOA (RAS homologue gene-family member A) and RAC1, which activate the stress kinase JNK (Jun N-terminal kinase) and ROCK (RHO-associated coiled-coil-containing protein kinase 1) and leads to remodelling of the cytoskeleton and changes in cell adhesion and motility. WNT-Ca2+ signalling is mediated through G proteins and phospholipases and leads to transient increases in cytoplasmic free calcium that subsequently activate the kinase PKC (protein kinase C) and CAMKII (calcium calmodulin mediated kinase II) and the phosphatase calcineurin.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sinigrin (administration), Interleukin-1 beta (increased levels), Tumor necrosis factor alpha (increased levels), Interleukin-6 (increased levels), Cofilin, Fibronectin 1 (increased levels), Alpha-smooth muscle actin (increased levels), Collagen type I (increased levels), Collagen type III (increased levels), Tissue inhibitor of metalloproteinases 1 (increased levels), Glycogen synthase kinase 3 beta, Beta-catenin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sinigrin reduces cardiac inflammation and fibrosis by modulating the Wnt/GSK-3/-catenin signaling pathway. This pathway regulates the stabilization and nuclear translocation of -catenin, which influences the expression of genes involved in cell proliferation and tissue remodeling. Inhibition of this pathway by sinigrin leads to decreased levels of inflammatory cytokines such as IL-1, TNF-, and IL-6, as well as reduced fibrotic markers including fibronectin 1, -SMA, collagen types I and III, and TIMP-1. These effects contribute to the attenuation of extracellular matrix deposition, fibroblast proliferation, and cardiomyocyte disorganization, thereby alleviating cardiac fibrosis and inflammation."}], "pathway_id": "rno04310", "pubmed_id": "41005146", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Insulin binding to its receptor results in the tyrosine phosphorylation of insulin receptor substrates (IRS) by the insulin receptor tyrosine kinase (INSR). This allows association of IRSs with the regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt, a serine kinase. Akt in turn deactivates glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase (GYS) and thus glycogen synthesis. Activation of Akt also results in the translocation of GLUT4 vesicles from their intracellular pool to the plasma membrane, where they allow uptake of glucose into the cell. Akt also leads to mTOR-mediated activation of protein synthesis by eIF4 and p70S6K. The translocation of GLUT4 protein is also elicited through the CAP/Cbl/TC10 pathway, once Cbl is phosphorylated by INSR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Procyanidin A2 (administration), AMP-activated protein kinase, Protein kinase B (phosphorylated), Solute carrier family 2, facilitated glucose transporter member 4 (increased expression), Beclin 1 (increased levels), Microtubule-associated protein 1 light chain 3 beta (LC3B) (increased levels), Autophagy-related protein 5 (increased levels), Sequestosome 1 (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Procyanidin A2 activates AMP-activated protein kinase and phosphorylates protein kinase B, leading to increased expression of solute carrier family 2, facilitated glucose transporter member 4 and enhanced glucose uptake. It also modulates autophagy by increasing the levels of Beclin 1, microtubule-associated protein 1 light chain 3 beta, and autophagy-related protein 5, while decreasing sequestosome 1. These actions contribute to improved glucose tolerance and glycogen synthesis in hepatic and muscular tissues."}], "pathway_id": "rno04910", "pubmed_id": "41271919", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Insulin binding to its receptor results in the tyrosine phosphorylation of insulin receptor substrates (IRS) by the insulin receptor tyrosine kinase (INSR). This allows association of IRSs with the regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt, a serine kinase. Akt in turn deactivates glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase (GYS) and thus glycogen synthesis. Activation of Akt also results in the translocation of GLUT4 vesicles from their intracellular pool to the plasma membrane, where they allow uptake of glucose into the cell. Akt also leads to mTOR-mediated activation of protein synthesis by eIF4 and p70S6K. The translocation of GLUT4 protein is also elicited through the CAP/Cbl/TC10 pathway, once Cbl is phosphorylated by INSR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin (administration), Peroxisome Proliferator-Activated Receptor Gamma (modulated), Insulin Receptor (activated), Insulin Receptor Substrate 1 (phosphorylated), Insulin Receptor Substrate 2 (phosphorylated), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (activated), Protein Kinase B (activated), AMP-Activated Protein Kinase (modulated), Glucose Transporter Type 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin modulates insulin signaling by regulating the expression of key components of the PI3K-AKT and AMPK pathways. Activation of the insulin receptor (IR) leads to phosphorylation of insulin receptor substrates 1 and 2 (IRS1 and IRS2), which recruit and activate phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). PI3K then activates protein kinase B (AKT), promoting glucose uptake through the translocation of glucose transporter type 4 (GLUT4) to the cell membrane. Oxytocin also influences peroxisome proliferator-activated receptor gamma (PPAR) and AMP-activated protein kinase (AMPK), both of which regulate glucose and lipid metabolism. These effects collectively enhance insulin sensitivity and improve glucose homeostasis."}], "pathway_id": "rno04910", "pubmed_id": "41167707", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Insulin binding to its receptor results in the tyrosine phosphorylation of insulin receptor substrates (IRS) by the insulin receptor tyrosine kinase (INSR). This allows association of IRSs with the regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt, a serine kinase. Akt in turn deactivates glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase (GYS) and thus glycogen synthesis. Activation of Akt also results in the translocation of GLUT4 vesicles from their intracellular pool to the plasma membrane, where they allow uptake of glucose into the cell. Akt also leads to mTOR-mediated activation of protein synthesis by eIF4 and p70S6K. The translocation of GLUT4 protein is also elicited through the CAP/Cbl/TC10 pathway, once Cbl is phosphorylated by INSR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Di(2-ethylhexyl) phthalate (elevated levels), Mono(2-ethylhexyl) phthalate (elevated levels), Phosphatidylinositol-4,5-bisphosphate 3-kinase, Protein kinase B, Forkhead box protein O1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Di(2-ethylhexyl) phthalate and its metabolite Mono(2-ethylhexyl) phthalate inhibit the PI3K/Akt signaling pathway, leading to suppression of glucose homeostasis and induction of -cell dedifferentiation. This inhibition facilitates the nuclear translocation of FoxO1, contributing to impaired glucose-stimulated insulin secretion and metabolic dysfunction."}], "pathway_id": "rno04910", "pubmed_id": "41101618", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Insulin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Insulin binding to its receptor results in the tyrosine phosphorylation of insulin receptor substrates (IRS) by the insulin receptor tyrosine kinase (INSR). This allows association of IRSs with the regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K activates 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt, a serine kinase. Akt in turn deactivates glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase (GYS) and thus glycogen synthesis. Activation of Akt also results in the translocation of GLUT4 vesicles from their intracellular pool to the plasma membrane, where they allow uptake of glucose into the cell. Akt also leads to mTOR-mediated activation of protein synthesis by eIF4 and p70S6K. The translocation of GLUT4 protein is also elicited through the CAP/Cbl/TC10 pathway, once Cbl is phosphorylated by INSR.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N,N-Dimethylarginine (increased levels), D-Glucose (elevated levels), PRMT4 (activated), mTOR (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRMT4 activation in response to elevated glucose levels increases asymmetric dimethylarginine (ADMA) production, which disrupts insulin signaling. This disruption contributes to skeletal muscle atrophy. PRMT4 also facilitates proteasome-mediated protein degradation, which releases free amino acids that activate mTOR signaling, further influencing metabolic and atrophy-related processes in skeletal muscle."}], "pathway_id": "rno04910", "pubmed_id": "41078314", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Collecting duct acid secretion - Rattus norvegicus (rat)\n**Pathway Description**: One of the important roles of the collecting duct segment of the kidney nephron is acid secretion. As daily food intake loads acid into the body, urinary acid excretion is essential, and urine pH can drop as low as 4.5. The alpha-intercalated cell of collecting duct is the main responsible for hydrogen secretion into the urine. The carbon dioxide, which is generated in the cells and enters from the blood, is changed to carbonic acid. This carbonic acid is divided into hydrogen ion and bicarbonate ion. Intracellular CA II catalyses the formation of these ions. The hydrogen ion is secreted into the lumen by the luminal H(+)-ATPase. The bicarbonate ion is transported to the blood side by the anion exchanger type 1. Hydrogen ion in the lumen is trapped by urinary buffers. These include ammonium and phosphate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium ion, Potassium Cation, Chloride, Ammonium Chloride, Cgmp, Hydrogen-potassium ATPase, Hydrogen-potassium ATPase 2, Sodium-potassium-chloride cotransporter, Atrial natriuretic peptide (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During metabolic acidosis, type A intercalated cells in the collecting duct secrete sodium ions (Na+) via a pathway involving the basolateral Na+-K+-2Cl- cotransporter and the apical H+-K+-ATPase 2 (HKA2) functioning in Na+/K+ exchange mode. Atrial natriuretic peptide (ANP) stimulates HKA2 activity through cGMP, promoting sodium secretion and countering the sodium-retaining effects of aldosterone. This mechanism contributes to the resolution of sodium retention and facilitates the renal adaptation to acid load."}], "pathway_id": "rno04966", "pubmed_id": "31188029", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melatonin (administration), Chloroquine Phosphate, Glutathione, Glutathione Disulfide, Malonaldehyde, Iron (elevated levels), Tumor protein p53 (activated), Phosphorylated tumor protein p53 (phosphorylated), Ataxia-telangiectasia mutated (activated), Ferritin heavy chain 1, Solute carrier family 7 member 11, Superoxide dismutase 2 (upregulated), Glutathione peroxidase 4 (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of iron and lipid peroxidation contribute to ferroptosis in cardiomyocytes. Activation of the ATM/p53 signaling pathway enhances p53 phosphorylation, which in turn promotes cellular stress responses and mitochondrial dysfunction. Inhibition of this pathway by melatonin reduces lipid peroxidation and restores the expression of antioxidant enzymes such as SOD-2 and GPX4. This leads to decreased ferroptosis and protection of cardiomyocytes from ischemia/reperfusion injury."}], "pathway_id": "rno04115", "pubmed_id": "41184216", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Asperosaponin VI, Semaglutide (administration), Klotho, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Akebia saponin D and Semaglutide synergistically modulate the Klotho-TP53 signaling axis to alleviate diabetic nephropathy and osteoporosis. Activation of this axis reduces oxidative stress and inflammation, restores glomerular structure and reduces renal fibrosis, while also improving bone microarchitecture and metabolic homeostasis."}], "pathway_id": "rno04115", "pubmed_id": "41268608", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Serdemetan, MDM2, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Pharmacological inhibition of MDM2 activates the p53 signaling pathway, leading to enhanced osteogenic differentiation and mineralization in bone marrow stromal cells. Concurrently, p53 activation suppresses osteoclast formation and bone resorption in macrophages. This dual regulation is associated with upregulation of osteogenic genes and downregulation of osteoclast-related markers, alongside increased autophagy. These effects contribute to improved bone regeneration and restoration of trabecular bone architecture."}], "pathway_id": "rno04115", "pubmed_id": "41138651", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ethanedioic acid, calcium salt (1:1), Oxalate (elevated levels), Fisetin, TP53 (increased expression), RPS3, LXN, NOS2, CD163, CDKN2A (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of oxalate induce premature senescence in renal tubular epithelial cells through activation of the LXN/Rps3/p53 signaling pathway. This senescence is associated with increased expression of p53 and p16, and the secretion of SASP factors. The SASP alters the polarization of macrophages toward an M1-like phenotype, promoting a proinflammatory environment that facilitates calcium oxalate crystal deposition in the kidney. Inhibition of the LXN/Rps3/p53 pathway reduces SASP secretion and prevents M1-like macrophage polarization, thereby decreasing intrarenal crystal accumulation."}], "pathway_id": "rno04115", "pubmed_id": "41112268", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenine (administration), TP53 (phosphorylation), PRKAA1, MAPK1 (phosphorylation), NFKB1 (activation), MAPK8 (activation), MAPK14 (activation), NOS2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Adenine activates AMPK signaling, which increases phosphorylation of TP53 and reduces phosphorylation of MAPK1 (ERK). This leads to decreased activation of NFKB1 (NF-B) and suppression of inflammatory mediator production. Concurrently, LPS-induced activation of MAPK8 (JNK) and MAPK14 (p38) contributes to NF-B signaling and inflammation. Increased TP53 phosphorylation inhibits ERK signaling and modulates the inflammatory response in vascular smooth muscle cells."}], "pathway_id": "rno04115", "pubmed_id": "41075915", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nobiletin (administration), Hesperetin (administration), Berberine (administration), TP53 (inhibited), AKT1 (activated), GPX4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of the p53 signaling pathway by Nobiletin, Hesperetin, and Berberine reduces ferroptosis in thyroid follicular cells. These compounds also partially activate AKT signaling and enhance glutathione metabolism, promoting cell survival and preventing ferroptosis-related cell death in hypothyroid conditions."}], "pathway_id": "rno04115", "pubmed_id": "41047052", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: p53 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein and integrate these stress responses with other signal transduction pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TP53 (elevated levels), CDKN1A (elevated levels), CDKN2A (elevated levels), IL6 (reduced expression), TNF (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of p53, p21, and p16 contribute to cellular senescence. Downregulation of these proteins reduces senescent phenotypes and enhances cell proliferation and migration. Inhibition of p53 and its downstream effectors, such as p21 and p16, is associated with improved osteogenic differentiation potential. Concurrently, reduced expression of pro-inflammatory cytokines IL-6 and TNF- supports a less senescent and more regenerative cellular environment."}], "pathway_id": "rno04115", "pubmed_id": "40877889", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Urate, Toll-like receptor 4 (activated), Myeloid differentiation primary response 88, Nuclear factor kappa B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4 activation promotes NF-B signaling through the MyD88-dependent pathway, resulting in the production of proinflammatory cytokines and synovial inflammation. In gouty arthritis, monosodium urate crystals stimulate TLR4, leading to NF-B activation and exacerbation of inflammatory responses. Modulation of TLR4 and MyD88 expression reduces NF-B activation, thereby attenuating synovitis and inflammatory signaling."}], "pathway_id": "rno04620", "pubmed_id": "41326463", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tanshinone Iia, Toll-like receptor 4 (elevated levels), Nuclear factor kappa B subunit 1, Myeloid differentiation primary response 88 (elevated levels), Nuclear factor kappa B subunit p65 (phosphorylation), Inhibitor of kappa light polypeptide gene enhancer in B-cells (degradation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tanshinone IIA interacts with TLR4 and NFKB1, downregulating TLR4 and MyD88 expression and inhibiting NF-B p65 phosphorylation while preventing IB degradation. This suppression of the TLR4/NF-B signaling cascade reduces the production of proinflammatory cytokines such as IL-1, IL-6, and TNF-, thereby attenuating neuroinflammation and apoptosis associated with cerebral ischemia-reperfusion injury."}], "pathway_id": "rno04620", "pubmed_id": "41265260", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Galectin-3 (elevated expression), Toll-like receptor 4 (activated), Myeloid differentiation primary response 88 (activated), Nuclear factor kappa B (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Galectin-3 promotes the progression of erectile dysfunction by inducing oxidative stress and activating the TLR4/MyD88/NF-B signaling pathway. This activation leads to the initiation of inflammatory profibrotic cascades, which contribute to the deterioration of erectile function."}], "pathway_id": "rno04620", "pubmed_id": "41204281", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Toll-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified as homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. TLR signaling pathways are separated into two groups: a MyD88-dependent pathway that leads to the production of proinflammatory cytokines with quick activation of NF-{kappa}B and MAPK, and a MyD88-independent pathway associated with the induction of IFN-beta and IFN-inducible genes, and maturation of dendritic cells with slow activation of NF-{kappa}B and MAPK.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 10-Hydroxydec-2-enoic acid (administration), Toll-like receptor 4 (upregulation), Myeloid differentiation primary response 88 (upregulation), Nuclear factor kappa B (nuclear translocation), Inhibitor of kappa light polypeptide gene enhancer in B-cells, alpha (phosphorylated and degraded).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated TLR4 expression activates the MyD88-dependent signaling pathway, leading to IB phosphorylation and degradation, which enables NF-B nuclear translocation. This results in the upregulation of pro-inflammatory cytokines and contributes to myocardial inflammation and oxidative stress. 10-hydroxydec-2-enoic acid suppresses TLR4 and MyD88 upregulation, reduces TLR4-MyD88 interaction, and inhibits IB phosphorylation and NF-B nuclear translocation, thereby attenuating inflammatory and oxidative stress responses in the myocardium."}], "pathway_id": "rno04620", "pubmed_id": "41175588", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glycosylphosphatidylinositol (GPI)-anchor biosynthesis - Rattus norvegicus (rat)\n**Pathway Description**: Cell surface proteins can be attached to the cell membrane via the glycolipid structure called glycosylphosphatidylinositol (GPI) anchor. Hundreds of GPI-anchored proteins have been identified in many eukaryotes ranging from protozoa and fungi to mammals. All protein-linked GPI anchors share a common core structure, characterized by the substructure Man (a1-4) GlcN (a1-6) myo-inositol-1P-lipid. Biosynthesis of GPI anchors proceeds in three stages: (i) preassembly of a GPI precursor in the ER membrane, (ii) attachment of the GPI to the C-terminus of a newly synthesized protein in the lumen of the ER, and (iii) lipid remodeling and/or carbohydrate side-chain modifications in the ER and the Golgi. Defects of GPI anchor biosynthesis gene result in a genetic disorder, paroxysmal nocturnal hemoglobinuria.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (administration), Palmitic Acid (administration), 1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-2-4-(trans-4-methylcyclohexyl)aminocarbonylaminosulfonylphenylethyl-2-oxo-, CD73 (translocated from DIGs), 5'-nucleotidase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The GPI-anchored protein CD73, a 5'-nucleotidase, is transferred from adiposomes to adipocytes via detergent-insoluble glycolipid-enriched microdomains (DIGs) and subsequently localizes to lipid droplets (LD). This translocation is mediated by intact GPI anchors and is associated with increased lipid synthesis in adipocytes. The movement of CD73 from DIGs to LD enhances the lipogenic response to signals such as hydrogen peroxide, palmitic acid, and glimepiride. This mechanism supports paracrine regulation of lipid metabolism within adipose tissue."}], "pathway_id": "rno00563", "pubmed_id": "20590586", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fluoxetine (elevated levels), GJB2, GJA1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated fluoxetine levels upregulate the expression of GJB2 (connexin 36) and GJA1 (connexin 43), which are essential components of gap junctions that facilitate intercellular communication. This increased expression enhances gap junctional communication between neurons and glial cells, contributing to the modulation of brain connectivity and potentially alleviating depressive phenotypes."}], "pathway_id": "rno04540", "pubmed_id": "40498164", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Connexin-43, Connexin-36.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin-43 and Connexin-36 form hemichannels that assemble into functional gap junction channels at the cell membrane, enabling direct intercellular communication between adjacent cells. These channels facilitate the exchange of ions, small molecules, and second messengers, supporting electrical coupling and metabolic coordination. Gap junctional communication plays a critical role in tissue homeostasis and is modulated by intracellular calcium levels, pH, and phosphorylation events."}], "pathway_id": "rno04540", "pubmed_id": "40039089", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbenoxolone (administration), connexin-43 (uncoupled), gap junction protein alpha 1a (reduced expression), sodium voltage-gated channel alpha subunit 5.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of connexin-43 (Cx43), encoded by GJA1a, impairs gap junctional communication in the aging myocardium. This impairment is partially offset by increased sodium current density, mediated by enhanced expression of SCN5a. The elevated sodium current contributes to the preservation of longitudinal conduction velocity despite diminished intercellular coupling and increased fibrosis. Carbenoxolone, a Cx43 uncoupling agent, reveals that gap junction functionality has a greater impact on conduction velocity in younger myocardium."}], "pathway_id": "rno04540", "pubmed_id": "40683525", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, Ins(1,4,5)P3, Inositol 1,4,5-trisphosphate receptor type 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Astrocyte leaflets interface with synapses and are interconnected via gap junctions, enabling cytosolic continuity between astrocytic domains. These domains facilitate the propagation of calcium signals through gap junction-mediated intercellular communication. Synaptically induced calcium events in leaflets are mediated by IP3 receptor type 1, leading to the integration of inputs from multiple neurons. This calcium signaling supports the functional coordination of synapses and circuits at different spatiotemporal scales."}], "pathway_id": "rno04540", "pubmed_id": "40997814", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Connexin-43 (forms punctate structures).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Connexin-43 (Cx43) is expressed in ventral boundary cap cells during embryonic development. At early stages, Cx43 localizes in the cytoplasm, potentially regulating histogenetic processes, while at later stages, Cx43 forms punctate structures representing gap junction plaques between adjacent cells, facilitating intercellular communication."}], "pathway_id": "rno04540", "pubmed_id": "39589621", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (-)-Loganin (administration), Corticosterone, Fluoxetine, H-Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg-OH, Xav-939, Cx43 (increased phosphorylation at Ser368), CTNNB1 (increased levels), GSK3B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impaired astrocytic gap junctions, mediated by Connexin43 (Cx43), contribute to the pathophysiology of depression. Cx43 dysfunction is associated with increased phosphorylation at Ser368, which disrupts intercellular communication. Loganin restores Cx43 expression and reduces its phosphorylation, thereby preserving gap junction integrity. This effect is mediated, in part, through the GSK-3/-catenin signaling pathway, where loganin promotes GSK-3 phosphorylation at Ser9 and increases -catenin levels. These molecular changes enhance astrocytic communication and alleviate depressive-like behaviors."}], "pathway_id": "rno04540", "pubmed_id": "39732296", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-Octanol (administration), Gap 27, 5-Bromo-2'-deoxyuridine, Connexin-43.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "General blockade of gap junctions with 1-Octanol reduces the proliferation of postnatal subventricular zone neural precursor cells and promotes glial differentiation, increasing the proportion of astrocytes and oligodendrocyte precursors. Connexin-43-specific blockade with Gap27 does not significantly alter the differentiation pattern of these cells. Gap junctional communication is associated with the regulation of cell proliferation and lineage commitment in postnatal neural progenitor cells."}], "pathway_id": "rno04540", "pubmed_id": "38927995", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Gap junction - Rattus norvegicus (rat)\n**Pathway Description**: Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication is essential for many physiological events, including embryonic development, electrical coupling, metabolic transport, apoptosis, and tissue homeostasis. Communication through Gap Junction is sensitive to a variety of stimuli, including changes in the level of intracellular Ca2+, pH, transjunctional applied voltage and phosphorylation/dephosphorylation processes. This figure represents the possible activation routes of different protein kinases involved in Cx43 and Cx36 phosphorylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbenoxolone (administration), Riluzole (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gap junction coupling facilitates synchronized rhythmic burst firing in ventromedial hypothalamic neurons by enabling intercellular calcium signaling and electrical communication. Disruption of gap junctions with carbenoxolone or inhibition of persistent sodium channels with riluzole abolishes this synchronized activity, indicating that both mechanisms contribute to the generation and maintenance of rhythmic bursting."}], "pathway_id": "rno04540", "pubmed_id": "39400580", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Rattus norvegicus (rat)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calpastatin, TATA box-binding protein (cleavage), Calpain (inhibited activity), C-terminal TBP fragments (mislocalization).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated calpain activity leads to the cleavage of TATA box-binding protein (TBP), resulting in the formation of C-terminal TBP fragments that mislocalize to the cytoplasm. This mislocalization contributes to the depletion of neuronal proteins and facilitates TBP aggregation. Disruption of calcium signaling and synaptogenesis further exacerbates neurodegeneration. Inhibition of calpain activity reduces TBP cleavage and aggregation, thereby mitigating neuronal loss and improving cell viability."}], "pathway_id": "rno05017", "pubmed_id": "35482253", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spinocerebellar ataxia - Rattus norvegicus (rat)\n**Pathway Description**: The autosomal dominant spinocerebellar ataxias (SCAs) are a group of progressive neurodegenerative diseases characterised by loss of balance and motor coordination due to the primary dysfunction of the cerebellum. Compelling evidence points to major aetiological roles for transcriptional dysregulation, protein aggregation and clearance, autophagy, the ubiquitin-proteasome system, alterations of calcium homeostasis, mitochondria defects, toxic RNA gain-of-function mechanisms and eventual cell death with apoptotic features of neurons during SCA disease progression.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Cysteine (administration), Hydrogen Sulfide (production), Ataxin-1, Ataxin-3, Cacng2, Metabotropic glutamate receptor 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "D-cysteine promotes dendritic growth in primary cultured Purkinje cells through hydrogen sulfide production. This effect counteracts the dendritic development impairment caused by mutant ataxin-1, ataxin-3, and Cacng2 proteins associated with spinocerebellar ataxia. D-cysteine also prevents the reduction of metabotropic glutamate receptor 1 (mGluR1) and suppresses glial activation in early-stage motor dysfunction. These actions collectively inhibit the progression of motor deficits and support neuronal function in SCA models."}], "pathway_id": "rno05017", "pubmed_id": "34157318", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAP1A (activated), ELN (increased expression), SPP1 (increased expression), TAGLN (reduced expression), ACTA2 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rap1 signaling is activated in pulmonary artery smooth muscle cells and promotes phenotypic transformation by reducing contractile marker expression (TAGLN, ACTA2) and increasing synthetic marker expression (ELN, SPP1). This process is associated with decreased actin microfilament organization and enhanced cellular proliferation."}], "pathway_id": "rno04015", "pubmed_id": "39287558", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose (elevated levels), RAP1A (activation), AKT1, NFKB1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of D-glucose induce increased RAP1A expression, likely through activation of AKT1. This promotes RAP1A translocation from the nucleus to the cytoplasm, where it activates NFKB1 signaling. This pathway contributes to -cell dysfunction and the progression of glucotoxicity."}], "pathway_id": "rno04015", "pubmed_id": "38570110", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Di(2-ethylhexyl) phthalate (elevated levels), Monobutyl phthalate, RAS-related protein 1 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of di(2-ethylhexyl) phthalate (DEHP) induce apoptosis and autophagy in thyroid cells. This effect is associated with modulation of the Rap1 signaling pathway, which regulates cell survival and death processes. Inhibition of Rap1 reduces both apoptosis and autophagy, suggesting that Rap1 activity is a key mediator of these cellular responses."}], "pathway_id": "rno04015", "pubmed_id": "38522500", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Rap1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Rap1 is a small GTPase that controls diverse processes, such as cell adhesion, cell-cell junction formation and cell polarity. Like all G proteins, Rap1 cycles between an inactive GDP-bound and an active GTP-bound conformation. A variety of extracellular signals control this cycle through the regulation of several unique guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). Rap1 plays a dominant role in the control of cell-cell and cell-matrix interactions by regulating the function of integrins and other adhesion molecules in various cell types. Rap1 also regulates MAP kinase (MAPK) activity in a manner highly dependent on the context of cell types.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ethanedioic acid, calcium salt (1:1), Glyoxylic Acid, miR-184 (elevated levels), Insulin-like growth factor 1 receptor (activated), Myeloid cell leukemia 1 (upregulated), BCL2-like 1 (upregulated), Caspase-3 (inhibited), Ras-related protein 1 (activated), NFE2-related factor 2, Heme oxygenase 1, Nuclear factor kappa B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of miR-184 suppress the Rap1 signaling pathway, contributing to renal cell damage. Inhibition of miR-184 activates Rap1, which attenuates inflammation, apoptosis, and oxidative stress in renal cells exposed to calcium oxalate. IGF1R is a direct target of miR-184, and its activation counteracts the damaging effects of miR-184. The Nrf2/HO-1 and NF-B pathways are modulated in response to miR-184 levels, influencing cellular redox balance and inflammatory responses. Downregulation of miR-184 enhances cell survival by upregulating anti-apoptotic proteins such as Mcl1 and Bcl-XL, while reducing Caspase-3 activity."}], "pathway_id": "rno04015", "pubmed_id": "38154105", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cocaine addiction - Rattus norvegicus (rat)\n**Pathway Description**: Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences.There is strong evidence that the dopaminergic system that projects from the ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAc), and to other forebrain sites, is the major substrate of reward and reinforcement for both natural rewards and addictive drugs. Cocaine binds strongly to the dopamine-reuptake transporter, preventing the reuptake of dopamine into the nerve terminal. Because of this blocking effect, dopamine remains at high concentrations in the synapse and continues to affect adjacent neurons, producing the characteristic cocaine \"high.\" Activated D1 receptor activates the PKA signaling pathway, and this pathway plays a critical role in mediating the behavioral responses to cocaine administration. Cocaine-induced neuroadaptations, including dopamine depletion, may underlie craving and hedonic dysregulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dopamine (Release), Dopamine receptor D1 (Activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dopamine signaling in the nucleus accumbens core is modulated by contextual cue presentation, with non-contingent cues increasing dopamine release and contingent cues decreasing it. This bidirectional regulation contributes to cue reactivity and escalated drug consumption, key features of substance use disorder. Activation of the D1 receptor by dopamine initiates signaling pathways that reinforce drug-seeking behavior."}], "pathway_id": "rno05030", "pubmed_id": "41224753", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cocaine addiction - Rattus norvegicus (rat)\n**Pathway Description**: Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences.There is strong evidence that the dopaminergic system that projects from the ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAc), and to other forebrain sites, is the major substrate of reward and reinforcement for both natural rewards and addictive drugs. Cocaine binds strongly to the dopamine-reuptake transporter, preventing the reuptake of dopamine into the nerve terminal. Because of this blocking effect, dopamine remains at high concentrations in the synapse and continues to affect adjacent neurons, producing the characteristic cocaine \"high.\" Activated D1 receptor activates the PKA signaling pathway, and this pathway plays a critical role in mediating the behavioral responses to cocaine administration. Cocaine-induced neuroadaptations, including dopamine depletion, may underlie craving and hedonic dysregulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), Aminolevulinate Synthase 1, Aminolevulinate Synthase 2, Ferrochelatase (deficiency), Delta-Aminolevulinic Acid Dehydratase (deficiency), Porphobilinogen Deaminase (deficiency), Uroporphyrinogen Decarboxylase (deficiency), Coproporphyrinogen Oxidase (deficiency), Protoporphyrinogen Oxidase (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid is the initial and rate-limiting substrate in the heme biosynthesis pathway, synthesized primarily by ALAS1 in the liver and ALAS2 in erythroid cells. Deficiencies in enzymes such as FECH, ALAD, PBGD, UROD, CPOX, or PPOX lead to the accumulation of pathway intermediates, including 5-aminolevulinic acid and porphobilinogen, which are toxic and contribute to the development of acute intermittent porphyria. This condition manifests as hepatic dysfunction, neurological symptoms, and neuropsychiatric disturbances due to the disruption of heme homeostasis and the accumulation of neurotoxic porphyrin precursors."}], "pathway_id": "rno05030", "pubmed_id": "40644799", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cocaine addiction - Rattus norvegicus (rat)\n**Pathway Description**: Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences.There is strong evidence that the dopaminergic system that projects from the ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAc), and to other forebrain sites, is the major substrate of reward and reinforcement for both natural rewards and addictive drugs. Cocaine binds strongly to the dopamine-reuptake transporter, preventing the reuptake of dopamine into the nerve terminal. Because of this blocking effect, dopamine remains at high concentrations in the synapse and continues to affect adjacent neurons, producing the characteristic cocaine \"high.\" Activated D1 receptor activates the PKA signaling pathway, and this pathway plays a critical role in mediating the behavioral responses to cocaine administration. Cocaine-induced neuroadaptations, including dopamine depletion, may underlie craving and hedonic dysregulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cocaine (administration), Dopamine (enhanced release), 4-(2-Chlorophenyl)butan-2-amine hydrochloride (administration), Pramipexole (administration), SLC6A3 (phosphorylation increased), DRD3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cocaine blocks dopamine transporters (DAT, SLC6A3), leading to elevated extracellular dopamine levels and dysregulated DAT function. Dopamine D3 receptors (DRD3) modulate DAT activity, with biased agonists like SK609 reducing DAT phosphorylation and attenuating cocaine-induced dopamine uptake inhibition. In contrast, unbiased D3R agonists like pramipexole increase DAT phosphorylation, enhance dopamine release, and promote cocaine-seeking behavior. These effects are mediated through the mesolimbic dopamine pathway and involve changes in dopamine transmission and receptor signaling dynamics."}], "pathway_id": "rno05030", "pubmed_id": "40570201", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cocaine addiction - Rattus norvegicus (rat)\n**Pathway Description**: Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences.There is strong evidence that the dopaminergic system that projects from the ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAc), and to other forebrain sites, is the major substrate of reward and reinforcement for both natural rewards and addictive drugs. Cocaine binds strongly to the dopamine-reuptake transporter, preventing the reuptake of dopamine into the nerve terminal. Because of this blocking effect, dopamine remains at high concentrations in the synapse and continues to affect adjacent neurons, producing the characteristic cocaine \"high.\" Activated D1 receptor activates the PKA signaling pathway, and this pathway plays a critical role in mediating the behavioral responses to cocaine administration. Cocaine-induced neuroadaptations, including dopamine depletion, may underlie craving and hedonic dysregulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cocaine (administration), Benzoylecgonine, Glutamate transporter 1 (reduced expression), Nucleus accumbens.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cocaine and its metabolite benzoylecgonine are present in blood and brain tissue following oral self-administration, with their concentrations correlating with cocaine consumption. Reduced expression of the glial glutamate transporter GLT-1 in the nucleus accumbens is associated with cocaine self-administration, contributing to altered glutamate homeostasis. This glutamate dysregulation is linked to the incubation of drug-seeking behavior, particularly lever pressing, which intensifies over extended periods of abstinence. These neurobehavioral changes reflect the persistent neuroadaptations induced by cocaine exposure."}], "pathway_id": "rno05030", "pubmed_id": "40582418", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cocaine addiction - Rattus norvegicus (rat)\n**Pathway Description**: Drug addiction is a chronic, relapsing disorder in which compulsive drug-seeking and drug-taking behavior persists despite serious negative consequences.There is strong evidence that the dopaminergic system that projects from the ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAc), and to other forebrain sites, is the major substrate of reward and reinforcement for both natural rewards and addictive drugs. Cocaine binds strongly to the dopamine-reuptake transporter, preventing the reuptake of dopamine into the nerve terminal. Because of this blocking effect, dopamine remains at high concentrations in the synapse and continues to affect adjacent neurons, producing the characteristic cocaine \"high.\" Activated D1 receptor activates the PKA signaling pathway, and this pathway plays a critical role in mediating the behavioral responses to cocaine administration. Cocaine-induced neuroadaptations, including dopamine depletion, may underlie craving and hedonic dysregulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphodiesterase 10A, Zinc Finger E-Box Binding Homeobox 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphodiesterase 10A (PDE10A) regulates cyclic nucleotide levels in medium spiny neurons, influencing dopamine signaling and synaptic plasticity. Altered PDE10A activity is associated with cocaine use disorder and may contribute to disrupted neurotransmitter activity and synapse organization in the caudate nucleus."}], "pathway_id": "rno05030", "pubmed_id": "40204703", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Endometrial cancer - Rattus norvegicus (rat)\n**Pathway Description**: Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tetrabromobisphenol A (administration), TP53, ERBB2, ESR1, PGR.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Exposure to Tetrabromobisphenol A is associated with the development of uterine carcinomas characterized by increased TP53 mutations and overexpression of ERBB2. These tumors exhibit estrogen receptor-alpha positivity and progesterone receptor negativity, and their molecular and morphological features align with those of high-grade type I endometrial carcinomas. This pattern suggests a disruption in endometrial cell proliferation and genomic stability, potentially through estrogen-dependent and TP53-mediated pathways."}], "pathway_id": "rno05213", "pubmed_id": "26353976", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii, Cycloheximide, HIF1A, USP22, PATZ1 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of PATZ1 transcriptionally activate USP22 by binding to its promoter. USP22 binds to and stabilizes the HIF-1 protein through deubiquitination, thereby increasing its transcriptional activity. This stabilization of HIF-1 contributes to cardiomyocyte injury and fibrosis in chronic heart failure. Overexpression of HIF-1 can counteract the protective effects of USP22 knockdown, indicating a direct regulatory axis in cardiac dysfunction."}], "pathway_id": "rno04066", "pubmed_id": "41254007", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rhaponticin (administration), HIF1A (inhibited expression), PCNA (expression), CXCR4 (expression), BGLAP (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Rhaponticin interacts with HIF1A, a key component of the HIF-1 signaling pathway, and inhibits its expression under hypoxic conditions. This inhibition is associated with the promotion of PCNA, CXCR4, and BGLAP expression, which supports cell proliferation, migration, and osteogenic differentiation. These effects contribute to enhanced alveolar bone repair and reduced gingival inflammation in the context of periodontitis."}], "pathway_id": "rno04066", "pubmed_id": "41315502", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cobalt chloride (cocl2), HIF1A (stabilized), HVCN1 (activated), NOX2 (inhibited), NLRP3 (activated), PTGS2 (upregulated), NFKB1 (activated), SOCS3, GAP43, STX12, POU4F1, VDAC1 (restored distribution).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hypoxia stabilizes HIF-1, which activates transcriptional responses to low oxygen conditions. Under hypoxic stress, the Nox2-Hv1-ROS axis generates excessive reactive oxygen species, leading to mitochondrial dysfunction and oxidative stress. This contributes to NLRP3 inflammasome activation, NF-B signaling, and inflammatory responses. HIF-1 upregulation also promotes COX2 expression, further amplifying inflammatory mediators. These events are associated with retinal cell death, glial activation, and disruption of retinal architecture. Inhibition of the Nox2-Hv1-ROS axis reduces mitochondrial ROS accumulation and restores VDAC1 distribution, which helps preserve intracellular pH and mitochondrial function. Suppression of oxidative stress and inflammation via this pathway attenuates HIF-1 signaling and protects retinal cells from hypoxia-induced injury."}], "pathway_id": "rno04066", "pubmed_id": "41226841", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Artenimol, D-Glucose, HIF1A (elevated levels), HMOX1 (increased expression), KIM1, LTF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of HIF-1 and HO-1 are associated with increased mitochondrial dysfunction and apoptosis in high-glucose-exposed renal epithelial cells. Dihydroartemisinin promotes the ubiquitination and degradation of HIF-1, thereby reducing its activity and mitigating the HIF-1/HO-1 pathway. This suppression attenuates oxidative stress and mitochondrial apoptosis, leading to the alleviation of epithelial-mesenchymal transition and extracellular matrix deposition, which are key drivers of renal tubulointerstitial fibrosis."}], "pathway_id": "rno04066", "pubmed_id": "41028107", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MKNK2, HIF-1, KLF7.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MKNK2 promotes HIF-1 signaling activation, leading to M1 microglia polarization and contributing to neurological injury and brain damage. KLF7 represses MKNK2 transcription, thereby inhibiting HIF-1 signaling and M1 polarization while promoting M2 polarization, which ameliorates pathological outcomes associated with ischemic stroke."}], "pathway_id": "rno04066", "pubmed_id": "40923147", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: HIF-1 signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. It consists of two subunits: an inducibly-expressed HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Under normoxia, HIF-1 alpha undergoes hydroxylation at specific prolyl residues which leads to an immediate ubiquitination and subsequent proteasomal degradation of the subunit. In contrast, under hypoxia, HIF-1 alpha subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Eventually, HIF-1 acts as a master regulator of numerous hypoxia-inducible genes under hypoxic conditions. The target genes of HIF-1 encode proteins that increase O2 delivery and mediate adaptive responses to O2 deprivation. Despite its name, HIF-1 is induced not only in response to reduced oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Kaempferide (administration), IL1B, IFNG (elevated levels), HIF1A (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Kaempferide modulates the HIF-1 signaling pathway by regulating the expression of IFN- and HIF-1. These molecules contribute to inflammatory responses and cartilage degradation in osteoarthritis. Inhibition of these pathways by Kaempferide reduces the production of inflammatory cytokines and slows the progression of cartilage destruction."}], "pathway_id": "rno04066", "pubmed_id": "40960306", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cellular senescence - Rattus norvegicus (rat)\n**Pathway Description**: Cellular senescence is a state of irreversible cellular arrest and can be triggered by a number of factors, such as telomere shortening, oncogene activation, irradiation, DNA damage and oxidative stress. It is characterized by enlarged flattened morphology, senescence-associated beta-galactosidase (SA-b-gal) activity, secretion of inflammatory cytokines, growth factors and matrix metalloproteinases, as part of the senescence-associated secretory phenotype (SASP). Cellular senescence is functionally associated with many biological processes including aging, tumor suppression, placental biology, embryonic development, and wound healing.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mci-186, D-Galactose (administration), Tumor Necrosis Factor-alpha (elevated levels), Tumor Protein p53 (upregulated), Cyclin-Dependent Kinase Inhibitor 1A (upregulated), Cyclin-Dependent Kinase Inhibitor 2A (upregulated), Caspase 3 and Caspase 7 (increased activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "D-Galactose induces cellular senescence through increased oxidative stress and DNA damage, leading to upregulation of p53, p21, and p16, which promote cell cycle arrest. This process is accompanied by elevated levels of Tumor Necrosis Factor Alpha (TNF-) and increased caspase 3/7 activity, indicative of apoptosis. Edaravone mitigates these effects by reducing oxidative stress markers such as lipid peroxidation and protein carbonylation, and by downregulating p53, p21, and p16 expression, thereby protecting cells from senescence and DNA damage."}], "pathway_id": "rno04218", "pubmed_id": "41254185", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cellular senescence - Rattus norvegicus (rat)\n**Pathway Description**: Cellular senescence is a state of irreversible cellular arrest and can be triggered by a number of factors, such as telomere shortening, oncogene activation, irradiation, DNA damage and oxidative stress. It is characterized by enlarged flattened morphology, senescence-associated beta-galactosidase (SA-b-gal) activity, secretion of inflammatory cytokines, growth factors and matrix metalloproteinases, as part of the senescence-associated secretory phenotype (SASP). Cellular senescence is functionally associated with many biological processes including aging, tumor suppression, placental biology, embryonic development, and wound healing.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CDKN1A (elevated expression), NFKB1, CEBPB.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated p21 expression in macrophages contributes to cellular senescence, characterized by cell cycle arrest and secretion of pro-inflammatory factors as part of the senescence-associated secretory phenotype. This senescent macrophage subtype interacts with effector T cells through CXCL chemokines, amplifying alloimmune responses and promoting graft injury. Senescent macrophages accumulate during rejection and are associated with T cell-mediated rejection, pathological Banff lesions, and poor graft survival."}], "pathway_id": "rno04218", "pubmed_id": "41142786", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cellular senescence - Rattus norvegicus (rat)\n**Pathway Description**: Cellular senescence is a state of irreversible cellular arrest and can be triggered by a number of factors, such as telomere shortening, oncogene activation, irradiation, DNA damage and oxidative stress. It is characterized by enlarged flattened morphology, senescence-associated beta-galactosidase (SA-b-gal) activity, secretion of inflammatory cytokines, growth factors and matrix metalloproteinases, as part of the senescence-associated secretory phenotype (SASP). Cellular senescence is functionally associated with many biological processes including aging, tumor suppression, placental biology, embryonic development, and wound healing.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ethanedioic acid, calcium salt (1:1), Fisetin (administration), Oxalate, LXN (genetic silencing), RPS3, TP53, CDKN2A, NOS2, CD163.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxalate-induced cellular senescence in renal tubular epithelial cells increases the secretion of senescence-associated secretory phenotype (SASP) factors, which promote M1-like macrophage polarization. This inflammatory macrophage polarization contributes to increased calcium oxalate crystal deposition in the kidney. Activation of the LXN/Rps3/p53 signaling pathway enhances this senescence and associated inflammatory response. Inhibition of this pathway, either through fisetin treatment or genetic silencing of LXN, reduces epithelial cell senescence, suppresses SASP factor production, and diminishes M1-like macrophage polarization, thereby decreasing intrarenal calcium oxalate crystal accumulation."}], "pathway_id": "rno04218", "pubmed_id": "41112268", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Goralatide, Silica, EGFR (elevated expression), STAT3 (activation), ACTA2 (expression), CASP3 (activity), CASP8 (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of EGFR and STAT3 contributes to the progression of lung fibrosis in silicosis. Ac-SDKP reduces the levels of EGFR and STAT3 proteins in lung tissue, thereby attenuating fibrotic changes. This downregulation is associated with decreased -SMA expression, a marker of myofibroblast activation, and reduced caspase 3 and 8 activity, indicating a modulation of apoptosis. These effects suggest that Ac-SDKP inhibits fibrosis through suppression of the EGFR/STAT3 signaling pathway."}], "pathway_id": "rno04012", "pubmed_id": "41178064", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Daidzein (administration), Neuregulin-1 (restored levels), ERBB2 (restored levels), AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Daidzein reduces oxidative stress and mitigates cardiac damage following myocardial infarction by restoring Neuregulin-1 and ERBB2 levels, which activate AKT1 signaling. This pathway contributes to cardioprotection by decreasing inflammation, tissue damage, and fibrosis."}], "pathway_id": "rno04012", "pubmed_id": "40651887", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gefitinib (administration), EGFR, SOX9 (overexpression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EGFR inhibition by Gefitinib enhances bone fracture healing by promoting oxidative phosphorylation and fatty acid oxidation in periosteal stem cells. This metabolic shift counteracts the negative effects of lipid-reduced serum on osteoblastic differentiation. SOX9 overexpression attenuates these beneficial effects, indicating that EGFR inhibition modulates bone metabolism and callus formation through interactions with the SOX9 transcriptional program."}], "pathway_id": "rno04012", "pubmed_id": "40294988", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, ALAS1, ALAS2, ALAD, PBGD, UROD, CPOX, PPOX, FECH, HMBS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid is the first substrate in the heme biosynthesis pathway, which is catalyzed by ALAS1 in the cytoplasm and ALAS2 in the mitochondria. ALAD converts 5-aminolevulinic acid into porphobilinogen, which is further processed by PBGD and UROD to produce uroporphyrinogen III. CPOX and PPOX sequentially oxidize uroporphyrinogen to coproporphyrinogen and protoporphyrinogen, respectively. FECH and HMBS catalyze the final steps in heme synthesis, converting protoporphyrinogen into heme. Mutations or dysregulation in any of these enzymes can disrupt heme production, leading to the accumulation of toxic intermediates, which contribute to the development of porphyria and associated clinical manifestations such as neurological symptoms and photosensitivity."}], "pathway_id": "rno04012", "pubmed_id": "40129983", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ErbB signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces the formation of receptor homo- and heterodimers and the activation of the intrinsic kinase domain, resulting in phosphorylation on specific tyrosine residues (pY) within the cytoplasmic tail. Signaling effectors containing binding pockets for pY-containing peptides are recruited to activated receptors and induce the various signaling pathways. The Shc- and/or Grb2-activated mitogen-activated protein kinase (MAPK) pathway is a common target downstream of all ErbB receptors. Similarly, the phosphatidylinositol-3-kinase (PI-3K) pathway is directly or indirectly activated by most ErbBs. Several cytoplasmic docking proteins appear to be recruited by specific ErbB receptors and less exploited by others. These include the adaptors Crk, Nck, the phospholipase C gamma (PLCgamma), the intracellular tyrosine kinase Src, or the Cbl E3 ubiquitin protein ligase.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neuregulin 1 (up-regulation), ErbB4 (up-regulation), Glutamate receptor ionotropic AMPA 1 (expression), Glutamate receptor ionotropic NMDA 1 (expression), Glutamate receptor ionotropic NMDA 2A (expression), Glial fibrillary acidic protein (activation), GABA-A receptor, Postsynaptic density protein 95 (expression), Synaptophysin (expression), Brain-derived neurotrophic factor (expression), Nerve growth factor (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Up-regulation of neuregulin 1 (NRG1) and ErbB4 signaling promotes the expression of glutamate receptors (GLUA1, GLUN1, GLUN2A), neurotrophic factors (BDNF, NGF), and synaptic proteins (PSD95, SYP), which collectively enhance synaptic integrity and reduce hippocampal neuronal damage. This pathway also suppresses glial activation and neuronal apoptosis, thereby improving the synaptic microenvironment."}], "pathway_id": "rno04012", "pubmed_id": "39701678", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Saikosaponin A (administration), Serotonin (restored levels), NFKB1 (suppressed p65 activity), TNF (increased expression), IL6 (increased expression), IL1B (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the NF-B signaling pathway leads to increased expression of pro-inflammatory cytokines TNF, IL6, and IL1B, which contribute to neuroinflammation and exacerbate anxiety-like behaviors. Suppression of NF-B p65 activity reduces the production of these cytokines and alleviates neuroinflammatory processes. Concurrently, restoration of hippocampal serotonin levels supports serotonergic neurotransmission, which further contributes to the amelioration of PTSD-like behavioral outcomes. Saikosaponin A modulates both inflammatory and neurotransmitter pathways to exert its therapeutic effect."}], "pathway_id": "rno04064", "pubmed_id": "41308877", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Octopamine, Ferulic Acid, Vitexin 2''-O-rhamnoside, Tumor necrosis factor alpha (elevated levels), Interleukin 1 beta (elevated levels), Mitogen-activated protein kinase (inhibited), Nuclear factor kappa B (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of NF-B and MAPK signaling reduces the production of pro-inflammatory mediators such as TNF- and IL-1. This suppression attenuates leukocyte and neutrophil infiltration, lipid peroxidation, and enhances antioxidant defenses, thereby mitigating inflammatory responses."}], "pathway_id": "rno04064", "pubmed_id": "41302395", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-((2-Hydroxy-3-methoxybenzylidene)amino)-2-methylbenzoic acid, Resatorvid, TLR2 (activation), TLR4 (activation), MYD88, NF-kappa B (activation), IL1A (upregulation), IL6 (upregulation), TNF (upregulation), RUNX2 (expression), TNFSF11, COL1A1, CTNNB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR2 and TLR4 activation triggers MyD88/NF-kB signaling, which promotes inflammatory responses by upregulating IL1A, IL6, and TNF. This inflammation impairs osteogenic processes such as RUNX2 expression, Collagen-I synthesis, and -catenin signaling. Inhibition of TLR2/TLR4 suppresses NF-kB activation, reduces inflammatory cytokines, and enhances bone regeneration by promoting osteogenic differentiation and matrix production."}], "pathway_id": "rno04064", "pubmed_id": "41264993", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Melatonin (administration), Sirtuin 1, Nuclear factor kappa B (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Melatonin enhances the deacetylation activity of Sirtuin 1 (SIRT1), which targets Nuclear factor kappa B (NF-B) for deacetylation. This deacetylation inhibits the transcriptional activation of NF-B, thereby reducing the expression of pro-inflammatory genes and attenuating inflammatory responses in astrocytes. This mechanism contributes to the suppression of neuroinflammation and promotes neuroprotective outcomes."}], "pathway_id": "rno04064", "pubmed_id": "41254317", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Serotonin, Isoproterenol, (8R)-1,5,8-trimethyl-8,9-dihydro-7H-benzo(e)(1)benzofuran-6-one, nuclear factor kappa-light-chain enhancer of activated B cells (inhibition), tumor necrosis factor alpha (elevated levels), BCL2-associated X protein (activation), B-cell lymphoma 2, caspase 3 (activation), cyclooxygenase 2, inducible nitric oxide synthase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of tumor necrosis factor alpha (TNF-) and activation of nuclear factor kappa-light-chain enhancer of activated B cells (NF-B) contribute to inflammation and apoptosis in myocardial tissue. Activation of BCL2-associated X protein (Bax) and caspase 3 promotes programmed cell death, whereas B-cell lymphoma 2 (Bcl-2) exerts anti-apoptotic effects. Inhibition of cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) reduces inflammatory signaling. Modulation of NF-B and the Bax/Bcl-2/caspase-3 signaling axis attenuates myocardial injury and supports cardioprotection."}], "pathway_id": "rno04064", "pubmed_id": "41259547", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NF-kappa B signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Nuclear factor-kappa B (NF-kappa B) is the generic name of a family of transcription factors that function as dimers and regulate genes involved in immunity, inflammation and cell survival. There are several pathways leading to NF-kappa B-activation. The canonical pathway is induced by tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) or byproducts of bacterial and viral infections. This pathway relies on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. Atypical pathways are IKK-independent and rely on phosphorylation of IkappaB-alpha on Tyr42 or on Ser residues in IkappaB-alpha PEST domain. The non-canonical pathway is triggered by particular members of the TNFR superfamily, such as lymphotoxin-beta (LT-beta) or BAFF. It involves NIK and IKK-alpha-mediated p100 phosphorylation and processing to p52, resulting in nuclear translocation of p52/RelB heterodimers.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Propionic Acid (administration), Toll-like receptor 4 (activation), Nuclear factor kappa B, Myeloid differentiation primary response 88, Interleukin 6 (production), Interleukin 1 beta (production), Tumor necrosis factor alpha (production), Mucin 2 (expression), Occludin (expression), Claudin 1 (expression), Zonula occludens 1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4 activation triggers NF-B signaling through the MyD88-dependent pathway, leading to the production of pro-inflammatory cytokines such as IL-6, IL-1, and TNF-. This inflammatory cascade contributes to neuroinflammation and neuronal injury. Modulation of this pathway via the gut-brain axis can suppress inflammatory signaling and restore intestinal barrier integrity through upregulation of mucin and tight junction proteins, including MUC2, occludin, claudin-1, and ZO-1. Propionic acid, a short-chain fatty acid, may support this protective effect by reinforcing gut barrier function and modulating immune responses."}], "pathway_id": "rno04064", "pubmed_id": "41248567", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Linoleic Acid (changes in metabolism), Citrulline, Sphingosine 1-Phosphate, alpha-smooth muscle actin (expressed), transforming growth factor beta 1, SMAD family member (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D signaling is modulated by changes in linoleic acid metabolism, which influences lipid second messenger production and cellular processes such as membrane trafficking and actin remodeling. Disruption in this signaling pathway contributes to pulmonary fibrosis through altered inflammatory and fibrotic responses. Transforming growth factor beta 1 (TGF-1) activates the Smad signaling cascade, promoting fibrotic outcomes. Sphingosine-1-phosphate and citrulline are associated with metabolic adjustments that support anti-inflammatory and antifibrotic effects. Alpha-smooth muscle actin (-SMA) expression reflects myofibroblast activation, a key feature of fibrotic tissue remodeling."}], "pathway_id": "rno04072", "pubmed_id": "40857957", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (produced), PLD1, GFAP (upregulated), STAT3 (activated), FAK, AURKA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D1 (PLD1) produces phosphatidic acid (PA), which promotes astrocytic differentiation in hippocampal neural stem/progenitor cells. Phosphatidic acid activates signal transducer and activator of transcription 3 (STAT3), a key mediator in this process. This activation is regulated by the focal adhesion kinase (FAK)/aurora kinase A (AURKA) signaling pathway, which modulates STAT3 activity and, consequently, the expression of glial fibrillary acidic protein (GFAP), a marker of astrocytic differentiation."}], "pathway_id": "rno04072", "pubmed_id": "36162649", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phospholipase D signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival. PLD activity can be stimulated by a large number of cell surface receptors and is elaborately regulated by intracellular factors, including protein kinase C isoforms, small GTPases of the ARF, Rho and Ras families and the phosphoinositide, phosphatidylinositol 4,5-bisphosphate (PIP2). The PLD-produced PA activates signaling proteins and acts as a node within the membrane to which signaling proteins translocate. Several signaling proteins, including Raf-1 and mTOR, directly bind PA to mediate translocation or activation, respectively.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PA(16:0/16:0) (production), 5-Aminolevulinic Acid, Phospholipase D, Phospholipase D1 (overexpressed), Phospholipase D2, Mechanistic Target of Rapamycin (activated), Mechanistic Target of Rapamycin Complex 1, AMPA Receptor, Brain-Derived Neurotrophic Factor (translation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase D (PLD) catalyzes the production of phosphatidic acid (PA), a lipid second messenger that binds and activates mTORC1 in the postsynaptic compartment. This interaction is specifically induced by the loss of excitatory synaptic input and does not occur during long-term potentiation. Activation of mTORC1 through PA promotes presynaptic compensation and the translation of Brain-Derived Neurotrophic Factor (BDNF), which is essential for homeostatic synaptic plasticity. Overexpression of Phospholipase D1, but not D2, recapitulates these effects, indicating a distinct role for PLD1 in coupling synaptic inactivity to mTORC1-dependent signaling."}], "pathway_id": "rno04072", "pubmed_id": "29311141", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin-13 (administration), Nrf2 (activation), HMOX1 (activation), NQO1 (activation), PRKAA1 (activation), GSK3B (modulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Apelin-13 activates the Nrf2 signaling pathway and its downstream effectors HMOX1 and NQO1, while also modulating the AMPK/GSK3B axis. This activation reduces oxidative stress and attenuates ferroptosis, thereby improving cardiac function and reducing myocardial inflammation."}], "pathway_id": "rno04371", "pubmed_id": "39971890", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Malonaldehyde (accumulation), NFKB1 (elevated levels), TNF (elevated levels), TGFB1 (increased expression), APLN (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of NF-B and TNF- promote inflammation and oxidative stress, leading to renal dysfunction and tissue damage. Increased TGF- expression contributes to fibrosis and further impairs renal function. Apelin signaling is upregulated in response to injury and may modulate inflammatory and oxidative pathways. Activation of the TNF-/NF-B/TGF-/apelin signaling pathway results in malondialdehyde accumulation, a marker of lipid peroxidation and oxidative damage. Modulation of this pathway can alleviate renal injury by reducing inflammation, oxidative stress, and fibrotic responses."}], "pathway_id": "rno04371", "pubmed_id": "39570475", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Triphenyltetrazolium chloride, APJ (activation), PIK3CA (phosphorylated), AKT1 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the apelin receptor (APJ) leads to phosphorylation of phosphatidylinositol 3-kinase (PI3K), which subsequently activates protein kinase B (AKT). This APJ/PI3K/AKT signaling cascade contributes to neuroprotection by reducing infarct volume in ischemic stroke models."}], "pathway_id": "rno04371", "pubmed_id": "38910191", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Apelin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Apelin is an endogenous peptide capable of binding the apelin receptor (APJ), which was originally described as an orphan G-protein-coupled receptor. Apelin and APJ are widely expressed in various tissues and organ systems. They are implicated in different key physiological processes such as angiogenesis, cardiovascular functions, cell proliferation and energy metabolism regulation. On the other hand, this ligand receptor couple is also involved in several pathologies including diabetes, obesity, cardiovascular disease and cancer.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Apelin-13 (administration), APJ, G protein-coupled receptor, G protein subunit alpha q (activated), Phosphatidylinositol-4,5-bisphosphate 3-kinase (activated), Protein kinase B (activated), Mechanistic target of rapamycin kinase (activated), G protein subunit alpha i.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "APJ homodimers inhibit autophagy through Gq and PI3K/Akt/mTOR pathways upon Gi signaling. This suppression of autophagy contributes to neuroprotection in vascular dementia. Apelin-13 reduces APJ homodimer levels and promotes endogenous neural stem cell proliferation in the hippocampal dentate gyrus. APJ, a G protein-coupled receptor, generates distinct signaling outcomes when homodimerized compared to its monomeric form."}], "pathway_id": "rno04371", "pubmed_id": "39042220", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Non-small cell lung cancer - Rattus norvegicus (rat)\n**Pathway Description**: Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EGFR Inhibitor STX-721 (administration), EGFR (mutated (exon20 insertion)), ERBB2 (mutated (exon20 insertion)).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "EGFR and HER2 exon20 insertion mutations contribute to the pathogenesis of non-small cell lung cancer by promoting uncontrolled cell proliferation. STX-721 functions as a covalent, irreversible inhibitor of EGFR and HER2 exon20 insertion mutants, selectively suppressing their oncogenic activity while maintaining selectivity over wild-type receptor isoforms."}], "pathway_id": "rno05223", "pubmed_id": "39824516", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin, SOCS2 (elevated levels), CTNNB1, LEF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of SOCS2 promote myocardial fibrosis by enhancing the nuclear translocation of -catenin, a key component of the Wnt/-catenin signaling pathway. This nuclear localization of -catenin activates downstream transcriptional processes, including the upregulation of fibrogenic genes. The transcription factor LEF1 binds to the promoter region of SOCS2, forming a positive feedback loop that sustains activation of the pathway. This mechanism contributes to the transformation of fibroblasts into myofibroblasts, leading to cardiac dysfunction and the progression of dilated cardiomyopathy."}], "pathway_id": "rno05414", "pubmed_id": "39084528", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Monosodium Glutamate (administration), Tannic Acid (administration), IGF1 (elevated expression), TTN (elevated expression), ACTB (elevated expression), LMNA (elevated expression), EDN1 (elevated expression), NPPB (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of IGF1, TTN, ACTB, LMNA, EDN1, and NPPB is associated with the progression of dilated cardiomyopathy. These genes are involved in structural and functional aspects of cardiac tissue. Monosodium glutamate increases the mRNA levels of these genes in rat heart tissues, contributing to the development of cardiomyopathy. Tannic acid reduces the upregulation of these genes, suggesting a potential therapeutic role in mitigating the molecular mechanisms underlying dilated cardiomyopathy."}], "pathway_id": "rno05414", "pubmed_id": "39318238", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Dilated cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Dilated cardiomyopathy (DCM) is a heart muscle disease characterised by dilation and impaired contraction of the left or both ventricles that results in progressive heart failure and sudden cardiac death from ventricular arrhythmia. Genetically inherited forms of DCM (\"familial\" DCM) have been identified in 25-35% of patients presenting with this disease, and the inherited gene defects are an important cause of \"familial\" DCM. The pathophysiology may be separated into two categories: defects in force generation and defects in force transmission. In cases where an underlying pathology cannot be identified, the patient is diagnosed with an \"idiopathic\" DCM. Current hypotheses regarding causes of \"idiopathic\" DCM focus on myocarditis induced by enterovirus and subsequent autoimmune myocardium impairments. Antibodies to the beta1-adrenergic receptor (beta1AR), which are detected in a substantial number of patients with \"idiopathic\" DCM, may increase the concentration of intracellular cAMP and intracellular Ca2+, a condition often leading to a transient hyper-performance of the heart followed by depressed heart function and heart failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin, CLSTN1 (elevated expression), SERCA2, PI3K-AKT, CaMK2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of CLSTN1 in the heart under doxorubicin exposure promotes dilated cardiomyopathy through downregulation of SERCA2 and increased phosphorylation of PI3K-AKT and CaMK2, leading to cardiac chamber enlargement and heart failure. This mechanism is associated with enhanced cardiomyocyte toxicity, contributing to the progression of heart dysfunction."}], "pathway_id": "rno05414", "pubmed_id": "36350487", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Levofloxacin (administration), AMPA receptor, GluA1, Vesicular glutamate transporter 1 (upregulated), Vesicular GABA transporter (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Levofloxacin enhances excitatory glutamatergic synaptic transmission by increasing the frequency and amplitude of AMPA receptor-mediated excitatory postsynaptic currents, while simultaneously suppressing GABAergic inhibitory synaptic transmission by reducing the frequency of GABAergic miniature inhibitory postsynaptic currents. This dual effect is associated with upregulated vesicular glutamate transporter 1 and downregulated vesicular GABA transporter expression. Levofloxacin also alters GluA1 subunit trafficking by decreasing internalization and promoting plasma membrane insertion, contributing to increased synaptic strength. These changes in glutamatergic and GABAergic signaling lead to neuronal hyperexcitability and increased seizure susceptibility."}], "pathway_id": "rno04724", "pubmed_id": "40915475", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Corticosterone (exposure), Grin1 (reductions in mRNA levels), Dlg4 (reductions in mRNA levels), Grin2b (increased protein expression), Sdhc, Mmp2 (persistent elevation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Corticosterone exposure leads to sustained reductions in Grin1 and Dlg4 mRNA levels in the hypothalamus, contributing to impaired glutamatergic signaling. NR2B protein expression increases in the hippocampus during corticosterone exposure but normalizes upon recovery, while PSD-95 levels decrease in hippocampal subregions, indicating disrupted synaptic structure. Persistent elevation of MMP-2 in the dentate gyrus suggests ongoing extracellular matrix remodeling, which may underlie long-lasting synaptic dysfunction and neuroplastic changes."}], "pathway_id": "rno04724", "pubmed_id": "41273623", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid (increased availability).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated glutamate release from presynaptic terminals during long-term potentiation results from increased exocytotic events, enhanced release of glutamate from individual synaptic vesicles, and altered exocytotic dynamics. This increased glutamate availability in the synaptic cleft contributes to synaptic plasticity and facilitates long-lasting strengthening of synaptic connections."}], "pathway_id": "rno04724", "pubmed_id": "40801168", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glutamate receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glutamate acts on postsynaptic glutamate receptors to mediate fast excitatory synaptic transmission. The synaptic cleft anchors pre- and postsynaptic compartments through trans-synaptic bridges, which are primarily non-covalent associations. Disruption of the cleft, such as by mechanical dissociation, separates presynaptic elements from the postsynaptic membrane, allowing isolation of postsynaptic densities (PSDs) associated with glutamatergic receptors. This process facilitates the study of postsynaptic membrane components in a more native-like environment."}], "pathway_id": "rno04724", "pubmed_id": "40448157", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid (increased hippocampal efflux), Insulin, VGLUT2 (reduced expression), GluA1, GluN2B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of vesicular glutamate transporter 2 (VGLUT2) in the hippocampus leads to decreased synaptic concentrations of L-glutamic acid, impairing glutamatergic synaptic transmission. This deficit in glutamate neurochemistry is associated with synaptic plasticity impairments in hippocampal glutamatergic synapses. Hippocampal-specific insulin resistance exacerbates these effects and increases hippocampal glutamate efflux, particularly in response to high-dose insulin administration."}], "pathway_id": "rno04724", "pubmed_id": "40452372", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ADGRB2, PSD95 (enrichment at large postsynaptic sites).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "ADGRB2 is highly enriched at large postsynaptic sites marked by PSD95. Loss of ADGRB2 impairs glutamatergic synapse development and reduces the density of mature mushroom-shaped dendritic spines containing PSD95. This results in decreased spine volume and head diameter, indicating a role for ADGRB2 in regulating the structural maturation of glutamatergic synapses."}], "pathway_id": "rno04724", "pubmed_id": "40451404", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Glutamatergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system(CNS). Glutamate is packaged into synaptic vesicles in the presynaptic terminal. Once released into the synaptic cleft, glutamate acts on postsynaptic ionotropic glutamate receptors (iGluRs) to mediate fast excitatory synaptic transmission. Glutamate can also act on metabotropic glutamate receptors (mGluRs) and exert a variety of modulatory effects through their coupling to G proteins and the subsequent recruitment of second messenger systems. Presynaptically localized Group II and Group III mGluRs are thought to represent the classical inhibitory autoreceptor mechanism that suppresses excess glutamate release. After its action on these receptors, glutamate can be removed from the synaptic cleft by EAATs located either on the presynaptic terminal, neighboring glial cells, or the postsynaptic neuron. In glia, glutamate is converted to glutamine, which is then transported back to the presynaptic terminal and converted back to glutamate.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Glutamic Acid (released), N-methyl-D-aspartate receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glutamate is released from presynaptic vesicles in vagal afferent terminals via both evoked and spontaneous mechanisms. Both release pathways draw from a shared vesicle pool but are regulated by distinct functional controls. The released glutamate binds to a common population of postsynaptic NMDA receptors, contributing to baseline and evoked action potential firing in nucleus of the solitary tract neurons. Spontaneous release modulates resting activity, while evoked release encodes stimulus-driven signals."}], "pathway_id": "rno04724", "pubmed_id": "40320913", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphorylated AKT (Phosphorylated), Phosphatidylinositol 3-kinase, Beta-catenin (Stabilized and nuclear translocated), Lymphoid Enhancer-Binding Factor 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphatidylinositol 3-kinase (PI3K) activates phosphorylated AKT (p-AKT), which subsequently promotes the stabilization and nuclear translocation of beta-catenin. The beta-catenin-Lymphoid Enhancer-Binding Factor 1 (LEF1) complex then drives transcription of genes involved in cell survival, proliferation, and tissue repair. This signaling cascade supports axonal and myelin regeneration, reduces fibrosis and neuroinflammation, and enhances motor function recovery following spinal cord injury."}], "pathway_id": "rno04151", "pubmed_id": "41316483", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Butyrate (administration), 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, GPR41, Phosphorylated AKT (increased phosphorylation), BCL2 (increased expression), BAX (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sodium butyrate activates the GPR41/PI3K/Akt signaling pathway, leading to increased phosphorylation of Akt. This activation promotes the expression of the antiapoptotic protein BCL2 while reducing the expression of the proapoptotic protein BAX. As a result, neuronal apoptosis is inhibited, and early brain injury is attenuated. This pathway contributes to reduced neurological deficits and brain edema following subarachnoid hemorrhage."}], "pathway_id": "rno04151", "pubmed_id": "41342722", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: PI3K-Akt signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation, proliferation, growth, and survival. The binding of growth factors to their receptor tyrosine kinase (RTK) or G protein-coupled receptors (GPCR) stimulates class Ia and Ib PI3K isoforms, respectively. PI3K catalyzes the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn serves as a second messenger that helps to activate Akt. Once active, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, protein synthesis, metabolism, and cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Chlorogenic Acid (administration), STAT3, PIK3CA, AKT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Chlorogenic acid binds to PIK3CA and AKT1, inhibiting the activation of the PI3K/AKT signaling pathway. This inhibition suppresses inflammatory mediator production, modulates T-cell subsets, and reduces neutrophil extracellular trap formation, thereby mitigating acute respiratory distress syndrome."}], "pathway_id": "rno04151", "pubmed_id": "41298226", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Rattus norvegicus (rat)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Prnp (suppressed), Nrg1 (upregulated), Gdf6 (upregulated), Oas1 (upregulated), Isg20 (upregulated), Cd80 (upregulated), Clu (induced), Il17 (upregulated), Isg15 (upregulated), Rsad2 (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Prnp expression is essential for Creutzfeldt-Jakob disease (CJD) infection and is upregulated during proliferative arrest in normal neurons. This arrest also increases transcripts associated with neuronal differentiation, such as Neuregulin-1 and GDF6. Concurrently, innate immune pathways are activated, including upregulation of OAS1, ISG20, CD80, and cytokine/chemokine genes. Clusterin (CLU) is induced, likely to bind misfolded proteins. In contrast, CJD-infected (CJ+) neurons suppress neuronal differentiation transcripts, including Prnp, and exhibit enhanced activation of interferon and anti-viral pathways, such as those involving Il17, ISG15, and RSAD2 (viperin). These mechanisms suggest that CJD infection modulates both developmental and immune processes in neurons."}], "pathway_id": "rno05020", "pubmed_id": "40434970", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Rattus norvegicus (rat)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRNP (reduced concentrations), Recombinant PRNP protein, Synthetic PRNP peptides.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced concentrations of prion protein (PrP) in cerebrospinal fluid (CSF) occur during prion disease progression. This decrease affects both N- and C-terminal domains of the protein and is not an artifact of immunoassay detection methods. The reduction in CSF PrP is a genuine consequence of the disease process, likely due to altered protein expression or post-translational modifications such as misfolding or proteolytic cleavage. These changes affect the availability of detectable PrP in the extracellular space, influencing the utility of PrP as a pharmacodynamic biomarker in symptomatic patients."}], "pathway_id": "rno05020", "pubmed_id": "31558565", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Prion disease - Rattus norvegicus (rat)\n**Pathway Description**: Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Zinc, PRNP, GRIA1 and GRIA2, PTP.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The cellular prion protein (PRNP) facilitates the uptake of zinc into neuronal cells. This process requires the octapeptide repeats and the amino-terminal polybasic region of PRNP but does not involve endocytosis. Prion protein-mediated zinc influx is associated with interactions between PRNP and the AMPA receptor subunits GRIA1 and GRIA2. This mechanism reduces intracellular tyrosine phosphatase (PTP) activity. Disruption of PRNP, either through familial mutations or prion infection, abolishes this zinc uptake, potentially contributing to neurodegeneration by altering neuronal zinc homeostasis and phosphatase activity."}], "pathway_id": "rno05020", "pubmed_id": "23072804", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAC1 (activation), PAK1 (activation), CAMK2A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAC1 activation triggers dendritic spine enlargement and actin polymerization through the downstream activation of PAK1. This signaling pathway supports structural long-term potentiation independently of CAMK2A activity. The persistent structural changes induced by RAC1 are critical for synaptic memory encoding."}], "pathway_id": "rno04720", "pubmed_id": "41249054", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbamic acid, ethyl ester.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Long-term potentiation in the hippocampal-medial prefrontal cortex circuit enhances cortical slow wave oscillations and population silence events in the medial prefrontal cortex. This synaptic plasticity modulates the amplitude and timing of down states, contributing to the regulation of cortical network dynamics and potentially supporting synaptic homeostasis."}], "pathway_id": "rno04720", "pubmed_id": "41139317", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-tert-butylhydroxylamine, synaptophysin, postsynaptic density protein 95, N-methyl-D-aspartate receptor (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Long-term potentiation induces protein-specific changes in S-palmitoylation without affecting global levels. Synaptophysin and postsynaptic density protein 95 exhibit distinct temporal patterns of palmitoylation influenced by synaptic activity. N-methyl-D-aspartate receptor activation triggers rapid, target-specific palmitoylation responses, contributing to synaptic vesicle cycling, cytoskeletal dynamics, and neurotransmitter release. Disruption of S-palmitoylation impairs the organization of neuronal spiking and the induction of long-term potentiation, particularly in the stratum radiatum of the hippocampus. Palmitoylation thus functions as a dynamic post-translational regulator of synaptic plasticity and neuronal network function."}], "pathway_id": "rno04720", "pubmed_id": "41074974", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAB10 (inactivated), RAB4A (activated), AMPA receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inactivation of RAB10 facilitates AMPA receptor trafficking and structural plasticity of dendritic spines during long-term potentiation. Persistent inactivation of RAB10 enhances synaptic strength and contributes to the induction of structural long-term potentiation. In contrast, transient activation of RAB4A supports early phases of this process. These opposing regulatory actions of RAB10 and RAB4A modulate the structural and functional changes underlying synaptic plasticity."}], "pathway_id": "rno04720", "pubmed_id": "40986440", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2,5-Dimethoxy-4-iodoamphetamine (administration), serotonin receptor 2A (bound by 2,5-dimethoxy-4-iodoamphetamine).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "2,5-dimethoxy-4-iodoamphetamine binds to serotonin receptor 2A, inducing a reversal of synaptic plasticity from long-term depression to long-term potentiation in claustrum neurons projecting to the anterior cingulate cortex. This change in synaptic plasticity is associated with alterations in excitatory and inhibitory neurotransmission and modifies intrinsic action potential dynamics in these neurons."}], "pathway_id": "rno04720", "pubmed_id": "41145210", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CaMK2A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CaMK2A undergoes cytoplasmic polyadenylation in response to synaptic activation, which modulates its translational efficiency. During long-term potentiation, changes in poly(A) tail length and composition of mRNAs, including Camk2a, reflect dynamic post-transcriptional regulation necessary for synaptic plasticity. These modifications contribute to localized protein synthesis required for the maintenance and expression of synaptic strength."}], "pathway_id": "rno04720", "pubmed_id": "40962679", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Long-term potentiation - Rattus norvegicus (rat)\n**Pathway Description**: Hippocampal long-term potentiation (LTP), a long-lasting increase in synaptic efficacy, is the molecular basis for learning and memory. Tetanic stimulation of afferents in the CA1 region of the hippocampus induces glutamate release and activation of glutamate receptors in dendritic spines. A large increase in [Ca2+]i resulting from influx through NMDA receptors leads to constitutive activation of CaM kinase II (CaM KII) . Constitutively active CaM kinase II phosphorylates AMPA receptors, resulting in potentiation of the ionic conductance of AMPA receptors. Early-phase LTP (E-LTP) expression is due, in part, to this phosphorylation of the AMPA receptor. It is hypothesized that postsynaptic Ca2+ increases generated through NMDA receptors activate several signal transduction pathways including the Erk/MAP kinase and cAMP regulatory pathways. The convergence of these pathways at the level of the CREB/CRE transcriptional pathway may increase expression of a family of genes required for late-phase LTP (L-LTP).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Win 55212-2 (administration), L-Glutamic Acid, Gamma-Aminobutyric Acid, Activity-regulated cytoskeleton-associated protein (elevated expression), FBJ murine osteosarcoma viral oncogene homolog, Zinc finger protein 268.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "WIN 55,212-2 modulates long-term potentiation by altering glutamate release probability and GABAergic inhibition. This results in an increased field excitatory postsynaptic potential (fEPSP) slope following high-frequency stimulation, indicating enhanced synaptic efficacy. WIN 55,212-2 also elevates the expression of the immediate early gene Arc in the dentate gyrus, suggesting activation of synaptic plasticity mechanisms. These effects occur without significant changes in population spike amplitude, indicating a postsynaptic locus of action. The combined reduction of glutamate and GABA via feedforward and feedback processes contributes to the modulation of synaptic plasticity."}], "pathway_id": "rno04720", "pubmed_id": "40935312", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ethanol, IHH (elevated expression), alpha-smooth muscle actin (inhibited), mucin 1 (enhanced expression), cytokeratin 19 (enhanced expression), von Willebrand factor (enhanced expression), proliferating cell nuclear antigen (enhanced expression), vimentin, smoothened (increased levels), GLI family zinc finger 1 (increased levels), GLI family zinc finger 3 (increased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Indian Hedgehog (IHH) activates the Hedgehog signaling pathway by increasing the levels of SMO, GLI1, and GLI3. This activation promotes endometrial tissue regeneration, increases glandular and vascular density, and inhibits fibroblast marker alpha-smooth muscle actin (-SMA), thereby reducing endometrial fibrosis. Concurrently, IHH enhances the expression of angiogenesis markers such as von Willebrand factor (vWF) and proliferating cell nuclear antigen (PCNA), as well as epithelial markers like cytokeratin 19 (CK19) and mucin 1 (MUC-1), supporting tissue repair and functional maturation. These effects collectively improve endometrial thickness and fertility outcomes."}], "pathway_id": "rno04340", "pubmed_id": "40301068", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dapagliflozin (administration), Sonic Hedgehog (expression), Patched 1 (expression), Smoothened (expression), GLI family zinc finger 1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dapagliflozin inhibits the Hedgehog signaling pathway by reducing the expression of Sonic Hedgehog (Shh), Patched 1 (Ptch1), Smoothened (Smo), and GLI family zinc finger 1 (Gli-1). This downregulation suppresses the transduction of Hedgehog signals, thereby modulating cellular processes such as proliferation and differentiation that depend on this pathway."}], "pathway_id": "rno04340", "pubmed_id": "40350466", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-Nitrosodiethylamine (elevated levels), Embelin (administration), Shh (activation), Ptch1 (activation), Smo (activation), Gli1 (activation), TNF (increased expression), IL6 (increased expression), IL1B (increased expression), TP53 (increased expression), CASP3 (increased expression), BCL2 (decreased expression), BAX (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Diethylnitrosamine induce liver injury through activation of oxidative stress, inflammation, and apoptosis. Activation of the Sonic Hedgehog (Shh) signaling pathway, including upregulation of Shh, Ptch1, Smo, and Gli1, contributes to this pathological response. Increased expression of pro-inflammatory cytokines such as TNF, IL6, and IL1B, along with upregulation of apoptotic genes Tp53, Casp3, and Bax, and downregulation of the anti-apoptotic gene Bcl-2, promote liver cell death. Inhibition of these processes by Embelin leads to reduced oxidative stress, suppression of inflammation and apoptosis, and modulation of the Shh signaling pathway, thereby protecting liver tissue from damage."}], "pathway_id": "rno04340", "pubmed_id": "40613636", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Arsenite (administration), Dimethylarsinic Acid (administration), SMO (increased expression), SHH (increased expression), GLI1 (increased expression), GLI2 (increased expression), SUFU (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Sodium arsenite and dimethylarsinic acid induce renal fibrosis by activating the Hedgehog signaling pathway. This activation is characterized by increased expression of SHH, SMO, GLI1, and GLI2, along with decreased expression of SUFU. The upregulation of GLI1, a key transcriptional activator in this pathway, contributes to the transcription of fibrosis-related genes, resulting in renal tubular destruction and impaired renal function."}], "pathway_id": "rno04340", "pubmed_id": "40669272", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Purmorphamine (administration), Ethanol (consumption), Hedgehog, Sonic Hedgehog (level), Patched (expression), Smoothened.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Purmorphamine activates the Hedgehog signaling pathway by stimulating the Smoothened receptor. In rats exposed to ethanol, administration of Purmorphamine alters anxiety-like behavior during early abstinence. Ethanol consumption influences the expression of Sonic Hedgehog and Patched mRNAs in the amygdala. A negative correlation exists between the level of Sonic Hedgehog mRNA in the amygdala and the time spent in the open arms of an elevated plus maze, suggesting a role for Hedgehog pathway components in anxiety regulation following alcohol withdrawal."}], "pathway_id": "rno04340", "pubmed_id": "39647823", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium fructoborate (administration), DDIT3 (reduced levels), Smo agonist SAG, Sonic Hedgehog, GLI Family Zinc Finger 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Calcium Fructoborate regulates the Sonic Hedgehog/GLI1 signaling pathway through modulation of DDIT3 expression. Inhibition of the Hedgehog pathway by Calcium Fructoborate is associated with reduced DDIT3 levels, which contributes to the suppression of chondrocyte apoptosis, cartilage matrix degradation, and inflammatory responses, thereby mitigating osteoarthritis progression."}], "pathway_id": "rno04340", "pubmed_id": "39572483", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hedgehog signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Hedgehog (Hh) signaling pathway has numerous roles in the control of cell proliferation, tissue patterning, stem cell maintenance and development. The primary cilium is an important center for transduction of the Hedgehog signal in vertebrates. In Hh's absence, the Ptch receptor localizes to the cilium, where it inhibits Smo activation. Gli proteins are phosphorylated by PKA, CKI and GSK3B and partially degraded into truncated Gli repressor form (GliR) that suppresses Hh target gene transcription in the nucleus. In Hh's presence, Ptch disappears from the cilium, and activated Smo contributes to the translocation of the protein complex Gli, Sufu, Kif7 to ciliary tip, where Gli dissociates from the negative regulator Sufu. The production of Gli activator form (GliA) occurs and the increased nuclear accumulation of GliA results in activation transcription of Hh target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nonylphenol (administration), Purmorphamine, Sonic Hedgehog (activation), E2F transcription factor 1 (increased levels), Cyclin (increased levels), SRY-box transcription factor 2 (decreased levels), Ki-67 antigen (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Exposure to nonylphenol inhibits the activation of Sonic Hedgehog (Shh) signaling, leading to reduced levels of downstream effectors such as E2F1 and cyclins. This suppression impairs neural precursor cell proliferation and contributes to depletion of the neural precursor cell pool in the hippocampal dentate gyrus. Activation of Shh signaling is essential for maintaining cell proliferation in this region, and its inhibition correlates with decreased Sox2- and Ki67-positive cells."}], "pathway_id": "rno04340", "pubmed_id": "39111523", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Bacterial invasion of epithelial cells - Rattus norvegicus (rat)\n**Pathway Description**: Many pathogenic bacteria can invade phagocytic and non-phagocytic cells and colonize them intracellularly, then become disseminated to other cells. Invasive bacteria induce their own uptake by non-phagocytic host cells (e.g. epithelial cells) using two mechanisms referred to as zipper model and trigger model. Listeria, Staphylococcus, Streptococcus, and Yersinia are examples of bacteria that enter using the zipper model. These bacteria express proteins on their surfaces that interact with cellular receptors, initiating signalling cascades that result in close apposition of the cellular membrane around the entering bacteria. Shigella and Salmonella are the examples of bacteria entering cells using the trigger model. These bacteria use type III secretion systems to inject protein effectors that interact with the actin cytoskeleton.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (Accumulation), protoporphyrin IX (Accumulation), ALAS1 (Dysregulation), ALAD (Dysregulation), FECH (Dysregulation), CPOX (Dysregulation), UROD (Dysregulation), HMBS (Dysregulation), Ferrochelatase (Dysregulation), ALAS2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulation of heme biosynthesis pathway enzymes, including ALAS1, ALAD, FECH, CPOX, UROD, HMBS, and Ferrochelatase, leads to the accumulation of intermediates such as 5-aminolevulinic acid and protoporphyrin IX. This disruption results in the development of various porphyrias, including acute intermittent porphyria and porphyria cutanea tarda. The accumulation of heme precursors causes oxidative stress and mitochondrial dysfunction, contributing to neurological symptoms and hepatic dysfunction. In erythropoietic protoporphyria, mutations in FECH or ALAS2 lead to protoporphyrin accumulation in erythroid cells, resulting in photosensitivity and skin lesions."}], "pathway_id": "rno05100", "pubmed_id": "36600181", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Rattus norvegicus (rat)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRDM9, HORMAD2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PRDM9 positions meiotic DNA breaks in rat oocytes, and its deficiency leads to non-homologous synapsis (NHS), where non-homologous chromosomes synapse instead of homologous pairs. NHS is associated with reduced HORMAD2 levels and diminished crossing-over below the minimum required for euploidy. This results in meiotic checkpoint bypass and chromosome segregation errors, increasing oocyte aneuploidy. The combination of NHS and reduced crossing-over contributes to premature ovarian failure and reproductive defects."}], "pathway_id": "rno04114", "pubmed_id": "35596034", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Rattus norvegicus (rat)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cilostamide (administration), Rolipram (administration), Camp (elevated levels), Phosphodiesterase 3A, Phosphodiesterase 4D.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphodiesterase 3A and 4D regulate cAMP levels by degrading cyclic adenosine monophosphate. Inhibition of PDE 3A by cilostamide and PDE 4D by rolipram increases intracellular cAMP levels in rat oocytes. Elevated cAMP levels maintain diplotene arrest and prevent spontaneous meiotic resumption. Cilostamide is more potent than rolipram in this context, as it significantly reduces PDE 3A expression and more effectively inhibits meiotic progression."}], "pathway_id": "rno04114", "pubmed_id": "32302597", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Rattus norvegicus (rat)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp (high levels), Camp (elevated levels), phosphodiesterase 3A (low activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "High levels of cyclic guanosine monophosphate (cGMP) and low activity of phosphodiesterase 3A (PDE3A) in growing oocytes correlate with meiotic incompetence. PDE3A normally degrades cAMP, and its reduced activity prevents the necessary decrease in cAMP levels required for the resumption of meiosis. This biochemical imbalance impairs the ability of the oocyte to initiate meiotic maturation."}], "pathway_id": "rno04114", "pubmed_id": "31401933", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Rattus norvegicus (rat)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sb-203580 (Administration), p38 MAPK alpha (Active), phospho-p38 MAPK alpha (Phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of p38 mitogen-activated protein kinase (p-p38 MAPK) increases during rat oocyte meiotic maturation, reaching maximal levels at metaphase I and metaphase II. The active form of the kinase is primarily localized in the cytoplasm around the chromosomes or the spindle. Inhibition of p38 MAPK activity by SB203580 disrupts spindle formation and reduces the rates of germinal vesicle breakdown and polar body extrusion, indicating a critical role for p38 MAPK in maintaining normal meiotic progression."}], "pathway_id": "rno04114", "pubmed_id": "29430805", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Oocyte meiosis - Rattus norvegicus (rat)\n**Pathway Description**: During meiosis, a single round of DNA replication is followed by two rounds of chromosome segregation, called meiosis I and meiosis II. At meiosis I, homologous chromosomes recombine and then segregate to opposite poles, while the sister chromatids segregate from each other at meoisis II. In vertebrates, immature oocytes are arrested at the PI (prophase of meiosis I). The resumption of meiosis is stimulated by progesterone, which carries the oocyte through two consecutive M-phases (MI and MII) to a second arrest at MII. The key activity driving meiotic progression is the MPF (maturation-promoting factor), a heterodimer of CDC2 (cell division cycle 2 kinase) and cyclin B. In PI-arrested oocytes, MPF is initially inactive and is activated by the dual-specificity CDC25C phosphatase as the result of new synthesis of Mos induced by progesterone. MPF activation mediates the transition from the PI arrest to MI. The subsequent decrease in MPF levels, required to exit from MI into interkinesis, is induced by a negative feedback loop, where CDC2 brings about the activation of the APC (anaphase-promoting complex), which mediates destruction of cyclin B. Re-activation of MPF for MII requires re-accumulation of high levels of cyclin B as well as the inactivation of the APC by newly synthesized Emi2 and other components of the CSF (cytostatic factor), such as cyclin E or high levels of Mos. CSF antagonizes the ubiquitin ligase activity of the APC, preventing cyclin B destruction and meiotic exit until fertilization occurs. Fertilization triggers a transient increase in cytosolic free Ca2+, which leads to CSF inactivation and cyclin B destruction through the APC. Then eggs are released from MII into the first embryonic cell cycle.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp (levels), Camp, phosphodiesterase 5A (increased activity), phosphodiesterase 1A, luteinizing hormone (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Luteinizing hormone lowers cyclic guanosine monophosphate levels in granulosa cells, thereby releasing meiotic arrest in oocytes. This reduction in cGMP is partly mediated by increased activity of phosphodiesterase 5A, which hydrolyzes cGMP. Phosphodiesterase 5A activity is enhanced through phosphorylation at serine 92, a site targeted by protein kinase A. The combined actions of phosphodiesterase 5A and phosphodiesterase 1A contribute to the resumption of meiosis, as evidenced by nuclear envelope breakdown."}], "pathway_id": "rno04114", "pubmed_id": "27009040", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Colorectal cancer - Rattus norvegicus (rat)\n**Pathway Description**: Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1,2-Dimethylhydrazine, Cyclin D1 (elevated expression), Bcl-2 (elevated expression), p53 (activation), Caspase-3, Nuclear factor kappa B (activation), Cyclooxygenase 2 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of cyclin D1 and Bcl-2 promotes cell proliferation and inhibits apoptosis in colorectal cancer. Activation of nuclear factor kappa B (NF-B) and cyclooxygenase 2 (COX-2) contributes to chronic inflammation and tumor progression. p53 activation can induce apoptosis, while caspase-3 serves as an executioner in the apoptotic cascade. Modulation of these proteins can influence cancer growth and severity."}], "pathway_id": "rno05210", "pubmed_id": "40951476", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Colorectal cancer - Rattus norvegicus (rat)\n**Pathway Description**: Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5'-Atp (Elevated levels), Adenosine (Elevated levels), P2RX7 (Inhibition), CD39, CD73, ADORA2A (Inhibition), APC, Apc.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the P2RX7 receptor on colon carcinoma cells promotes the release of extracellular vesicles containing CD39 and CD73 ectonucleotidases. These vesicles elevate extracellular ATP and adenosine levels, facilitating tumor metastasis. P2RX7 and ADORA2A signaling upregulation enhances vesicle-mediated tumor dissemination and cytokine release, including IL-17 and IL-23, within the metastatic niche. Inhibition of P2RX7 and ADORA2A reduces vesicle release, metastasis engraftment, and pro-inflammatory cytokine levels, thereby suppressing tumor progression and dissemination."}], "pathway_id": "rno05210", "pubmed_id": "40759630", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Colorectal cancer - Rattus norvegicus (rat)\n**Pathway Description**: Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Erlotinib (administration), Sulindac (administration), Major Histocompatibility Complex class I (upregulation), Major Histocompatibility Complex class II (upregulation), NLR Family CARD Domain-Containing Protein 5, CD4, CD8, CD68, Forkhead Box P3, Arginase 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Erlotinib and sulindac treatment upregulates MHC class I and II expression in a subset of colon polyps and tumor cell lines. This effect is associated with increased tumor-associated CD4+ T cell infiltration and CD68+ macrophage presence, while decreasing Foxp3+ regulatory T cells and Arg1+ immunosuppressive cells. NLR family CARD domain-containing protein 5 (Nlrc5) plays a critical role in mediating MHC expression. These changes contribute to immune microenvironment remodeling, promoting a more permissive helper immune response and tumor suppression through enhanced interferon- signaling."}], "pathway_id": "rno05210", "pubmed_id": "40072251", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Colorectal cancer - Rattus norvegicus (rat)\n**Pathway Description**: Colorectal cancer (CRC) is the second largest cause of cancer-related deaths in Western countries. CRC arises from the colorectal epithelium as a result of the accumulation of genetic alterations in defined oncogenes and tumour suppressor genes (TSG). Two major mechanisms of genomic instability have been identified in sporadic CRC progression. The first, known as chromosomal instability (CIN), results from a series of genetic changes that involve the activation of oncogenes such as K-ras and inactivation of TSG such as p53, DCC/Smad4, and APC. The second, known as microsatellite instability (MSI), results from inactivation of the DNA mismatch repair genes MLH1 and/or MSH2 by hypermethylation of their promoter, and secondary mutation of genes with coding microsatellites, such as transforming growth factor receptor II (TGF-RII) and BAX. Hereditary syndromes have germline mutations in specific genes (mutation in the tumour suppressor gene APC on chromosome 5q in FAP, mutated DNA mismatch repair genes in HNPCC).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1,2-Dimethylhydrazine, Linagliptin (administration), BCL2, BAX (upregulation), NFKB1 (elevated levels), NFATC1, VEGFA, IL6 (upregulation), PTGS2 (upregulation), JAK2, STAT3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of NF-B activate inflammatory pathways that promote colorectal cancer progression. Upregulation of IL-6 and COX-2 further supports tumor growth and angiogenesis via VEGF. NFAT mediates the expression of these inflammatory mediators. JAK2/STAT3 signaling is activated in tumor cells, contributing to cell survival and proliferation. Linagliptin suppresses NF-B and NFAT activity, reduces IL-6, COX-2, and VEGF levels, and inhibits JAK2/STAT3 signaling. This results in increased Bax expression and decreased Bcl-2, inducing apoptosis in tumor cells. These molecular changes lead to a reduction in dysplastic crypt foci and adenocarcinoma formation, thereby ameliorating colorectal cancer."}], "pathway_id": "rno05210", "pubmed_id": "40070168", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Spexin (elevated hepatic signaling), Forkhead Box O1 (increased expression), Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (increased expression), Carnitine Palmitoyltransferase 1A (increased expression), Peroxisome Proliferator-Activated Receptor Alpha (increased expression), AMP-Activated Protein Kinase (increased expression), Sirtuin 1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated hepatic spexin signaling correlates with reduced insulin resistance in diabetic rats. This is associated with increased expression of FOXO-1, PGC-1, CPT1A, PPAR, AMPK, and SIRT-1, which collectively promote lipolysis, reduce gluconeogenesis, and suppress lipogenesis. These molecular changes coincide with decreased inflammation and oxidative stress in the liver, indicating a protective metabolic effect."}], "pathway_id": "rno04068", "pubmed_id": "40841811", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Forkhead box O1 (Activation), Forkhead box O3 (Activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The FoxO1 and FoxO3 transcription factors regulate genes involved in autophagy, immune responses, and inflammatory pathways. Activation of these factors contributes to the modulation of immune cell infiltration in rheumatoid arthritis synovial tissues, influencing disease progression and potential therapeutic targets."}], "pathway_id": "rno04068", "pubmed_id": "40644421", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Genistein (administration), Quercetin (administration), Carbacyclin, Linoleic Acid, Caffeic Acid (administration), PTPN11, LCK, STAT3, GRB2, FYN, SRC, PIK3R1, LYN, EGFR, PIK3CA, mTOR (activated), FOXO3A (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Genistein, quercetin, and caffeic acid modulate the PI3K-AKT signaling pathway, leading to the activation of mTOR and the downstream transcription factor FOXO3A. This pathway regulation enhances hematopoietic and immune-related cytokine production, increases bone marrow nucleated cell count, and improves thymus and spleen indices. These effects contribute to the mitigation of leukopenia through the restoration of normal hematopoietic and immune functions."}], "pathway_id": "rno04068", "pubmed_id": "40513324", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: FoxO signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The forkhead box O (FOXO) family of transcription factors regulates the expression of genes in cellular physiological events including apoptosis, cell-cycle control, glucose metabolism, oxidative stress resistance, and longevity. A central regulatory mechanism of FOXO proteins is phosphorylation by the serine-threonine kinase Akt/protein kinase B (Akt/PKB), downstream of phosphatidylinositol 3-kinase (PI3K), in response to insulin or several growth factors. Phosphorylation at three conserved residues results in the export of FOXO proteins from the nucleus to the cytoplasm, thereby decreasing expression of FOXO target genes. In contrast, the stress-activated c-Jun N-terminal kinase (JNK) and the energy sensing AMP-activated protein kinase (AMPK), upon oxidative and nutrient stress stimuli phosphorylate and activate FoxOs. Aside from PKB, JNK and AMPK, FOXOs are regulated by multiple players through several post-translational modifications, including phosphorylation, but also acetylation, methylation and ubiquitylation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Quercetin (administration), Nobiletin, Kaempferol, Luteolin (administration), Ginsenoside Rh2 (administration), Formononetin, Interleukin-1, Signal Transducer and Activator of Transcription 3, Matrix Metallopeptidase 9, Vascular Endothelial Growth Factor A, Protein Kinase B (activation), Hypoxia-Inducible Factor 1 Subunit Alpha, Forkhead Box O3 (activation), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (inhibition), Protein Kinase B (Phosphorylated), Toll-Like Receptor 4, Caspase-3, Tumor Necrosis Factor, Interleukin-17.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the FoxO signaling pathway is associated with the regulation of genes involved in apoptosis, oxidative stress resistance, and immune response. Phosphorylation of FoxO3 by AKT1 leads to its cytoplasmic retention and reduced transcriptional activity. Inhibition of the PI3K-AKT signaling axis results in increased FoxO3 nuclear localization and activation, which in turn promotes the expression of genes involved in stress resistance and apoptosis. Upregulation of FoxO3 is linked to reduced inflammation and oxidative stress in response to cellular stressors. In the context of chronic obstructive pulmonary disease, modulation of the FoxO3 pathway by bioactive compounds such as quercetin, luteolin, and ginsenoside Rh2 may contribute to the suppression of inflammatory mediators and improvement in lung function."}], "pathway_id": "rno04068", "pubmed_id": "39066538", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Butylphthalide (administration), YAP1 (elevated levels), phosphorylated YAP1 (reduced phosphorylation), BECLIN1, LC3B (microtubule-associated protein 1 light chain 3 beta), Hippo signaling pathway (inactivated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dl-3-n-butylphthalide inactivates the Hippo signaling pathway, leading to elevated levels of YAP1 and reduced phosphorylation of YAP1. This inhibition prevents YAP1 nuclear translocation and suppresses autophagy, thereby reducing neuronal apoptosis and injury following spinal cord injury."}], "pathway_id": "rno04390", "pubmed_id": "41104600", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon Tetrachloride, Levodopa (administration), YAP1 (phosphorylated), DRD1 (elevated expression), ACTA2 (reduced expression), AST, ALT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated dopamine receptor D1 (DRD1) expression activates the Hippo signaling pathway, resulting in increased phosphorylation of Yes-associated protein 1 (YAP1). Phosphorylated YAP1 is retained in the cytoplasm, preventing its nuclear translocation and transcriptional activity. This inhibition of YAP1 function contributes to the attenuation of liver fibrosis, as evidenced by reduced collagen deposition and -smooth muscle actin (ACTA2) expression. Levodopa, a dopamine precursor, enhances this process by upregulating DRD1 and modulating Hippo/YAP1 signaling."}], "pathway_id": "rno04390", "pubmed_id": "40937451", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Iodoacetate, Yes-associated protein 1 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated fluid shear stress activates the Hippo/YAP pathway in articular cartilage superficial layer cells, promoting inflammation and catabolic processes. Activation of YAP contributes to the progression of osteoarthritis by modulating cellular responses to mechanical stress."}], "pathway_id": "rno04390", "pubmed_id": "40449759", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferulic Acid (administration), Transforming Growth Factor Beta 1, MST1, TEAD4, Phosphatase and Tensin Homolog, Cyclooxygenase 2, Glucose Transporter Type 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ferulic acid interacts with TGF-1 and modulates the Hippo signaling pathway by influencing MST1 and TEAD4 activity. This modulation reduces oxidative stress and inflammation in renal tissue, thereby ameliorating diabetic nephropathy. Concurrently, ferulic acid affects PTEN, COX2, and GLUT3, contributing to the improvement of renal function and metabolic status."}], "pathway_id": "rno04390", "pubmed_id": "40164664", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling is an evolutionarily conserved signaling pathway that controls organ size from flies to humans. In humans and mice, the pathway consists of the MST1 and MST2 kinases, their cofactor Salvador and LATS1 and LATS2. In response to high cell densities, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ, promoting its cytoplasmic localization, leading to cell apoptosis and restricting organ size overgrowth. When the Hippo pathway is inactivated at low cell density, YAP/TAZ translocates into the nucleus to bind to the transcription enhancer factor (TEAD/TEF) family of transcriptional factors to promote cell growth and proliferation. YAP/TAZ also interacts with other transcriptional factors or signaling molecules, by which Hippo pathway-mediated processes are interconnected with those of other key signaling cascades, such as those mediated by TGF-beta and Wnt growth factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1 (activated), PIK3CA, MYC.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 activation in the Hippo signaling pathway promotes cell cycle activity by interacting with PIK3CA and MYC. This interaction enhances cardiomyocyte proliferation through the integration of Hippo and growth factor signaling modules."}], "pathway_id": "rno04390", "pubmed_id": "39866065", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: B cell receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: B cells are an important component of adaptive immunity. They produce and secrete millions of different antibody molecules, each of which recognizes a different (foreign) antigen. The B cell receptor (BCR) is an integral membrane protein complex that is composed of two immunoglobulin (Ig) heavy chains, two Ig light chains and two heterodimers of Ig-alpha and Ig-beta. After BCR ligation by antigen, three main protein tyrosine kinases (PTKs) -the SRC-family kinase LYN, SYK and the TEC-family kinase BTK- are activated. Phosphatidylinositol 3-kinase (PI3K) and phospholipase C-gamma 2 (PLC-gamma 2) are important downstream effectors of BCR signalling. This signalling ultimately results in the expression of immediate early genes that further activate the expression of other genes involved in B cell proliferation, differentiation and Ig production as well as other processes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lyn (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phosphorylation of the tyrosine-protein kinase Lyn (LYN) is a key event in B cell receptor signaling. Activation of LYN leads to downstream signaling events that regulate B cell proliferation, differentiation, and antibody production. Inhibition of LYN phosphorylation suppresses BCR signaling, thereby reducing B cell activation and effector functions."}], "pathway_id": "rno04662", "pubmed_id": "40706389", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: B cell receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: B cells are an important component of adaptive immunity. They produce and secrete millions of different antibody molecules, each of which recognizes a different (foreign) antigen. The B cell receptor (BCR) is an integral membrane protein complex that is composed of two immunoglobulin (Ig) heavy chains, two Ig light chains and two heterodimers of Ig-alpha and Ig-beta. After BCR ligation by antigen, three main protein tyrosine kinases (PTKs) -the SRC-family kinase LYN, SYK and the TEC-family kinase BTK- are activated. Phosphatidylinositol 3-kinase (PI3K) and phospholipase C-gamma 2 (PLC-gamma 2) are important downstream effectors of BCR signalling. This signalling ultimately results in the expression of immediate early genes that further activate the expression of other genes involved in B cell proliferation, differentiation and Ig production as well as other processes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide acetate (administration), 5-Aminolevulinic Acid, Spleen tyrosine kinase (active), B cell receptor, Fc epsilon receptor I, Lyn tyrosine kinase, Phospholipase C gamma 2, Immunoglobulin alpha chain, Immunoglobulin beta chain.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Spleen tyrosine kinase (Syk) plays a central role in B cell receptor (BCR) signaling by mediating downstream phosphorylation events following antigen engagement. Inhibition of Syk activity with P505-15 suppresses BCR-mediated B cell signaling and activation, as well as Fc receptor 1-mediated basophil degranulation. This suppression disrupts immune cell function and reduces inflammatory responses in rheumatoid arthritis models. Syk inhibition specifically targets signaling pathways required for immune activation without affecting Syk-independent processes, thereby modulating immune function and alleviating inflammation."}], "pathway_id": "rno04662", "pubmed_id": "22040680", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Piracetam, AMPK (activation), SIRT1 (upregulation), Nrf2 (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AMPK activation leads to the upregulation of SIRT1 and Nrf2, which collectively mitigate oxidative stress and neuroinflammation, thereby reducing pyroptotic and necroptotic cell death and improving cognitive function."}], "pathway_id": "rno04152", "pubmed_id": "41251844", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dorsomorphin dihydrochloride, METTL3 (elevated levels), AMP-activated protein kinase (activation), Smooth muscle protein 22 alpha (increased expression), Alpha-smooth muscle actin (increased expression), Tumor necrosis factor alpha (suppressed expression), Interleukin 1 beta (suppressed expression), Inducible nitric oxide synthase (suppressed expression), Interleukin 6 (suppressed expression), Matrix metalloproteinase 9 (suppressed expression), Matrix metalloproteinase 3 (suppressed expression), CD68 antigen.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of METTL3 promote vascular stability by modulating the AMPK signaling pathway. METTL3 upregulation increases the expression of contractile markers such as SM-22 and -SMA in vascular smooth muscle cells (VSMCs), while suppressing pro-inflammatory cytokines including TNF-, IL-1, iNOS, IL-6, and matrix metalloproteinases MMP-9 and MMP-3. This leads to inhibition of VSMC proliferation and migration, and promotion of apoptosis. Activation of the AMPK pathway by METTL3 also reduces macrophage infiltration, as evidenced by decreased CD68 immunofluorescence, and enhances vessel wall integrity and thickness. These effects are attenuated by the AMPK inhibitor Compound C, indicating that the beneficial outcomes are mediated through AMPK activation."}], "pathway_id": "rno04152", "pubmed_id": "41290742", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methanol (exposure), Zln005 (administration), AMP-activated protein kinase (reactivated via PGC-1), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (activated by ZLN005), Sirtuin 3 (regulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methanol exposure down-regulates the expression levels of AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1), and sirtuin 3 (SIRT3), leading to mitochondrial dysfunction and oxidative stress. This disruption contributes to neurobehavioral impairments and neuronal damage. Activation of PGC-1 through ZLN005 partially reverses these effects by modulating the AMPK/PGC-1/SIRT3 pathway, thereby mitigating mitochondrial and oxidative damage."}], "pathway_id": "rno04152", "pubmed_id": "41273494", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gallic Acid, Protocatechuic Acid, Rhein, AMP-activated protein kinase (activated), AMP-activated protein kinase subunit alpha, Nuclear factor (erythroid-derived 2)-like 2 (activated), Sterol regulatory element-binding transcription factor 1 (inactivated), Fatty acid synthase (inactivated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of AMP-activated protein kinase (AMPK) leads to the suppression of energy-consuming biosynthetic pathways and the promotion of catabolic processes such as fatty acid oxidation. AMPK activation also results in the inactivation of SREBP1 and FAS, thereby reducing hepatic lipid synthesis. Concurrently, AMPK activation enhances the activity of Nrf2, which mitigates oxidative stress. These effects collectively contribute to the attenuation of hepatic inflammation and fibrosis associated with nonalcoholic steatohepatitis."}], "pathway_id": "rno04152", "pubmed_id": "41214635", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Oxytocin, peroxisome proliferator-activated receptor gamma, insulin receptor (enhanced expression), insulin receptor substrate 1 and 2 (enhanced expression), phosphoinositide 3-kinase (enhanced expression), protein kinase B (activated), AMP-activated protein kinase (activated), solute carrier family 2 member 4 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Oxytocin modulates insulin signaling by enhancing the expression of insulin receptor (INSR), insulin receptor substrates 1 and 2 (IRS1 and IRS2), and phosphoinositide 3-kinase (PI3K), which activates protein kinase B (AKT). Concurrently, oxytocin activates AMP-activated protein kinase (AMPK), promoting glucose uptake through increased expression of solute carrier family 2 member 4 (GLUT4) in visceral adipose tissue. These actions improve insulin sensitivity and glucose metabolism, thereby mitigating insulin resistance and supporting -cell function."}], "pathway_id": "rno04152", "pubmed_id": "41167707", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Theaflavin (administration), AMP-activated protein kinase, Sterol regulatory element-binding transcription factor 1, Sirtuin 1, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, Uncoupling protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Theaflavins activate the AMPK/SREBP-1 and AMPK/SIRT1/PGC-1/UCP1 pathways, thereby mitigating lipid and energy metabolism. This activation contributes to the reduction of body weight, lipid deposition, and systemic inflammation. Concurrently, Theaflavins promote intestinal barrier integrity and modulate gut microbiota composition, which supports metabolic homeostasis and reduces immune activation."}], "pathway_id": "rno04152", "pubmed_id": "41061287", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: AMPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: AMP-activated protein kinase (AMPK) is a serine threonine kinase that is highly conserved through evolution. AMPK system acts as a sensor of cellular energy status. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either interfere with ATP production (eg, deprivation for glucose or oxygen) or that accelerate ATP consumption (eg, muscle contraction). Several upstream kinases, including liver kinase B1 (LKB1), calcium/calmodulin kinase kinase-beta (CaMKK beta), and TGF-beta-activated kinase-1 (TAK-1), can activate AMPK by phosphorylating a threonine residue on its catalytic alpha-subunit. Once activated, AMPK leads to a concomitant inhibition of energy-consuming biosynthetic pathways, such as protein, fatty acid and glycogen synthesis, and activation of ATP-producing catabolic pathways, such as fatty acid oxidation and glycolysis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Adenine (administration), AMP-activated protein kinase (activated), Tumor protein p53 (phosphorylated), Nuclear factor kappa B, Extracellular signal-regulated kinase (dephosphorylated), c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, Inducible nitric oxide synthase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Adenine activates AMP-activated protein kinase (AMPK) signaling, which leads to increased phosphorylation of tumor protein p53 and reduced phosphorylation of extracellular signal-regulated kinase (ERK), resulting in the suppression of nuclear factor kappa B (NF-B) activation. This cascade attenuates the expression and secretion of proinflammatory mediators in vascular smooth muscle cells."}], "pathway_id": "rno04152", "pubmed_id": "41075915", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NOD-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting various pathogens and generating innate immune responses. The intracellular NOD-like receptor (NLR) family contains more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. NOD1 and NOD2, two prototypic NLRs, sense the cytosolic presence of the bacterial peptidoglycan fragments that escaped from endosomal compartments, driving the activation of NF-{kappa}B and MAPK, cytokine production and apoptosis. On the other hand, a different set of NLRs induces caspase-1 activation through the assembly of multiprotein complexes called inflammasomes. The activated of caspase-1 regulates maturation of the pro-inflammatory cytokines IL-1B, IL-18 and drives pyroptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Epigallocatechin Gallate (administered), Acetaminophen, N-Acetyl-L-Cysteine, NLR family pyrin domain containing 3 (activated), Thioredoxin-interacting protein (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Endoplasmic reticulum stress activates thioredoxin-interacting protein (TXNIP), which in turn interacts with and activates NLR family pyrin domain containing 3 (NLRP3) inflammasome. Activation of the NLRP3 inflammasome leads to caspase-1 activation and the maturation of pro-inflammatory cytokines, contributing to liver injury. Epigallocatechin-3-gallate mitigates this process by attenuating ER stress, thereby reducing inflammasome signaling and protecting the liver from damage."}], "pathway_id": "rno04621", "pubmed_id": "41340591", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NOD-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting various pathogens and generating innate immune responses. The intracellular NOD-like receptor (NLR) family contains more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. NOD1 and NOD2, two prototypic NLRs, sense the cytosolic presence of the bacterial peptidoglycan fragments that escaped from endosomal compartments, driving the activation of NF-{kappa}B and MAPK, cytokine production and apoptosis. On the other hand, a different set of NLRs induces caspase-1 activation through the assembly of multiprotein complexes called inflammasomes. The activated of caspase-1 regulates maturation of the pro-inflammatory cytokines IL-1B, IL-18 and drives pyroptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Chalcone, Malonaldehyde, Glutathione, SIRT1, HMGB1 (elevated levels), NLRP3, CASP1, GSDMD, NRF2, NFKB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of HMGB1 activate the NLRP3 inflammasome, leading to cleavage of CASP1 and subsequent activation of GSDMD, which triggers pyroptotic cell death. SIRT1 suppresses HMGB1 expression, thereby inhibiting NLRP3 inflammasome activation. Concurrently, SIRT1 enhances mitochondrial function and reduces oxidative stress by upregulating NRF2. These effects collectively mitigate myocardial ischemia and reperfusion injury."}], "pathway_id": "rno04621", "pubmed_id": "41217228", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NOD-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting various pathogens and generating innate immune responses. The intracellular NOD-like receptor (NLR) family contains more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. NOD1 and NOD2, two prototypic NLRs, sense the cytosolic presence of the bacterial peptidoglycan fragments that escaped from endosomal compartments, driving the activation of NF-{kappa}B and MAPK, cytokine production and apoptosis. On the other hand, a different set of NLRs induces caspase-1 activation through the assembly of multiprotein complexes called inflammasomes. The activated of caspase-1 regulates maturation of the pro-inflammatory cytokines IL-1B, IL-18 and drives pyroptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Asperosaponin VI, NLRP3 (suppression of inflammasome activation), NF-kappa B (inhibition), Interleukin-1 beta (maturation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of IL-1 induce pyroptosis in nucleus pulposus cells, which contributes to intervertebral disc degeneration. Activation of the NF-B signaling pathway promotes the expression of NLRP3, a key component of the inflammasome complex, leading to caspase-1 activation and the maturation of pro-inflammatory cytokines such as IL-1. Inhibition of NF-B suppresses NLRP3 inflammasome activation, reduces pyroptosis, and restores extracellular matrix integrity, thereby delaying the progression of intervertebral disc degeneration."}], "pathway_id": "rno04621", "pubmed_id": "41093224", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: NOD-like receptor signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Specific families of pattern recognition receptors are responsible for detecting various pathogens and generating innate immune responses. The intracellular NOD-like receptor (NLR) family contains more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. NOD1 and NOD2, two prototypic NLRs, sense the cytosolic presence of the bacterial peptidoglycan fragments that escaped from endosomal compartments, driving the activation of NF-{kappa}B and MAPK, cytokine production and apoptosis. On the other hand, a different set of NLRs induces caspase-1 activation through the assembly of multiprotein complexes called inflammasomes. The activated of caspase-1 regulates maturation of the pro-inflammatory cytokines IL-1B, IL-18 and drives pyroptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CID 121513902, Toll-like receptor 4 (inhibition), Nuclear factor kappa B (inhibition), NLR family pyrin domain containing 3 (inhibition), Caspase 1 (activation), Interleukin 1 beta (cleavage), Interleukin 18 (cleavage).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4 activates the NF-B signaling pathway, leading to the upregulation of NLRP3 inflammasome components. Activation of NLRP3 results in the cleavage and activation of caspase-1, which in turn processes pro-IL-1 and pro-IL-18 into their mature forms and triggers pyroptosis. This process contributes to inflammation and endothelial injury. Inhibition of TLR4 suppresses NF-B and NLRP3 activation, thereby reducing pyroptosis, inflammation, and oxidative stress."}], "pathway_id": "rno04621", "pubmed_id": "41106569", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Rattus norvegicus (rat)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dimethyldiphenylphosphonium iodide, Acetylcholine, Norepinephrine, Phenylephrine, Nitric Oxide (synthesis), Inducible nitric oxide synthase (increased expression), Toll-like receptor 4, NADPH oxidase 2 (activation), Reactive oxygen species (production), p38 mitogen-activated protein kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Long-term exposure to streptolysin O induces inducible nitric oxide synthase (iNOS) expression in endothelial cells through toll-like receptor 4-mediated activation of NADPH oxidase 2, leading to reactive oxygen species production and p38 mitogen-activated protein kinase signaling. This results in increased nitric oxide synthesis, which inhibits vascular smooth muscle contraction and endothelium-dependent relaxation, thereby impairing vascular function and contributing to oxidative stress."}], "pathway_id": "rno04270", "pubmed_id": "40023601", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Rattus norvegicus (rat)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dehydrocorydaline (administration), Cnn1 (expression), Myh11 (expression), Acta2 (expression), Spta1 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dehydrocorydaline upregulates the expression of vascular smooth muscle cell contractile phenotype markers, including calponin 1 (Cnn1), myosin heavy chain (Myh11), and alpha-smooth muscle actin (Acta2). This effect is mediated through the upregulation of spectrin alpha, erythrocytic 1 (Spta1), which is necessary for the increased expression of contractile markers. Dehydrocorydaline also inhibits vascular smooth muscle cell proliferation and migration, and it reduces carotid artery atherosclerotic plaque formation and macrophage infiltration. These actions contribute to the maintenance of the vascular smooth muscle cell contractile phenotype and the attenuation of atherosclerosis."}], "pathway_id": "rno04270", "pubmed_id": "39833304", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Rattus norvegicus (rat)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 1-Methyl-4-Prop-1-En-2-Ylcyclohexene (at higher concentrations), Potassium Chloride, Phenylephrine Hydrochloride, NG-nitro-L-arginine methyl ester, Ruthenium Red, Indomethacin (administration), Methyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-3-pyridinecarboxylate, Barium ion.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Limonene modulates vascular smooth muscle contraction in a biphasic manner. At low concentrations, it enhances phenylephrine-induced contraction, likely through arachidonic acid metabolism, as this effect is blocked by indomethacin. At higher concentrations, it inhibits contraction, potentially via calcium channel modulation, as it promotes relaxation in contractions induced by calcium agonists. Limonene does not appear to significantly affect nitric oxide signaling or TRP channel activity in this context."}], "pathway_id": "rno04270", "pubmed_id": "39551421", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Rattus norvegicus (rat)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (administration), Diacetyldichlorofluorescein, ACTA2 (reduced expression), TAGLN (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hydrogen peroxide induces oxidative stress in vascular smooth muscle cells, leading to increased reactive oxygen species production and promotion of phenotypic switching from the contractile to the synthetic phenotype. This transition is associated with reduced expression of contractile markers ACTA2 and TAGLN. Phoenixin-14 attenuates oxidative stress by decreasing intracellular reactive oxygen species levels, thereby preserving the contractile phenotype of vascular smooth muscle cells and inhibiting their migration and invasion. This mechanism contributes to the prevention of intracranial aneurysm formation and rupture."}], "pathway_id": "rno04270", "pubmed_id": "39148253", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Vascular smooth muscle contraction - Rattus norvegicus (rat)\n**Pathway Description**: The vascular smooth muscle cell (VSMC) is a highly specialized cell whose principal function is contraction. On contraction, VSMCs shorten, thereby decreasing the diameter of a blood vessel to regulate the blood flow and pressure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hesperetin (administration), Methyl 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-3-pyridinecarboxylate, Potassium Cation, L-type calcium channel (activity), adenylyl cyclase, soluble guanylyl cyclase, phosphodiesterase 3, phosphodiesterase 4, phosphodiesterase 5, phosphodiesterase 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hesperetin inhibits L-type calcium channel activity, thereby reducing calcium influx into vascular smooth muscle cells. This inhibition leads to a decrease in depolarizing contraction and induces vasorelaxation. The effect of hesperetin is not mediated through cyclic nucleotide pathways or phosphodiesterase enzymes, as it remains effective in the presence of adenylyl cyclase, guanylyl cyclase, and PDE inhibitors. Direct modulation of L-type calcium channels by hesperetin contributes to the relaxation of pre-contracted vascular smooth muscle."}], "pathway_id": "rno04270", "pubmed_id": "38236522", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: VEGF signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration of endothelial cells and promoting their survival and vascular permeability. For example, the binding of VEGF to VEGFR-2 leads to dimerization of the receptor, followed by intracellular activation of the PLCgamma;PKC-Raf kinase-MEK-mitogen-activated protein kinase (MAPK) pathway and subsequent initiation of DNA synthesis and cell growth, whereas activation of the phosphatidylinositol 3' -kinase (PI3K)-Akt pathway leads to increased endothelial-cell survival. Activation of PI3K, FAK, and p38 MAPK is implicated in cell migration signaling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tanshinone Iia Sulfonate, Hydrogen Peroxide, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor 2 (activated), Phospholipase C gamma (activated), Protein Kinase C (activated), Raf Kinase (activated), Mitogen-Activated Protein Kinase Kinase (activated), Mitogen-Activated Protein Kinase (activated), Phosphatidylinositol 3-Kinase (activated), Protein Kinase B (activated), Focal Adhesion Kinase (activated), Mitogen-Activated Protein Kinase 14 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the VEGF signaling pathway is initiated by the binding of Vascular Endothelial Growth Factor A to Vascular Endothelial Growth Factor Receptor 2, which induces receptor dimerization and downstream signaling. This activates the PLCgamma;PKC-Raf kinase-MEK-MAPK cascade, promoting endothelial cell proliferation and DNA synthesis. Simultaneously, activation of the PI3K-Akt pathway enhances endothelial cell survival and vascular permeability. Additionally, the involvement of FAK and p38 MAPK supports cell migration. These processes collectively drive angiogenesis and vascular remodeling."}], "pathway_id": "rno04370", "pubmed_id": "41206417", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: VEGF signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration of endothelial cells and promoting their survival and vascular permeability. For example, the binding of VEGF to VEGFR-2 leads to dimerization of the receptor, followed by intracellular activation of the PLCgamma;PKC-Raf kinase-MEK-mitogen-activated protein kinase (MAPK) pathway and subsequent initiation of DNA synthesis and cell growth, whereas activation of the phosphatidylinositol 3' -kinase (PI3K)-Akt pathway leads to increased endothelial-cell survival. Activation of PI3K, FAK, and p38 MAPK is implicated in cell migration signaling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cobalt chloride (cocl2), Vascular endothelial growth factor A (upregulation), Hypoxia-inducible factor 1-alpha (upregulation), Nuclear factor erythroid 2-related factor 2 (enhancement), Reactive oxygen species.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "VEGF upregulation promotes angiogenesis by activating endothelial cell proliferation, migration, and tube formation. Hypoxia and oxidative stress further enhance VEGF and HIF-1 expression, contributing to pathological neovascularization. Nrf2 activation suppresses oxidative stress by inducing antioxidant pathways. Inhibition of VEGF signaling and enhancement of Nrf2 activity reduce neovascular lesion formation and preserve retinal architecture."}], "pathway_id": "rno04370", "pubmed_id": "41016543", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: VEGF signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells and it is considered to be a crucial signal transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration of endothelial cells and promoting their survival and vascular permeability. For example, the binding of VEGF to VEGFR-2 leads to dimerization of the receptor, followed by intracellular activation of the PLCgamma;PKC-Raf kinase-MEK-mitogen-activated protein kinase (MAPK) pathway and subsequent initiation of DNA synthesis and cell growth, whereas activation of the phosphatidylinositol 3' -kinase (PI3K)-Akt pathway leads to increased endothelial-cell survival. Activation of PI3K, FAK, and p38 MAPK is implicated in cell migration signaling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 6,7-Dimethyl-3-((methyl-(2-(methyl-((1-(3-(trifluoromethyl)phenyl)indol-3-yl)methyl)amino)ethyl)amino)methyl)chromen-4-one (administration), TNFRSF1A (inhibited), VEGFA (elevated expression), MAPK1 (elevated expression), PIK3CA (elevated expression), AKT1 (elevated expression), ICAM1 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of TNFR1 by CAY10500 leads to elevated expression of VEGFA, MAPK1, PIK3CA, and AKT1. This activation promotes angiogenesis and cell proliferation, contributing to gastric tissue healing. Concurrently, CAY10500 reduces the expression of ICAM1, which is associated with cell adhesion pathways."}], "pathway_id": "rno04370", "pubmed_id": "41090239", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methotrexate (administration), 5-Aminolevulinic Acid, L-Histidine, L-Methionine, Tetrahydrofolic acid (reduced concentrations), Methyltetrahydrofolate (reduced concentrations), Formyltetrahydrofolate (reduced concentrations), 10-Formyltetrahydrofolate dehydrogenase (diminished activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methotrexate perturbs folate-dependent one-carbon metabolism by reducing hepatic tetrahydrofolate, methyltetrahydrofolate, and formyltetrahydrofolate concentrations. This leads to a diminished activity of 10-formyltetrahydrofolate dehydrogenase, which affects the catabolism of histidine-derived carbon to CO2. Although oxidative carbon flow remains largely unchanged, reductive carbon flow from histidine to methionine is significantly reduced. This results in a 54% decrease in total carbon flow through the hepatic folate-dependent one-carbon pool, primarily due to a reduction in the reductive pathway toward methyltetrahydrofolate and methionine synthesis."}], "pathway_id": "rno00670", "pubmed_id": "8761428", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Methyltetrahydrofolic acid, L-Homocysteine, GNMT (increased activity), PEMT (upregulated), BHMT (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated glycine N-methyltransferase (GNMT) activity and abundance occur in diabetic conditions, influencing folate, methyl group, and homocysteine metabolism. 5-methyltetrahydrofolate allosterically inhibits GNMT, indicating a regulatory feedback mechanism. Folate deficiency leads to increased GNMT activity, contributing to hyperhomocysteinemia. In response, betaine-homocysteine S-methyltransferase (BHMT) expression is upregulated, partially attenuating homocysteine levels. Phosphatidylethanolamine N-methyltransferase (PEMT) is also upregulated, suggesting an increased demand for choline metabolism in the diabetic state."}], "pathway_id": "rno00670", "pubmed_id": "16835399", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Histidine, 10-Formyltetrahydrofolate (larger proportion), 5-Methyltetrahydrofolic acid (reduced proportion), Carbon Dioxide (enhanced production), histidase, urocanase, 10-formyltetrahydrofolate dehydrogenase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated histidine catabolism increases the carbon flux through the one-carbon pool, leading to enhanced CO2 production. This process is mediated by enzymes including histidase, urocanase, and 10-formyltetrahydrofolate dehydrogenase. Under conditions of hyperthyroidism and folate deficiency, the flux of carbon from histidine to CO2 is significantly increased, with a larger proportion entering the 10-formyltetrahydrofolate pool compared to the 5-methyltetrahydrofolate pool. These changes reflect a shift in folate-dependent one-carbon metabolism toward the oxidation of histidine-derived carbon."}], "pathway_id": "rno00670", "pubmed_id": "8638944", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Serine, L-Methionine, S-Adenosylmethionine (elevated levels), Adenosylhomocysteine (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The folate-dependent one-carbon metabolism facilitates the de novo synthesis of methionine from serine through reductive carbon flow. S-adenosylmethionine and S-adenosylhomocysteine levels are elevated in vitamin A-deficient conditions, yet the irreversible loss rate of hepatic serine and methionine, the transfer quotient from serine to methionine, and the folate-dependent carbon flow to methionine remain unchanged. This indicates that the pathway maintains its functional capacity to generate methionine via homocysteine remethylation despite altered S-adenosylmethionine and S-adenosylhomocysteine concentrations."}], "pathway_id": "rno00670", "pubmed_id": "8598552", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Leucovorin, 10-Formyltetrahydrofolate (elevated consumption), 5-Methyltetrahydrofolic acid (increased proportion), Tetrahydrofolic acid (depletion), S-Adenosylmethionine, L-Methionine, L-Homocysteine.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Methyl group deficiency increases the reliance on folate-dependent one-carbon metabolism for methionine biosynthesis. This results in elevated consumption of folate derivatives such as 5-formyltetrahydrofolate and 10-formyltetrahydrofolate, leading to a depletion of total liver folate levels. Over time, the proportion of 5-methyltetrahydrofolate in the folate pool increases, suggesting a shift in folate utilization. Tetrahydrofolate serves as a central cofactor in these reactions, and its depletion reflects increased metabolic demand. Restoration of methionine and choline in the diet reverses these metabolic changes."}], "pathway_id": "rno00670", "pubmed_id": "2784833", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: One carbon pool by folate - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: dCTP (reduced levels), Deoxythymidine triphosphate (reduced levels), dGTP (reduced levels), Datp (reduced levels), 5-Bromo-2'-deoxyuridine, Propidium Iodide.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Folate-derived one-carbon groups are essential for the de novo synthesis of purines and pyrimidines, which are precursors for deoxynucleotide triphosphates (dNTPs) such as dCTP, dTMP, dGTP, and dATP. Depletion of folate leads to reduced levels of these dNTPs, resulting in nucleotide pool imbalances. This imbalance disrupts DNA synthesis and is associated with delayed progression through the S phase and G2/M phase of the cell cycle. The reduction in DNA synthesis is further indicated by decreased bromodeoxyuridine incorporation, reflecting impaired replication activity."}], "pathway_id": "rno00670", "pubmed_id": "8013406", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methylcellulose (4000 cps), Adjudin, YAP1, phosphorylated YAP1, actin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 and its phosphorylated form regulate Hippo signaling pathway activity in testicular tissue. Reduced levels of YAP and phospho-YAP correlate with disrupted actin cytoskeleton organization. Actin cytoskeleton remodeling influences the functional dynamics of the Hippo pathway, which in turn modulates sperm secretion processes in seminiferous tubules."}], "pathway_id": "rno04392", "pubmed_id": "40753289", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon Tetrachloride, Levodopa, YAP1 (inhibition), DRD1 (upregulation), phosphorylated YAP1 (phosphorylation), ACTA2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of dopamine receptor D1 (DRD1) promotes Hippo signaling pathway activity, resulting in increased phosphorylation of Yes-associated protein 1 (YAP1). Phosphorylated YAP1 is functionally inhibited, leading to reduced transcriptional activity of YAP1 and subsequent attenuation of liver fibrosis. This mechanism involves upregulation of DRD1, which modulates Hippo/YAP signaling to suppress pathological fibrotic processes in the liver."}], "pathway_id": "rno04392", "pubmed_id": "40937451", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Iodoacetate, YAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated fluid shear stress activates YAP1, which modulates inflammatory and catabolic responses in articular cartilage superficial layer cells. Persistent activation of YAP1 contributes to the progression of osteoarthritis through altered cellular metabolism and extracellular matrix degradation."}], "pathway_id": "rno04392", "pubmed_id": "40449759", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-Nitrosodiethylamine, YAP1 (inactivated), Phosphorylated YAP1, MST1 (upregulated), LATS1, Phosphorylated LATS1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Upregulation of MST1 and LATS1 promotes phosphorylation of YAP1, leading to its inactivation and degradation. Inactivated YAP1 cannot translocate to the nucleus to drive transcription of genes that promote cell proliferation. This suppression of YAP1 activity results in reduced hepatocellular carcinoma progression through inhibition of tumor cell proliferation and induction of apoptosis."}], "pathway_id": "rno04392", "pubmed_id": "40294930", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferulic Acid (administration), Transforming Growth Factor Beta 1 (activity), MST1 (activity), TEAD4 (activity), Phosphatase and Tensin Homolog (activity), Cyclooxygenase 2 (activity), Glucose Transporter Type 3 (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ferulic acid modulates the TGF-1/Hippo signaling crosstalk to ameliorate diabetic nephropathy. This involves suppression of TGF-1 activity and regulation of Hippo pathway components, including MST1 and TEAD4. Inhibition of COX2 and PTEN, along with modulation of GLUT3 and oxidative stress markers, contributes to reduced renal inflammation and improved kidney function."}], "pathway_id": "rno04392", "pubmed_id": "40164664", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: YAP1, MYC, PIK3CA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "YAP1 activates the Hippo signaling pathway and promotes cardiomyocyte proliferation by crosstalking with the growth factor module through PIK3CA and MYC, thereby enhancing cell cycle activity."}], "pathway_id": "rno04392", "pubmed_id": "39866065", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Hippo signaling pathway - multiple species - Rattus norvegicus (rat)\n**Pathway Description**: Hippo signaling pathways control diverse aspects of cell proliferation, survival, and morphogenesis in eukaryotes. The core organization of these networks is conserved over a billion years of evolution, with related forms described in animals and fungi. In Drosophila and mammals, Hippo/MST co-operate with Mats/Mob1 and Salvador/WW45 to activate Warts/LATS, which negatively regulates Yorkie/YAP. Yorkie/YAP interact with Scalloped/TEAD to promote gene transcriptions and control organ size through the balance between cell proliferation and apoptosis. In C. elegans, WTS-1 YAP-1 EGL-44 axis is conserved and regulates thermotolerance and healthy lifespan. In S. cerevisiae, the LATS-related Dbf2 or Dbf20 kinase in complex with Mob1 controls mitotic exit and cytokinesis, and the Hippo/MST family of kinases, STE-20, modulates Tec1, the putative yeast TEAD ortholog.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dexamethasone (administration), YAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dexamethasone promotes alveolar epithelial cell differentiation and activates the Hippo/YAP signaling pathway, which supports alveolar regeneration and protects against pulmonary inflammation and acute lung injury."}], "pathway_id": "rno04392", "pubmed_id": "39632101", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Th17 cell differentiation - Rattus norvegicus (rat)\n**Pathway Description**: Interleukin (IL)-17-producing helper T (Th17) cells serve as a subset of CD4+ T cells involved in epithelial cell- and neutrophil mediated immune responses against extracellular microbes and in the pathogenesis of autoimmune diseases. In vivo, Th17 differentiation requires antigen presentation and co-stimulation, and activation of antigen presenting-cells (APCs) to produce TGF-beta, IL-6, IL-1, IL-23 and IL-21. This initial activation results in the activation and up-regulation of STAT3, ROR(gamma)t and other transcriptional factors in CD4+ T cells, which bind to the promoter regions of the IL-17, IL-21 and IL-22 genes and induce IL-17, IL-21 and IL-22. In contrast, the differentiation of Th17 cells and their IL-17 expression are negatively regulated by IL-2, Th2 cytokine IL-4, IL-27 and Th1 cytokine IFN-gamma through STAT5, STAT6 and STAT1 activation, respectively. Retinoid acid and the combination of IL-2 and TGF-beta upregulate Foxp3, which also downregulates cytokines like IL-17 and IL-21. The inhibition of Th17 differentiation may serve as a protective strategy to 'fine-tune' the expression IL-17 so it does not cause excessive inflammation. Thus, balanced differentiation of Th cells is crucial for immunity and host protection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, Activator protein 1, Potassium calcium-activated channel subfamily N member 4, Mechanistic target of rapamycin complex 1, Interleukin-2 (elevated levels), Interferon gamma (elevated levels), Interleukin-17A (elevated levels), Interleukin-22 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AP-1 activates KCNN4-mediated Ca2+ signaling in CD4+ T cells, which enhances mTORC1 activity. This signaling cascade promotes Th1/Th17 differentiation and suppresses autophagy. The increased Th1/Th17 cell differentiation is associated with elevated levels of IL-2, IFN-, IL-17A, and IL-22, contributing to the progression of chronic non-bacterial prostatitis."}], "pathway_id": "rno04659", "pubmed_id": "39729199", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Bladder cancer - Rattus norvegicus (rat)\n**Pathway Description**: The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-butyl-N-(4-hydroxybutyl)nitrosamine, POLR3G (elevated expression), Wnt5a and Wnt5b (increased expression), DVL2, LRP6, phosphorylated LRP6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of POLR3G promotes bladder cancer progression by enhancing cell proliferation, migration, and invasion. This effect is partially mediated through the Wnt signaling pathway, as downregulation of POLR3G leads to reduced expression of Wnt5a and Wnt5b, as well as decreased activity of downstream components such as DVL2 and phosphorylated LRP6. These changes are associated with reduced activation of the Wnt and MAPK signaling pathways, which are key regulators of tumor growth and metastasis. Additionally, POLR3G influences RNA polymerase activity and apoptotic processes, further contributing to its oncogenic role in bladder urothelium."}], "pathway_id": "rno05219", "pubmed_id": "39039528", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Bladder cancer - Rattus norvegicus (rat)\n**Pathway Description**: The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Arsenic (exposure), Sodium Arsenite, Matrine (administration), NADPH oxidase 2 (expression), NLR family pyrin domain containing 3 (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Arsenic exposure increases reactive oxygen species production and activates NOX2, which in turn promotes NLRP3 inflammasome activation. This leads to enhanced cell proliferation, migration, and angiogenesis in bladder epithelial cells. Matrine reduces NOX2 expression and suppresses NLRP3 inflammasome activity, thereby inhibiting these pro-tumorigenic processes and preventing malignant transformation of uroepithelial cells."}], "pathway_id": "rno05219", "pubmed_id": "39201564", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Bladder cancer - Rattus norvegicus (rat)\n**Pathway Description**: The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dabogratinib (administration), Erdafitinib (administration), Fibroblast Growth Factor Receptor 3 (frequently activated through mutations or gene fusions), Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, Fibroblast Growth Factor Receptor 4, Harvey rat sarcoma viral oncogene homolog, Tumor Protein p53, Retinoblastoma-1 (altered), E-cadherin, Matrix Metalloproteinases, Vascular Endothelial Growth Factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fibroblast Growth Factor Receptor 3 (FGFR3) is frequently activated through mutations or gene fusions in urothelial carcinomas, particularly in nonmuscle invasive bladder cancers. This activation promotes oncogenic signaling via the receptor tyrosine kinase-Ras pathway, contributing to tumor progression. In contrast, muscle-invasive and metastatic urothelial cancers often exhibit alterations in TP53 and RB, leading to more aggressive tumor behavior. FGFR3 activation also enhances tumor invasion and metastasis by modulating the tumor microenvironment, including the expression of E-cadherin and matrix metalloproteinases (MMPs), as well as promoting angiogenesis through vascular endothelial growth factor (VEGF). Targeted inhibition of FGFR3 with selective inhibitors can suppress these oncogenic signals and reduce tumor progression."}], "pathway_id": "rno05219", "pubmed_id": "39258897", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neutrophil extracellular trap formation - Rattus norvegicus (rat)\n**Pathway Description**: Neutrophils play a central role in innate immune defense. One of the mechanisms of neutrophil action is the formation of neutrophil extracellular traps (NETs), the extracellular structures composed of chromatin coated with histones, proteases and granular and cytosolic proteins that help catch and kill microorganisms. NETs are formed by a process known as \"NETosis\" that can be triggered by microorganisms and endogenous stimuli, such as damage-associated molecular patterns and immune complexes, and involves activation in most cases of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, which produces reactive oxygen species (ROS). Recent study has reported that there are two different mechanisms of NETosis, including a lytic NETosis and a vital NETosis. Lytic NETosis begins with nuclear delobulation and the disassembly of the nuclear envelope and continues with loss of cellular polarization, chromatin decondensation and plasma membrane rupture. Vital NETosis can occur independently of cell death and involves the secreted expulsion of nuclear chromatin that is accompanied by the release of granule proteins through degranulation.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Propionic Acid (administration), Trichostatin A, histone deacetylase 1, histone deacetylase 2, histone deacetylase 3, histone deacetylase 6, histone H4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Propionic acid inhibits histone deacetylases (HDACs), including HDAC1, HDAC2, HDAC3, and HDAC6, thereby increasing histone H4 acetylation. Reduced HDAC activity suppresses neutrophil extracellular trap (NET) formation and promotes neutrophil apoptosis. In contrast, decreased propionate levels enhance HDAC activity, reduce histone acetylation, and drive excessive NET production while impairing neutrophil apoptosis, contributing to exacerbated lung inflammation and pneumonia severity."}], "pathway_id": "rno04613", "pubmed_id": "40647346", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Rattus norvegicus (rat)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132, MTOR (inhibited), RPS6KB1, OPA1 (cleaved), OMA1 (suppression), TSC2, PHB, PHB1 (reduced abundance), PRKAA1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of MTOR increases ubiquitination of PHB1 and reduces its abundance, indicating proteasomal degradation. This loss of PHB1 disrupts the suppression of OMA1 activity in the inner mitochondrial membrane, allowing OMA1 to cleave OPA1. OPA1 cleavage promotes mitochondrial fragmentation and impairs mitochondrial bioenergetics, leading to metabolic dysfunction. AMPK activity modulates this mTOR-PHB1-OMA1-OPA1 pathway, particularly under metabolic stress conditions."}], "pathway_id": "rno03050", "pubmed_id": "40450326", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Rattus norvegicus (rat)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hypericin (administration), P2RX7 (suppressed), NFE2L2 (stabilized levels), GPX4 (enhanced activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated P2RX7 activity promotes NFE2L2 degradation through increased proteasome activity, driven by calcium ion accumulation. Hypericin suppresses P2RX7 expression, reducing proteasome activation and stabilizing NFE2L2 levels. This stabilization enhances GPX4 activity, counteracting ferroptosis and mitigating inflammation, ultimately improving cardiac autonomic function in diabetic conditions."}], "pathway_id": "rno03050", "pubmed_id": "40412558", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Rattus norvegicus (rat)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation, SMAD family member 2, Fibronectin 1 (expression), Transforming growth factor beta 1, Calcium-sensing receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Calcium ion promotes the degradation of SMAD family member 2 through the proteasome pathway, which reduces its phosphorylation and inhibits the expression of fibronectin 1. This degradation of SMAD2 suppresses the transcriptional activity of fibronectin, a key component of the extracellular matrix, thereby attenuating extracellular matrix accumulation and potentially mitigating renal fibrosis. This process is independent of SMAD2 gene expression and involves both post-translational and transcriptional regulation of fibronectin."}], "pathway_id": "rno03050", "pubmed_id": "39777704", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Proteasome - Rattus norvegicus (rat)\n**Pathway Description**: The proteasome is a protein-destroying apparatus involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. It is capable of degrading a variety of cellular proteins in a rapid and timely fashion and most substrate proteins are modified by ubiquitin before their degradation by the proteasome. The proteasome is a large protein complex consisting of a proteolytic core called the 20S particle and ancillary factors that regulate its activity in various ways. The most common form is the 26S proteasome containing one 20S core particle and two 19S regulatory particles that enable the proteasome to degrade ubiquitinated proteins by an ATP-dependent mechanism. Another form is the immunoproteasome containing two 11S regulatory particles, PA28 alpha and PA28 beta, which are induced by interferon gamma under the conditions of intensified immune response. Other regulatory particles include PA28 gamma and PA200. Although PA28 gamma also belongs to a family of activators of the 20S proteasome, it is localized within the nucleus and forms a homoheptamer. PA28 gamma has been implicated in the regulation of cell cycle progression and apoptosis. PA200 has been identified as a large nuclear protein that stimulates proteasomal hydrolysis of peptides.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gastrodin (administration), MG-132, HTT, 20S proteasome (colocalization with mutant huntingtin protein), LC3B, SQSTM1, LAMP1, RBM33, HCN1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gastrodin promotes the degradation of mutant huntingtin protein (mHtt) by enhancing the activity of the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway (ALP). It increases the colocalization of the 20S proteasome with mHtt and restores proteasome peptidase activity, which is suppressed in the presence of mHtt. Additionally, Gastrodin enhances the interaction between LC3B and lysosomal membrane protein 1 (LAMP1), indicating activation of ALP. These effects are associated with reduced mHtt aggregation and protection against mHtt-induced neuronal damage."}], "pathway_id": "rno03050", "pubmed_id": "39062952", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RGS9 (reduced expression), HTR2C (reduced expression), PDYN (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of RGS9, HTR2C, and PDYN in the medial prefrontal cortex correlates with altered dopaminergic, serotonergic, and peptidergic signaling. These changes contribute to impaired social novelty discrimination and modified social behavior, including reduced sociability and increased social interaction. These effects are mediated through neuroactive ligand-receptor interactions, particularly in monoaminergic and peptidergic pathways."}], "pathway_id": "rno04082", "pubmed_id": "38920671", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Formaldehyde, CHRNA7, ADRA2A, ADRB2, NOS2 (down-regulated), phospho-ERK (down-regulated), PI3K (down-regulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Regulation of neuroactive ligand-receptor interactions involving CHRNA7, ADRA2A, and ADRB2 modulates pain signaling pathways. Down-regulation of NOS2, phospho-ERK, and PI3K in spinal microglia contributes to the suppression of inflammatory responses and nociceptive signaling. This mechanism is associated with reduced mechanical, thermal, and cold pain thresholds, as well as improved gait behavior. The interaction between neuroactive ligands and their receptors plays a central role in the modulation of pain and neuroinflammation through the HIF-1 signaling pathway."}], "pathway_id": "rno04082", "pubmed_id": "38212003", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calb2, Rsph1, Ccdc114, Acta2, Ttll9, Dnah1, Dlx2, Dlx1, Ccdc40, Ccdc113.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuroactive ligand-receptor interactions modulate synaptic transmission and cellular signaling in response to extracellular signals. These interactions are associated with dopaminergic synapse activity, long-term depression, and axon guidance, which are essential for cognitive function and neural plasticity. Disruption of these pathways contributes to poststroke cognitive impairment. Key genes such as Calb2, Dlx2, and Dlx1 are involved in these signaling processes, influencing receptor expression and synaptic function."}], "pathway_id": "rno04082", "pubmed_id": "34280480", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Synephrine (administration), Paeoniflorin (administration), Naringin (administration), ADRA2A, HTR2A, F2RL1, F2RL3, TRPV1, Protein Kinase C, Protein Kinase A, Interleukin-1 Beta, Nerve Growth Factor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Synephrine, paeoniflorin, and naringin modulate neuroactive ligand-receptor interaction pathways by targeting key proteins such as ADRA2A, HTR2A, TRPV1, PKC, and PKA. These compounds also influence inflammatory processes through F2RL1, F2RL3, and IL-1, while affecting neurotrophic signaling via NGF. This coordinated modulation contributes to the regulation of visceral hypersensitivity and the amelioration of irritable bowel syndrome symptoms."}], "pathway_id": "rno04082", "pubmed_id": "33845366", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hesperidin (administration), isochlorogenic acid A (administration), 4,5-Dicaffeoylquinic acid, 3,4-Dicaffeoylquinic acid, Chlorogenic Acid (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hesperidin, isochlorogenic acid A, isochlorogenic acid B, isochlorogenic acid C, and chlorogenic acid regulate multiple signaling pathways involved in neuroactive ligand-receptor interaction, protein digestion and absorption, cholesterol metabolism, and AGE/RAGE signaling. These compounds exert synergistic effects that modulate receptor-ligand interactions on the cell membrane, influencing intracellular signaling cascades associated with anxiety. Their combined action leads to an attenuation of anxiety-related behaviors and neurochemical imbalances."}], "pathway_id": "rno04082", "pubmed_id": "33069789", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GNG13, C3, CCL2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuroactive ligand-receptor interactions contribute to the development of neuropathic pain through the activation of inflammatory and immune responses. Genes such as GNG13, C3, and CCL2 are involved in these signaling processes, promoting chemotaxis and cytokine-receptor interactions. These molecular events are closely associated with the complement and coagulation cascades, which further modulate pain-related neuroinflammatory conditions."}], "pathway_id": "rno04082", "pubmed_id": "32536116", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (synthesized), ALAS2 (defects), FTH1 (mutations), FTL (mutations), SLC25A38 (defects), FECH (defects), ALAD (defects), PPOX (defects), UROD (defects), CPOX (defects), HMBS (defects).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "5-aminolevulinic acid (5-ALA) is synthesized by ALAS2 and is a precursor in the heme biosynthesis pathway. Defects in genes such as FECH, ALAD, PPOX, UROD, CPOX, and HMBS disrupt heme production, leading to the accumulation of toxic intermediates like protoporphyrin. This results in protoporphyria, characterized by neurological and hepatic dysfunction. Disruption of ALAS2 or SLC25A38 affects mitochondrial iron homeostasis, contributing to anemia and iron overload. Mutations in FTH1 and FTL impair iron storage, leading to ferroportin deficiency and systemic iron accumulation. These perturbations in heme and iron metabolism contribute to neurodegeneration, cognitive impairment, and developmental delay."}], "pathway_id": "rno04082", "pubmed_id": "33771644", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Chlorobiphenyl (elevated exposure), neurotransmission ligand receptors (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated exposure to 2-chlorobiphenyl during gestation and lactation leads to reduced expression of neurotransmission ligand receptors in the striatum, cerebral cortex, and hippocampus of male offspring. This reduction is associated with impaired neuroactive ligand receptor interactions and synaptic dysfunction, contributing to neurodevelopmental and neurobehavioral alterations."}], "pathway_id": "rno04082", "pubmed_id": "32402713", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Monocrotaline, Gamma-Aminobutyric Acid, Svop, adrenergic receptor alpha-1 (dysregulated expression), adrenergic receptor beta-1 (dysregulated expression), adrenergic receptor beta-2 (dysregulated expression), cholinergic receptors (dysregulated expression), gamma-aminobutyric acid receptors (impaired function).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulated expression of neuroactive ligand receptors, including cholinergic and adrenergic receptors such as alpha1, beta1, and beta2 subtypes, contributes to pulmonary vascular remodeling and elevated pulmonary artery pressure. Concurrently, impaired gamma-aminobutyric acid receptor function and altered inflammatory responses are associated with the progression of pulmonary arterial hypertension."}], "pathway_id": "rno04082", "pubmed_id": "32176619", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, SNCA, CHRM2 (increased expression), CHRNA2 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of CHRNA2 at the cell membrane enhances cholinergic signaling, which activates the neuroactive ligand receptor interaction pathway. This signaling promotes neurogenesis and supports motor function recovery following spinal cord injury. The -synuclein protein modulates these processes, with its knockdown leading to increased expression of CHRM2 and CHRNA2, thereby enhancing cholinergic synaptic transmission and receptor interaction."}], "pathway_id": "rno04082", "pubmed_id": "31726970", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neuroactive ligand signaling - Rattus norvegicus (rat)\n**Pathway Description**: Neuroactive ligand signaling is a process where receptors and ligands on the cell membrane initiate intracellular signaling pathways. It plays a crucial role in the development of various brain disorders.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Morphine (administration), PD-168077, OPRM1 (bound by Morphine), DRD4 (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Morphine binds to the  opioid receptor (OPRM1), inducing alterations in intracellular signaling pathways that contribute to the development of addiction. Activation of the dopamine D4 receptor (DRD4) counteracts these morphine-induced changes by modulating transcriptional networks and adaptive signaling. This interaction influences the nigrostriatal dopamine pathway and leads to distinct transcriptional profiles that reflect functional integration between OPRM1 and DRD4. The combined activation of these receptors results in altered gene expression patterns, including enrichment in neuroactive ligand receptor interaction pathways."}], "pathway_id": "rno04082", "pubmed_id": "29743514", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: TNF signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Tumor necrosis factor (TNF), as a critical cytokine, can induce a wide range of intracellular signal pathways including apoptosis and cell survival as well as inflammation and immunity. Activated TNF is assembled to a homotrimer and binds to its receptors (TNFR1, TNFR2) resulting in the trimerization of TNFR1 or TNFR2. TNFR1 is expressed by nearly all cells and is the major receptor for TNF (also called TNF-alpha). In contrast, TNFR2 is expressed in limited cells such as CD4 and CD8 T lymphocytes, endothelial cells, microglia, oligodendrocytes, neuron subtypes, cardiac myocytes, thymocytes and human mesenchymal stem cells. It is the receptor for both TNF and LTA (also called TNF-beta). Upon binding of the ligand, TNFR mediates the association of some adaptor proteins such as TRADD or TRAF2, which in turn initiate recruitment of signal transducers. TNFR1 signaling induces activation of many genes, primarily controlled by two distinct pathways, NF-kappa B pathway and the MAPK cascade, or apoptosis and necroptosis. TNFR2 signaling activates NF-kappa B pathway including PI3K-dependent NF-kappa B pathway and JNK pathway leading to survival.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Octopamine, Ferulic Acid, Apigenin-8-C-glucoside-2'-rhamnoside, TNF (downregulation), IL1B, MAPK, NFKB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of TNF induce inflammatory signaling through the activation of NF-B and MAPK pathways. Downregulation of TNF and suppression of NF-B and MAPK signaling reduces the production of pro-inflammatory mediators such as IL-1 and nitric oxide. Inhibition of these pathways also attenuates leukocyte and neutrophil infiltration, contributing to the overall anti-inflammatory effect. Concurrently, suppression of oxidative stress through enhanced antioxidant defenses further supports the reduction of inflammatory damage."}], "pathway_id": "rno04668", "pubmed_id": "41302395", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Rattus norvegicus (rat)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid, CRF receptor 1, Protein kinase A, small-conductance calcium-activated potassium channel, large-conductance calcium-activated potassium channel, KCNN2, corticotropin-releasing hormone, corticotropin-releasing hormone receptor 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Corticotropin-releasing factor (CRF) activates its receptor CRF receptor 1 (CRFR1), leading to the activation of protein kinase A (PKA). This signaling cascade modulates the activity of small-conductance (SK-type) and large-conductance (BK-type) calcium-activated potassium channels, increasing neuronal excitability. CRF also suppresses GABAergic synaptic transmission onto lateral habenula neurons through retrograde endocannabinoid signaling, which inhibits presynaptic neurotransmitter release. This mechanism contributes to depolarization-induced suppression of inhibition (DSI), a form of short-term synaptic plasticity."}], "pathway_id": "rno04723", "pubmed_id": "29511121", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Rattus norvegicus (rat)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Arachidonylglycerol, CB1, MT1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "2-arachidonoylglycerol (2-AG) acts as a key endocannabinoid within the hypophysial pars tuberalis (PT), where it activates the CB1 receptor. This signaling contributes to both retrograde and anterograde pathways that regulate hypothalamic thyroid hormone conversion and prolactin secretion. Activation of CB1 receptors on folliculo-stellate and corticotroph cells modulates neuroendocrine and stress responses. Melatonin, via MT1 receptors, influences PT function by encoding photoperiodic information. These interactions support the PT's role in seasonal rhythm regulation and hypothalamic-pituitary communication."}], "pathway_id": "rno04723", "pubmed_id": "28511899", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Rattus norvegicus (rat)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Win 55212-2, N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide, Cannabinoid receptor 1 (CB1R) (activation), Gamma-aminobutyric acid (release).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cannabinoid receptor 1 (CB1R) activation inhibits gamma-aminobutyric acid (GABA) release through retrograde endocannabinoid signaling. This mechanism reduces GABAergic transmission at presynaptic terminals, modulating anxiety and stress responses. Chronic ethanol exposure disrupts this signaling, leading to diminished CB1R-mediated suppression of GABA release and contributing to anxiogenesis."}], "pathway_id": "rno04723", "pubmed_id": "26786379", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Retrograde endocannabinoid signaling - Rattus norvegicus (rat)\n**Pathway Description**: Endogenous cannabinoids (endocannabinoids) serve as retrograde messengers at synapses in various regions of the brain. The family of endocannabinoids includes at least five derivatives of arachidonic acid; the two best characterized are arachydonoyl ethanolamide (anandamide, AEA) and 2-arachydonoil glycerol (2AG). They are released from postsynaptic neurons upon postsynaptic depolarization and/or receptor activation. The released endocannabinoids then activate the CB1 receptors (CB1R) at presynaptic terminals and suppress the release of inhibitory transmitter GABA (depolarization-induced suppression of inhibition, DSI) or excitatory transmitter glutamate (depolarization-induced suppression of excitation, DSE) by inhibiting Ca2+ channels. Besides the well-known expression of the CB1R in the plasma membrane, this receptor is also present in mitochondrial membranes, where it reduces the mitochondrial respiration and contributes to DSI. Whereas DSI and DSE result in short-term synaptic plasticity, endocannabinoids also mediate long-term synaptic changes (eCB-LTD). Persistent activation of CB1 receptors over a period of minutes triggers eCB-LTD by a RIM1alpha-dependent mechanism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-Arachidonylglycerol (synthesis), Orlistat, N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide, Protease-activated receptor 1 (stimulated), Cannabinoid receptor 1 (activated), Diacylglycerol lipase (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Stimulation of Protease-activated receptor 1 (PAR1) induces retrograde endocannabinoid signaling through the synthesis of 2-arachidonoylglycerol (2-AG), which activates Cannabinoid receptor 1 (CB1R). Activation of CB1R in the lateral hypothalamus promotes rapid eye movement sleep (REMS) and increases food intake. Inhibition of Diacylglycerol lipase (DAGL), the enzyme responsible for 2-AG synthesis, blocks these effects, indicating that 2-AG serves as an upstream mediator of PAR1-induced changes in sleep and feeding behavior."}], "pathway_id": "rno04723", "pubmed_id": "24996194", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tetrodotoxin, Secretin receptor, Inositol 1,4,5-trisphosphate receptor (inhibited), Protein kinase A (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Secretin binds to secretin receptors expressed in interstitial cells of Cajal (ICC) of the deep muscular plexus (ICC-DMP), triggering Gs-coupled cAMP production and subsequent activation of protein kinase A (PKA). PKA then inhibits inositol 1,4,5-trisphosphate (IP3) receptors, leading to suppression of intracellular calcium (Ca2+) transients in ICC-DMP. This inhibition reduces intestinal contractions and suppresses excitatory enteric neurotransmission."}], "pathway_id": "rno04024", "pubmed_id": "41198902", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (S)-4-((S)-2-Phenyl-butyl)-4,5-dihydro-oxazol-2-ylamine, Epptb, L-Tyrosine,N-(1-oxooctadecyl)-L-a-aspartyl-L-leucyl-L-isoleucyl-L-a-glutamyl-L-a-glutamyl-L-alanyl-L-alanyl-L-seryl-L-arginyl-L-isoleucyl-L-valyl-L-a-aspartyl-L-alanyl-L-valyl-L-isoleucyl-L-a-glutamyl-L-glutaminyl-L-valyl-L-lysyl-L-alanyl-L-alanylglycyl-L-alanyl-, Camp, TAAR1 (activated), PKA (activated), Epac 2 (activated), CaMKII (activated), Adenylyl cyclase, A-kinase anchoring proteins.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of TAAR1 by RO5256390 induces intracellular calcium signaling through both extracellular calcium influx and intracellular calcium release. This response is mediated by adenylyl cyclase and requires localized protein kinase A (PKA) activity, which is anchored to microdomains via A-kinase anchoring proteins (AKAPs). Displacement of PKA from AKAPs reduces the calcium response, indicating the importance of spatially restricted signaling. Epac 2, but not Epac 1, and downstream calmodulin-dependent protein kinase II (CaMKII) are essential for the calcium response, highlighting the role of a cAMP-regulated network in coordinating calcium entry and release."}], "pathway_id": "rno04024", "pubmed_id": "41338995", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Urocortin-2, Corticotropin-Releasing Hormone Receptor 2, Protein Kinase A (activation), cAMP Response Element-Binding Protein (upregulation), B-cell lymphoma 2 (upregulation), Nuclear Factor Kappa B (suppression), Ras Homolog Family Member A (downregulation), BCL2-Associated X Protein (upregulation), Glial Cell-Derived Neurotrophic Factor (enhanced secretion).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Urocortin 2 binds to Corticotropin-Releasing Hormone Receptor 2, activating the cAMP-PKA signaling pathway. This activation leads to phosphorylation and upregulation of cAMP Response Element-Binding Protein and B-cell lymphoma 2, promoting neuronal survival and axonal regeneration. Concurrently, it suppresses Nuclear Factor Kappa B signaling and downregulates RhoA and BCL2-Associated X Protein, reducing apoptosis and neuroinflammation. Additionally, Urocortin 2 promotes the conversion of A1 astrocytes to A2 astrocytes and enhances Glial Cell-Derived Neurotrophic Factor secretion, supporting a regenerative environment."}], "pathway_id": "rno04024", "pubmed_id": "40946945", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cAMP signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: cAMP is one of the most common and universal second messengers, and its formation is promoted by adenylyl cyclase (AC) activation after ligation of G protein-coupled receptors (GPCRs) by ligands including hormones, neurotransmitters, and other signaling molecules. cAMP regulates pivotal physiologic processes including metabolism, secretion, calcium homeostasis, muscle contraction, cell fate, and gene transcription. cAMP acts directly on three main targets: protein kinase A (PKA), the exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated ion channels (CNGCs). PKA modulates, via phosphorylation, a number of cellular substrates, including transcription factors, ion channels, transporters, exchangers, intracellular Ca2+ -handling proteins, and the contractile machinery. Epac proteins function as guanine nucleotide exchange factors (GEFs) for both Rap1 and Rap2. Various effector proteins, including adaptor proteins implicated in modulation of the actin cytoskeleton, regulators of G proteins of the Rho family, and phospholipases, relay signaling downstream from Rap.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Forskolin (administered), Cyclic AMP, Protein Kinase A (activated by Forskolin), Phosphorylated Protein Kinase A (restored levels), Paired box 6 (restored expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of the cAMP-PKA signaling pathway reduces phosphorylated Protein Kinase A (P-PKA) levels, which in turn decreases the transcription of Pax6. This leads to abnormal differentiation of conjunctival stem cells (CjSCs), impairing their stemness and proliferation. Activation of the cAMP-PKA pathway with Forskolin restores P-PKA levels and rescues the differentiation defect, thereby mitigating the pathogenic effects associated with impaired stem cell function."}], "pathway_id": "rno04024", "pubmed_id": "40912100", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Sulfide (H2S-induced vasodilation), Filipin, ATP-binding cassette sub-family A member 1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Shear stress increases the expression of ATP-binding cassette sub-family A member 1 (ABCA1) in endothelial cells, which facilitates the efflux of membrane cholesterol. This reduction in membrane cholesterol content enhances hydrogen sulfide (H2S)-dependent vasodilation. Inhibition of ABCA1 results in elevated membrane cholesterol levels and impairs H2S-induced vasodilation, indicating that ABCA1-mediated cholesterol transport is essential for maintaining endothelial function and blood vessel relaxation."}], "pathway_id": "rno02010", "pubmed_id": "41047668", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bardoxolone Methyl (administration), Oleanolic Acid, Bile salt export pump (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Bardoxolone methyl reduces the expression of the bile salt export pump, leading to cholestasis in rats. This reduction in bile salt export impairs hepatobiliary function and increases the risk of cholangioma formation."}], "pathway_id": "rno02010", "pubmed_id": "41320260", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rosmarinic Acid (administration), Uric Acid (elevated levels), ATP-binding cassette sub-family G member 2 (upregulated expression), urate transporter 1 (upregulated expression), solute carrier family 2 member 9, xanthine oxidase, adenosine deaminase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of uric acid contribute to hyperuricemia and associated renal and intestinal dysfunctions. Rosmarinic acid modulates the expression of ATP-binding cassette sub-family G member 2 (ABCG2) in the intestine and kidney, and urate transporter 1 (URAT1) in the kidney, thereby promoting uric acid excretion. Rosmarinic acid binds tightly to these transporters, as demonstrated by molecular dynamics simulations, reducing the equilibrium dissociation constants with URAT1 and ABCG2. This interaction enhances the elimination of uric acid and ameliorates hyperuricemia by restoring renal and intestinal function. Additionally, rosmarinic acid inhibits xanthine oxidase and adenosine deaminase activities, further decreasing uric acid production."}], "pathway_id": "rno02010", "pubmed_id": "40684489", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ABCB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced placental expression of P-glycoprotein (ABCB1) is associated with obesity and leads to placental dysfunction. This reduction may increase susceptibility to P-gp substrates, potentially contributing to fetal growth restriction and an elevated risk of pregnancy complications."}], "pathway_id": "rno02010", "pubmed_id": "40725223", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Pimonidazole, Methylene Blue, Ferrostatin-1, Deferoxamine, Liproxstatin-1, solute carrier family 7 member 11, glutathione peroxidase 4, acyl-CoA synthetase long-chain family member 4, nuclear receptor coactivator 4, ferritin heavy chain 1, ferritin light chain.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid peroxidation. This process is driven by the depletion of glutathione peroxidase 4 (GPX4), a key enzyme that reduces lipid hydroperoxides. SLC7A11, a system xc subunit, facilitates cystine uptake, which is essential for glutathione synthesis and GPX4 activity. Reduced SLC7A11 expression leads to cystine starvation, glutathione depletion, and subsequent GPX4 inactivation. Acyl-CoA synthetase long-chain family member 4 (ACSL4) promotes the incorporation of polyunsaturated fatty acids into membrane phospholipids, increasing susceptibility to peroxidation. Nuclear receptor coactivator 4 (NCOA4) mediates ferritinophagy, the selective autophagy of ferritin, resulting in intracellular iron release. Elevated iron levels, combined with lipid peroxidation, lead to oxidative stress and membrane damage, culminating in ferroptosis. Ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL) regulate intracellular iron homeostasis, with their downregulation contributing to iron accumulation and ferroptotic cell death."}], "pathway_id": "rno02010", "pubmed_id": "40869211", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glutathione, Cadmium (elevated levels), MK-571 sodium (administration), ABCC1, ATP-binding cassette transporter family.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cadmium in the renal tissue promote nephrotoxicity. The ATP-binding cassette transporter ABCC1 facilitates cadmium efflux from renal cells. Glutathione enhances this efflux by increasing ABCC1 activity, likely through direct binding to the transporter. Inhibition of ABCC1 with MK571 reduces cadmium efflux, indicating that ABCC1 plays a critical role in the renal excretion of cadmium."}], "pathway_id": "rno02010", "pubmed_id": "40659077", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: ABC transporters - Rattus norvegicus (rat)\n**Pathway Description**: The ATP-binding cassette (ABC) transporters form one of the largest known protein families, and are widespread in bacteria, archaea, and eukaryotes. They couple ATP hydrolysis to active transport of a wide variety of substrates such as ions, sugars, lipids, sterols, peptides, proteins, and drugs. The structure of a prokaryotic ABC transporter usually consists of three components; typically two integral membrane proteins each having six transmembrane segments, two peripheral proteins that bind and hydrolyze ATP, and a periplasmic (or lipoprotein) substrate-binding protein. Many of the genes for the three components form operons as in fact observed in many bacterial and archaeal genomes. On the other hand, in a typical eukaryotic ABC transporter, the membrane spanning protein and the ATP-binding protein are fused, forming a multi-domain protein with the membrane-spanning domain (MSD) and the nucleotide-binding domain (NBD).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cinnamaldehyde (administration), Puerarin (increased bioavailability), Verapamil, Ko 143, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, P-glycoprotein, multidrug resistance-associated protein, ATP-binding cassette transporter.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "P-glycoprotein and multidrug resistance-associated protein mediate the efflux transport of puerarin, limiting its absorption. Cinnamaldehyde reduces the efflux ratio of puerarin by inhibiting these efflux transporters, thereby enhancing its absorption and cellular retention. This increased bioavailability of puerarin contributes to reduced cerebral infarction and attenuated inflammatory damage in ischemic stroke. Concurrently, cinnamaldehyde promotes the release of anti-inflammatory factors, further supporting neuroprotection."}], "pathway_id": "rno02010", "pubmed_id": "40381675", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PPP1R32 (reduced expression), CDH1 (reduced expression), CTNNB1 (reduced expression), CASP3 (cleavage).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of PPP1R32 disrupts adherens junctions in polarized ependymal cells by causing delocalization or reduced expression of CDH1 and CTNNB1. This disruption leads to cell detachment and apoptosis, as evidenced by cleavage of CASP3. These molecular changes result in ependymal cell denudation and ventriculomegaly."}], "pathway_id": "rno04520", "pubmed_id": "34535732", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PPM1G, CTNNA1 (dephosphorylated), CTNNB1, JAM2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PPM1G dephosphorylates -catenin, maintaining its proper localization at the cell membrane and preserving the integrity of adherens junctions. Loss of PPM1G activity results in increased phosphorylation of -catenin, leading to its cytoplasmic mislocalization and disruption of the actin cytoskeleton. These changes compromise the structure and function of adherens junctions, impairing the blood-testis barrier. Concurrently, reduced expression of JAM2 and increased phosphorylation of -catenin contribute to Sertoli cell dysfunction and apoptosis."}], "pathway_id": "rno04520", "pubmed_id": "39952314", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CTNNA1, CTNNB1, ARPC2, ACTN1, CTNNB1 (phospho Y654) (phosphorylated (Y654)), VCL, Zyxin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "During epithelial-mesenchymal transition, -catenin accumulates at the leading edges of migrating cells alongside ArpC2 and -actinin, promoting actin cytoskeleton remodeling. Phosphorylated -catenin (Y654) localizes to integrin adhesion complexes, where it associates with -catenin, vinculin, zyxin, and -actinin. These interactions suggest that catenins not engaged in adherens junctions contribute to cell migration by modulating integrin-mediated adhesion and actin dynamics."}], "pathway_id": "rno04520", "pubmed_id": "38727316", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (elevated levels), Hemin, ALAS1 (mutated), ALAS2, FECH (mutated), ALAD, CPOX, PPOX, UROD, UROS, HMBS (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid and protoporphyrin IX in the blood and urine are indicative of disruptions in heme biosynthesis. Accumulation of these intermediates is associated with the clinical manifestations of porphyria, including photosensitivity and neurovisceral symptoms. Mutations in genes encoding enzymes such as ALAS1, FECH, and HMBS lead to impaired heme synthesis, resulting in the accumulation of porphyrins and their precursors. This biochemical dysregulation is directly linked to the development of erythropoietic protoporphyria and porphyria cutanea tarda. In hepatic porphyria, the accumulation of 5-aminolevulinic acid and protoporphyrin IX is associated with oxidative stress and mitochondrial dysfunction, contributing to the pathophysiology of the disease."}], "pathway_id": "rno04520", "pubmed_id": "33605402", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon Tetrachloride, CDH1, WWTR1, TGFB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dissociation of E-cadherin-containing adherens junctions between hepatic stellate cells and hepatocytes leads to increased TAZ-mediated mechanotransduction, promoting hepatic stellate cell activation. Reconstitution of these junctions through E-cadherin expression suppresses TAZ activity and maintains a quiescent state in hepatic stellate cells."}], "pathway_id": "rno04520", "pubmed_id": "33345995", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ZO-1, CTNNB1 (stabilized at the membrane).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CTNNB1 localizes to adherens junctions and contributes to the maintenance of endothelial barrier integrity. A decrease in cytosolic CTNNB1 is associated with reduced cerebral edema formation. Stabilization of CTNNB1 at the membrane may preserve adherens junction integrity and limit vascular leakage."}], "pathway_id": "rno04520", "pubmed_id": "32068571", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Adherens junction - Rattus norvegicus (rat)\n**Pathway Description**: Cell-cell adherens junctions (AJs), the most common type of intercellular adhesions, are important for maintaining tissue architecture and cell polarity and can limit cell movement and proliferation. At AJs, E-cadherin serves as an essential cell adhesion molecules (CAMs). The cytoplasmic tail binds beta-catenin, which in turn binds alpha-catenin. Alpha-catenin is associated with F-actin bundles directly and indirectly. The integrity of the cadherin-catenin complex is negatively regulated by phosphorylation of beta-catenin by receptor tyrosine kinases (RTKs) and cytoplasmic tyrosine kinases (Fer, Fyn, Yes, and Src), which leads to dissociation of the cadherin-catenin complex. Integrity of this complex is positively regulated by beta -catenin phosphorylation by casein kinase II, and dephosphorylation by protein tyrosine phosphatases. Changes in the phosphorylation state of beta-catenin affect cell-cell adhesion, cell migration and the level of signaling beta-catenin. Wnt signaling acts as a positive regulator of beta-catenin by inhibiting beta-catenin degradation, which stabilizes beta-catenin, and causes its accumulation. Cadherin may acts as a negative regulator of signaling beta-catenin as it binds beta-catenin at the cell surface and thereby sequesters it from the nucleus. Nectins also function as CAMs at AJs, but are more highly concentrated at AJs than E-cadherin. Nectins transduce signals through Cdc42 and Rac, which reorganize the actin cytoskeleton, regulate the formation of AJs, and strengthen cell-cell adhesion.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: E-cadherin (reduced expression), beta-catenin (reduced expression), claudin-2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of E-cadherin and beta-catenin in the cecal epithelium disrupts adherens junction integrity, leading to impaired cell-cell adhesion and increased intestinal permeability. This structural compromise is associated with heightened visceral sensitivity and contributes to the pathophysiology of intestinal barrier dysfunction."}], "pathway_id": "rno04520", "pubmed_id": "31887835", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Basal cell carcinoma - Rattus norvegicus (rat)\n**Pathway Description**: Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vismodegib (administration), Isopropanol, Hedgehog signaling protein (constitutively active).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Vismodegib inhibits hedgehog signaling, a pathway that is constitutively active in basal cell carcinoma. This inhibition leads to reduced tumor growth and anti-tumour activity. Topical delivery of vismodegib via binary ethosomes enhances localized drug delivery and reduces systemic side effects."}], "pathway_id": "rno05217", "pubmed_id": "31900659", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Basal cell carcinoma - Rattus norvegicus (rat)\n**Pathway Description**: Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: KRT1 (expressed), KRT2 (expressed), KRT10 (expressed), LOR (expressed), KRT4, KRT13, KRT17 (expressed), KRT19 (expressed), GLI2 (robustly expressed), MTOR (elevated levels), BCL2 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GLI2, a downstream effector of hedgehog signaling, is robustly expressed in keratocystic odontogenic tumor and basal cell carcinoma. This expression correlates with elevated levels of keratin 17, mammalian target of rapamycin (MTOR), and BCL2. Keratin 17 and keratin 19 are expressed in a pattern consistent with mucosal squamous epithelium and epithelial appendages, while keratin 1, keratin 2, keratin 10, and loricrin are associated with epidermal differentiation. These distinct keratin expression profiles indicate divergent histological and biological behaviors between keratocystic odontogenic tumor and orthokeratinized odontogenic cyst, reflecting their unique pathogenesis and differentiation patterns."}], "pathway_id": "rno05217", "pubmed_id": "20801488", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Basal cell carcinoma - Rattus norvegicus (rat)\n**Pathway Description**: Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SHH (elevated or altered), PTCH1, SMO, TP53.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated or altered sonic hedgehog (SHH) signaling contributes to the development of basal cell carcinoma (BCC). Mutations in SHH, PATCHED (PTCH1), and SMOOTHENED (SMO) lead to constitutive activation of the SHH signaling pathway, promoting cell proliferation. In contrast, UV-induced SHH mutations identified in xeroderma pigmentosum (XP) patients do not exhibit activating properties and do not induce transformation or proliferation similarly to wild-type SHH. These mutations are localized on the surface of the SHH protein and may alter its interaction with signaling partners, potentially affecting downstream signaling outcomes. Mutations in TP53 are also frequently observed in sporadic BCC, further contributing to uncontrolled cell growth."}], "pathway_id": "rno05217", "pubmed_id": "15150112", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Basal cell carcinoma - Rattus norvegicus (rat)\n**Pathway Description**: Cancer of the skin is the most common cancer in Caucasians and basal cell carcinomas (BCC) account for 90% of all skin cancers. The vast majority of BCC cases are sporadic, though there is a rare familial syndrome basal cell nevus syndrome (BCNS, or Gorlin syndrome) that predisposes to development of BCC. In addition, there is strong epidemiological and genetic evidence that demonstrates UV exposure as a risk factor of prime importance. The development of basal cell carcinoma is associated with constitutive activation of sonic hedgehog signaling. The mutations in SMOH, PTCH1, and SHH in BCCs result in continuous activation of target genes. At a cellular level, sonic hedgehog signaling promotes cell proliferation. Mutations in TP53 are also found with high frequency (>50%) in sporadic BCC.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PTCH1, SHH, SMO (mutant), E1A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activating mutations in the SMO gene lead to constitutive signaling through the Sonic hedgehog (SHH) pathway, promoting cell transformation and oncogenesis. In the absence of PTCH1-mediated inhibition, SMO facilitates continuous SHH signaling, which contributes to the development of basal cell carcinoma. Mutant SMO can cooperate with E1A to transform embryonic fibroblasts in culture and induce BCC-like skin abnormalities in transgenic mice."}], "pathway_id": "rno05217", "pubmed_id": "9422511", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vitamin D3 (Administration), Corticosterone, Brain-Derived Neurotrophic Factor (Suppressed), Vitamin D Receptor, Cyclic GMP-AMP Synthase (Elevated), Stimulator of Interferon Genes (Elevated), Iba1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated cGAS-STING signaling and microglial activation contribute to hippocampal neuroinflammation and are associated with stress-induced depression. Brain-derived neurotrophic factor (BDNF) expression is suppressed in this context, impairing neurotrophic support. Vitamin D3, through the vitamin D receptor (VDR), modulates immune signaling, reduces cGAS-STING activation, attenuates inflammatory gene expression, and enhances BDNF expression in the hippocampus, thereby counteracting the effects of chronic stress."}], "pathway_id": "rno04722", "pubmed_id": "41226472", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Vitamin D3 (elevated levels), Brain-Derived Neurotrophic Factor (regulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cholecalciferol promote hippocampal neuronal reorganization and proliferation, which are associated with the regulation of brain-derived neurotrophic factor (BDNF) signaling. This process contributes to the mitigation of depressive phenotypes and supports neurotrophin signaling, a key pathway in neural survival and plasticity."}], "pathway_id": "rno04722", "pubmed_id": "41131968", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Coenzyme Q10 (administration), Reserpine, PPARGC1A, FNDC5, BDNF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced hippocampal expression of PGC-1 and FNDC5 leads to decreased BDNF production, contributing to cognitive deficits and depressive-like behavior. Coenzyme Q10 administration enhances PGC-1/FNDC5/BDNF pathway activity, which mitigates mechanical allodynia, improves locomotor function, and reduces oxidative stress, thereby ameliorating behavioral and cognitive impairments."}], "pathway_id": "rno04722", "pubmed_id": "41339998", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dexmedetomidine (administration), ADRA2A, PIK3CA, AKT1, CREB1 (phosphorylated), BDNF (upregulated), NTRK2 (upregulated), HMGB1 (suppressed), TLR4 (reduced expression), NFKB1, TNF, CD86 (decreased), CD163 (increased).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dexmedetomidine activates the 2-adrenergic receptor (ADRA2A), which stimulates the PI3K/AKT signaling cascade and promotes CREB phosphorylation. This leads to the upregulation of BDNF and TrkB (NTRK2) gene expression, supporting neuronal survival and remyelination. Concurrently, it suppresses HMGB1, which reduces TLR4 expression and inhibits the NF-B (NFKB1) and TNF- signaling pathways, thereby diminishing neuroinflammation. These effects are accompanied by a shift in immune cell phenotype, as indicated by decreased CD86 and increased CD163 expression, promoting an anti-inflammatory state."}], "pathway_id": "rno04722", "pubmed_id": "41241331", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), protoporphyrin IX (accumulation), ALAS1 (Mutated), ALAS2 (Mutated), FECH (Mutated), PBGD (Mutated), UROS (Mutated), UROD (Mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulation of the heme biosynthesis pathway leads to the accumulation of 5-aminolevulinic acid and protoporphyrin IX, which cause oxidative stress and neurotoxicity. Mutations in enzymes such as ALAS1, ALAS2, FECH, PBGD, UROS, and UROD disrupt the normal flow of heme production, resulting in porphyria and associated symptoms including anemia and neurological dysfunction."}], "pathway_id": "rno04722", "pubmed_id": "41063208", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Gamma-Aminobutyric Acid (restored levels), Malonaldehyde (reduced levels), Nitric Oxide (reduced levels), Glutathione, (2S,3R,4R)-3,4-Bis(1,3-benzodioxol-5-ylmethyl)tetrahydro-2-furanol, dopamine (restored levels), norepinephrine (restored levels), brain-derived neurotrophic factor, cAMP response element-binding protein, caspase-3 (modulated), caspase-9 (modulated), interleukin-6 (reduced levels), interleukin-1 beta (reduced levels), tumor necrosis factor alpha (reduced levels), nuclear factor kappa-light-chain-enhancer of activated B cells.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of methamphetamine induce neurotoxicity through oxidative stress and inflammation, leading to cognitive deficits and apoptotic cell death. Activation of CREB promotes the expression of BDNF, which supports neuronal survival and synaptic plasticity. Modulation of caspase-3 and caspase-9 inhibits apoptosis. Reduction in pro-inflammatory cytokines such as IL-6, IL-1, and TNF-, along with suppression of oxidative markers like MDA and NO, contributes to neuroprotection. Simultaneously, restoration of neurotransmitters including dopamine, norepinephrine, and GABA supports cognitive function. These effects collectively enhance learning and memory by stabilizing neuronal function and reducing neurodegeneration."}], "pathway_id": "rno04722", "pubmed_id": "41010958", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: BDNF (decreased levels), CREB1 (decreased levels), BCL2 (decreased levels), MTOR, WNT.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impaired Wnt/BDNF signaling leads to decreased levels of BDNF, CREB, and BCL2 in the hippocampus, which contributes to disrupted synaptic plasticity and neurogenesis. These molecular changes are associated with the manifestation of autism-like behaviors, including increased grooming and social interaction deficits. Concurrently, upregulated mTOR expression further perturbs neuronal survival and development pathways."}], "pathway_id": "rno04722", "pubmed_id": "41057291", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Neurotrophin signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Neurotrophins are a family of trophic factors involved in differentiation and survival of neural cells. The neurotrophin family consists of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). Neurotrophins exert their functions through engagement of Trk tyrosine kinase receptors or p75 neurotrophin receptor (p75NTR). Neurotrophin/Trk signaling is regulated by connecting a variety of intracellular signaling cascades, which include MAPK pathway, PI-3 kinase pathway, and PLC pathway, transmitting positive signals like enhanced survival and growth. On the other hand, p75NTR transmits both positive and nagative signals. These signals play an important role for neural development and additional higher-order activities such as learning and memory.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Fisetin (administration), Brain-Derived Neurotrophic Factor (upregulated expression), Nerve Growth Factor (upregulated expression), Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (activated), Protein Kinase B (activated), cAMP Response Element-Binding Protein (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fisetin activates olfactory ensheathing cells, which in turn upregulate the expression of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). These factors promote neuronal survival and neurite outgrowth by activating the PI3K/Akt/CREB signaling cascade. This pathway enhances the anti-inflammatory environment and supports neuroprotection in degenerative conditions."}], "pathway_id": "rno04722", "pubmed_id": "40999096", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysine degradation - Rattus norvegicus (rat)\n**Pathway Description**: \n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Lysine, Gamma-Aminobutyric Acid (administered), L-Glutamic Acid (produced), 5'-Atp, 5'-Adp, Lactic Acid, Pyruvic Acid, AASS, ALDH7A1, DHTKD1, HADH, GLUD1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "L-lysine enhances glucose-stimulated insulin secretion (GSIS) through its catabolism mediated by AminoAdipate-Semialdehyde Synthase (AASS). AASS catalyzes the initial steps of lysine degradation in the mitochondria, contributing to glutamate production. This process supports GABA synthesis and signaling, which modulate -cell calcium responses and insulin release. Disruption of AASS activity reduces GABA content and glutamate availability, leading to impaired mitochondrial TCA cycle and oxidative phosphorylation (OXPHOS) function, as indicated by decreased ATP/ADP ratios and elevated lactate/pyruvate ratios. These metabolic alterations disrupt GSIS and are associated with -cell dysfunction observed in type 2 diabetes. Exogenous GABA supplementation restores insulin secretion in  cells with suppressed AASS activity, indicating a dual role for GABA as a metabolic substrate and signaling effector."}], "pathway_id": "rno00310", "pubmed_id": "41167553", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Kaposi sarcoma-associated herpesvirus infection - Rattus norvegicus (rat)\n**Pathway Description**: Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: TLR4 (upregulation), MyD88, CD14, MD2, IL6, IL1B, IL18, STAT3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TLR4 upregulation in KSHV-infected cells promotes chronic inflammation by activating the IL6-mediated STAT3 signaling pathway. This leads to sustained cellular proliferation and transformation, contributing to tumorigenesis. Co-receptors CD14 and MD2 support TLR4 signaling, while MyD88 acts as an adaptor in the TLR4 pathway. Persistent activation of this inflammatory cascade is associated with uncontrolled neoangiogenesis and the development of Kaposi sarcoma."}], "pathway_id": "rno05167", "pubmed_id": "29051178", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lead nitrate (administration), Liothyronine, NRF2, KEAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Lead nitrate induces metabolic reprogramming in hepatocytes, characterized by increased glycolysis and activation of both oxidative and non-oxidative phases of the pentose phosphate pathway, while simultaneously reducing oxidative phosphorylation. This metabolic shift is accompanied by the activation of the KEAP1-NRF2 pathway, which promotes hepatocyte proliferation. NRF2 serves as a central regulator of these metabolic alterations, driving a cancer-like metabolic phenotype in non-tumorigenic hepatocytes."}], "pathway_id": "rno00030", "pubmed_id": "41213925", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Glucose-6-Phosphate, Alloxan monohydrate (administration), G6PD (restored activity), PGD (restored activity), TKT (restored activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucose-6-phosphate is oxidized in the pentose phosphate pathway to generate ribulose-5-phosphate and NADPH. The enzymes glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (PGD), and transketolase (TKT) are essential for this metabolic process. In alloxan-induced diabetes, these enzyme activities are reduced, impairing the pathways amphibolic and energetic functions. Melatonin administration restores the activity of G6PD, PGD, and TKT, thereby supporting the production of NADPH and ribose-5-phosphate and maintaining cellular redox balance and nucleotide biosynthesis."}], "pathway_id": "rno00030", "pubmed_id": "39689200", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nicotinamide Adenine Dinucleotide Phosphate (increased levels), Glutathione (increased levels), Lactic Acid (no increase), Adrenergic receptor beta 3 (activation), Nuclear factor (erythroid-derived 2)-like 2 (activation), Kelch-like ECH-associated protein 1 (S-nitrosation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of adrenergic receptor beta 3 (ADRB3) increases the flux through the pentose-phosphate pathway, leading to elevated production of nicotinamide adenine dinucleotide phosphate (NADPH). This increase in NADPH enhances the synthesis of reduced glutathione, thereby reducing oxidative stress in cardiac myocytes. Concurrently, the pentose-phosphate pathway supports glucose oxidation without increasing lactate production, preserving mitochondrial function and promoting mitochondrial biogenesis. The transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) is activated through S-nitrosation of Kelch-like ECH-associated protein 1 (Keap1), further amplifying antioxidant and metabolic responses."}], "pathway_id": "rno00030", "pubmed_id": "40071326", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Phosphoribosyl Pyrophosphate, 2-(2,6-diaminohexanoylamino)acetic Acid, Transketolase (impaired activity), Zonula occludens-1 (decreased levels), Occludin (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impaired activity of the pentose phosphate pathway is associated with reduced transketolase expression, leading to altered ribose-5P metabolism and disrupted nucleotide biosynthesis. This metabolic disturbance correlates with decreased intestinal tight junction proteins ZO-1 and occludin, resulting in compromised intestinal barrier function. Concurrently, reduced tricarboxylic acid cycle intermediates and folate biosynthesis precursors indicate impaired energy production and one-carbon metabolism in neonatal intestinal tissue."}], "pathway_id": "rno00030", "pubmed_id": "39147244", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nicotinamide Adenine Dinucleotide Phosphate (supplementation), NFE2L2 (activation), KEAP1, G6PD (upregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NRF2 activation redirects glucose metabolism toward the pentose phosphate pathway, leading to increased production of NADPH and nucleotides. This metabolic shift helps prevent stress-induced DNA damage and reduces cardiomyocyte death, thereby protecting against cardiac dysfunction. The protective effects of NRF2 are mediated in part through upregulation of glucose-6-phosphate dehydrogenase, a rate-limiting enzyme of the pentose phosphate pathway. Supplementation with NADPH or nucleosides can rescue the protective effects of NRF2 in the absence of pathway activity."}], "pathway_id": "rno00030", "pubmed_id": "39657243", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nicotinamide Adenine Dinucleotide Phosphate (decreased production), Lactic Acid (increased lactate production), Glutathione (reduced glutathione), Malonaldehyde (elevated malondialdehyde levels), Hypoxia-inducible factor 1, HIF1A (elevated levels), G6PD, LDHA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of HIF1 in the hippocampus promote anaerobic glycolysis while reducing the activity of the pentose phosphate pathway. This leads to decreased production of NADPH and reduced glutathione, impairing antioxidant defenses and resulting in increased oxidative stress, as indicated by elevated malondialdehyde levels. Concurrently, increased lactate production reflects enhanced glycolytic flux under these conditions."}], "pathway_id": "rno00030", "pubmed_id": "37980886", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Pentose phosphate pathway - Rattus norvegicus (rat)\n**Pathway Description**: The pentose phosphate pathway is a process of glucose turnover that produces NADPH as reducing equivalents and pentoses as essential parts of nucleotides. There are two different phases in the pathway. One is irreversible oxidative phase in which glucose-6P is converted to ribulose-5P by oxidative decarboxylation, and NADPH is generated [MD:M00006]. The other is reversible non-oxidative phase in which phosphorylated sugars are interconverted to generate xylulose-5P, ribulose-5P, and ribose-5P [MD:M00007]. Phosphoribosyl pyrophosphate (PRPP) formed from ribose-5P [MD:M00005] is an activated compound used in the biosynthesis of histidine and purine/pyrimidine nucleotides. This pathway map also shows the Entner-Doudoroff pathway where 6-P-gluconate is dehydrated and then cleaved into pyruvate and glyceraldehyde-3P [MD:M00008].\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Copper (administration), Astaxanthin (administration), Glucose-6-phosphate dehydrogenase (activity), 6-Phosphogluconate dehydrogenase (activity), Glutathione reductase (activity), Glutathione S-transferase (activity), Thioredoxin reductase (activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Copper(II) ions inhibit the activity of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD), key enzymes in the pentose phosphate pathway, through non-competitive inhibition. This suppression reduces NADPH production, impairing the antioxidant system by decreasing glutathione reductase (GR), glutathione S-transferase (GST), and thioredoxin reductase (TrxR) activity. These effects contribute to oxidative stress and erythrocyte damage. Astaxanthin mitigates these inhibitory effects, restoring enzyme activity and reducing oxidative damage."}], "pathway_id": "rno00030", "pubmed_id": "34218382", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc gamma R-mediated phagocytosis - Rattus norvegicus (rat)\n**Pathway Description**: Phagocytosis plays an essential role in host-defense mechanisms through the uptake and destruction of infectious pathogens. Specialized cell types including macrophages, neutrophils, and monocytes take part in this process in higher organisms. After opsonization with antibodies (IgG), foreign extracellular materials are recognized by Fc gamma receptors. Cross-linking of Fc gamma receptors initiates a variety of signals mediated by tyrosine phosphorylation of multiple proteins, which lead through the actin cytoskeleton rearrangements and membrane remodeling to the formation of phagosomes. Nascent phagosomes undergo a process of maturation that involves fusion with lysosomes. The acquisition of lysosomal proteases and release of reactive oxygen species are crucial for digestion of engulfed materials in phagosomes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Leukotriene B4, Fc gamma R (ligated), Fc gamma receptor I, BLT1 (phosphorylated), G protein subunit alpha i3, Src (active).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fc gamma RI ligation induces the recruitment of BLT1 into lipid raft microdomains, where it forms a complex with G protein subunit alpha i3, Src kinase, and Fc gamma RI. This complex formation is dependent on Src-mediated phosphorylation of BLT1 and facilitates enhanced antimicrobial and microbicidal activity through improved signaling within lipid rafts."}], "pathway_id": "rno04666", "pubmed_id": "19657115", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Rattus norvegicus (rat)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, SDF2 like 1 (downregulation), Karyopherin alpha 3 (decreased expression), Transcription factor EB (reduced nuclear accumulation), cAMP responsive element binding protein 1 (reduced nuclear accumulation), Microtubule-associated protein 1 light chain 3B (LC3B), Sequestosome 1, Brain-derived neurotrophic factor (decreased expression), Nerve growth factor (decreased expression), Insulin-like growth factor 1 (decreased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SDF2L1 downregulation in Schwann cells leads to decreased KPNA3 expression, which in turn inhibits the nuclear import of transcription factors TFEB and CREB. Reduced nuclear accumulation of TFEB and CREB results in suppressed autophagy and decreased expression of neurotrophic factors such as BDNF, NGF, and IGF. This contributes to Schwann cell dysfunction, including reduced nerve conduction velocity and action potential amplitude, consistent with the pathophysiology of diabetic peripheral neuropathy."}], "pathway_id": "rno03013", "pubmed_id": "40294738", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Rattus norvegicus (rat)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Parishin (administration), UHRF1, GRP78 (deubiquitination).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "GRP78 accumulation in the cytoplasm facilitates its nuclear translocation through interactions with the nucleocytoplasmic transport machinery. This nuclear translocation of GRP78 enhances a gene network associated with endoplasmic reticulum stress and apoptosis, leading to intensified kidney tubular epithelial cell injury. UHRF1 downregulation disrupts both promoter methylation and protein ubiquitination of GRP78, contributing to this dysregulation. Inhibition of GRP78 nuclear translocation, such as by Parishin, mitigates endoplasmic reticulum stress and protects against kidney injury."}], "pathway_id": "rno03013", "pubmed_id": "40865719", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Rattus norvegicus (rat)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: miR-153, KPNA5 (reduced expression), NRF2 (reduced nuclear translocation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "miR-153 suppresses KPNA5 expression by binding to its 3'UTR, thereby inhibiting KPNA5-mediated nuclear translocation of NRF2. Reduced NRF2 nuclear translocation impairs the activation of antioxidant response pathways, leading to increased oxidative stress and contributing to cognitive deficits."}], "pathway_id": "rno03013", "pubmed_id": "40816766", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Rattus norvegicus (rat)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Ferulic Acid (administration), NUP155 (reduced expression), INO80 (reduced expression), TP53 (increased levels), CDKN1A (increased levels), CDKN2A (increased levels), H2AFX (increased levels), IL1B (elevated expression), IL6 (elevated expression), TNF (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "High fructose intake suppresses the nuclear export of INO80 mRNA, leading to reduced INO80 protein expression and induction of podocyte senescence. This effect is mediated through the downregulation of NUP155, a nucleoporin essential for mRNA export. Reduced NUP155 expression inhibits INO80 mRNA nuclear export, which in turn contributes to increased p53, p21, p16, and -H2AX levels, as well as elevated expression of pro-inflammatory cytokines IL-1, IL-6, and TNF-. Ferulic acid counteracts these effects by stabilizing and upregulating NUP155, thereby promoting INO80 mRNA nuclear export and alleviating podocyte senescence."}], "pathway_id": "rno03013", "pubmed_id": "39111625", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Nucleocytoplasmic transport - Rattus norvegicus (rat)\n**Pathway Description**: The exchange of molecules between the nucleus and cytoplasm is mediated through nuclear pore complexes (NPCs) embedded in the nuclear envelope. The NPC is composed of highly conserved, distinct structural modules: the inner pore ring, the cytoplasmic and nuclear rings as well as the cytoplasmic filaments and the nuclear basket. Nuclear transport receptors (e.g. importins and exportins) mediate translocation of cargos through the NPC. Cargo proteins harbouring a nuclear export signal (NES) bind to exportins and Ran-GTP to form an export complex in the nucleoplasm. Nuclear export of bulk mRNA is provided by the non-karyopherin transport proteins TAP-p15 in a Ran-GTP-independent manner. Several EJC factors are known to function in mRNA export.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: mitogen-activated protein kinase (reduced).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "A reduction in nuclear pore numbers decreases the nuclear import of signaling proteins such as mitogen-activated protein kinase, leading to reduced expression of immediate-early genes. This decline in nuclear transport capacity alters cellular responses to extracellular signals and contributes to changes in cardiac function, including reduced progression to heart failure under stress conditions."}], "pathway_id": "rno03013", "pubmed_id": "36283391", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Luteolin (administration), Vitamin D3, nuclear factor kappa B (nuclear translocation), translocase of outer mitochondrial membrane 6 (upregulation during calcification), PTEN-induced putative kinase 1, E3 ubiquitin protein ligase Parkin, bone morphogenetic protein 2, runt-related transcription factor 2, alpha-smooth muscle actin (reduced), smooth muscle protein 22-alpha (reduced), inhibitor of nuclear factor kappa-B kinase subunit alpha and beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Luteolin enhances PINK1/Parkin-mediated mitophagy by downregulating TOM6, thereby improving mitochondrial bioenergetics and attenuating vascular calcification. TOM6 upregulation during calcification promotes osteogenic differentiation and reduces contractile protein expression, while its suppression restores alpha-smooth muscle actin and smooth muscle protein 22-alpha. Inhibition of NF-B nuclear translocation by luteolin through binding to IKK/IKK reduces TOM6 transcription, reinforcing the mitophagy process."}], "pathway_id": "rno04137", "pubmed_id": "41232657", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Protein Phosphatase 1 Regulatory Subunit 17, Yes-Associated Protein 1 (phosphorylated), Protein Phosphatase 1, Protein Phosphatase 2A, PTEN-Induced Putative Kinase 1 (inhibited), E3 Ubiquitin Protein Ligase Parkin (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PPP1R17 suppresses mitophagy by promoting YAP1 phosphorylation, which inhibits YAP1's ability to activate Pink1 and Parkin transcription. This reduction in Pink1 and Parkin expression impairs the recognition and degradation of damaged mitochondria, leading to increased cerebral ischemia and ischemia-reperfusion injury."}], "pathway_id": "rno04137", "pubmed_id": "41276737", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetaminophen, Uric Acid (elevated levels), JNK (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hyperuricemia activates JNK signaling and suppresses mitophagy, leading to increased hepatocyte death and exacerbating acetaminophen-induced liver injury."}], "pathway_id": "rno04137", "pubmed_id": "41173055", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Urolithin A (administration), TFEB, NLRP3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Urolithin A promotes TFEB nuclear translocation, leading to upregulation of autophagy-lysosomal pathway genes. This facilitates the clearance of damaged mitochondria, reduces intracellular reactive oxygen species levels, and suppresses NLRP3 inflammasome activation. These processes collectively support axonal regeneration and remyelination while mitigating neuroinflammation, thereby enhancing peripheral nerve repair."}], "pathway_id": "rno04137", "pubmed_id": "41172819", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Silymarin (administration), mTORC1, AMPK subunit alpha-2, BCL2 (downregulation), PARK2 (reduced expression), MAP1LC3B (downregulation), PINK1 (reduced expression), BECN1, SQSTM1 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of BCL2 and MAP1LC3B are associated with increased mitophagy activity in hepatocytes. Downregulation of BCL2 and MAP1LC3B, along with reduced expression of PARK2 and PINK1, is linked to decreased mitophagy signaling. Increased expression of SQSTM1 suggests impaired autophagic flux. AMPK subunit alpha-2 and mTORC1 are involved in the regulation of mitophagy. Silymarin and exercise training reduce the expression of mitophagy-related genes and proteins, leading to attenuation of excessive mitophagy and potential hepatoprotective effects in the context of non-alcoholic fatty liver disease."}], "pathway_id": "rno04137", "pubmed_id": "41120449", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acacetin (administration), MAPK1, HMOX1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acacetin binds to mitogen-activated protein kinase 1 (MAPK1), inhibiting its expression and thereby relieving the negative regulation of MAPK1 on heme oxygenase 1 (HMOX1). This interaction enhances mitophagy in nucleus pulposus cells, which suppresses pyroptosis and mitigates intervertebral disc degeneration."}], "pathway_id": "rno04137", "pubmed_id": "41135274", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hnf1a (mutated (Q125ter)), Pink1 (suppressed by Hnf1a-Q125ter), Pdha1, Prkn (suppressed by Hnf1a-Q125ter), mTOR, Rps6kb1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hnf1a-Q125ter impairs mitophagy by suppressing the expression of Pink1 and Prkn. This suppression leads to mitochondrial dysfunction characterized by reduced mitochondrial number, decreased oxygen consumption, and altered mitochondrial morphology. Downregulation of the p-mTOR(ser2448)/p-p70S6K(Thr389) signaling pathway further contributes to impaired autophagy, exacerbating mitochondrial damage and energy metabolism deficits."}], "pathway_id": "rno04137", "pubmed_id": "41143604", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (accumulation), protoporphyrin IX (accumulation), ALAS1 (mutated), FECH (mutated), CPOX (mutated), PPOX (mutated), UROD (mutated), UROS (mutated), HMBS (mutated), ALAD (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid and protoporphyrin IX in individuals with porphyria result from impaired heme biosynthesis due to mutations in enzymes such as ALAS1, FECH, CPOX, PPOX, UROD, UROS, HMBS, or ALAD. These enzymatic deficiencies disrupt the normal progression of the heme synthesis pathway, leading to the accumulation of toxic intermediates. The accumulation of 5-aminolevulinic acid and protoporphyrin IX causes photosensitivity, neurological symptoms, abdominal pain, and cutaneous lesions. These phenotypic manifestations are directly linked to the biochemical dysregulation of the heme biosynthetic pathway."}], "pathway_id": "rno04137", "pubmed_id": "41106506", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Fluorouracil, Semaglutide, Exendin(9-39)amide, PINK1, PRKN, NRF2, HMOX1, EIF2AK3, ATF6, HSPA5, DDIT3, STAR, DAZL.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the GLP-1 pathway attenuates testicular dysfunction by enhancing the PINK1/Parkin axis and promoting mitochondrial biogenesis. This process mitigates endoplasmic reticulum stress and oxidative stress through the activation of the Nrf2/HMOX1 signaling pathway. Concurrently, it improves steroidogenesis and spermatogenesis by upregulating STAR and DAZL expression, as well as increasing serum FSH, LH, and testosterone levels. These effects collectively preserve mitochondrial integrity and function, preventing the onset of testicular toxicity."}], "pathway_id": "rno04137", "pubmed_id": "41072890", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Mitophagy - animal - Rattus norvegicus (rat)\n**Pathway Description**: Mitochondria act as the energy powerhouse of the cell, and are essential for eukaryotic cells to grow and function normally. However, deleterious byproducts of oxidative phosphorylation process called reactive oxidative species (ROS) lead to mitochondrial dysfunction. If the damage is too excessive to be repaired, such mitochondria are selectively recognized and targeted for degradation by a specific mode of autophagy, termed mitophagy. The loss of the mitochondrial membrane potential can induce mitophagy, involving the kinase PINK1 and the E3 ligase Parkin. PINK1 serves as the sensor for the mitochondrial depolarization and recruits Parkin, followed by ubiquitin-dependent recruitment of mitophagy receptors. There are also several PINK1/Parkin-independent mitophagy pathways, in which a group of LIR-containing receptors are required in response to different stimuli. Mitophagy contributes to the maintenance of a healthy mitochondrial network and the prevention of programmed cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Atraric Acid (administration), Forkhead Box O3 (nuclear translocation), PTEN-induced putative kinase 1, E3 ubiquitin-protein ligase Parkin, NACHT, LRR and PYD domains-containing protein 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated reactive oxygen species (ROS) levels lead to mitochondrial dysfunction and oxidative stress, contributing to cardiac injury. Activation of the FoxO3a-PINK1/Parkin pathway promotes mitophagy, a selective autophagic process that removes damaged mitochondria. This pathway helps restore mitochondrial function and reduces oxidative damage. Concurrently, NLRP3 inflammasome activation drives inflammatory responses, which are suppressed by the activation of mitophagy. Atraric acid enhances this protective mechanism by promoting FoxO3a nuclear translocation, thereby activating PINK1/Parkin-mediated mitophagy and inhibiting NLRP3 inflammasome activation."}], "pathway_id": "rno04137", "pubmed_id": "41093125", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Rattus norvegicus (rat)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide, Glutathione, Glutathione Disulfide, Glutaredoxin 1, Catalase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "The mammalian peroxisomal membrane is permeable to both reduced and oxidized glutathione, allowing these molecules to equilibrate across the membrane. This permeability facilitates the maintenance of reduced cysteine residues in intraperoxisomal proteins, even in the presence of hydrogen peroxide. Glutathione plays a more significant role than peroxisomal catalase in protecting these proteins from oxidative damage. The absence of a detectable thiol-disulfide oxidoreductase in the peroxisomal matrix suggests that glutathione redox cycling is a key mechanism for preserving intraperoxisomal redox homeostasis."}], "pathway_id": "rno04146", "pubmed_id": "37257275", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Rattus norvegicus (rat)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Clofibric Acid (administration), Glycerophospholipids, cephalins, Arachidonic Acid, Oleic Acid, Palmitic Acid, LPCAT3 (upregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Clofibric acid increases the formation of specific phosphatidylethanolamine (PE) molecular species, particularly those containing arachidonic acid and palmitic acid, which are essential for the biogenesis of peroxisomal membranes. This effect is mediated through both acyl chain remodeling of existing PE molecules, driven by up-regulated expression of the LPCAT3 enzyme, and de novo synthesis of PE containing 16:0-18:1. The increased production of these PE species correlates with an expansion of the peroxisomal membrane mass, leading to peroxisome proliferation in the liver."}], "pathway_id": "rno04146", "pubmed_id": "33945875", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Rattus norvegicus (rat)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methimazole, PEX11B (high levels), Dnm1l (high levels), PEX19 (elevated levels), PEX16 (elevated levels), PEX5 (elevated levels), PEX26 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Peroxisomal biogenesis in brown adipocytes occurs via two distinct pathways: the canonic pathway and the de novo pathway. The canonic pathway is supported by high levels of PEX11B and Dnm1l (Drp1), leading to the formation of dumbbell-like and 'pearls on strings' peroxisomal structures. The de novo pathway becomes prominent over time and is characterized by elevated levels of PEX19, PEX16 (PMP70), PEX5 (Pex5S), and PEX26. This transition from canonic to de novo biogenesis is associated with an increase in peroxisomal number and structural heterogeneity. Peroxisomal origin also involves direct formation from mitochondria, indicating a mutual regulatory relationship between these two organelles in brown adipocytes."}], "pathway_id": "rno04146", "pubmed_id": "34571897", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Rattus norvegicus (rat)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: High mobility group box 1 (translocates), Mitochondrially encoded cytochrome c oxidase I, Catalase, Dynamin-related protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "HMGB1 translocates to mitochondria and peroxisomes in response to ischemic injury. Within these organelles, HMGB1 colocalizes with catalase in peroxisomes and with MTCO1 in mitochondria. This translocation is associated with mitochondrial fission, as HMGB1 also colocalizes with Drp1, a key mediator of mitochondrial division."}], "pathway_id": "rno04146", "pubmed_id": "32155899", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Peroxisome - Rattus norvegicus (rat)\n**Pathway Description**: Peroxisomes are essential organelles that play a key role in redox signalling and lipid homeostasis. They contribute to many crucial metabolic processes such as fatty acid oxidation, biosynthesis of ether lipids and free radical detoxification. The biogenesis of peroxisomes starts with the early peroxins PEX3, PEX16 and PEX19 and proceeds via several steps. The import of membrane proteins into peroxisomes needs PEX19 for recognition, targeting and insertion via docking at PEX3. Matrix proteins in the cytosol are recognized by peroxisomal targeting signals (PTS) and transported to the docking complex at the peroxisomal membrane. Peroxisomes' deficiencies lead to severe and often fatal inherited peroxisomal disorders (PD). PDs are usually classified in two groups. The first group is disorders of peroxisome biogenesis which include Zellweger syndrome, and the second group is single peroxisomal enzyme deficiencies.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide (administration), PEX14 (phosphorylated at Ser232), PEX5, Catalase, PEX14 Ser232Asp mutant.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hydrogen peroxide-induced phosphorylation of PEX14 at Ser232 suppresses the peroxisomal import of catalase. This modification selectively impairs the interaction between catalase and the PEX14-PEX5 complex, leading to increased cytosolic levels of catalase. The cytosolic accumulation of catalase enhances the cell's resistance to oxidative stress, suggesting a regulatory mechanism by which peroxisomes counteract oxidative damage through spatiotemporal control of catalase import."}], "pathway_id": "rno04146", "pubmed_id": "32831175", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Homocysteine (elevated plasma levels), microRNA-155, Signal Transducer and Activator of Transcription 3.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated plasma homocysteine levels activate a miR-155-mediated signaling cascade involving STAT3, which promotes oncogenic transformation and exacerbates benign prostatic hyperplasia by inducing inflammatory and anti-apoptotic pathways."}], "pathway_id": "rno05206", "pubmed_id": "40774579", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Astaxanthin, Doxorubicin, 7,12-Dimethylbenz(a)anthracene, NOTCH1 (decreased protein expression), MicroRNA-34a (elevated levels), CDKN1A (increased protein levels), BIRC5 (protein levels), BAX (increased protein levels), MicroRNA-146a (downregulation), MicroRNA-210 (downregulation), NFKB1 (reduced protein levels), VEGFA (reduced protein levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of miR-34a decrease NOTCH1 protein expression, which contributes to the suppression of cell cycle progression by increasing CDKN1A protein levels and promotes apoptosis by reducing BIRC5 and increasing BAX protein levels. Downregulation of miR-146a and miR-210 is associated with reduced NFKB1 and VEGFA protein levels, indicating a reduction in angiogenesis. These molecular interactions suggest that miR-34a plays a central role in inhibiting tumor progression through the modulation of the NOTCH1 signaling pathway."}], "pathway_id": "rno05206", "pubmed_id": "40447066", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sorafenib, miR-22 (downregulation), SLC2A1, HIF1A.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Downregulation of miR-22 promotes tumor aggressiveness and metabolic reprogramming in hepatocellular carcinoma. miR-22 targets GLUT1, a key glucose transporter, to modulate the HIF1A pathway, leading to a glycolytic shift and enhanced cancer cell plasticity. This contributes to sorafenib resistance by promoting survival under metabolic stress."}], "pathway_id": "rno05206", "pubmed_id": "40332478", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-Methyl-N'-nitro-N-nitrosoguanidine, miR-21 (downregulation), BCL2 (decreased expression), PTEN (restored activity), BAX (increased expression), CASP3 (increased expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of miR-21 suppress PTEN expression, which in turn leads to the downregulation of BAX and CASP3 and the upregulation of BCL2. This imbalance inhibits mitochondrial apoptosis. Downregulation of miR-21 restores PTEN activity, increases BAX and CASP3 expression, and decreases BCL2, thereby promoting mitochondrial swelling, rupture, and apoptosis in precancerous gastric mucosal cells."}], "pathway_id": "rno05206", "pubmed_id": "41084451", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MIR21 (elevated levels), MIR27A (variable expression), MIR221 (elevated levels), MIR429 (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of miR-21 and miR-221 promote oncogenesis by repressing tumor suppressor gene expression. Inhibition of these miRNAs through photodynamic therapy reduces their pro-oncogenic activity, thereby suppressing tumor progression. MiR-27a exhibits variable expression patterns in breast cancer, while miR-429, a tumor-suppressive miRNA, is downregulated in disease progression and remains low despite therapeutic intervention."}], "pathway_id": "rno05206", "pubmed_id": "39945951", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MicroRNAs in cancer - Rattus norvegicus (rat)\n**Pathway Description**: MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21 - 23 nucleotides in length, which controls gene expression post-transcriptionally either via the degradation of target mRNAs or the inhibition of protein translation. Using high-throughput profiling, dysregulation of miRNAs has been widely observed in different stages of cancer. The upregulation (overexpression) of specific miRNAs could lead to the repression of tumor suppressor gene expression, and conversely the downregulation of specific miRNAs could result in an increase of oncogene expression; both these situations induce subsequent malignant effects on cell proliferation, differentiation, and apoptosis that lead to tumor growth and progress. The miRNA signatures of cancer observed in various studies differ significantly. These inconsistencies occur due to the differences in the study populations and methodologies used. This pathway map shows the summarized results from various studies in 9 cancers, each of which is presented in a review article.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MIR21 (elevated expression levels), MIR27A (elevated expression levels), MIR221, MIR429 (significantly higher expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression levels of MIR21 and MIR27A in the thymus are associated with reduced tumor burden following surgical removal and photodynamic therapy in breast cancer. These microRNAs may act as pro-oncogenic regulators, and their increased levels correlate with tumor suppression. In contrast, MIR429, a tumor-suppressive microRNA, shows significantly higher expression in the thymus after treatment, indicating a potential role in restoring normal thymic function and inhibiting oncogenic processes."}], "pathway_id": "rno05206", "pubmed_id": "39777705", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EB1, DSP, GJA1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Desmoplakin (DSP) interacts with end-binding 1 (EB1) at the microtubule plus ends near sites of cell-cell contact. This interaction modulates microtubule organization and dynamics. Disruption of the DSP-EB1 interaction, as seen in certain disease-associated mutations, impairs the membrane targeting and function of connexin 43 (GJA1), a key component of gap junctions. This misregulation contributes to the development of arrhythmogenic cardiomyopathy by disrupting intercellular communication and structural integrity at cell junctions."}], "pathway_id": "rno05412", "pubmed_id": "25225338", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SB 216763 (administered), Plakoglobin (increased), Plakophilin (increased), N-cadherin (increased), Glycogen synthase kinase 3 beta.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in plakoglobin or plakophilin disrupt the shear stress-induced increase in plakoglobin and N-cadherin at cell-cell junctions. This leads to impaired mechanical stress response in cardiac myocytes, resulting in increased apoptosis under shear stress conditions. The abnormal response is mediated through a mechanism involving glycogen synthase kinase 3 beta (GSK3), as inhibition of GSK3 with SB216763 restores normal cellular responses. These disruptions contribute to the pathogenesis of arrhythmogenic right ventricular cardiomyopathy by promoting myocyte death and impairing desmosomal function."}], "pathway_id": "rno05412", "pubmed_id": "25253076", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Arrhythmogenic right ventricular cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease that may result in arrhythmia, heart failure, and sudden death. The hallmark pathological findings are progressive myocyte loss and fibrofatty replacement, with a predilection for the right ventricle. A number of genetic studies have identified mutations in various components of the cardiac desmosome that have important roles in the pathogenesis of ARVC. Disruption of desmosomal function by defective proteins might lead to death of myocytes under mechanical stress. The myocardial injury may be accompanied by inflammation. Since regeneration of cardiac myocytes is limited, repair by fibrofatty replacement occurs. Several studies have implicated that desmosome dysfunction results in the delocalization and nuclear translocation of plakoglobin. As a result, competition between plakoglobin and beta-catenin will lead to the inhibition of Wnt/beta-catenin signaling, resulting in a shift from a myocyte fate towards an adipocyte fate of cells. The ryanodine receptor plays a crucial part in electromechanical coupling by control of release of calcium from the sarcoplasmic reticulum into the cytosol. Therefore, defects in this receptor could result in an imbalance of calcium homeostasis that might trigger cell death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lamr1 (mutated), HP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutant LAMR1 interacts with heterochromatin protein 1 (HP1), leading to alterations in chromatin architecture and specific changes in gene expression in cardiomyocytes. This interaction disrupts transcriptional regulation and contributes to early cell death, resulting in right ventricular dysplasia."}], "pathway_id": "rno05412", "pubmed_id": "14730304", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc epsilon RI signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. Mast cells that are thus activated release preformed granules which contain biogenic amines (especially histamines) and proteoglycans (especially heparin). The activation of phospholipase A2 causes the release of membrane lipids followed by development of lipid mediators such as leukotrienes (LTC4, LTD4 and LTE4) and prostaglandins (especially PDG2). There is also secretion of cytokines, the most important of which are TNF-alpha, IL-4 and IL-5. These mediators and cytokines contribute to inflammatory responses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: IgE-Fc epsilon RI (crosslinked), Lyn, LAT, ERM, Cofilin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Antigen crosslinking of IgE-Fc epsilon RI triggers the recruitment and co-localization of Lyn kinase and the LAT scaffold protein on mast cell microvilli, facilitating the initiation of transmembrane signaling. This process is supported by the localization of signaling proteins within ordered lipid nanodomains, which are enriched in microvillar membranes. The structural interplay between ordered lipid domains and actin-binding proteins ERM and cofilin contributes to the spatial organization of signaling complexes, enabling efficient mast cell activation in response to antigenic stimulation."}], "pathway_id": "rno04664", "pubmed_id": "40674419", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc epsilon RI signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. Mast cells that are thus activated release preformed granules which contain biogenic amines (especially histamines) and proteoglycans (especially heparin). The activation of phospholipase A2 causes the release of membrane lipids followed by development of lipid mediators such as leukotrienes (LTC4, LTD4 and LTE4) and prostaglandins (especially PDG2). There is also secretion of cytokines, the most important of which are TNF-alpha, IL-4 and IL-5. These mediators and cytokines contribute to inflammatory responses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Pioglitazone, peroxisome proliferator-activated receptor gamma (activation), nuclear factor erythroid 2-related factor 2 (activation), carnitine palmitoyltransferase 1A (expression), acyl-CoA synthetase long-chain family member 4 (expression), Fc epsilon RI.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "PPAR- inhibits FcRI-mediated mast cell activation by modulating intracellular signaling pathways. Activation of PPAR- suppresses degranulation and reduces the phosphorylation levels of FcRI signaling molecules. PPAR- agonists upregulate the expression of PPAR-, Cpt1a, and Acsl4 in mast cells. This pathway also involves the NRF2 signaling cascade, which contributes to the anti-inflammatory effects. These molecular interactions collectively dampen the inflammatory response associated with mast cell activation."}], "pathway_id": "rno04664", "pubmed_id": "40057631", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Fc epsilon RI signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. Mast cells that are thus activated release preformed granules which contain biogenic amines (especially histamines) and proteoglycans (especially heparin). The activation of phospholipase A2 causes the release of membrane lipids followed by development of lipid mediators such as leukotrienes (LTC4, LTD4 and LTE4) and prostaglandins (especially PDG2). There is also secretion of cytokines, the most important of which are TNF-alpha, IL-4 and IL-5. These mediators and cytokines contribute to inflammatory responses.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Agk-2 (administration), Sirtuin 2, Fc epsilon RI, Tumor Necrosis Factor Alpha (elevated levels), Interleukin 4 (elevated levels), Interleukin 5 (elevated levels), Nuclear Factor Kappa B, NFE2-Related Factor 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AGK2 inhibits mast cell degranulation by suppressing Fc epsilon RI signaling and intracellular calcium influx. This suppression leads to reduced expression of pro-inflammatory cytokines, including Tumor Necrosis Factor Alpha, Interleukin 4, and Interleukin 5. The inhibition occurs through the regulation of transcription factors Nuclear Factor Kappa B and NFE2-Related Factor 2. Sirtuin 2 promotes mast cell activation, and its inhibition by AGK2 attenuates inflammatory responses and airway inflammation."}], "pathway_id": "rno04664", "pubmed_id": "32565308", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine, Serotonin, neuroligin, neurexin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuroligin and neurexin isoforms contribute to synaptic specificity in the enteric nervous system. Certain isoforms of neuroligin and neurexin promote cholinergic synapse formation, while others facilitate serotonergic synaptogenesis. These cell adhesion molecules recruit presynaptic and postsynaptic elements, respectively, and their alternative splicing modulates the establishment of synaptic connections."}], "pathway_id": "rno04725", "pubmed_id": "40327378", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ginsenoside Rg1 (administration), Acetylcholine (deficient), L-Glutamic Acid (deficient), Adcy1 (activation), Kdr (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of Adcy1 and Kdr enhances cholinergic synapse integrity, leading to improved acetylcholine signaling. Concurrent modulation of the PI3K-AKT pathway attenuates oxidative stress and supports neuronal function. Ginsenoside Rg1 restores amino acid homeostasis and neurotransmitter balance, including acetylcholine and glutamate, thereby alleviating cognitive deficits and neuronal damage."}], "pathway_id": "rno04725", "pubmed_id": "40424986", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Acetylcholine (synthesis), Acetylcholinesterase, Choline transporter, Nicotinic acetylcholine receptor, Muscarinic acetylcholine receptors.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acetylcholine binds to nicotinic acetylcholine receptors and muscarinic acetylcholine receptors, leading to rapid cellular depolarization or modulation of intracellular signaling pathways. Acetylcholine is hydrolyzed by acetylcholinesterase into choline and acetate, with choline being reuptaken via the choline transporter for reuse in acetylcholine synthesis. In the hippocampus, alterations in cholinergic synapse density coincide with changes in oscillatory activity during sleep, particularly in non-REM and REM phases. Increased cholinergic synapses during early amyloid plaque stages partially restore theta-gamma coupling and sharp wave-ripple activity, suggesting a compensatory role of the cholinergic system in maintaining hippocampal network integrity."}], "pathway_id": "rno04725", "pubmed_id": "40349073", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Cholinergic synapse - Rattus norvegicus (rat)\n**Pathway Description**: Acetylcholine (ACh) is a neurotransmitter widely distributed in the central (and also peripheral, autonomic and enteric) nervous system (CNS). In the CNS, ACh facilitates many functions, such as learning, memory, attention and motor control. When released in the synaptic cleft, ACh binds to two distinct types of receptors: Ionotropic nicotinic acetylcholine receptors (nAChR) and metabotropic muscarinic acetylcholine receptors (mAChRs). The activation of nAChR by ACh leads to the rapid influx of Na+ and Ca2+ and subsequent cellular depolarization. Activation of mAChRs is relatively slow (milliseconds to seconds) and, depending on the subtypes present (M1-M5), they directly alter cellular homeostasis of phospholipase C, inositol trisphosphate, cAMP, and free calcium. In the cleft, ACh may also be hydrolyzed by acetylcholinesterase (AChE) into choline and acetate. The choline derived from ACh hydrolysis is recovered by a presynaptic high-affinity choline transporter (CHT).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sirolimus, acetylcholine receptor, mechanistic target of rapamycin complex 1, muscle-specific kinase (increased), Agrin (increased), low-density lipoprotein receptor-related protein 4 (decreased), cholinergic receptor nicotinic beta 1 subunit, cholinergic receptor nicotinic delta subunit, cholinergic receptor nicotinic epsilon subunit, protein kinase B, histone deacetylase 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Acetylcholine receptor (AChR) subunit gene expression is modulated following muscle contraction, with Agrin (Agrn) and muscle-specific kinase (MuSK) playing roles in neuromuscular junction maintenance. During early recovery from contraction, Agrn expression increases while LRP4 decreases. In the late recovery phase, AChR subunit gene expression (Chrnb1, Chrnd, Chrne) and agrin and MuSK protein levels are altered. Mechanistic target of rapamycin complex 1 (mTORC1) and Akt-HDAC signaling are activated in the early phase but not in the late phase. AChR subunit gene expression changes occur independently of the rapamycin-sensitive mTORC1 pathway, as rapamycin treatment does not disrupt these changes and may slightly enhance AChR gene expression in myotubes."}], "pathway_id": "rno04725", "pubmed_id": "39501426", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Alcoholic liver disease - Rattus norvegicus (rat)\n**Pathway Description**: Alcoholic liver disease (ALD) refers to the damages to the liver and its functions due to alcohol overconsumption. It ranges from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Alcohol consumption promotes liver inflammation by increasing the translocation of gut-derived endotoxins to the portal circulation and activating Kupffer cells to produce TNF-alpha through the LPS/Toll like receptor (TLR) 4 pathways. TNF-alpha\u0005 induces hepatocellular damage. When alcohol intake is chronic and heavy, steatosis is caused via generation of acetaldehyde, reactive oxygen species (ROS) and ER stress. ROS inhibits key hepatic transcriptional regulators such as AMP-activated kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-alpha), which are responsible for fatty acid oxidation and export via ACC and CPT-1. The blockade of AMPK also leads to overexpression of SREBP-1, resulting in an increase of de novo lipogenesis. Moreover, excessive intracellular ROS production induced by ethanol and its metabolite have a critical role in ethanol-induced apoptosis, which may be the critical process in the exacerbation of ALD. It is inferred that the apoptotic signal derived from ROS that was produced by NOX, is mainly transduced through the JNK and p38 MAPK pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ethanol (administration), MG-132, valosin-containing protein (reduced), hydroxysteroid (17-beta) dehydrogenase 13 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ethanol-induced reduction of valosin-containing protein (VCP/p97) disrupts the removal of targeted proteins from cellular membranes for degradation. This leads to increased lipid droplet content in hepatocytes and elevated levels of hydroxysteroid dehydrogenase 1713 (HSD1713), which contributes to hepatic steatosis. Disruption of lysosome function and chaperone-mediated autophagy further increases HSD1713 levels, exacerbating lipid accumulation in the liver."}], "pathway_id": "rno04936", "pubmed_id": "40728522", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Alcoholic liver disease - Rattus norvegicus (rat)\n**Pathway Description**: Alcoholic liver disease (ALD) refers to the damages to the liver and its functions due to alcohol overconsumption. It ranges from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Alcohol consumption promotes liver inflammation by increasing the translocation of gut-derived endotoxins to the portal circulation and activating Kupffer cells to produce TNF-alpha through the LPS/Toll like receptor (TLR) 4 pathways. TNF-alpha\u0005 induces hepatocellular damage. When alcohol intake is chronic and heavy, steatosis is caused via generation of acetaldehyde, reactive oxygen species (ROS) and ER stress. ROS inhibits key hepatic transcriptional regulators such as AMP-activated kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-alpha), which are responsible for fatty acid oxidation and export via ACC and CPT-1. The blockade of AMPK also leads to overexpression of SREBP-1, resulting in an increase of de novo lipogenesis. Moreover, excessive intracellular ROS production induced by ethanol and its metabolite have a critical role in ethanol-induced apoptosis, which may be the critical process in the exacerbation of ALD. It is inferred that the apoptotic signal derived from ROS that was produced by NOX, is mainly transduced through the JNK and p38 MAPK pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: SREBF1 (Elevated expression), SLC27A5 (Normal levels), ACAT1 (Increased levels), UGT1A1 (Normal levels), CYP2D10 (Normal levels), HSP90B1 (Normal levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of SREBF1 and SLC27A5 in alcoholic liver disease contributes to steatosis and inflammation through altered lipid metabolism. Increased levels of ACAT1, UGT1A1, and SLC27A5 are associated with lipid accumulation and inflammatory responses. Alcohol abstinence modulates the half-lives of these proteins, restoring normal levels of CYP2D10, UGT1A1, SLC27A5, and HSP90B1, which are regulated by the SREBF1 transcription factor. This modulation reduces oxidative stress, inflammation, and hepatic lipid accumulation by normalizing protein turnover and metabolic pathways."}], "pathway_id": "rno04936", "pubmed_id": "40516455", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Alcoholic liver disease - Rattus norvegicus (rat)\n**Pathway Description**: Alcoholic liver disease (ALD) refers to the damages to the liver and its functions due to alcohol overconsumption. It ranges from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Alcohol consumption promotes liver inflammation by increasing the translocation of gut-derived endotoxins to the portal circulation and activating Kupffer cells to produce TNF-alpha through the LPS/Toll like receptor (TLR) 4 pathways. TNF-alpha\u0005 induces hepatocellular damage. When alcohol intake is chronic and heavy, steatosis is caused via generation of acetaldehyde, reactive oxygen species (ROS) and ER stress. ROS inhibits key hepatic transcriptional regulators such as AMP-activated kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-alpha), which are responsible for fatty acid oxidation and export via ACC and CPT-1. The blockade of AMPK also leads to overexpression of SREBP-1, resulting in an increase of de novo lipogenesis. Moreover, excessive intracellular ROS production induced by ethanol and its metabolite have a critical role in ethanol-induced apoptosis, which may be the critical process in the exacerbation of ALD. It is inferred that the apoptotic signal derived from ROS that was produced by NOX, is mainly transduced through the JNK and p38 MAPK pathways.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Silibinin (administration), Ursodeoxycholate sodium, KEAP1, NFE2L2, HMOX1, BCL2 (increased levels), BAX (decreased levels), CASP3, CASP3 (cleaved) (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Silibinin, when encapsulated in liposomes composed of sodium ursodeoxycholate, reduces alcohol-induced liver damage by mitigating oxidative stress and fat accumulation. It modulates the Nrf2/Keap1/HO-1 pathway to enhance antioxidant defenses. Additionally, it influences apoptotic signaling by increasing BCL2 levels and decreasing BAX, CASP3, and cleaved CASP3, thereby reducing hepatocyte apoptosis."}], "pathway_id": "rno04936", "pubmed_id": "39931930", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, METTL14 (elevated expression), NLRP3 (upregulation), YTHDF1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated METTL14 expression promotes m6A modification of NLRP3, enhancing its stability and contributing to pyroptosis. This process is mediated by the m6A reader protein YTHDF1, which facilitates NLRP3 upregulation. The resulting pyroptosis leads to myocardial damage in the context of diabetic cardiomyopathy."}], "pathway_id": "rno05415", "pubmed_id": "41091242", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Diabetic cardiomyopathy - Rattus norvegicus (rat)\n**Pathway Description**: Diabetic cardiomyopathy has been defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independent of a recognized cause such as coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy broadly involves hyperglycemia, increased circulating fatty acids, and insulin resistance contributing to reactive oxygen species (ROS) generation, mitochondrial dysfunction, impaired calcium metabolism, Renin-Angiotensin System (RAS) activation, and altered substrate metabolism. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, contractile dysfunction, endothelial cell damage and eventually heart failure. In the process of cardiac fibrosis, cardiac fibroblasts are the final effector cell.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Streptozocin, Sitagliptin (administration), VEGF (elevated levels), FLT1 (elevated levels), mTOR (upregulated signaling).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of VEGF and FLT-1 contribute to vascular and myocardial dysfunction in diabetic cardiomyopathy. mTOR signaling is upregulated in this condition, promoting pathological remodeling and stress responses. Sitagliptin reduces oxidative stress and suppresses the expression of VEGF and FLT-1, thereby mitigating inflammation, apoptosis, and myocardial stress. This results in improved vascular health and reduced cardiac fibrosis, ultimately supporting cardiac function."}], "pathway_id": "rno05415", "pubmed_id": "40867548", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Decabromodiphenylethane (exposure), 5-Aminolevulinic Acid, Notch signaling pathway genes, Arrestin domain-containing protein 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Exposure to Decabromodiphenyl ethane increases the production of Arrestin domain-containing protein 1-mediated microvesicles, which directly activate the Notch signaling pathway. Activation of the Notch pathway leads to lipid accumulation and disrupts normal lipid metabolism in the liver."}], "pathway_id": "rno04330", "pubmed_id": "41205570", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: LOXL2 (reduced expression), Notch signaling pathway.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "LOXL2 expression is reduced in degenerated discs and its overexpression inhibits the Notch signaling pathway, thereby delaying cellular senescence in nucleus pulposus cells. This suppression of Notch signaling attenuates oxidative stress and extracellular matrix degradation, which are key contributors to intervertebral disc degeneration."}], "pathway_id": "rno04330", "pubmed_id": "41074010", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Astragaloside IV (administration), microRNA-21 (upregulated), Notch2 (suppressed), Runx2 (increased expression), Osteopontin (elevated expression), Alkaline Phosphatase (elevated activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Astragaloside IV upregulates microRNA-21 (miR-21) expression, which directly targets and suppresses the expression of the Notch2 receptor. Inhibition of Notch2 signaling relieves the suppression of osteogenic differentiation. This leads to increased expression of osteogenesis-related genes such as Runx2 and Osteopontin (OPN), as well as elevated Alkaline Phosphatase (ALP) activity, promoting calcium nodule formation and enhancing the osteogenic capacity of bone marrow mesenchymal stem cells."}], "pathway_id": "rno04330", "pubmed_id": "41184110", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JAG1 (intracellular transport and sorting into exosomes), ALG-2, SEC31A, PDCD6IP, YAP1, SOX9, Notch1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "JAG1 interacts with Notch receptors on recipient cells to activate the Notch signaling pathway. This activation is facilitated by exosomes derived from YAP1-positive, Sox9-positive liver progenitor cells. ALG-2, SEC31A, and PDCD6IP (Alix) are involved in the intracellular transport and sorting of JAG1 into exosomes. YAP1 induces hepatocyte reprogramming into Sox9-positive liver progenitor cells and promotes the release of JAG1-positive exosomes, which in turn activate Notch signaling in neighboring cells, thereby enhancing liver regeneration."}], "pathway_id": "rno04330", "pubmed_id": "40796539", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Icariin (administration), HIF2A (upregulated), VEGFA (upregulated), NOTCH1 (upregulated), NOTCH2 (upregulated), NOTCH3 (upregulated), PDGFB, FGF2, IL10, TGFB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Icariin enhances the reparative capacity of adipose-derived stem cells on skin radiation damage by upregulating the expression of HIF-2, VEGF, and Notch1, Notch2, and Notch3. This leads to increased angiogenesis and reduced inflammatory responses, resulting in improved tissue regeneration, collagen deposition, and vascularization in irradiated skin tissue."}], "pathway_id": "rno04330", "pubmed_id": "40659593", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Astaxanthin, 7,12-Dimethylbenz(a)anthracene, Doxorubicin, Notch1 (expression), microRNA-34a (elevated levels), Cyclin-dependent kinase inhibitor 1A (expression), Baculoviral IAP repeat-containing 5 (expression), BCL2-associated X protein (expression), microRNA-146a (downregulation), microRNA-210, Nuclear factor kappa B (levels), Vascular endothelial growth factor (levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of microRNA-34a inhibit the expression of Notch1 protein, leading to suppressed Notch signaling. This downregulation of Notch1 reduces cell cycle progression by increasing the expression of Cyclin-dependent kinase inhibitor 1A (p21). Additionally, microRNA-34a promotes apoptosis by decreasing the expression of Baculoviral IAP repeat-containing 5 (survivin) and increasing the expression of BCL2-associated X protein (Bax). Downregulation of microRNA-146a and microRNA-210 correlates with decreased levels of Nuclear factor kappa B (NF-B) and Vascular endothelial growth factor (VEGF), respectively, indicating a reduction in angiogenic activity."}], "pathway_id": "rno04330", "pubmed_id": "40447066", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch, Notch signaling pathway.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Notch signaling regulates the phenotypic plasticity of vascular smooth muscle cells in response to mechanical strain. Cyclic equibiaxial and uniaxial strain downregulate Notch signaling, leading to reduced contractile characteristics of vascular smooth muscle cells. This reduction is most pronounced when maximum principal strain values are compared, indicating a direct relationship between mechanical strain and Notch signaling activity in these cells."}], "pathway_id": "rno04330", "pubmed_id": "40434193", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Berberine (administration), Notch1 (modulated by Berberine), Hes1 (altered expression), Bcl-2 (altered expression), Bax (altered expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Berberine modulates the Notch signaling pathway by interacting with Notch1, leading to altered expression of downstream targets such as Hes1, Bcl-2, and Bax. This modulation influences apoptotic processes in myocardial tissue, potentially contributing to reduced cell death and improved tissue structure following ischemia-reperfusion injury."}], "pathway_id": "rno04330", "pubmed_id": "40415366", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Notch signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Notch signaling pathway is an evolutionarily conserved, intercellular signaling mechanism essential for proper embryonic development in all metazoan organisms in the Animal kingdom. The Notch proteins (Notch1-Notch4 in vertebrates) are single-pass receptors that are activated by the Delta (or Delta-like) and Jagged/Serrate families of membrane-bound ligands. They are transported to the plasma membrane as cleaved, but otherwise intact polypeptides. Interaction with ligand leads to two additional proteolytic cleavages that liberate the Notch intracellular domain (NICD) from the plasma membrane. The NICD translocates to the nucleus, where it forms a complex with the DNA binding protein CSL, displacing a histone deacetylase (HDAc)-co-repressor (CoR) complex from CSL. Components of an activation complex, such as MAML1 and histone acetyltransferases (HATs), are recruited to the NICD-CSL complex, leading to the transcriptional activation of Notch target genes.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Notch receptor, Cystic Fibrosis Transmembrane Conductance Regulator, CFTR High Expressers (specification), Mastermind-like 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Notch signaling reactivation within the secretory lineage promotes the specification of CFTR high expressers (CHEs), a distinct intestinal epithelial cell population. This secondary signaling event distinguishes CHEs from other secretory cells, and involves the recruitment of transcription factors such as MAML1. CHEs contribute to luminal pH regulation and are associated with cystic fibrosis pathophysiology through their expression of CFTR."}], "pathway_id": "rno04330", "pubmed_id": "40371707", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Rattus norvegicus (rat)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Dihydrotestosterone (elevated exposure), Thapsigargin (administration), Kisspeptin-10 (administration), Kiss1 (reduced levels), GT1-7 hypothalamic neuronal cell line.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated dihydrotestosterone (DHT) exposure leads to downregulation of kisspeptin (Kiss1) expression and activation of the unfolded protein response (UPR) in hypothalamic neuronal cells. Reduced kisspeptin levels enhance UPR signaling, contributing to endoplasmic reticulum (ER) stress and insulin resistance. Administration of kisspeptin-10 (Kp10) suppresses UPR activation and attenuates ER stress and insulin resistance induced by DHT or thapsigargin, a known ER stress inducer. This effect is observed both in vitro in GT1-7 hypothalamic cells and in vivo in a rat model of polycystic ovary syndrome."}], "pathway_id": "rno04141", "pubmed_id": "34389474", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Rattus norvegicus (rat)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: EAG1 (ER-localized immature core-glycosylated and nascent nonglycosylated), CUL7, MKRN1, ERAD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MKRN1 interacts with ER-localized immature core-glycosylated and nascent nonglycosylated Eag1 proteins, promoting their polyubiquitination and subsequent ER-associated proteasomal degradation. This mechanism contributes to the early stage of Eag1 maturation and quality control within the ER. In contrast to CUL7, which regulates both ER and peripheral quality control of Eag1, MKRN1 is specifically involved in the degradation of nascent Eag1 at the ER. Together, CUL7 and MKRN1 form a dual ubiquitination system that ensures the efficient removal of misfolded Eag1 proteins."}], "pathway_id": "rno04141", "pubmed_id": "33647316", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Rattus norvegicus (rat)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neuregulin 2 (presence), NMDA receptor (activation), ErbB4 (activation), Kv2.1 (altered clustering and activation), ADAM10 (activation), ADAM17.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "NMDA receptors regulate the accumulation and shedding of pro-neuregulin 2 at endoplasmic reticulum-plasma membrane junctions in neurons. NMDAR activation promotes ectodomain shedding of NRG2 via ADAM10, leading to ErbB4 receptor tyrosine kinase activation. This signaling pathway modulates intrinsic excitability of GABAergic interneurons by reducing voltage-gated sodium channel currents and altering Kv2.1 channel clustering and activation. NRG2 and Kv2.1 function cooperatively within an activity-dependent pathway that responds to extracellular glutamate levels."}], "pathway_id": "rno04141", "pubmed_id": "31240601", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Protein processing in endoplasmic reticulum - Rattus norvegicus (rat)\n**Pathway Description**: The endoplasmic reticulum (ER) is a subcellular organelle where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained within the ER lumen in complex with molecular chaperones. Proteins that are terminally misfolded bind to BiP and are directed toward degradation through the proteasome in a process called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER causes ER stress and activates a signaling pathway called the unfolded protein response (UPR). In certain severe situations, however, the protective mechanisms activated by the UPR are not sufficient to restore normal ER function and cells die by apoptosis.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Activating Transcription Factor 6.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activating Transcription Factor 6 (ATF6) plays a central role in the unfolded protein response (UPR), a cellular signaling pathway that modulates proteostasis under conditions of endoplasmic reticulum stress. Activation of ATF6 transcriptionally reprograms proteostasis, leading to the amelioration of cellular damage and the preservation of tissue function during ischemia/reperfusion injury. In the absence of ATF6, the protective effects are diminished, resulting in increased susceptibility to apoptosis and tissue dysfunction."}], "pathway_id": "rno04141", "pubmed_id": "30643122", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Rotenone (administration), 1,2,3,3a-Tetrahydro-3a-hydroxy-6-methyl-1-phenyl-4H-pyrrolo(2,3-b)quinolin-4-one.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Modulation of focal adhesions and intracellular force influences fibrosis differentiation. Disruption of stress fibers and focal adhesions by rotenone and blebbistatin attenuates fibrogenic differentiation of stem cells. Increased intracellular force stimulates soft tissue fibrosis."}], "pathway_id": "rno04510", "pubmed_id": "36961871", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Neomycin, Verapamil, Talin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reversible shear stress influences endothelial cell adhesion and migration through the modulation of calcium signaling and cell adhesion molecules. Activation of L-type voltage-gated calcium channels facilitates intracellular calcium influx, which is essential for adhesion and angiogenesis. Talin, a focal adhesion protein, also contributes to mechanosensitive regulation of these processes. Inhibition of calcium channels or Talin disrupts these effects, reducing endothelial cell function and vascularization."}], "pathway_id": "rno04510", "pubmed_id": "40690837", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Alkaline Phosphatase, Alizarin, ITGA11 (elevated expression), Focal Adhesion Kinase (increased phosphorylation and activity), Phosphoinositide 3-Kinase (activation), Protein Kinase B (activation), Glycogen Synthase Kinase 3 Beta (activation), Catenin Beta 1 (stabilization and nuclear translocation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of integrin 11 (ITGA11) promotes osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) by activating the focal adhesion pathway. This activation involves increased phosphorylation and activity of focal adhesion kinase (FAK), which sequentially activates phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and glycogen synthase kinase 3 beta (GSK3). Inhibition of GSK3 leads to stabilization and nuclear translocation of -catenin, enhancing the transcription of osteogenic genes. This cascade results in increased alkaline phosphatase (ALP) activity and mineralized nodule formation, contributing to enhanced bone formation and osseointegration."}], "pathway_id": "rno04510", "pubmed_id": "39755586", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: ACTA2 (elevated expression), ITGB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased extracellular matrix stiffness promotes the differentiation of cardiac fibroblasts into myofibroblasts, a process mediated by focal adhesions and integrin 1 signaling. This phenotypic switching is characterized by elevated expression of -smooth muscle actin (ACTA2), a key marker of myofibroblast activation. Integrin 1 (ITGB1) facilitates mechanosensitive signaling at focal adhesions, leading to cytoskeletal reorganization and the induction of a contractile phenotype."}], "pathway_id": "rno04510", "pubmed_id": "39043765", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Zearalenone (administration), RAC3 (expression), CCND1 (expression), EP300 (expression), CTNNB1 (expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Zearalenone inhibits the expression of RAC3, CCND1, EP300, and CTNNB1, which are components of focal adhesion pathways. This inhibition disrupts focal adhesion structures in testicular Leydig and Sertoli cells, impairing cell adhesion and contributing to testicular damage and male reproductive dysfunction."}], "pathway_id": "rno04510", "pubmed_id": "36288102", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Endothelin-1 (administration), GC-1008, vinculin (upregulated), focal adhesion kinase (upregulated), talin (upregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Upregulation of vinculin, focal adhesion kinase (FAK), and talin during hepatic stellate cell (HSC) activation promotes focal adhesion formation and actin cytoskeleton reorganization. These proteins are localized at the ends of actin filaments and are involved in the structural and signaling functions of focal adhesions. Stimulation with endothelin-1 and transforming growth factor beta increases the size and distribution of vinculin-containing focal adhesions, contributing to HSC activation and the fibrogenic response."}], "pathway_id": "rno04510", "pubmed_id": "35960334", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Focal adhesion - Rattus norvegicus (rat)\n**Pathway Description**: Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: GAS2-like 1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Gas2L1, a component of the cytoskeleton that mediates the interaction between microtubules and microfilaments, does not regulate focal adhesion dynamics or cell migration in response to microgel topography. Surface-bound microgels modulate focal adhesion dynamics, leading to reduced adhesion turnover and less dynamic focal adhesions. Increased microgel cross-linking reduces focal adhesion turnover in Sertoli cells, influencing both adhesion and motility."}], "pathway_id": "rno04510", "pubmed_id": "34555082", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Calcium signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Ca2+ that enters the cell from the outside is a principal source of signal Ca2+. Entry of Ca2+ is driven by the presence of a large electrochemical gradient across the plasma membrane. Cells use this external source of signal Ca2+ by activating various entry channels with widely different properties. The voltage-operated channels (VOCs) are found in excitable cells and generate the rapid Ca2+ fluxes that control fast cellular processes. There are many other Ca2+-entry channels, such as the receptor-operated channels (ROCs), for example the NMDA (N-methyl-D-aspartate) receptors (NMDARs) that respond to glutamate. There also are second-messenger-operated channels (SMOCs) and store-operated channels (SOCs).\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Calcium Cation (influx), Piezo1, Phosphoinositide 3-kinase, Protein kinase B, Nuclear factor kappa B.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Calcium ion influx through Piezo1 channels activates the PI3K-AKT signaling cascade, which in turn modulates the NF-B pathway to regulate inflammatory responses and cartilage integrity. Activation of this Piezo1-mediated calcium signaling pathway contributes to the maintenance of joint homeostasis under mechanical stress. Dysregulation of this axis is associated with cartilage degradation and inflammation observed in osteoarthritis."}], "pathway_id": "rno04020", "pubmed_id": "41173085", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Signal Transducer and Activator of Transcription 3 (activation), Janus Kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the JAK/STAT3 signaling pathway in astrocytes leads to structural remodeling, reduced synaptic coverage, and contributes to the manifestation of cocaine-induced motor hyperactivity. This pathway plays a key role in mediating astrocytic reactivity in response to cocaine exposure."}], "pathway_id": "rno04630", "pubmed_id": "41223924", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid, Phospholipase C gamma 1 (knockdown), Interleukin 4 (increased levels), Janus kinase 2 (activation), Signal transducer and activator of transcription 3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phospholipase C gamma 1 (PLC1) knockdown in bone marrow mesenchymal stem cells (BMSCs) increases interleukin 4 (IL-4) expression and secretion, which activates the JAK2-STAT3 signaling pathway. This activation promotes M2-like macrophage polarization and enhances BMSC osteogenic differentiation and migration. The reciprocal interaction between PLC1-knockdown BMSCs and reparatively polarized macrophages synergistically improves bone regeneration."}], "pathway_id": "rno04630", "pubmed_id": "41259956", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: N-Methyl-N'-nitro-N-nitrosoguanidine, Naringin, Neohesperidin, Narirutin, JAK2, STAT3, phosphorylated JAK2 (phosphorylated), phosphorylated STAT3 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of JAK2 and STAT3 phosphorylation reduces the activation of the JAK2/STAT3 signaling pathway, which is associated with the suppression of cell proliferation, migration, and invasion in models of chronic atrophic gastritis. This attenuation of the pathway contributes to the amelioration of gastric histopathological alterations and inflammatory responses."}], "pathway_id": "rno04630", "pubmed_id": "41077317", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Chloride (elevated dietary intake), Interleukin-6 receptor, Janus kinase, Signal transducer and activator of transcription.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated dietary sodium intake increases the activation of the IL-6 receptor-JAK-STAT signaling pathway in intestinal B cells and T follicular helper (Tfh)-like cells. This pathway promotes inflammatory immune responses and contributes to the pathogenesis of salt-sensitive hypertension through enhanced B cell and Tfh cell activity in the gut."}], "pathway_id": "rno04630", "pubmed_id": "40670501", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Genistein (administration), Quercetin (administration), Caffeic Acid (administration), Linoleic Acid, PTPN11, LCK, STAT3, GRB2, FYN, SRC, PIK3R1, LYN, EGFR, PIK3CA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Genistein, quercetin, and caffeic acid modulate the JAK-STAT signaling pathway by influencing the activity of STAT3 and related kinases such as LCK, FYN, and SRC. These compounds also interact with the PI3K-AKT signaling axis through targets like PIK3R1 and PIK3CA, which in turn affects downstream transcription factors including mTOR and FOXO3A. This dual modulation enhances hematopoietic and immune functions, leading to increased thymus and spleen indices and improved bone marrow nucleated cell counts, thereby counteracting leukopenia."}], "pathway_id": "rno04630", "pubmed_id": "40513324", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: JAK-STAT signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes. In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: JAK2, STAT3, BCL2 (increased levels), BAX (decreased levels), CASP3 (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the JAK2/STAT3 signaling pathway leads to increased expression of pro-apoptotic proteins BAX and CASP3, while decreasing the expression of the anti-apoptotic protein BCL2, thereby promoting neuronal apoptosis. Inhibition of this pathway results in reduced apoptosis, increased BCL2 expression, and decreased BAX and CASP3 levels, which collectively contribute to the protection of neurons in spinal cord injury."}], "pathway_id": "rno04630", "pubmed_id": "40551645", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Rattus norvegicus (rat)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Lactoferrin (administration), Mechanistic Target of Rapamycin Kinase (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated oxidative stress and endoplasmic reticulum stress contribute to thyroid tissue damage and cellular apoptosis. Lactoferrin mitigates these effects by reducing oxidative stress and inflammatory cell infiltration in thyroid tissue. Additionally, lactoferrin alleviates endoplasmic reticulum stress and prevents cellular apoptosis. These protective effects are primarily mediated through the inhibition of mTOR signaling pathway activation."}], "pathway_id": "rno05320", "pubmed_id": "39576556", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Rattus norvegicus (rat)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Ursolic Acid (administration), Interleukin-17A (elevated levels), Tumor necrosis factor alpha (elevated levels), Reactive oxygen species (elevated levels), CD4 positive T cell (increased frequency (expressing CD25 and Forkhead box P3)), Forkhead box P3, Heme oxygenase 1, Ferritin heavy chain 1, Glutathione peroxidase 4, Solute carrier family 7 member 11, Acyl-CoA synthetase long-chain family member 4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Ursolic acid suppresses ferroptosis by modulating Th17/Treg balance and improving gut microbiota composition. It reduces levels of interleukin-17A, tumor necrosis factor alpha, and reactive oxygen species. Ursolic acid decreases the frequency of CD4+ interleukin-17A+ Th17 cells while increasing the frequency of CD4+ CD25+ FoxP3+ Treg cells. It upregulates ferroptosis inhibitors including heme oxygenase 1, ferritin heavy chain 1, glutathione peroxidase 4, and solute carrier family 7 member 11. Concurrently, it downregulates ferroptosis inducers such as reactive oxygen species and acyl-CoA synthetase long-chain family member 4, thereby mitigating autoimmune thyroiditis inflammation."}], "pathway_id": "rno05320", "pubmed_id": "40203793", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Rattus norvegicus (rat)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Malvidin (administration), Stigmasterol (administration), gamma-Sitosterol (administration), Chrysoeriol (administration), mitogen-activated protein kinase, glycogen synthase kinase 3 beta, thyroid-stimulating hormone receptor, notch receptor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Malvidin, stigmasterol, poriferast-5-en-3beta-ol, and chryseriol interact with target proteins including thyroid-stimulating hormone receptor (TSHR), mitogen-activated protein kinase (MAPK), glycogen synthase kinase 3 beta (GSK3), and notch receptor. These interactions modulate the T-cell action pathway, which is central to the progression of Hashimoto's thyroiditis. Inhibition of these signaling components contributes to the restoration of immune function and alleviation of autoimmune-induced thyroid damage."}], "pathway_id": "rno05320", "pubmed_id": "37929726", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Autoimmune thyroid disease - Rattus norvegicus (rat)\n**Pathway Description**: The classification of autoimmune throid disease (AITD) includes Hashimoto's thyroiditis (HT) or chronic autoimmune thyroiditis and its variants, Graves' disease (GD) and autoimmune atrophic thyroiditis or primary myxedema. HT is characterized by the presence of goitre, thyroid autoantibodies against thyroid peroxidase (TPO) and thyroglobulin (Tg) in serum and varying degrees of thyroid dysfunction. During HT, self-reactive CD4+ T lymphocytes (Th) recruit B cells and CD8+ T cells (CTL) into the thyroid. Disease progression leads to the death of thyroid cells and hypothyroidism. Both autoantibodies and thyroid-specific cytotoxic T lymphocytes (CTLs) have been proposed to be responsible for autoimmune thyrocyte depletion. In GD, the TSH-R is the most important autoantigen. Antibodies directed against it mimic the effects of the hormone on thyroid cells, TSH, stimulating autonomous production of thyroxine and triiodothyronine and causing hyperthyroidism. The presence of TSH-R-blocking antibodies that bind the TSH receptor in a similar fashion to the antibodies in patients with Grave's disease but that block rather than activate the receptor explains some cases of atrophic hypothyroidism.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: (+)-Dioscin (administration), NFKB1 (downregulation), MTOR (inhibition), TLR4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dioscin suppresses the inflammatory response and alleviates autoimmune thyroiditis by inhibiting the mTOR and TLR4/NF-B signaling pathways. Downregulation of TLR4 and NF-B reduces the activation of inflammatory processes, while inhibition of mTOR attenuates immune cell activity and metabolic signaling linked to autoimmunity. This pathway suppression results in reduced thyroid autoantibody production and improved thyroid function."}], "pathway_id": "rno05320", "pubmed_id": "37551407", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Carbohydrate digestion and absorption - Rattus norvegicus (rat)\n**Pathway Description**: Dietary carbohydrate in humans and omnivorous animals is a major nutrient. The carbohydrates that we ingest vary from the lactose in milk to complex carbohydrates. These carbohydrates are digested to monosaccharides, mostly glucose, galactose and fructose, prior to absorption in the small intestine. Glucose and galactose are initially transported into the enterocyte by SGLT1 located in the apical brush border membrane and then exit through the basolateral membrane by either GLUT2 or exocytosis. In a new model of intestinal glucose absorption, transport by SGLT1 induces rapid insertion and activation of GLUT2 in the brush border membrane by a PKC betaII-dependent mechanism. Moreover, trafficking of apical GLUT2 is rapidly up-regulated by glucose and artificial sweeteners, which act through T1R2 + T1R3/alpha-gustducin to activate PLC-beta2 and PKC-beta II. Fructose is transported separately by the brush border GLUT5 and then released out of the enterocyte into the blood by GLUT2.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, Mannitol, Phlorizin, Phloretin, SLC5A1 (inhibited activity), SLC2A2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Glucose absorption in the small intestine occurs via transcellular transport mediated by SGLT1 in the apical membrane and GLUT2 in the basolateral membrane. A paracellular transport mechanism also contributes to glucose absorption, particularly in the proximal intestine. Inhibition of SGLT1 activity leads to increased paracellular transport, suggesting a regulatory link between transcellular and paracellular pathways. Both transcellular and paracellular mechanisms contribute to overall glucose absorption, with transcellular transport accounting for the majority under normal conditions."}], "pathway_id": "rno04973", "pubmed_id": "40186371", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Carbohydrate digestion and absorption - Rattus norvegicus (rat)\n**Pathway Description**: Dietary carbohydrate in humans and omnivorous animals is a major nutrient. The carbohydrates that we ingest vary from the lactose in milk to complex carbohydrates. These carbohydrates are digested to monosaccharides, mostly glucose, galactose and fructose, prior to absorption in the small intestine. Glucose and galactose are initially transported into the enterocyte by SGLT1 located in the apical brush border membrane and then exit through the basolateral membrane by either GLUT2 or exocytosis. In a new model of intestinal glucose absorption, transport by SGLT1 induces rapid insertion and activation of GLUT2 in the brush border membrane by a PKC betaII-dependent mechanism. Moreover, trafficking of apical GLUT2 is rapidly up-regulated by glucose and artificial sweeteners, which act through T1R2 + T1R3/alpha-gustducin to activate PLC-beta2 and PKC-beta II. Fructose is transported separately by the brush border GLUT5 and then released out of the enterocyte into the blood by GLUT2.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 2-(4-Methoxyphenoxy)propanoic acid, TAS1R2 (activation), TAS1R3 (activation), GNAT3 (activation), SLC5A1, SLC2A2 (normalization of expression), GLP1 (secretion), GLP2 (secretion).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of sweet taste receptors (TAS1R2 and TAS1R3) in the intestinal epithelium triggers a signaling cascade involving G-gustducin, leading to the activation of phospholipase C (PLC) and protein kinase C (PKC). This pathway enhances the expression and apical trafficking of SGLT1 and GLUT2, facilitating glucose uptake and transport across the intestinal brush border. GLP-1 and GLP-2 secretion is also stimulated, contributing to improved glucose homeostasis. Downregulation of GLUT2 expression in intestinal segments correlates with impaired glucose absorption, whereas its normalization supports efficient glucose transport."}], "pathway_id": "rno04973", "pubmed_id": "39263491", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Carbohydrate digestion and absorption - Rattus norvegicus (rat)\n**Pathway Description**: Dietary carbohydrate in humans and omnivorous animals is a major nutrient. The carbohydrates that we ingest vary from the lactose in milk to complex carbohydrates. These carbohydrates are digested to monosaccharides, mostly glucose, galactose and fructose, prior to absorption in the small intestine. Glucose and galactose are initially transported into the enterocyte by SGLT1 located in the apical brush border membrane and then exit through the basolateral membrane by either GLUT2 or exocytosis. In a new model of intestinal glucose absorption, transport by SGLT1 induces rapid insertion and activation of GLUT2 in the brush border membrane by a PKC betaII-dependent mechanism. Moreover, trafficking of apical GLUT2 is rapidly up-regulated by glucose and artificial sweeteners, which act through T1R2 + T1R3/alpha-gustducin to activate PLC-beta2 and PKC-beta II. Fructose is transported separately by the brush border GLUT5 and then released out of the enterocyte into the blood by GLUT2.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Fructose, (+)-Lactose, CID 91333377, SGLT1, GLUT2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Fructose competes with glucose for transport via SGLT1 and GLUT2, thereby reducing the intestinal absorption of glucose-dependent drugs. Lactose enhances intestinal permeability, which may facilitate the absorption of glucose transporter-dependent drugs. SGLT1 and GLUT2 mediate the uptake and efflux of glucose and related molecules across the intestinal epithelium, and their activity is modulated by the presence of competing carbohydrates."}], "pathway_id": "rno04973", "pubmed_id": "38834905", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii, 5-Aminolevulinic Acid, Fibroblast Growth Factor Receptor 1 (activation), Angiotensin II Type 1 Receptor (activation), Extracellular Signal-Regulated Kinase (activation), Mas Receptor (downregulation), Soluble Guanylyl Cyclase Alpha Subunit (downregulation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Angiotensin II activates the Fibroblast Growth Factor Receptor 1 (FGFR1) and Angiotensin II Type 1 Receptor (AT1 receptor) in renal epithelial cells, leading to increased oxidative stress and fibrotic responses. This activation occurs via the ERK/MAPK signaling pathway. Concurrently, Angiotensin II downregulates the protective pathways mediated by the Mas Receptor (MAS1) and soluble Guanylyl Cyclase Alpha Subunit (pGC-A)."}], "pathway_id": "rno04010", "pubmed_id": "41274591", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Octopamine, Ferulic Acid, Vitexin 2''-O-rhamnoside, Tumor necrosis factor alpha (elevated), Mitogen-activated protein kinase (inhibited), Nuclear factor kappa B (inhibited), Interleukin 1 beta (elevated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of mitogen-activated protein kinase (MAPK) and nuclear factor kappa B (NF-B) signaling reduces the production of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-) and interleukin 1 beta (IL-1). This suppression attenuates inflammatory responses, including leukocyte and neutrophil infiltration, and decreases the secretion of nitric oxide and TNF- in activated macrophages. Concurrently, the downregulation of oxidative stress markers and enhancement of antioxidant defenses contribute to the anti-inflammatory and cytoprotective effects."}], "pathway_id": "rno04010", "pubmed_id": "41302395", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: QPCT (overexpressed), ARHGEF37 (overexpressed), FLNC (overexpressed), LGALS7 (overexpressed).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Dysregulation of the MAPK signaling pathway, coupled with the aberrant overexpression of QPCT, ARHGEF37, FLNC, and LGALS7, contributes to the pathogenesis of benign prostatic hyperplasia. These molecular alterations likely drive non-malignant proliferation of prostate tissues through activation of downstream effectors in the MAPK cascade, promoting cellular growth and tissue remodeling."}], "pathway_id": "rno04010", "pubmed_id": "41306978", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Scutellarin (administration), L-Glutamic Acid, HSP90AA1, Mitogen-activated protein kinase, Small interfering RNA (administration).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Scutellarin mitigates retinal ganglion cell degeneration by modulating the HSP90AA1-MAPK signaling pathway. This interaction suppresses apoptosis, a process associated with excitotoxicity-induced damage. The protective effects are dependent on HSP90AA1, as its knockdown abolishes the neuroprotective action of Scutellarin."}], "pathway_id": "rno04010", "pubmed_id": "41251525", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Resiniferatoxin, Protein tyrosine phosphatase receptor type K (elevated expression), Dual specificity phosphatase 1, Mitogen-activated protein kinase 14.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Protein tyrosine phosphatase receptor type K (PTPRK) activates the DUSP1/p38 MAPK signaling pathway in dorsal root ganglia, leading to increased mechanical allodynia, thermal hypoalgesia, and inflammation. This pathway contributes to the development of postherpetic neuralgia through enhanced inflammatory responses and altered neural signaling."}], "pathway_id": "rno04010", "pubmed_id": "41253902", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cyasterone (administration), Betavulgarin (administration), Kaempferol (administration), Quercetin (administration), TP53, NFKB1, PRKCA.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Cyasterone, Betavulgarin, Kaempferol, and Quercetin modulate the MAPK signaling pathway by interacting with key regulatory proteins, including TP53, NFKB1, and PRKCA. These compounds influence cell proliferation, regulate apoptosis-related gene expression, and reduce oxidative stress. Activation of the MAPK pathway contributes to improved spermatogenesis and sperm function, while also supporting testicular structural integrity and reducing spermatogenic cell apoptosis."}], "pathway_id": "rno04010", "pubmed_id": "41188309", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: MAPK signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. Mammals express at least four distinctly regulated groups of MAPKs, extracellular signal-related kinases (ERK)-1/2, Jun amino-terminal kinases (JNK1/2/3), p38 proteins (p38alpha/beta/gamma/delta) and ERK5, that are activated by specific MAPKKs: MEK1/2 for ERK1/2, MKK3/6 for the p38, MKK4/7 (JNKK1/2) for the JNKs, and MEK5 for ERK5. Each MAPKK, however, can be activated by more than one MAPKKK, increasing the complexity and diversity of MAPK signalling. Presumably each MAPKKK confers responsiveness to distinct stimuli. For example, activation of ERK1/2 by growth factors depends on the MAPKKK c-Raf, but other MAPKKKs may activate ERK1/2 in response to pro-inflammatory stimuli.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sodium Iodoacetate, Glutathione (reduced), Ferrous cation (elevated levels), SLC7A11, GPX4, MAPK14 (activated), MMP13, IL1B, TNF.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of iron(2+) and reduced glutathione contribute to ferroptosis in chondrocytes. SLC7A11 and GPX4 mediate the cellular defense against ferroptosis by maintaining glutathione-dependent lipid peroxidation. Activation of p38 MAPK promotes inflammation and extracellular matrix degradation through upregulation of MMP-13, IL-1, and TNF. Inhibition of these pathways preserves cartilage structure and enhances subchondral bone microarchitecture."}], "pathway_id": "rno04010", "pubmed_id": "41163114", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132 (administration), UCHL1, SPAST (degradation), 26S proteasome complex.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "UCHL1 interacts with and regulates the degradation of SPAST, a microtubule-severing enzyme. This regulation occurs via the 26S proteasome pathway, as demonstrated by the suppression of SPAST degradation when the proteasome is inhibited by MG132. The degradation of SPAST modulates microtubule severing, which in turn influences hippocampal neurite length and branching."}], "pathway_id": "rno04120", "pubmed_id": "40272610", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CircRNA ITCH, Homeobox C10 (degradation), BRCA1 DNA repair associated (increased stability), Insulin-like growth factor 2 mRNA-binding protein 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "CircRNA ITCH promotes the ubiquitination degradation of Homeobox C10 by enhancing the stability of BRCA1 mRNA. This stabilization is achieved through the direct interaction of CircRNA ITCH with IGF2BP2, which mediates m6A modification of BRCA1 mRNA. The increased stability of BRCA1 mRNA facilitates ubiquitination of HOXC10, thereby promoting osteogenic differentiation in the context of disuse osteoporosis."}], "pathway_id": "rno04120", "pubmed_id": "40148953", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132, Sirolimus, mTOR (inhibited), p70 S6 kinase, Optic Atrophy 1 (cleaved), Oma1 protease (released), Prohibitin 1 (ubiquitinated), Tuberous Sclerosis Complex 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of mTOR leads to increased ubiquitination and proteasomal degradation of Prohibitin 1 (PHB1), which disrupts the interaction between PHB and OMA1 in the mitochondrial inner membrane. This loss of interaction releases OMA1, allowing it to cleave Optic Atrophy 1 (OPA-1), resulting in mitochondrial fragmentation and impaired bioenergetic function. This pathway contributes to metabolic dysfunction, particularly under metabolic stress conditions."}], "pathway_id": "rno04120", "pubmed_id": "40450326", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hydrogen Peroxide, Forkhead box D3 (O-GlcNAc modified), Stress-induced phosphoprotein 1 (activated), High mobility group box 1 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Increased O-GlcNAc modification of Forkhead box D3 (FOXD3) stabilizes the protein and enhances its expression. FOXD3 suppresses the transcription of Stress-induced phosphoprotein 1 (STUB1), which functions as an E3 ubiquitin ligase. Reduced STUB1 activity diminishes the ubiquitination and subsequent proteasomal degradation of High mobility group box 1 (HMGB1). Elevated HMGB1 levels contribute to oxidative stress and apoptosis. Inhibition of FOXD3 O-GlcNAc modification promotes STUB1-mediated ubiquitination and degradation of HMGB1, thereby reducing oxidative stress and apoptosis."}], "pathway_id": "rno04120", "pubmed_id": "40272767", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Doxorubicin, CDC20 (elevated levels), CCDC69 (downregulated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of CDC20 attenuate doxorubicin-induced apoptosis by downregulating CCDC69 expression. This interaction contributes to the protection of cardiomyocytes against doxorubicin-induced damage, reducing inflammation, fibrosis, and cell atrophy."}], "pathway_id": "rno04120", "pubmed_id": "40045239", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Bafilomycin A1, MG-132, alpha-synuclein (intracellular), cathepsin D, DJ-1, leucine-rich repeat kinase 2, protein kinase B (activated), extracellular signal-regulated kinase (activated), p38 mitogen-activated protein kinase (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Alpha-synuclein degradation in pericytes occurs through the autophagy-lysosome system and the ubiquitin-proteasome system. This process is regulated by the activation of Akt, ERK, and p38 MAPK signaling pathways, which are triggered by intracellular alpha-synuclein. Inhibition of these kinases impairs alpha-synuclein clearance, while pharmacological inhibition of autophagy or the proteasome also prevents its degradation."}], "pathway_id": "rno04120", "pubmed_id": "40004079", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: D-Glucose, Palmitic Acid, MIC60 (K48-linked ubiquitination at Lys285), MARCH5, TRAP1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "MARCH5 promotes K48-linked ubiquitination of MIC60 at Lys285, leading to its degradation. This degradation results in mitochondrial dysfunction and apoptosis in cardiomyocytes. TRAP1 inhibits this process by competitively binding to MIC60, thereby preventing MARCH5-mediated ubiquitination and degradation."}], "pathway_id": "rno04120", "pubmed_id": "37679468", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MG-132, Transcription factor EB (insolubilized and ubiquitinated), proteasome inhibitor.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Hyperphosphatemia promotes vascular calcification via downregulation of Transcription factor EB (TFEB) in vascular smooth muscle cells. Under hyperphosphatemic conditions, TFEB becomes insolubilized and is degraded through the ubiquitin-proteasome system, leading to lysosomal dysfunction and reduced lysosome biogenesis. This disruption in autophagy-lysosomal pathway contributes to the progression of vascular calcification."}], "pathway_id": "rno04120", "pubmed_id": "34921974", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ubiquitin mediated proteolysis - Rattus norvegicus (rat)\n**Pathway Description**: Protein ubiquitination plays an important role in eukaryotic cellular processes. It mainly functions as a signal for 26S proteasome dependent protein degradation. The addition of ubiquitin to proteins being degraded is performed by a reaction cascade consisting of three enzymes, named E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 (ubiquitin ligase). Each E3 has specificity to its substrate, or proteins to be targeted by ubiquitination. Many E3s are discovered in eukaryotes and they are classified into four types: HECT type, U-box type, single RING-finger type, and multi-subunit RING-finger type. Multi-subunit RING-finger E3s are exemplified by cullin-Rbx E3s and APC/C. They consist of a RING-finger-containing subunit (RBX1 or RBX2) that functions to bind E2s, a scaffold-like cullin molecule, adaptor proteins, and a target recognizing subunit that binds substrates.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: CDYL (elevated levels), TRIM32, TRIM32 (RING) (mutated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRIM32, an E3 ubiquitin ligase, mediates the ubiquitylation and subsequent degradation of CDYL, an epigenetic regulator. This degradation reduces CDYL protein levels, thereby promoting dendrite arborization and increasing dendritic complexity in neurons. Loss of TRIM32 activity, such as in the RING mutant lacking E3 ligase function, results in elevated CDYL levels and diminished dendritic branching. This regulatory mechanism contributes to the control of dendritic morphology and may influence the development of neurodevelopmental disorders."}], "pathway_id": "rno04120", "pubmed_id": "34888944", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phototransduction - Rattus norvegicus (rat)\n**Pathway Description**: Phototransduction is a biochemical process by which the photoreceptor cells generate electrical signals in response to captured photons. The vertebrate cascade starts with the absorption of photons by the photoreceptive pigments, the rhodopsins, which consist of a membrane embedded chromophore, 11-cis-retinal, and a G-protein-coupled receptor, opsin. The photon isomerizes 11-cis-retinal to all-trans-retinal which induces a structural change that activates the opsin. This triggers hydrolysis of cGMP by activating a transducinphosphodiesterase 6 (PDE6) cascade, which results in closure of the cGMP-gated cation channels (CNG) in the plasma membrane and membrane hyperpolarization. The hyperpolarization of the membrane potential of the photoreceptor cell modulates the release of neurotransmitters to downstream cells. Recovery from light involves the deactivation of the light- activated intermediates: photolyzed rhodopsin is phosphorylated by rhodopsin kinase (RK) and subsequently capped off by arrestin; GTP-binding transducin alpha subunit deactivates through a process that is stimulated by RGS9.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Carbon, 11-Cis-Retinal, Retinal, Rhodopsin (phosphorylated), Opsin (activated), Phosphodiesterase 6 (activated), Cyclic nucleotide-gated channel (closure), Rhodopsin kinase, Arrestin, Transducin alpha subunit (activated), Regulator of G protein signaling 9.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Absorption of photons by rhodopsin in photoreceptor cells initiates phototransduction by isomerizing 11-cis-retinal to all-trans-retinal, leading to opsin activation. This activates phosphodiesterase 6, which hydrolyzes cGMP, resulting in closure of cyclic nucleotide-gated channels and membrane hyperpolarization. Hyperpolarization modulates neurotransmitter release to downstream cells. Rhodopsin kinase phosphorylates light-activated rhodopsin, and arrestin subsequently binds to terminate the signal. Transducin alpha subunit deactivation is enhanced by regulator of G protein signaling 9. In retinal degeneration, the integration of graphene oxide into polymeric nanoimplants enhances photovoltaic efficiency, restoring retinal activity and visual function by eliciting light-driven responses in degenerated photoreceptor tissues."}], "pathway_id": "rno04744", "pubmed_id": "41027857", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Phototransduction - Rattus norvegicus (rat)\n**Pathway Description**: Phototransduction is a biochemical process by which the photoreceptor cells generate electrical signals in response to captured photons. The vertebrate cascade starts with the absorption of photons by the photoreceptive pigments, the rhodopsins, which consist of a membrane embedded chromophore, 11-cis-retinal, and a G-protein-coupled receptor, opsin. The photon isomerizes 11-cis-retinal to all-trans-retinal which induces a structural change that activates the opsin. This triggers hydrolysis of cGMP by activating a transducinphosphodiesterase 6 (PDE6) cascade, which results in closure of the cGMP-gated cation channels (CNG) in the plasma membrane and membrane hyperpolarization. The hyperpolarization of the membrane potential of the photoreceptor cell modulates the release of neurotransmitters to downstream cells. Recovery from light involves the deactivation of the light- activated intermediates: photolyzed rhodopsin is phosphorylated by rhodopsin kinase (RK) and subsequently capped off by arrestin; GTP-binding transducin alpha subunit deactivates through a process that is stimulated by RGS9.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ivabradine, Cilobradine, Hyperpolarization-activated cyclic nucleotide-gated channels (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Inhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in photoreceptor cells leads to retinal dysfunction. This inhibition disrupts feedback current mechanisms and promotes sustained responses in photoreceptor cells, resulting in prolonged a- and b-wave latencies in electroretinography (ERG) and altered waveform morphology. These changes suggest impaired phototransduction and altered membrane potential dynamics in response to light stimuli."}], "pathway_id": "rno04744", "pubmed_id": "38401854", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane, Necrostatin-1, Ferrostatin-1, Dimethyl Sulfoxide.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Necroptosis contributes to myocardial injury and pathological cardiac remodeling following myocardial infarction. Inhibition of necroptosis, along with apoptosis, reduces tissue damage and improves cardiac function by attenuating mitochondrial dysfunction and inflammatory responses. This process leads to the preservation of cardiac structure and function in post-ischemic heart conditions."}], "pathway_id": "rno04217", "pubmed_id": "40851081", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Piperine (administration), Boro-Scopol, NRF2 (upregulated), HMOX1 (upregulated), CASP8 (restored expression), TNF (downregulated), FAS (downregulated), TNFSF10 (downregulated), MLKL (downregulated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Piperine modulates oxidative stress and inflammation by upregulating Nrf2 and HMOX1 while restoring CASP8 expression. It also downregulates TNF, FAS, TNFSF10, and MLKL, which are associated with necroptosis and inflammatory signaling. These actions contribute to cognitive enhancement and neuroprotection in models of cognitive impairment."}], "pathway_id": "rno04217", "pubmed_id": "41118083", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Juglone (administration), FOS (reduced levels), USP53 (downregulation), Mixed lineage kinase domain-like protein (ubiquitination and degradation), Gasdermin D (ubiquitination and degradation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Juglone inhibits necroptosis and pyroptosis by suppressing the expression of FOS, which directly regulates the deubiquitinating enzyme USP53. Reduced FOS levels lead to downregulation of USP53, thereby promoting the ubiquitination and degradation of MLKL and GSDMD. This cascade alleviates programmed cell death in injured neurons."}], "pathway_id": "rno04217", "pubmed_id": "41045624", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NLRP3 (reduction in activity), ASC (elevated expression), CASP1 (elevated expression), IL1B (maturation and release), IL18 (maturation and release), TNF, VEGFR2, RIPK1 (reduction in activity), MLKL (reduction in activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of NLRP3, ASC, and caspase-1 contributes to the activation of the NLRP3 inflammasome, leading to the maturation and release of IL-1 and IL-18, which promote inflammation. Concurrently, increased levels of RIPK1 and MLKL drive necroptosis. This combination of inflammasome activation and necroptosis amplifies inflammatory responses and tissue damage. Reduction in NLRP3, RIPK1, and MLKL activity suppresses both pathways, attenuating inflammation and programmed necrosis."}], "pathway_id": "rno04217", "pubmed_id": "40418410", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Osimertinib, receptor-interacting serine-threonine kinase 3 (phosphorylation), mixed lineage kinase domain-like protein (activation), pyruvate dehydrogenase kinase 4 (elevated expression), B-cell receptor-associated protein 31, fission 1 protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of PDK4 promotes excessive mitochondria-associated endoplasmic reticulum membrane (MAM) formation, leading to mitochondrial calcium overload and mitochondrial dysfunction. This contributes to necroptotic cell death through the phosphorylation of RIP3 and activation of MLKL. PDK4 facilitates the interaction between BAP31 and FIS1 at MAMs, enhancing mitochondrial fission and depolarization. These processes culminate in cardiotoxicity, characterized by myocardial damage and impaired cardiac function."}], "pathway_id": "rno04217", "pubmed_id": "40789497", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Necroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Necroptosis is a programmed form of necrosis. It can be initiated by different stimuli, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), Fas ligand (FasL), interferon (IFN), LPS, viral DNA or RNA, DNA-damage agent and requires the kinase activity of receptor-interacting protein 1 (RIPK1) and RIPK3. Its execution involves ROS generation, calcium overload, the opening of the mitochondrial permeability transition pore, mitochondrial fission, inflammatory response and chromatinolysis. Necroptosis participates in many pathogenesis of diseases, including neurological diseases, retinal disorders, acute kidney injury, inflammatory diseases and microbial infections.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferrous cation (elevated intracellular levels), Glutathione (decreased levels), Malonaldehyde (increased levels), Glutathione peroxidase 4 (downregulates_expression), Ferritin heavy chain 1, B-cell lymphoma 2, Heme oxygenase 1, BCL2-associated X protein, Receptor-interacting serine-threonine kinase 1 (upregulates_expression), Mixed lineage kinase domain-like protein, Receptor-interacting serine-threonine kinase 3, Solute carrier family 39 member 14, Solute carrier family 39 member 8, Cytochrome b-245 beta chain, Acyl-CoA synthetase long-chain family member 4, Acyl-CoA synthetase long-chain family member 1, Acyl-CoA synthetase long-chain family member 6, Interleukin 1 beta (increased production), Interleukin 6 (increased production).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated intracellular levels of iron and reactive oxygen species contribute to lipid peroxidation, which is mitigated by glutathione peroxidase 4 (GPX4). Downregulation of GPX4 and ferritin heavy chain 1 (FTH1) enhances lipid peroxidation, promoting ferroptosis. Simultaneously, upregulation of receptor-interacting serine-threonine kinase 1 (RIPK1) and mixed lineage kinase domain-like protein (MLKL) activates the necroptotic pathway. These processes are associated with increased production of pro-inflammatory cytokines such as interleukin 1 beta (IL-1) and interleukin 6 (IL-6), as well as decreased glutathione (GSH) and increased malondialdehyde (MDA) levels, indicating oxidative stress and cellular damage."}], "pathway_id": "rno04217", "pubmed_id": "40327971", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Methyl (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylate, Regulator of G protein signaling 7 (reduced levels), Protein kinase, cGMP-dependent, type I (elevated expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated expression of Protein kinase, cGMP-dependent, type I (PKG1) inhibits cell apoptosis, inflammation, and oxidative stress while enhancing mitochondrial membrane potential. Activation of the cGMP-PKG signaling pathway contributes to the suppression of atrial fibrillation progression and improves cardiac function by reducing cardiac fibrosis. Inhibition of PKG1 activity by KT-5823 reverses these protective effects. Reduced levels of Regulator of G protein signaling 7 (RGS7) lead to increased PKG1 expression, thereby promoting the anti-fibrotic and anti-apoptotic effects associated with cGMP signaling."}], "pathway_id": "rno04022", "pubmed_id": "40086518", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: L-Arginine, endothelial nitric oxide synthase (reduced expression), cGMP-dependent protein kinase (diminished activation), soluble guanylate cyclase (reduced expression), testosterone (decreased levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of endothelial nitric oxide synthase (eNOS) and soluble guanylate cyclase (sGC) leads to decreased production of nitric oxide (NO) and cyclic GMP (cGMP), respectively. This results in diminished activation of cGMP-dependent protein kinase (PKG), which normally promotes relaxation of penile vascular smooth muscle. Consequently, impaired smooth muscle relaxation contributes to erectile dysfunction. Decreased testosterone levels further exacerbate this condition."}], "pathway_id": "rno04022", "pubmed_id": "40783828", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp (elevated levels), Nitric Oxide, cGMP-dependent protein kinase, Transient Receptor Potential Cation Channel Subfamily C Member 6 (phosphorylated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of cyclic guanosine monophosphate (cGMP) activate cGMP-dependent protein kinase (PKG), which phosphorylates TRPC6, reducing its calcium conductance and suppressing NFAT activation. This leads to calcium desensitization and smooth muscle relaxation. PKG also activates mitochondrial ATP-sensitive potassium (mitoKATP) channels, promoting the release of reactive oxygen species (ROS) and inducing cardioprotection. In cardiac myocytes, PKG-mediated signaling inhibits myocyte hypertrophy and reduces pro-fibrotic activity, thereby improving endothelial function and preventing cardiac fibrosis."}], "pathway_id": "rno04022", "pubmed_id": "40378592", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Cgmp (elevated levels), Camp, Adora1, Kcnmb2, Ednrb, Rock2, Prkg2, Creb3l3, RhoA, Mypt1 (phosphorylated), Mylpf (phosphorylated), Prkg1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of guanosine 3',5'-cyclic monophosphate (cGMP) activate cGMP-dependent protein kinase 2 (PRKG2), which phosphorylates downstream targets such as myosin phosphatase target subunit 1 (MYPT1) and myosin light chain (MLC20), leading to smooth muscle relaxation and reduced myofilament sensitivity to calcium. Concurrently, the activation of PRKG2 suppresses RhoA and ROCK2 signaling, which are involved in myosin contraction and cell hypertrophy. This modulation of cGMP/PKG signaling contributes to the reduction of pathological features associated with chronic atrophic gastritis, including gastric tissue atrophy and impaired motility."}], "pathway_id": "rno04022", "pubmed_id": "39701680", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Podophyllotoxin, Protein Kinase G (activation), Mechanistic Target of Rapamycin (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Activation of the cGMP-PKG signaling pathway leads to the phosphorylation of downstream effectors, including mTOR. This interaction suppresses autophagy, a cellular process essential for the removal of damaged organelles and protein aggregates. The inhibition of autophagy contributes to the accumulation of cellular stress and dysfunction, which may exacerbate cellular injury and promote hepatotoxic outcomes."}], "pathway_id": "rno04022", "pubmed_id": "39644570", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: cGMP-PKG signaling pathway - Rattus norvegicus (rat)\n**Pathway Description**: Cyclic GMP (cGMP) is the intracellular second messenger that mediates the action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiologic processes. The elevated intracellular cGMP level exerts its physiological action through two forms of cGMP-dependent protein kinase (PKG), cGMP-regulated phosphodiesterases (PDE2, PDE3) and cGMP-gated cation channels, among which PKGs might be the primary mediator. PKG1 isoform-specific activation of established substrates leads to reduction of cytosolic calcium concentration and/or decrease in the sensitivity of myofilaments to Ca2+ (Ca2+-desensitization), resulting in smooth muscle relaxation. In cardiac myocyte, PKG directly phosphorylates a member of the transient potential receptor canonical channel family, TRPC6, suppressing this nonselective ion channel's Ca2+ conductance, G-alpha-q agonist-induced NFAT activation, and myocyte hypertrophic responses. PKG also opens mitochondrial ATP-sensitive K+ (mitoKATP) channels and subsequent release of ROS triggers cardioprotection.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nitric Oxide (production), Cgmp (synthesized), TRPV1, TRPA1, Soluble guanylate cyclase subunit beta (activated), Protein kinase G, Protein kinase G type I (activated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "TRPV1 and TRPA1 mediate calcium influx, which stimulates nitric oxide (NO) production. NO activates the NO-cGMP-protein kinase G (PKG) signaling pathway by stimulating soluble guanylate cyclase, leading to the synthesis of cyclic guanosine monophosphate (cGMP). cGMP activates PKG1, which modulates intracellular signaling to reduce nociceptive signaling and alleviate hyperalgesia. This pathway contributes to analgesic effects by suppressing mechanical and thermal allodynia associated with neuropathic pain."}], "pathway_id": "rno04022", "pubmed_id": "39104725", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Candesartan (administration), 3-Nitropropionic acid, Angiotensin-(1-7), Angiotensin II Type 1 receptor, Angiotensin II Type 2 receptor, Mas receptor, cAMP response element-binding protein, Brain-derived neurotrophic factor, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, c-Jun N-terminal kinase, c-Jun transcription factor, Survivin, Nuclear factor kappa B (elevated levels), Interleukin 1 beta (elevated levels), NAD(P)H quinone dehydrogenase 1, Heme oxygenase 1, Glial fibrillary acidic protein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Candesartan mitigates striatal degeneration and mitochondrial dysfunction by modulating the renin-angiotensin system, specifically by activating the Ang II/AT2R/Ang-(1-7)/Mas receptor axis. This activation enhances the production of neurotrophic proteins CREB, BDNF, and PGC1-, which reduce inflammatory mediators such as NF-B and IL-1 while increasing antioxidant levels like NQO1 and HO-1. Candesartan also inhibits the JNK/c-Jun signaling pathway and activates the anti-apoptotic protein survivin. These mechanisms collectively reduce neuronal death and improve cognitive, motor, and memory functions in Huntington disease."}], "pathway_id": "rno05016", "pubmed_id": "40956543", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: HTT (reduction), CREB1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduction of wild-type huntingtin (HTT) leads to increased nuclear size relative to the soma, DNA decompaction, and a progressive loss of heterochromatin in hippocampal neurons. This is accompanied by biphasic changes in nuclear phosphorylated cAMP response element-binding protein (pCREB) signaling, indicating altered transcriptional regulation. These nuclear structural changes suggest that HTT plays a critical role in maintaining nuclear stability and heterochromatin integrity."}], "pathway_id": "rno05016", "pubmed_id": "40748251", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-Nitropropionic acid, calpain-2 (activated), Cdk5 (proteolytic cleavage into p25 fragment), p25, MEF-2 (disrupted), calpastatin, BAX, TP53, CASP3, BCL2, cytochrome c (released), AIFM1 (released).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of calpain-2 promote proteolytic cleavage of Cdk5 into its active p25 fragment, which contributes to neurodegeneration by impairing neuronal function and promoting apoptosis. p25 Cdk5 also disrupts MEF-2 activity, a pro-survival transcription factor. Calpain-2 activation leads to the release of mitochondrial cytochrome c and AIF, which trigger both caspase-dependent and caspase-independent apoptotic pathways. BAX and p53 promote mitochondrial outer membrane permeabilization, while caspase-3 executes apoptotic cell death. BCL2 counteracts this process by inhibiting mitochondrial dysfunction and apoptosis."}], "pathway_id": "rno05016", "pubmed_id": "40252127", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Arbutin (administration), 3-Nitropropionic acid, Adenosine (restored), Hypoxanthine (restored), Xanthine (restored), Adenine (restored), AKT1, NFE2L2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Arbutin interacts with Akt and Nrf2 signaling pathways, mitigating oxidative stress and preventing neuronal cell death. It also restores purine nucleoside imbalances by modulating adenosine and its metaboliteshypoxanthine, xanthine, and adeninethereby reducing neurodegenerative effects and histological damage in Huntington's disease models."}], "pathway_id": "rno05016", "pubmed_id": "39929340", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Silymarin (administration), 3-Nitropropionic acid.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuroinflammation contributes to neuronal death and gliosis in Huntington disease. Silymarin mitigates these pathological processes by reducing gliosis and improving motor coordination, thereby protecting neurons and preserving striatal structure."}], "pathway_id": "rno05016", "pubmed_id": "39089590", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Huntington disease - Rattus norvegicus (rat)\n**Pathway Description**: Huntington disease (HD) is an autosomal-dominant neurodegenerative disorder that primarily affects medium spiny striatal neurons (MSN). The symptoms are choreiform, involuntary movements, personality changes and dementia. HD is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine (polyQ) close to the amino-terminus of the HD protein huntingtin (Htt). Mutant Htt (mHtt) has effects both in the cytoplasm and in the nucleus. Full-length huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and neuritic aggregates. mHtt also alters vesicular transport and recycling, causes cytosolic and mitochondrial Ca2+  overload, triggers endoplasmic reticulum stress through proteasomal dysfunction, and impairs autophagy function, increasing neuronal death susceptibility. N-terminal fragments containing the polyQ strech translocate to the nucleus where they impair transcription and induce neuronal death.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-Nitropropionic acid (administration), CD9, CD81.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "3-nitropropionic acid induces neurodegeneration and gliosis through mechanisms involving oxidative stress and mitochondrial dysfunction, leading to neuronal loss and motor dysfunction. Administration of extracellular vesicles expressing CD9 and CD81 mitigates these effects by reducing neuroinflammation, enhancing antioxidant activity, and partially preserving neuronal populations."}], "pathway_id": "rno05016", "pubmed_id": "38609056", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Hypochlorous Acid (elevated levels), Cathepsin B, Cathepsin H, Cathepsin L, Alpha-1 antitrypsin.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of hypochlorous acid in the respiratory tract increase the activity of cysteine cathepsins B and H in blood plasma, indicating lysosome membrane destabilization and the release of lysosomal enzymes. This enzymatic release contributes to oxidative stress, a hallmark of cellular damage and dysfunction."}], "pathway_id": "rno04142", "pubmed_id": "40936202", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Mannose 6-phosphate, FGFR, M6PR (increased expression), Transcription factor EB (activation), Transcription factor E3 (activation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "FGF receptors regulate the expression of M6P receptor genes in response to FGF signaling and during the cell cycle through the activation of transcription factors TFEB and TFE3. This regulation supports the mannose 6-phosphate pathway, which is essential for the trafficking of lysosomal hydrolases to lysosomes, thereby maintaining lysosome biogenesis and function."}], "pathway_id": "rno04142", "pubmed_id": "40747612", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Amlexanox (elevated levels), Camp, phosphodiesterase, protein kinase A (activated), nuclear factor kappa B (inhibited), signal transducer and activator of transcription 3 (inhibited).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of amlexanox increase cyclic adenosine monophosphate through inhibition of phosphodiesterase isoforms, leading to activation of protein kinase A. This activation restores lysosomal acidity and enhances lysosomal function. Concurrently, amlexanox suppresses nuclear factor kappa B and signal transducer and activator of transcription 3 pathways, reducing the production of pro-inflammatory cytokines and glial activation. These actions collectively alleviate oxidative stress, endoplasmic reticulum stress, and neuroinflammation, while preserving hippocampal neuronal viability and reducing dendritic loss."}], "pathway_id": "rno04142", "pubmed_id": "40765831", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RAB26, EEF1A1.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RAB26 facilitates the lysosomal translocation and subsequent degradation of EEF1A1, thereby suppressing pathological myocardial hypertrophy and cardiac remodeling. This process contributes to the maintenance of cardiac function and the prevention of cardiomyocyte apoptosis under stress conditions."}], "pathway_id": "rno04142", "pubmed_id": "40609824", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: MitoTEMPO (administration), Clioquinol (administration), cGAS (activation), STING1 (activation), Interleukin-6 (increased), Interleukin-4 (reduced), Interleukin-10 (reduced).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Impaired lysosomal function disrupts mitophagic flux, leading to the accumulation of damaged mitochondria and elevated reactive oxygen species (ROS) production. This mitochondrial dysfunction contributes to oxidative stress and inflammatory responses, as evidenced by increased levels of IL-6 and reduced IL-4 and IL-10. The cGAS-STING signaling pathway is activated under these conditions, promoting inflammation. Interventions such as mitoTEMPO and clioquinol can restore mitochondrial function and lysosomal activity, respectively, thereby alleviating oxidative stress and inflammation."}], "pathway_id": "rno04142", "pubmed_id": "40449272", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Sylvatesmin, CTR1, FDX1, LIAS.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Phillygenin promotes the lysosomal localization and degradation of the copper transporter 1 (CTR1), which reduces copper accumulation and attenuates cuproptosis in cardiomyocytes. This process alleviates oxidative stress, inflammation, and mitochondrial injury, thereby improving cardiac function and reducing myocardial damage."}], "pathway_id": "rno04142", "pubmed_id": "40523538", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Lysosome - Rattus norvegicus (rat)\n**Pathway Description**: Lysosomes are membrane-delimited organelles in animal cells serving as the cell's main digestive compartment to which all sorts of macromolecules are delivered for degradation. They contain more than 40 hydrolases in an acidic environment (pH of about 5). After synthesis in the ER, lysosomal enzymes are decorated with mannose-6-phosphate residues, which are recognized by mannose-6-phosphate receptors in the trans-Golgi network. They are packaged into clathrin-coated vesicles and are transported to late endosomes. Substances for digestion are acquired by the lysosomes via a series of processes including endocytosis, phagocytosis, and autophagy.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: NLRX1 (elevated expression), galectin-3 (expression), mTOR, TFEB (phosphorylation).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated NLRX1 expression in microglial cells promotes galectin-3 expression on lysosomes, leading to lysosomal dysfunction. This impairs microglial phagocytosis of neutrophil extracellular traps (NETs) via the mTOR/TFEB signaling pathway. Phosphorylation of mTOR inhibits the nuclear translocation of TFEB, which is essential for lysosomal biogenesis and function. As a result, the impaired phagocytic capacity of microglia contributes to the accumulation of NETs and subsequent neuronal damage in cerebral ischemia and reperfusion injury."}], "pathway_id": "rno04142", "pubmed_id": "40399533", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensinogen, Angiotensin-Converting Enzyme, Angiotensin II, Angiotensin II Receptor Type 1 (activated), Angiotensin-Converting Enzyme 2, Mas Receptor (activated), Angiotensin IV, Insulin-Regulated Aminopeptidase.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Angiotensinogen is cleaved by renin to form angiotensin I, which is further converted by angiotensin-converting enzyme (ACE) to angiotensin II (Ang II). Ang II activates the Angiotensin II Receptor Type 1 (AT1R), leading to vasoconstriction, renal sodium reabsorption, and aldosterone secretion, which collectively contribute to elevated blood pressure and the development of hypertension. In parallel, angiotensin-converting enzyme 2 (ACE2) catalyzes the formation of angiotensin-(1-7), which activates the Mas receptor to exert counter-regulatory effects. Angiotensin IV (Ang IV) binds to insulin-regulated aminopeptidase (IRAP), modulating additional physiological responses. Disruption of this balance can result in pathological conditions such as apoptosis and hypertension. Restoration of the renin-angiotensin system equilibrium suppresses apoptotic processes and supports neuroprotection and cardioprotection."}], "pathway_id": "rno04614", "pubmed_id": "41269991", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii (elevated levels), Angiotensin-(1-7) (elevated levels), Nitrite (elevated levels), Nitrate (elevated levels), Bmpr2 (deficiency), Smad5 (deficiency), ACE2 (deficiency), AT1R, MAS receptor (deficiency).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of angiotensin II activate the angiotensin II receptor type 1 (AT1R), contributing to vasoconstriction and pulmonary arterial hypertension. Fenofibrate reduces angiotensin II levels and the Ang II/Ang-(1-7) ratio in lung tissue, while preserving angiotensin-converting enzyme 2 (ACE2) and MAS receptor expression. This modulation enhances angiotensin (1-7) signaling, which counteracts the pathological effects of the renin-angiotensin system. Additionally, fenofibrate preserves Bmpr2/Smad5 expression and maintains nitrite and nitrate levels, which are associated with vascular function and reduced pulmonary artery remodeling. These effects collectively reduce right ventricular pressure overload and pulmonary vascular resistance."}], "pathway_id": "rno04614", "pubmed_id": "41226292", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin II receptor type 1 (activation), Angiotensin-converting enzyme 2 (upregulated), Mas-related G protein-coupled receptor D (upregulated), Angiotensin-converting enzyme, Tumor necrosis factor alpha (elevated), A disintegrin and metalloproteinase domain 17 (elevated).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Angiotensin II receptor type 1 (AT1R) activation mediates vasoconstriction and sodium reabsorption, contributing to elevated blood pressure. In response, angiotensin-converting enzyme 2 (ACE2) and Mas-related G protein-coupled receptor D (MasR) are upregulated as counter-regulatory components of the renin-angiotensin system (RAS). Tumor necrosis factor alpha (TNF) and ADAM17 are elevated in perivascular adipose tissue, promoting inflammation and vascular dysfunction. These changes are associated with cardiac and renal impairments, leading to the progression of cardiovascular complications."}], "pathway_id": "rno04614", "pubmed_id": "41096804", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ace (reduced expression), Agtr1 (reduced expression), Ace2 (reduced expression).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Reduced expression of Ace, Agtr1, and Ace2 contributes to RAAS dysregulation in FGR-prone females, which may interact with redox imbalance and oxidative stress to impair lung development and alter innate immune responses."}], "pathway_id": "rno04614", "pubmed_id": "41056372", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii (elevated levels), Angiotensin-(1-7), angiotensin II receptor type 1 (up-regulation), angiotensin II receptor type 2, angiotensin-converting enzyme (increased activity).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Angiotensin II activates the angiotensin II receptor type 1 in the cardiac system, promoting vasoconstriction and influencing the inotropic state of cardiomyocytes. Elevated angiotensin II levels are associated with increased angiotensin-converting enzyme activity and up-regulation of the angiotensin II/angiotensin-converting enzyme/angiotensin II type 1 receptor axis in response to zinc deficiency. This activation is linked to reduced calcium transient amplitude and diminished cellular shortening in isolated cardiomyocytes."}], "pathway_id": "rno04614", "pubmed_id": "40812241", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Diosmin (administration), Diosmetin (administration), Telmisartan (administration), Angiotensin II Type 1 Receptor (elevated levels), Mas Receptor (activation), Matrix Metalloproteinase-9 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated angiotensin II signaling through the angiotensin II type 1 receptor (AT1R) contributes to hypertension and cardiovascular remodeling by promoting vasoconstriction, sodium retention, and oxidative stress. Activation of the classical renin-angiotensin system (RAS) increases markers of oxidative stress and endothelial dysfunction, while downregulating protective pathways. In contrast, the non-classical RAS, including the Mas receptor (MasR), mediates anti-inflammatory and anti-fibrotic effects. Diosmin modulates the RAS by reducing classical RAS indicators, enhancing non-classical RAS activity, and attenuating oxidative stress. It also downregulates AT1R and matrix metalloproteinase-9 in cardiac tissue, which may contribute to improved vascular and left ventricular function. Diosmetin, a metabolite of diosmin, binds to AT1R with lower affinity compared to telmisartan, suggesting a partial mechanism for its cardiovascular benefits."}], "pathway_id": "rno04614", "pubmed_id": "40749341", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Renin-angiotensin system - Rattus norvegicus (rat)\n**Pathway Description**: The renin-angiotensin system (RAS) is a peptidergic system with endocrine characteristics regarding to the regulation of the blood pressure and hydro-electrolytic balance. In the classical RAS, the enzyme renin cleaves its substrate angiotensinogen (Agt) forming the decapeptide angiotensin I that is in turn cleaved by angiotensin-converting enzyme (ACE) to produce the angiotensin II (Ang II), a key player of this system. Ang II activates its AT1 receptor (AT1R), the principal receptor that mediates the majority of the known actions of Ang II in the kidney, including vasoconstriction, renal sodium (Na+) reabsorption, and aldosterone secretion, increasing blood pressure and contributing to the development of hypertension. In addition to (ACE)/Ang II/AT1R and AT2R axis, other signaling pathways in the RAS, such as ACE2/angiotensin-(1-7)/Mas and Ang IV/IRAP, and other active peptide of the RAS, with physiological relevance as Ang III, Ang A and alamandine, are now widely recognized.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Angiotensin Ii (elevated levels), ZD-7155 (administration), AT1R (inhibited by ZD-7155), Agt, ACE.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of Angiotensin II in the subfornical organ (SFO) enhance sodium appetite in 5/6 nephrectomized rats fed a high-sodium diet. This increase in sodium appetite is mediated through the activation of the angiotensin II type 1 receptor (AT1R). Inhibition of AT1R with ZD 7155 attenuates this effect, reducing sodium intake. Concurrently, elevated Angiotensin II levels in the kidney and SFO are associated with increased blood pressure and worsening renal injury."}], "pathway_id": "rno04614", "pubmed_id": "40731077", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: RBM20, U1 small nuclear ribonucleoprotein, U2 small nuclear ribonucleoprotein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "RBM20 binds to intronic RNA sequences and represses exon splicing, particularly when localized near 3' and 5' splice sites. RBM20 interacts with U1 and U2 snRNPs, leading to spliceosome stalling at complex A. This interference disrupts normal splicing of pre-mRNA, contributing to alternative splicing patterns that may impair cardiac function and promote dilated cardiomyopathy and heart failure."}], "pathway_id": "rno03040", "pubmed_id": "24960161", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Nav1.6 (expression of functional adult form), exon 18N of SCN8A (contains stop codon), exon 18A of SCN8A (selected in tissue-specific and developmentally regulated manner), Rbfox1, SRSF1, SRSF2, HNRNPA1, PTBP1, HNRNPA2B1, HNRNPD.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Exon 18N of the Nav1.6 sodium channel transcript contains a stop codon that leads to the production of a truncated mRNA, which is targeted for nonsense-mediated decay. This decay mechanism prevents the expression of a nonfunctional protein variant. In contrast, exon 18A is selected in a tissue-specific and developmentally regulated manner to produce the functional adult form of the channel. This mutually exclusive splicing is regulated by a combination of cis-acting elements in the exons and flanking introns that bind both positive (e.g., Rbfox1, SRSF1, SRSF2) and negative (e.g., HNRNPA1, PTBP1, HNRNPA2B1, HNRNPD) splicing factors. The relative abundance of these splicing regulators determines the inclusion of either 18N or 18A, ensuring that only the appropriate isoform is expressed in a given tissue and developmental stage."}], "pathway_id": "rno03040", "pubmed_id": "22434879", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, SNRNP200, RP9, DHX38.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Mutations in core spliceosomal proteins such as PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, SNRNP200, and splicing factors like RP9 and DHX38 disrupt the accuracy of pre-mRNA splicing, leading to retinitis pigmentosa. These proteins are essential components of the spliceosome, a complex responsible for the precise excision of introns and ligation of exons during mRNA maturation. Despite their ubiquitous expression, mutations in these proteins result in tissue-specific retinal degeneration, suggesting that the retina is particularly sensitive to splicing defects."}], "pathway_id": "rno03040", "pubmed_id": "27302685", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 5-Aminolevulinic Acid (elevated levels), protoporphyrin IX (accumulation), ALAS1, ALAS2, FECH (dysfunctional), CPOX (dysfunctional), UROD (dysfunctional), HMBS (dysfunctional), SLC25A38.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of 5-aminolevulinic acid (5-ALA) are metabolized via the heme biosynthetic pathway to protoporphyrin IX (PpIX), which accumulates when downstream enzymes such as FECH, CPOX, UROD, or HMBS are dysfunctional. This accumulation leads to mitochondrial iron overload and reactive oxygen species (ROS) production, triggering oxidative stress and ferroptosis. The biosynthesis of 5-ALA is catalyzed by ALAS1 in the cytoplasm and ALAS2 in erythroid cells. SLC25A38 facilitates the transport of succinyl-CoA, a cofactor required for ALAS activity, into mitochondria. Disruption in these processes impairs heme synthesis and contributes to cellular toxicity."}], "pathway_id": "rno03040", "pubmed_id": "18455493", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: AID, CTNNBL1, PRP19, CDC5L.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "AID interacts with CTNNBL1, a spliceosome-associated factor that is part of the Prp19 complex and interacts with CDC5L. This interaction may facilitate AID targeting during antibody diversification processes such as hypermutation and class switching. CTNNBL1s association with the spliceosome suggests a potential linkage between AID recruitment and transcriptional activity at target genes."}], "pathway_id": "rno03040", "pubmed_id": "18722174", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: heterogeneous nuclear ribonucleoprotein.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Neuron-specific splicing pathways are regulated by RNA binding proteins, including heterogeneous nuclear ribonucleoproteins (hnRNPs), which influence spliceosome assembly and pre-mRNA splicing. These proteins modulate the selection of splice sites, thereby determining the inclusion or exclusion of exons in the mature mRNA transcript."}], "pathway_id": "rno03040", "pubmed_id": "16314261", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Spliceosome - Rattus norvegicus (rat)\n**Pathway Description**: After transcription, eukaryotic mRNA precursors contain protein-coding exons and noncoding introns. In the following splicing, introns are excised and exons are joined by a macromolecular complex, the spliceosome. The standard spliceosome is made up of five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6 snRNPs, and several spliceosome-associated proteins (SAPs). Spliceosomes are not a simple stable complex, but a dynamic family of particles that assemble on the mRNA precursor and help fold it into a conformation that allows transesterification to proceed. Various spliceosome forms (e.g. A-, B- and C-complexes) have been identified.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Transforming Growth Factor Beta, Transforming Growth Factor Beta Receptor Type 2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Transforming Growth Factor Beta (TGF) modifies the spliceosome, influencing the inclusion of the EIIIA exon in fibronectin transcripts during alternative splicing. This modification can occur either directly through TGF signaling intermediates or indirectly via the products of genes regulated by TGF. In the context of liver injury, TGF overrides promoter-dependent regulation of fibronectin splicing, resulting in the production of the EIIIA-containing fibronectin isoform, which plays a role in early injury response events."}], "pathway_id": "rno03040", "pubmed_id": "15604136", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Tlr4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Tlr4 signaling contributes to ferroptosis, a regulated form of cell death characterized by lipid peroxidation and iron-dependent reactive oxygen species accumulation. Activation of Tlr4 promotes neuronal damage in conditions such as cerebral ischemia/reperfusion injury. Reduction in Tlr4 activity may alleviate ferroptosis and improve neuronal integrity in ischemic stroke."}], "pathway_id": "rno04216", "pubmed_id": "41264060", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Paeonol (administration), ACSL4 (increased ubiquitination), NEDD4L.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Paeonol promotes the interaction between NEDD4L and ACSL4, thereby increasing the ubiquitination level of ACSL4. This modification reduces the susceptibility of cells to ferroptosis, particularly under hypoxic conditions. Reduced ferroptosis contributes to the alleviation of placental and renal damage and the lowering of blood pressure."}], "pathway_id": "rno04216", "pubmed_id": "41354906", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferrostatin-1, 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone, ML385, DRP1, MFN1, MFN2, NRF2, HMOX1, GPX4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of reactive oxygen species and mitochondrial dysfunction contribute to ferroptosis, a form of iron-dependent, lipid peroxidation-mediated cell death. Activation of the Nrf2/HO-1/GPX4 signaling pathway suppresses oxidative stress and inhibits ferroptosis. Inhibition of DRP1-mediated mitochondrial fission promotes mitochondrial fusion via MFN1/2, which further protects against ferroptosis and neuronal damage. Mdivi-1, by targeting DRP1 and activating Nrf2 signaling, reduces mitochondrial and neuronal injury associated with ferroptosis."}], "pathway_id": "rno04216", "pubmed_id": "41254362", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Erastin, Orexin-A, OX1R, Nrf2, HO-1, SLC7A11 (elevated levels), GPX4 (elevated levels).\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Orexin-A inhibits neuronal ferroptosis by activating the OX1R/Nrf2 signaling pathway. This activation suppresses oxidative stress, upregulates OX1R and HO-1 protein expression, elevates ferroptosis-related markers SLC7A11 and GPX4, and promotes Nrf2 nuclear translocation. These effects collectively reduce mitochondrial damage, restore antioxidant capacity, and prevent lipid peroxidation-driven cell death."}], "pathway_id": "rno04216", "pubmed_id": "41239140", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Ferrous cation (elevated levels), Malonaldehyde, Glutathione (synthesis), Glutathione peroxidase 4, Acyl-CoA synthetase long-chain family member 4, Solute carrier family 7 member 11.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of iron(II) ions contribute to lipid peroxidation and reactive oxygen species (ROS) accumulation, leading to ferroptosis. Malondialdehyde, a byproduct of lipid peroxidation, serves as a marker of this process. Glutathione depletion reduces the cell's capacity to neutralize ROS, further promoting ferroptotic cell death. Glutathione peroxidase 4 (GPX4) mitigates lipid peroxidation by reducing lipid hydroperoxides, while acyl-CoA synthetase long-chain family member 4 (ACSL4) promotes the incorporation of polyunsaturated fatty acids into membrane phospholipids, increasing susceptibility to peroxidation. Solute carrier family 7 member 11 (SLC7A11) regulates the cystine-glutamate antiporter system, influencing glutathione synthesis and thereby affecting ferroptosis resistance. Impairment of these regulatory proteins increases neuronal vulnerability to ferroptosis, resulting in cognitive dysfunction and hippocampal tissue damage."}], "pathway_id": "rno04216", "pubmed_id": "41229168", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: Chrysin (administration), ML385 (administration), NFE2L2, GPX4.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "Elevated levels of reactive oxygen species and lipid peroxidation drive ferroptosis, a regulated form of cell death. Ferroptosis contributes to nerve injury and cognitive dysfunction in intracerebral hemorrhage. Activation of the Nrf2/GPX4 signaling pathway suppresses ferroptosis by reducing oxidative stress and lipid peroxidation. Chrysin enhances Nrf2/GPX4 pathway activity, thereby inhibiting ferroptosis and alleviating nerve injury and cognitive dysfunction. Inhibition of Nrf2 by ML385 reverses these protective effects, confirming the pathway's role in mediating chrysins neuroprotective action."}], "pathway_id": "rno04216", "pubmed_id": "41231360", "species": "rno"}
{"messages": [{"role": "user", "content": "**Pathway Name**: Ferroptosis - Rattus norvegicus (rat)\n**Pathway Description**: Ferroptosis is a regulated form of cell death and characterized by a production of reactive oxygen species (ROS) from accumulated iron and lipid peroxidation. It can be induced by experimental compounds (e.g.,erastin, RSL3) or clinical drugs(e.g., sulfasalazine, sorafenib) in cancer cell and certain normal cells. It is involved in multiple physiological and pathological processes, such as cancer cell death, neurodegenerative disease, tissue damage and acute renal failure.\n\nIn the context of this pathway, the following biological alterations were observed:\n**Observed Entities**: 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2 (overexpression), NFKB1 (Nuclear Factor Kappa B Subunit 1), Adenovirus overexpressing SIRT2.\n\nBased on the pathway context and biological principles, generate a coherent mechanism analysis explaining how these entities interact to produce the observed phenotype."}, {"role": "assistant", "content": "SIRT2 overexpression leads to the deacetylation of NF-B p65, which inhibits ferroptosis and oxidative stress. Inhibition of ferroptosis reduces neuronal apoptosis and promotes spinal cord injury repair, resulting in improved motor function recovery. Elevated NF-B p65 acetylation, in contrast, enhances ferroptosis and oxidative stress, worsening cellular damage."}], "pathway_id": "rno04216", "pubmed_id": "41225360", "species": "rno"}
